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This thesis consists of 85 publications, of which 21 have been
submitted for other degrees and are only included for completeness,
leaving 6A assessable works. These fall into four broad categories,
population cytogenetics, clinical genetics and cytogenetics, studies
on amniotic fluid and prenatal diagnosis, and studies of heritable
fragile sites on human chromosomes.
The section on population cytogenetics includes most of the Australian
studies on XYY males, epidemiological studies on Down syndrome in
Australia and studies on the cytogenetics of paediatric necropsies.
The clinical cytogenetics section mainly contains clinical case reports,
which include a description of one of the first recognised insertional
translocations in man, an important paper on trisomy 9 and one of the
first discussions of genetic counselling of pericentric inversion
carriers. This section also includes papers on gene mapping, alpha-1-
antitrypsin phenotypes in chromosome abnormalities with descriptions of
a new alpha-1-antitrypsin allele and studies on sister chromatid exchange
in various groups of individuals with the documentation of an increase in
this phenomenon in patients with multiple sclerosis.
The section on prenatal diagnosis includes studies of the enzymology of
amniotic fluid and cultured amniotic fluid cells, the discovery of
rapidly adhering cells in amniotic fluid and documentation of their
increased numbers in amniotic fluid surrounding fetuses with neural tube
defects, and studies of chromosomal mosaicism in cultured amniotic fluid
cells.
The most important section of this thesis is the final one on studies of
heritable fragile sites on human chromosomes. This section documents
the discovery of the tissue culture requirements for the expression of
fragile sites in lymphocyte culture, the finding of several new folate
sensitive fragile sites and the co-discovery of the BrdU requiring
fragile site at 10q25. Contributions to establishing fragile X-linked
mental retardation as the second commonest genetic cause of mental
retardation after Down syndrome, and population cytogenetic data for
fragile sites are presented. Genetic linkage studies with fragile sites
have established that a fragile site is coded for at the locus of the
fragile site. Micronucleus studies have suggested that the folate
sensitive fragile sites might be special examples of chromosome damage
due to deprivation of DNA precursors.
3.
Ill THE SUBMISSION
This submission includes the major published works of the candidate.
Published abstracts of papers presented to conferences have not been
included nor have minor comments published as letters to editors.
Two sections of the submission contain papers included in theses
submitted for the degrees of M.Sc. in the University of Melbourne and
Ph.D. in the University of Edinburgh. These papers are included for
completeness but are not an assessable part of this submission.
There are thus 64 papers which form the examinable portion of this
thesis. They are divided into four sections but there is
considerable overlap and assignment of some papers to any
particular section is arbitrary.
The four sections are :
1. Population Cytogenetics
2. Clinical Genetics and Cytogenetics
3. Studies of Amniotic Fluid and Prenatal Diagnosis
4. Fragile Sites on Human Chromosomes
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Sutherland, G.R.
8.
37 Further exclusions by deletion mapping. Ann. Genet.,
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D. Fragile Sites on Human Chromosomes
59 Fragile sites on human chromosomes: Demonstration of
their dependance on the type of tissue culture medium.
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60 Marker X chromosomes and mental retardation.
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Sutherland, G.R.
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76 The fragile X chromosome: Current methods.
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77 Heritable fragile sites on human chromosomes.
X. New folate sensitive fragile sites : 6p23, 9p21, 9q32,
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79 Heritable fragile sites and micronucleus formation.
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81 Regional localisation for HLA by recombination with a
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Mulley, J.C., Hay, J., Sheffield, L.J., Sutherland, G.R.
15.
82 A search for linkage in families with fragile sites.
Hum. Genet.., (1983), in press. Mulley, J.C., Nicholls, C.,
Sutherland, G.R.
83 Thymidylate synthetase inhibitors and fragile site
expression in lymphocytes. Am. J. Hum. Genet.., (1983),
in press. Jacky, P.B., Sutherland, G.R.
84 Protease inhibitor (PI) phenotype of individuals with
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* Denotes Review Article
( ) Previously submitted for the degree of M.Sc.
[ ] Previously formed part of Ph.D. thesis.
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V SYNOPSIS OF PUBLISHED WORK
A. Population Cytogenetics
Much of this section was the basis of my M.Sc. thesis and as
such is not formally assessable as part of this submission.
I have a continual interest in the contribution of chromosome
abnormalities to mental handicap and my studies of whole
institutional populations (9,1 A) form a significant
contribution in this field. Most other similar studies have
involved selection of particular patient groups.
My early work on XYY males (10) was the only major study of
this condition carried out in Australia.
I have an on-going interest in Down syndrome (11) as the
commonest chromosome abnormality in man, and my epidemiological
work on this disorder (16) was the first to be carried out in
Australia since the early studies of Collman and Stoller (see 16
for references to their work), although it was being carried out
concurrently with another Australian study of which I was unaware
at the time (Mulcahy, 1979).
Perhaps the most important part of the work on population
cytogenetics has been that on paediatric autopsies (12,13,15,18).
Only two other series of paediatric autopsies have been studied
chromosomally (Machin, 197A; Kuleshov, 1976).
17.
The paper on ai-antitrypsin phenotypes in chromosome
abnormalities (17) is a major work on this topic which
remains controversial (Fagerhol and Cox, 1981).
B. Clinical Genetics and Cytogenetics
Some of this section relates to clinical case reports and is
not now of great scientific interest, although it usually did
contribute at the time of publication. Several of the reports
are still of interest and include a description of one of the
first recognised insertional translocations (22,23), an
important paper on trisomy 9 (25), and one of the first
discussions of genetic counselling of pericentric inversion
carriers (26).
My collaboration with Mr. J.C. Mulley has produced several
publications in the area of gene assignment to chromosomes
(32,35,37) and constitutes a significant proportion of the
available data on exclusion mapping. We also discovered a
new allele for ai-antitrypsin (39) and examined the
distribution of ai-antitrypsin phenotypes in fragile site
carriers (84).
Collaboration with Dr. R.S. Seshadri has resulted in several
papers on sister chromatid exchange (31,33,36,38) including the
first report of an increase in this phenomenon in multiple
sclerosis (31).
18.
C. Studies of Amniotic Fluid and Prenatal Diagnosis
Much of this work was carried out as part of my Ph.D. project
in this University, and some of the papers in this section for
assessment have resulted from my collaboration during the
period with Dr. J. Butterworth on the enzymology of amniotic
fluid and the cells from it in tissue culture (42,49,56).
During my doctoral studies I made two new findings, the first
was that urine cells can be grown in tissue culture (41) and
the second that amniotic fluid from pregnancies in which the
fetus has a neural tube defect have greatly increased numbers
of cells which rapidly adhere to the substrate in tissue
culture flasks. I, perhaps erroneously, called these cells
macrophages; they have now become known as 'rapidly adhering
cells' although there is good evidence that some of them are
macrophages, many are most likely cells of neural origin.
This work has now been greatly extended by Gosden (see Gosden
and Brock, 1978, for details) and immunohistochemical studies
are helping to delineate the nature of the cells involved
(Cremer et al., 1981). The documentation of this work (54)
on rapidly adhering cells and other articles on aspects of
prenatal diagnosis (55-60) are for assessment as is a brief
letter (57) recording an observation which went much of the way
towards settling controversy about a-fetoprotein levels in the
amniotic fluid surrounding fetuses with Turner syndrome.
My detailed documentation of mosaicism in amniotic fluid cell
cultures (55) helped in the early understanding of what remains
a difficult problem to interpret and deal with.
19.
D. Fragile Sites on Human Chromosomes
This topic has absorbed most of my research efforts over the
last seven years and is by far the most important section of
this thesis.
This work stemmed from my discovery of the tissue culture
requirements for expression of fragile sites. The preliminary
results of this work were presented to the Genetical Society in
London (Sutherland, 1977) in November 1976 and subsequently
published in Science (59).
My preliminary observations were followed by detailed studies
of the tissue culture requirements for fragile site expression
in lymphocytes, with some work on other cell types, and formed
the basis of two papers which remain the major works on
fragile sites (62,63). This early work dealt mainly with
what have now become known as the folate sensitive fragile sites.
Later studies on the use of thymidylate synthetase inhibitors (83)
documented for the first time the use of FCdR to induce the
folate sensitive fragile sites. The folate insensitive fragile
sites have now been the subject of an extensive study (85) that
has documented a range of compounds which will induce the
fragile sites at 16q22 and 17p12.
Much more work has been done on fragile sites including the
documentation of five further folic acid sensitive fragile sites
(69,77), the discovery of the BrdU requiring fragile site at
10q25 (67) and a study of its population cytogenetics and
segregation (72). The importance of the fragile site at Xq27
20.
as a diagnostic marker for one form of X-linked mental
retardation and some of the clinical and cytogenetic features
of this syndrome have been documented (64,66,68). A possible
role for the folate sensitive autosomal fragile sites in the
aetiology of mental retardation has been suggested from work
on population cytogenetics (71) and efforts are continuing
to confirm or refute this suggestion. Linkage studies with
fragile sites (75,81) have shown that control of expression
of the fragile site is probably located at the fragile site
and (82) provided a considerable amount of exclusion data for
other genes from areas near fragile sites.
My collaboration with Dr. Beek in the application of the
techniques used in studies of mutagenesis to the study of
fragile sites is in its early stages. However, the two
publications (79,80) which have ensued suggest that the
biochemical knowledge gained about chromosome breakage at
fragile sites might be relevant to an understanding of other
forms of apparently non-specific chromosome breakage.
The work on fragile sites has been summarised in three invited
review articles. The first on the autosomal fragile sites
(73) was published in Karyogram, the official publication of
the (American) Association of Cytogenetic Technologists, and
is not a fully referenced paper in accord with the format of
that journal. The second (74) is mainly concerned with the
fragile X but views this chromosome in its context as one of
the folate sensitive fragile sites. The third (78) is the
written version of a paper I was invited to present at the
21 .
Second Annual Bristol-Myers symposium on Nutrition Research
entitled 'Nutritional Factors in the Induction and
Maintenance of Malignancy' in Washington in December 1982.
The work on fragile sites has been the subject of numerous
editorial comments (Hecht and Kaiser-McCaw, 1979, 1980;
Gerald, 1980, 1981; Turner and Opitz, 1980; Lancet 1981;
Hecht et al., 1981) and has been instrumental in opening up
a whole new area of cytogenetics. Virtually every diagnostic
cytogenetics laboratory has changed, or will soon need to
change, its way of performing chromosome studies to ensure
that the folate sensitive fragile sites are detected.
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VI EXPLANATIONS RE JOINT AUTHORSHIP
Publications 1-8 formed part of the candidate's M.Sc. thesis in the
University of Melbourne and publications 40,41,43-48,50-53 were
appended to the candidate's Ph.D. thesis in the University of
Edinburgh. Since these two groups of papers cannot form an
assessable part of this submission, and are only included for the
sake of completeness, no explanations of their authorship are given.
Unless otherwise stated, all cytogenetics, tissue culture and family
studies were carried out by me. I offer the following comments
regarding papers jointly written:
9 This work was done by me, at my own instigation, and
the paper was written by me. Dr. S. Wiener was a
sessional consultant physician in charge of the
laboratory.
10 This is a compilation of all the studies on XYY males
which had been done in Victoria to the time of
publication. For Dr. S. Wiener see 9;
Dr. A.A. Bartholomew was consultant forensic
psychiatrist who provided access to and details of
the-individuals studied. Ms. M.G. Fitzgerald was a
cytogeneticist at the Royal Children's Hospital,
Melbourne, who studied the two XYY males found there.
The paper was written by me.
11 See 9. S.W. corrected the proofs.
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12,13 This work was done in part by me and the remainder by
my research assistant, Ms. R. Bauld. Dr. A.D. Bain
was consultant pathologist in charge of the
department, the autopsies were carried out by him or
under his supervision. I wrote the paper.
14 This work was mostly done by me, the concept was mine,
the paper was written by me. Mr. A.R. Murch did some
of the cytogenetics, Drs. A.J. Gardiner and C. Wiseman
provided clinical information about the patients.
Dr. R.F. Carter was the consultant pathologist in
charge of my unit.
15,18 See 12,13. Dr. I.I. Smith was a pathologist in
Edinburgh who performed some of the autopsies.
16 This project was a joint one involving all authors.
I wrote the paper. Dr. S.R. Clisby is a medical
practitioner and Mr. G. Bloor a social worker with
Intellectually Retarded Services.
17 This was a joint project. Mr. J.C. Mulley is a
member of the staff of my unit who did the PI typing.
The paper was jointly written.
19 This was a joint project. A. Carmichael was a medical
student spending a period in the area of genetics in
mental retardation partly under my supervision.
Dr. H. Flynn was a medical practitioner who wrote the
paper.
25.
20 I wrote the paper. See 10.
21 I wrote this paper. Ms. M.G. Fitzgerald did some
of the cytogenetics. The patient had been under the
management of Professor D.M. Danks who provided
considerable advice and help during this study.
22,23 Mrs. E. Grace was a cytogeneticist who worked under
my supervision, she did most of the work and wrote the
papers on Dr. G.D. Stark's patient. Dr. A.D. Bain was
consultant pathologist in charge of the department.
24 I did most of the cytogenetics and dermatoglyphics but
had little direct involvement in the publication.
25 I wrote the paper, Dr. R.F. Carter did the autopsies,
Dr. L.L. Morris did the radiology.
26 I wrote the paper. Dr. A.J. Gardiner provided clinical
details of the patient. Dr. R.F. Carter was pathologist
in charge of the unit.
27 See 26. I wrote the paper.
28 I wrote the paper. Drs. G.F. Binns and R.F. Carter did
the histology, Dr. R. Dow, gynaecologist, provided
clinical details.
29 I prepared this article. Dr. J.G. Rogers was involved
in the prenatal diagnosis.
26.
31 I wrote the paper. Mrs. E. Baker is my senior
technician and research assistant who did most of
the technical work. Dr. A. Black, neurologist,
provided samples from the patients.
Dr. R.S. Seshadri was a full collaborator and did
the statistics.
32 For Mr. J.C. Mulley, see 17. G.D. Bryant did the
blood groups. This was a joint project between
J.C.M. and G.R.S., the paper was jointly written.
33 Some of the technical work was done under my supervision,
my involvement in the publication was minimal.
34 I wrote the paper. Mrs. H. Eyre is a technician in my
unit who did some of the cytogenetics under my supervision.
35 I wrote the paper. Mr. J.C. Mulley performed the genetic
marker studies. Dr. E. Goldblatt, cardiologist, was in
charge of the patient.
36 A joint project by Dr. R.S. Seshadri and G.R.S.
For Mrs. E. Baker see 31. The paper was jointly
written by R.R.S. and G.R.S.
37 See 32.
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38 This was a joint project involving G.R.S., R.R.S. and
A.A.M. The SCE was carried out by E.B. under my
supervision. R.K. and D.W. were staff in the
laboratory of R.R.S. and A.A.M. The paper was
jointly written by R.R.S. and G.R.S.
39 For J.C.M. see 17. D.W.C. controls a reference
laboratory for the confirmation of new PI alleles and
provided this service. The paper was jointly
written by J.C.M. and G.R.S.
42,49,56 This series of papers were from a joint project by
Dr. J. Butterwoth, biochemist, and G.R.S. All were
jointly written. Other authors include Dr. A.D. Bain,
pathologist in charge of the department, and
Mr. D.M. Broadhead, research assistant to J.B.
54 I wrote this paper. Dr. D.J.H. Brock measured the
alphafetoprotein levels, Dr. J.B. Scrimgeour performed
the amniocenteses.
55 I wrote this paper. Mrs. S.M. Bowser-Riley was a
cytogeneticist working under my supervision who did
some of the cytogenetics. Dr. A.D. Bain, see 42.
57 I wrote this letter. Ms. D. Holt measured the
alphafetoprotein, Dr. J.G. Rogers was involved in the
prenatal diagnosis.
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64 I wrote this paper. Dr. P.L.C. Ashforth measured
the testicles.
66 I wrote this paper. Mr. P. Leonard was a cytogeneticist
working under my supervision who did most of the silver
staining.
67 I wrote this paper. For Mrs. E. Baker see 31. This
discovery was made during a joint project (36) of
Dr. R.S. Seshadri and G.R.S.
68 I wrote this letter and did the testicular measurements.
The patients were under the control of Dr. C.G. Judge
and their chromosomes had been studied in the laboratory
of Dr. S. Wiener.
69 I wrote this paper. Mrs. L. Hinton was a technician in
my unit who did some of the cytogenetics under my
supervision.
75 I wrote this paper. For Mrs. E. Baker see 31 .
Mr. J.C. Mulley assisted with the linkage analysis.
76 Dr. F. Hecht wrote the paper, Dr. P.B. Jacky, now on
my staff, organised the workshop. I helped in the
organisation of the workshop, commented upon the
manuscript and provided the figure.
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77 I wrote the paper. Dr. P.B. Jacky and Mrs. E. Baker
did some of the cytogenetics, Ms. A. Manuel did some
of the family study on the patient with fra(9)(p21)
and provided blood samples from this patient.
79 This was a joint project involving all authors.
Dr. B. Beek was a senior geneticist from West Germany
who spent a short sabbatical period in my laboratory,
the paper was jointly written by B.B. and G.R.S.
80 As for 84, except that I wrote the paper and P.B.J, did
most of the micronucleus scoring.
81 Paper jointly written by J.C.M. and G.R.S. Dr. J. Hay
did the HLA typing, Dr. L.J. Sheffield referred the
index case.
82 A joint project. Paper largely written by J.C.M.
Catherine Nicholls was our graduate research assistant
who determined many of the genetic markers under the
supervision of J.C.M.
83 A joint project, the paper was jointly written.
84 A joint paper, the paper was jointly written.
85 A joint paper, I wrote the paper.
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VIII PUBLICATIONS
A 1
Letter to the Editor
reprinted from The Lancet, January 20, 1968, p. 150
XYY MALES IN A MELBOURNE PRISON
Sir,—An unusually, high proportion of males with antisocial
or criminal behaviour have an XYY chromosome comple¬
ment.1-3 These XYY males tend to be tall and dull.
We have lately begun a study of the prisoners in H.M. Prison
Pentridge, a multipurpose prison in Melbourne. Its daily
population of about 1200 inmates includes individuals convicted
or remanded for various crimes and offences ranging from
murder to drunkenness and vagrancy. Some of the inmates
are high-grade mental defectives or psychotics who at their
trial were found unfit to plead or were found not guilty on the
grounds of " insanity". The leucocytes of 34 prisoners,
69-821I2 in. (175-210 cm.) tall, have so far been cultured and
karyotyped. Of these 34 prisoners, 30 had a normal chromo¬
some constitution, 3 had 47 chromosomes with an XYY
chromosome complement, and 1 was an XYY/XYYY mosaic.
The clinical diagnosis in all 4 XYY subjects was psychopathy:
1 had committed murder,4 and another had been found unfit to
plead to the same crime; no abnormality in the external sex
organs was detectable in any of the 4, and 2 had children.
Other findings in these 4 men are shown in the accompanying
table. These results strongly support the concept that an extra
Y chromosome is associated with antisocial or criminal
behaviour which leads to confinement in an institution.
The incidence of XYY in the general population seems to be
less than Cl'2%,1 and it is also low 5 amongst those who are
mentally ill. In 30 mentally retarded men without criminal
record who were 72 in. (183 cm.) and taller, and in more than
300 retarded boys, we have found none with an XYY chromo¬
some complement. In the original report by Jacobs et al.1
there was a significant increase in height of males with two
Y chromosomes. Statistical analysis 6 suggests that an extra Y
1. Jacobs, P. A., Brunton, M., Melville, M. M., Brittain, R. P., McClemont,
W. F. Nature, Lond. 1965, 208, 1351.
2. Casey, M. D., Segall, C. J., Street, D. R. K., Blank, C. E. ibid. 1966,
209, 641.
3. Price, W. H., Strong, J. A., Whatmore, P. B., McClemont, W. F.
Lancet, 1966, i, 565.
4. Bufns, C. The Tait Case. Melbourne, 1962.
5. Casey, M. D., Blank, C. E., Street, D. R. K., Segall, L. J., McDougall,
J. H., McGrath, P. J., Skinner, J. L. Lancet, 1966, ii, 859.
6. Hunter, H. ibid. 1966, i, 984.
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3 5 17 19
Genotype XYY XYY XYY/XYYY XYY
Year of birth 1935 1947 1924 1916
Height 82-5 in. 70 in. 70 in. 71-5 in.
(210 cm.) (178 cm.) (178 cm.) (182 cm.)
Biacromial diameter 17 in. 151/, in. 15l/» in. 16 in.
(43 cm.) (39 cm.) (39 cm.) (41 cm.)
Intercristal diameter 13 in. 10Vi in. IVIt in. 12'/j in.
(33 cm.) (27 cm.) (29 cm.) (32 cm.)
Maternal age at birth
(yr.) 46 29 29 32
Paternal age at birth
(yr.) 43 32 33 38
Birth-rank 8 2 4 4
Fertility 1 girl Nil Nil 1 child
( ? sex)
I .Q. by Wechsler adult
scale (verbal/per¬
formance/full-scale) 97/106/101 65/85/71 94/95/94 79/92/84
Plasma-testosterone
(p.g. per 100 ml.) 0-65 0-66
Crime Attempted Murder Murder Larceny
murder
but not an extra X chromosome is associated with excessive
height. However, in the 9 subjects described by Price et ah,3
4 were under 72 in. (183 cm.) and 1 was only 67 in. (170 cm.)
high. Our tallest subject had a sister who was even taller
(86 in., 218 cm.), and a grandfather alleged to have been over
72 in. (183 cm.). Further studies on the stature of parents and
siblings of XYY subjects are obviously desirable.
Most XYY boys have average intelligence.7 The number of
XYY subjects with lowered intelligence was not statistically
different from that of similar patients who had no extra
chromosome.8 2 ofour 4 XYY subjects had normal intelligence.
So far no XYY male has been described with a superior
intelligence. The possibly deleterious effect of an extra Y
chromosome on intelligence may be age-dependent, becoming
more pronounced with increasing age when the associated
personality disturbance is severe. The electroencephalogram
(e.e.g.) was considered abnormal in 3 of our XYY subjects,
but, since the incidence of abnormal e.e.g. (often non-specific)
findings in our prison population is not known, the prediction 0
that a high frequency of abnormal e.e.g.s will be found in
XYY subjects remains unproven.
7. Balodimos, M. C., Lisco, H., Irwin, I., Merrill, W., Dingman, J. 1 .
J. clin. Endocr. Metab. 1966, 26, 443.
8. Price, W. H., Whatmore, P. B. Br. med. J. 1967, i, 533.
9. Forssman, H., Hambert, G. Lancet, 1966, ii, 282.
We were unable to confirm the increase of plasma-
testosterone reported in 1 case.10
A retarded boy with an XYYY genotype has been described
previously,11 but case no. 17 (see table) seems to be the first
reported of an XYY/XYYY mosaic; the details of his karyotype
will be published later.
Chromosome Laboratory, Saul Wiener
St. Nicholas Hospital, Melbourne. GRANT SUTHERLAND.
Psychiatric Clinic,
H.M. Prison Pentridge, Melbourne. ALLEN A. BARTHOLOMEW.
Department of Medicine,
Monash University, Melbourne. BRYAN HUDSON.
10. Welch, J. P., Borgaonkar, D. S., Herr, H. M. Nature, Lond. 1967,
214, 500.




Letter to the Editor
reprinted from The Lancet, December 21, 1968, p. 1352
A NORMAL XYY MAN
Sir,—All previously reported XYY men have been found
either in penal or mental institutions or because of a personal
or family history suggesting a chromosomal abnormality. We
report here a case discovered by chance.
A 41-year-old man donated a sample of blood required for
testing a new batch of tissue-culture medium. He was the first
volunteer we approached, and after successful culture his
chromosomes were incidentally counted. He is the only child
of a father and mother who were 26 and 19 years old res¬
pectively when he was born. His mother had severe puerperal
sepsis and during her illness, according to his father, the infant
was fed on " boiled water ". During the " depression " years
food was scarce, and he developed rheumatic fever and later
poliomyelitis, which severely interrupted his schooling. He
joined the army in 1948 and worked as a medical orderly until
he was honourably discharged 18 months later. During the
next 15 years, he had several semiskilled labouring jobs. For
the past 3 years, he has been employed at this hospital.
The man has always been a teetotaller and has never smoked.
According to his father, he was a placid and obedient child.
He has never been in conflict with the Law, has financially
supported needy members of his family, and is exceptionally
fond of his parents, with whom he lives. He is of cheerful
disposition and mild temperament, has no apparent beha¬
vioural disturbance, and has never required psychiatric advice.
Shyness and fear of poverty seem to have prevented him from
getting married.
The subject was found to be 182 cm. tall, and weighed 76 kg.
His arm-span was 190-5 cm., and the biacromial and bitro-
chanteric distances were 40-5 cm. and 32-5 cm., respectively.
He had a highly arched V-shaped palate and, in addition to his
permanent cuspids, he had retained deciduous upper cuspids.
The little fingers were abnormally short but his digital and
palmar creases were normal. His trunk had a rash caused by
tinea versicolor. Genitalia and body hair were of normal
2
development. His heart and lungs were clinically clear and his
blood-pressure was 130/70 mm. Hg, with a regular pulse of
80 per minute. Electrocardiogram was normal with a PR
interval of 014 second. Electroencephalogram showed non¬
specific abnormalities (excess low-voltage theta and delta
activities). Vision for red and green was normal. His I.Q.
(Wechsler) was 97 in both verbal and performance tests.
Culture of his leucocytes showed a karyotype of 47, XYY. The
karyotype of his father was 46, XY.
Recently, Court Brown et al.1 have described a 34-year-old
XO/XYY mosaic of normal intelligence and free from
behavioural disturbance. This case and the present one show
the difficulty of characterising XYY males, but it is evident
that they may lead a normal life. Reliable data on the incidence
of the XYY genotype in the population are indeed required.2
Chromosome Laboratory,
St. Nicholas Hospital, SaUL WIENER
Melbourne. GRANT SUTHERLAND.
1. Court Brown, W. M., Price, W. H., Jacobs, P. A. Br. med.J. 1968, ii, 325.




7 Adam Street, Adelphi, London W.C.2
A Murderer with 47,XYY and an
Additional Autosomal Abnormality
S. WIENER, G. SUTHERLAND and ALLEN A. BARTHOLOMEW
Reprinted from The Australian and New Zealand
Journal of Criminology
A Murderer with 47,XYY
and an Additional
Autosomal Abnormality
S. WIENER*, G. SUTHERLAND** AND ALLEN A. BARTHOLOMEW* * *
CASE reports are now accumulating relating to "patients" found to have
the karyotype 47,XYY1. Many of these reports, although from selected
samples, have tended to demonstrate a relationship between the extra Y
chromosome and criminality or "criminal propensities"2.
The case presently described is of interest from two points of view.
In the first place the individual was charged with murder (1961) and
convicted of that crime after his defence of insanity had been rejected by
the jury. He was sentenced to death, a mandatory sentence in the State
of Victoria, and after an appeal to the State Full Court2a and an application
for leave to appeal to the High Court of Australia had been rejected the
death sentence was confirmed by the Govenment of the day. This led to
an application for leave to appeal to the Judicial Committee of the Privy
Council in London which was refused. After this, somewhat unusual litiga¬
tion took place in the Victorian courts in their lunacy jurisdiction3 and
later further efforts were made in the original criminal jurisdiction4.
The matter ended when the Government commuted the death sentence
and the prisoner was certified to a security mental hospital. The overall
story has been well set out in general terms by Burns5.
After a short stay in the security mental hospital the prisoner was
returned to prison to continue serving his sentence — natural life im¬
prisonment. In 1967 we began a karyotype survey of our prison population
and this prisoner was provisionally reported to be an XYY/XYYY mosaic6.
Further study has led to the conclusion that his karyotype is 47,XYY, Dp+.
"Consultant Pathologist, M.D. (Melb.), PhD. (Melb.), M.R.A.C.P.
**B.Sc. (Melb.), Geneticist. Both of the Chromosome Laboratory, St. Nicholas Hospital,
Mental Health Department of Victoria.
***M.B. (Lond.), D.P.M. (Lond.). Psychiatrist Superintendent, H.M. Prison Pentridge,
Melbourne.
1. Nielsen, J. (1968) "The XYY Syndrome in a Mental Hospital" Brit.J.Criminol. 8 186;
Court Brown, W.M., Price, W.H. and Jacobs, P.A. (1968) "Further Information on the
Identity of 47,XYY Males" Brit.Med.J. ii 325.
2. Although this is so at least two cases have been reported of "normal" males with the
XYY chromosome constitution; Court Brown et al. Ibid; Wiener, S. and Sutherland, G.
(1968) "A Normal XYY Man" Lancet ii 1352.
2a. R v Tait (1963) V.R. 520.
3. See Feltham, J.D. (1964) "The Common Law and the Execution of Insane Criminals"
4 Melbourne University Law Review 434; Re Tait (1963) V.R. 532.
4. Tait v R (1963) V.R. 547.
5. Burns, C. (1962) The Tait Case. Melbourne University Press.
6. Wiener, S., Sutherland, G., Bartholomew, A.A., and Hudson, B. (1968) "XYY Males
>n a Melbourne Prison" Lancet i 150.
20
r
AUST. & N.Z. JOURNAL OF CRIMINOLOGY (1969): 2, 1 21
The presentation here will set out firstly the clinical history of the
prisoner in some detail, secondly the chromosomal picture will be given and
finally the matter will be discussed from two points of view. These two
aspects will be the finding of a chromosomal abnormality in its own right
and secondly the importance of the abnormal finding in this case where the
individual might very well have been hanged in 1962; five years or so
before we were in a position to determine that he had an abnormal
chromosome constitution.
Clinical History
The prisoner was born in Scotland in December 1924 and he was the
fourth of five children. Nothing is known of his early history other than
his father was a publican given to heavy drinking and aggressive be¬
haviour. The prisoner attended an elementary school until aged about
9 years when he sustained injuries following a fall of some 40 feet. The
major injury was a dislocation of the left knee. He was also knocked un¬
conscious for an unknown period and, in all, was detained in hospital for
a period of about six months. After this he was sent to a special school
for physically and mentally handicapped children. This was largely due
to the fact that he was on crutches and had missed a considerable amount
of schooling. This reason was given to the Crown psychiatrist by the
prisoner's estranged wife who was "certainly not very friendly" toward
her husband and the defence endeavoured to maintain that the need for
special schooling was indicative of mental backwardness as a child.
In his book, Burns comments that7 "as a child (the prisoner) was
fey; as a young man childish" and gives a description given by one of the
prisoner's sisters that in his younger days
He wasn't silly or anything like that. He was just slow and very childish.
He was always bringing home stray animals. It used to keep Mum
poor taking them to the vet. He loved reading comics. Even in the
Navy in the war he read comics. If he read a sad comic or heard a
sad play on the wireless he would cry. He wasn't one for the girls. He
loved to go to the pictures or a dance now and then. But he never
hung around with corner boys. He was a big child. Bertie (the family's
name for him) could never make a decision — he always used to
ask us about simple things, such as whether he should go to the
pictures.
After leaving the special school at the age of about 14 years he worked
as a messenger boy for a short period until beginning an apprenticeship
as a motor mechanic. In 1943 (when aged 18 years) he joined the Royal
Navy as a stoker and served both in the Mediterranean and off Singapore.
Whilst in the navy he began to drink heavily and develop homosexual
tendencies. Indeed, during his time in the service he admitted to "a certain
amount of buggery".
He was demobilized in 1947 and married a Lithuanian girl the follow¬
ing year. The girl's brother was in Australia and persuaded them to
emigrate. They came to Australia in 1952 and almost as soon as they
arrived the marriage began to break up, which it did finally in 1954,
7. Burns, C. op. cit. p.24.
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due largely to the husband's heavy drinking. However, Burns8 comments
that apart from the drinking "there is some evidence that his sexual
abnormalities were becoming more pronounced and that at least once,
perhaps twice, he had violently assaulted his wife and threatened to kill
her". After his wife left him he began to drink even more heavily.
Between 1954 and 1959 he wandered round the continent earning
money from casual labour, getting into minor trouble with the law and
drinking heavily. During this period his sexual deviance became more
pronounced and after a period of having heterosexual relations with abori¬
ginal women he abandoned such behaviour and found satisfaction in
transvestism and sado-masochism. As Burns puts it9
His sexual satisfaction came from wearing or handling women's
underclothes, which he either bought or stole, from making compulsive
sexual assaults on young women, attempting roughly to handle their
breasts against their will and from inflicting pain on himself by in¬
serting sharp instruments in his anal canal while masturbating.
On August 6th, 1959, after heavy drinking he assaulted a seventy-
year-old woman and as a result was charged with robbery with assault
(there is some evidence that, apart from taking money, he indulged his
sexual drive by handling the woman's breasts), was convicted and sen¬
tenced to three years imprisonment being ordered to serve two years before
becoming eligible for parole. He was seen by a psychiatrist at the start of
his sentence and it was simply noted that he was a heavy drinker, possibly
an alcoholic; that he was a social isolate; that he had sexual problems of
some five years' standing including transvestism; and that he had requested
treatment. At no time over the following two years was he in receipt of
treatment.
He was released from prison on 27th July, 1961, after having served
some 22 months of his sentence. He was on parole and had a special con¬
dition attached that he should abstain from alcohol. Between the date
of his release and the murder (8th August, 1961) he was seen by his parole
officer on six occasions and on the 7th August was seen by a psychiatrist.
When seen by the psychiatrist (10.30 a.m.) the parolee was sober, agreed
that he had been drinking since his discharge from prison but denied
he was an alcoholic and refused to consider any suggestions of possible
treatment.
The following day, being out of work, he drank quite heavily and con¬
sumed at least half a bottle of whisky and "a few beers". He wanted more
to drink but had no money. He remembered a vicarage from previous con¬
tact and so went there and broke in. Once inside he rummaged around
looking for money when the vicar's aged mother disturbed him. In the
prisoner's words, "I did my block," and punched her. He then, the order
of events is not known, removed her clothing and dressed himself in her
undergarments and placed a torch in her vagina. He denied any recollection
of the latter behaviour.
When seen after the murder (22nd August, 1961) he showed little
anxiety and simply said, "I'm in a real mess now". He was investigated
with both psychological tests and electro-encephalographic recording.
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average intelligence the IQ (WAIS full score) being 94. Other tests (TAT
and Rorschach) suggested that there was a "neurotic adjustment" but
that there was no other evidence of gross mental illness.
The electro-encephalogram was reported upon (by the late Dr. A.
King) as "is not suggestive of organic cerebral disorder. It reflects his
personality but does not show organic disease".
Because of the apparent late onset of his sexual deviance and because
of his alcoholic nomadic way of life a blood test for syphilis was done but
found to be negative.
Finally, additional physical measurements were taken (height, bi-
acromial and intercristal diameters) and these have been set out else¬
where10.
Whilst in prison under sentence of death the prisoner remained
essentially mentally stable and only very occasionally demonstrated any
evidence of becoming "psychotic". This period was exceedingly stressful
to him as his execution had a date set on some four occasions, the date
being changed as a result of the various appeals taking place in the
courts11. He was finally "certified" to a mental hospital under the pro¬
visions of the Mental Health Act {Vict.) 1959, s.52. However, this step was
taken after his sentence had been commuted whilst an appeal was being
considered in the High Court of Australia. When announcing that the
death sentence had been commuted by the Government the Premier, Mr.
(now Sir Henry) Bolte, said that events had culminated in a stay of
execution for a further indefinite period by order of the High Court. This
had followed frequent postponements in the immediate past. "The conse¬
quent effect on the mental condition of the prisoner has finally resulted
in the issue of certificates under the new Mental Health Act that his mental
health had been substantially impaired"12. It is important to recognize
that the prisoner was not certified as "insane" but as suffering from "a
psychiatric or other illness which substantially impairs mental health"13
This act of certification cannot be construed as indicating that the prisoner
had been "insane" since at least August 196114.
The prisoner remained in a security mental hospital for a little less
than three months. He returned to H.M. Prison Pentridge on the 18th
January, 196315. Since that time it would appear that he has remained in
"normal" mental health and he has certainly not required any specific
treatment — psychopharmacotherapy or psychotherapy.
Cytogenetics
Method: Blood for chromosome studies was collected by venepuncture
(15 ml in a heparinized syringe) and transported to the laboratory. About
4-5 hours elapsed before the leucocytes were separated for culture. The
leucocytes were added to a tissue culture medium of T199 with 20% foetal
calf serum at a concentration of 7 x 105 per 1 ml of medium. The cultures
10. Wiener et al. (1968) op. cit.
11. Howard, C. (1963) "Time and the Judicial Process" 37 Aust.L.J. 39; Idem, "An Australian
Letter: The Principle of Fair Trial" (1963) Crim.L.R. 603.
12. Burns, C. op. cit. p.141.
13. Mental Health Act (Victoria) 1959, sec.3. It should be noted that this Act came into
operation on November 1st 1962; 8 hours before the prisoner was to be executed on
the final date set.
14. See correspondence (1963) Crim.L.R. 870.
15. The Age (Melbourne) 21st January 1963.
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were harvested according to the method of Moorhead et al.15a and stained
with Giemsa. Skin cultures were prepared and harvested by the method
described by Ferguson16.
Results: Three leucocyte cultures and one skin fibroblast culture17
were undertaken and the results are set out in Table 1. The results of
TABLE 1 Results of the Chromosome Counts
Number of Chromosomes
45 46 47 48 49 Total
Leucocyte 1 2 3 78 17 — 100
Leucocyte 2 2 3 48 6 — 59
Leucocyte 3 1 5 91 2 1 100
Skin Fibroblast — — 73 3 — 80
the first two leucocyte cultures were rejected due to a high increase in
chromatid breaks and aneuploid cells. The final leucocyte culture and the
skin culture gave a consistent karyotype of 47,XYY, Dp+ (See Figures 1
and 2)
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FIG. 2. Chromosomes from groups D and G showing the appearance of the Dpt-chromosome
(arrowed) and the Y chromosomes from a further five cells.
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with random differences in the aneuploid cells. Satellites were not detected
on the Dp+ chromosome although it was occasionally in "satellite
associations" with both D and G — group chromosomes.
Comment on Cytogenetic Findings: The reasons for the increased
breakage and aneuploidy in the first two leucocyte cultures is uncertain,
however similar results were encountered in cultures from other subjects
in the same batch of medium. It was therefore suspected that some toxic
factor in the medium was responsible. The prisoner was not on any medica¬
tion at the time of the first culture but did have a barium meal just
prior to the second.
FOOTNOTES TO PREVIOUS PAGE
15a. Moorhead, P.S., Nowell, P.C., Willman, W.J., Battips, D.M. and Hungerford, D.A. (1960)
"Chromosome Preparations of Leucocytes Cultured from Human Peripheral Blood"
Exp.Cell.Res. 20 6 i 3.
16. Ferguson, J. (1962) "Chromosome Studies of Human Cells in Tissue Culture"
Med.J.Aust. i 40.
17. We should like to thank Miss J. Ferguson of the Commonwealth Serum Laboratories
for preparing the skin fibroblast culture.
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Aberrant D — group chromosomes of the type presented here in which
the origin of the extra material in the short arm is unknown, appear to
have a low incidence in the normal population. Hungerford and Chandra18
reported finding a Dp+ chromosome in a normal girl and subsequently
in her father and paternal uncle. In a study of 756 individuals Court Brown
et aZ.19 found four cases; three of these were clinically normal and one
had primary amenorrhoea. However, the same chromosome was found in
four presumably normal members of her family. Ferrier et al20 studied
an XO/XY/XYY male pseudohermaphrodite whose father carried a Dp+
chromosome with no apparent clinical abnormality.
It is therefore probable that in some individuals Dp+ chromosomes
may be present in the absence of any detectable clinical abnormality
and, as Ferrier et al.21 suggests, may be "part of asymptomatic variation
found in the general population". Nevertheless, we do not know that the
Dp+ chromosome in association with the extra Y chromosome is without
clinical effect.
Discussion
Two matters appear to be important in this case. The first matter
concerns the significance of the extra Y chromosome in relation to crime.
If one accepts that the incidence of the XYY chromosome constitution in the
general population be less than 0.2%22 then the finding of a greater
incidence of this karyotype in a delinquent or criminal population tends
to lead to the conclusion that the extra Y chromosome may well be a
factor in some cases of anti-sociality. However, the position is very far
from clear and there is no doubt that at the present time unduly exag¬
gerated claims are being made. An example of this is the statement made
by Mackay23 that
studies have indicated that approximately 50% of tall (over 6ft.)
males with criminal tendencies have the XYY constitution.
Although the murderer described in this article did have the XYY
chromosome constitution (plus the additional autosomal abnormality) we
are not attempting in any way to set out an immediate causal relationship
between the karyotype and the anti-social behaviour. A fair comment
regarding the XYY constitution and anti-social behaviour has been made
by Court Brown et al. who wrote that24
18. Hungerford, D.A. and Chandra, H.S. (1966) "Further Studies of a Kindred Having an
Aberrant Autosome (13-15) Without Apparent Phenotypic Effect" J. Genet. 59 239.
19. Court Brown, W.M., Buckton, K.E., Jacobs, P.A„ Tough, I.M., Kuenssberg, E.V. and
Knox, J.D.E. (1966) "Chromosome Studies on Adults" Eugenics Laboratory Memoirs
XLII. The Galton Laboratory, University College London. Cambridge University Press,
London/NewYork.
20. Ferrier, P.E., Ferrier, S.A., Scharer, K.O., Genton, N., Hedinger, C. and Klein, D. (1967)
"Multiple Chromosome Aberrations: XO/XY/XYY mosaicism and a Translocation in
the Same Family" Helv.paedial. Acta. 22 516.
21. Ibid.
22. Jacobs, P.A., Brunton, M., Melville M.M. and McClemont, W.F. (1965) "Aggressive
Behaviour, Mental Subnormality and the XYY Male" Nature (Lond.). 208 1351;
Court Brown, W.M. (1968). "Chromosomes and Crime" New Scientist 31st October, p.235.
23. Mackay, E.V. (1967) "The Clinical Significance of Disorders of the Sex Chromosomes"
Med.J.Aust. ii 552.
24. Court Brown, W.M., Price W.H. and Jacobs, P.A. (1968) "The XYY Male" Brit.med.J
iv 513.
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the only conclusion that can be reached at present about a male with
extra Y chromosome is that, by comparison with an XY male, he
incurs some increased risk of developing a psychopathic personality.
There are no data which permit a quantitative evaluation of this in¬
crease; it may be small or it may be considerable.
There is, however, no evidence which indicates that an XYY male is
inexorably bound to develop anti-social and criminal traits . . .
It is considered unlikely that the XYY chromosome constitution would
be important in relation to the raising of a defence of insanity to any
criminal charge25, although the finding might be useful in a defence based
upon diminished responsibility. It has been clearly stated26 that "Criminal
responsibility is assessed on evidence of a man's state of mind", the test
being of a cognitive nature, and not on possible aetiological factors. There
is therefore no reason to suppose that the prisoner concerned in this
article would have been any more successful in his insanity defence even
if, in 1961, he and his legal advisers had been aware of his chromosome
constitution.
Whilst it may be true that the XYY finding may not be of great
interest in terms of criminal responsibility it is likely that
ethical problems are likely to be much more serious in relation to
the wider social consequences of the diagnosis. In the criminal field,
difficulty will not be in the court, but will occur when the parole board
has to try to assess the significance of an XYY constitution in a
recidivist of otherwise unexceptional mentality who is due for release27.
This brings one to the second matter which is concerned with punish¬
ment, and, in particular, hanging as a criminal sanction. Quite apart
from the morality of hanging persons, of sound mind, found guilty of
murder, there is the difficulty of what one means by "of sound mind".
Very frequently a "normal murderer", who might be a perpetrator of a
crime passionel, will have his death sentence commuted because the
murder was "normal" or "understandable". It is likely that the more
"abnormal" or "not understandable" murder will be committed by a more
psychiatrically disturbed individual. In other words, if the "normal" murder¬
er has his sentence commuted and the "abnormal" murderer also has his
sentence commuted on the basis of his abnormality then there is virtually
no need to retain hanging as a criminal sanction. It is a sobering thought
to reflect that if this prisoner had been known to have had the described
chromosomal abnormalities in 1961-2 he would possibly have had his death
sentence quickly commuted. It may well be with hanging that any one
executed might later be found to have suffered from a disease or disorder
which, had it been recognized prior to execution, would have constituted
a ground for clemency. The case of Sodeman28 is relevant here in that
25. See Bartholomew, A.A. (1968) "The Extra Y Chromosome and Criminal Behaviour"
(Editorial Annotation) Aust.N.Z.J.Psychiat. 2 6; "Medico-Legal" in Brit.med.J. (1968)
iv 389; Fox, R. (1969) "XYY Chromosomes and Crime" Aust.N.Z.J. Criminol. 2, 1, 5, and
Bartholomew, A.A., and Sutherland, G. (1969) "A Defence of Insanity and the Extra Y
Chromosome: R v Hannell" Aust.N.Z.J. Criminol. 2, 1, 29.
26. "Medico-Legal" op. cit.
27. Gibbens, T.C.N. (1968) "Genetics and Ethics" New Scientist 31st October, p.236.
28. R v. Sodeman (1936) V.L.R. 99; (1936) 55C.L.R. 192. See also Morris, N. and Howard, C
(1964) "Studies in Criminal Law" Clarendon Press, p.49.
28 AUST. & N.Z. JOURNAL OF CRIMINOLOGY (1969): 2, 1
at his post mortem after his execution it was noted that he suffered "from
brain damage so extensive that the doctors wondered how he had sur¬
vived and functioned at all at the time he committed the murders"29.
One wonders, if capital punishment be continued, how many who are
hanged would not perhaps have later been found to have suffered from
some significant abnormality.
It is certain that genetic research has done little more than get
started and it is also very likely that in the months and years to come
further abnormalities will be recognized, abnormalities effecting behaviour
ajid possibly correlating with anti-sociality, perhaps aggressive and
criminal anti-sociality. Without going the whole way in terms of genetically
determined behaviour, one may note the comment of Parsons30 that with
mice
investigations have shown a correlation between strains for alcohol
preference and an enzyme breaking down alcohol, namely liver alcohol
dehydrogenase (A.D.H.) . . . The mouse results do indicate, however,
that a behavioural trait, the desire to drink alcohol, may have some
biochemical basis . . . Recent work is showing more and more that
there is at least some genetic and biochemical basis to human be¬
haviour.
On this basis it may well be that this murderer may not have been a fully
responsible person in relation to his general anti-sociality (his XYY
constitution?) or, at another level, his alcoholism. It is becoming ever more
accepted that alcoholism is a disease, without any concern as to its possible
genetic basis, and in the United States there is a trend in the direction of
accepting the alcoholic as a sick person and certainly not responsible for
his condition31, and presumably not responsible for many of the acts which
stem from intoxication in such a person. One may simply summarize the
position by saying that we are far too ignorant at this time to say with
any meaningful certainty "This man is 'normal'" or even "responsible".
Inevitably to hang any person is to take away the life of an individual
who may well be abnormal in terms of tomorrow's knowledge.
29. Burns, C. op. cit.
30. Parsons, P.A. (1967) "Genes, Behaviour and Biology" La Trobe University Inaugural
Lecture. F.W. Cheshire, Melbourne.
31. Editorial (1968) "Alcohol and Crime" Aust.N.Z.J. Criminol. 1 65.
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IN a recent trial of a man charged with murder, heard in the Supreme
Court of Victoria (R v Hannell, unreported), considerable interest was
aroused, and much inaccurate comment, in relation to the basis of the
defence raised: the defence of insanity. During the course of the psychiatric
evidence given for the defence it was stated that the accused man had a
chromosome constitution of 47,XYY and this led to such headlines as
"Killer with odd cells is insane"1, "Not guilty for killer with criminal
trait"2 and "Jury clears XYY man: Insanity"3. These headlines, and
the texts they headed, give the impression that the accused successfully
raised the defence of insanity on the basis of his chromosomal abnormality.
This is not a true representation of the position.
Although an aspect of this trial has been commented upon briefly
in the Journal as an Editorial4, it is thought that the whole case, clinical
features, genetic findings and the evidence offered to the court, should
be presented in full.
Clinical Features
Clinical History. He was born in Victoria one of twin boys, both having
an older sister and later two younger brothers. He was the second of the
twins to be born and his mother thinks that he suffered some birth injury.
Further, the mother commented, "He's always been a problem child," and
stated that he was sick for the first two years of his life. From the Royal
Children's Hospital the early clinical history was that he had seven ad¬
missions over the first seventeen months of his life. His first admission was
for prematurity (birth weight 41b 3ozs), a transient systolic murmur,
vomiting and diarrhoea, and sclerema. His second admission was for the
sclerematous condition. The third admission was for asthmatic bronchitis
* M.B. (Lond), D.P.M. (Lond), M.A.N.Z.C.P., Psychiatrist Superintendent, H.M. Prison
Pentridge, Melbourne.
** B.Sc. (Melb), Geneticist, Chromosome Laboratory, St. Nicholas Hospital, Melbourne.
1. Herald (Melbourne) 9th October, 1968.
2. Australian (Melbourne) 10th October, 1968.
3. Sun (Melbourne) 10th October, 1968.
4. Editorial (1968) "The Defence of Insanity and XYY" Aust.N.Z.J. Criminol. 1, 4, 199.
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and a hypochromic anaemia (haemoglobin 37%) which required a blood
transfusion. The fourth occasion of hospitalization was for bilateral otitis
media requiring bilateral paracentesis, and a condition of gastro-enteritis.
The fifth occasion was for further investigation of the anaemia (haemo¬
globin 48%) and another blood transfusion, whilst the sixth and seventh
admissions were for a right basal pneumonia and a subsequent persistent
cough.
Against this hospital background his mother continued: "He has always
been much slower than his twin, he was slow at everything. You wouldn't
think they were twins. He was twenty months before he walked." He was
considered very backward at school and left when aged 14 years and in
the 5th grade. When he left he could barely read and write and had little
knowledge or understanding of simple arithmetic.
Since leaving school he has had "a large number of jobs", most of
them casual work and labouring tasks. His social activities included an
interest in swimming and horse-riding but he tended to do these alone as
"he wasn't one for making friends, particularly girl friends". He very rarely
drank alcohol but was a heavy smoker. His only previous offence was
"Loitering for homosexual purposes"; he was fined in the adult court.
The relationship of H with his family was that he got on "extra well"
with his father and "very well" with his twin and younger brothers. He
had an indifferent relationship with his mother who separated from her
husband when H was about 15 years of age. It is said the separation took
place due to the excessive drinking of the mother. After the separation
H lived with the mother for various periods of time but at intervals he
would "suddenly leave the home and go off and live somewhere else".
The Alleged Offence: The killing of the victim (his aged landlady)
took place on Easter Sunday, 26th March, 1967. The general background
would appear to have been that two weeks or so prior to Easter, H had
gone hop-picking with his mother but that he suddenly returned to Mel¬
bourne without saying anything to her. A possible explanation for this
somewhat precipitous return is that H's father had promised to have him
over Easter but had gone away: later both parents felt that this had
caused H to be lonely over the Easter period.
The killing is best described as a virtually motiveless attack on a
78 year-old lady by stabbing. Owing to the near inability of the prisoner
to tell an accurate, connected or consistent story, one cannot be certain
of the exact sequence of events, but a likely reconstruction is that he was
lodging with the victim; that he went out of the house with a knife and
cut the lead from the outside television antenna to the sets in the house
(he says, "I don't know" why); he then knocked on both her front door
and window, and when admitted, asked if her television set was working
properly; when the landlady answered "no" he offered to do something
about it and the offer was accepted; on leaving the landlady's flat he stated,
"I sort of tripped on my heel and pushed her and she fell down," after
which he stabbed her — "I don't know why I did it". After this he ran
away and caught a train to Werribee (some 30 miles away) where he
visited an aunt and found his mother there. He remained the night return¬
ing to his room on Easter Monday at about mid-day. Some 12 hours later
(12.50 a.m. on the Tuesday) he telephoned the police having earlier broken
some glass beside the landlady's front door in order to get in and turn
her TV set either down or off. When the police wireless patrol arrived he
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told them a story of having heard a burglar breaking glass and running
away. The police reassured him and promised to return later. When they
did return they found the body of the old lady. H initially persisted in his
story (with variations) of a burglar but then suddenly broke down and
admitted the killing.
Examinations in Custody: H was first seen in H.M. Prison Pentridge
on 4th April, 1967, when it was known that he was accused of the murder
of his landlady. It was immediately apparent that he was intellectually
very dull and only able to give a very poor account of his background in
general and the events surrounding the killing. Subsequent examinations
made it clear that he had little idea regarding what he was alleged to have
done and even less idea or understanding of what was involved in a trial.
As a result he was tested by the psychologist (Mr. E. Plumridge) who
reported:
Intellectual Assessment: The W.A.I.S.
Verbal I.Q. = 65
Performance I.Q. 83 Full Scale I.Q. = 71
The full scale score and the quality of test responses is consistent
overall with borderline defective intelligence.
Rorschach: There were but eight scoreable responses of the simple usual
kind. The responses as such were reality based. The formal quality
of responses were consistent with below average intelligence.
The clinical impression plus the formal testing led to the Crown being in¬
formed in July 1967 that H was considered "On a very fine balance of
probabilities ... to have been legally responsible for his actions at the
time of the alleged offence" and that "he is also a borderline case regarding
'fitness to plead' ". He appeared in the Supreme Court in July 1967 when
the issue of fitness to plead was raised (vide infra). He was found unfit
to plead and was returned to H.M. Prison Pentridge.
On his return to the prison he became involved in a karyotype survey
and was thus found to have a chromosome constitution of 47,XYY. This
lead to an investigation of the karyotypes of the father and twin brother.
Cytogenetics: Blood for chromosome studies was collected by vene¬
puncture (15 ml in a heparinized syringe) and transported to the labora¬
tory. About 4-5 hours elapsed before the leucocytes were separated for
culture. The leucocytes were added to a tissue culture medium of T199
with 20% foetal calf serum at a concentration of 7 x 105 per 1 ml of medium.
The cultures were harvested according to the method of Moorhead et al.5
and stained with Giemsa.
Results: The chromosome counts of the prisoner, his twin brother and
the father are shown in Table 1 on the next page. The karyotype of the
prisoner was 47,XYY (See Figure 1, also on the next page). Both the non-
identical twin and the father had the normal male karyotype of 46,XY.
5. Moorhouse, P.S., Nowell, P.C., Mellman, W.J., Battips, D.M., and Hungerford, D.A. (1960)
"Chromosome Preparations of Leucocytes Cultured from Human Peripheral Blood" Exp.Cell
Res. 20, 613.
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TABLE 1. Chromosome Counts of Prisoner, Twin Brother and Father.
Subject 46 47 Total
Prisoner (H) 1 19 20
Twin brother 20 — 20
Father 20 — 20
FIGURE 1. Karyotype showing the extra Y chromosome.
Electro-encephalographic Investigation-. This was carried out for two
reasons. The first was as a routine investigation, particularly in those
found to have chromosomal abnormalities. The second reason was that
when the prisoner was first seen he had some historical evidence of periodic
clouding of consciousness and since then he has clearly had episodes of
motiveless aggressive outbursts with no later recollection.
The report on the electro-encephalographic recording concluded with
the comment:
The record is abnormal in the presence of the background slow
activity and the somewhat more marked slow activity in the right
temporal region. This is consistent with a diagnosis of mental deficiency,
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although it is unusual to find abnormal records other than with the
most severe types of deficiency. The focal slow activity suggests that
certainly one temporal region is likely to be malfunctioning. Whether
this is an epileptic type of disorder must be a clinical decision and
the record offers no evidence to help make this (Report by Dr. N.
Gordon).
It was concluded finally, on clinical grounds, that H did suffer from
a temporal lobe epilepsy and that he might very well have suffered from
such a "fit" at the time he stabbed the old lady.
As a result of these further investigations it was reported to the
Crown that the earlier opinion (vide supra) had been modified so that it
was now thought the prisoner was "on a very fine balance" legally ir¬
responsible at the time of the alleged offence. It was also indicated that a
trial might well take place although his "fitness to plead" might well
change on the day of a trial due to the increase in stress.
Physical Findings: Physical examination demonstrated no significant
abnormalities. His genitalia were quite normal, he had no acne and had no
old scarring from acne. Some physical measurements were recorded and
these have been reported elsewhere6.
The Court Hearings
On the 28th July, 1967, H appeared in the Supreme Court of Victoria,
in Melbourne (Starke J.), and the preliminary issue of the fitness of the
prisoner to plead and to stand his trial was raised pursuant to the provisions
of Section 393 of the Crimes Act, [1958], The defence did not contest the
Crown's case that the prisoner was unfit to plead and the basis of that
case was the evidence of a psychiatrist that H was a mental defective
(verbal I.Q. on the WAIS being 65) and that he satisfied the criteria of
"unfitness" as set out in R v Presser, [1958] V.R. 45. H was found unfit to
plead and thus insane within the meaning of Section 393 and was there¬
fore ordered by the court to be kept in strict custody until the Governor's
pleasure be known.
H was returned to H.M.Prison Pentridge and remained there until he
was again presented before the Supreme Court in Melbourne (Monahan J.)
on the 8th October, 1968. On this occasion the issue of fitness to plead
was not canvassed before a jury but both counsel assured the trial judge
that they were both satisfied that the accused man was, at that time, fit
to plead and stand his trial.
As the defence raised was one of insanity, counsel for the accused
made a number of admissions on behalf of his client and the Crown case
was further expedited by reason of little or no cross-examination of the
Crown witnesses. The Crown case closed at about 4 p.m. on the first day
and counsel for the defence then indicated that the accused would stand
mute and a psychiatrist called as the only witness.
During the few remaining minutes of the first day the psychiatrist
was qualified and he indicated to the court the various matters taken into
consideration and relied upon in forming his conclusions concerning the
psychiatric status of the accused and his responsibility at the time of the
6. Wiener, S., Sutherland, G., Bartholomew, A.A., and Hudson, B. (1968) "XYY Males in a
Melbourne Prison" Lancet i 150.
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alleged offence. At this stage it was given in evidence that electro-
encephalographic examination revealed an abnormal recording with a
particular focus in the right temporal lobe — a focal abnormality describ¬
ed as an epileptic focus. It was also stated at this time that a "blood test"
was done which revealed an abnormal chromosome constitution, 47,XYY
rather than the normal 46,XY, a chromosome constitution which would
be found in every cell in his body7 including the brain. At this point the
court adjourned until the following day. And at this same point the medical
evidence had not been other than descriptive. There had been no attempt
to relate the electro-encephalogram and the chromosome abnormality to
the matter of responsibility at the time of the alleged offence.
The following morning H was again examined prior to his being placed
in the dock, and the view was expressed that it was doubtful whether he
was any longer fit to stand his trial. In the event, the psychiatrist, who was
continuing his evidence, was asked a question about the intelligence of the
accused. Then the following question was asked and answered:
Q. These three matters, that is, the E.E.G., the blood test and the
general intelligence level, taken together with the general history
that you have been able to gather, have you come to some conclusion
in respect of the condition of this accused so far as the legal definition
of insanity is concerned?
A. Yes. I consider now that at the time of the alleged offence he was
suffering from a mental disease or disorder productive of a defective
reason, such that I am sure he did not know that what he was doing
was wrong, or at least he could not argue about the wrongness of his
act with a reasonable degree of composure.
A further four short questions followed by three general questions in cross-
examination ended the medical evidence.
The prosecutor then, in the absence of the jury, indicated to the trial
judge that there was doubt about the capacity of the prisoner being fit to
continue standing his trial after the first five or ten minutes of the day's
hearing. The prosecutor put the matter thus:
it was thought advisable just to conclude sufficient evidence to found
a decision on the lines that both the Crown and the defence desire
and then to draw this matter to Your Honor's attention in case Your
Honor felt you should investigate this to see whether the trial should
continue . . . What we had in mind, Your Honor, is that, having in
the first five minutes got the doctor's opinion, perhaps Your Honor
might see fit to ask the jury if they want to hear any more.
The trial judge was favourably disposed to this view and remarked
I will do that, but I should have to give them (the jury) a sort of
abbreviated charge, wouldn't I? I would have to warn them that I
can only receive one verdict, for instance.
Whilst the trial judge considered that there was merit in the suggestion
put to him he, in turn, made the suggestion that before he gave his ab¬
breviated charge, the medical witness should be recalled and give evidence
7. It is recognised that the cells in the testes that have undergone reduction division will not
contain 47.XYY but the comment was made in general terms.
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of his opinion given at the earlier hearing in July 1967 regarding H's un¬
fitness to plead. This was done and the judge then charged the jury.
The charge took the form of explaining the problem of H being possibly
unable to continue standing his trial. The judge then said:
in your absence, the learned prosecutor has suggested to me — and
I think it is a proper suggestion that he has made — that I might
consult you in regard to this matter and ask you whether you think
you could reach a verdict at this stage without further ado. Now the
only verdict that I could receive in this case at this stage would be one
of not guilty. It is inconceivable that I could receive a verdict of guilty
without the case proceeding right to the bitter end. It is equally in¬
conceivable that in this case I could receive a verdict of not guilty
simpliciter, that is, that the prisoner should be allowed to go free,
having regard to the evidence that you have heard . . . Now if you felt
at this stage that you had heard enough to enable you to make up
your minds that this man committed the act that caused this woman's
death, but that he was not criminally responsible for that act because
at the time that he did the act he was suffering from such a defect or
disorder or disturbance of his mind due to a mental disease as to be
unable fully to appreciate the nature and quality of the act that he
did, or that he was unable, for that same reason, to appreciate the
wrongness of what he was doing, then you may say, at this stage, that
you are satisfied he is not guilty of murder because he was insane at
the time of the act that is relied upon by the Crown in presenting him
here on a charge of murder.
The judge went on to speak of the notion of insanity in the criminal law,
and continued his charge:
you have heard . . . today that this man is just a borderline mental
defective. His intelligence quotient is far, far below the average mini¬
mum that is regarded as normal. He is less than normal mentally in
regard to his intelligence and the doctor has further expressed the
opinion that at the time this man — if he did this act, and I do not
suppose you have any doubt that he did do it — this man at the time
that he did this act was not capable of reasoning with some degree of
calmness and composure to consider the Tightness or wrongness of
the act that he was about to do or perform.
The charge ended with the statement that if a jury should find an accused
not guilty on the ground of insanity then Section 420 of the Crimes Act,
1958, provides for such a person to be kept in strict custody until the
Governor's pleasure is known.
Discussion
Two matters are of interest in this case. Firstly, there is the matter of
the prisoner being a further example of a male with the karyotype 47,XYY.
Secondly there is the importance, or lack of importance, of the 47,XYY
karyotype in a criminal trial where the defence of insanity is raised.
As far as the social and medical background of this prisoner is concern¬
ed one may only say that he was from the first a mentally retarded in¬
dividual and that he was always a problem including a history of one
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prior conviction, as an adult, for loitering for homosexual purposes. His
only skin lesion has been that of sclerema neonatorum and he has no
history of acne. One may also note that he is not an alcoholic, or even a
problem drinker. Another feature of interest is that he is not unduly tall
being only 5' 10" (178cms). In other words, of the triad of features commonly
associated with the 47,XYY syndrome H is mentally dull but not particu¬
larly tall and with little, from the historical point of view, that may be
termed "criminal propensity".
As has been recorded, H has a twin brother who has a normal male
karyotype, 46,XY. This karyotype finding only confirms clinical impression;
the two twin brothers look different and behave differently, the other
twin being of average intelligence.
When one turns to the criminal law and the defence of insanity, and
particularly in regard to the trial of H, the first matter to note was the
abrupt ending of the trial. This sudden termination of the case meant, as
has been indicated, that the medical evidence was not fully presented and
not evaluated through the agency of cross-examination. Indeed, the
psychiatric evidence, lasting in all perhaps 20 minutes, was little more
than a statement of three findings and an assertion of legal insanity, and
thus non-responsibility, at the time of the alleged offence. The three find¬
ings, mental deficiency, an abnormal electro-encephalogram and the karyo¬
type were described with equal emphasis and only the aspect of mental
deficiency was indicated clearly as reducing understanding and thus per¬
haps produce a state of legal non-responsibility. Although the electro¬
encephalographs record was described as abnormal with a temporal lobe
focus, no evidence was given that at the time of the alleged offence the
prisoner very possibly suffered from some epileptic episode. Similarly, al¬
though the chromosome constitution was described as abnormal no
evidence was given as to any possible significance. Again, because of the
swift end to the trial, there was no detailed charge by the judge to the
jury, and the only clinical feature the judge commented upon was the
mental deficiency. This part of the charge has already been quoted. There
was not one word about the electro-encephalogram or the chromosomes.
It is for reasons such as these that one may not contend that the
verdict was based on the "extra Y chromosome". One may not even say that
the "extra Y chromosome" played any part at all in the verdict. It is, in
fact, quite possible that the jury would have returned the same verdict on
the basis of his mental deficiency alone, his abnormal electro-encephalo-
graph and his epilepsy alone, or both, without there being any mention
of his genetic make up.
Quite apart from this particular case and trial, it must be recognized
that the karyotype 47,XYY is a recent finding and is still a rare finding.
Fox7a writes that the first case was reported in 1961 and that there are
still less than a 100 reported cases. Then again, it is very difficult to
evaluate our present findings for, as Court Brown et al have written,8
the bulk of our information on XYYs is based on the examination of
adults found from the surveying of groups of men which by definition
consists of men the great majority of whom, if not all, have criminal
7a. Fox, R.G. (1969) "XYY Chromosomes and Crime" Aust.N.Z.J.Criminol. 2, I, 5.
8. Court Brown, W.M., Price, W.H., and Jacobs, P.A. (1968) "The XYY Male" Brit.med.J. iv 513
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records. The second feature is our lack of knowledge of the incidence
of XYY males at birth or in the general adult population of men.
Whilst it may be that the possession of the extra Y chromosome does lead
to a greater likelihood of developing a psychopathic personality and be¬
coming involved with anti-social behaviour there is, nevertheless, no reason
to suppose that the extra Y chromosome must inevitably lead to such a
result. At least two cases have been described recently of "normal" males
with the XYY constitution, one a mosaic. Court Brown et al9 has described
a case, a mosaic 45,X/47, XYY, or possibly 45,X/47, XYY/46XY, synoptically
as follows:
Normal schooling, leaving at 15 years. Worked as errand boy, then
apprentice electrician, and now as trained electrician. No behavioural
disturbances. Tends to faint easily. E.E.G. normal. Married with two
normal sons both having a 46,XY chromosome complement. Average
intelligence.
As the authors comment, such a case raises the general question of "to
what extent the presence of a second (and maybe a third) cell line may
modify the effects of a 47,XYY line.
In Melbourne, Wiener and Sutherland10 have given a description of
a further "normal" 47,XYY male: a local 41-year-old, single, hospital
worker; always considered a placid obedient child; rheumatic fever and
poliomyelitis as a child which interfered with schooling; joined army in
1948 and honourably discharged 18 months later; various semi-skilled
labouring; never in conflict with law; teetotal; exceptionally fond of his
parents with whom he lives; 182cms. tall; non-specific E.E.G. abnormali¬
ties IQ 97 on both verbal and performance tests.
As Court Brown et aln have written in regard to behaviour and XYY
sex chromosomes
our own experience in Edinburgh suggests a spectrum of behaviour
ranging from the apparently normal through those with a mild
personality defect to those who are severe psychopaths.
If this be a fair comment, and there is no reason to doubt that it is, then
an extra Y chromosome cannot, in our present state of knowledge, be
accepted as a basis for legal insanity leading to a lack of criminal responsi¬
bility. The best that may be said at this time is that
Studies showing the incidence of chromosome abnormalities among
offenders and the mentally ill may provide supporting evidence of the
likelihood of mental abnormality in the case of an individual who has
a chromosome abnormality12.
The important word here is "supporting"; but the test for insanity remains
a cognitive test and is most certainly not concerned with various aetiolo-
gical matters. High blood pressure and cerebral arteriosclerosis may produce
a mental state satisfying the requirements of the law on insanity (See
R v Kemp (1956) 40 C.A.R. 121) but an increased blood pressure or arterial
disease per se is not sufficient. So also is the case with a chromosomal
abnormality.
9. Court Brown, W.M., Price, W.H., and Jacobs, P.A. (1968) "Further Information on the
Identity of 47,XYY males" Brit.med.J. ii 325.
10. Wiener, S., and Sutherland, G. (1968) "A Normal XYY Man" Lancet ii 1352.
11. Court Brown, W.M., Price, W.H, and Jacobs, P.A. (1968) "The XYY Male Brit.med.J. iv 513.
12. "Medico-Legal" (1968) "Abnormal Chromosome" Brit.med.J. iv 398.
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ALCOHOLISM, DRUG DEPENDENCY AND SEX CHROMOSOME
ABNORMALITIES1
Allen A. Bartholomew, m.b., b.s., d.p.m., and G. Sutherland, b.sc.
Department of Mental Health, Victoria
A selected sample of 143 prisoners was
investigated for the presence of sex chromosome
abnormalities. The incidence of abnormal sex
chromosome findings in this criminal population
was very low, and any such abnormalities are simply
interesting findings. However, there is likely to
be an increased incidence of sex chromosome
abnormalities in a population of alcoholics.
The finding of a 47.XYY karyotype in a well-known
criminal, Tait (Wiener et alii, 1968; Wiener et alii, 1969),
and in the highly publicized case of Hannell (Wiener
et alii, 1968; Bartholomew and Sutherland, 1969), as well
as in two further cases of less notoriety (Wiener et alii,
1968), led to the notion that, whilst perhaps tallness and
a degree of mental retardation might be correlates of
the 47.XYY chromosome constitution, the most meaningful
correlation might be that of psychopathic personality
(Bartholomew, 1968a).
If such a proposition be accepted then it is clearly
worthwhile looking at a population of "alcoholics" and
"drug-dependent" individuals (Bartholomew, 19686). Such
persons are not infrequently diagnosed as "psychopaths"
and they often have a long history of behaviour disorder
that has not responded to a variety of treatment techniques;
indeed their abuse of alcohol and/or drugs may date
back many years. This comment may not be true of
all "alcoholics" but would seem to be true of very many
who are seen in a prison setting. Apart from these
theoretical considerations it is of interest that Nielsen
(1968) describes three patients with 47,XYY chromosome
constitutions found in a "state hospital and a forensic
psychiatric ward" who were above 180 cm (about 5 ft 11 in.)
tall. All three patients might well be termed "psychopathic",
all had a full scale IQ of between 92 and 100 and, in
addition, all three had "an alcoholic problem". On the
other hand, in the review of the XYY problem by Price
and Whatmore (1967), it is apparent that of their nine
subjects, eight had IQs of between 60 and 80 and, due
to their early hospitalization, did not have a chance of
demonstrating alcoholism or drug dependence; the mean
age of their admission to the State hospital was 20 years
and the mean age of their first committal to a hospital
was 15 years. In a survey of a further 15 males who
had either a 47,XYY complement or were mosaics in
whom this cell line predominated (Court Brown et alii,
1968a), only one of a total of 10 patients aged over
20 years (a 46,XY/47,XYY) had any note regarding
alcoholism.
1 Read at the Fourth Summer School of Alcohol Studies held
at St Vincent's Hospital, Melbourne, January 30, 1969.
The problem of the sex chromosomes and alcoholism
should not be restricted to the 47,XYY constitution.
Nielsen (1964) found four cases of delinquency and
three of severe alcoholism in ten cases of. Klinefelter's
syndrome in a mental hospital in Sweden, whilst Hunter
(1968) found two cases of alcoholism in 17 cases of 47,XXY.
Fox (1969) possibly puts the matter fairly when he writes:
There have been some strong suggestions that this
defect (47,XXY) is linked with anti-social behaviour,
especially alcoholism and homosexuality, but as yet
few findings of significance have been reported.
Apart from the interest in the relationship between
the sex chromosomes and alcoholism, the opportunity of
carrying out this investigation in a prison setting is
additionally worthwhile when one recalls the extraordinary
claim of Mackay (1967), namely, that "studies have
indicated that approximately 50% of tall (over 6 ft) males
with criminal tendencies have the XYY constitution".
METHOD
All that need be said under this heading is that our
sample of 143 prisoners is in no way random as regards
the prison population. Initially we began looking for
subjects who were tall and preferably of dull intelligence.
Gradually we thought of a possible correlation between
XYY and psychopathy and, later, with our interest in
alcoholism and drug abuse (dependency), included
alcoholics and those convicted and imprisoned for
drunkenness and disorderliness.
The technique adopted for karyotyping was as follows:
blood was collected by venepuncture (15 ml in a heparinized
syringe) and transported to the laboratory. About 4 to
5 hours elapsed before the leucocytes were separated for
culture. The leucocytes were added to a tissue culture
medium of T199 with 20% foetal calf serum at a concen¬
tration of 7 x 10" per millilitre of medium. The cultures
were harvested according to the method of Moorhead
et alii (1960).
RESULTS
In all, 143 prisoners were karyotyped and eight (5-6%)
were recognized as having sex chromosome abnormalities.
Of these, four were XYY, one was XYY plus an autosomal
abnormality (Wiener et alii, 1969), two were XXY, and
one was XXY/XY mosaic. Data relating to these eight
cases are presented in Table 1.
These cases may be considered as five XYY (3-5%)
and three XXY (2%) constitutions in a total of 143
subjects. The figure of 3-5% for XYY patients is very
similar to the incidence found by Price and Whatmore
August 30, 1969 THE MEDICAL JOURNAL OF AUSTRALIA 441
Table l
Data of Eight Cases Demonstrating Sex Chromosome Abnormalities
12345678
Genotype XYY> XYY XYY
Age (years) (on 1.1.69) .... 45 22 34
Height (inches) .. 70 70 82 • 5
Offence (" present") .. .. Murder Murder® Attempted
murder
IQ (full-scale WAIS) .... 94 71 101
Previous imprisonment .. Several None Very many
Maudsley personality inventory
(extraversion/neuroticism) . . 21/12 18/10 22/6


















































1 Plus a further autosomal abnormality.
1 Found " not guilty on the grounds of insanity
8 An unreliable figure ; the prisoner tested quite differently at different times.
(1967) ill Carstairs, but it must be appreciated that
while some of our 143 men were selected in terms
of height, none of them were considered suitable for
transfer to an institution for the mentally defective or
mentally ill.
Because of our interest in alcoholism, we divided the
population of 143 into two groups: (i) non-alcoholics
(including non-drug takers), of which there were 47,
and (ii) alcoholics (including drug takers), of which
there were 96. The alcoholics we further divided into:
(i) those sentenced for being "drunk and disorderly"
(36 cases), and (ii) "serious offenders" considered as
alcoholic (60 cases) (see Bartholomew, 1968c).
Non-Alcoholics
Among the 47 subjects considered as non-alcoholic (and
non-drug abusers) there were three with sex chromosome
abnormalities, and in each case the karyotype was 47,XYY
(see Table 1). We say no more about this group.
Alcoholics
The "Drunk and Disorderly"
There were 36 cases in this group. The mean age
was 46 years (range, 23 to 72 years) and the mean
number of previous imprisonments was 46. The distribution
in terms of height was as follows: nine were under 70 in.,
20 were between 70 and 72 in. and seven had a height
in excess of 6 ft. The problem of assessing the IQ in
such a group is considerable and, although Raven's
Matrices were used, only 20 in the group either could,
or would, attempt the test, and only nine finished it.
It is thought that at least two-thirds of the group had
an IQ of between 90 and 110, or had had such an
intelligence before their deterioration through drink and
general neglect. No men in this group admitted taking
any drugs other than ethyl alcohol and methylated spirits.
The psychiatric diagnoses of these men would be various
but it is likely that the majority would be classed as
"psychopaths" or "inadequate personalities". This was
the diagnosis given for 17 of the men whose hospital
records were available.
There was not one case of sex chromosome abnormality
in this group.
The "Serious Offender" Alcoholic
In this group of 60 there were five patients with sex
chromosome abnormalities (8-3%). It was thought worth¬
while dividing the 60 prisoners into three subgroups:
(i) alcoholics simpliciter (42 cases), (ii) alcoholics also
taking, or having taken, drugs (14 cases), and (iii) those
who were drug dependent, taking little or no alcohol
(4 cases).
Alcoholics Simpliciter.—This subgroup of 42 patients had
a mean age of 29 years, with a range of 17 to 53 years.
Previous imprisonments averaged approximately eight per
Figure 1: Distribution of the "serious offenders" con¬
sidered as alcoholics simpliciter in terms of IQ, and
of the five subjects with sex chromosome abnormalities.
Number of cases : 14
XXY
IQ <90 90 to 110 >110
1 This prisoner was considered a " manipulator " and his various IQ test
results unreliable. His IQ was variously assessed as between 65 and 100 in
different hospitals and at different times.
man and many of the prisoners appeared to have evidence
of officially recognized delinquency in their childhood.
The IQ ranged from about 65 to 115, with a mean value
of 93. The distribution of the subgroup in terms of the. IQ
is shown in Figure 1, which also indicates the position
of the five cases in which there was sex chromosome
abnormality. The distribution of the subgroup in relation
to height is shown in Figure 2. It is worth noting that
of the 13 prisoners whose height was in excess of 6 ft,
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eight had an IQ of less than 90: in other words, they
might well have been thought to be likely to possess the
additional Y chromosome.
Alcoholics who were Also Drug Abusers.—For con¬
venience we have considered the 14 alcoholic prisoners
who were taking or had taken other drugs with the
very small group of four prisoners who were drug
dependent (and who frowned upon the taking of alcohol).
In this group of 18 there were no cases of sex chromosome
abnormality.
Figure 2: Distribution of the "serious offenders" con¬
sidered as alcoholics simpliciter in terms of height, and
of the five subjects with sex chromosome abnormalities.




<6 ft 10 in. 5 ft 10 in. to >6 ft 0 in.
6 ft 0 in.
These 18 prisoners were nearly identical with the
alcoholics simpliciter in terms of age distribution, previous
imprisonments, height and intelligence. They were, how¬
ever, distinguished to some extent by a greater "degree" or
severity of psychopathy, by greater social disorganization,
more mental hospital admissions, more suicide attempts
and, of course, by the taking of drugs.
It is difficult to assess histories relating to the taking
of drugs, and one is aware that some of the stories may
be considerably exaggerated or even invented. All 18
prisoners who alleged they took drugs claimed that they
had smoked "pot", often regularly and over a reasonably
long period of time. Five of the 14 alcohol-drug takers
and all four pure drug takers claimed to have taken
"trips" with LSD, six of them more than twice and four
of them in excess of three times. Two of these individuals
also claimed to have been treated by psychiatrists with LSD
or equivalent drugs. Twelve of the prisoners, including
the four pure drug takers, claimed to have taken, on
occasions, morphine, heroin and cocaine. All 18 claimed
to have taken both barbiturates and amphetamines over
a long period of time and in considerable quantities. These
drugs were taken either by mouth or by intravenous
injection.
All four of the pure drug takers were of dull average
intelligence, all were between 5 ft 10 in. and 6 ft tall, all
had a number of previous imprisonments, all had had a
disturbed childhood (two were expelled from school), and
three were, considered homosexual, one of these being a
homosexual prostitute.
DISCUSSION
It has to be admitted that this paper presents negative
findings, in that the incidence of abnormal sex chromosome
findings in a criminal population is not great; indeed,
it is very small. Our figure for the incidence of such
abnormalities in a prison population is in the vicinity
of 5%, with a slightly higher figure in the case of
"alcoholics" who are "serious offenders". It should be
noted that among our "serious offenders" there were 13
whose height was in excess of 6 ft, so that if Mackay
(1967) was correct in his comment we should have found
at least six cases of 47.XYY which would, alone, give
a 10% incidence of sex chromosome abnormalities. In
fact, the two patients with 47.XYY constitution were both
under 6 ft in height. Thus the. comment of Mackay is
not supported by these findings.
A matter which should be stressed is that the extra
Y chromosome has been given great publicity in relation
to criminal behaviour, and psychopathy in general. How¬
ever, the findings presented here do suggest that the
extra X (Klinefelter's syndrome) is to be considered just
as carefully as the extra Y chromosome. Our results
support the comment of Court Brown et alii (19686)
when they wrote:
To call an extra Y chromosome the "criminal"
chromosome as has been done by the popular news
media seems odd, when no such notoriety is accorded
the extra X chromosome in XXY males, for there are
reasons to believe that they also incur some added risk
of behavioural disturbances.
On the other hand it should be recorded that in some 170
consecutive male alcoholics investigated in the alcoholism
out-patient clinic at St Vincent's Hospital, Melbourne, not
one chromatin-positive patient was found (Garson, 1969).
Another feature of interest in our results is that the
five prisoners found to be XYY were by no means, as
a group, the most severe psychopaths that one sees
in a forensic psychiatric practice. Further, as has been
shown (Table 1), the four prisoners able to do the test
tended to score quite highly on extraversion and low
on neuroticism as assessed on the Maudsley Personality
Inventory (Bartholomew, 1963).
This very preliminary piece of research indicates that
sex chromosome abnormalities cannot be seen as anything
very much more than interesting findings in this population
and that such abnormalities may correlate with personality
difficulties and behaviour disorders, but cannot be seen as
being a causal factor in either criminality or alcoholism,
including drug dependency. One needs to remember the
cases now being described of "normal" men who have a
47,XYY constitution or a 47,XYY mosaic (Wiener and
Sutherland, 1968; Court Brown et alii, 1968a). However,
there would seem little doubt that there is likely to be
an increased incidence of sex chromosome abnormalities
in a population of alcoholics. If the present estimates
of an incidence in the general male population of 0-2%
for the. 47,XXY constitution and less than 0-2.% for the
XYY karyotype are accepted, then incidence figures in
a deviant population are likely to be greater, perhaps
especially in those with a low and low average intelligence.
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ADDENDUM
Since the original paper was written, a further 21 males
have been karyotyped and this has resulted in the
identification of a prisoner with a 47,XXY karyotype and,
a prisoner with 47.XYY karyotype. The XXY individual
is a male aged 31 years, and 69 in. tall. He was convicted
of arson, has a full-scale Wechsler's adult intelligence
scale (WAIS) rating of 95, has one previous conviction
(for buggery), and is considered to be an alcoholic. The
XYY individual is a youth aged 17 years who is 71 in. tall,
was convicted of buggery, has a full-scale WAIS rating
of 85, has no previous convictions, and is not considered
to he an alcoholic or drug-dependent person. He is
considered to be a confirmed homosexual and was earlier
diagnosed as a schizophrenic who was successfully treated.
This second patient has been under the care, of Dr L. Chatz,
whom we thank for the information made available to us.
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Chromosome Survey in a Security
Ward: Total Ascertainment
G. SUTHERLAND* and ALLEN A. BARTHOLOMEW**
THE notion of the increased incidence of the additional Y chromosome in a
population of antisocial individuals, particularly amongst those who tend
to be tall and dull, is becoming generally accepted. To these features might
be added the diagnosis of psychopathic personality (Bartholomew, 1968).
However, whilst the number of case reports of XYY individuals is increasing,
there are few reported surveys of total ward or hospital populations. Price
and Whatmore (1967) found two cases of XYY in the population of 119
in the West Wing of the Carstairs Security Hospital which was composed of
mentally ill patients who "exhibited dangerous, violent or criminal pro¬
pensities".
We have recently carried out a karyotype survey in the maximum
security ward for the male mentally ill (including some who are mentally
retarded) in the State of Victoria. The ward is attached to a general mental
hospital (Aradale). The ward accommodates 50 patients; during the time
of the study 55 patients were investigated.
Method
The technique of karyotyping has been described elsewhere (Wiener
et al., 1969).
Results
Karyotype: Three abnormal karyotypes were detected. Two were 47,
XYY and the third was 46,XY, 16q+.
The Population: This had a mean age of 36.2 years (range 19-60 years)
and a mean duration of intermittent or continuous mental hospitalization
of 17 years (range 1-34 years). The patients were held under a number of
different sections of the Mental Health Act, 1959; the majority (51) being
"certified" under some section of the Act.
Diagnosis: On the basis of a study of the clinical records we have cate¬
gorised the population under three headings:
Schizophrenic 41
Psychopathic Personality 11
Chronic Brain Syndrome and Epilepsy 3
A number of patients in all groups were considered to be "mildly mentally
retarded" but this was only a clinical impression.
* B.Sc., Geneticist, St. Nicholas Hospital, Melbourne.
** M.B., B.S., D.P.M., M.A.N.Z.C.P., Psychiatrist Superintendent, H.M. Prison, Pentridge,
Melbourne.
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Height: The height distribution of this population is shown in Figure 1.






Mean height = 68.14 inches (S.D. 3.81 inches).
Clinical Features: These, as they relate to the two cases of 47, XYY,
are set out in Table 1.
TABLE 1. Clinical information concerning the two patients with the 47,XYY karyotype.
A B
Age 25 years 42 years
Height 78 inches 78 inches
Intelligence WAIS (F.S.) 88 "Dull"
Diagnosis Schizophrenic Psychopath and borderline defective
Age of first hospitalization 14 years 31 years
Age started present hospitalization 21 years 34 years
Previous criminal record None A number of property offences
Discussion
The incidence of two cases of 47,XYY in a population of 55 patients
is larger than that found by Price and Whatmore (1967) in their West Wing.
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However, it is difficult, if not impossble, to compare such institutions. In
Victoria, for example, men found not guilty on the grounds of insanity or
found unfit to plead are not automatically sent to security hospital wards
(Bartholomew and Sutherland, 1969a), wards where there is also no clear
separation between "mentally subnormal patients" and those suffering
from "mental illness".
Although family studies were not possible, the aberrant chromosome
in the patient with 46,XY, 16q-(- was considered to be a normal variant
(Court Brown et al., 1966); the patient was 68 inches tall and diagnosed as
suffering from schizophrenia.
Our results support the correlation between the extra Y chromosome
and height but any correlation with psychopathy cannot be deduced due
to the small sample size.
It is of interest that no case of 47,XXY was found in this study as in
a karyotype survey of prisoners we found four such cases in 164 prisoners
(Bartholomew and Sutherland, 1969b).
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The incidence of chromosome abnormalities in the population is discussed with
emphasis on current work being done on the screening of newborn babies. Sampling tech¬
niques and sample size are discussed. Findings from surveys so far available are sum¬
marized and some of their possible implications regarding the Australian population are
considered.
Since the associations between chromosomal
abnormality and clinical syndromes of mal-
development were first described in 1959
(Lejeune et al., Jacobs and Strong., Ford et
al., Jacobs et al.) there has been increasing
interest in the epidemiology of all the chromo¬
some abnormalities in both institutional and
the general populations. With the knowledge
that chromosomal and developmental abnor¬
malities need not be causally related (Carr,
1963, Pitt et al., 1964) it has become increas¬
ingly desirable for data on the incidence of
chromosomal abnormalities in the population
at birth to be obtained. This data is essential
to determine the significance of chromosome
abnormalities detected in individuals and for
comparison with the frequency of such abnor¬
malities as may be found in highly selected
groups.
TECHNIQUES
There are three main techniques which may
be used for the detection of individuals with
chromosome abnormalities. Each has its ad¬
vantages and limitations.
1. Recognition of a clinical syndrome which
results directly from a chromosome abnor¬
mality. This is very useful for the well defined
syndromes such as the autosomal trisomies,
since very large numbers at risk can be sur¬
veyed by routine clinical examination; doubt¬
ful and atypical cases may however be missed.
Hence any estimates of frequency from this
approach will always be minimum estimates.
The rare and more obscure syndromes will
probably not be diagnosed in the neonatal
period.
2. Sex chromatin studies can identify most
cases involving numerical abnormalities of the
X chromosome, and much less reliably, some
structural abnormalities. Sex chromatin de¬
termination can be performed relatively easily
on the buccal mucosal cells, or, if done at
birth, on amniotic membrane cells (Mikamo,
1968). A serious limitation of this technique
is that most cases of mosaicism will be missed;
this is especially so since the incidence of
mosaicism in Turner's Syndrome is probably
higher than in any other chromosome disorder
(Hecht and MacFarlane, 1969). The recently
reported technique for identifying the Y chro¬
mosome in interphase nuclei (Pearson et al.,
1970) may enable large populations to be
screened for Y chromosome abnormalities
using buccal mucosal or amniotic membrane
cell methods. The sensitivity and reliability of
this technique must await further study.
3. Chromosome analysis. This is the only
technique capable of detecting all chromo¬
some abnormalities. However, full chromo¬
some analysis is an expensive and time con¬
suming procedure, involving the microscopy of
about 30 cells per case with photographic
analysis of a few of these cells and the pre¬
paration of a karyotype. Even then a few cases
of mosaicism with small numbers of non-modal
cells will be missed. In a survey of selected
newborns, Walzer et al. (1969) showed that
this technique can be abbreviated to the study
of only two cells with very little loss of sen-
Received 10th July, 1970.
1. (Mr.) Cytogeneticist, Chromosome Laboratory, St. Nicholas
Hospital, Carlton South, Victoria, Australia, 3053.
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TABLE 1
Frequency of Sex Chromatin Anomalies in Neonates
(Court Brown, 1968)
Anomaly Incidence
Chromatin positive males 1.7/1000 males
Chromatin negative females .3/1000 females
Doubly chromatin positive females 1.1/1000 females
sitivity of the method. Most, if not all mosaics
would escape detection using this method, but
it is the best technique available for screening
work, and will probably remain so until com¬
puter analysis is fully developed and a full
chromosome analysis can be performed on
each case.
PROGRESS
From clinical recognition of a syndrome,
much data is available for the most common
autosomal abnormality, mongolism, 47,21+2
As early as 1933, before the chromosomal
basis of this syndrome was confirmed, Jenkins
estimated its frequency as 1 in 636. This
differs little from the incidence of 1 in 688
which was found by (Tollman & Stolier (1962)
in a survey of all live births in Victoria from
1942 until 1957. This is the most compre¬
hensive study yet published, and by far the
most reliable estimate, since the number at
risk was 780,168, from which 1134 mongols
were ascertained. The frequencies of Ed¬
wards' (47,E+) and Patau's (47,D+) syn¬
dromes have been estimated by Taylor (1968)
2. Chromosome complements are expressed the Chicago
notation (Chicago Conference, 1966). However when
both sexes are involved the sex chromosome complement
is omitted, e.g.. for mongols of both sexes 47.21+ rather
than 47,XX (or XY),21 + . In some cases sex chromosome
abnormalities may be referred to only by the sex chromo¬
some complement, e.g., for Klinefelter's Syndrome XXY
instead of 47,XXY.
as 1 in 6766 and 1 in 7602 respectively, how¬
ever, due to their rarity and the numbers in¬
volved, these figures must be accepted as very
approximate. Probably the next most common
autosomal syndrome is the 'cri-du-chat' (46,
Bp—) which has an estimated incidence of
between 1 in 50,000 and 1 in 100,000 (Polani,
1970). The other autosomal syndromes such
as I8p—, 18q—, 13q—, Dr, etc., are all extre¬
mely rare, not many cases of each having been
described, and any estimates of their frequency
must await further study.
The sex chromatin anomalies and their
frequencies are listed in Table 1. Chromosome
analysis following detection (Court Brown,
1969), reveals that of the chromatin positive
males, 1.3/1000 have straight Klinefelter's
Syndrome, 47,XXY, and .4/1000 are mosaics,
mainly 46.XY/47XXY; males with more than
two X chromosomes are very rare. Almost all
chromatin negative females have Turner's Syn¬
drome, 45 ,X. The doubly chromatin positive
females are mainly 47,XXX (1.0/1000) the
remainder being mosaics; females with more
than three X chromosomes are extremely rare.
Chromosome analysis of large numbers of
newborns has commenced only fairly recently,
and so far results for the major chromosome
abnormalities are available for 1015 females
and 6784 males. The main reason for this sex
ratio is that it is largely interest in Y chromo¬
some abnormalities which has prompted these
studies. It is also probable that information
obtained from the males about translocations
and the minor chromosome anomalies (Dp+,
Gp+, 17ps, etc) will also be valid for females.
In fact, abbreviated chromosome analysis of
females may prove unrewarding since it is
probably no more sensitive than sex chromatin
determination in detecting chromosome ano¬
malies limited to females. Of the 1015 fe-
TABLE 2
Results of Chromosome Screening of Newborn Males
Abnormalities
Series Nos.
studied XYY XXY Mongols
Trans-
locations Others
Sergovich et al., (1969) 1066 4 1 — 1 —
Lubs and Ruddle (1969) 2222 3 4 2 2 1
Ratcliffe et al., (1970) 3496 5 3 5 6 1
TOTAL 6784 12 8 7 9 2
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males studied (Sergovich et al., 1969), two
were mongols, one had the 'cri-du-chat' syn¬
drome, and one was a t(DqDq) translocation
carrier, the only normal infant whose chromo¬
some abnormality would have gone undetected
by clinical examination. The results for the
males are shown in Table 2. Here the inci¬
dence of major abnormality is 5.6/1000.
All the XYY and most of the translocation
carriers would have gone undetected by clinical
examination and most of the XXY would have
required sex chromatin determination for their
detection.
A NOTE ON SAMPLE SIZE AND TECHNIQUE
Probably the best method of determining
the incidence of chromosomal abnormalities in
newborns is the study of consecutive live births
in a hospital or group of hospitals. There are,
however limitations on a sample ascertained
in this way. The hospital or hospitals con¬
cerned may serve only a limited section of the
population. In a survey being carried out in
Melbourne (Wiener et al., unpub.) most of
those tested have come from the economically
depressed classes and include a high propor¬
tion of immigrants. This is a difficult problem
to overcome. In countries where expected
normal births are domiciliary, those born in
hospital would again be a selected group.
There is some evidence (Mikamo 1968) that
there is seasonal variation in the incidence of
X chromosome abnormalities; it may be wise
to conduct surveys over yearly periods. The
results of Walzer et al. (1969) are not in¬
cluded in Table 1 because of their method of
sampling. They excluded all infants with signifi¬
cant malformation, any condition requiring
special medical or nursing care, those delivered
by caesarean section and those with low birth
weight (less than 5 pounds). In view of the
report by Chen et al. (1970) of an association
between low birth weight and chromosome
abnormality in mentally retarded patients, they
may have selected out many cases of chromo¬
some abnormality.
Sample size is of course important if the
results are to be meaningful. If the frequency
of XYY males from the above data is con¬
sidered, the problem can be illustrated. The
observed frequency is 12 in 6784, which is
about .18%, however the 95% confidence
limits range from .08% to .28%. The ques¬
tion which immediately arises is how many
neonates will have to be screened to give reli¬
able incidence figures? It can be shown that
for 95% confidence limits (Hoel, I960, p. 153)
the number necessary 8* 3.8416 (1—p)p where
e2
p is the estimated frequency of occurrence
and e is the permissible error. To be able to
state, with 95% confidence, that the frequency
of XYY males lies between 1.5 and 2/1000
it is necessary to examine 107,377 newborn
males.
DISCUSSION
Many more newborns must be screened be¬
fore even the relative frequencies of the various
chromosome abnormalities can be established.
On theoretical grounds it has been suggested
that XYY should be less frequent than XXY
(Court Brown, 1968), however if the above
figures are considered then XYY is the most
frequently observed chromosome abnormality
in males, followed by XXY, and mongolism,
the rarer syndromes being lead by Edwards'
and Patau's. The position of translocation
carriers in this incidence ranking is uncertain.
Court Brown et al. (1966) found about .5%
of adults were heterozygous for a structural
rearrangement. In the 7799 newborns studied
so far, there have been only 10 with transloca¬
tions, and at least two of these had Patau's
Syndrome. Hence the observed incidence of
structural rearrangements in apparently normal
infants is not more than 8 in 7799, which is
significantly different from .5%.
It is of interest to apply the incidence figures
to the Australian population. In 1967 there
were 229,296 live births in Australia (Year
Book Australia, 1969). Of these it is expected
that there were about 330 mongols, 210 XYY
males, 150 XXY males and about 3 cases each
of Edwards' and Patau's Syndromes. There
would have been about 35 45,X Turner's Syn¬
drome cases and about 120 XXX females.
Many of those with a chromosome anomaly
have a higher mortality rate than normal
children. Edwards' and Patau's Syndrome
cases usually do not reach 6 months of age,
mongols have a higher infant mortality rate
than normals, and those who live to adulthood
have a lower life expectancy than either nor¬
mals or other non-mongol retardates. Turner's
syndrome is often associated with congenital
heart disease which increases the mortality
rate. There is some evidence that XXY males
have a slightly increased neonatal mortality,
but this has not been determined with certainty
(Court Brown, 1969). From the history of
childhood illness of many XYY males who
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have been detected in adulthood, there is the
possibility that they may be selected against,
but to what degree, if any, must await further
study.
A major question is what happens to those
who survive? The majority of the autosomal
trisomies either die in early childhood or spend
their lives as residents of institutions for the
mentally defective. The Turner's Syndrome
cases who survive have normal mental de¬
velopment and probably normal physical de¬
velopment until puberty, when they may pre¬
sent as endocrine problems, due to failure of
puberty or short stature, where they may be
correctly diagnosed for the first time, or as
infertility problems if their chromosomal status
escapes detection until after marriage. Those
individuals who have an extra X chromosome
(XXY, XXX) have a tendency to be mildly
mentally retarded and to have behaviour prob¬
lems which may bring them into conflict with
the law. The frequency of XXY males in
hospitals for the mentally subnormal is 7.6/
1000 males and of XXX females is 5.6/1000
females (Court Brown, 1968). Bartholomew
and Sutherland ( 1969) found 4 XXY males in
164 prisoners. However not all those with an
extra X chromosome are retarded or behave
abnormally. Some of the XXY males may be
detected by partial failure of puberty or at
infertility clinics after marriage. Some of the
XXX females will develop normally, both
mentally and sexually, and are fertile. The
relative proportions which follow each course
of development are unknown.
There is even less knowledge of what
happens to the XYY males. However, certain
things are known; they grow taller than XY
males; they are over-represented in prisons
and hospitals for the criminally insane; they
may develop perfectly normally (Wiener &
Sutherland, 1968). They are fertile but may¬
be hypofertile. They would be extremely dif¬
ficult to give genetic advice, since most of
those with abnormal children have been as¬
certained because of this. There is only one
known case where an XYY male may have
passed his abnormality to a son (Sundequist
and Hellstrom, 1969) and in no known cases
have XXY offspring been produced. It would
appear that a newborn XYY male would have
about a twenty fold increased chance of end¬
ing up in a prison or hospital for the criminally
insane, since the frequency of XYY at birth is
about .18% and in such institutions is about
3% (Court Brown, 1968).
With so much uncertainty about the de¬
velopment of some of these individuals with
chromosome abnormalities, there arises the
problem of what to do when one is identified
as having such an abnormality. This problem
has been discussed in a write-in symposium
(Amarose & Burks, 1969) and the diversity of
opinions on many of the aspects discussed,
reflects the need for more information regard¬
ing the development of persons with chromo¬
some disorders.
What may we expect to gain from the chro¬
mosome screening of newborns? Apart from
the basic information regarding the frequency
of the various abnormalities, there is the
identification of the affected individuals. This
presents an invaluable opportunity to study
their development and perhaps to answer some
of the questions which still remain about this.
There is also the possibility of prophylatic
treatment of some of these disorders. There
is some evidence that hormone replacement
therapy is helpful to XXY males especially if
given in early adolescence, effecting an im¬
provement of secondary sexual characteristics
and possibly in having a beneficial effect on
behavioural patterns (Myhre et ah, 1970).
There is evidence that similar therapy can help
maintain secondary sexual characteristics in
Turner's Syndrome and that administration of
human growth hormone may lead to some in¬
crease in the height of these girls, most of
whom are less than 5 feet tall (Tzagournis,
1969).
In the future it may become possible to
screen all newborns for chromosomal and
metabolic abnormalities and to treat these by
some form of genetic engineering. It will be
the information provided by the present sur¬
veys which will largely determine whether such
mass screening would be economically feasible.
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Chromosome Survey in a
Mental Deficiency Security
Ward: Total Ascertainment
G. SUTHERLAND* AND ALLEN A. BARTHOLOMEW**
WE have published previously the results of a chromosome survey in a
security ward for the mentally ill (Sutherland and Bartholomew, 1970),
a ward not dissimilar to the west wing of the Carstairs Hospital that was
investigated by Price and Whatmore (1967). We now report the results
of a chromosome survey in a security ward for the male mentally retarded,
a ward in a mental hospital (Aradale) that has much in common with
the east wing of the Carstairs Hospital (Price and Whatmore, 1967). During
the period of investigation 371 patients were examined and karyotyped.
Method
The technique of karyotyping has been described elsewhere (Wiener et
al., 1969).
Results
Karyotype: Four abnormal karyotypes were found: 48,XXYY; 47,XXY;
46,XX; and 47,XY,G+. Thus, of the population of 37, three cases of sex
chromosome abnormality were found, all examples of Klinefelter's syn¬
drome; an incidence of 8.1%.
Population: This had a mean age of 33.2 years (range 14-58 years) and
a mean mental hospitalization history of 13.5 years (range, less than 1 to
42 years). The patients were held under a number of different sections of
the Mental Health Act, 1959; the majority (24) being "certified".
The Diagnosis: All the patients had been diagnosed by the mental hos¬
pital staff as mentally retarded and all had been designated as R0, R1 or R2
* B.Sc., Geneticist, St. Nicholas Hospital, Melbourne.
** M.B., B.S., D.P.M. (Lond.), M.A.N.Z.C.P., M.A.P.S., Psychiatrist Superintendent,
H.M. Prison Pentridge. The authors thank Dr. S. Wiener for his interest and en¬
couragement during this study, Dr. P. Wood, Psychiatrist Superintendent of Aradale
Hospital, for permission to investigate the patients, and Mr. Ian Barker for technical
assistance. We also thank the Mental Health Authority for permission to publish this
report.
1. During the period of the investigation there were 38 patients in the ward, but in one case
it proved impossible to obtain an adequate specimen of blood. The patient was 51 years
of age, the diagnosis was R29E.P, he was 69 inches tall and had 26 years of hospitalization.
He was a "non-certified" patient.
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under the World Health Organization classification. Using such a system
the population was categorized into:
RO (IQ = 68-85) 3
R1 (IQ = 52-67) 16
R2 (IQ = 36-51) 18
37
The second digit in 31 of the cases as 9 which indicated that the mental
retardation was of unspecified aetiology. Further, 13 cases included the
letter B in the diagnostic formulation, which indicated "Behavioural dis¬
order", 8 included the letter E (epilepsy), 4 included the letter P (psychosis
present), and one case each had the letter A (alcoholism) and S (suicide
attempt).
Height: The distribution of height of the population is shown in
Figure 1.











Clinical Features: These, as they relate to the three cases having abnor¬
malities of the sex chromosomes, are set out in Table 1 (see next page). All
had features consistent with the diagnosis of Klinefelter's syndrome. The
patient with the karyotype 47,XY,G+ was a typical case of Down's syn¬
drome and had been diagnosed prior to the present chromosome study.
Discussion
The main concern in undertaking this survey was interest in the inci¬
dence of the extra Y chromosome. Price and Whatmore (1967) found seven
cases of 47,XYY in a population of 196 patients from the east wing of Car-
stairs Hospital. However, they found only two cases of Klinefelter's syndrome
(XY/XXY/XXYY and XXY) among these patients. Hence it is of
interest that we have found no cases of the extra Y chromosome, but three
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TABLE 1
Clinical information concerning the three patients with sex chromosome abnormalities.
A B C
Karyotype 47,XXY 48.XXYY 46,XX
Age 55 yrs. 35 yrs. 19 yrs.
Height 68 inches 73 inches 68 inches
Intelligence R2 R1 R1
Aetiology of
retardation Unspecified Unspecified Following trauma
or physical agents
Age of first
hospitalization 52 yrs. 14 yrs. Uncertain
Age started
present
hospitalization 52 yrs. 31 yrs. 19 yrs.
Previous
criminal




cases of Klinefelter's syndrome in our patient population. The difference
in incidence may well not be valid in view of the small numbers involved
and the difficulty that we have pointed out earlier (Sutherland and Bar¬
tholomew, 1970) in comparing such institutions.
It is of interest that the three cases of Klinefelter's syndrome had
different karyotypes. The case of 48,XXYY was 73 inches tall, perhaps
supporting the notion that the extra Y chromosome may lead to increased
height, even in the presence of Klinefelter's syndrome (Hunter, 1969). The
much rarer case of 46,XX in a male is at present under investigation and
will be published in detail elsewhere. Suffice to say that the clinical picture
was that of a typical case of Klinefelter's syndrome — a normal penis,
hypoplastic testes and lack of facial hair.
Our three patients described here all demonstrated a psychopathic
personality starting early in life and this tends to agree with the general
proposition that abnormality of the sex chromosomes may well correlate
with psychopathy. This has been suggested by Bartholomew (1968) in the
case of the extra Y cases, while Burnand et al. (1967) have commented
regarding Klinefelter's syndrome.
(Some psychological tests) tended to show Klinefelter males to be
of psychopathic type of personality with difficulties concerning aggres¬
sive impulses.
Similarly, Hunter (1969) considered that 14 of 15 cases of Klinefelter's
syndrome were abnormal personalities best described as "predominantly
inadequate or passive psychopaths". He also writes:
When considering the effects of chromosome aneuploidy on the nervous
system available evidence demonstrates no obvious changes in peri-
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pheral nerve, spinal cord, or medullary function. Most effects appear
to result from malfunction at cortical level. There is failure to learn,
leading to intellectual subnormality, delinquency, and anti-social
activity. Emotional control is underdeveloped resulting in immaturity
of emotional response and erethism.
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CHROMOSOME STUDIES IN A MENTAL DEFICIENCY
HOSPITAL: TOTAL ASCERTAINMENT
GRANT R. SUTHERLAND' and SAUL WIENER*
Chromosome studies on individuals suffer¬
ing from mental defects are common but the
screening of the total population of a mental
deficiency hospital has not, to our knowledge,
been reported. Such a survey was recently
completed at St. Nicholas Hospital, Carlton.
This is a hospital of 150 beds for mentally
defective children. Most of the children are
severely or profoundly retarded. The age
range is from 3 months to 16 years with the
majority being in the 2 to 12 years range.
METHODS
Blood was collected from a heel or finger-
prick and cultured by standard methods. Two
metaphases from each patient were examined
in detail and the chromosomes of a further 10
metaphases were counted by the technical staff.
When a chromosome abnormality was detected
at least 20 more cells were examined and a
few selected for analysis after photomicro¬
graphy.
RESULTS
During the period of this study 161 children
were in the hospital. Of these, 159 were
available for chromosome analysis, one died
and another was discharged before they could
be studied. There were 89 boys and 70 girls.
The results are summarised in Table 1.
Boys
Seventy-six boys had normal male karyo¬
types. A 47, XY, G+ karyotype was found
in 12 boys, all of whom had been clinically
diagnosed as having Down's syndrome. One
boy had a small extra chromosome similar in
appearance to the Philadelphia chromosome;
1. (Mr) Cytogeneticist, St. Nicholas Hospital. Present ad-
dre°s Royal Hospital for Sick Children, Edinburgh, Scot-
!?nl.
2. (Dr) Consultant Pathologist, St. Nicholas Hospital.
Address for reprints: Dr Saul Wiener, P.O. Box 105, Carl¬
ton, South Victoria, Australia, 3053.
he had none of the features of Down's syn¬
drome.
Girls
Sixty-three girls had normal female karyo¬
types. Five had 47, XX, G+ karyotypes and
had been recognised as cases of Down's syn¬
drome. Another girl with Down's syndrome
had 48 chromosomes. She had an extra G
group chromosome and a small centric frag¬
ment with satellites on both arms, similar in
appearance to a (Gp Gp) chromosome. This
family had been studied before the survey be¬
gan. Another girl with a karyotype of 47, XX,
G+ was regarded as a possible case of trisomy
22 (Ferguson and Pitt, 1963).
DISCUSSION
Of the 159 children studied, 13 had had
chromosome studies done previously, these in¬
cluded the irregular mongol and the two non-
mongols with abnormal karyotypes. Hence no
chromosome abnormality was found in 139
non-mongol children who had not been studied
previously and no irregular mongol was found
amongst the 14 mongols who had not been
previously studied.
The results show that, apart from Down's
syndrome, chromosome abnormalities do not
play a very significant role in the etiology of
mental defect as seen at St. Nicholas Hospital.
No sex chromosome abnormalities were de¬
tected. For a population showing the severity
of mental retardation seen here, the expected
frequency of sex chromosome abnormalities is
about twice that found in the newborn popula¬
tion (0.2%). On this basis the absence of sex
chromosome abnormalities in the 159 children
is in accordance with expectation.
The results of this survey contrast markedly
with a total ascertainment study of a male
mental deficiency security ward (Sutherland
and Bartholomew, 1971) in which the patients
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TABLE 1
Results of Chromosome Studies on 159 Children
Regular Mongols Normal Other* Total
Males 12 (2) 76 (4) 1 (1) 89 (7)
Females 5 (1) 63 (3) 2 (2) 70 (6)
Total 17 (3) 139 (7) 3 (3) 159 (13)
* see text
Figures in parentheses are numbers in each group which had been studied prior to the start of this
survey.
ranged from borderline to moderately retarded.
Amongst the 38 patients studied there were
three with sex chromosome abnormalities
(karyotypes 46, XX male, 47, XXY and 48,
XXYY) and one with Down's Syndrome.
Total ascertainment studies of mental de¬
ficiency institutions when viewed against
chromosome studies of unselected newborns,
will provide valuable information regarding the
relationship between chromosome abnormali¬
ties and mental retardation.
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Fifteen XYY males have been identified in Vic¬
toria over a period of ten years ending in February,
1971. Details of some have not been published to
date; others have been the subject of publications,
either as individuals or in small groups. This paper
collates these various reports, and presents informa¬
tion regarding the unpublished cases. The possible
effects of the extra Y chromosome on an individual
are considered.
Before 1965, only a dozen XYY males had been described,
most of them suffering from hypogenitalism (Balodimos
et alii, 1966). In 1965, it was shown that there was a high
incidence of XYY and XXYY males in institutional popu¬
lations (Casey et alii, 1966; Jacobs et alii. 1965); these
findings have since been confirmed. The report briefly sum¬
marizes the work in Victoria which has led to the identifi¬
cation of 15 XYY males. The cases which have not been
published previously are briefly described, and, using cor¬
rect case identification, those already published are now
fully documented.
METHODS AND CYTOGENETICS
The methods used in the survey work have been described
elsewhere (Wiener et alii, 1968). In surveys, 10 cells per
patient were examined, and, when possible, cultures were
repeated in all cases in which abnormal karyotypes were
found. The cases detected at laboratories other than the
Chromosome Laboratory at St Nicholas Hospital were found
during routine chromosome analyses.
RESULTS
Institutional surveys (Table 1) have resulted in the
detection of eight XYY males; another was a hospital staff
member who volunteered some blood to test a batch of
culture medium; and six have been identified in public
hospitals in Melbourne (four of these were at the Royal
Children's Hospital). With two exceptions, all have karyo-
1 Read at the Third Human Cytogenetics Conference, Sydney,
March 16, 1971.
2 Cytogeneticist, St Nicholas Hospital, Carlton.
'Consultant Pathologist, St Nicholas Hospital, Carlton.
' Psychiatrist Superintendent, H.M. Prison Pentridge, Coburg.
5 Cytogeneticist, Royal Children's Hospital, Parkville.
Address for reprints: Mr G. R. Sutherland, Department of
Pathology. Royal Hospital for Sick Children and University of
Edinburgh, Edinburgh EH9 ILN, Scotland, U.K.
types 47,XYY. There is one 46XY/47XYY mosaic, and one
subject has a structurally abnormal autosome (karyotype
47,XYY,Dp+, Wiener et alii, 1968).
Clinical Findings
The 15 XYY males comprise 12 adults (a boy, aged
14 years, is included in this group), and three young
children with congenital malformations who were identified
at the Royal Children's Hospital. The cases not previously
published include those of the following three babies.
Case 1.—This child (M.101163) was referred for chromosome
analysis at the age of three years. He was born four weeks
prematurely, to a 33-year-old woman and her 33-year-old
husband. The birth weight was 5 lb 7-5 oz. He was the fourth
child in a family of five. When he died at the age of six years,
Table l






H.M. Prison, Pentridge 266 5 5
Turana 78 1 1
Aradale Hospital:
J ward3 55 2 —
TC3 ward* 38 — 4
1 Prisoners from Pentridge and Turana (a youth training centre) were
selected on the bases of height, criminal history and psychiatric diagnosis,
Patients from Aradale were studied on a total ascertainment basis.
2 Six patients with 47.XXY ; one patient with 46,XY/47,XXY ; one
patient with 46,XXmale; one patient with 48,XXYY ; one patient with
47,XY,G+ (Down's syndrome).
■ Sutherland and Bartholomew (1970).
' Sutherland and Bartholomew (1971).
he was 104 cm tall, and he had a head circumference of
47-5 cm. He had an unusual facies, and was severely mentally
retarded. He suffered from cerebral palsy and epilepsy, and
had microcephaly, scaphocephaly and hydrocephaly. Other
features included mild obesity, hypoplastic genitalia and
bilateral undescended testes. He was regarded as a possible
example of the Praeder-Willi syndrome. Post-mortem
examination confirmed that death had been due to a respira¬
tory disorder with right pulmonary collapse and right
thoracic empyema. Visceral abnormalities noted included
agenesis of the right kidney and ureter, a Meckel's diver¬
ticulum, and an accessory spleen.
Case 2.—This child (N.161270) was born after 41 weeks'
gestation; the birth weight was 5 lb, the length at birth
46 cm, and the head circumference 33 cm. Pregnancy was
complicated by glycosuria and by hyperemesis, for which an
unknown antiemetic had been taken. The child had an odd
facies and other malformations including a left phocomelia
and congenital heart defects. Death occurred at the age of
one month after a series of convulsive episodes. Post-mortem
examination revealed the following malformations; incomplete
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Table 2
Case Age at Height IQ Criminal Record Mode of Discovery Clinical Features Other References'
Number Discovery (cm)
A. 33 years 210 101 Attempted murder, rape Selected from Pentridge Psychopath 2, Case 3; 6, Case 3;
191035 population 7 ; 10, Case 3
B.
190447












2, Case 1 ; 3 ; 5 : 6, Case 17 ;
10, Case 17 ; 11
D.
050516












2, Case 5 ; 6, Case 42
F.
270252





25 years 198 88 None Total ascertainment of
security ward for mentally
ill




" Dull " Larceny Total ascertainment of
security ward for mentally
ill
Schizophrenic 8, Case B.
I.
280147
20 years 197 95 None Height, referred by endo¬
crinologist












" Dull " Larceny
K.0
Height and behaviour prob¬






41 years 182 97 None Itandom (see text) Normal man 9
M.
101163








2 weeks 483 — None Malformed child Congenital malformations,
died 25.2.71 (mosaic
XY/XYY)
1 References are numbered as follows : 1, Bartholomew and Sutherland (1969a) ; 2, Bartholomew and Sutherland (19696) : 3, Burns (1962) ; 4, Cowling
el alii (1969); 5, Feltham (1964) ; 6, Hudson et alii (1909) ; 7, Marcus and Richmond (1970) ; 8, Sutherland and Bartholomew (1970); 9, "Wiener and Sutherland
(1968); 10, Wiener et alii (1968) ; 11, Wiener et alii (1969).
* Age at 6 years; normal for age, 121 cm.
' Birth length.
transverse fissure of the right lung; incomplete oblique
fissure of the left lung; and hypoplastic kidneys. Cardiac
malformations demonstrated were the tetrad of Fallot, a
patent ductus arteriosus, a patent foramen ovale and per¬
sistent left superior vena cava. The genitalia were normal,
with the testes in the scrotum. The brain was moderately
oedematous.
Case 3.—This child (0.261270) was the third infant, and
the second live-born child, of a 21-year-old women and her
25-year-old husband. The second pregnancy resulted in the
birth of a macerated fcetus at term. The patient was the
result of an uncomplicated pregnancy which ended, 16 days
after the expected date of confinement, in a labour compli¬
cated by meconium staining of the liquor during the second
stage. The child was born in poor condition and treated for
meconium inhalation. The birth weight was 5 lb 9-5 oz, the
length was 48 cm and the head circumference was 32-5 cm.
The child was noted to have an unusual facies due to a
malshaped nose and small eyes with redundant tissue of the
eyelids. Other malformations included a high arched palate,
bilateral undescended testes and rocker-bottom feet with
large toes. On the fourth day of life there was a massive
cerebral hemorrhage, and hydrocephalus developed. Chromo¬
some analysis revealed 46XY/47XYY mosaicism. Death from
bronchopneumonia occurred at the age of two months. Post¬
mortem examination revealed no visceral abnormalities, with
the exception of absence of the gall-bladder; the common bile
duct was patent. No genital anomalies were noted at
this time. There was gross hydrocephalus, the brain being
markedly enlarged with distended ventricles and the cortex
thinned to 2 cm
Only two of the 12 adults have not been the subject of
a publication. They are the 14-year-old boy mentioned
above, and the boy whose abnormality was detected in a
general hospital.
Case 4.—The patient (K.270956) was born to a 24-year-old
woman and her 22-year-old husband. He had three younger
sisters and was the heaviest baby of the family. At the age
of two years he may have suffered brain damage when he
impaled his head (left temporo-parietal area) on a tap. He
spent two weeks in hospital at four years for broncho¬
pneumonia. At the age of eight years, his Binet IQ was 94,
but at 13 years, the Wechsler Intelligence Scale for Children
test placed him at the "RO" level (WHO classification
of borderline retardation). At the age of 12 years, his bone
age was estimated to be 15 years, and at this time he was
referred for chromosome studies because of intractable
behaviour problems and an excessive height. 73-25 in. At
the age of 13 years, he was 76-25 in. tall, and still growing
at the rate of a quarter of an inch per month. When last
measured at the age of 14 years 6 months, he was 77-25 in.
tall. His behaviour problems (lying, stealing, truancy) had
drawn the attention of the police to him since he was eight
years old. At 13-5 years, he was charged in the Children's
Court with larceny involving the removal of tools from a
shed. An electroencephalographic examination revealed a
posterior temporal focus, but as he had been "dazed" in a
car accident a few days previously, the significance of this
finding is uncertain. A repeat EEC examination, although
recommended, was not carried out. He does not suffer
seizures.
JUNE 10, 1972 THE MEDICAL JOURNAL OF AUSTRALIA 1251
Case 4.—This patient (J.301049) was referred to an endo¬
crinologist at the age of 17 years because of excessive height,
gynsecomastia and a "female voice". Investigations included
chromosome studies on blood and skin, and both revealed an
Xl'Y karyotype. He had undergone surgery for bilateral
undescended testes at the age of 13 years. A psychiatrist's
report reads: ". . . excessive sensitivity, anxiety, histrionic
behaviour and homosexual traits. Poor school record." He
has no criminal record.
DISCUSSION
When the possible effects of the extra Y chromosome are
under consideration, attention may he focused on several
areas of development. They include physical characteristics
such as height, the incidence of congenital malformations,
and parameters of a psychological nature such as mental
disorder, antisocial behaviour and intelligence.
The relevance of increased height was considered by
Court Brown (1968), who estimated that 50% of XYY males
will be taller than 6 ft. In our series, height was a factor
which led to identification of all except three of the adults
(L., G., and H.), although their heights were 70 in.. 78 in.
and 78 in. respectively. It is reasonable, therefore, to con¬
clude that XYY males will, on the average, be taller than
XY males, but the exact differences between the height
distribution of XYY males and that of XY males must
await prospective studies.
The presence of the extra Y chromosome in the three
children with multiple congenital malformations (M., N.,
O.,) may be regarded as a fortuitous finding unrelated
to their clinical conditions. One reason for this conclusion
is that about 2,000 males have been karyotyped in Victoria
because of "congenital abnormality and/or mental retarda¬
tion", and only these three have been found to have an
XYY sex complement. This does not differ from the inci¬
dence of 1-8 per 1,000 found in the newborn population
(Sutherland, 1970). The incidence of congenital malfor¬
mations among XYY males is probably not greater than
among XY males.
Psychological characteristics (antisocial behaviour, men¬
tal disorder and intelligence) are harder to resolve, as they
are now more difficult to measure than physical ones, can
alter with time, and to some extent are interrelated. In
spite of intense screening of institutional populations for
XYY males, only eight of the 15 in this series were dis¬
covered in this way. Of the four adults found outside
institutions, three had no criminal record and did not
show the antisocial type of behaviour which would lead
them to an institution. Two points are clear. First, there
is an increased prevalence of XYY males in Victorian
institutions of the prison or security-ward type above that
in the newborn population. This differs from the results
of surveys of 2,500 boys in penal institutions in Scotland
(Jacobs et alii, 1971), in which no increase in the frequency
of XYY males in the institutions studied was found.
Secondly, the notion that XYY males inevitably show anti¬
social behaviour leading to incarceration is demonstrably
false.
The frequency of personality disorder shown by XYY
males may be the reason for their increased prevalence in
institutions, since it may be a reflection of the tendency of
persons with severe personality disorder to be committed
to institutions. Bartholomew (1968) has suggested that the
majority of XYY males will have some personality disorder
with a tendency to psychopathy. There is some such dis¬
order in 11 of the 12 adults in this series: seven are classed
as psychopaths, two as neurotics, one as schizophrenic and
one as a borderline defective with epilepsy.
The effect of the extra Y chromosome on intelligence is
far from clear, but a trend towards a lower IQ than normal
is noticeable. In this series, the nine adults formally tested
have a mean IQ of 87 (range 65 to 101), while the other
three adults are regarded as "dull". There are three possible
explanations for this trend. First, it may be an artefact
due from the smallness of our sample; this is unlikely,
however, as most (but not all) XYY males reported in the
literature are of dull normal intelligence. Secondly, IQ
testing of persons with personality disorders may be
unreliable. In fact, one patient, D, had his IQ assessed as
between 65 and 100, in different hospitals at different times
(Bartholomew and Sutherland, 19696). Finally, it is
possible that the extra Y chromosome exerts a lowering
effect on IQ similar to its apparent elevating effect on
height.
Some other possible effects of the extra Y chromosome
have been reported. Price (1968) noted an increase in the
P-R interval on the electrocardiogram; however, this
finding has not been confirmed by others (e.g., Char and
Borgaonkar, 1971). Penrose (1967) found the total finger¬
print ridge count (TRC) of 14 XYY males to be 133-6,
compared with a control value of 145 for XY males. In
this series, the mean TRC of nine adults is 136-2 (range
101 to 178). Changes in the hormonal status of XYY
males have been sought, but have not been conclusively
demonstrated (Hudson et alii, 1969).
Much information has been accumulated about XYY
males. It has come from the discovery of such persons
through surveys of institutional populations and newborn
children and the routine karyotyping of congenitally mal¬
formed children. However, a complete picture of the
development of XYY males will not be obtained until those
identified as neonates have been followed up for 20 years
or more.
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CYTOGENICS OF 271 MONGOLS
G. R. SUTHERLAND1 and S. WIENER-
From the Chromosome Laboratory, St. Nicholas Hospital, Melbourne
SYNOPSIS
The cytogenic findings in 271 mongols are described and discussed. The cases were
ascertained by routine referral and also by total ascertainment studies of institutionalised
mongols. 23 of the 271 did not have regular mongol karyotypes. It is suggested that all
mongols should be referred for chromosomal studies.
Since the establishment of the St. Nicholas
Hospital Chromosome Laboratory in 1963,
cytogenic studies have been carried out on
271 mongols. They have been studied for
two main reasons; one group was studied
as the result of referral for the confirmation
of a clinical diagnosis, and/or to provide in¬
formation on which to base genetic advice
to their parents. The second group was
studied during total ascertainment surveys of
three institutional populations. One case was
in a security ward for the mentally defective
(Sutherland and Bartholomew, 1971); 18
cases were in St. Nicholas Hospital when all
inpatients were studied (Sutherland and Wie¬
ner, 1972), and 176 were studied during a
survey of all mongols in the Children's Cot¬
tages, Kew, in Melbourne. One child was in¬
cluded in both the St. Nicholas and the Child¬
ren's Cottages surveys and there were 44 whose
chromosomes had been examined earlier, at
the time of their referral as patients (see
Table 1).
METHODS
The standard leucocyte culture techniques
were used in all cases. In those studied as
patients, 20 (or more if indicated) cells were
examined, whereas 2 cells per patient were
examined in the total ascertainment surveys.




In 23 the karyotypes were other than 47,XX
(or XY),G-|— These consisted of
9 mosaics with karyotypes 46,XX(or
XY)/47,XX(or XY),G+
8 were t(DqGq) translocation carriers
4 were t(GqGq) translocation carriers;
1 case had extra small centric fragment in
addition to the extra G-group chromosome
(See Sutherland and Wiener (1972) for de¬
tails of this patient), and
1 case had a Dp-f chromosome.
Family studies were not possible in this last
case, but the Dp-j- chromosome is considered
to be a normal/variant (Lubs and Ruddle,
1971).
The method of ascertainment of those with
irregular karyotypes is shown in Table II.
Where possible, family studies were done on all
the non-mosaic irregular cases, and the origins
of the translocations are shown in Table III.
DISCUSSION
Because only 2 cells per patient were ex¬
amined in the total ascertainment studies, only
mosaics with a large proportion of normal
cells would have been detected. This probably
accentuates the difference in the incidence of
mosaicism found in the course of surveys (1
in 150) as compared with the incidence in
patients referred for chromosome studies. In
addition, doubtful cases of mongolism are
more likely to be referred for chromosome
studies than typical cases, and the incidence
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of mosaicism in the former group is expected
to be greater.
The incidence of traslocations is 2.9% for
t(DqGq) and 1.5% for t(GqGq). This does
not differ significantly from that found in other
studies. Dey (1971) found 3.1% with
t(DqGq) and 0.6% with t(GqGq) in 160
Australian mongols. Richard's (1969) review
of 2,466 cases of mongolism yielded equal
numbers of each type of translocation (2.1%).
In our experience the majority of transloca¬
tion mongols are not being detected by the
rather haphazard selection of mongol patients
TABLE I
Ascertainment of 271 Cases of Mongolism
Ascertainment Male Female Total
Kew Survey 115* 61 176*
St. Nicholas
Survey 12* 6 18
Patients not
included above** 40 38 78
Totals 167* 105 272*
*one case was in both the Kew and St. Nicholas surveys.
♦♦includes the case found in security ward (Sutherland and
Bartholomew, 1971).
TABLE II
Ascertainment of 23 Irregular Cases
t(DqGq) t(GqGq) Mosaic Other
Ascertainment Male Female Male Female Male Female Male Female
Survey (new cases) 4 2 2 1
Patient referral 2 1 1 2 6 2
Total 6 2 3 1 2 7 2
for referral. Of the 8 t(DqGq), only one was
found among the 121 routine patient referrals,
whereas 6 were found in 150 new cases ex¬
amined during surveys. Of the 4 with t(GqGq)
there were 2 in each group. It is therefore ad¬
visable that all mongols be referred for chromo¬
some study regardless of whether the parents
seek genetic conselling. The detection in the
population of translocation carriers who
have an increased risk of producing mon¬
gol offspring, should be regarded as the prime
reason for cytogenetic studies on all mongols.
With the advent of chromosome analysis in
the foetus, it is possible to give appropriate
practical counsel to these translocation carri¬
ers.
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TABLE III
Origins of the Translocations
Translocation Familial Sporadic Unknown
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Letter to the Editor
Reprinted from THE LANCET, A pril 20, 1974, pp. 752
CHROMOSOME ABNORMALITY AND
PERINATAL DEATH
Sir,—We read with interest Dr Machin's report (March
30, p. 549) on the incidence of chromosome abnormalities
in perinatal deaths. We have been attempting to karyotype
all late abortions, stillbirths, and neonatal deaths coming
to necropsy in the Edinburgh area. The results for the
perinatal deaths in our series for the first year are shown
in table I. The chromosome abnormalities detected
included 5 cases of trisomy 18 and 1 case each of trisomy 21,
table i chromosome findings in 213 perinatal deaths






Macerated stillbirth 52 3 1 (33)
Non-macerated stillbirth . . 47 32 1 (3-1)
Neonatal death 114 98 7 (7-0)
Total 213 133 9 (6-8)







None 81 3 (3-7)
Primarily c.n.s. 28 0(0)
Not primarily c.n.s. 24 6(25)
Total 133 9 (6-8)
triple-X female, unbalanced reciprocal translocation, and
mosaicism for an extra C-group chromosome.
The chromosome findings according to the types of
congenital malformations are shown in table II.
These findings are very similar in a number of respects
to those of Dr Machin. The incidence of chromosome
abnormalities in perinatal deaths is 10 times greater than
that in the neonatal population in Edinburgh (1 in 140).1
The types of chromosome abnormality are more similar
to those found in liveborn infants than in abortuses.
Trisomy E is the most commonly encountered chromosome
abnormality. Obtaining chromosome results from macer¬
ated fetuses is difficult, but this group is worthy of study
because it appears to have a high incidence of chromosome
2
abnormality. Most of the chromosome abnormalities are
found in cases of multiple congenital malformation not
primarily affecting the central nervous system. Even in
cases in which there is no congenital malformation the
incidence of chromosome abnormality is about 5 times
greater than expected.
We support Dr Machin's contention that chromosome
studies should become a routine part of the perinatal
necropsy.
Full details of this study will be published elsewhere.
This work was supported in part by the Distillers Co. Ltd.
grant to the University of Edinburgh.
Royal Hospital for Sick Children
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Edinburgh
Bauld, R., Sutherland, G. R., and Bain, A. D. (1974). Archives of Disease in
Childhood, 49, 782. Chromosome studies in investigation of stillbirths and
neonatal deaths. Chromosome studies have been attempted on all late abortions,
stillbirths, and neonates coming to necropsy in Edinburgh over a 1-year period.
Results were obtained in 153 cases and of these 7-2% had chromosome abnormalities.
It is suggested that chromosome studies should become a routine part of the perinatal
necropsy.
With the decrease in perinatal mortality in recent
years the genetic component in this problem has
assumed increasing significance. There is only one
report of cytogenetic studies having been carried out
on a consecutive series of perinatal deaths (Machin,
1974). Chromosome abnormalities in such a
population were found to be 10 times more frequent
than in unselected liveborn infants. Over a period
of one year ending on 30 September 1973,
chromosome studies were carried out on all late
abortions, stillbirths, and neonates coming to
necropsy in this department.
Materials and methods
All routine necropsies on late abortions, stillbirths, and
neonatal deaths in the Edinburgh area are carried out in
this department. For the purpose of this study they
were categorized as follows.
Abortions: fetuses of more than 20 but of less than 28
weeks' gestation.
Perinatal deaths: stillbirths of more than 28 weeks'
gestation and all liveborn infants who have not lived for
more than one week, regardless of gestation. These
were further divided in 3 groups, macerated stillbirths,
nonmacerated stillbirths, and early neonatal deaths.
Older neonates: those who lived for more than one week
but for less than 28 days.
Where possible, chromosome studies were carried out
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on all such cases; three techniques were used. (1) Heart
blood lymphocyte culture which was attempted only in
the case of liveborn infants who had been dead for less
than 8 hours. (2) Spleen lymphocyte culture in the
presence of phytohaemagglutinin using the method of
Bain and Gauld (1964). (3) Fibroblast culture for which
a variety of tissues are suitable. In this survey gonad
and pericardium were the main tissues used. Towards
the end of the survey fibroblast culture of placental
amnion from macerated stillbirths was attempted
(Machin, 1974). The tissue was collected aseptically at
necropsy, placed in a sterile vial containing culture
medium, and transported to the laboratory. Explants of
tissue were set up in glass culture bottles using a
chicken-plasma clot technique. After these primary
cultures had been subcultured, chromosome results were
obtained using standard methods. A minimum of 10
cells per case were analysed and then checked by an
independent observer; a karyotype was prepared.
When chromosome banding was required the technique
of Grace and Bain (1972) was employed.
Results
During this survey there were 242 consecutive
necropsies in the categories selected for chromosome
studies. Chromosome studies were not attempted
on 42 macerated stillbirths in the early part of the
survey, nor in 16 other instances for a variety of
reasons (such as severe pyogenic infection).
The chromosome findings according to category
are shown in Table I. A high percentage of
chromosome abnormalities were found among the
abortions and macerated stillbirths, but the numbers
were too small to attach significance to these
findings. The figures for perinatal deaths are more
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TABLE I
Chromosome results by category
Status Total no. of necropsies Chromosome studiesattempted
Results Abnormal karyotypes
No. o/
. 0 No. %
Abortion 9 5 5 100 2 40
Macerated stillbirths 52 14 3 21 1 33
Nonmacerated stillbirths 47 39 32 82 1 31
Early neonatal deaths 114 108 98 91 7 7-1
Older neonates 20 18 15 83 — —
Total 242 184 153 83 11 12
representative of the incidence of chromosome
abnormalities in the population studied since the
numbers are larger. It is interesting to note that no
chromosome abnormalities were found in the 'older
neonates'.
The tissues from which chromosome results were
obtained are listed in Table II. A number of the
TABLE II
Tissue from which results were obtained
Tissue No. attempted No. successful
Blood (during life) 10 10
Heart blood 2 2
Spleen 102 27
Other tissue
(fibroblast cultures) 145 114
results were obtained from blood lymphocyte
culture established before death. The number of
heart blood samples used in the study was small
because of the time delay between death and
necropsy, which was usually greater than 8 hours,
generally about 2 days, and occasionally up to 5
days. Approximately one-quarter of the spleen
samples yielded chromosome results. When results
were obtained from these tissues, the slower
fibroblast cultures were discarded. Of the 145
cases where fibroblast cultures were continued there
were 31 cases where chromosome results were not
obtained. This was due to bacterial contamination
in 7 cases, and to primary growth failure in 24 cases.
In 11 of these 24 cases the tissue was from macerated
fetuses and growth failure was not unexpected. In
these fetuses all the cells are dead, but placental
amnion may contain viable cells which are suitable
for fibroblast culture. In 13 cases there was no
apparent reason for the growth failure.
The chromosome results according to primary
necropsy findings are shown in Table III. The
overall incidence of chromosome anomalies was 7%.
TABLE III

















































Total 242 153 11 7-2
Of 61 cases with severe congenital malformations
there were 6 with chromosome abnormalities, an
incidence of 10%. Of the remaining 91 cases
without significant congenital malformations 4 (4%)
had chromosome abnormalities. Except for the
cases of Edwards's syndrome and the unbalanced
translocation, the other chromosome abnormalities
were not suspected either clinically or at necropsy.
This includes the case of Down's syndrome, an
infant of 26 weeks' gestation where the extra
chromosome was identified as number 21 using
G-banding. Details of the cytogenetics of the 11
abnormal cases are listed in Table IV. In all cases
analysis of 40 cells was attempted in order to rule out
mosaicism, but this was considered unlikely in Case
479, where the unbalanced karyotype was of paternal
derivation, and only 25 cells were examined. When
non-modal cells were observed the loss of
chromosomes appeared to be random. Failure to
examine 40 cells in other cases was due to loss of the
cell strain; this was also one reason for not
3
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TABLE IV
Cytogenetic findings in the cases with abnormal karyotypes
Case no. Category Karyotype Tissue
Chromosome counts
45 46 47 3N Total
246 Early neonatal death 47, XX, +21 Spleen 2 3 45 50
218 ,, 47, XY, + 18 Fibroblast 40 40
472 Macerated stillbirth 47, XY, + 18 Fibroblast (amnion) 2 9 11
351 Early neonatal death 47, XX, + 18 Spleen 1 39 40
387 „ 47, XX, + 18 Blood 2 38 40
419 47, XX, +18 Fibroblast 1 5 34 40
264 Nonmacerated stillbirth 47, XXX Fibroblast 35 35
479 Early neonatal death 46, XY, der 13, t(7; 13) (q36; q22) pat. Heart blood 25 25
461 46, XX/47, XX, + C Fibroblast 28 4 32
294 Abortion 46, XY/47, XY, + C Fibroblast 49 6 55
297 3J 69, XXY Fibroblast 50 50
TABLE V
Seasonal incidence of chromosome abnormalities
Oct Nov Dec Jan Feb Mar Apr May June July Aug Sept
Chromosome results 9 11 17 12 8 12 16 13 13 15 10 16
Chromosome
abnormalities 1 1 1 1 1 1 1 1 3
Trisomy 18 1 1 1 1 1
distributed proportionately into the various age
groups.
Discussion
The only reported study comparable to the
present one is that of Machin (1974) who karyotyped
500 unselected perinatal deaths in the London area
over a 3-year period. This series is compared with
the present one in Table VII. The findings in the
two series are in close agreement, especially if the
two categories, abortions and older neonates, not
studied by Machin (1974) are excluded. The
incidence of chromosome abnormality in the
Edinburgh survey would then be 6-8% compared
with 5-6% for the comparable data from London.
The incidence of 7 • 2% of chromosome abnormality
in the present series is 10 times higher than the
incidence of 0-71% of chromosome abnormalities
detected in a series of 11,000 unselected liveborn
infants also studied in Edinburgh (Ratcliffe and
Keay, 1973). Hence, the only two series of
chromosome studies on perinatal deaths agree that
there is an excess of infants with chromosome
abnormalities dying in this period.
The types of chromosome abnormality detected in
perinatal deaths are compatible with survival beyond
birth and are not generally of the type usually seen in
early abortions (Hamerton, 1971). In both series
the most frequently encountered chromosome
identifying the extra C group chromosomes in the
two mosaics. Studies of histological sections of
Case 461 showed some cells which appeared to have
two sex chromatin bodies. Similar studies of Case
294 showed no evidence of sex chromatin.
The seasonal incidence of the birth of
chromosomally abnormal cases is shown in Table V.
These appear to be randomly distributed overall,
but there does seem to be some clustering of the E
trisomies.
The cases of chromosome abnormality were not
uniformly distributed with respect to maternal age,
as can be seen from Table VI, a higher proportion
being born to older mothers. The ages of 11
mothers were not ascertained and these were
TABLE VI
Distribution of cases with chromosome abnormalities
according to the age of the mother
Age intervals (yr)
<20 20-24 25-29 30-34 35-39 >40
All karyotyped
infants 12 59 51 17 9 5
Chromosomally
abnormal — 3 4 1 1 2
Abnormal
karyotype (%) 5-1 7-8 5-9 111 40
Chromosome studies in investigation of stillbirths and neonatal deaths 785
TABLE VII
Comparison of the results of two chromosome surveys carried out on infants dying in the perinatal period
Category
Series
Machin (1974), London This study Edinburgh
No. karyotyped % abnormal No. karyotyped % abnormal
Late abortion 5 40
Macerated stillbirth 34 8-8 3 33
Nonmacerated stillbirths 122 41 32 31
Early neonatal deaths 344 5-8 98 71
Older neonates — 15 0
Total 500 5-6 153 7-2
abnormality was trisomy 18. In the series of
Machin (1974) 8 out of 28 infants with chromosome
abnormality had trisomy 18, and in the present series
this abnormality accounted for 5 of the 11 cases
found. Hence, the present findings support the
contention (Bain, 1973; Machin, 1974) that trisomy
18 may be more common than was originally
estimated by Taylor (1968).
As would be expected, most of the chromosome
abnormalities were associated with congenital
malformations. If the severe congenital malforma¬
tions were subdivided according to whether or not
they were primarily of the CNS (anencephaly, spina
bifida, encephalocele, etc.), it is seen that while the
overall chromosome abnormality rate in congenital
malformations is 10-2% these were confined
exclusively to those cases in which the mal¬
formations did not primarily involve the CNS, and
in this group the incidence of chromosome
abnormality was 18-9%. Machin (1974) did not
divide his congenital malformations in this manner,
but found that 13% of this whole group had a
chromosome abnormality.
In those without recognizable malformations
there were 4-4% with a chromosome abnormality
and these are of particular interest since they were
unsuspected and would have gone undetected but
for this survey. Machin (1974) found that 2 • 5 % of
his cases without malformations had a chromosome
abnormality. Hence, even in perinatal deaths
where there is no congenital malformation, the
incidence of chromosome abnormality is about 5
times greater than that in unselected liveborn
infants.
Seasonal clustering of the chromosome
abnormalities was not apparent in the present series
as a whole, but 4 of the 5 cases of trisomy 18 were
found in the period from April to September. This
corresponds with the findings of Machin (1974)
whose 8 cases with this abnormality occurred
between March and July. Taylor (1968) found that
there was a clustering of both D and E trisomic
infants in the period from June to November. All
these periods of increased incidence of trisomy 18
overlap, but they do indicate that this anomaly is less
likely to occur in the winter months than at other
times of the year. Others have reported seasonal
variations in the incidence of chromosome
abnormalities (e.g. Robinson et al., 1969; Jongbloet,
1970; Nielsen, Petersen, and Therkelsen, 1973), but
little data from chromosome surveys of unselected
neonates has been analysed in this manner.
The increase in the incidence of chromosome
abnormalities with maternal age is well recognized;
nevertheless, the relation between maternal age and
chromosome abnormality in the two series of studies
on perinatal deaths is striking. The stillbirths and
neonatal deaths from mothers younger than 20 years
had about a 1% chance of having a chromosome
abnormality, yet those from mothers older than 40
years had a 30 to 40% chance of having such an
abnormality. Mothers in this latter group should
routinely be offered antenatal diagnosis of
chromosome abnormalities (Sutherland, 1972; Bain
and Sutherland, 1973).
The techniques for obtaining chromosome results
at post mortem have lower success rates than
similar studies during life. Obtaining results from
macerated fetuses is particularly difficult, though
amnion culture (Machin, 1974), which was only
attempted towards the end of the present series, has
produced results on occasions when other cultures
have failed. This is obviously the method of choice
for such fetuses and it is anticipated that in future
chromosome results will be obtained from a
proportion of these. When suitable tissue is
available from nonmacerated stillbirths or from
neonates then success rates in the vicinity of 90%
should be attained. The elimination of microbial
contamination of cultures could increase the success
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rate, but this still leaves a number of cases of
unexplained primary growth failure.
Hence it has been shown, in two different centres,
that chromosome abnormalities are present in 5 to
10% of perinatal deaths. In view of this it is
suggested that chromosome studies should become
an integral part of the perinatal necropsy.
Chromosome results from dead neonates are
particularly valuable when counselling parents. A
normal result suggests that the chances of recurrence
should be sought from the other pathological
findings and an abnormal result indicates that
amniocentesis in subsequent pregnancies should be
strongly considered.
Some necropsies in this series were carried out by Dr.
J. M. Anderson. We thank Mrs. Elizabeth Grace and
Mrs. Susan Bowser-Reilly for help with cytogenetic
studies, and Mrs. Eleanor Cochrane and Miss Dorothy
Seymour for help with the tissue culture.
We thank the M.R.C. Clinical and Population
Cytogenetics Unit for allowing us to use their results on
some of the infants studied while alive. This work was
supported in part by the Distillers Co. Ltd. grant to the
University of Edinburgh.
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Appendix
This appendix consists of the main pathological
findings in the 11 cases with chromosome abnormalities
listed in Table IV in the text.
Fig. 1.—Case 218. Note abnormal ears, flexion deformity
of right fingers, short great toes, rocker-bottom feet.
Case 246. Karyotype 47,XX, -t-21; age 1J hr;
gestation 26 weeks; weight at necropsy 1335 g. No
recognizable malformations; gross ascites and sub¬
cutaneous oedema confined to the trunk. Brain and
meninges normal. Heart normal. Small intestine was
narrow indicating ascites had been present for some time.
Case 218. Karyotype 47,XY, + 18; age 31 hr;
gestation 38 weeks; weight at necropsy 1880 g. External
features were in keeping with a chromosome abnormality
but not typical of trisomy 18. Ears abnormal.
Unilateral flexion deformities of the fingers; right talipes
equinovarus; left foot had a rocker-bottom appearance;
great toes short. Single umbilical artery. No Simian
creases. Head: anterior falx cerebri defect, adhesion of
cerebral hemispheres. Heart: high interventricular
septal defect. No other visceral abnormality. See Fig.
1.
Case 472. Karyotype 47,XY, + 18; stillborn
(macerated); gestation 39 weeks; weight at necropsy 1193
g. Multiple abnormalities; ears primitive, small and
with only partial separation of the pinnae from the scalp.
Microphthalmia, hypertelorism, microstomia, and
micrognathia. Bilateral flexion deformities of fingers;
dysplastic nails; no Simian creases. Exomphalos.
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Fig. 2.—Case 4 72. Note maceration, flexion deformity of
fingers, short great toes, small penis, grossly oedematous
umbilical cord.
Normal placenta with grossly oedematous umbilical
cord; single umbilical artery. Small penis; un¬
descended testes. Oedematous legs. Brain normal.
Heart enlarged with transposition of the great vessels and
ventricular septal defect. Malrotation of the ileum and
ascending colon; absent appendix. Meckel's diverti¬
culum with ectopic pancreatic tissue at its tip. Left
hydroureter with ureteric stenosis, right double ureter.
See Fig. 2.
Case 351. Karyotype 47,XX,+ 18; age 6J hr;
gestation 34 weeks; weight at necropsy 1395 g.
Multiple abnormalities; odd facies with large mandible;
exomphalos; right talipes equinovarus; partial syndactyly
of 4th and 5th toes. Brain normal. Heart: ventricular
septal defect. Single umbilical artery.
Case 387. Karyotype 47,XX,+ 18; age 48 hr;
gestation 38 weeks; weight at necropsy 1249 g.
Multiple external abnormalities. Odd facies. Nipples
widely spaced. Exomphalos. Bilateral partial
syndactyly of 3rd and 4th fingers. Flexion deformity of
both thumbs, but no flexion deformity of other fingers.
Bilateral single transverse palmar creases. Bilateral
talipes with rocker-bottom feet; short great toes. Brain
normal. Oesophageal atresia, jejunal stenosis. Heart:
atrial septal defect; ventricular septal defect, mitral
#1
Fig. 3.—Case 387. Note exomphalos, talipes, short great
toes.
atresia, widely persistent ductus arteriosus. Horseshoe
kidney. Hypoplastic uterus; vesicovaginal fistula. See
Fig. 3.
Case 419. Karyotype 47,XX,+ 18; age 14 hr;
gestation 35 weeks; weight at necropsy 1020 g. Twin
pregnancy—other twin chromosomally normal.
Multiple external abnormalities. Odd facies with
micrognathia; ears flattened with the helix under¬
developed. Flexion deformities of fingers and bilateral
single palmar creases. Rocker-bottom feet; short great
toes. Exomphalos. Head: anterior falx defect with
fusion of the cerebral hemispheres in this region.
Oesophageal atresia. Heart: high interventricular septal
defect. Meckel's diverticulum with ectopic pancreatic
tissue at its tip. Kidneys normal.
Case 264. Karyotype 47,XXX; stillborn; gestation
31 weeks; weight at necropsy 1512 g. No obvious
external deformity. Brain and spinal cord showed
normal developmental features consistent with 30-32
weeks' gestation. Lungs airless. Multiple petechial
haemorrhages present over the visceral pleura and
pericardium. Heart normal. No visceral or genital
abnormality. Rhesus isoimmunization.
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Fig. 4.—Case 479. Note anomalous genitalia, bilateral
equinovarus deformity, large head.
Case 294. Karyotype 46,XY/47,XY, + C; abortion;
gestation 27 weeks; weight at necropsy 1125 g. No
external deformities recognized. Brain and meninges:
normal, developmental features consistent with 26 weeks'
gestation. Multiple petechiae present over both lungs.
Heart normal. No visceral abnormalities.
Case 461. Karyotype 46,XX/47,XX, + C; age 58 hr;
gestation 32 weeks; weight at necropsy 1580 g. Infant
showed discoloured anterior abdominal wall. Epi-
canthic folds; micrognathia, low-set ears. Brain and
meninges normal. Thoracic organs normal. Patchy
infarction of the intestine from midileum distally.
Large intestine severely affected. Liver extremely
congested. Death due to enterocolitis.
Case 297. Karyotype 69,XXY; abortion; gestation
23 weeks; weight at necropsy 500 g. Male fetus with no
obvious external abnormality. Brain meninges and
spinal cord normally developed for 20 weeks' gestation.
Thoracic organs structurally normal. Right kidney
showed cystic dysplasia and was 3 times normal size; left
kidney normal. No other visceral abnormality.
Placenta weighed 423 g.
Case 479. Karyotype 46,XY, der 13, t(7; 13) (q36;
q22) pat.; age 6 days; gestation 39 weeks; weight at
necropsy 2578 g. Anomalous external genitalia.
Severe bilateral equinovarus with syndactyly of 4th and
5th digits. Head was large; bilateral microphthalmia;
cerebral holosphere with hydranencephalus. Spinal
cord normal. All thoracic organs normal. No visceral
abnormality except for hypoplastic kidneys. See Fig. 4.
A 14
Hum. Genet. 34, 231—245 (1970)
© by Springer-Verlag 1976
Cytogenetic Survey of a Hospital for the Mentally Retarded
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Summary. A cytogenetic survey of all 588 patients in Strathmont Training Centre, an
Australian hospital for the mentally retarded, was carried out. Abnormal karyotypes were
found in 90 (15.3%) patients, of whom 73 (12.4%) had clinical Down syndrome, 12 (2.04%)
other autosomal abnormalities, and 5 (0.85%) sex chromosome abnormalities.
Introduction
Whilst chromosome studies are often performed on patients with mental
retardat ion there have been few studies in which the total population of a hospital
for the mentally retarded has been karyotyped (Sutherland and Wiener, 1971;
Fujita and Fujita, 1974; Cassiman et al., 1975). Accordingly, we report here a
cytogenetic survey of the whole population of Strathmont Training Centre, a
large Australian hospital for the mentally retarded.
Materials and Methods
The Hospital
Strathmont Training Centre is a residential institution for the mentally retarded. Residents
come from all areas of the State of South Australia. There is a waiting list for admission and
priority is based on social rather than medical criteria. All admissions are informal. When the
Centre first opened in 1971 a number of residents were transferred from long stay wards for
the retarded within the State psychiatric hospitals, and a number of people were admitted
directly from the community. Nearly all admissions at present are directly from the com¬
munity with a very small number coming via general hospitals or other institutions.
Borderline retarded people are not normally admitted to the Centre, and mildly retarded
people are only admitted if there are other significant factors which make admission desirable.
In this latter case an attempt would be made to deal with the problem and then find the
person more appropriate accommodation within the community.
Cytogenetics
Capillary blood samples were collected by fingerprick for a standard microculture chromo¬
some technique. In any cases of repeated failure using this method venous blood was collected
and similarly cultured. If indicated, skin biopsies were collected for fibroblast chromosome
* Present Address: Department of Pathology, Sir Charles Gairdner Hospital, Western
Australia 6008.
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studies. A list of all inpatients on 20th February 1975 was prepared and those who had not
been previously karyotyped were then studied. This report pertains then to the completed
studies on all the 588 patients in the hospital on that date. A minimum of 30 cells per patient
were counted and analysed microscopically and one or two were photographed and a karyotype
prepared. Appropriate banding studies were employed to identify aberrant chromosomes but
karyotypes apparently normal by unhanded criteria were not studied further. Parental chromo¬
somes were studied if possible in all cases of chromosome abnormality but paternity checks
were not mado.
All cases with aberrant karyotypes were examined clinically. All individuals with trisomy G
were examined to ensure that they did have Down syndrome. Ages and W.H.O. classification
numbers (International Classification of Diseases, 1967) were extracted from patients' records
to provide data on the degree of retardation and diagnostic categories.
Kesults
The population of 588 consisted of 330 males and 258 females. The age distribu¬
tion of the population is shown in Table 1, the mean age was 28.5 years (range
4—75 years). The diagnostic categories (International Classification of Diseases,
1967) into which the patients had been assigned are shown in Table 2, only
four of the individuals with abnormal chromosomes (other than Down syndrome)
had been recognised as such prior to this survey. The degree of retardation of
the patients is shown in Table 3.
There were 272 males and 226 females with normal karyotypes and 90 individu¬
als with abnormal karyotypes (Table 4). There were 73 individuals with Down
syndrome, all had been recognised as such clinically and there were no patients
who were thought to have Down syndrome who had normal karyotypes. There
were 5 sex chromosome abnormalities, one had karyotype 46,X,+21/47,XX,+21
clinically she was not typically Down syndrome and had not been diagnosed as
such. There were 12 other autosomal abnormalities, three of which [inv(19),
t(13:14),t(2:10)] appeared to be euploid. Clinical and cytogenetic data on the
Table 1. Age distribution of the population according to chromosomal status
Age (years) Normal Down Other Total
karyotype syndrome abnormality
0— 4 3 3
5— 9 30 8 2 40
10—14 79 14 1 94
15—19 74 9 2 85
20—24 65 4 4 73
25—29 62 4 3 69
30—34 38 6 1 45
35—39 24 6 — 30
40 44 18 4 1 23
45—49 30 5 1 36
50—54 27 8 — 35
55—59 19 3 1 23
60—64 16 2 1 19
65—69 8 — — 8
70—74 5 — — 5
498 73 17 588
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Table 2. Diagnostic classifications of the patients studied, as obtained from their records,
showing the distribution of chromosome abnormalities not associated with Down syndrome
Following infections and intoxications 60
Following trauma or physical agents 102 (4)a
With disorders of metabolism, growth or nutrition 19
Associated with gross brain disease 12
Unknown prenatal influences 57 (4)
Chromosome anomalies 76 (3)
Associated with prematurity 15




a Numbers in parentheses represent the chromosome abnormalities not associated with
Down syndrome found within each group.
Table 3. Degree of mental retardation according to chromosomal status
Normal Down Other Total
karyotype syndrome abnormality
Borderline (IQ 68—85) 7 7
Mild (IQ 52—67) 65 9 2 76
Moderate (IQ 36—51) 116 29 3 148
Severe (IQ 20—35) 195 31 7 233
Profound (IQ < 20) 115 4 5 124


















46,XX,der(9)t(9; ?)(p2 ? ; ?)
4o,XX,t(13; 14)(13qter->cen^+4qter)
46,XX,t(2;10)(q22;pl3)
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Table 5. Chromosome counts on mosaics diagnosed during this survey
Case No. Counts Karyotype
^44 45 46, + mar 46 47 48
21/69 2 16 132 1 46,X,+21/47,XX,+21
53/71 10 33 17 45,X/46.X, + mar/46,XX
94/71 6 25 46,XY/47,XY, + 21
243/74 14 19 46,XX/47,XX,+21
patients with sex chromosome anomalies and autosomal anomalies other than
Down syndrome are given in the appendix. Chromosome counts on the four
mosaics encountered are shown in Table 5.
Discussion
Apart from the present study there have been 3 surveys published in which
the total population of a hospital for the mentally retarded has been karyotyped.
The results of these surveys are summarised in Table 6: also included in this table
are the results of a survey by Newton et al. (1972a,b) who karyotyped all patients
older than 15 years in such a hospital. The populations of the hospitals in these
surveys are similar with respect to degree of retardation but the 3 previous total
population studies involved only young patients. The findings in all the series in
Table 6 are similar except for that of Fujita and Fujita (1974) where Down
syndrome is greatly under-represented and sex chromosome anomalies over-
represented; this is probably due to the small hospital population of 59.
Table 6. Cytogenetic surveys of hospitals for the mentally retarded













No. °Z/o No. 0//o No. 0/,0
Sutherland and 3 months to
Wiener (1971) 12 years
Mostly less


















than 50 111 13.0 18 2.10 3 0.35 857
Present series 4 to 75 years 86% less
than 51 73 12.4 12 2.04 5 0.85 588
Total 306 10.5 48 1.64 20 0.69 2918
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Down syndrome is the most common chromosome anomaly encountered in
hospitals for the mentally retarded, often accounting for 10—15% of the inmates.
The slightly lower incidence of this anomaly in the series of Newton et al. (1972b),
may be due to the acceptance by the hospital they surveyed of patients from
the courts who are unlikely to have Down syndrome, and to the different age
distribution of the population. The sex ratio of the Down syndrome patients
in the present study of 2.17 was similar to that of 2.0 found in another large
Australian hospital for the mentally retarded (Pitt et al., 1972), but intermediate
between that of Cassiman et al. (1975) which was 3.6 and that of Newton et al.
(1972 b), which was 1.48. This excess of males with Down syndrome must reflect
a greater liability of males to hospitalisation compared with females as suggested
by Pitt ct al. (1972). The number of cases of Down syndrome is too small to
assess the relative frequencies of the various chromosomal forms but they do
not appear to differ from other Australian series of karyotyped individuals with
this disorder (Dey, 1970; Sutherland and Wiener, 1972).
Patients with small additional marker chromosomes form the next most com¬
mon group of autosomal anomalies after Down syndrome. This group appears to
be heterogeneous both cytogenetically and clinically, and in most instances the
marker chromosomes remain unidentified and their etiological significance cannot
be determined with certainty. Additional marker chromosomes are found in
about 1 in 3000 unselected liveborn neonates (Nielsen and Sillesen, 1975) and are
usually not associated with phenotypic abnormality detectable in the neonatal
period. In the series summarised in Table 6 at least 13 such patients have been
identified, an incidence 13 times greater than in the unselected neonates.
Jacobs (1974) has suggested that the presence of de novo structural rearrange¬
ments may be of etiological significance in mental retardation. In the present
series there were 3 apparently euploid structural rearrangements, a Robertsonian
translocation, a reciprocal translocation and a pericentric inversion, and of these
only the reciprocal translocation, t(2;10), was shown to have arisen de novo.
Even the finding of one such mutant out of 3 possible cases lends some support
to Jacob's hypothesis, as apparently euploid de novo structural rearrangements
are rare.
The frequency of X chromosome aneuploidy is increased amongst inmates of
hospitals for the mentally retarded but this is more marked amongst patients
with an IQ greater than 50 (Court Brown, 1969). Although none of the patients
with X chromosome aneuploidy in the present study has an IQ greater than 50,
none is severely or profoundly retarded with the exception of the one who also
has an autosomal aneuploidy. The finding of one XYY male does not suggest
that this condition is disproportionately represented in the population studied.
The contribution of chromosome abnormality to the etiology of mental retarda¬
tion as seen in the present and similar surveys is highly significant. The series
summarised in Table 6 show an incidence of chromosome abnormality of .12.8%
compared with an incidence of 0.575% in unselected neonates (Nielsen and Sillesen,
1975). However, apart from Down syndrome which accounts for 10.5% of this
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incidence figure, chromosome abnormality is probably responsible for only about




Age 62, weight 44.7 kg, height 162.5 cm.
Birth weight, parental ages, unknown.
Moderately retarded emaciated old man with absent body hair, widely spaced nipples
without gynaecomastia, bilateral cataracts, kyphosis, testicular atrophy and a small penis.
Record of aggressive but not violent behaviour.
Case No. 621/75
Karyotype 47,XXY
Age 55, weight 48.1 kg, height 168 cm, head circumference 57 cm.
Birth weight, parental ages, unknown.
IQ (WAIS) 48 (full scale). Mild gynaecomastia with deeply pigmented nipples, sparse
body and scalp hair, small testes, normal penis and pubic hair, bilateral pes cavus. Schizo¬
phrenic and diabetic.
Fig. 1. Case 21/69. Karyotype 46,X,+21/47,XX,+21
Fig. 2. Case 55/71. Karyotype 47,XY,+mar
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Case No. 70/75
Karyotype 47,XYY
Age 24, weight 62.1 kg, height 187 cm, head circumference 54 cm.
Parental ages: mother 21 years, father unknown. Birth weight 1.36 kg.
IQ, (Binet) 75 at 7 years of age. E.E.G. showed a focus in the posterior right temporal lobe.
Subject to fits of uncontrollable rage, has a low frustration tolerance and these have lead
to arrest by the police on several occasions. Clinically a large, well built man with no physi¬
cal abnormality.
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Fig. 3a—e. F- and G-group and marker chromosomes of (a) case 55/71, (b) case 415/74,
(c) case 343/73, (d) case 77/74 and (e) case 53/71. Conventionally stained chromosomes are
in the upper row and G-banded in the lower row, banded chromosomes are not included in (e).
The markers in (c) and (d) are bisatellited, the others do not show satellites
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Case No. 21/69 (Fig. 1)
Karyotype 46,X,+21/47,XX, + 21
Age 38, weight 36.6 kg, height 149 cm, head circumference 51 cm.
Parental ages unknown. Birth weight 4.20 kg.
Severely mentally retarded woman who lacks the typical appearance of Down syndrome
but has many of the clinical findings: brachycephaly, epicanthic folds. Brushfield spots,
mongoloid slant of the palpebral fissures, mid-facial hypoplasia. Somatic features of Turner
syndrome absent but no record of menstruation in hospital records. Marked thoraco-lumbar
kyphosis and a protuberant abdomen. Parental chromosomes not studied.
Case No. 55/71 (Fig. 2)
Karyotype 47,XY,-f mar (Fig. 3 a)
Age 6 years, weight 20.01 kg, height 114 cm, head circumference 50 cm.
Parental ages: mother 25 years, father 42 years. Birth weight 3.60 kg.
Born at term, perinatal anoxia due to mild respiratory distress syndrome. Right inguinal
hernia repaired at 12 weeks of age. An E.E.G. at 3 years of age was abnormal, showing
a moderate degree of non-specific cerebral dysrhythmia of non-focal type. At 4% years
Vineland Social Maturity Scale score was 2.0 years. Now a phenotypically normal boy
with flat feet and mild spastic quadriplegia who suffers from epileptic seizures. Both parents
have normal karyotypes.
Case No. 415/74 (Fig. 4)
Karyotype 47,XX,+mar (Fig. 3b)
Age 23 years, weight 56 kg, height 144.5 cm, head circumference 52.5 cm.
Parental ages: mother 42 years, father 46 years. Birth weight 3.72 kg.
Fig. 4. Case 415/74. Karyotype 47,XX,+mar
Fig. 5. Case 343/73. Karyotype 47,XY,+mar
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Profoundly retarded and obese with unusual fat distribution — large rolls over the elbows,
posterior costal margins and lower abdominal wall. Flexion contractures of the fingers
and a left simian crease. Hirsuite with synophrys. Secondary sexual characteristics normal
and she menstruates. Both parents have normal karyotypes.
Case No. 343/73 (Fig. 5)
Karyotype 47,XY,+mar (Fig. 3c)
Age 15 years, weight 31.2 kg, height 142 cm, head circumference 56 cm.
Parental ages: both 34 years. Birth weight 3.23 kg.
Anoxic at birth, inguinal hernia repair 2 years of age, uncontrolled epileptic seizures since
age of 5 weeks. Severe mental retardation, prominent occiput and frontal bossing of head,
left simian crease, spastic quadriplegia; all other findings normal. Mother normal karyotype,
father not tested.
Case No. 77/74 (Fig. 6)
Karyotype 47,XY,+mar (Fig. 3d)
Age 45 years, weight 60.2 kg, height 165 cm, head circumference 58 cm.
Parental ages: mother 32 years, father 34 years. Birth weight 4.10 kg.
Severely retarded man with fixed flexion deformities of the elbows and knees, and marked
gynaecomastia with deeply pigmented nipples. Unusual facial appearance with very
prominent ant ihel ices (there is a small pit on the right tragus) and a bulky tongue which
constantly protrudes. Suffers from grand mal epilepsy. Maternal karyotype normal, father
not available for study.
(i EE ' •' - 7
Pfig. 6. Case 77/74. Karyotype 47,XY,+mar
Fig. 7. Case 53/71. Karyotype 45,X/46,X,«j/mar/46,XX
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Case No. 53/71 (Fig. 7)
Karyotype 45,X/46,X,+mar/46,XX (Fig. 3e)
Age 12 years, weight 32 kg, height 125 em, head circumference 49.5 cm.
Parental ages: mother 23 years, father 27 years. Birth weight 1.98 kg.
Moderately retarded short stocky girl with unusual facial appearance, low set ears with
small tragi, shield chest with widely spaced nipples, increased carrying angles of the elbows
and dimples over the greater trochanters. Epileptic since the age of 2 years. Severely
abnormal E.E.G. with continuous subclinical epileptic discharges from the left middle
and posterior temporal areas. Both parents have normal karyotypes.
Case No. 485/73 (Fig. 8)
Karyotype 46,XX,r(13)
Age 23 years, weight 49.5 kg, height 142 cm, head circumference 50 cm.
Birth weight 1.57 kg.
Profoundly retarded, small brachycephalic microcephalic with eccentric constricted pupils
and protuberant tongue. Long thin hands with tapering terminal phalanges. Secondary
sexual characteristics normal and menstruation regular. Very hypertonic with sustained
ankle clonus and maintains a bizzare posture with thighs flexed and legs crossed on chest.
Both parents dead.
Fig. 8. Case 485/73. Karyotype 46,XX,r(13)
Fig. 9. Case 393/73. Karyotype 46,XY,r(18)
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Case No. 39-3/73 (Fig. 9)
Karyotype 46,XY,r(18)
Age 21 years, weight 28.9 kg, height 143 cm, head circumference 50 cm.
Parental ages: mother 29 years, father 28 years. Birth weight 2.50 kg.
Numerous malformations: microcephaly, brachycephaly, mid-facial hypoplasia, enoph-
thalmos, divergent strabismus, atretic ear canals, carp mouth. Left testis impalpable, large
redundant scrotum. Leg musculature wasted, bilateral equinovalgus deformity with over¬
riding of the third toes. Wrists hyperextensible, thumbs proximal and palmar creases
normal. Repaired hiatus hernia. Vineland Social Maturity Scale score at 13 years was
1.0 years. Both parents have normal karyotypes.
Case No. 143/70
Karyotype 46,XX,5p-
Age 30 years, weight 61.8 kg, height 156 cm, head circumference 51.5 cm.
Parental ages: mother 31 years, father 33 years. Birth weight 3.29 kg.
Severely retarded microcephalic woman with multiple malformations: mild hypertelorism,
divergent strabismus, mongolian slant to the palpebral fissures, and lumbar lordosis.
Menstruates, normal secondary sexual characteristics. Violent and has to be kept away
from children; had injured nursing staff. Did not have the "cri" characteristic of this
syndrome. Both parents had normal karyotypes.
io $*• Tii TiidBinWlt if 12
Fig. 10. Case 360/73. Karyotype 46,XY,ins(2)(2pter->2q21:: ?: :2q21 -*2qter)
Fig. 12. Case 52/67. Karyotype 46,XN,der(9),t(9; ?)(p2 ?; ?)
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Fig. 11. Case 360/73. Karyotype 46,XY,ins(2)(2pter->2q21:: ?:: 2q21->2qter)
Case No. 344/73
Karyotype 46.XY,inv( 19) (p 13q 13)mat.
(Full details of this patient have been published — Sutherland et al., 1976).
Case No. -360/73 (Fig. 10)
Karyotype 46,XY,ins(2)(2pter^2q21::?::2q21-s-2qter) (Fig. 11)
Age 21 years, weight 45 kg, height 155 cm. head circumference 58 cm.
Parental ages: mother 29 years, father 35 years. Birth weight 2.41 kg.
Moderately retarded (IQ at 3 years 40—50) until the age of 17 years when he suffered
ECHO virus encephalitis. After this became very violent but this settled and is now severely
retarded (Vineland Social Maturity Scale score 3 years immediately post-encephalitis).
Malformations include hypertelorism, broad base of nose, bilateral epicanthic folds, hypo¬
plastic mandible, abnormal hands and feet. Marked camptodactyly of the left second and
fifth digits with enlargement of the proximal interphalangeal joints and fixed flexion
deformity, all toes except the first have varus deformity. Both parents have normal
karyotypes.
Case No. 52/67 (Fig. 12)
Karyotype 46,XX,der(9),t(9; ?)(p2 ?; ?) (Fig. 13)
Age 29 years, weight 50 kg, height 152 cm, head circumference 51.5 cm.
Parental ages: both 24 years. Birth weight 2.84 kg.

























Fig. 13. Case 52/G7. Karyotype 46,XX,der(9),t(9; ?)(p2 ?; ?)
Profoundly retarded, mildly microcephalic, with minimal phenotypic abnormality. Valgoid
ankles, atrophic changes in the lower limbs. Grand mal epilepsy. Both parents have
normal karyotypes.
Case No. 330/74
Karyotype 45,XX,t(l 3; 14) (13qter ->cen ^14qter)
Age 25 years, weight 41.5 kg, height 152 cm, head circumference 54.5 cm.
Parental ages: mother 22 years, father 21 years. Birth weight 3.41 kg.
Severely retarded, hirsuite with excessive face and body hair, odd face with synophrys,
short philtrum, upturned tip of nose and carp mouth (which may have been due to dental
anomalies), palate high and arched. Epileptic since the age of 2 years; E.E.G. shows
cortical damage in the right mid-temporal lobe which was epileptogenic. Mother has
normal karyotype, father dead.
Case No. 103/70
Karyotype 46,XX,t(2; 10)(q22;pl3) (Fig. 14)
Age 8 years, weight 18.9 kg, height 122.5 cm, head circumference 49.5 cm.
Parental ages: mother 18 years, father 24 years. Birth weight 2.92 kg.
Small, profoundly retarded, low set ears (right ear also rotated anti-clockwise), divergent
strabismus, broad shield-shaped chest with increased anterior-posterior diameter, mild
pectus carinatum and widely spaced nipples. Camptodactyly of the fourth and fifth
fingers bilaterally, mild talipes equinovarus and stooped gait with increased lumbar
lordosis. E.E.G. at 8 months of age showed an excess delta rhythm but not hypsarrhythmia.
Both parents have normal karyotypes.
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Fig. 14. Case 103/70. Karyotype 46,XX,t(2; 10)(q22;pl3)
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Chromosome studies at the paediatric necropsy
BY GRANT R. SUTHERLAND, RODNEY F. CARTER
Cytogenetics Unit, Department of Histopathology, Adelaide Children's Hospital,
North Adelaide, 8.A. 5006, Australia
RHONA BAULD, IAN I. SMITH AND A. DOUGLAS BAIN
Department of Pathology, Royal Hospital for Sick Children,
Edinburgh EH9 1LF, Scotland
Studies by Machin (1974), Bauld, Sutherland & Bain (1974) and Kuleshov (1976) have shown
that the incidence of major chromosome abnormalities in perinatal deaths is ten times greater
than that in liveborn infants. This report extends the findings from Edinburgh (Bauld et al. 1974)
to cover a full 4-year period ending in September 1976 and documents the results of a similar study
carried out over a full 2-year period ending in May 1977 at the Adelaide Children's Hospital.
MATERIALS AND METHODS
Edinburgh. All routine necropsies on late spontaneous abortions, therapeutic abortions following
prenatal diagnostic studies, stillbirths and neonatal deaths in the Lothian area were carried out by
the Department ofPathology at the Royal Hospital for Sick Children. Necropsies on older children
dying in hospital were also included in the study as were sudden infant deaths examined under
instruction from the Procurator Fiscal.
Adelaide. All routine necropsies following deaths within the Adelaide Children's Hospital were
studied. In addition some stillbirths and neonatal deaths were referred by private practitioners
for necropsy and all sudden infant deaths in Adelaide were examined under the authority of the
Coroner.
Definition of the terms 'perinatal death' and 'older neonate' are given by Bauld et al. (1974).
In addition, in this report the term infant is used to denote a baby aged more than 28 days but less
than 366 days, and child refers to deaths occurring on or after the 366th day of life. In Edinburgh
chromosome studies were carried out wherever possible and without selection in all abortus,
perinatal, neonatal and infant necropsies but some selection was applied to childhood deaths.
In Adelaide chromosome studies were carried out in all necropsies and this series can be con¬
sidered to be on unselected consecutive necropsies.
The methods of chromosome study for the Edinburgh series have been published (Bauld et al.
1974). Chromosome banding was carried out in most cases during the last two years of the period
ofstudy. In Adelaide virtually all results were obtained from skin fibroblast culture; 30 metaphases
per case were examined microscopically and a karyotype prepared. Skin was collected for this
purpose from the edge of the ventral incision at the beginning of the necropsy. Where chromosome
studies had been carried out during life these results were used. Banding was employed in all cases
of significant malformation except for isolated central nervous system and cardiac lesions, to
delineate any chromosome abnormalities detected. G-, C- or Q-banding was used as required.
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Table 2. Chromosome results according to category of necropsy, Adelaide series
Chromo¬ Abnormal
some Normal karyotype karyotype
studies Success¬ <— A- 1 ( *_
Category Total attempted ful Male Female No. 0//0
Therapeutic abortion 6 6 5 2 2 1 20
Spontaneous abortion 2 2 0 0 O 0 0
(less than 20 weeks)
Spontaneous abortion 1 1 1 1 O 0 0
(more than 20 weeks)
Macerated stillbirth 10 10 7 3 3 1 14
Non-macerated stillbirth 13 13 11 6 5 0 0
Early neonatal death 52 52 48 36 12 0 0
Later neonatal death 29 29 22 7 12 3 13-6
Older than 28 days 116 116 107 56 47 4 3'7
Older than 1 year 102 99 94 58 29 7 6-4
Total 33i 328 295 169 110 16 5'4
RESULTS
All necropsies carried ont in both series are shown according to category in Table 1 (Edinburgh)
and Table 2 (Adelaide). In the Edinburgh series chromosome studies were attempted on 83% of
necropsies and a chromosome result was obtained for 65%; the corresponding figures for the
Adelaide series are 99% and 89%. Reasons for failure to attempt chromosome study included
maceration (mainly in the earlier part of the Edinburgh series as the technique of amnion culture
in these cases was not in use at that time), severe pyogenic infection, arrival of specimens in
fixative, loss of samples over holiday periods, etc. Erom these tables it can be seen that the popu¬
lations studied are very different; only 19% of the Edinburgh series was older than 28 days
compared with 65 % of the Adelaide series.
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Table 3. Chromosome results according to primary cause of death (therapeutic abortions
and abortions of less than 20 weeks gestation excluded), Edinburgh series
Chromo¬ Abnormal
some Normal karyotype karyotype
studies Success¬ ,— ( X
Cause of death Total attempted ful Male Female No. %
Macerated without 188 127 47 25 19 3 6-4
malformation
Macerated with 29 20 3 0 0 3 (100)
malformations
Prematurity associated 180 172 157 102 53 2 i'3
disease
Primary c.n.s. 138 120 IOI 32 69 0 0
malformation
Severe congenital 116 107 98 39 33 26 27
malformations
Congenital heart 80 67 62 37 23 2 3'3
malformation
Primary anoxia 185 168 143 74 67 2 i'4
Infection 64 4i 34 17 16 I 2-9
S.I.D.S. 58 56 40 17 21 2 5'°
Leukaemia S 0 0 0 0 O 0
Other malignancy 12 2 1 0 0 I (100)
Trauma 33 29 26 15 11 O O
Mendelian disorders 22 16 15 7 8 O O
Miscellaneous 40 30 27 i7 10 O O
Total 1150 955 754 382 33° 42 5'6
The chromosome results according to primary cause of death for all the cases in each series, with
the exception of abortions of less than 20 weeks and therapeutic abortions, are shown in Tables
3 and 4. A similar breakdown of findings pertaining only to perinatal deaths (to allow comparison
of these series with other published series) are shown in Tables 5 and 6.
There are only two major groups in which chromosome abnormalities are not prominent; these
are deaths due to primary central nervous system malformations (mainly anencephaly and spina
bifida) and the sudden infant death syndrome (s.i.d.s.). Of the two infants in the latter group in
the Edinburgh series the 48,XXTT/49,XXTT, +8 had failed to thrive from birth but the
46, AT/47, XY, 4- 8 was a true case of s.i.d.s. Although traumatic death may have an association
with chromosome abnormality via its association with mental subnormality and consequent
increased accident mortality, the finding of a balanced translocation in this group in the Adelaide
series is fortuitous. The chromosome abnormalities detected are shown in Tables 7 and 8. These
abnormalities are of the type usually seen in live-born infants rather than abortuses with ex¬
ception of the triploids and the two macerated foetuses who were mosaics for trisomy 2. These
mosaics showed no malformations, although the one with karyotype 46,AT/47,XY, + ace/48,
XY, +2, + ace* has an unusual facial appearance with protuberant eyes, antimongoloid slanting,
palpebral fissures and low-set ears with a maldeveloped helix; its placenta showed hydatidiform
change and the possibility of triploidy had been considered.
Chromosome counts in the mosaics from the Edinburgh series are shown in Table 9. The mosaic
in the Adelaide series showed karyotype 46,XX in 50 cells and 46,XX,<(9; 14)(g34;gl2) in 31 cells
* ace - small acentric fragment.
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Table 4. Chromosome results according to primary cause of death (therapeutic abortions
and abortions of less than 20 weeks gestation excluded), Adelaide series
Chromo- Abnormal
some Normal karyotype karyotype
studies Success- , * N , *
Cause of death Total attempted fill Male Female No. °//o
Macerated without i 1 I 0 1 0 0
malformation
Prematurity associated 13 13 12 8 4 0 0
disease
Primary c.n.s. 17 17 14 5 9 0 0
malformation
Severe congenital 28 28 28 10 11 7 22*2
malformations
Congenital heart 44 44 44 28 13 3 6-8
malformation
Primary anoxia 27 27 21 16 4 1 4-8
Infection 27 27 26 11 13 2 7.7
S.I.D.S. 78 78 66 39 27 0 0
Leukaemia 10 IO 7 4 3 0 0
Other malignancy 13 12 10 7 2 1 10
Trauma 32 30 30 22 7 1 3'3
Mendelian disorders 10 IO 10 6 4 0 0
Miscellaneous 23 23 21 11 10 0 0
Total 323 320 290 167 108 15 5'2
Table 5. Perinatal deaths in the Edinburgh series
Chromo- Abnormal
some Normal karyotype karyotype
studies Success¬ ( A ( ^
Cause of death Total attempted ful Male Female No. %
Macerated without 179 125 46 24 19 3 6-5
malformation
Macerated with 26 18 3 0 0 3 (100)
malformations
Prematurity associated 158 iSi 139 93 45 1 °'7
disease
Primary c.n.s. 116 106 88 27 61 0 O
malformation
Severe congenital 74 72 67 28 24 15 22
malformations
Congenital heart 3° 3° 26 15 11 0 O
malformation
Primary anoxia 152 143 123 67 54 2 1-6
Infection 11 9 7 1 5 1 (14-3)
Malignancy 2 2 1 0 0 1 (100)
Trauma 14 14 13 7 6 0 O
Mendelian disorders 7 7 7 2 5 0 O
Miscellaneous 16 16 15 8 7 0 O
Total 78s 693 535 272 237 26 4*9
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Table 6. Perinatal deaths in the Adelaide series
Chromo- Abnormal
some Normal karyotype karyotype
studies Success¬ f A y r A
Cause of death Total attempted ful Male Female No. °//o
Macerated without i 1 1 0 1 O 0
malformation
Macerated with o 0 0 0 0 O 0
malformations
Prematurity associated 12 12 11 8 3 O 0
disease
Primary c.n.s. 2 2 2 1 1 O 0
malformation
Severe congenital 11 11 11 5 6 O 0
malformations
Congenital heart 12 12 12 10 2 O 0
malformation
Primary anoxia 26 26 20 15 4 I 5
Infection 3 3 3 2 1 O 0
Malignancy i 1 0 0 0 O 0
Trauma I 1 1 1 0 O 0
Mendelian disorders 2 2 2 2 0 O 0
Miscellaneous 4 4 3 1 2 O 0
Total 75 75 66 45 20 I i*5
examined. This mosaicism was found in fibroblasts from replicate primary cultures of skin. In
addition to chromosome abnormalities a number of diseases due to single gene defects were
recognized in both series of necropsies. These are listed in Table 10.
In five macerated stillbirths from the Edinburgh series the chromosomal sex and the phenotypic
sex did not correspond. These results have not been included and are listed in the tables as though
they had not been attempted. One of these was a male, almost certainly affected by Down's
syndrome, yet amnion culture revealed a normal female karyotype. Enquiries suggested that it
was highly probable that the placenta which accompanied the foetus at necropsy was the wrong one.
Of the other cases three were male foetuses and one a female foetus. Whilst the possibility that
some of these represent genuine discordance between phenotypic and genetic sex more plausible
explanations are that the wrong placentae were sent for necropsy or possibly that amnion
culture in some cases may yield maternal cell growth.
DISCUSSION
Chromosome studies have now been carried out on unselected paediatric necropsies in four
centres - Adelaide, Edinburgh, London and Moscow (Table 11). The results obtained from each
centre are similar for deaths occurring in the perinatal period, the frequency ofmajor chromosome
abnormality being 1-5 % in Adelaide, 4-9 % in Edinburgh, 5-6 % in London and 6-9 % in Moscow.
The incidence in Adelaide is lower than in the other centres, but this may be due to differences in
the types of neonates admitted to the Adelaide Children's Hospital and the relatively small
numbers in this part of the Adelaide series. Frequently the more severely malformed infants with
chromosome abnormalities are not admitted to the Adelaide Children's Hospital but die during
the perinatal period in maternity hospitals.
12-2
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48, XXYY/49, XXYY, +8
46, XY/47, XY, + ace/48, XT, +2, +ace
46, XX/47, XX, +2
47, IF, +C
47, XI, +9
46, XY/47, XY, + C (3)
46, XX/47, XX, +C
46, xr/47, xr, +8
47, XX, +13
47, xr, +13
46, XX, -14, +<(139147)
47, xr, +18
47, XX, + 18
47, xr, +21








46, xr, tfer( 13), <(7; 13X936; q22)pat
69, xxr (2)
Comments
2 months old, congenital heart disease
1 therapeutic abortion 5131 -week stillbirth
3 hours old, bilateral renal dysplasia
8 months old, s.i.d.s.
34-week stillbirth
37 wook macerated stillbirth
3 5-week stillbirth
35-week stillbirth, trisomy 9 syndrome
26-week abortion; 5-month multiple malformations;
36-week hydropic stillbirth
2-month congenital heart disease; 2-days
infectious death
8 months old, s.i.d.s.
20 days old
12 hours old
6 days old, only malformations bicornuate uterus
and ventricular septal defect
2 stillbirths; 2 early neonatal deaths
3 therapeutic abortions; 5 early neonatal deaths;
1 infant
3 therapeutic abortions; 1 macerated stillbirth;
1 early neonatal death; 1 later neonatal death;
2 infants
1 therapeutic abortion; 1 macerated stillbirth;
1 early neonatal death; 2 infants; 2 children
1 hour old, congenital hepatic liaemangioma
Stillbirth at term, anoxic death
6 days old, multiple malformations
13-week abortion; 20-week abortion





47, XX, + 21
47, XX, +18
46, XY, 7p +
46, XY, inv(2)(pi 1913)
46, XY, <(12; 16X924; pn)
46, XX, <(1; 5X925; P13)
46, XX/46, XX, <(9; 14X934; 912)
69, xxr
Comments
(3) 1 therapeutic abortion; 2 older neonates with con¬
genital heart disease
1 year old with congenital heart disease
(4) 9 years old; 1 year old; 4 months old; 5 weeks old
8 years old
7 months old
Unbalanced translocation, not maternal
8 days old, infectious deatli
Normal child, traumatic death
Normal child, rhabdomyosarcoma
Normal child, part aboriginal, infectious death
Macerated 3 3-week foetus
Only tlie series reported from Adelaide and Edinburgh have included studies on unselected
paediatric autopsies beyond the perinatal period. These are summarized in Table 11. In macerated
stillbirths it can be seen that chromosome abnormality has the highest incidence. In non-macerated
stillbirths the frequency of chromosome abnormality drops to 3-8% but continues to increase
with age until it reaches 7-1% in children. The increased incidence of chromosome abnormalities
associated with death after the perinatal period has not been noted previously and is accounted
for mainly by infants with Down's syndrome.
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Table 9. Chromosome counts in cases of mosaicism detected in the Edinburgh series
Chromosome number
A
Karyotype Tissue 45 46 47 48 49
45, X/46, X, dic(X)(pn) Urine 7 8 — — —
Pleural fluid 32 27 — — .—
48, XXrr/49, XXYY, +8 Testis — — — 42 4
Pericardium — —• — 5
46, XX/47, XX, 4- c* Pericardium —- 28 4 —
46, XX/47, XX, +G Pericardium — 20 5 —
46, xr/47, xr, +c* Testis — 49 6 —
46, XY/47, XY, +C Testis — 70 5 —
46. Xr/47, XY, +C Amnion 3 27 4 —
46, xr/47, xr, +8 Testis 1 25 3 —•
46, XX/47, XX, 4-2 Amnion -— 43 20 —
46, Xr/47, XY, -faee/48, XY, +2, 4-ace Amnion — 12 15 3
* Previously published in Bauld el at. (1974).





























* One of these was in an infant with 47,XI7', +21.
f One therapeutic abortion.
f Therapeutic abortion following prenatal diagnosis.
Table 11. Results from four series of chromosome studies in unselected paediatric autopsies
Machin Kuleshov
(i974) (1976) This report This report Abnormal
Status London Moscow Edinburgh Adelaide Total (%)
Macerated 34 (3)* 22 (3) 49 (6) 7 (1) 112 (13) n-6
stillbirth
Non -macerated 122 (s) 61 (3) 146 (5) 11 (0) 34° (i3) 3-8
stillbirth
Early neonatal 344 (20) 92 (6) 34° (15) 48 (0) 824 (41) 5'°
death
Late neonatal — — 64 (2) 22 (3) 86 (s) 5-8
death
Infant — — 96 (10) i°7 (4) 203 (14) 69
Child — — — 94 (7) 94 (7) 7'4
* Number studied (number abnormal).
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Chromosome abnormalities are of course not the only genetic disorders associated with paediatric
death. Machin & Crolla (1974) recognized 9 infants with disorders due to genes of major effect
amongst 728 perinatal necropsies (1-24%). In the whole Edinburgh series (excluding early and
therapeutic abortions) there were 22 such disorders recognized in 1,150 necropsies (1-91 %) and
in Adelaide 10 in 323 (3-10%). All these figures must be regarded as minimal since some of these
disorders may not be recognized, especially in perinatal deaths.
A number of chromosome mosaics were diagnosed in this study. In view of reports (Littlefield &
Mailhes, 1975; Harnden et al. 1976) of chromosomally abnormal clones arising in skin fibroblast
cultures it is possible that some of the mosaics diagnosed could be due to artifact and not reflect
constitutional chromosome status. The most frequent type of mosaicism involved a minor cell
line with an additional C-group chromosome. The cell strains involved were often poorly growing and
sufficient material could not be obtained to allow precise identification of the additional chromo¬
somes. Harnden et al. (1976) state that abnormal clones have only been observed to arise in adult
skin cultures and have not been seen in foetal skin cultures. Most of the tissues used in the present
studies were not skin, and it is known that clones can arise in amniotic fluid cultures which are
foetal in origin (Sutherland, Bowser-Riley & Bain, 1975). There can be little doubt about the
validity of the results of the 45, A/46,X,dic(X) mosaic as this was found from two tissues.
Similarly, the translocation mosaic in the Adelaide series was diagnosed from replicate primary
cultures and is most unlikely to be artifact.
Amongst the 535 perinatal deaths which were successfully karyotyped in the Edinburgh series
there were four cases of Down's syndrome. This is more than four times the accepted incidence of
this condition at birth. Similarly Down's syndrome was disproportionately represented in the
London and Moscow series. As has already been pointed out by Bain et al. (1976), these findings
may help to explain the discrepancy between the epidemiologically derived risk figure of 1-3%
for older women having a child with Down's syndrome (Hook, 1976) and the figure of 4-6%
derived by Ferguson-Smith (1976) from prenatal diagnostic results. It is unlikely that the epi¬
demiological data would have included macerated stillbirths and some of the infants dying in
the first week of life as these would probably have remained undiagnosed.
There can be little doubt that chromosomal studies are an important part of the investigation
of paediatric deaths. Information has been gained concerning selection against the chromosomally
abnormal, which begins at conception and continues well into childhood. The chromosome results
obtained are of great value in genetic counselling, even in those instances where the chromosomes
are found to be normal since there is little point in offering prenatal chromosome studies to
parents who have had an abnormal baby which was found to have a normal karyotype. In con¬
clusion, it is suggested that chromosome studies should be an integral part of the paediatric
necropsy, except for deaths due to primary central nervous system lesions, s.i.d.s. in apparently
normal healthy infants and trauma. However, in dealing with s.i.d.s. it can be argued that it is
essential to obtain as much information as possible; routine chromosome studies are perhaps
justifiable on this basis.
summary
The results of chromosome studies from 1193 consecutive paediatric necropsies in Edinburgh
and 331 in Adelaide are given. In the Edinburgh series 51 major chromosome abnormalities were
detected in 780 (6-5%) necropsies where chromosome studies were successful and in Adelaide
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I (i in 295 (5-4%) were found. It is suggested that chromosome studies sbordd become an integral
part of the paediatric necropsy except for deaths due to primary central nervous system lesions
and trauma.
We thank the many people who have assisted with this study, including pathologists who conducted
necropsies and collected samples for us, cytogeneticists from other institutions who allowed us to use chromo¬
some results from patients studied during life and the following people for assistance with tissue culture and
cytogenetics: Susan Bowser-Riley, Elizabeth Grace and Janet Watson in Edinburgh, and Lynene Day,
Helen Eyre, Trudy Hocking and Erica Woollatt in Adelaide.
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In a survey of Down's syndrome in South
Australia, 921 persons, both living and deceased,
were identified ; 717 individuals with the disorder
were living in South Australia. Cytogenetic con¬
firmation of the diagnosis had been made in 774
cases. From 1955 to 1977, the over-all incidence
of Down's syndrome at birth was found to be
1.175/1000 live births. The incidence of Down's
syndrome was significantly lower over the last
five years of this period than for the first 18 years;
thus it appears that the incidence of Down's syn¬
drome in South Australia is falling. Analysis of
maternal age changes with time has not re¬
vealed any changes to the maternal age-specific
rates for Down's syndrome, although the rate for
mothers aged 25 years or younger appears to be
falling. The proportion of Down's syndrome babies
born to women aged 35 years or more has de¬
creased from 65.7% for those born before 1950 to
30.4% for those born from 1975 to 1977; similarly,
the median maternal age has fallen from 37.12
years to 28.25 years. Regression analyses of
maternal age rates fdr Down's syndrome by single
years have produced figures suitable for genetic
counselling. A plea is made that Down's syndrome
should become a notifiable condition.
No comprehensive study of the epidemiology of Down's .
syndrome has been carried out in Australia since that of Collmann
and Stoller in Victoria, which covered the period from 1942 to
1957! The pattern of maternal age at birth has been changing
since that period, and this could be expected to change the
incidence of Down's syndrome at birth. The effects of this para¬
meter have been studied for the period from 1939 to 1964 in
Victoria.2 Furthermore, there had been a clinical impression that
the mothers of children with Down's syndrome who were seen
at Intellectually Retarded Services were younger than those seen
in the past. With the advent of prenatal diagnostic programmes
aimed at reducing the frequency of Down's syndrome at birth,
up-to-date information on the epidemiology of Dovvn's syndrome
is essential for such programmes to be properly planned, and their
impact to be assessed. A survey of Down's syndrome over the
period from 1950 until the end of 1977 was carried out in South
Australia to identify all births in this State which had resulted in
children with Down's syndrome, and to identify all living persons
with Down's syndrome in the State.
METHODS
The records of all public institutions which may have had dealings with
persons suffering from Down's syndrome were searched to identify cases.
These included public hospitals, mental health institutions, special schools,
sheltered workshops, and so on. Notices requesting information about
persons with Down's syndrome were placed in the AMA Gazette, country
medical practices were contacted by letter, and newspaper publicity was
obtained asking parents or next of kin to contact the survey.
" Chief Cytogeneticist.
t Medical Officer.
t Assistant Senior Social Worker.
§ Director of Histopathology.
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When an individual with Down's syndrome had been identified, the
next of kin was approached by telephone, letter or personal visit, and asked
to supply information regarding the time and place of conception and birth
of the subject. Data concerning ages and occupations of the parents, and
family structure, were also collected. If the subject was still alive, every
effort was made to carry out cytogenetic studies, if these had not already
been done. No diagnosis of Down's syndrome was accepted in the absence
of chromosome studies, unless it had been made unequivocally by a medical
practitioner. This report covers all cases born before January 1, 1978. Data
on total live-birth occurrences and parental ages were supplied by the
Australian Bureau of Statistics.
Hook and Chambers have used regression analysis to estimate rates of
Down's syndrome by single-year maternal-age intervals.3 Their regression
was of the form lny=C,x+C0, where y is the rate of Down's syndrome
births per 1000 live births, x is maternal age, and C,, C0 are constants.
They divided the maternal age into two ranges, from 20 years to 31 years
and from 33 years to 49 years. Similar regression analysis was carried out
by means of Statistical Package for the Social Sciences" for the data from
1960 to 1977, for the age ranges 20-31 and 33—47.5 years. The latter
range has been determined as in Hook and LindsjoT
RESULTS
A total of 921 individuals with Down's syndrome were identified,
comprising 498 males and 423 females (sex ratio 1.18). The
distribution of the Down's syndrome cases is shown in Table 1.
Of the 717 living cases only 256 (36%) were institutionalized. The
sex ratio suggests that there might have been an underascertain-
ment of females. Hence, the sex ratio according to period of birth
for those born in South Australia was calculated (Table 2), and
this shows an increase in male:female sex ratio up to 1.56 for the
period from 1975 to 1977. It is inconceivable that sex could be a
factor in ascertainment in infancy. However, it should be noted
that none of these sex ratios is significantly different from 1.06.
Table 1







Unknown 4 4 1 .00 (1%)
Living at home 238 196 1 .21 (47%)
Strathmont Training Centre 50 24 2.08 (8%)
Minda Home Inc. . . 84 67 1 .25 (17%)
Other institutions . . 14 17 0.82 (3%)
Adopted/fostered . . 13 6 2.17 (2%)
Dead 95 109 0.87 (22%)
Total 498 423 1.18 100
The diagnosis of Down's syndrome had been confirmed by
chromosome analysis in 774 cases and the distribution of the
various' chromosomal forms are shown as follows.
Regular trisomy 21 . .







Only 23 of the living persons with Down's syndrome have not had
a chromosomal analysis.
There were 818 individuals with Down's syndrome, who had
been born in South Australia; their birth dates ranged from 1888 to
1977. Of those born in South Australia all were conceived in
South Australia, except for six who had been conceived in other
States, and eight who had been conceived outside Australia. The
places of conception (taken as places of residence of the mothers
at the time of conception) of 28 of those born in South Australia
were unknown.
Fluctuations in the incidence of Down's syndrome are shown in
Figure 1. The incidence appears to be lower up to the early 1 960s
than from this time until 1971. The most likely explanation of this
is under-ascertainment in the early part of this period. The drop in
incidence since 1971 is unlikely to be due to this factor, and may
represent a real decrease in the incidence of Down's syndrome.
If the incidence of Down's syndrome'over the last five years is
compared with that of the period from 1955 to 1 972 as in Table 3,
then there has been a significant decrease.
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Table 2
Sex Ratio of Persons With Down's Syndrome According to Period
of Birth
Period of Birth
Number of Affected Persons
Sex
RatioTotal Males Females
Before 1 950 190 100 90 1.11
1950 to 1954 71 39 32 1 .22
1955 to 1959 107 49 58 0.84
1960 to 1964 124 68 56 1 .21
1965 to 1969 154 83 71 1.17
1970 to 1974 126 71 55 1 .29
1975 to 1977 46 28 18 1 .56
Total . . 818 438 380 1.15
Table 4
Maternal Age at Birth of Individuals With Down's Syndrome Born in
South Australia: Changes With Time
Number of Maternal Age
Down's (Years)
Year of Birth Syndrome
Persons Mean Median
Before 1 950 181 35.93 37.12
1950 to 1954 71 35.03 36.67
1955 to 1959 107 34.86 36.80
1 960 to 1 964 123 33.94 34.75
1965 to 1969 154 32.64 32.50
1970 to 1974 124 30.60 29.17
After 1975 46 30.51 28.25
Total . . 806 33.67 34.87
The age of the mother at the birth of the Down's syndrome
individual was known for 806 of the 818 such persons born in
South Australia. This age ranged from 16 to 49 years (mean
33.67 ±standard deviation 7.72 years). There has been a fall in
the mean and median maternal ages for mothers of children with
Down's syndrome which has been more marked than the fall in
the maternal age of the general population (Table 4, Figure 2).
Because of the fall in the proportion of older mothers in the
population, the proportion of Down's syndrome children born to
years. The impact of prenatal diagnosis on these figures is minimal.
There were only three pregnancies terminated for fetal Down's
syndrome in the period from 1975 to 1977, one in the 35 to 39
years age group, and two in the 40 to 44 years age group. These




Figure 1: Fluctuations in the incidence of Down's syndrome in South Australia since
1955. Also shown is the birth rate in South Australia. The data from which the incidence
figures were calculated can be obtained from the authors.
these women had fallen (Table 5). The mothers of the Down's
syndrome persons in the survey who were born before 1950 were
aged 40 years or older in 33.4% of cases, and 35 years or older in
65.7% of cases. In the last three years of the survey these propor¬
tions had fallen to 13.3% and 30.4% respectively.
To determine whether the maternal age-specific rates of Down's
syndrome had changed with time these were calculated for
quinquennial maternai age groups over time (Table 6). It appears
that there has been no change in the age-specific rates over tRe
period studied. The lower rates for the period from 1955 to 1959
are probably due to under-ascertainment, since it is to be expected
that ascertainment would be more complete for the more recent
Table 3
Comparison of Down's Syndrome Births Over the Last Five Years With













X2 = 7.82; P< 0 . 01.
24-
1950 '55 '60 '65 '70 '75 '80
year
Figure 2: Changes in the mean and median maternal ages for mothers of Down's
syndrome infants and for mothers of live-born infants in South Australia.
The regression equation obtained for the age group of 20 to 31
years was 1ny=0.06325x-1.98775 (SE slope = 0. 02379; SE
intercept = 0.61 229); and for the age group 33 to 47.45 years it
was 1 ny=0 . 24823x-7 . 89579 (SE slope=0. 01 847; SE inter-
Table 5
Proportions of Infants With Down's Syndrome and Total Live Infants Born
to Women of Advanced Age in South Australia
Interval
Maternal Age













Before 1 950 65.7% 35.4%
1951 to 1954 1 3 . 5% 66.2% 3.1% 30.9%
1955 to 1959 1 3 .4% 59.3% 3.1% 32.4%
1960 to 1964 1 3.0% 51 .2% 3 .0% 30. 9%
1965 to 1969 9 .8% 44. 2% 2 . 5% 22.1 %
1970 to 1974 5.9% 35. 5% 1 .3% 21 .0%
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Table 6
Age-Specific incidence Rates" for Down's Syndrome 1955 to 1977
in South Australia +
Maternal 1955 1960 1965 1970 1975
Age to to to to to
(Years) 1959 1964 1969 1974 1977
19 and
younger . . 0.324 0 0.541 0.679 0.181
20 to 24 0.429 0.588 0.587 0.651 0.351
25 to 29 0.459 0.560 1 .000 0.807 0.831
30 to 34 0.767 1 .189 1 .785 1 .263 0.792
35 to 39 2.850 2.353 4.439 3.650 3.603
40 to 44 9.997 11 .07 10.87 18.72 18.37
45 and older 31 .41 27.62 44.20 22.22 0
Total 1 .094 1 .158 1 .468 1 .155 0.807
* Infants with Down's syndrome per 1000 live births,
t Copies of the data used to calculate these rates are available from the
authors.
cept= 0.74371). The observed incidences and the regression lines
are shown in Figure 3. Table 7 shows the observed and regression-
derived rates for Down's syndrome by single years, and similar
regression-derived rates from other studies.
DISCUSSION
A major problem in a study such as this, where retrospective
ascertainment was used, is to know how complete it has been.
It is believed that ascertainment is virtually complete for living
individuals, but becomes progressively incomplete for the deceased
as one goes back in time. Although there was a constant excess of
males, the sex ratio of the Down's syndrome cases does not differ
significantly from that of the population. Hence, it can be assumed
that there has been no ascertainment bias related to sex. Evans et
alii found a non-significant excess of males with Down's syndrome,
born in Manitoba between 1965 and 1974.6
Recently published surveys of Down's syndrome give incidences
ranging from 1.501/1000 live births from Massachusetts for the
period from 1 958 to 1965,7 to 1.148/1000 live births from Copen¬
hagen for the period from 1960 to 1971,8 Chromosome studies on
54 749 consecutive neonates gave an incidence of 1.15/1000.®
The incidence of 1.175/1000 found in the present study for the
period from 1955 to 1977 is consistent with that found in other
recently published series, and not far below that of 1.32/1000
for the most recent period studied, from 1953 to 1 957, by Collmann
and Stoller.2
Fluctuations in the annual incidence of Down's syndrome were
demonstrated in Victoria.1 Similar fluctuations have been shown
in South Australia. These fluctuations make it difficult to be
certain that Down's syndrome is really decreasing in incidence in
South Australia. While it appears that the incidence of Down's
syndrome is falling, it may be a few years yet before it is possible to
be certain of this. There have been 24 known cases of Down's
syndrome in South Australia in 1978, and two more aborted after
amniocentesis. Stoller has suggested that long cycles in incidence
may operate in some instances.10
Table 7
Total Number of Down's Syndrome and Live Births in South Australia 1960 to 1977 by Age of Mother"
Down's | • . p
Age of Mother Syndrome Live Births ^ ^qqq Incidence1 ^ew ^ork3 Mass.7 Sweden5
<15 0 177 0
15 0 877 0
16 2 2 833 0.706
17 4 6 574 0.608
18 4 11 158 0.358
19 5 15 470 0.323
20 11 19514 0.564 0.49 0.52 0.57 0.64
21 12 24 011 0.500 0.52 0.59 0.60 0.67
22 10 27315 0.366 0.55 0.65 0.64 0.71
23 14 29 904 0.468 0.59 0.71 0.67 0.75
24 28 30 568 0.916 0.63 0.77 0.70 0.79
25 29 29 578 0.980 0.67 0.83 0.74 0.83
26 16 27 109 0.590 0.71 0.89 0.77 0.87
27 21 23 765 0.884 0.76 0.95 0.80 0.92
28 19 20 723 0.917 0.81 1 .01 0.84 0.97
29 10 17 730 0.564 0.86 1 .07 0.87 1 .02
30 13 15171 0.857 0.91 1.13 0.90 1 .08
31 14 12 636 1.11 0.97 1 .21 0.93 1.14
32 19 10 787 1 .76 1 .09 (int) 1 .38 1.15 1 .25
33 ■13 9 093. 1 .43 1 .34 1 .69 1 .55 1 .47
34 14 7 823 1 .79 1 .72 2.15 1 .98 1 .92
35 18 6 897 2.61 2.21 2.74 2.53 2.51
36 11 5 744 1 .92 2.83 3.49 3.22 3.28
37 18 4 931 3 : 65 3.63 4.45 4.11 4.28
38 17 4172 4.07 4.65 5.67 5.24 5.60
39 20 3 416 5.85 5.96 7.21 6.68 7.32
40 16 2 525 6.34 7.64 9.19 8.52 9.57
41 19 1 876 10.13 9.79 11.71 10.86 12.51
42 17 1 293 13.15 12.55 14.91 13.85 16.36
43 22 842 26.13 16.09 19.00 17.66 21 .39
44 16 500 32.00 20.62 24.20 22.51 27.96
45 5 267 18.73 26.43 30.84 28.71 36.55
46 8 135 59.25 33.88 39.28 36.61 47.79
47 0 48 0 43.42t 50.04 46.68 62.47
48 2 19 105.26 55.66t 63.75 59.52 81 .62
49 0 7 0 71.34t 81 .21 75.89 106.76
*
Regression-derived estimates of incidence are compared with other published regression-derived incidence figures,
t By extrapolation of regression line.
int = interpolated.
Mass= Massachusetts.
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Collmann and Stoller predicted that, with the fall in mean
maternal age of the population, the incidence of Down's syndrome
would fall.2 They showed this to be so for three consecutive
quinquennial periods in Victoria from 1943 to 1957. Evans et alii6
reported an "apparent overall decrease" in the incidence of Down's
syndrome, and suggest that this may have been due to falling
maternal age. They also found that the age-specific incidence of
Down's syndrome children born to women aged from 35 to 39
years increased over their period of study. Mikkelsen et alii made a
similar observation.8 In the present study, the age-specific incidence
for women aged from 35 to 39 years has been fairly constant over
the last 15 years. The low incidence of Down's syndrome in this
study for the period from 1975 to 1977 may be due not only to a
changing maternal age distribution but also to a marked drop in
age-specific incidence of Down's syndrome children born to
mothers aged less than 25 years, compared with the preceding
10 years.
The proportion of women over 35 years of age giving birth in
South Australia has fallen since 1 964. Similar findings of decreasing
maternal age in the general population have been recorded in
other communities.6 9 This change in maternal age distribution
appears to be associated with, and may indeed be responsible for,
the apparent decreasing incidence of Down's syndrome in South
Australia. Future trends will be difficult to interpret because of the
increasing application of prenatal diagnosis to the older age groups.
MATERNAL AGE (Years)
Figure 3: Rates of Down's syndrome per 1000 live births by maternal age. Actual values
are plotted and regression lines are shown.
Over the last three years in South Australia, 30.4% of mothers of
children with Down's syndrome have been aged 35 years or more,
yet only 4.1 % of the women giving birth were in this category. This
fact gives support to the recent recommendation of the NHMRC11
that all women over the age of 35 years should be offered amnio¬
centesis. Adequate laboratory facilities for this already exist in
South Australia, but are under-used.
The proportions of chromosomal types of Down's syndrome seen
in South Australia are similar to those seen in New South Wales,12
and Victoria.13
The risk figures for Down's syndrome to be used in genetic
counselling have been the subject of considerable controversy.1^1
Some authors have advocated the use of risk figures from epidemio¬
logical studies such as the present one,15 16 whereas others have
regarded the figures obtained from prospective prenatal diagnostic
studies as being more appropriate.17 1819 Since the two sets of
figures are rather different, the controversy is a real one. The
reasons for the discrepancy may be the number of Down's
syndrome fetuses lost during the second and third trimesters,20
.and in the perinatal period.21
For genetic counselling in South Australia, the best epidemio¬
logical figures are those derived from the regression equation
(Table 7). These figures are similar to those obtained by means of
a similar statistical treatment from New York,3 Massachusetts,7
and Sweden.5 As yet, there are no figures for risks of Down's
syndrome by single-year maternal-age intervals from prenatal
diagnostic series based on large numbers for Australia. It is to be
hoped that such figures will become available in the near future,
as figures derived from such data are useful for genetic counselling.
The present survey will be maintained as an ongoing project to
monitor Down's syndrome in South Australia. South Australia
has only about 10% of the population of Australia, hence any
changes in the occurrence of Down's syndrome in this State
cannot be assumed to represent those in Australia as a whole,
although they may do so. The task of monitoring Down's syndrome
is made more difficult, because this is not a notifiable condition.
A plea is made for this disorder to be made notifiable, and for the
data to be kept in a central registry. Down's syndrome is the most
common single identifiable cause of mental retardation in the
community, yet its distribution and occurrence in the community
are poorly known.
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Distribution of an-Antitrypsin (PI) Phenotypes in Chromosome Abnormalities
John C. Mulley and Grant R.Sutherland
Cytogenetics Unit. Department of Histopathology, Adelaide Children's Hospital, North Adelaide. S.A. 5006, Australia
Summary. PI phenotypes (including subtypes) were determined
for 168 individuals with chromosomal abnormalities ascer¬
tained in Adelaide. These included patients with mosaicism,
trisomy 21, trisomy 13, trisomy 18, and various sex chromo¬
some aberrations (45,X, 47,XXX, 47,XXY, 47.XYY, and
48.XXXY). Data did not support an existing proposition that
mildly deficient PI phenotypes predispose to abnormal chromo¬
some segregation during mitosis or meiosis. Phenotypic dis¬
tributions of each group were statistically similar to control
populations of cord bloods and bloods donors.
Introduction
ai-Antitrypsin (anAT) is the major regulator of proteolytic
activity in humans. A glycoprotein, it occurs in many body
fluids and inhibits a variety of proteases (Morse 1978a).
Genetic heterogeneity is determined at the PI locus by a null
allele and 32 confirmed codominant alleles (Cox et al. 1980).
Most variants are infrequent, although the alleles PI*S, PI*Z,
PI*F, and PI*I are relatively common and associated with
reduced on AT serum levels.
The clinical importance of ouAT relates primarily to severe
deficiency associated with the PI Z phenotype. Severe aiAT
deficiency predisposes to adult pulmonary emphysema and
childhood cirrhosis of the liver (Fagerhol 1976; Morse 1978b).
Although PI S-Z is also considered deficient, the association
with these diseases is weaker. Clear disease associations have
not been demonstrated with the common mildly deficient
phenotypes PI S, PI M-S, and PI M-Z, or the less common PI F,
PI I. PI F-I, PI I-Z, and PI F-Z phenotypes.
Apart from the established disease associations, PI pheno¬
types with reduced cnAT concentration have been tentatively
implicated in the genesis of recurrent miscarriages (Aarskog et
al. 1978), abnormal chromosome segregation during mitosis
(Aarskog and Fagerhol 1970; Kueppers et al. 1975; Fineman et
al. 1976), and meiotic nondisjunction with advanced maternal
age (Fineman et al. 1976). This investigation extends the sample
size of the chromosomal abnormalities previously studied, and
examines PI phenotypes from additional groups with chromo¬
some abnormalities from a population where phenotypic fre¬
quencies are known. All common aiAT variants, including
alleles determining aiAT deficiency, are reliably classified
isoelectric focusing (Hoffmann and van den Broek 1977; Wardet
al. 1977) and PI M can be subdivided by high resolution
isoelectric focusing (Frants and Eriksson 1978; Kueppers and
Christopherson 1978).
Offprint requests to: J. C. Mulley
Materials and Methods
All chromosomal aberrations were diagnosed amongst neonates, chil¬
dren, and adults referred to the Cytogenetics Unit of the Adelaide
Children's Hospital up to September 30, 1980. Samples from trisomy 21
individuals were collected in conjunction with a survey of Down syn¬
drome in South Australia (Sutherland et al. 1979). The control data
were derived from a local survey of blood donors (Mulley 1980) and of
cord bloods from a survey now in progres. aiAT was phenotyped as
previously described (Mulley 1980). Genetic nomenclature follows the
recommendations of Shows et al. (1979).
Contingency tests were applied with a correction for continuity.
Phenotypes were classified for statistical purposes as either PI M, or not
PI M which represented all mildly deficient phenotypes. All PI M sub¬
types were grouped as PI M since the aiAT concentration of subtypes is
equivalent (Kueppers and Christopherson 1978), although the complete
subtype classification is presented.
Results
auAT phenotypes from patients with a variety of deletions are
given in Table 1. The exclusion of familial translocations and
inversions by family study and paternity testing indicated that
the deletions were probably sporadic in origin from at least
eight of the propositi. Although two low frequency alleles (PI*F
and PP"Z) were detected from only 11 families, there is no
evidence of an association between non PI M phenotypes and
the occurrence of spontaneous deletions.
Table 1. PI Phenotypes in patients with presumed sporadic deletions





1 4q(27—*31) Ml M1-M3 M1-M3 88%
2 4q(27->31) M1-M2 " a —
3 5p(I4->pter) M1-M2 M1-M3 M1-M2 79%
4 7q(22) Ml Ml Ml 80%
5 12p(12) Ml Ml Ml 95%
6 12p( 13) and 15q(15) Ml M1-M2 Ml 85%
7 12p(ter) and 19p(ter)
or 19q(ter)
Ml-F a a —
8 18p(11) Ml Ml M1-M2 61%








Table 2. Distribution of PI phenotypes among chromosome abnormalities arising from abnormal chromosome segregation
Chromosome abnormality PI Phenotype
Ml M1-M2 M1-M3 M2--M3 M2 M3 Ml-S M2-S Ml-Z M2-Z Ml-F M3-F M2-1
1. Mosaics 5 2 3 — — — 1 1 _______
a) Sex chromosome mosaics 3 2 2 — — — — 1 _____
b) Autosomal mosaics 2 — 1 — — — 1 — _____
2. Trisomy 21" 55 18 14 1 1 2 1 — 6—2—1
a) Maternal age < 30 years 8 7 1 1 1 1 — — 1 — — — 1
b) Maternal age > 35 years 30 7 9 — 1 1 — 3 — 2 — —
3. Trisomy 13 1 1 — — 1 — — — _ _ — _ _
4. Trisomy 18 — — 1 — — — — — _____
5. Sex chromosome
Abnormalities (total) 23 9 3 — 1 — 1 1 — 1 — 1 —
a) 45.X 6 1 — — — — 1 — _____
b) 47.XXX 5 — — — 1 — — — _ _ _ _ _
c) 47.XXY 11 7 2 — — — — 1 _ _ _ _ —
d) 47.XYY — 1 1 — — — — - — 1 — 1 —
e) 48.XXXY 1
" Total trisomy 21 includes the subclasses where maternal age was unknown or between 30 and 35 years, in addition to the two subclasses presented
(see text)
Table 3. PI allele frequencies from control populations and major test groups examined
Population No. Allele frequency
P1*M1 PI*M2 P1*M3 PI*S PI*Z PI*F PPG PI*I
Controls
Blood donors 220 0.65 0.14 0.13 0.061 0.016 — — 0.002
Cord bloods 220 0.70 0.16 0.08 0.027 0.014 0.005 0.002 0.002
Trisomy 21 101 0.75 0.11 0.09 0.005 0.030 0.010 — 0.005
Maternal age < 30 years 21 0.60 0.26 0.10 — 0.024 — — 0.024
Maternal age >35 years 53 0.77 0.07 0.10 0.009 0.028 0.019 — —
Sex chromosome abnormalities" 40 0.74 0.16 0.05 0.025 0.013 0.013 — —
47.XXY 21 0.74 0.19 0.05 0.024 — _ _ _
Mosaics" 12 0.67 0.13 0.13 0.083 — _ _ _
Sex chromosome mosaics 8 0.63 0.19 0.13 0.063 — _ _ _
Deletions 11 0.82 0.09 0.05 — — 0.05 — —
" Subclasses with small sample sizes are omitted












46.XY/46, XY,del( 18p) M1-M3
46,XY/47,XY,+8 MI
46,XY/46,XY,t( 15; 18)(p 13;q 12) Ml
46,XY/47,XY,+r(?) Ml-S
The phenotypic distributions from the other classes of
chromosome abnormality are presented in Table 2. Allele
frequencies from all groups, and from subgroups with reason¬
able numbers, are given in Table 3. Standard errors of these
estimates are considerable, given the small sample sizes in¬
volved. Phenotypic distributions were not signiticantly different
between any test group and the control populations. The 12
mosaics (Table 4) show no significant increase in non PI M
phenotypes compared with controls. It should be noted that
oply six of the mosaics studied involved malsegregation of
normal chromosomes, rather than structurally altered ones.
Similarly, neither autosomal trisomies nor sex chromosome
abnormalities arising from meiotic nondisjunction show any
increase of non PI M phenotypes compared with controls.
The trisomy 21 results were subdivided according to mater¬
nal age, where known. Of the 101 trisomy 21 individuals stud-
178
Table 5. Basis for proposed associations between mildly deficient phenotypes and chromosome aberrations
Study No. Allele frequency
PI*F PI*M P1*S PI*Z PI*MLAMB
Mosaics
Aarskog and Fagerhol (1970)
Kueppers et al. (1975) 21
Fineman et al. (1976) 19
Trisomy 21















ied, maternal age axceeded 35 years in 53 individuals and was
less than 30 years in 21 individuals. For the remaining 27,
maternal age was either unknown or between 30 and 35 years.
The phenotypic distribution of each subgroup was not signif¬
icantly different from that of the control populations.
Discussion
Samples of both adult blood donors and cord bloods were
chosen as control populations because of age heterogeneity
within test groups. Allele frequencies from the controls are
given in Table 3, and are similar to recent estimates obtained by
isoelectric focusing from North America (Kueppers and Chri-
stopherson 1978) and southern England (Arnaud et al. 1979).
However, the PI*S frequency of 0.061 from adult blood donors
and 0.027 from cord bloods causes significant heterogeneity
(0.01 <T<0.05) between the two control populations, with and
without subtyping. This divergence is presumably a chance
effect since pooling the control populations would in fact result
in a PI*S frequency of 0.044. comparable to another Australian
estimate of 0.045 from a Melbourne control group of cord
bloods (McPhee et al. 1980).
Results of previous investigations suggestive of an associa¬
tion between non PI M phenotypes and chromosomal aber¬
rations are summarised in Table 5. Significantly increased
heterozygosity was due to higher frequencies of non PI*M
alleles among sex chromosome mosaics, and among trisomy 21
where maternal age exceeded 35 years. The PI*MLAMB subtype
reported by Fineman et al. (1976) was not recorded in the
present study, indeed its existence as a distinct variant is un¬
confirmed (Cox et al. 1980) and the relationship with PI M sub¬
types is unclear.
No evidence supporting an association between PI pheno¬
types and cytogenetic aberrations was found in the present
study. The preliminary report by Aarskog and Fagerhol (1970)
and subsequent studies by Arnaud et al. (1976) and McPhee et
al. (1980) showed no relationship between PI and trisomy 21,
but information on maternal age was unavailable. Although
trisomy 21 is strongly correlated with maternal age, random
selections of cases will always include a significant proportion
where maternal age is less than 35 years (see Table 3). Despite
subdivision on the basis of maternal age, Guanti and di Loreto
(1980) and the present study found no evidence of a possible
causal relationship between PI phenotypes and trisomy 21
where maternal age exceeded 35 years. The initial hypothesis
proposing such an association was probably based on a chance
observation resulting from a small sample size.
A genetic predisposition leading to multiple births and/or
chromosomal abnormalities has been discussed (Lieberfarb et
al. 1978). However, cuAT would appear to be an unlikely
component of such a genetic predisposition to meiotic non¬
disjunction. Further data is necessary to reject conclusively the
suggested association between auAT phenotypes and abnormal
chromosome segregation during mitosis. While a degree of
racial heterogeneity involving non PI*M alleles at the PI locus
has been established, no evidence for a corresponding hetero¬
geneity in the frequency of cytogenetic abnormalities has been
documented. The aspect of a genetic predisposition to multiple
births involving aqAT remains open to investigation.
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From the Department ofHistopathology, Adelaide Children's Hospital, North Adelaide, SA 5006 Australia
summary Chromosome studies were attempted on 97% of necropsies carried out in the
Department of Histopathology of the Adelaide Children's Hospital over the four-year period
ending May 1981. Results were obtained from 89% of necropsies of which 7-5% had major
chromosome abnormalities. The chromosome results are analysed according to the category of
the necropsy and to primary cause of death. It is recommended that cytogenetic studies be
performed on all stillbirths and infants dying at less than 28 days of age except in cases of isolated
CNS malformation, sudden infant death syndrome (SIDS), trauma, or known single gene defects.
Chromosome studies carried out on several series of
paediatric necropsies up to 1977 were summarised
by Sutherland et al1 and the recommendation made
that such studies should form part of most paediatric
necropsies. The present report documents the
cytogenetic findings on all necropsies at the
Adelaide Children's Hospital over an additional
period of four years and makes further, more
detailed, recommendations concerning the applica¬
tion of chromosome studies at the paediatric nec¬
ropsy.
Material and methods
All routine paediatric necropsies at the Adelaide
Children's Hospital were studied. During the period
of study the annual necropsy rate fluctuated bet¬
ween 75% and 80%, the majority of those not com¬
ing to necropsy having died from long standing ill¬
nesses such as cystic fibrosis, thalassaemia and
malignant disease. In addition some stillbirths and
neonatal deaths occurring outside the Hospital were
referred for necropsy and all sudden infant deaths in
South Australia were examined under the authority
of the Coroner. Such studies were carried out for a
six-year period ending May 1981; the results of the
first two years have been published,1 hence this
report covers the last four years of the period.
Methods of chromosome study have been previ¬
ously recorded.' Perinatal deaths are defined as
stillbirths of more than 28 weeks gestation and
liveborn infants who lived for less than one week,
regardless of gestation. The perinatal deaths were
Accepted for publication 25 August 1982
further subdivided into macerated stillbirths, non-
macerated stillbirths and early neonatal deaths.
Older neonate refers to a baby dying between 8 and
28 days after birth, infant to a death occurring bet¬
ween 29 and 365 days after birth and child to a
death occurring on or after the 366th day of life.
Results
The chromosome results are shown by category of
necropsy in Table 1. Chromosome results were
obtained for 89% of necropsies, the major area of
failure being macerated stillbirths where results
were obtained from only 54% of those studied.
Despite their high failure rate, macerated stillbirths
are considered worthy of study since they yielded
the second highest proportion of chromosome
anomalies. Therapeutic abortions of course had the
highest yield since in many cases these were per¬
formed as the result of a prenatal diagnosis of a
chromosome abnormality.
The chromosome findings according to cause of
death are shown in Table 2 for the whole series
excluding the therapeutic abortions and spontane¬
ous abortions of less than 20 wk gestation. The
chromosome abnormalities found in the SIDS were
a 46,XY/47,XYY mosaic and a t(X;5) in a male
known to have this abnormality poor to death, hav¬
ing been investigated for severe hypospadias.
The chromosome abnormalities detected are
shown in Table 3. The majority of these are typical
of those found at prenatal diagnosis (mainly auto¬
somal trisomies) or of those dying in childhood—for
example, Down's syndrome. There was one case of
the very rare 45,X male found in a babe dying on the
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Table 1 Chromosome results according to category ofnecropsy
Category Total Chromosome Successful Normal karyotype Abnormal karyotype
studies
attempted Male Female No %
Therapeutic abortion 31 29 28 6 9 13 46
Spontaneous abortion 7 7 3 3 0 0 0
(less than 20 wk)
Spontaneous abortion 4 4 3 3 0 0 0
(more than 20 wk)
Macerated stillbirth 51 48 26 12 9 5 19
Non-macerated stillbirth 21 20 19 7 10 2 11
Early neonatal death 38 38 38 20 13 5 13
Later neonatal death 25 25 24 15 9 0 0
Older than 28 days 210 208 199 107 87 5 2-5
Older than 1 yr 151 143 141 84 52 5 3-5
Total 538 522 481 257 189 35 7-5
Table 2 Chromosome results according to primary cause ofdeath (therapeutic abortions and abortions ofless than 20 wk
gestation excluded)







Macerated without malformation 41 37 18 7 9 2 11
Macerated with malformation 3 3 2 0 0 2 (100)
Prematurity associated disease 3 3 3 2 1 0 0
Primary CNS malformations 41 41 38 17 21 0 0
Severe congenital malformations 49 49 47 14 9 23 49
Congenital heart malformation 56 56 56 29 25 2 3-6
Primary anoxia 23 22 19 11 7 1 5-3
Infection 27 27 25 14 11 0 0
SIDS 142 141 135 81 52 2 1-5
Leukaemia 15 15 15 9 6 0 0
Other malignancy 18 18 18 11 7 0 0
Trauma 54 45 44 28 16 0 0
Mendelian disorders 21 21 20 14 6 0 0
Miscellaneous 37 37 37 18 18 0 0
Total 530 575 477 255 188 32 6-7
trisomy 2 had 17/27 cells examined showing trisomy
2. This was one of macerated twins stillborn at 37
wk gestation; there was a single placenta and
chromosome studies were from amnion. The main
necropsy finding was of intrauterine hypoxia and
there was evidence of growth disturbance at the cos-
tochondral junction. The findings in the second twin
were similar except that the karyotype was normal
female. The infant with del(5p) was an intrapartum
death and apart from borderline microcephaly no
unusual findings were made at necropsy.
Discussion
The incidence and type of chromosome abnor¬
malities detected in this series is similar to other
published series.1-3 The repeated finding of mosaic
trisomy 2 is of interest since there is some doubt as
to whether this is a true chromosome abnormality or
an in vitro chromosome change which is particularly
likely to occur when amnion is used for chromosome
study. In the present series the finding of mosaic
trisomy 2 in one of probably monozygous twins,
with the other having a normal karyotype, suggests
Table 3 Chromosome abnormalities detected
Chromosome abnormality No
(a) Amongst the 47,XX or XY, + 21 6
therapeutic abortions 46,XX,rob(13;14)mat, + 21 1
triploid 2










47,XX or XY, + 21 5
46,XY/47,XY, + 21 1









second day of life from cardiac failure due to a
hypoplastic left heart. His external genitals were
normal as was testicular histology. The mosaic
142 Sutherland, Carter
Table 4 Results of chromosome studies on unselected
paediatric necropsies*
Status No studied No abnormal % abnormal
Macerated stillbirth 138 18 13
Non-macerated stillbirth 359 15 4-2
Earlv neonatal death 862 46 5-3
Late neonatal death 1 10 5 4-5
Infant 402 19 4-7
Child 235 12 5-1
'Taken from references 1-3 and the present series.
that this finding is most likely to be due to in vitro
change.
In Table 4 the results of this series of paediatric
necropsies have been added to those summarised
previously.1 In the macerated stillbirth group the
incidence of chromosome abnormality is around
13% and in all other groups it is in the region of
4-5%. Apart from occasional sex chromosome
abnormalities and balanced translocations, virtually
all the chromosome abnormalities in infants and
children had been recognised prior to necropsy.
The value of chromosome results, even the nor¬
mal results, cannot be over-emphasised. Genetic
counselling should be offered to all couples who lose
a child in the perinatal period and since the question
of prenatal diagnosis arises in most genetic counsel¬
ling situations knowledge of the chromosome results
of the dead child are particularly valuable. In the
present series the finding of del(5p) in a stillbirth,
potentially a case of the cri du chat syndrome, was of
immense help to the parents. It provided them with
a reason for the death, alleviated some of their grief
with the knowledge that had the child survived it
would have been severely handicapped, and after
they themselves had been shown to have normal
karyotypes, provided positive reassurance that the
recurrence risk was very small.
There are several causes of death in which
chromosome abnormalities are no more common
than amongst unselected liveborn children. These
include deaths due to primary CNS malformation
(mainly anencephaly and spina bifida), SIDS,
trauma and known single gene defects. Since these
diagnostic categories will usually be known by the
time of the necropsy, and since there are very few
unknown chromosome abnormalities detected in
babies who have lived for more than one month, the
following guidelines are suggested for the use of
chromosome studies at the paediatric necropsy.
Studies should be done on all infants dying at less
than 28 days of age and on all stillbirths, except in
cases of isolated CNS malformation, SIDS, trauma
or known single gene defects. It is important that
these exceptions are properly identified and not
interpreted too loosely. For example, it is important
to ensure that a CNS malformation is an isolated
defect and not just one of many malformations pres¬
ent as occurred in one case of trisomy 18 in the
present series where the most obvious feature prior
to detailed examination of the neonate was spina
bifida. Obviously infants older than 28 days in whom
there are indications for chromosome studies should
be karyotyped if this has not heen done prior to
necropsy.
Assistance with the tissue culture and cytogenetics
was provided by Elizabeth Baker, Helen Eyre,
Trudy Hocking and Erica Woollatt. Some of the
necropsies were carried out by Drs GF Binns, AJ
Bourne and G Phillips. Mr J Stappers' care and
diligence in collecting material for chromosome
analysis at necropsy greatly contributed to the suc¬
cess of this study.
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SIX CASES OF THE CRI-DU-CHAT SYNDROME*
HELEN FLYNN1, ALLAN CARMICHAEL2 and GRANT R. SUTHERLAND2
SUMMARY
Six cases of the cri-du-chat syndrome are presented. Brief case histories are given along
with clinical description, cytogenetics and dermatoglyphics. The problem of diagnosing
this syndrome in older children is discussed and it is pointed out that the 'cat cry' can persist
into early adulthood. A case of Wolf's syndrome is also described so that comparison of
these two cytogenetically similar syndromes can be made.
During the past six years six cases of
cri-du-chat syndrome have been recognized at
Children's Collages, Kcw. It is the purpose
of this paper to describe them, and to compare
the clinical features with those of another dis¬
order, Wolfs syndrome, a case of which has
recently been seen at St. Nicholas Hospital.
It is interesting to consider the reasons which
prompted chromosome analysis for these
children; three cases were discovered when a
chromosomal survey was done of patients with
epicanthic folds, and a history of 'cat cry' in
infancy was subsequently obtained by question¬
ing the parents. In two other cases a history
of abnormal cry in the neo-natal period was
given by the parents on admission, thus sug¬
gesting chromosome analysis. Another, a 17-
year-old girl, was noticed by the Charge Nurse
to have a wail like a cat: she mentioned this
on several occasions to the doctors concerned
in her care, but as her appearance was so un¬
like that described for cri-du-chat no action
was taken. The Sister's persistence finally re¬
sulted in chromosome analysis being per¬
formed and her diagnosis was confirmed.
SUMMARY OF THE CASE HISTORIES
Case 1: C. H. Female, born 2nd August,
1957. (Fig. 1)
She was the second child, with four normal
siblings. Both parents were twenty five years
at her birth. Pregnancy was normal, gestation
40 weeks, labor normal. Birth weight 2,750
gm. She would not suck and had a high weak
*Presented at AGSOMD Conference Adelaide SA Oct. 1970.
1. Medical Officer, Childrens Cottages, Kew Vic. Aust. 3101
2. Medical Officer, Alfred Hospital, Prahran Vic. Aust. 3181
Participation in this study was during an effective period
whilst a fifth year Medical Student at Monash University.
3. Cytogenticist, St. Nicholas Hospital, Carlton Vic. Aust.
3053
Figure 1. C.H. Note prominent lower lip, low
set ears, epicanthic folds.
cry. The doctor said to the mother, 'you have
a pussycat for a baby'.
Case 2: E. H. Female born 21st August,
1949. (Fig. 2)
Mother was 26 years and father 34 years
at her birth. She was the second child and had
three normal siblings. The mother contracted
mumps in the second trimester, and noticed
that foetal movements were thenceforward
sluggish. Delivery was normal. Birth weight
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Figure 2. R.H., E.H., W.W. Note dissimilar facial
appearances.
3,430 gm. She did not suck well and failed to
thrive. A friend hearing the baby's voice said,
"Where's the cat?".
Case 3: R. H. Male, born 6th March, 1962.
(Fig. 2)
A paternal first cousin had Down's Synd¬
rome, and a paternal first cousin once re¬
moved was severely retarded. At the time of
his birth, his mother was 36 years, his father
35 years. There were two normal siblings, two
miscarriages, and one stillbirth. The patient
was the youngest child. Gestation was 40
weeks, labor normal. Birth weight 3,070
gm. The cry was immediately noted to be
abnormal like a kitten wailing. The child
sucked poorly, had episodes of twitching and
cyanosis, and failed to thrive.
Case 4: W. W. Male, born 31st January,
1960. (Fig. 2)
The mother was 24, the father 25 years,
at his birth. He was the second child in a family
of five. Three of his siblings were normal, and
one mildly retarded. Labor was induced at
thirty-six weeks, followed by a normal delivery
with birth weight 2,590 gm. In the neo-natal
period he cried like a kitten, and presented
feeding difficulties.
Case 5: M. F. Female, bom 5th December,
1952. (Fig. 3)
She was third born and has three normal
siblings. Her mother was 23 years, her father
24 years at her birth. Labor was induced
following an ante partum haemorrhage at
thirty-five weeks, and birth weight was 2,650
gm.; there is no history available about the
child's cry in infancy, but she would not suck
and failed to thrive. Her cry is still recog¬
nizably feline, at the age of 18.
Case 6: A. W. Female, born 22nd August,
1962, and died 1969.
Her mother was 25, her father 33 years at
birth. Her mother had one normal child, and
then six miscarriages before birth of the
patient. Labor occurred at thirty-six weeks,
producing an infant whose birth weight was
1,680 gm. The baby remained in hospital for
five weeks, and was always difficult to feed.
Figure 3. M.F. Note virtually normal appearance.
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Later in hospital it was noted that she was
noisy, "making her own peculiar sound", and
this was recognized to be the cri-du-chat on
chromosome analysis at 4 years. She had a
bilateral congenital dislocation of the hips,
diagnosed at birth, and was treated for 'coeliac
disease' at eighteen months. She died in 1969
as a result of a febrile illness.
Since Lejeune et al. first described cri-du-
chat in 1963 many other cases have been re¬
corded. Apart from the cry the most constant
features have been severe mental and physical
retardation. Some fairly constant facial char¬
acteristics have been described, such as hyper¬
telorism, epicanthus, low set ears, micrognathia,
and oblique palpebral fissures.
The most striking feature is of course the
cry. Three of our patients, aged respectively
8 years, 18 years, and 21 years, still have a
recognizable 'cat cry'. The cry from the 21
year old girl recently started a search around
the ward for "the fighting cats." In two other
children there is no definite cat sound, but
when distressed they produce a high pitched
wail. Not all parents volunteered a history of
cri-du-chat, but most remembered it when the
direct question was asked. If this question
were included in routine history taking of
retarded children, an earlier diagnosis may
result.
Growth retardation was common in our pat¬
ients but not invariable. The height of one boy
(R.H.) was at the seventy-fifth percentile,
while one girl (M.F.) had a height at the
fiftieth percentile. The others varied from
below the third to the tenth percentile in
height.
All these patients had extremely small
heads. In each case the head circumference
measured less than three standard deviations
below the mean for age, and in one child
(A.W.) it was 9 standard deviations below
the mean.
Their facial appearance is not sufficiently
characteristic to enable a diagnosis to be made
on these grounds alone. Four of our cases are
at present in-patients at Children's Cottages,
Kew, and when seen together their resemblence
to each other is not striking. The facial ap¬
pearance of one girl (M.F.) is relatively
normal.
The moon-shaped or round face frequently
described in cri-du-chat cases was not seen in
any of our patients. Their faces were variously
long and thin, triangular, broad—in short they
varied as much as do normal individuals.
Perhaps if seen in infancy they would have
presented round faces.
In five of these six patients epicanthic folds
were present. The question of hypertelorism is
more difficult to decide. A flat wide nasal
bridge was present in every case, giving the
impression of widely spaced eyes. Without
exact measurements in ratio to the small and
narrow head, hypertelorism cannot definitely
be diagnosed.
A similar problem attaches to the description
of oblique palpebral fissures. Assigning dir¬
ection to the slant of the eyes is difficult in
the presence of epicanthi. However, three
patients did appear to have an anti-mongoloid
slant, two a mongoloid slant, and one was
normal. Four children had a convergent
strabismus. We found no characteristic shape
or position of the ears. Several patients had
ears which were mildly abnormal in shape or
size but no common pattern was seen. The
position varied, but the ears were mainly low
set. Micrognathia was an infrequent finding,
appearing in only two children. The relative size
of the mandible probably increases with age.
Three of the six patients had a high arched
palate. A constant feature was a wide generous
mouth, with full lips. The mouth usually
turned down at the corners.
The external genitalia were infantile in one
male (R.H.) and one female patient (A.W.).
An interesting finding was that two of the fe¬
males (M.F. and E.H.) had a profuse growth
of axillary hair which extended beyond the
usual limits. These two females aged 18 and
21 years were both menstruating.
Abnormalities in the hands and feet were
common. Four of the six patients have short
incurved fifth fingers. One patient (A.W.) had
an absent fifth toe on the left foot, and
syndactyly of the fourth and fifth toes on the
right foot. Three of the patients have ab¬
normally short fourth toes. Two have hyper-
extensible elbows.
Neurological examination revealed hyper-
tonicity of varying degree in all cases except
one. Two children had ankle clonus, and three
had a Babinski response. One boy (R.H.) with
pale skin and fair hair, had fundi resembling
an albino's. Although the retina was poorly
pigmented, the optic discs were normal. One
girl (C.H.) also has pale fundi, although her
skin is dark.
On psychological assessment, five of the
patients were found to be functioning in the
profoundly retarded range. One girl (C.H.)
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Figure 4. B-group chromosomes from all of the patients presented. In the six cases of
'cri-du-chat' syndrome the deleted chromosome is placed fourth, in the case of Wolf's syn¬
drome it is placed second. Note variation in the amount of deleted material.
aged 13 years cannot yet walk without sup¬
port. M.F. aged 18 years functions in the
severely retarded range and has several words
of speech. They are all amiable, friendly
individuals, responsive to affection. The two
males were notably hyperactive and dis-
tractible.
All patients showed marked susceptibility
to infection, especially skin infection of the
staphylococcal type. Self mutilation in the
form of scratching and head banging was a
common feature and the numerous skin in¬
fections may have been secondary to this.
Respiratory infections were much more com¬
mon than in other institutionalised patients.
Five of these six patients have had infectious
hepatitis at different times. This is a higher
incidence than one would expect, and in con¬
junction with the other infections mentioned,
may represent increased susceptibility to in¬
fection. Australia Antigen studies were done
on our four in-patients, but were all negative.
CYTOGENETICS
Leucocyte cultures on all the cases were
prepared using standard methods. Where
possible chromosome studies were carried out
on the parents. In one case (C.H.) skin
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cultures were performed (Pitt et al., 1966).
In all cases the karyotype was 46 XX (or
XY), Bp-, with the deletion being present in
all cells. Two cases (E.H. and R.H.) were
originally thought to have karyotypes 46 XX
(or XY), Cinv. (Pitt et al. 1967), this error
was corrected in a later paper (Roboz and
Pitt, 1969). The amount of genetic material
deleted varied from case to case. It ranged
from most of the short arm (e.g. R.H.) to
only about 1/3 of it (e.g. M.F.) (see Fig. 4.).
In the five cases in which the parents could be
studied all had normal karyotypes.
DERMATOGLYPHICS
Some of the dermatoglyphic features of the
patients are summarised in Table 1.
Fingerprint patterns showed a slight excess
of whorls and a corresponding decrease in
frequency of ulnar loops. The frequencies of
radial loops and arches were normal. Total
ridge counts were within the normal range.
The axial triradii were slightly more distal than
normal, being located mainly in the t1 position.
Every case had a pattern in the fourth inter-
digital area on at least one hand. Palmar
creases were abnormal on one hand in five
cases. There were 3 simian creases, one Syd¬
ney line and one transitional crease. Two cases
had a single interphalangeal crease on the right
fifth finger. There were no true thenar patterns
and only one true hypothenar pattern and one
parathenar pattern in the series. One case
(A.W.) showed dermatoglyphic, but not
clinical evidence of zygodactyly of the fingers.
This is the child who had syndactyly of the toes.
The hallucal patterns were mainly large distal
loops.
The dermatoglyphic findings in the cri-du-
chat cases are similar to those of Warburton
and Miller (1967) with the exception that in
our series there was not an excess of finger
tip arch patterns.
TABLE 1
Some Dermatoglyphic Data on the Cases Presented
Case Finger Print Patterns



















R.H. R w R u u u 161 IV 46 Normal 2 Ld (large)
L w w u u u IV 53 Simian 2 14 (
C.H. R u A u u u 64 IV 47 Normal 2 Ld (large)
L u U u u u IV 45 Normal 2 Ld (large)
W.W. R w R u u u 98 36 Sydney 1 Ld (small)












































R w A u w u IV 34 Transi¬ 2 Ld (large)
M.F. 177 tional
























* d-triradius absent, axial triradius in t position. There were no thenar or hypothenar patterns in this
series except for W.W. who had a loop radial on the left hypothenar area and C.H. who had a
parathenar loop distal on the right palm.
W = Whorl U — Ulnar loop L = Loop R = Radial loop A =: Arch
superscripts — d = distal, t = Tibial
244 Australian Journal of Mental Retardation
OTHER INVESTIGATIONS
Four of our patients had skull X-rays and
skeletal surveys. No abnormalities were found.
The chest X-rays of the same patients are
currently normal.
Haematological investigations were done on
each patient but no unexpected abnormalities
were found.
Electro-encephalograms were obtained from
two patients only. The tracing was within
normal limits in one (R.H.). Another (E.H.)
had a non-specifically diffusely abnormal
record.
Recently another child from St. Nicholas
Hospital was found to have a karyotype of
46,XX,Bp-, however this child was shown to
have Wolf's syndrome rather than the cri-
du-chat syndrome.
In 1965 Wolf and others described a chromo¬
some disorder in which there is deletion of
the short arm of a chromosome number four,
rather than a number five. A cytogenetic dis¬
tinction between these two pairs of chromo¬
somes can be made only by autoradiography.
The physical appearance of the subjects with
Wolfs syndrome and those with the cri-du-chat
syndrome varies in certain important details,
and in the absence of autoradiography the
diagnosis can be made by considering the
phenotype. The main difference is the absence
of 'cat cry' in Wolf's syndrome. So far
about 20 cases have been described in the
literature, and the features reported include
seizures, abnormal dermatoglyphics, cranial
asymmetry, prominent eyes, ptosis, hyper¬
telorism, flat nose, cleft or very high palate,
pre-auricular tags and dimples.
The patient, a female, (M.C.) was born
on 30-6-67. Her mother was 27 and her father
31 years at her birth. One normal child was
born, then two miscarriages and one stillbirth
preceded the birth of our patient, (see Fig. 5)
Maternal urinary oestriol levels were low
from thirty weeks, and a Caesarean section
was performed at thirty-eight weeks. Birth
weight was 1,970 gm. Resuscitation was neces¬
sary and the baby did not breathe for two
minutes. Congenital dislocation of the left
hip was present. Nasolacrimal duct obstruction
was a persistent problem in infancy. There
have been frequent febrile convulsions. Rates
of growth and development have been slow.
In view of her multiple anomalies, chromo¬
some analysis was performed. The karyotype
was 46,XX,Bp-, with the deletion being
Figure 5. M.C. This is the child with Wolf's
Syndrome.
present in all cells. The parents both had
normal karyotypes.
When examined at the age of three years her
height was 83.5 cms., below the third per¬
centile, weight 9.25 Kg., below the third
percentile, and her head circumference 41.5
cms., which is six standard deviations below
the mean for age. She had marked cranial
and facial asymmetry, and hypertelorism with
a divergent strabismus. Her eyes were very
prominent, and there was ptosis of the lids.
Her ears were low set and asymmetrical, there
was a pre-auricular pit on one side and a pre¬
auricular skin tag had been removed from the
other. The nose was flat and the palate ex¬
tremely high. There was a grade II systolic
murmur present, maximal at the apex.
The left arm was one inch shorter than the
right, the left leg one inch shorter than the
right leg. She was generally hypotonic and had
an extensor plantar response. Hair was present
on the vulva. The hands had low set thumbs
and flexion deformities of the fifth fingers. The
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feet were equinus. The dermatoglyphics showed
no striking features except for a bilateral mid-
palmar ridge dysplasia which has been des¬
cribed by Van Kempen and Jongbloet (1967)
as a distinguishing feature of Wolfs Syndrome.
She was unable to sit without support, had
a clumsy grasp, and could eat only pureed
food. She appeared to function at about a level
of four months. Her cry, although described as
'peculiar and breathless' had never been
thought feline or high pitched. X-rays of skull,
chest and skeletal structures were normal.
Urine chromatography gave a normal pattern.
Considering the absence of a 'cat cry' the
dermatoglyphics, and the clinical findings, the
diagnosis of Wolf's syndrome was made.
DISCUSSION
Six cases of cri-du-chat have been described,
and one case of Wolf's syndrome. It may be
useful to consider a composite picture of the
cri-du-chat syndrome as it appears in rel¬
atively mature individuals. If the diagnosis is
not made in infancy, the cry may still be the
basis of diagnosis in adult life, for it can
persist.
Even without a feline sound, cri-du-chat
may be suspected in a patient with the follow¬
ing characteristics. He is small, profoundly
retarded, and microcephalic. The eyes have
epicanthic folds and a squint, the mouth is
wide, the lips are full and the nasal bridge
is flat and broad. There are minor anomalies
of the hands and feet, and abnormal derm¬
atoglyphics. Self-mutilation is common, and
there has been a succession of skin infections
and much respiratory disease.
Finally, the case history should be read.
The psychologists' report on one case pro¬
vided a clue. The report reads, in part: "Only
one word sound was noted; this she produced
in response to all questions or requests to
imitate the examiner. She did, however pro¬
duce the correct sound was noted ABLENR
duce the correct sound when asked, 'What
does a pussy say?'
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A MALE WITH KARYOTYPE 46,XX
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Whilst the usual phenotype associated with the
46,XX karyotype is that of a normal female, a
number of near normal males have been described
with this chromosome constitution. In a recent
discussion of the nature and origin of these males
de la Chapello- [1] knew of about 50 cases from
the literature, personal communications and his own
observations, the majority of whom had clinical
findings consistent with Klinefelter's syndrome.
When presenting the results of Xg blood group
studies on persons with sex chromosome abnorma¬
lities, Sanger et al. [2] reported on 34 XX males.
We report here another case of a male with the
stigmata of Klinefelter's syndrome and a 46,XX
karyotype.
CASE HISTORY
The propositus, LAE 290451, was identified as having
a normal female karyotype during a chromosomal survey
of the patients in a security ward for the mentally defec¬
tive [3]. He had been in the hospital only a short time
prior to ascertainment and had been transferred to the
security ward from the general section of the hospital
for allegedly pestering female patients ; an offence which
he denied.
He was born in Queensland and what little is known
of his early history was supplied to us from that State.
He was an illegitimate child who spent most of his early
years in orphanages. He was an object of ridicule in the
orphanage due to his low intelligence level (IQ was
assessed as 62) and he reacted with violence and aggres¬
sion, eventually attempting to set fire to the orphanage.
He was subsequently transferred to a Youth Hospital,
classed as unmanageable, certified and admitted to a
mental hospital at the age of 11 years. Electro-encephalo-
graphic investigation at this time demonstrated «marked
dysrhythmia with much diffuse slow activity». His beha¬
viour improved as he became older and he worked on
unskilled tasks in the hospital grounds. He was discharged
into his mother's care in 1968; at this stage being regarded
as having a behaviour problem with mild mental retarda¬
tion. Nothing more is known of him until he was
admitted to Aradale Hospital (Victoria) in April, 1970,
following his apprehension for travelling on a train
without a ticket. He absconded before full clinical studies
could be completed and he still remains at large.
Clinical Examination
The patient appeared as a slightly dull, well built 19-vear
old man, 68 inches tall. He had severe acne on the face
extending on to the chest, back and upper arms which
presented as active pustules and much scarring. The facial
scarring was so severe that we were uncertain whether his
lack of facial hair was due to widespread destruction of
the hair follicles or was primarily associated with his
chromosome abnormality. Body hair distribution was that
of a normal male and was extremely profuse, especially on
the limbs (fig. 1). Clinically there was no abnormality
detected in the cardio-respiratory system. The penis was
normally developed but the scrotum contained small testes
of normal consistency. The anus and perineum were clini¬
cally normal. He was unable to provide a sample of semen
and according to the hospital staff he was not sexually
active. His colour vision was normal and he was Xga + .
(*) Present Address: Department of Pathology, Royal
Hospital for Sick Children and University of Edinburgh,
Sciennes Road, Edinburgh EH9 1LF, Scotland.
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F;g. 1. — The propositus. Note acne scarring on chest,
profuse body and apparently normal genitalia.
Fig. 2. — Karyotype of the propositus.
Cytogenetic Studies
Two blood leucocyte cultures were done at different
times. Fifty cells were counted and examined for the
presence of a Y chromosome or any evidence of a trans¬
location, and a further fifty cells were scored for the
number of G group chromosomes. There was no evidence to
suggest that cells with other than a 46.XX chromosome
complement were present (fig. 2). Skin fibroblast culture
gave a similar result from the analysis of 42 cells. Buccal
nucosal nuclei showed a normal female sex chromatin patt¬
ern. Fluorescent studies using quinacrine mustard on inter¬
phase nuclei showed no evidence of a Y chromosome in 200
buccal epithelial cell nuclei and 100 leucocyte nuclei. Con¬
trol studies on XX, XY and XYY material yielded results
appropriate to the number of Y chromosomes for both
types of interphase nuclei. Fluorescent studies were not
done on metaphase chromosomes.
planation is supported by the Xg studies since the
distribution of Xg types found in XX males most
closely resembles that found in Klinefelter's syn¬
drome rather than that in normal males or females
[2].
The severity of the symptoms shown by XX
males appears to vary greatly, ranging from normal
members of the community whose only complaint
is sterility, to mental hospital patients such as the
one presented here. When more cases have been
documented the degree of clinical variation may
be as great as that seen in 47,XXY Klinefelter's
syndrome, the only essential features being a
46,XX karyotype and testicular hypoplasia with
subsequent sterility.
DISCUSSION
The reasons for the development of the Kline¬
felter phenotype in persons with an apparently
normal female karyotype remain unclear. Possible
explanations which have been tendered include
undemonstrated mosaicism, Y to X or Y to auto¬
some translocations, gene mutation, and the loss
of the Y chromosome from an XXY zygote after
sex differentiation has been initiated. This last ex¬
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SUMMARY
A 19-year old man with a normal female karyotype
(46,XX) and the stigmata of Klinefelter's syndrome is
described. He had a long history of antisocial behaviour
and was ascertained when a security ward for the mentally
defective was surveyed for chromosome abnormalities.
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UNE OBSERVATION D'HOMME 46.XX
par G.R. Sutherland, S. Wiener and A.A. Bartholomew
Department of Pathology, Royal Hospital for Sick Children and University of Edinburgh
Sciennes Road, Edinburgh EH9 1LF, Scotland
(Ann. Genet., 1972, 15, n° 3, 187-189)
RESUME
Les auteurs rapportent 1'observation d'un jeune homme de
19 ans ayant un caryotype feminin normal (46,XX) et
atteint d'un syndrome de Klinefelter. II avait un lourd
parse de conduite antisociale, et a ete depiste au cours
d'une enquete sur les anomalies chromosomiques chez des
debiles mentaux dangereux hospitalises en milieu psychia-
trique.
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Syndrome de Klinefelter* familial et genetique. — Arrie-
ration mentale. — Phenotype. — Caryotype.
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Difficulty in Showing Mosaicism
in the Mother of Three Mongols
Parental mosaicism for trisomy-21 is a recognized
reason for the birth of mongol children, and the
possibility of parental mosaicism may be suspected
especially in couples who produce more than one
'regular' mongol. However, in a recent review,
Richards (1970) found only 11 documented
instances of this occurrence. We wish to describe
another woman in whom mosaicism was suspected
clinically but was difficult to show by chromosome
studies.
Findings
This family presented for investigation at the Royal
Children's Hospital in 1963 because the parents had
two mongol children. The family pedigree is shown
in the Fig. Chromosome studies were carried out at
this time on the children, parents, and relatives as
indicated. The two mongol children and the maternal
uncle were shown to have regular trisomy-G and all
the other relatives studied were normal. The results
obtained in the abnormal individuals are shown in the
Table.
The mother was short in stature and borderline in
intelligence, and her facial appearance and head shape
strongly suggested mongolism. A second blood
sample and a bone marrow sample were therefore
examined in an endeavour to find some trisomic cells.
Unfortunately, a skin biopsy failed to grow. Even
though mosaicism was not shown, it was considered so
likely that the parents were told that the chance of
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Fig.—Family pedigree.
having another mongol child could be as high as 50%.
In 1970 the family was referred to St. Nicholas
Hospital for chromosome study by a clinician who was
not aware that studies had already been performed.
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father and G trisomy in the two mongol children, but
revealed 5 cells with 47 chromosomes among 70 cells
counted from the mother. In 4 of these cells the extra
chromosome was from the G group, and in the remaining
cell it was a C group chromosome. On these results
maternal mosaicism with karyotype 46,XX/47,
XX,G+ was diagnosed.
In 1971 the couple elected to have a further child
despite the risks involved. A male mongol was born
in December 1971. His karyotype has been confirmed
as 47,XY,G + .
Discussion
The difficulty of excluding chromosomal mosai¬
cism has long been recognized, and this family
re-emphasizes the need to study large numbers of
cells from several tissues of both parents when two
or more regular mongols are born to a couple.
In this family, studies concentrated on the mother
because she showed some clinical features of
mongolism, but the initial investigations failed to
reveal the mosaicism despite counting 59 cells
from two tissues. Fortunately, appropriate genetic
advice was still given.
The occurrence of another regular mongol in the
family is also of interest, but his mother was 40
years old at his birth, so this may represent a
chance occurrence.
Summary
A case of maternal mosaicism leading to the
production of three mongol children is reported.
The difficulty of detecting the trisomic cell line
and the need to examine large numbers of cells is
emphasized.
We thank Drs. Ann Morgan, David Pitt, and Saul
Wiener for their assistance with this study; Dr. O.
Margaret Garson for the bone marrow studies and
confirming the trisomic state of the third child; and the
Mental Health Authority for permission to publish
this paper.
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Letter to the Editor
reprinted from THE LANCET, July 29, 1972, p. 231
FAMILIAL INSERTIONAL TRANSLOCATION
Sir,—We were interested to read the report by Dr. Gray
and colleagues (July 8, p. 92) in which they described an
insertional translocation in a child with multiple congenital
abnormalities. We have been studying a familial trans¬
location in which an interstitial segment of the long arms of
chromosome no. 7 has been inserted into the long arms
of chromosome no. 3. The translocation was detected when
chromosome studies were carried out on a 3-year-old girl
referred on account of multiple congenital abnormalities;
full clinical details will be described elsewhere.
Chromosome preparations were made from short-term
leucocyte cultures of peripheral blood. The banded karyo¬
types were prepared using a modified Leishman technique.1
The affected child had karyotype 46,XX,3q+ mat and the
mother and sister had karyotype 46,XX,t(3q +;7q—). The
Fig. 1—Chromosome pairs nos. 3 and 7 from four metaphases
from the balanced karyotype showing banding patterns.
3 7 3q+ 7q-
Fig. 2—Idiogram of the banding patterns from the balanced
karyotype.
The break points are indicated thus
2
maternal grandparents and a sister of the mother had normal
karyotypes. An analysis of the banding patterns from the
balanced karyotype was made to identify the break points.
Metaphase spreads in which the chromosomes were least
contracted were selected and photographed. Partial karyo¬
types of chromosome pairs nos. 3 and 7 from four of these
cells is presented in fig 1. An idiogram (fig. 2) of the
banding patterns of the translocated chromosomes was
constructed according to the convention decided upon at
the Fourth Standardisation Conference on Human Cyto¬
genetics.2
The figures show that both a band and an interband have
been removed, interstitially, from 7q. Examination of a
number of metaphase spreads indicated that it was the
distal broad band in 7q that had been translocated rather
than the proximal. The break points were interpreted as
being in the regions 7q22 and 7q32. The break in chromo¬
some no. 3 was probably in the region 3q27, and this was
the position in which the segment of 7q was inserted. Since
there is no evidence of any reciprocal exchange of material
from 3q to 7q, the simplest explanation of this translocation
is that it arose by a three-break event in the gametes of one
of the grandparents. The affected child is trisomic for the
segment of 7q that has been inserted into 3q, and it is
reasonable to assume that the clinical anomalies are directly
associated with this trisomy.
Insertional translocations have been induced in Droso-
phila 3 and the mouse.4 These translocations have been
observed directly on the polytene chromosomes from
Drosophila and in meiotic chromosome preparations from
the mouse. Since the study of meiotic chromosome prep¬
arations in man is difficult because of the problems in
obtaining suitable material, it is only since banding tech¬
niques have been developed that elucidation of chromosomal
rearrangements has become possible. In Drosophila,
insertional translocations are relatively rare when compared
with terminal translocations, and the same will probably be
true in man.
Department of Pathology, ft GRACE
Royal Hospital for Sick Children, n' p ^
and University of Edinburgh, (j- K' SUTHERLAND
Edinburgh EH9 1LF. A. D. BAIN.
1. Grace, E., Bain, A. D. J. clin. Path, (in the press).
2. Fourth Standardisation Conference on Human Cytogenetics, Paris,
September, 1971.
3. Lindsley, D. L., Grell, E. H. Genetic Variations of Drosophila
melanogaster. Carnegie Institute, 1968.




7, Adam Street, Adelphi, London, W.C.2.
B 23
PARTIAL TRISOMY OF 7q RESULTING FROM
A FAMILIAL TRANSLOCATION
Elizabeth Grace, G.R. Sutherland, G.D. Stark,
and A.D. Bain
Department of Pathology, Royal Hospital for Sick Children
and the University of Edinburgh {Scotland).
INTRODUCTION
The development of banding techniques has
enabled not only the accurate identification of
individual chromosome pairs but also the localisation
of the break points in chromosomes where re¬
arrangements have occurred. Before the advent of
these techniques the interpretation of chromosomal
anomalies involving the C group had been difficult
because of inadequate methods of identification.
This report describes a 2 year old girl who presented
with severe psychomotor retardation and who was
found to be trisomic for part of the long arm of
chromosome number 7. This trisomy was associated
with a balanced insertional translocation in the
mother. A detailed description of the morphology
and origin of the translocation has been published
previously (Grace, Sutherland and Bain, 1972).
CASE REPORT
The proposita is the second child of healthy unrelated
parents who were both aged 30 at the time of her birth.
Her older sister is well and there is no family history of
congenital anomaly or developmental retardation (fig. 1).
She was born by breech delivery at full term. Birth
weight 2 800 g. She required endotracheal intubation and
positive pressure ventilation for one minute before respira¬
tion was established. She was slow to feed initially but
was fit for discharge at the age of two weeks.
0 unbalanced translocation 46,XX,3q + mat
(3) normal karyotype
Q not tested, normal phenotype
Fig. 1. — Pedigree of the family.
Grace Elizabeth, Sutherland G.R., Stark G.D., Bain
A.D. (1973). — Partial trisomy of 7q resulting from a
familial translocation. Ann. Genet., 16, n" 1, 51-54.
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Fig. 2. — Full face and profile of the proposita at the age of 1 } years.
She was first admitted to hospital at the age of 10 months
suffering from severe bronchiolitis. Following recovery,
she was noted to be severely retarded in all aspects of
development. She was small for her age, her height (68 cm)
and weight (7,6 kg) being below the 25th percentile.
Occipitofrontal circumference was normal at 46 cm. The
facial appearance was odd with bilateral epicanthic folds,
almond-shaped eyes, flat nose and everted lower lip; the
ears were large and low set (fig. 2). She had broad,
proximally-placed thumbs and broad first toes.
She was extremely apathetic and did not smile nor could
she follow objects with her eyes or localise sounds. The
optic fundi were normal but there was a rotatory nystagmus
and a left concomitant, convergent strabismus. There was
some head lag when pulled up from supine and she was
unable to sit without support. Her hands were open but
she did not grasp or reach out for objects. The posture
was one of generalised flexion; there was a slight increase
in tone and in reflexes in the lower limbs with bilateral
ankle clonus. Primitive reflexes were absent but parachute
and Landau reactions were poorly developed. The clinical
diagnosis was one of severe mental handicap and mild
diplegia.
The patient was examined again at the age of 3 years
when the visual and auditory abnormalities, which were
noted at the age of 10 months, were attributed to severe
mental retardation rather than to a physical defect.
Cytogenetic studies.
Chromosome preparations were made from short-term
cultures of heparinised peripheral blood. The banded karyo¬
types were prepared according to the method of Grace and
Bain (1972).
Orcein stained chromosome preparations from the propo¬
sita were first made at the age of 2 years and the
abnormally long number 3 chromosome was noted. Cultures
were set up from the family in order to obtain preparations
for banding and the extra material on the number 3
chromosome was identified as being derived from part of
the long arms of the number 7 chromosome. The proposita
had the karyotype 46,XX,3q + mat and the mother and sister
46,XX,t(3q-)-;7q —) (figs 3a and 3b). Detailed examination
of the banding patterns revealed the translocation to be
insert'.onal rather than terminal (Grace. Sutherland and
Bain, 1972). The proposita is trisomic for an interstitial
segment of the long arms of chromosome number 7. The
maternal grandparents and one of the aunts had normal
karyotypes; the other aunt is domiciled abroad and could
not be examined. Table I lists the number of cells analysed
and the karyotypes of the members of the family who
were tested.
There was no evidence of mosaicism for the translocation
in either the mother II.2 or the maternal grandparents
1.1 and 1.2.
Dermatoglyphics.
Some of the dermatoglyphic characteristics of the propo¬
sita, her mother and sister are shown in table II. The
palmar and plantar configurations of the proposita are
represented in figure 4. The unusual features in the dermato¬
glyphics include the presence of three radial loops on the
fingertips and abnormal palmar creases. Finger prints were
not of sufficient quality to enable an accurate ridge count
to be made, probably due to the perpetual sucking of the
fingers, but was estimated to be about 90. The only signifi¬
cant feature of the proposita which is apparent when
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and their karyotypes





11.2 30 46,XX,t(3q + ;7q —)
II.3 10 46,XY
III.I 30 46,XX,t(3q + ;7q —)
111.2 30 46,XX,3q + mat.
compared to her mother and sister is a slight decrease
in pattern intensity evidenced by the lower total ridge
count(TRC) and absence of hypothenar patterns.
Other investigations.
Prior to recognition of the chromosomal abnormality,
investigations were directed towards excluding metabolic and
degenerative diseases of the central nervous system.
On electro-encephalography, there was asymmetry of
background activity but no epileptic discharges. Skeletal
X.ray survey was negative but lumbar air encephalography
revealed slight ventricular dilatation and an increase in the
width of sulci suggesting cerebral atrophy. All biochemical
investigations were within normal limits.
Table II
dermatoglyphic characteristics of the proposita,
her mother and her sister
Finger-print patterns Maximal TRC Palmar formula (*)
atd angle
i 11 111 iv v
Proposita R U RL RL U u 4*. 00 o approx. 90 IV t 4
L U RL A u u 45" IV t 4
Mother R u U A u u 76° 103 IIIT H H t t"tb 4
L u RL U u u 78° IV H H t t"t" 4
Sister R u U RL u u 470 133 IV H t tb 4
L u u U u u 440 IV H t t" 4
(*) after Penrose and Loesch (1970). U = ulnar loop. RL = radial loop. A = arch.




This is the first reported instance of a confirmed
trisomy for part of the long arms of chromosome
number 7. An examination of the banding patterns
indicated that the broad band of 7q furthest from
the centromere, together with a light interband, had
been inserted into the long arms of chromosome
number 3.
The clinical abnormalities which had been describ¬
ed in the proposita are assumed to be the direct
consequence of the excess chromosomal material,
however, a comparison of the present case with
previous reports of partial trisomy for Cq is non-
contributory to the discussion because of the
uncertainty of identification in those cases. Differen¬
tial staining techniques have proved valuable in this
case and will help to bring some order to a large
number of C group chromosome abnormalities
which have previously been unclassifiable. A syn¬
drome associated with trisomy of chromosome
number 8 has already been described (Caspersson
et al., 1972 ; de Grouchy et al., 1971), and two
cases of partial trisomy of lOq have been identified
(de Grouchy et al., 1972; Laurent, pers. comm.).
Fig. — 4. — Diagram of the plantar and palmar dermato-
glyphic patterns of the proposita.
PARTIAL TRISOMY OF 7q RESULTING FROM
A FAMILIAL TRANSLOCATION
TRISOMIE PARTIELLE DE 7q DUE A
UNE TRANSLOCATION FAMILIALE
by Elizabeth Grace, G.R. Sutherland, G.D. Stark and
A.D. Bain
Department of Pathology, Royal Hospital for
Sick Children and the University of Edinburgh (Scotland)
(Ann. Genet., 1973, 16, n° 1, 51-54).
par Elizabeth Grace, G.R. Sutherland, G.D. Stark et
A.D. Bain
Department of Pathology, Royal Hospital for
Sick Children and the University of Edinburgh (Scotland)
(Ann. Genet., 1973, 16, n<> 1, 51-54).
SUMMARY
This report describes a 2 year old girl who presented
with severe psychomotor retardation associated with an odd
facies involving bilateral epicanthic folds, almond-shaped
eyes and low set ears. These features are attributed to
trisomy for an interstitial segment of 7q arising from a
familial translocation.
RESUME
Les auteurs decrivent le cas d'une fille de 2 ans atteinte
de retard psychomoteur grave associe a une dysmorphic
faciale avec epicanthus bilateral, yeux en amande, et oreilles
bas situees. Ces anomalies sont attribuees a une trisomie
pour un segment interstitiel de 7q due a une translocation
famiiiale.
KEY-WORDS : Trisomy. — Chromosomes, human, 6-12.
Chromosome aberrations. — Chromosome abnormalities.
Psychomotor disorders.
MOTS-CLES : Trisomie. — Chromosomes humains 6-12. —
Aberration chromosomique. — Anomalies par aberration
chromosomiques. — Troubles psychomoteurs.
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A GIRL WITH WOLF-HIRSCHORN SYNDROME
AND MOSAICISM 46,XX/46,XX,4P-
G. G. JUDGE, O. M. GARSON, D. B. PITT and G. R. SUTHERLAND
Children's Cottages, Kew Victoria, Melbourne University Department of Medicine,
St. Vincent's Hospital, Melbourne, and St. Nicholas Hospital,
Melbourne, Australia
SUMMARY
Chromosomal analysis of an eleven-year-old mentally retarded girl showed
46,XX/46,XX,4p— karyotype. Subsequent clinical examination demonstrated that
she has features of Wolf-Hirschorn syndrome. (Sidbury et al., 1964; Wolf et al., 1965;
Hirschorn et al., 1965.)
INTRODUCTION
The Wolf-Hirschorn syndrome has features, some of which are shared by the
"cri-du-chat" syndrome, but others which are specific. Several authors (Miller, 1970;
Wilson et al., 1970; Passarge et al., 1970) regard the phenotype as a distinct clinical
entity. Others, however (Carter et al., 1969), believe diagnosis to be difficult on
clinical grounds alone. Possibly there is variability in the extent of the deletion and
this could be a source of phenotypic variability (Taylor et al., 1970).
Fig. 1. Build of proposita Fig. 2. Facies.
Received 29th August, 1973
li 5?/





The patient is the eldest child in a family of six children. The mother has had no
miscarriages. She was aged twenty-seven years at the time of the patient's birth.
Father is the same age. Both parents are of normal intelligence. Mother is mildly
dependent on alcohol. The youngest child in the family suffers from strabismus and
dyslalia.
CASE HISTORY
Mother states that there was poor foetal activity during the pregnancy. She took "nerve"
tablets. The birth was normal and the birth weight 2282 gr. A small umbilical hernia was
present.
The proband did not walk until five years of age. Speech commenced at seven years and is
still delayed. At the age of two years she suffered her first epileptic seizure. She has attended a
Day Centre for retarded children. Clitoral enlargement has always been present and breast
development commenced at the age of eight years.
PRESENT STATUS
The patient's build is slight (see Fig. 1), her height being 138 cm (at the 25th percentile),
her weight 25.4 kg (3rd-10th percentile) and her head circumference 46.5 cm (5 S.D. > mean).
She has marked kyphosis.
The face is moon-shaped with proptosis of the eyes (see Fig. 2). The eye slant is upwards,
and there are epicanthi. The eyebrows are sparse, particularly medially. The nose is flattened
and has two tips rather than one. The ears are low set. There is poor development of the lobule
and lower portions of the ears. She has gingivitis and the palate is high. There is micrognathia.
The complexion is sallow and there is a hairy pigmented mole over the right eyebrow.
There is a systolic bruit at the apex, possibly due to a small septal defect. There are well-
developed breasts and the clitoris is enlarged. The fingers are long and spidery with hyper-
convex nails which are striated in an axial direction. The feet are valgoid. There is acrocyano¬
sis of the hands and feet. The dimples over the posterior superior iliac spines are more prominent
than normal. There are pronounced dimples over the spines of the scapulae (see Fig. 3).
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Fig. 3. Illustrates
shoulder dimpling of the
proposita.
Fig. 4(right). B group
chromosomes from four
cells. The deletion is
present in the upper two
groups, not in the lower.
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Table 1
Chromosome counts
Patient Tissue 44 45 46 46, 4p- Total Karyotype
Proposita Blood 1 6 23 5 54 46,XX/46,XX,4p-
Blood 2 4 23 6 33
Bone
Marrow 3 3 25 19 50
Mother Blood 30 30 46,XX
Father Blood 1 29 30 46,XY
Psychologically she tests in the severely retarded range (IQ20-35) (Merrill-Palmer Scale).
Radiography of the pubic and carpal bones showed the bone age to be normal. Electro¬
encephalography showed a non-specifically diffusely abnormal record without frank paroxys¬
mal discharges.
CYTOGENETIC STUDIES
Stimulated lymphocyte cultures were performed on the proposita and her parents by a
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were of normal female chromosome constitution (46,XX), but on each of the two occasions
there was a small percentage of cells (15-18 per cent) which showed a deletion ofapproximately
two-thirds of the short arms of a B group chromosome (Fig. 4 and Table I). Direct bone
marrow preparations using a modification of the method of Kiossoglou et al. (1964) showed a
similar mosaic picture, but the percentage of cells containing the deleted B group chromosome
was 36 per cent. The hypodiploid cells present in all three cultures were due to a random
loss of chromosomes and therefore the cells were probably broken in preparation.
The giemsa banding technique ofSchnedl (1971) was applied to the bone marrow chromo¬
somes, and allowed identification of the deleted B group chromosome as a No. 4. In the spreads
with normal chromosomes, the B group chromosomes 4 and 5, could be readily paired,
according to their banding patterns.
Chromosome studies in the lymphocytes of the parents showed no abnormality.
DERMATOGLYPHICS
The dermatoglyphic features are shown in Fig. 5. The total finger ridge count is thirty-
nine. The axial triradii are in the mid-palmar area (66°, 52, 6 per cent; 74°, 56, 6 per cent right
and left respectively). The palmar creases are abnormal with the proximal transverse crease
reaching the ulnar border of the palm, the so-called Sydney line (Purvis-Smith and Menser,
1968). There is ridge dysplasia on the peripheral areas of the fingerprints and on some parts of
the soles; it is not evident on the palms.
DISCUSSION
The clinical features of the Wolf-Hirschorn syndrome show an aggregation which
is specific and which in only a few instances resembles the cri-du-chat syndrome. As
with the majority of autosomal conditions associated with mental retardation there is
the usual high incidence of short stature, microcephaly, micrognathia, low-set ears,
epicanthi, strabismus, etc. A review of published cases is shown in Table 2 and
examination of this table indicates the features specific to 4p- syndrome. Facial and
cranial distortion, midline cranial defects, iris deformities, hypospadias in the male,
skin dimples, and the absence of the cat-cry, were considered specific by some authors
(Wilson et al., 1970). Other authors have included eyelid ptosis, broad nasal base, a
full upper lip, sparse eyebrows on the medial half (giving a startled expression),
enlarged clitoris, premature pubarche, pre-auricular sinuses, epilepsy, proptosis,
dislocated hip, dysplasis of the skin ridges of the hands, bone defects, "volar pads"
(Van Kempen and Jongbloet, 1968; Miller et al., 1970). In particular there is a high
incidence of epilepsy in 4p- syndrome, as opposed to a low incidence in other auto¬
somal conditions. The frequency of epilepsy in the 4p- syndrome appears to be a
distinct point of differentiation from the 5p- syndrome. This may be related to the
very low birth weight in 4p-, as it has been pointed out (Taylor et al., 1970) that the
birth weight in 4p- syndrome is the lowest mean birth weight of any chromosomal
anomaly. The incidence of premature puberty and enlarged clitoris in the female
and hypospadias in the male is also increased. Such genital anomalies do not occur
with the cri-du-chat syndrome.
Clinical features in our case suggest a diagnosis ofWolf-Hirschorn syndrome, and
this is confirmed by cytogenetic studies. Some modification of clinical features may be
the result of mosaicism. We believe this to be the first case in which mosaicism for a
deletion of the short arm of chromosome number 4 has been demonstrated. Mosascism
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for deleted number 5 chromosome has been reported (Antich et al., 1968) and pheno-
typically is consistent with the cri-du-chat syndrome. Chromosome studies on the
mother of a child with 4p- syndrome (Taylor et al 1970) showed one cell out of one
hundred with the deleted B chromosome, but the authors considered that the most
likely explanation of this was temporary chimerism.
Features which are present, but which are common to both the 4p- and 5p-
syndrome, include mental retardation, microcephaly, growth disorder, epicanthi,
low birth-weight, hypotonia, strabismus, low-set ears, and a high arched palate.
The features in our case which are specific to the 4p- syndrome are the absence of
cat-cry, clitoral enlargement, early breast development, proptosis, epilepsy, and
under-developed dermal ridge patterns. Minor features present, and again specific
for the 4p- syndrome, include absence of the medial halfof the eyebrows, the presence
of sacral and shoulder dimples (Wilson et al., 1970) and a possible heart defect.
Features which are absent in our case but which would have added further
evidence in favour of the 4p- syndrome include a midline defect such as cleft lip and/
or palate, iris deformity and a "fishlike" mouth. The dermatoglyphics are consistent
with the diagnosis of Wolf's syndrome, especially in view of the ridge dysplasia and
the low pattern intensity of the digits. The arch proximal patterns on the halluces are
unusual. Similar patterns have been reported in three cases with deleted B-group
chromosome (Warburton and Miller, 1967).
On clinical grounds the 4p- phenotype can be distinguished from that of the cri-
du-chat syndrome but neither can be readily diagnosed in isolation from numerous
other cases of mental retardation (with multiple congenital anomalies) without the
aid of chromosomal analysis.
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Summary. Two infants with trisomy involving chromosome 9 are described. One had
complete trisomy 9 and the other karyotype 47,XX,+der(9),t(7;9) (p22;q32)mat. A trisomy
9 syndrome is delineated, consisting of features of the trisomy 9p syndrome and various
other malformations. These include abnormalities of the cardiovascular and urogenital systems,
cranial suture anomalies, dislocation of the hips and knees and early death. A possible rela¬
tionship of some of these findings to regions of 9q involved in cases of partial trisomy 9 is
suggested.
Introduction
Trisomy of the short arm of chromosome 9 results in a defined clinical syndrome
(Rethore et al., 1970, 1973; Rethore and Lafourcade, 1974). However, the clinical
syndrome associated with trisomy of the whole of chromosome 9 has not been
fully characterised, indeed only 5 cases of complete (Juberg et al., 1970; Feingold
and Atkins, 1973) or mosaic (Haslam et al., 1973; Bowen et al., 1974; Schinzel
et al., 1975) trisomy 9 have been reported. The present paper records 2 similar
cases, one with complete trisomy 9 and the other with trisomy of much of this
chromosome resulting from 3:1 meiotic disjunction of a maternal translocation
t(7 ;9)(p22;q32). As in the previously reported cases these 2 infants had features
of the trisomy 9p syndrome and a variety of other malformations. An analysis
of recorded cases of complete and partial trisomy 9 shows a pattern of mal¬
formations occurring in addition to those of the trisomy 9p syndrome as the long
arm of the chromosome is involved in increasing amount, until finally a trisomy 9
syndrome can be delineated.
Case Histories
Case 1
The proposita was the first child born to a 28-year-old woman and her 33-year-old husband.
The parents were of Greek origin. Delivery was normal with birth weight 1880 g and Apgar
scores of 7 at 1 min and 8 at 4 min. Gestation immediately prior to delivery was estimated
radiologically to be 35 weeks but was 40 weeks by dates. The infant was small (length 38 cm)
and microcephalic (occipito-frontal circumference 30 cm) with many congenital malformations
(Fig. 1). These included low hair-line, low-set ears, marked micrognathia and hypertelorism
with microphthalmos and pinpoint pupils. The mouth was large and down-turned at the corners.
There was a widely open sagittal suture with a large posterior fontanelle and the metopic
suture was palpable. The sternum was short and prominent, there was a sacral dimple with
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Fig. i. The proposita, Case 1
associated tuft of hair, the anus was small. There were multiple limb abnormalities which
included flexion deformities of the arms and hands, bilateral simian creases, absence of the
terminal phalanges of the thumb and index fingers and hyperconvex nails. There was fixed
dislocation of the hips, unstable dislocated knees and talipes calcaneovalgus. The grasp reflex
could not be demonstrated but the Moro reflex was present.
Death from bronchopneumonia occurred at the age of 17 days. Autopsy findings included
a persistent left superior vena cava with absence of the left innominate vein, and a widely
patent ductus arteriosus. The right lung was bilobed. The ovaries were long (1.5 cm) and narrow
but histologically normal. The kidneys were half normal size and the ureters were dilated and
thin-walled. The caecum and ascending colon were abnormally suspended, being bound by a
mesocolon to the underside of the liver. The cerebellar vermis was very hypoplastic and the
fourth ventricle was correspondingly increased to about 4 times normal size.
Radiological Findings. Apart from confirming a number of the clinical findings several
unusual radiographical features were present . These included bilateral hypoplasia of the pubic
bones and an angulated appearance of the ischia. There was left dislocation of the head of the
radius and hypoplasia of the distal humerus and the fibulae. There was hypoplasia of the ala
of the sacrum with poorly developed sacro-iliac joints associated with lack of development of
the iliac wings posteriorly.
Cytogenetics. The infant was found to have an extra chromosome which best fitted the
C group, it showed a secondary constriction similar to that usually encountered in chromo¬
some 9 and could be distinguished from the other C-group chromosomes. This chromosome was
not fully identified before the child died. There was a single X-chromatin body in 25% of cells
from a buccal mucosal smear, doubly chromatin positive nuclei not being seen. The father
had a normal male karyotype but the mother carried an apparently balanced reciprocal trans¬
location (Fig. 2), having a karyotype 46,XX,t(7;9)(p22;q32). The karyotype of the proposita
was considered to be 47,XX,4~der(9),t(7;9)(p22;q32)mat.
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Fig. 2. Karyotype 46,XX,t(7;9)(p22;q32) from the mother of Case 1
Case 2
The propositus was the second child born to a 28-year-old woman and her 32-year-old
husband. The parents were of Greek origin. The pregnancy was uneventful and ended in a
breech delivery after 38 weeks' gestation. Birth weight was 1433 g, length 40 cm, head circum¬
ference 27.5 cm and the Apgar score was 7 at 1 min. There were multiple congenital mal¬
formations including hypertelorism, microcephaly with a large anterior fontanelle and widely
open cranial sutures. The ears were low-set, there were epicanthic folds and micrognathia. The
genitalia were ambiguous; the penis was small with hypospadias, there was a rudimentary
divided scrotum and the testes were in the inguinal canal. A post-anal dimple was present.
There were multiple limb abnormalities. The forearms were pronated and the hands showed
ulnar deviation and flexion deformities with the index fingers tending to over-ride the middle
fingers; the fifth fingers were clinodactylous. Simian creases were bilateral. There was talipes
calcaneovalgus and bilateral dislocation of the hips, knees and elbows. Some of the toes on the
left foot were hypoplastic. Moro and grasp reflexes were normal. The child failed to thrive
and weighed only 2.3 kg when he died at the age of 3% months. The principle finding at
autopsy was of a congenitally malformed heart. There was a persistent left superior vena cava,
a widely patent ductus arteriosus, a large ventricular septal defect and a bicuspid pulmonary
valve.
Radiological Findings. There were a number of unusual features detected radiographically.
The pubic bones were absent on both sides and the iliac wings hypoplastic posteriorly. The
fibulae were small and poorly developed and the distal humeri hypoplastic. The hands showed
bilateral hypoplasia of the first metacarpals and absence of the distal phalanges of the thumbs
and the mid-phalanges of the fifth fingers. The fifth segment of the sacrum was absent and
there was hypoplasia of the inferior portion and ala resulting in poorly developed sacro-iliac
joints.
Cytogenetics. An extra C-group chromosome was present in 58 out of 60 cells from leucocyte
culture, the remaining 2 had apparently normal karyotypes by non-banded criteria so that
the possibility of mosaicism cannot be excluded. The extra chromosome was identified as a
number 9 using G-banding (Fig. 3). X-chromatin was not seen. The mother had a normal
karyotype, the father was not available for study.
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Fig. 3. Karyotype 47,XY,—9 from the propositus, Case 2
Discussion
A number of cases involving trisomy for varying amounts of chromosome 9
have been recorded and a trisomy 9p syndrome has been delineated (Rethore et al.,
1970, 1973; Rethore and Lafoureade, 1974). In most cases this results from a
parental translocation involving chromosome 9. The trisomy arises either from
3 :1 meiotic disjunction (Lindenbaum and Bobrow, 1975) in cases with 47 chromo¬
somes (tertiary trisomy) or inheritance of an unbalanced form of the translocation
in cases with 46 chromosomes. In tertiary trisomic cases there is also trisomy for
the telomeric region of the other chromosome involved in the translocation.
Whilst this additional imbalance cannot be ignored it probably has minimal
phenotypic effect since such telomeric regions are most probably heterochromatic
(Ford, 1973).
The clinical features of the trisomy 9p syndrome are shown in Table 1. Table 2
lists recorded cases of trisomy involving more of chromosome 9 than just the
Table 1. Principle clinical findings which constitute the trisomy 9p syndrome (modified from
Rethore et al., 1973)
Mental retardation
Craniofacial malformations
Microcephaly, prominent forehead, antimongoloid slant of the palpebral fissures, hyper¬
telorism, enophthalmos, prominent fleshy nose, low-set abnormal ears
Skeletal anomalies
Hypoplastic phalanges, clinodactyly of the fifth finger, hypoplastic nails
Dermatoglyphic characteristics
Simian creases, absence or fusion of palmar triradii b and c
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trisomy 9p syndrome
micrognathia, cranial suture abnor¬
malities, urogenital anomalies, early death
congenital heart malformations
congenital dislocation of hips and knees
Fig. 4. Provisional relationship of clinical findings to chromosomal region as determined from
cases of partial trisomy 9
short arm. Most of these cases have features of the trisomy 9p syndrome indeed
8 of the cases listed were considered to have this syndrome when they were re¬
ported. As the amount of chromosome 9 involved in the trisomy increases so
additional clinical features become more constant. Addition of region 9ql to the
trisomy appears to have little phenotypic effect over and above the trisomy 9p
syndrome. This is not surprising as most of this region is heterochromatic. Once
region 9q2 is also added the following anomalies appear: micrognathia, abnormali¬
ties of the cranial sutures involving widely patent fontanelles, malformations of
the urogenital and cardiovascular systems, and early death.
Once region 9q3 begins to be included then abnormalities of articulation of
the hips and knees are found. Other abnormalities of articulation include dis¬
location of the head of the radius, seen in both cases in this report and one other
(Feingold and Atkins, 1973). There were no apparent additional findings when
the whole of chromosome 9 was involved. Mosaicism appeared to have little effect
with the possible exception that life may be prolonged. Both cases described in
this report had multiple bony abnormalities which were only detected radio-
logically. There was considerable similarity between the two cases and a more
detailed radiological assessment will be published elsewhere.
Trisomy of part of the long arm of 9 without the associated trisomy 9p has been
reported in 2 cases (Turleau et al., 1975). Clinically these did not closely resemble
the cases summarised in Table 2. Prenatal diagnosis of trisomy 9 has been reported
(Francke et al., 1975); examination of the foetus showed a number ofmalformations
but detailed pathology was obscured by autolysis.
Delineation of a trisomy 9 syndrome can now be attempted. Over and above
the findings in trisomy 9p (Table 1) there will be abnormalities of the urogenital
and cardiovascular systems, micrognathia, abnormalities of the cranial sutures
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with widely patent fontanelles, abnormalities of articulation, especially of the
hips and knees, and death at an early age. In cases of partial trisomy 9 involving
more than 9p then the clinical findings will depend on the amount of 9q present.
A tentative outline of the possible relationship between clinical findings and the
amount of extra chromosome is given in Figure 4. In view of the very wide
clinical expression associated with autosomal trisomy, both the constitution of
the trisomy 9 syndrome and the relationship of the various clinical findings to
regions of the chromosome will almost certainly require modification as further
cases are described.
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Familial pericentric inversion of
chromosome 19,inv(19) (p13q13)
with a note on genetic counselling
of pericentric inversion carriers
Grant R. Sutherland, Andrew J. Gardiner, and Rodney F. Carter
The Adelaide Children's Hospital (Inc.), North Adelaide, South Australia
An inmate of a hospital for the mentally retarded was found during a cytogenetic screen¬
ing programme to have karyotype 46,XY,inv(19)(pl3ql3)mat. Clinical, cytogenetic and
family findings are presented and it is concluded that the chromosome abnormality was
probably not the cause of the patient's retardation. The problem of genetic counselling of
inversion carriers is examined in some detail and estimates of risk are given.
Received 19 December 1975, revised 5 February, accepted for publication 11 February 1976
Abnormalities of the F-group chromosomes
are encountered infrequently in clinical
cytogenetics. There are reports of transloca¬
tions involving chromosomes of this group,
but no studies on a pericentric inversion
have been published. During the cytogenetic
screening of the inmates of a hospital for
the mentally retarded, a patient was found
to have a pericentric inversion of chromo¬
some 19, which was shown to be familial.
Carriers of pericentric inversions are de¬
tected from time to time; the problems of
counselling these individuals are discussed.
Case History
The propositus was the first child born to a
primiparous 32-year-old woman and her 42-
year-old husband, both of Italian origin.
After a normal vaginal delivery at term the
infant was cyanosed with an Apgar score of
5. Birth weight was 3.05 kg. Several cya¬
notic episodes occurred in the neonatal
period and head circumference increased
from 33.5 to 35.5 cm in the first 7 days of
life, but subdural haematoma was excluded.
Development progressed slowly with many
seizures, up to 8-10 per day, which were
very difficult to control, and with episodes
of aggressive behaviour which caused prob¬
lems in management. At 5.3 years of age
his score on the Vineland Social Maturity
Scale was 2.9 years. At 7 years his air en¬
cephalogram showed dilation of the left
cerebral ventricle consistent with diffuse
atrophic changes in the left hemisphere.
On examination at age 16 the propositus
was found to be a severely retarded micro¬
cephalic (head circumference 52 cm) youth
who showed no other external malforma¬
tions. He had a prominent mandible and
large hands and feet. He had a left divergent
strabismus, held his mouth open with con¬
stant drooling and showed gingival hyper¬
trophy. He was still having frequent grand
mal epileptic seizures and outbursts of ag-
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Fig. 1. G-banded karyotype 46,XY,inv(19)(p13q13) of the propositus. Unbanded F-
from another cell are also shown.
and G-group chromosomes
gressive behaviour. Chest, heart, abdomen
and external genitalia were all clinically
normal. He was 155 cm tall and weighed 60
kg-
Cytogenetic Studies
Analysis of G-banded chromosomes from
lymphocyte culture showed that the propo¬
situs had a pericentric inversion of chromo¬
some 19 (Fig. 1). The banding pattern of
chromosome 19 is such that the location of
break points is difficult to determine, but
since the 12 bands in the propositus were
not separated by the inversion, his karyotype
was interpreted as 46,XY,inv(19)(pl3ql3).
Family studies showed the presence of an
identical inversion chromosome in the
mother and both normal siblings of the pro¬
positus (Fig. 2).
Discussion
Pericentric inversions of chromosome 19
have been recorded by Jacobs et al. (1974)
in a male with delayed onset of puberty
whose father was an inversion heterozygote,
and by Hamerton et al. (1975) in a child
56 SUTHERLAND, GARDINER AND CARTER
/
Q| Q inv (19) (pl3q13) carrier
[n] normal male karyotype
y propositus
Fig. 2. The family pedigree.
with Down's syndrome whose mother car-
ried the inversion. There is no evidence that
these inversions are other than chance find¬
ings. In the present case the birth history,
lack of obvious congenital malformation,
and similarity of the inversion chromosome
in unaffected individuals, suggest that the
chromosome abnormality is not associated
with the mental retardation of the propo¬
situs.
When phenotypically normal individuals
are identified as inversion heterozygotes a
problem arises as far as genetic counselling
is concerned. Translocations ascertained via
balanced carriers have not been reported to
produce unbalanced forms (Jacobs et al.
1970). Similarly, pericentric inversions as¬
certained via inversion heterozygotes have
not produced recombinant forms; hence
some reassurance can be given to inversion
carriers so ascertained. There is also evi¬
dence that small inversions where both
break points are close to the centromere and
involve mainly centric heterochromatin, as
in chromosomes No. 9 (Madan & Bobrow
1974), No. 3 (Soudek et al. 1974) and No.
10 (de la Chapelle et al. 1974) can be re¬
garded as variants without pathological sig¬
nificance.
When a pericentric inversion is known to
have produced a recombinant form the
situation becomes more difficult. It is not
possible to define accurately the risk for the
production and survival of recombinant ga¬
metes; it will depend on the size of the
inverted segment and the frequency of
chiasmata. It should be noted than an un¬
even number of chiasmata between two
chromatids in an inversion loop will always
produce two unbalanced gametes with com¬
plementary recombinant chromosomes
which should be cytologically recognisable.
One recombinant chromosome will be
smaller than the non-recombinant chromo¬
somes and the other larger, provided that
the original inversion produced an alteration
in arm ratio. Warter et al. (1973) recorded
a family in which a male with an inv(5) had
offspring with both recombinant forms.
Families in which pericentric inversions
segregate and which have been ascertained
via a recombinant form are shown in Table
1. The inversions involved are different, and
grouping them together is probably invalid.
However, these data are all that are avail¬
able on which to base estimates of recur¬
rence risks. In assembling this table the pro¬
geny of inferred carriers of unknown sex
were not included as this would lead to an
excess of inversion heterozygotes (Hamer-
ton 1970). Unkaryotyped individuals with a
normal phenotype or those in whom there
was no suggestion of chromosomal path¬
ology were listed separately ("normals"), as
were others who could be inferred to be
recombinants (this did not include abor¬
tions). If the data in Table 1 are corrected
for single ascertainment (by elimination of
all probands), then the recurrence risk for
recombinants is 2/59 (3.4 %); and if all the
inferred recombinants are included, the fi¬
gures become 8/77 (10.4 %). In either in-
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"Normal" Inferred Sex of
Karyo¬ segre- recom¬ parent of
typed gants binants karyo¬
recom¬ not not typed
binants karyo¬ karyo¬ recom¬
typed typed binants!
Ferguson-Smith
(1967) C (10) 3 1 1 1 2 3 F
Wilson et al. (1970) 4 8 2 5 1 2 - F
Parrington &
Edwards (1971) 13* 3 2 - 1 - 1 F
Hauksdottir et al.
(1972) 13 26 13 11 2 6 1 F, F
Surana & Conen
(1972) D 3 1 1 1 - - M
Dutrillaux et al.
(1973) 10 2 - 1 1 - - F
Taysi et al. (1973) 13 5 1 3 1 - - F
Warter et al. (1973) 5 3 1 - 2 - -
Escobar et al.
(1974) 13 2 - 1 1 - - F
Jacobs et al
(1974)** 18 4 3 - 1 - - F
Fujimoto et al.
(1975) 8 11 5 5 1 2 1 F
Total 70 29 28 13 12 6 2 M, 10 F
** Also Frackiewicz (1975) pers. comm.
* McDermott & Parrington (1975).
t F - female; M - male.
stance these figures will be minimal, as as¬
certainment may not be complete.
If the sex of the inversion heterozygote
who produced the recombinant is considered
(Table 1), then of 12 heterozygotes, 10 were
females and 2 were males. Such ascertain¬
ment bias is also noted when t(DqGq) he¬
terozygotes are identified by their offspring
with Down's syndrome; however, this re¬
flects the increased risk that such female
heterozgotes will produce unbalanced
forms (Hamerton 1970). By analogy, female
inversion heterozygotes may be more likely
to have recombinant offspring. In addition,
if the higher genetic recombination fractions
in females (e.g. Weitkamp et al. 1973) are a
reflection of increased chiasma frequency,
and if this holds for inverted chromosomes,
then the probability of recombinants from
female inversion heterozygotes would be
greater than from males.
Apart from the production of recombi¬
nants, there is the possibility that an inverted
chromosome can interfere with normal
meiotic disjunction of other chromosomes
(Leonard et al. 1975). These authors review¬
ed the occurrence of aneuploidy associated
with pericentric inversions and found three
cases of Turner's syndrome associated with
an inv(2), and five autosomal trisomies as¬
sociated with other inverted chromosomes.
In view of the frequency of about 1 in 7,500
(Nielsen & Sillesen 1975) of autosomal in¬
versions, the few associations with aneu-
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ploidy may just be chance. Nondisjunction
of recombinant chromosomes leading to par¬
tial trisomies is another source of abnormal
offspring. Gray et al. (1962) recorded a
woman with a pericentric inversion of chro¬
mosome 21 who produced a child with
Down's syndrome in whom both recombi¬
nant chromosomes from an inversion loop
cross-over were present; Jacobs et al. (1974)
detected an infant with karyotype 47,XX,
inv(18), + rec(18) whose mother was an in¬
version heterozygote.
Conclusion
The risks for the production of abnormal
offspring by inversion heterozygotes were
derived by pooling heterogeneous data and
must be regarded as unreliable. Neverthe¬
less at the present time they provide the
only available guide in a difficult area. For
the practical purposes of genetic counselling,
risks of 5 % for male and 10 % for female
inversion heterozygotes to produce recom¬
binants, when a previous recombinant is
known within the family, should be accu¬
rate enough for patients to arrive at in¬
formed decisions. In a family in which an
inversion has segregated without producing
recombinants a nominal risk of about 1 %
could be offered as guidance. These risk
figures would include any risk for the pro¬
duction of aneuploids as well as recom¬
binants. Either circumstance would be ade¬
quate indication for prenatal chromosome
analysis.
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Whilst ring chromosomes have been reported for
the sex chromosomes and most of the autosomes,
a ring chromosome 2 has not been described. This
paper reports the first case of 46,XX/46,XX,r(2)
mosaicism which was found in a severely mentally
retarded and physically handicapped girl. Observa¬
tions on the behaviour of the ring chromosome are
recorded.
CASE REPORT
The proposita (fig. 1) was the second child born to
42-year-old parents. The first child born three years pre¬
viously was well. The mother had Addison disease (adre¬
nal insufficiency) for which she had been under treatment
for some years prior to and during her pregnancy. Delivery
was by elective lower segment caesarean section at 39
weeks gestation because of cephalopelvic disproportion and
maternal Addison disease. Apgar score was 8 and there
were no resuscitation problems. Microcephaly (head cir¬
cumference 29cm) and multiple anomalies were noted at
birth. Birth weight was 2.2 kg. There were feeding difficul¬
ties and the child was kept in hospital until five weeks of
age. Developmental milestones were grossly delayed. She
could sit at 18 months but never learned to walk and can
only say one or two words. At seven years she was func¬
tioning at the level of 6 — 8 months. Examination at the
age of seven years showed a small (height 106 cm, span
97cm) obese (26.7 kg) profoundly retarded girl. Her head
was small (circumference 43 cm) and unusually shaped
having a very flattened occiput. She had an old facial ap¬
pearance with bilateral epicanthi, flattened nose and absent
ear lobes. Skull X-ray confirmed the gross microcephaly and
showed fusion of the coronal and sagittal sutures; there
was no intracranial calcification or other specific feature
noted. She could see and hear, ear canals and eyes appea¬
red normal. There was a high arched palate. The neck
was short and webbed. There was no breast tissue and the
chest appeared shield-like with widely spaced nipples. The¬
re was a blind sacro-coccygeal sinus; anus and external
genitalia were normal. The fat distribution was unusual
with buffalo hump and marked truncal obesity but small
forearms, hands and feet. Multiple abnormalities of the
limbs and their articulation were present. The forearms
could not be fully pronated, there were flexion deformities
of the elbows and shoulders. The wrists were hypermobilc
and appeared to readily subluxate, the thumbs were incur¬
ving and there was a right simian crease. Radiography
showed that the fourth metacarpals were abnormally short.
A congenital dislocation of the left hip had been treated
satisfactorily at six months of age but the left leg was
held in external rotation and there was decreased abduction
of the right hip.
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Fig. 1. — The proposita aged
seven years.
Cytogenetics
Cytogenetic studies on blood lymphocytes had been car¬
ried out in this Department on two occasions shortly after
birth of the proposita. The first when she was six days of
age and again at seven weeks of age. Unfortunately the
preparations had deteriorated and were unsuitable for re¬
examination. However results obtained from 100 metapha-
ses scored on each occasion at that time indicated that 5
and 11 percent respectively of the cells were tetraploids
containing rings and that of the diploid cells about half had
a normal female karyotype and half contained a monocen-
tric ring in place of a normal chromosome number two.
Chromosome studies on blood lymphocytes were repea¬
ted in 1977 when the child was seven years of age and
Tabi.f. I
Cytogenetic studies carried out at age 7 years
Diploid Cells
Normal _2 Ri Ri Ri Rod * * Ro Total
21 2 119 1 3 1 147
these results are show in table I and figs. 2 and 3. 193
consecutive metaphases were examined of which 46 were
tetraploid (tetraploidy = 22 per cent) and a further 16 te-
traploid cells were scored. These results strongly suggest
that the frequency of tetraploid cells has increased and the
frequency of normal diploid cells has decreased since
chromosome studies were carried out in the neonatal pe¬
riod. Of the diploid cells only 14 percent appeared to have
a normal female karyotype.
The great majority of cells showed a monocentric ring
chromosome identified by banding to be a number 2 with
break points at p25 and q37 (fig. 2). This chromosome see¬
med to be remarkably stable in diploid cells ; the only
evidence of instability was in three of these cells in which
the ring had apparently formed a rod-shaped chromosome
equivalent in size and morphology to chromosome 1, in
two cells in which the ring chromosome had been lost, in
one cell in which there were two rings and in one cell in
which the size of the ring had altered significantly and
was replaced by a small ring. In the diploid cells there was
no evidence of rings with more than one centromere and
no open rings or pulverised rings were seen. There was
much more evidence of ring instability in the tetraploid
cells (fig. 3). Of the 62 cells examined 32 showed a dicen¬
tric ring and three cells showed two monocentric rings equi¬
valent in size and morphology to the monocentric rings
seen in the diploid cells. Instability was evidenced by open
rings and the formation of large dicentrics presumably due
to breaking of the ring, however these dicentrics appeared
as rod-shaped chromosomes. A number of the tetraploid
cells showed partial pulverisation of the chromosomes, ho¬
wever in no case was a tetraploid cell seen in which only
the ring was pulverised. One octoploid cell was seen in
which there were apparently interlocking dicentric rings
(fig. 3 f).
DISCUSSION
Formation of the r(2) chromosome has resulted
in very little loss of chromosomal material and is
present in mosaic form with normal cells, and yet
the proposita is severely physically and mentally
handicapped. It is possible that this degree of mal-
development is less related to deletion of genetic
material than to some disturbance in the regulation
of cell division since the instability of the ring ap¬
pears to be manifesting itself by the induction of
tetraploidy. Hoo et al. (1974) suggested that the cli¬
nical stigmata in a child with a r( 13) chromosome
could have been due to the subsequent behaviour
of the ring chromosome rather than the deletion
per se which was minimal. Furthermore it has been
Tetraploid Cells
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Ro = small monocentric ring. * = interlocking in one cell. * * = abnormal rod chromosomes.
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Fig. 2. — G. banded chromosomes 2 from two diploid metaphases
showing break points at p25 and q37.
pointed out (Zdansky et al., 1975) that the pheno-
typic consequences of ring chromosomes are varia¬
ble and that there are no well defined clinical syn¬
dromes associated with ring autosomes.
Few reports of ring chromosomes mention tetra-
ploid cells and when referred to these are usually
present only at the expected frequency of 1-2 per
cent for lymphocyte cultures. Bobrow et al. (1973)
found about 10 per cent tetraploid cells in lympho¬
cyte metaphases from a patient with a r(l) chromo¬
some. The only dicentric rings observed in that
patient were in the tetraploid cells, the ring being
fairly stable in the diploid cells in that less than
5 per cent of diploid cells showed other than a nor¬
mal sized monocentric ring. The behaviour of this
r(l) chromosome was similar to that of the r(2) in
the present case. In a patient with a r(4) previously
described from this Department (Carter et al.,
1969) the frequency of tetraploidy was 5 per cent
Hecht (1969) recorded 4-5 per cent tetraploidy
in another child with a r(4). The model of ring
chromosome behaviour put forward by Pathak and
Sinha (1972) does not account for the production
of tetraploidy which would appear to be a conse¬
quence of dicentric ring formation in some cases,
particularly when the ring chromosome is a large
chromosome. However, Kirstemacher and Punnett
(1970) concluded from an extensive literature survey
that the stability of ring chromosomes in Man was
unrelated to their size. The mechanism by which
tetraploid formation occurs is unclear but Hoo et al.
(1974) suggested that the formation of tetracentric
rings led to the formation of tetraploid cells by distur¬
bing anaphase in a case with a r( 13).
Most reports of mosaicism involving ring chro¬
mosomes have not recorded changes in the fre¬
quency of the various cell types. Packer et al. (1974)
reported a child with 46,XX/46,XX,r(4) mosaicism
in which the proportion of cells with the ring rose
from 9 p. cent to 72 p. cent over a period of seven
years. Hecht (1969) reported an increase in fre¬
quency of cells with a ring chromosome from 54
p. cent to 95 p. cent in a child with 45,XY,-4/46,
XY,r(4) mosaicism over a four year period. In this
latter case the changes in proportion of the cell
types is unexpected since at conception this child
was probably 46,XY,r(4) with subsequent loss of
the ring from some cells. However, it would appear
that cells containing a ring are at a selective advan¬
tage in vivo in some cases.
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Fig. 3. — Appearance of the ring chromosome and its derivatives
in polyploid cells, (a) and (b) dicentric rings in tetraploid cells,
(c) and (d) large dicentrics showing sister chromatird reunion
in tetraploid cells, (e) open dicentric ring in a tetraploid cell, (f)
interlocking dicentric rings in an octoploid cell.
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Summary. — A severely mentally retarded and physically handicapped girl is des¬
cribed who has 46,XX/46,XX.r(2)(p25q37) mosaicism. This is the first ring 2 chromosome
to be described in Man. Studies of the behaviour of the ring showed that it was stable in
diploid cells which had increased in frequency over a period of seven years, but unstable
in tetraploid cells which were at a much higher frequency than in normal individuals. It is
concluded that in some cases the phenotypic consequences of ring chromosome formation
may be due more to their disturbing the regulation of cell division than to the loss of
genetic material. Current models of ring chromosome behaviour do not account for the
induction of tetraploidy.
KEY-WORD : Ring chromosome 2.
MOSAIQUE 46,XX/46,XX,r(2)(p25q37) : ETUDES CLINIQUE ET CYTOGENETIQUE
Resume. — Une malade severement encephalopathe et porteuse d'une mosai'que :
46,XX/46,XX,rf2)(p25q37) est decrite. Cette observation est la premiere d'un chromosome
2 en anneau chez l'homme. Celui-ci etait stable dans les cellules diploi'des et la frequence
s'etait accrue pendant une periode de 7 ans, mais instable dans les cellules tetraploi'des dont
la frequence etait plus elevee que chez des individus normaux. Les auteurs concluent que
dans certains cas les consequences phenotypiques des chromosomes en anneau peuvent etre
dues davantage a leur action sur la regulation de la division cellulaire qu'a la perie
de materiel genetique. Les modeles proposes jusqu'a present dans la mecanique des
chromosomes en anneau ne rendent pas compte de la production des cellules tetraploi'des.
MOT-CLE : Chromosome 2 en anneau.
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46,XY Females
by G. R. Sutherland, G. F. Binns, R. F. Carter, and Ruth Dow
from the Department of Histopathology, Adelaide Children's Hospital,
and the Department of Gynaecology, Royal Adelaide Hospital
In man the Y chromosome is strongly male-
determining and individuals with a normal Y
chromosome are almost always males. There
are exceptions to this, however, and a few
conditions are known in which phenotypic
females have apparently normal male chromo¬
some complements. The two best defined
disorders of this type are testicular feminization
and XY pure gonadal dysgenesis (Swyer
syndrome). Whilst relatively rare these con¬
ditions are of importance in that they can be
familial and XY females are at high risk of
tumour development in their dysgenetic
gonads. This paper reports three XY females
with pure gonadal dysgenesis, two of whom
are sisters.
CASE 1
The proposita was the result of the first
pregnancy of a 22-year-old woman and her
non-consanguineous 24-year-old husband.
Hydrocephaly had been diagnosed antenatally
and birth at term was by instrumental
delivery. Investigations during the second
week of life showed marked asymmetry of the
skull with prominence of the right parietal
region, widening of sutures, agenesis of the
corpus callosum, moderate ventricular dilata¬
tion and a very large Dandy-Walker cyst. A
cisterno-peritoneal shunt was installed, but
intermittent shunt blockages occurred from
the age of seven months so it was converted to
a cisterno-atrial shunt. From the age of 16
months she began having convulsions and
final admission to hospital was at the age of
22 months. She was then shown to have
hypertension and chronic renal failure; an
intravenous pyelogram showed small shrunken,
malrotated kidneys. She was treated with
diuretics and hypotensive agents but gradually
deteriorated, with increasing oedema and
persistently high plasma urea and creatinine.
She died at the age of 23 months.
The main relevant autopsy findings were
confined to the kidneys and brain. The right
kidney was about half normal size and of an
abnormal shape with the hilum in the centre
of the anterior surface. The arterial supply was
highly abnormal, two small arteries of about
1.5 mm external diameter arising from the
posterior aspect of the lower abdominal aorta
just above the bifurcation and entering the
kidney on the posterior aspect of its lower pole.
A few small unilocular cysts about 1.5 mm
diameter and filled with clear fluid were
present in the superficial cortex and visible on
the external surface. Microscopically these
cysts were similar to those seen in multicystic
dysplasia although interpretation of the renal
pathology was somewhat hindered by the
advanced pyelonephritic changes present. Two
larger cystic areas about 15 mm diameter
protruded from the upper pole. On incision
these were seen to be filled partly by honey¬
combed grey tissue which microscopically
proved to consist of primitive to well-
differentiated renal tubules and occasional
glomeruli lying between numerous cysts lined
by either flattened or obvious renal-type
epithelium.
The left kidney was about one-third normal
size but of normal shape. The surface was
marked by slightly elevated fine cysts up to
2 mm in diameter. Vascular anomalies were
again present, two veins arising from the
posterior aspect of the lower pole, running
behind the aorta, and then fusing before
entering the inferior vena cava just above the
junction of the common iliac veins. Cysts of
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the smaller type were again present with
similar distribution and microscopical ap¬
pearances, and this kidney also showed
pyelonephritic changes.
The abnormalities in the kidneys clearly
indicate renal dysgenesis but of a complex
type that cannot be readily classified within
any of the currently accepted systems of
nomenclature. The pyelonephritic changes
were considered to be secondary and un¬
doubtedly the cause of the child's death from
renal failure.
The brain showed hydrocephalus due to a
Dandy-Walker malformation and there was
associated agenesis of the corpus callosum.
The internal and external genitalia were
thought to be normal macroscopically so only
the right ovary was taken for routine histo¬
logical study. Microscopically there was an
outer shell of tissue resembling ovarian stroma
which covered an internal mass of tumour.
This was considered to be a gonadoblastoma
arising in a streak ovary. Section through the
outer end of the fallopian tube showed fimbria
externally but internally tubules resembling
epididymis and, in one area, rete testis.
Routine skin fibroblast culture showed a
normal male karyotype, 46,XY. Chromosome
studies on the parents, siblings, and mother's
sisters were all normal. An extensive family
history did not suggest that the XY pure
gonadal dysgenesis was familial.
CASE 2
The proposita approached her family doctor at
age 16 years for advice regarding lack of breast
development. On initial examination she was
noted to have no breast development and
infantile external genitalia; she had never
menstruated. Investigation included chromo¬
some studies which revealed a normal male
karyotype, 46,XY. Detailed gynaecological
examination at the age of 17 years revealed a
prepubertal appearance in a girl 168 cm tall.
There was no axillary hair, there was no
evidence of any breast tissue, and the nipples
were of male type. She was, however, not
muscular but of definitely feminine habitus.
There were a few long dark streaky hairs over
the mons and the external genitalia were
infantile; there was no clitoral enlargement.
Vaginal examination was not possible as there
was a tight tender hymen; rectal examination
was normal. The girl enjoyed good health, was
of normal intelligence and socially female.
Gonadectomy was performed and both
gonads measured 1.5 x 0.5 x 0.5 cm. Micro¬
scopically the right ovary showed the typical
appearance of a streak gonad without evidence
of neoplasia. The left ovary showed the typical
appearance of a gonadoblastoma but without
any evidence of transformation to other
tumour types (Figure 1). There was a small
infantile uterus and fallopian tubes were
present. Hormone replacement therapy was
instituted and one year later there has been
little in the way of breast development but
periodic withdrawal bleeding occurs.
Family studies indicated that the proposita
had three sisters (Figure 2), and one of these
was found to have a normal male karyotype,
46,XY. Extensive investigation of more distant
relatives did not reveal any individuals in
whom this condition might have been
suspected.
A
FIG. 2: Case 2 (left) and her three siblings, two of whom
are normal females and one (second from right) is Case 3.
CASE 3
This girl is a sister of Case 2 and was ascertained
by family studies. Detailed gynaecological
examination at the age of 14 years showed an
underdeveloped girl 158 cm tall. There was no
breast development and no axillary or pubic
hair. She had never menstruated. External
genitalia were infantile in appearance with no
clitoral enlargement. Vaginal examination was
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not possible because of the presence of a tight
hymen. Rectal examination was normal except
that there was a fullness and tenderness on the
right of the pelvis suggestive of a small mass.
Gonadectomy was performed and the left
ovary measured 2 x 0.5 x 0.5 cm and micro¬
scopically had the appearance of a streak
ovary. The right gonad measured 2.5 x 1 x 1 cm
and microscopically was shown to be a
gonadoblastoma without any evidence of
transformation to other tumours. The internal
genitalia were similar to those of Case 2. Her
response to hormone replacement therapy has
been similar to her older sister's. The two other
sisters with normal female karyotypes showed
completely normal development for their ages.
DISCUSSION
Associations of hydrocephalus with renal
anomalies are well-known (D'Agostino et a/.,
1963, Cases 9 and 10; Goldston et a/., 1963;
Miranda et a/., 1972) as are associations of
pseudohermaphroditism with renal anomalies
(Franks and Northcutt, 1963; Drash et at.,
1 970; Barakat et a!., 1974). The association of
renal and cerebral anomalies with XY pure
gonadal dysgenesis shown in our Case 1 may
be fortuitous as such an association has not
been previously recorded.
The familial occurrence of XY pure gonadal
dysgenesis is best shown in the families
reported by Sternberg et at. (1968) and
Espiner et at. (1970). In these families there
were affected individuals in three sibships.
Siblings with XY gonadal dysgenesis have
been reported on numerous occasions. The
inheritance pattern seen is strongly suggestive
of X-linkage but the possibility of sex-limited
dominant transmission cannot be excluded.
XY gonadal dysgenesis probably represents a
heterogeneous group of disorders. The majority
of patients are of normal to slightly increased
height, lack secondary sexual characteristics,
have streak gonads, and are not masculinized.
However, others have been reported to show
some features of Turner syndrome and some
are masculinized to a greater or lesser extent.
Differences in expression of the gene responsi¬
ble may account for some of this variation.
Barr et at. (1967) described a family in which
one sibling had XY pure gonadal dysgenesis,
another had male pseudohermaphroditism, and
a son of their sister had marked hypospadias.
Some of the phenotypic variations, particularly
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masculinization, may well be due to tumour
formation. Not all patients with gonadal
tumours are virilized but when there is clinical
evidence of tumour hormonal secretion this is
usually androgenic (Scully, 1970).
Dysgenetic gonads in individuals who carry
a Y chromosome are prone to tumour develop¬
ment. Manuel et at. (1976) estimated that
27.5 per cent of patients with XY gonadal
dysgenesis will develop tumours by the age
of 30 years. The tumours are most commonly
gonadoblastomas but frequently are dys-
germinomas and more rarely are chorio¬
carcinomas and embryonal carcinomas. Case 1
in this report appears to be the youngest
patient recorded to have developed a gonado-
blastoma. Manuel et at. (1976) did not find
gonadal tumours in individuals below the age
of five years and suggested that in XY gonadal
dysgenesis only about 2 per cent will develop
tumours before the age of 10 years.
In view of the risk of tumour development in
individuals with XY gonadal dysgenesis, and
considering that the gonads will be functionless
in any case, we believe they should be removed
at the time the diagnosis is made. There can be
no good reason for delaying gonadectomy for,
as the first case in this report shows, tumour
can be present before the age of two years.
Moreover, in addition to the risk of malignant
transformation and even metastasis occurring
before the primary tumour has been detected,
there is also the possibility of inappropriate
virilization occurring in some cases.
ADDENDUM
Swanson and Chapler (1978) have reported
two XY females with renal anomalies (horse¬
shoe kidneys) and suggest that all XY females
should have their urologic systems evaluated.
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Denouement and Discussion
Fetal Turner's Syndrome
Fig 1.—Fetus with Turner's syndrome depicting marked cervical sac and generalized lymphedema.
Fig 2.—Posterior view of the cervical sac.
Fig 3.—Lymphedema on the dorsum of the feet.
Manifestations
In the fetus the main features of
Turner's syndrome are gross lymph¬
edema with large cervical fluid-
filled sacs. The cervical sacs may be
extremely large and are most likely
associated with the webbing of the
neck found in patients with Turner's
syndrome. There have been reports of
elevated a-fetoprotein levels in the
amniotic fluid of fetuses with Tur¬
ner's syndrome. Some believe that this
is due to obtaining fluid from the
cervical sac rather than the amniotic
fluid. Although the majority of pa¬
tients both with Turner's syndrome
survive, a substantial number of
fetuses with Turner's syndrome do
not come to term. The reason for this
is not known.
Genetics
The karyotype in the majority of
patients with Turner's syndrome is
45,X. However, 209 to 309 have
various types of mosaicism including
X/XX, X/XY, and X/XX/XY or a
structurally altered chromosome such
as an isochromosome X, ring X, or
partial deletion of the X chromosome.
There is generally no parental carrier
state predisposing to Turner's syn¬
drome and therefore the recurrence
risk is not much greater than that of
the general population. This condition
can be detected by performing chro¬
mosomal analysis on amniotic fluid.
Treatment
There is no treatment for the fetus
with Turner's syndrome. There is a
considerable risk of malignancy in
individuals with mosaic-type Turner's
syndrome that have a cell line contain¬
ing a Y chromosome (eg, XO/XY).
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for neurological disorders Grant R. Sutherland
Whilst it is clear that many neurological disorders are the
result of environmental factors, such as anoxia, trauma or
infection, there are also many which have a genetic compo¬
nent, such as epilepsy and the neural tube defects, or are
wholly genetic such as Down syndrome or Huntington
disease. Those disorders which are genetic or partly genetic
have recurrence risks which vary from 50 per cent for the
dominant disorders, such as Huntington disease, down to
less than one per cent for the recurrence of regular Down
syndrome to a young mother. Some disorders are readily
amenable to prenatal diagnosis and others are not.
What can genetic counselling offer?
(i) An explanation of what went wrong, with
consequent alleviation of guilt.
Grant R. Sutherland
Grant R. Sutherland, MSc (Melb), PhD (Edin) is Chief
Cytogeneticist at the Adelaide Children's Hospital and
Honorary Consulting Geneticist to The Queen Victoria
Hospital, South Australia. He was previously senior
Cytogeneticist at the Royal Hospital for Sick Children in Edin¬
burgh and an Honorary Fellow in the Faculty of Medicine of
the University of Edinburgh.
This article continues the series being provided by the
Australian Neurological Foundation.
(ii) A statistical figure for recurrence given in
comprehensible terms.
(iii) A discussion of alternative courses of action which
may include:
— continue reproduction;
— cease reproduction with possible mention of
abortion, contraception, sterilization or
adoption;
— prenatal diagnosis for future pregnancies;
— donor insemination, either if the husband is the
cause of the problem or if both parents contribute
to the risk.
The 'counselling' rather than the 'genetic' aspects of
genetic counselling cannot be overemphasized. When
parents produce an abnormal child they usually experience
the emotional reactions of loss, grief and guilt. It is
essential to cope with these reactions as well as giving
information, otherwise the information will be poorly
understood and might be rejected. There can be
considerable strains put on marital and other family
relationships (for example, with the in-laws). In spite of
these problems, full diagnostic evaluation of any child with
a potential genetic disorder should be carried out as soon as
possible after the problem has been recognized. Family
studies which may be necessary should also be carried out
at this time, as there might be others at risk of having
abnormal offspring.
The involvement of a social worker in helping families
cope with the problems of adjustment can be helpful. The
stress on genetics in this article merely reflects the bias of its
author.
From a geneticist's viewpoint, it is convenient to classify
neurological disorders with a genetic component according
to the type of inheritance pattern they follow. This may
have little relevance to any clinical classification, but is
useful since familial aggregation may be a clue to
diagnosis.
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Autosomal recessive (AR) disorders
Both parents of an individual with an AR disease must
be carriers of the gene involved. Carriers of such genes are
normal individuals; indeed, virtually everyone is a carrier
of two or three different recessive genes. There is usually
no relevant family history, although in the rarer disorders
the parents may be related to each other; this is more
common in some of the immigrant communities where
cousin marriage is often encountered. Examples of AR
disorders which can present as neurological problems are
shown in Table I.
Table I
Some autosomal recessive disorders
Friedreich ataxia
Hurler syndrome (mucopolysaccharidosis)




McKusick3 lists 521 proven AR disorders: many of these
are very rare and not associated with neurological disease,
but many are. Once parents have had a child with an AR
disorder, the recurrence risk for each and every subsequent
pregnancy is 1 in 4, or 25 per cent. This risk is high enough
to deter most couples from further reproduction, especially
when the disorder is severe and untreatable. A number of
AR disorders, such as phenylketonuria (PKU) can be
successfully treated.
• Accurate diagnosis, at the chromosomal or
molecular level, Is often an essential basis for the
provision of reliable genetic counselling.
Possible courses of action include prenatal diagnosis, as
many of the AR disorders are amenable to this procedure.
For this reason, it is important that every effort be made to
reach a diagnosis as soon as a child is recognized as having
a problem, so that recurrence can be prevented.
Diseases which can be prenatally diagnosed include the
neuronal storage diseases, such as Tay-Sachs and Gaucher
diseases, which are degenerative conditions associated with
mental deficit. The accuracy of diagnosis needed in this
area is demonstrated by the mucopolysaccharidoses, which
were previously called gargoyles, where all are AR diseases
except Hunter's syndrome, which is X-linked.
Another possible course of action is donor insemination,
which is applicable to AR disorders. Similarly, in any AR
case, if the parents separate and remarry there should be no
recurrence provided their new partners are not related to
their previous ones, or to themselves. Again, correct
diagnosis is essential as donor insemination would be
useless in X-linked diseases.
Autosomal dominant (AD) disorders
These are conditions which are passed directly from
parent to offspring. When a person is affected with an AD
disorder, half his/her children would be expected to have it
also. Table 2 lists a number of dominant disorders.
Table 2
Some autosomal dominant disorders
Charcot-Marie-Tooth disease (most common form)
Huntington disease (chorea)
Motor neurone disease (some families)
Neurofibromatosis (Von Recklinghausen disease)
Spastic paraplegia (some families)
Tuberous sclerosis
Waardenburg syndrome
• A detailed family history can often give a
clue to the type of inheritance a disease is follow¬
ing, but care must be taken as a common environ¬
ment can also produce multiple affected family
members.
Counselling is often difficult in dominant disorders. In
almost all cases there is no objective diagnosis possible,
that is, there is no consistent biochemical or chromosomal
abnormality demonstrable. This means that clinical
conditions which appear identical may have different
aetiologies. For example, motor neurone disease is usually
not familial, but some families have this following an AD
inheritance pattern. Charcot-Marie-Tooth disease is most
commonly dominant, but AR and X-linked forms also
exist. A detailed family history is particularly helpful in
differentiating patterns of inheritance.
Further problems are encountered with AD disorders
due to differences in penetrance and expression.
Penetrance simply refers to the occurrence or otherwise of
the disease in an individual who carries the gene for it; it is
an all or none phenomenon. Expression is the degree of
severity of the disease. These phenomena are important in
a condition like tuberous sclerosis. The majority of
individuals with this disorder are the result of a new
mutation. This means that the parents are running only a
very small risk that the condition may recur in subsequent
offspring, but half the offspring of the new mutant would
be expected to have the disease.
The severity of tuberous sclerosis varies greatly, such
that in some carriers of the gene it is not penetrant. Before
deciding that a child is a new mutant, the parents should be
examined under Wood's light for white macules, have skull
radiographs for intracranial calcification and undergo
fundoscopic examination for phakomata.
In Huntington disease, the age of onset of symptoms
ranges from early teenage until the seventh decade.
Consequently, members of a family in which this condition
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is present can never be certain that their unaffected
ancestors did not carry the gene, particularly if they died in
middle age from some intervening cause.
Genetic technology cannot offer a great deal to members
of a family with an AD disorder. Only a handful of these
conditions are amenable to prenatal diagnosis, and the risk
of recurrence is high (50 per cent). When a male is affected
then donor insemination can be discussed, but for females
there is no practical alternative to abstaining from
reproduction. Counselling can, however, put the problem
into perspective and pedigree analysis can often show that
the risks being run are small.
X-linked (XL) disorders
In this type of inheritance the gene responsible is located
on the X chromosome. The majority are recessive in that
they do not cause disease in females who have two X
chromosomes, but do in males who have only one X
chromosome. Some XL recessive disorders are shown in
Table 3.
Table 3




Hydrocephalus (aqueduct stenosis type)
Menke syndrome
Mental retardation (i) with markerX chromsome
(ii) without marker X chromosome
Muscular dystrophy, Duchenneand Becker types
In families with XL recessive disorders, any males who
reproduce will have all normal children but all their
daughters will be carriers. Carrier females who reproduce
will have normal daughters (although half of them will be
carriers) but half their sons will be affected.
It is often possible to detect the carrier status in females
with a fair degree of accuracy. For example, by measuring
creatinine phosphokinase levels in females from families
with Duchenne type muscular dystrophy, it is found that
about 70 per cent of carriers have increased levels of this
enzyme. For females in such families, pedigree analysis in
combination with biochemical studies can usually establish
carrier status with considerable reliability.
Most XL recessive disorders are not amenable to specific
prenatal diagnosis; however, since only males are affected,
prenatal sexing and termination of male foetuses can allow
couples where the wife is a carrier to have normal girls
without the risk of having an affected male. Foetal blood
sampling may be available in the near future, and should
allow prenatal diagnosis of Duchenne muscular dystrophy
in male foetuses at risk for this disorder.
XL mental retardation (Renpenning syndrome) has been
proposed to account for 20 per cent of retarded males with
IQs between 30 and 55 by Turner and Turner7 in New
South Wales, and is probably the commonest form of
familial mental retardation. It is a heterogeneous group of
conditions. In one form there is macro-orchidism which is
now associated with a visible chromosome lesion known as
a fragile site (Figure 1). In other forms without the
chromosome lesion, the diagnosis can only be made by
study of the family tree and exclusion of other aetiologies.
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Figure 1. Unbanded karyotype of a male with the form of X-
linked mental retardation showing a fragile site (arrow) on
theendoftheXchromosome.
XL dominant disorders are rare. An example is the oro-
facial-digital syndrome in which males are so severely
affected that death in utero occurs, but females survive
with varying expression of the condition.
• All couples at risk for having children with
neural tube defects should be informed that these
conditions are amenable to prenatal diagnosis.
Multifactorial disorders
There are many conditions which follow a multifactorial
pattern of inheritance (Table 4). There are a number of
properties of multifactorial inheritance which can be
noted:
(i) The incidence in first degree relatives (parents,
siblings, offspring) is usually five to 20 times that of
the general population. In more distant relatives the
incidence falls off rapidly.
(ii) The more affected members there are in the family,
the greater the chance that subsequent members will
be affected.
(iii) The incidence of the disorder will vary from one
population or ethnic group to another.
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(iv) One sex may be more commonly affected than the
other.
Two groups of disorders which follow multifactorial
inheritance are worthy of more detailed discussion because
they are not rare, and frequently give rise to enquiries.
Neural tube defects
The most frequently encountered neural tube defects are
anencephaly and spina bifida and, more rarely,
encephaloceles. Whilst these forms of neural tube defect
are diverse clinically they are similar genetically, since they
are all manifestations of failure of neural tube closure
during embryogenesis.
In Australia, the incidence of neural tube defects at birth
is 1.94/1,000 births4, of which about half have spina
bifida. The risk of recurrence of neural tube defects for
parents after the birth of an affected child is three to five
per cent, after two affected children 10 per cent, and for
the children of an individual with a neural tube defect
(usually spina bifida) two to three per cent. The risks are
increased for persons with a family history of neural tube
defect, and for those with minor spinal dysraphrsms or
spina bifida occulta, but the magnitude of the increase in
these cases is not well established. It should be noted that
precise diagnosis is again important, since on casual
inspection the AR Meckel syndrome can mimic a simple
encephalocele.
What can be done for couples at risk for children with
neural tube defects? Those neural tube defects which are
open lesions, (that is, not covered with skin) can be
prenatally diagnosed by measurement of amniotic fluid
alphafoetoprotein, which is raised in concentration in such
instances.1 Generally speaking, the closed lesions are much
less frequent and not nearly so handicapping as open ones,
hences couples at risk can be assured they can have a child
who will almost certainly not have an open neural tube
defect if at prenatal diagnosis their amniotic fluid alpha¬
foetoprotein is normal. Prenatal diagnosis will thus
identify a second affected child in a family. Identification
of the first affected child would be of much greater benefit.
Maternal serum alphafoetoprotein is high in nearly all
pregnancies where the foetus is anencephalic, and in about
60 per cent of those when the foetus has a different open
neural tube defect. Since the normal range of serum
alphafoetoprotein varies markedly with the gestational age,
the time at which the serum sample is collected and an
accurate gestational age are important. Sampling should be
at 16 weeks' gestation; sampling earlier than this gives less
reliable results.
In Glasgow, Ferguson-Smith et at2 showed that raised
serum alphafoetoprotein was associated with a foetal
neural tube defect in one in two cases after amniotic fluid
alphafoetoprotein has been measured. Pilot programmes
of maternal serum alphafoetoprotein screening are
currently well advanced in Australia.
• Before attempting to give genetic counsell¬
ing in epilepsy, complete neurological assess¬
ment is essential.
Epilepsy
Epilepsy can be difficult to define accurately, and is a
heterogeneous group of disorders ranging from isolated in¬
fantile convulsions through to congenital malformation
complexes, of which fitting is a component to the temporal
focal epilepsy with its characteristic EEG changes. In many
instances the occurrence of seizures can be positively
related to trauma, neoplasm or infection; in such cases
genetic contribution will be minimal and the risk to sibs or
offspring probably not increased. Where the epilepsy is
related to congenital malformations the aetiology of the
epilepsy is bound up with that of the malformation which
may be genetic.
Studies on epilepsy where the above factors are
eliminated, are complicated by the discordance between
clinical and EEG findings. In both centrencephalic epilepsy
(this group includes many cases of petit mal) and temporal
focal epilepsy, almost half first degree relatives have EEG
changes which would suggest that these conditions follow
an AD pattern of inheritance with incomplete penetrance.
The risks to sibs and offspring in such cases are about 1 in 8
to 1 in 10.
In some families, analysis of a pedigree suggests both AR
and AD patterns of inheritance. One form of myoclonic
epilepsy is certainly autosomal recessive.
• One in 150 live born children, and half of all




The most commonly encountered chromosome
abnormality is Down syndrome. This is the commonest
single cause of moderate to severe mental retardation in the
community, there being about 350 new cases born in
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Australia each year. Down syndrome is due to the presence
of an extra chromosome number 21, affected individuals
usually having 47 instead of the normal 46 chromosomes.
Down syndrome is usually sporadic in occurrence but a
number of familial cases which result from a translocation
in a parent occur. The sporadic cases are strongly related to
maternal age.
• Every child with Down syndrome should
have its chromosomes examined.
Before giving genetic counselling to parents of a Down
syndrome child, the child's chromosomes must be
examined. If the child has a 'regular' karyotype, that is 47
chromosomes, then it is a waste of resources to study the
parents' chromosomes; about 95 per cent of Down
syndrome cases have regular karyotypes (Figure 2).





















Figure 2. Banded karyotype of a 'regular' Down syndrome
female. Note the presence of the three number 21
chromosomes.
When the karyotype is regular, there is little evidence
that the risk of recurrence is greater than if the parents had
not had a child with Down syndrome. There are, however,
rare instances where one parent is mosaic: that is, has both
normal and 47 chromosome cells within its body: here, the
recurrence risk can be up to 50 per cent. (When Down
syndrome females reproduce, half their children are
normal and the other half have Down syndrome). Because
of this the recurrence risk is sometimes quoted5 at twice
that for parents who have not had a child with Down
syndrome (Table 5).
Parents who have had a child with Down syndrome are
often referred for amniocentesis in subsequent
pregnancies. Experience has shown6 that chromosome
abnormalities are not encountered any more frequently in
Table 5
Risks and recurrence risk of Down syndrome
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this group than would be expected by chance.
Amniocentesis may well be indicated for reasons of
anxiety, but in young parents there is certainly no genetic
indication. When amniocentesis is carried out on this
group, about one per cent of pregnancies will have a major
chromosome abnormality indicating foetal abnormality.
Although there is some evidence that the age of the
father is relevant to the risk of producing a child with
Down syndrome, and it can be demonstrated cytologically
that the extra chromosome is of paternal origin in a
proportion of cases, the only available risk figures for
Down syndrome are based on the maternal age. (Table 5)
• Couples with a family history of Down syn¬
drome should be referred for genetic counselling,
not amniocentesis.
If the child has an 'irregular' karyotype, then parental
chromosomes must be studied. If these are normal the
recurrence risk is virtually nil; there have been no reports of
more than one irregular Down syndrome individual in a
sibship where parental chromosomes are normal. The
commonest irregular karyotype is a 14/21 translocation; in
about two thirds of these cases parents will also carry the
translocation, thus having a total of only 45 chromosomes.
Recurrence risk is then significantly increased. If the
mother carries the translocation it is about 20 per cent, if
the father carries the translocation it is about two to three
per cent.
Women with a family history of Down syndrome are
often referred for amniocentesis without reference to a
genetic counsellor. In many cases the amniocentesis is quite
unnecessary because investigation of the family, possibly
with chromosome analysis of the Down syndrome
individual involved, will in most cases show that the Down
syndrome is of the regular variety and most unlikely to
recur. Even in cases where the Down syndrome is the result
of a familial translocation, the particular woman involved
may not be a carrier of the translocation and be at no
increased risk of having a child with Down syndrome.
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Figure 3. Banded karyotype of an 'irregular' Down
syndrome male. Note the chromosome 21 (small arrow)
translocated onto chromosome 14 (large arrow); there are
two other number 21 chromosomes present.
Other chromosome disorders
There are many other chromosome disorders which
cause mental retardation, often in association with
congenital malformations. Those which involve an extra
normal chromosome being present all (except for males
with two Y chromosomes) increase in frequency with
maternal age. Table 6 lists some of the more common
chromosome abnormalities. The presence of an extra
autosome, apart from chromosome 21, always leads to
severe malformation syndromes incompatible with
prolonged survival. Extra X chromosomes can cause mild
intellectual deficit in a proportion of those affected.
Table 6
Some chromosome abnormalities seen in live-born children
Edwards syndrome (trisomy 18)
Patau syndrome (trisomy 13)
Cri-du-chat syndrome (absence of short arm of
chromosome 5)
Klinefelter syndrome (male with extra X chromosome)
Triple-X female (female with extra X chromosome)
Trisomy 9p (trisomy for only the short arm of chromosome
9)
Since chromosome banding has come into regular use,
many clinical syndromes associated with extra or missing
parts of chromosomes have been delineated. Almost all of
these involve mental deficit to a greater or lesser extent.
Many of these new syndromes can be familial if they arise
from malsegregation of parental translocations.
A high proportion of individuals with chromosome
abnormalities die around the time of birth. Chromosome
studies should be part of every perinatal autopsy;
chromosome abnormality is now a more common finding
(about five per cent of cases) at perinatal autopsy than
Rhesus disease.
• Every pregnant woman over the age of 35
should be informed that she is running an increas¬
ed risk of chromosome abnormalities which are
prenatally diagnosable.
Prenatal diagnosis and parental age
It can be seen from Table 5 that the risk of having a child
with Down syndrome increases with maternal age. Many of
the other chromosome abnormalities also increase in
incidence with maternal age, although the rate of increase
is not as marked as for Down syndrome. Consequently, if
women of advanced age were offered prenatal diagnosis of
chromosome abnormalities, the incidence of these
disorders in the community could be reduced and the
individual couples saved much unhappiness Indeed, it is a
recommendation of the Australian National Health and
Medical Research Council that where facilities are
available, women older than 35 years should be offered
prenatal diagnosis.
The incidence of chromosome abnormality detected by
prenatal diagnosis is higher than that obtained from
epidemiological studies of live born infants. Table 7shows
the incidence of total chromosome abnormalities and of
Down syndrome detected at prenatal diagnosis. The
reasons for these risks being so high are uncertain:
however, there can be no doubt that some of these
pregnancies would have been lost as late abortions or
stillbirths.
Table 7
Incidence of chromosome abnormalities
found at amniocentesis at 16 weeks
according to mother's age
fotal chromosome










When counselling women in these age groups, it is
important to inform them of the risk of an abnormality
being detected which will indicate termination of their
pregnancy. It should be noted that if a woman is not
prepared to have a pregnancy terminated on the grounds of
foetal abnormality, there is little point in her having
amniocentesis. The reasons for this are that the procedure
is a costly one to the community and that there are definite
risks, albeit very small ones, associated with amniocentesis.
To pointlessly expose a foetus which is most likely to be
norma] to even a small risk without any possiblity of
benefit, must be regarded as unwarranted.
Whilst there are many theoretical risks involved in
amniocentesis, the only one which is realized significantly
is induction of abortion, which probably occurs after less
than 0.5 per cent of amniocenteses.
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• Amniocentesis is a safe procedure for
mother and foetus; the only real risk is that of in¬
ducing abortion, and this occurs in less than 0.5
percent of cases.
Summary: When parents have a child with any
problem, they usually become concerned about
the chances of this problem recurring if they have
further children, or of appearing in their
grandchildren. Similarly, persons with any
congenital disorder themselves or family history
of such disorder, often worry about their future
children. Genetic counselling can in most cases
provide reassurance that there is little need for
concern.
In those instances where the risks are real, they
can be put into perspective and often effectively
circumvented by procedures such as prenatal
diagnosis. Pregnant women of advanced age run
increased risks of having children with
chromosome disorders; it is of benefit to
individual couples and to the community to refer
such women for amniocentesis.
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INCREASED SISTER-CHROMATID EXCHANGE IN
MULTIPLE SCLEROSIS
To the Editor: The analysis of rates of sister-chromatid exchange
(SCE) has been shown to be a sensitive method of measuring DNA
damage.' SCE is increased after exposure to many mutagens and
carcinogens2 and in some viral illnesses.3 During a study of persons
exposed to a variety of environmental agents during pregnancy, we
encountered a woman with multiple sclerosis (MS) who had an un¬
explained elevation of SCE. This incidental finding was followed
up, and it was found that SCE is increased in MS.
Volunteers were sought from the South Australian MS-rehabili-
tation unit, and blood samples were collected from inpatients with
MS; data on current and long-term drug usage and smoking habits
were collected. The control groups consisted of healthy persons be¬
tween the ages of eight and 80 years. None were taking drugs ex¬
cept for oral contraceptives in some women, and only six smoked
cigarettes. Lymphocyte cultures were established from venous
blood samples in Ham's F10 culture medium; harvesting and dif¬
ferentia! staining were performed as previously described.' SCE
rates were determined by examination of 20 metaphases; SCE's at
the centromere were included in the count. All SCE rates were de¬
termined from coded slides by one observer (E.B.).
The results are shown in Figure 1. The SCE rate in MS patients
was higher than that of the control group (P<0.01 by Wilcoxon
rank-sum test), and this significance remained at the same level
even if the highest SCE rate of 19.8 exchanges per cell was omitted
from consideration. Half the patients with MS smoked cigarettes,
but there was no difference in SCE rates between the smokers and
nonsmokers in this group All but five of the MS patients were tak¬
ing one or more of the following drugs: methenamine mandelate,
diazepam, laxatives, steroids, cimetidine (one patient), and imi-
pramine in various combinations. The possibility that these drugs
could be responsible for the SCE findings must be considered, but
we are not aware of evidence that these agents cause any increase in
SCE. The finding of a high SCE rate among MS patients may re¬
flect the origin of the condition or may be due to some metabolite
produced by the disease. The possibility that MS may be caused by
a slow virus has been suggested,3 and viral infections have been
shown to cause an increase in SCE.3 However, we are aware of no
data on SCE in slow virus infections.
Our findings may indicate a basic DNA abnormality in MS that
could be responsible for the clinical manifestations of the disorder.
Inherited disorders of DNA repair can be associated with neuro¬
logic impairment, as seen in such diseases as ataxia telangiectasia
and some forms of xeroderma pigmentosum.' Field et al.' claim that
there is a strong genetic component in MS. The possibility that MS
may result from an inherited abnormality of DNA structure or re¬
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Figure 1. Rates of Sister-Chromatid Exchange (SCE) in Pa¬
tients with Multiple Sclerosis (MS) and Controls.
Andrew Black, M.B., F.R.A.C.P.
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PASTEURELLA MULTOCIDA SEPTICEMIA AND
PERITONITIS IN A CIRRHOTIC COCK TRAINER WITH
A PET PIG
To the Editor: Pasleurella multocida has been reported rarely as a
cause of spontaneous bacterial peritonitis and septicemia in pa¬
tients with hepatic cirrhosis.1'3 Among four previous case reports in
cirrhotic patients with clinically discernible peritonitis, the organ¬
ism was isolated only from the peritoneal fluid in two patients,1"3
from the blood alone in one,2 and from both the blood and the peri¬
toneal fluid in one.1 We wish to report on a patient in whom we iso¬
lated P. multocida from both the blood and the peritoneal fluid.3
The patient, a 48-year-old man, presented to the Veterans Ad¬
ministration Hospital, University of Alabama School of Medicine,
and reported hematemesis. Although he had a history of poor
general health from alcohol abuse and previous upper gastrointes¬
tinal-tract bleeding from esophageal varices associated with portal
hypertension and alcoholic cirrhosis, he had felt well enough before
B 32
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This paper reported the exclusion of the MNS blood group from
(4) (q2.7->31) . Whilst the paper was in press a blood grouping
error was detected, and as a consequence this exclusion is
now retracted.
ADDITIONS TO THE EXCLUSION MAP OF MAN
i.C. MULLEY1, G.D. BRYANT2,
G.R. SUTHERLAND'
SUMMARY
Exclusion mapping was applied to individuals with mono-
somic segments defined by chromosomal banding. A range
of genetic markers and blood groups was determined
resulting in new exclusions for unassigned markers at the
following segments : (3)(p25n>pter) - JK, GPT, PI ; (4)(q27->
31) - MNS, JK, PI, C3, F13A, F13B ; (7)(q22) - LU, F13A ;
(12)(p12) - MNS ; (12)(p13) and (15)(q15) - GPT, C3 ; (12)
(pter) and (19)(p or qter) - MNS, GPT, PI ; and (18)(q21-^
23) - MNS, JK, F13A. These exclusions may be useful for
narrowing the regional localisations of any genetic markers
subsequently assigned to the chromosome involved in the
exclusion. No new gene assignments were made from
cases where family data was available.
KEY-WORDS : Deletion mapping. — Exclusion mapping. — Chro¬
mosomal deletions.
Gene mapping by exclusion is applicable to cases
having unbalanced chromosomal rearrangements
with defined monosomic segments. The exclusion of
codominant loci provides supplementary mapping
data to that derived from somatic cell hybridisation
and segregation analysis. Test loci are excluded
when an individual with a deletion is heterozygous.
Gene assignments are indicated when obligate hetero-
zygotes (on the basis of parental phenotvpes) are
shown to be hemizygous. Possible misclassification.
the presence of null or silent alleles and incorrect
paternity require careful investigation for the confir¬
mation of assignments by deletion mapping. While
deletions can be useful for narrowing regional
localisations within chromosomes, the technique is
relatively inefficient for gene assignment. Exclusion
data is readily interpretable and considerable infor¬
mation has been obtained since the advent of chro¬
mosomal banding (Aitken et hi., 1975 [1] ; Aitken
and Ferguson-Smith, 1978 [2]).
resume
Supplements a la carte genique humalne par exclusions
La technique d'exclusion a ete appliquee pour I'obtention
de la carte genique chez des individus monosomiques
partiels. line serie de marqueurs genetiques et de groupes
sanguins ont ete determines et permettent de nouvelles
exclusions pour des marqueurs non encore localises aux
segments suivants : (3)(p25->pter) - JK, GPT, PI ; (4)(q27-»
31) - mns, JK, PI, C3, F13A, F13B ; (7)(q22) - lu, F13A ;
(12)(p12) - mns ; (12)(p13) et (15)(q15) - GPT, C3 ; (12)
(pter) et (19)(p or qter) - mns, GPT, PI ; et (18)(q21->23) -
mns, JK, F13A. Ces conclusions peuvent etre utiles pour
preciser les localisations des marqueurs ulterieurement
localises sur des chromosomes interesses par I'exclusion.
Aucune localisation nouvelle n'a pu etre obtenue a partir
des cas pour lesquels des donnees familiales etaient
disponibles.
MOTS-CL6S : Technique de deletion. — Technique d'exclusion.
— Deletions chromosomiques.
MATERIALS AND METHODS
Genetic markers were examined from patients
with deleted autosomal segments (3)(p25->-pter),
(4)(q27->31), (7)(q22), (12)(p 12), (12)(pter), (12)
(pi3), (15)(ql5), (18)(p 11), (18) (q21->23) and
(19)(p or qter) and a fetus with deleted (5)(pl4=>
pter).
The (3)(p25>>pter) deletion resulted from a
familial pericentric inversion inv(3)(p25q23). Apart
from the ten cases of autosomal deletion, another
1. Cytogenetics Unit, Department of Histopathology;
2. Department of Haematology,
The Adelaide Children's Hospital Inc., ADELAIDE, S.A.
5006 (Australia).
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Fig. 1. — Partial karyotypes from 10 cases with autosomal dele¬
tions as shown in table I. Full karyolypes are as follows
1. 46,XY,rec(3)dup(q)del(p)inv(3)(p25q23)pat., 2. and 3. 46,XY,del(4)
(q27q31), 4. 46.XY,del(5)(p14), 5. 46,XY,inv(7)(q11q22)del(7)(q22q22),
6. 46,XY,del(12)(p11p13), 7. 45,XY,t(12;15)(p13;q15), 8. 45,XX, ter rea
(12;19) (p13;p or q13), 9. 46,XX,del(18)(p11), 10. 46,XX,del(18) (q21q23).
family included a female proposita with del(X)
(pllp22). Deletions were delineated by trypsin-
Leishman G-banding and partial karyotypes for the
autosomal deletions are given in figure 1.
Samples of serum, plasma, red cells or fibroblasts
where available were stored and subsequently typed
by standard blood grouping and electrophoretic
procedures. PI was completely subtyped by isoelec¬
tric focusing (Mulley, 1980 [11]) and F13A and
F13B typed by agarose gel electrophoresis (Board,
1979, 1980 [3]). Locus designations follow the
recommendations of Shows et al. (1979) [13],
RESULTS
The results of autosomal genetic marker studies
are presented in table 1. No gene assignments were
made. New exclusions or extensions to existing
exclusions were determined for the unassigned loci
JK, MNS, LU, GPT, PI, F13A, FI3B and C3.
These may prove useful for regional localisation if
subsequent gene assignment is made to the chromo¬
some involved in the exclusion. Although new
exclusions were determined for the assigned markers
JK, RH, FY, PGM1, PGM3, AK1, ACPI, GLOl,
PGP, ESD and HPA, these were irrelevant for
regional localisation as all are assigned to other
autosomes.
The XG result from the family of the propositus
with del(X)(pl 1 ■$»p22) indicated anomalous inheri¬
tance involving the proposita (fig. 2). Paternity
testing (apart from XG) indicated that the probabi¬
lity of correct paternity was 97 %. This family either
suggests the localisation of XG to (X)(pl l»p22), or
demonstrates inactivation of the paternal XG allele
present on the deleted chromosome.
TABLE I. — List of exclusions for both assigned and unassigned





Assigned Loci Unassigned Loci




2 (4) (q27->31) JK, PGM3, HPA F133
3 (4) (q27»31) RH, ESD, PGM1 MNS, JK, PI, C3,
F13A
4 (5) (p14>pter) AK1, PGM3 MNS *, LU,
5 (7) (q22) ACP1, PGM1 GPT *, F13A
6 (12) (P12) RH, FY, GL01,
PGP
MNS





8 (12) (pter) and




9 (18) (P11) HPA*
10 (18) (q21 *>23) HPA* MNS, JK, F13A
* Previously 'excluded from the segment investigated (Aitken et
a!., 1975 ; Aitken and Ferguson-Smith, 1978).
DISCUSSION
The localisation of ACPI to the short arm of
chromosome 2 (Ferguson-Smith et al., 1973 [7])
remains the only locus to be assigned by deletion
mapping. Meanwhile, other unassigned loci have been
eliminated from significant regions of the genome :
MNS being the most notable (Aitken and Ferguson-
Smith, 1978 [2]). Additional portions of the genome
in the vicinity of assigned markers may be excluded
by segregation analysis when the absence of linkage
is demonstrated between the unassigned markers
and markers previously localised. Recent examples
of regional localisations arising from exclusion
mapping are HPA to (16)(cent->q22) (Ferguson-
Smith and Aitken, 1978 [8], ACPI to the distal
xg- Xg'
Fig. 2. — Pedigree showing anomalous XG inheritance in the pro¬
posita with caryotype 46,X,del(X)(p11p22).
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portion of band (2)(p23) (Emanuel et al., 1979 [6])
and ESD to (13)(q3l) or (13)(q32) pending confir¬
mation of a previous assignment to (13)(q3) (Tur-
leau et al., 1978 [14]).
XG is not normally inactivated (Fialkow, 1970
[9] ; Fialkow et al., 1970 [10] ; Ducos et al., 1971
[5] unlike other studied X-linked loci which are
subject to random inactivation. On this basis, XG is
apparently localised to (X)(pl l ^p22) given the
anomalous inheritance ; but this conclusion is inva¬
lidated by the occurrence of inactivation of XG
alleles carried on structurally abnormal X chromo¬
somes (Race, 1971 [12]). The alternative explanation
for the observed result is the inactivation of the
abnormal X of paternal origin.
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Sister Chromatid Exchange in
Aplastic Anemia
Ram Seshadri, Elizabeth Baker, Peter Leonard,
Grant Sutherland, and Alexander A. Morley
ABSTRACT: The incidence of sister chromatid exchanges (SCE) in the lymphocytes of patients with
aplastic anemia (AA) was determined before and after exposure to mitomycin C (MMC). The
"baseline" SCE rate was significantly higher in AA, but MMC-induced SCE rate was not differ¬
ent compared to controls. It is suggested that some patients with AA may have an underlying
DNA damage.
Idiopathic aplastic anemia (AA) is a syndrome of diverse etiology. Epidemiological
evidence suggests many cases are due to direct chemical toxicity to marrow cells, but
the infrequency of development of the disease in the total population at risk suggests
the possible existence of some individual predisposition, either genetic or acquired.
Our studies of an animal model of the disease and of the observations that lympho¬
cytes of individuals with AA have heightened susceptibility to the action of bleomy¬
cin, a cytotoxic agent known to interact with DNA, suggests that injury to marrow
cells might be the result of damage to DNA [1],
Although the relationship between sister chromatid exchange (SCE) and DNA
damage is still unclear, analysis of SCE has been shown to be a sensitive index of
damage to and repair of chromosomal DNA. Recent in vivo studies indicate that the
incidence of SCE may be used to detect exposure to potential mutagens and carcino¬
gens [2 - 4]. In this report we present our observations of the baseline and mitomycin
C (MMC)-induced SCE rate in the peripheral blood lymphocytes of individuals
with AA.
METHODS
Thirteen patients with AA were studied. Clinical and hematological data are present¬
ed in Table 1. Three patients were studied during the acute phase of the disease, but
the rest had recovered to variable extents after supportive care and androgen treat¬
ment. The suspected etiological agents in these patients are also shown in Table 1.
None of the patients were smokers. The control group consisted of 43 healthy volun¬
teers who had not been on any drugs except for contraceptives in some women. Their
ages ranged from 8-80 years.
Whole blood lymphocyte cultures were established in Hams F10 tissue culture
medium (Commonwealth Serum Laboratories, Melbourne, Australia) supplemented
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Table 1 Clinical data
Patient Time since Suspected Hematological findings
No. Age Sex diagnosis etiology Treatment at the time of study
1 31 M 5 years idiopathic androgens normal
2 12 F 6 months idiopathic androgens/steroids severe pancytopenia
3 67 F 2 years idiopathic androgens pancytopenia
4 31 F 1 year idiopathic androgens pancytopenia
5 51 M 7 years idiopathic androgens thrombocytopenia
6 13 M 2 years idiopathic nil pancytopenia
7 55 F 7 years gold nil normal
8 48 F 1 year idiopathic androgens normal
9 77 M 8 years idiopathic androgens normal
10 46 F 4 months penicillamine androgens/prednisolone severe pancytopenia
11 8 F 2 years idiopathic androgens/prednisolone moderate pancytopenia
12 25 M 1 year carbimizole androgens/prednisolone moderate pancytopenia
13 26 F 4 years idiopathic nil thrombocytopenia
with 20% fetal bovine serum to which 10 |Ug/ml of bromodeoxyuridine (Sigma)
had been added. Cultures were maintained for 70 hr in the dark and harvested after 2
hr exposure to colchicine. In four patients and controls, SCE rate was estimated after
exposing the cells during the last 24 hr of culture to varying concentrations of MMC
(Sigma). Differential chromatid staining was done by a modification of the method of
Korenberg and Freedlender [5]. Twenty metaphases from each subject were scored
for SCE. The chromosome preparations were also analyzed for excessive number of
breaks and unusual abnormalities.
RESULTS AND DISCUSSION
None of the patients showed excessive chromosome breaks or any other specific
chromosome abnormality. Table 2 shows the frequencies of SCE in the controls and
in AA. The mean baseline frequency of SCE/cell was 10.68 in controls and 12.66 in
the AA group. The difference was statistically significant (p < 0.01 Wilcoxon's rank
sum test). Both control and aplastic patients showed an increase in SCE rate after
exposure to MMC. The degree of increase in SCE was not significantly different in the
two groups (Table 3).
Our observation supports the previous study that some AA patients may have an
underlying DNA abnormality leading to bone marrow failure. Our recent biochemi¬
cal studies have also shown that lymphocyte DNA in AA is abnormal as indicated by
the increased number of strand breaks when compared with age-matched controls
[6]. These observations strongly point to an abnormality of DNA, either a propensity
for damage or an abnormality of repair. A recent preliminary report by Tsuboyama et
al. [7] suggested an abnormality in repair of ultraviolet damage to DNA in AA lym¬
phocytes.
Although the relation between SCE and DNA repair is unclear, analysis of SCE
formation has been used to differentiate between inherited diseases with defects in
DNA repair. Thus, in Bloom's syndrome an elevated SCE frequency has been ob¬
served. In contrast, normal SCE frequencies were detected in Fanconi's anemia, atax¬
ia telangiectasia, and xeroderma pigmentosum (reviewed in [8]). An SCE "stress test"
with MMC, developed to probe potential defects in SCE formation, showed a failure
of lymphocytes of Fanconi's anemia to respond to MMC with a normal increase in
SCE formation [9]. In contrast, lymphocytes from patients with xeroderma pigmento-
SCE in Aplastic Anemia 83
Table 2 Baseline SCE in AA lymphocytes















Group mean 37.7 12.66"
±2 SD 43.2 5.62
SEM - 0.75
Controls (N = 43)
Group mean 40.1 10.68
±2 SD 52.9 2.36
SEM ± _ 0.26
"p < 0.01 (Wilcoxon rank sum test); p < 0.02 if patient 3 were to be
excluded from the analysis.
sum develop a much greater increase in SCE than do identically treated normal cells
[10]. We did not find any significant difference between control and AA patients in
the "MMC stress test."
Since there is a linear relationship between carcinogen-induced mutation rate and
SCE frequency in cultured cells [11, 12], SCE formation may be a useful indicator of
those specific and probably rare DNA lesions that are responsible for mutagenesis
Table 3 MMC-induced SCE in AA lymphocytes
Mean SCE/metaphase
Concentrations of MMC (/xg/ml)
Subjects Baseline6 1 x io-2 3 X 102 1 X 10>
AA" 1 8.15 12.87 21.00 29.83
2 13.95 15.20 23.00 32.35
3 8.87 — 23.10 —
4 7.60 — 21.00 —
Controls 1 9.65 17.20 26.00 35.65
2 10.80 15.05 27.00 39.30
3 10.05 — 27.10 —
4 9.95 - 25.05 -
"Patient numbers do not correspond to Table 2.
''Concentration of bromodeoxyuridine was 5 pg/ml.
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and possibly carcinogenesis. Our observation of heightened SCE in AA is of interest,
as AA patients have an increased incidence of leukemia compared to the general
population [13].
This study was supported by a grant from The Channel 10 Children's Medical Research Founda¬
tion of South Australia.
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Two unusual G-band variants
of the short arm of chromosome 9
Grant R. Sutherland and Helen Eyre
Cytogenetics Unit, Department of Histopathology, Adelaide Children's Hospital, Australia
Two familial G-band variants of the short arm of chromosome 9 are described. One is
associated with C-band material, but the other is not and appears to involve euchromatin.
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Structural variation of chromosome no. 9
has been recognized for many years, and
with the advent of chromosome banding
techniques this variation has been shown to
be due mainly to the amount and position
of the C-band material (Madan & Bobrow
1974). Buckton et al. (1980) reported a vari¬
ant of the short arm of chromosome 9 in
which there was an additional dark band
proximal to the centromere in the short
arm and which did not involve C-barid
material.
This report describes two families, as¬
certained when a phenotypically abnormal
child referred for chromosome studies was
found to have an additional dark G-band
in the short arm of chromosome 9. The
variant chromosomes were initially sus¬
pected of being pathologically significant,
but were shown by family studies to be
harmless variants.
Materials and Methods
Cytogenetic studies were carried out using
standard lymphocyte culture methods. C-
banding was performed on aged slides using
saturated barium hydroxide, followed by
incubation in 2 X SSC and staining with
Leishmann. The G-banding on freshly pre¬
pared slides was carried out using a hydrogen
peroxide treatment prior to trypsinization,
followed by staining with Leishmann. Rep¬
lication banding was carried out after
BrdU incorporation for 6 h prior to harvest,
followed by staining with Hoechst 33258,
exposure to UV light and staining with
Leishmann.
Case 1. A 13-month-old female infant was
referred for chromosome studies because
of spastic quadriplegia and microcephaly.
There was a well-documented history of
intrauterine and perinatal hypoxia. Her no.
9 chromosomes are shown in Figure la.
Chromosome studies were carried out on
other members of the family (Fig. 2a) and
several were found to have apparently the
same variant (Fig. lb). All other chromo¬
somes were normal by C- and G-banding.
Case 2. A 15-month-old female infant with
developmental delay, hypotonic cerebral
palsy and abnormal cervical vertebrae was
referred for chromosome studies. Her no.
9 chromosomes are shown in Figure lc.
0009-9163/81/050331-04$02.50/0 © 1981 Munksgaard, Copenhagen





Fig. 1. C-banded, G-banded
and BrdU labelled chromo¬
some no. 9 pair from (a) the
proposita, and (b) a pheno-
typically normal member of
Family 1; (c) the proposita,
and (d) a phenotypically nor¬
mal member of Family 2. The
variant is on the left of each
pair.
Family studies (Fig. 2b) showed that other
normal individuals had karyotypes identical
to that of the proposita (Figs. Id and 3).
Cytogenetics
On G-banding, the variant chromosomes
from both families had an additional dark
band inserted into the middle of band
9pl3. This appeared as an additional light
band on replication banding. This extra
material gave the variant chromosome a
more metacentric appearance than the usu¬
al no. 9 chromosome, and the initial im¬
pression was that it was possibly associated
with an inversion of C-band material.
C-band staining revealed an average
amount of heterochromatin, which was con¬
fined to the long arm of the variant chro¬
mosome in Family 2. In this family the ad¬
ditional material was undoubtedly C-band
negative. In Family 1 there was a large
C-band with the centromere in the middle
of it. The C-band extended over the posi¬
tion of the dark G-band; hence, in this
family the variant dark G-band was also
C-band positive.
Discussion
The variation in the size of chromosome 9
has been long recognized, originally as a
secondary constriction of variable size (Fer-
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Fig. 2. Family pedigrees. Shaded symbols indicate presence of variant no. 9; N indicates its absence.
guson-Smith et al. 1962). The presence of
the C-band heterochromatin in the short
arm of 9, as opposed to the long arm, the
so-called pericentric inversion of C-band
heterochromatin, was demonstrated by
Wahrman et al. (1972) and shown to be a
not uncommon variant (Buckton et al.
1976, 1980). Madan & Bobrow (1974) dem¬
onstrated that the size of the C-band het¬
erochromatin was highly variable and
could range from very small to greater
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Fig. 3. G-banded karyotype from the father of the proposita of Family 2; the variant no. 9 is arrowed.
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this chromosome in apparently normal in¬
dividuals. Hence, variation in chromosome
9 has been well established, but it is due
almost entirely to variations in the amount
and position of C-band heterochromatin.
Madan (1978) recorded a G-band variant
of the long arm of chromosome 9 which
was within the region which is normally
dark-staining on C-banding; this was seen
only in individuals with large C-bands. In
the first family in the present report, it
would appear that a similar type of variant
is segregating; that is, a segment of a large
C-band is also expressed as a dark G-band.
Another G-band variant of chromosome 9
has been described by Berg et al. (1980).
On G-banding it was similar to the present
variants, but on C-banding it was different,
although the dark G-band was C-band posi¬
tive, as in Family 1.
The G-band variant of the short arm of
chromosome 9 in the second family in this
report appears to be very similar to that
recorded by Buckton et al. (1980). This
variant chromosome would appear to be
the only one involving chromosome 9 which
is not associated with C-band material. It
is important in clinical cytogenetics that
this variant be recognized as such, since
the presence of additional autosomal ma¬
terial, which is apparently euchromatic, is
generally associated with phenotypic ab¬
normality.
Acknowledgment
We thank Elizabeth Baker for assistance
with the cytogenetics.
References
Berg, J. M., H. A. Gardner, R. J. M. Gardner,
E. G. Goh, V. D. Markovic, N. E. Simpson
& R. G. Worton (1980). Dic(21;21) in a
Down's syndrome child with an unusual
chromosome 9 variant in the mother. J. med.
Genet. 17, 144-148.
Buckton, K. E., M. L. O'Riordan, P. A. Ja¬
cobs, J. A. Robinson, R. Hill & H. J. Evans
(1976). C- and Q-band polymorphisms in
the chromosomes of three human popula¬
tions. Ann. hum. Genet. 40, 99-112.
Buckton, K. E., M. L. O'Riordan, S. Ratcliffe,
J. Slight, M. Mitchell, S. McBeath, A. J.
Keay, D. Barr & M. Short (1980). A G-band
study of chromosomes in liveborn infants.
Ann. hum. Genet. 43, 227-239.
Ferguson-Smith, M. A., M. E. Ferguson-Smith,
P. M. Ellis & M. Dickson (1962). The sites
and relative frequencies of secondary con¬
strictions in human somatic chromosomes.
Cytogenetics 1, 325-343.
Madan, K. (1978). An extra band in human
9qh+ chromosomes. Hum. Genet. 43, 259-
264.
Madan, K. & M. Bobrow (1974). Structural
variation in chromosome No. 9. Ann. Ge¬
net. 17, 81-86.
Wahrman, J., J. Atidia, R. Goitein & T. Cohen
(1972). Pericentric inversions of chromo¬
some 9 in two families. Cytogenetics 11,
132-144.
Address:
Grant R. Sutherland, Ph.D.
Cytogenetics Unit
Department of Histopathology
The Adelaide Children's Hospital Inc.
North Adelaide, S.A. 5006
Australia
B 35
A LARGE KINDRED WITH AN INY(3) (p25q23) :
CLINICAL, CYTOGENETIC AND GENETIC MARKER STUDIES
G.R. SUTHERLAND, J.C. MULLEY, E. GOLDBLATT
A LARGE KINDRED WITH AN INV(3) (p25q23) :
CLINICAL, CYTOGENETIC AND GENETIC
MARKER STUDIES
G.R. SUTHERLAND1, J.C. MULLEY1,
E. GOLDBLATT-
SUTHERLAND G.R., MULLEY J.C., GOLDBLATT E. — A large
kindred with an inv(3)(p25q23) : clinical, cytogenetic and genetic
marker studies.
Ann. Genet., 1981, 24, n° 4, 202-205.
SUTHERLAND G.R., MULLEY J.C., GOLDBLATT E. — Un<8 grande
famille avec une inv(3)(p25q23) : etudes clinique, cytogenetique, et
des marqueurs genetiques. (In English).
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SUMMARY : A large kindred in which an inv(3)(p25q23)
is segregating is described. At least two malformed chil¬
dren with the recombinant chromosome rec(3)dup(q23->
qter)del(p25->pter) have been produced, both of whom
have the characteristic trisomy 3q syndrome. Genetic
marker studies showed that PI and GM are not linked to
the inversion break points. The PI-GM linkage group has
been excluded from much of chromosome 3 by deletion
mapping and linkage analysis of this kindred.
KEY-WORDS : Chromosome 3. — Pericentric inversion. — Re¬
combinant chromosome. — Genetic markers.
INTRODUCTION
A number of large pericentric inversions of chro¬
mosome 3 have been ascertained via malformed
children with recombinant chromosomes (Hirschhorn
et al., 1973 ; Fineman et ah, 1978 ; Rivera et ah,
1979 ; Kawashima and Maruyana, 1979). One lar¬
ge kindred has been described in which such an in¬
version has resulted in more than 20 recombinants
or presumed recombinants (Allderdice et ah, 1975).
The present report documents another large kindred
which was ascertained via a recombinant child in
South Australia in 1978. This kindred was indepen¬
dently ascertained in Western Australia and the
phenotype of the recombinant described (Mulcahy et
ah, 1979). The clinical features of the South Aus¬
tralian propositus are recorded, and cytogenetic and
genetic marker studies of the family presented.
RESUME : Les auteurs deorvent une grande famille dans
laqueWe segregue une inv(3)(q25q23). Au moins deux
enfants malformes avec le chromosome recombine rec(3)
dup(q23->qter)del(p25—»ter) sont nes I'un et I'autre avec
le phenotype caracteristique de la trisomie 3q. Une etude
des marqueurs gene'.iques a montre que PI et GM ne sont
pas lies au point de cassure de ['inversion. Le PI-GM
groups de linkage a ete exclu d'une grande partie du
chromosome 3 par une analyse de linkage de I'utilisation
des deletions dans cette famine.
MOTS-CL6S : Chromosome 3. — Inversion pericentrique. — Chro¬
mosome recombine. — Marqueurs genetiques.
CASE REPORT
The propositus was the second child born to healthy unre¬
lated parents. Delivery was by caesarean section at 38 week's
gestation and birth weight was 3,01 kg. The appearance
was unusual (fig. 1) and the following features were noted
on examination: slanting, curved palpebral fissures, an
unusual nose, high arched palate, micrognathia, odd ears
with pits on the helices, redundant skin folds on the back
of the neck, inverted nipples, bilateral simian creases, right
talipes calcaneo-valgus, left ectopic and right undescended
testes. Investigations at the age of three months showed a
hypertonic severely retarded infant, with a clinically dia¬
gnosed ventricular septal defect and probably atrial septai
defect. Intravenous pyelography showed a dysplastic right
kidney with dilated ureter. Radiography revealed retarded
skeletal maturity, closed or closing sagittal suture, scapho-
1. Cytogenetics Unit, Department of Histopathology;
2. Department of Cardiology,
The Adelaide Children's Hospital Inc., NORTH ADELAI¬
DE, S.A. 5006 (Australia).
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M 10 M1 — 1,2,3,5
III 34 M1-M3 N—D 1.2 O
Husband of 34 M1-M2 N 3,5
IV 23 M2-M3 N—D 1,3,5
24 M1 - 1,3,5
05 M1-M3 - 1,2,3,5
26 M1 - 1,3,5
V 13 M1-M2 N 3,5
Fig. 1. — The propositus.
cephaly, mild cervical and sacrococcygeal kyphosis, hypo¬
plastic third right rib and a mildly enlarged heart. The
child died in another hospital at 22 months of age; an
autopsy was not performed.
Cytogenetics
G-banded chromosome studies (fig. 2) showed that the
propositus had a recombinant chromosome rec(3)dup(q23—>
qter)del(p25^>pter) resulting from a paternal inv(3)(p25q23).
Family studies
Family studies (fig. 3) showed that the inv(3) chromosome
was present in many other members of the family. A number
of stillbirths and neonatal deaths had occurred, but records
were inadequate to indicate whether or not these were due
to recombinant chromosomes.
Genetic marker studies
The blood groups LU, MNS, JK. ABO, RH, FY, K (two
loci) and P. and enzyme and protein polymorphisms GALT,
GPT, PGP. ACPI. AK1, ADA, GLOl, PGD. ESD. PGM1,
HPA, E2, AMY2 and GM were determined using standard
serological and electrophoretic techniques. Genetic marker
results from the propositus and the GM results from infants
aged less than six months were not used for linkage analysis.
PI was completely subtyped by isoelectric focusing (Mulley,
1980) and FI3A and F13B typed by agarose electrophoresis
(Board, 1979 and 1980). In no instance were any of the
genetic marker results inconsistent with Mendelian inheri¬
tance or paternity. The results of the genetic marker studies
which were informative are shown in table I and the corres¬
ponding lod scores in table II.
J? M
*+ %
H & %" pi JjJ
Fig. 2. — G-banded chromosomes from three metaphases of the
propositus (right) showing the recombinant chromosome, and his
father (left) showing the inverted chromosome.
I © rec (3) dup (q 23 qter) del (p25—- pter
i ® inv( 3) (P25 q 23 )
• stillbirths or neonatal deaths
□ © normal karyotypes
normal karyotype ct amniocentesis
(*) Phenotypes of offspring indicate genotype to be GM 1/1,2. Fig. 3. — The family.
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TABLE II. — Lod scores between the inversion and PI,
GM and GALT.
e
.01 .05 .10 .15 .20 .25 .30
PI —2.908 —1.164 —0.632 —0.355 —0.184 —0.074 —0.005
GM —8.495 —5.000 —3.495 —2.615 —1.990 —1.505 —1.109
GALT —3.398 —2.000 —1.398 —1.046 —0.796 —0.602 —0.444
DISCUSSION
The phenotype of the propositus is typical of the
syndrome produced by partial trisomy 3q, either as
a result of recombination within an inversion or
malsegregation of a balanced translocation invol¬
ving this chromosome segment (Mulcahy et ah,
1979). The risk of inversion carriers producing re¬
combinant offspring has been previously discussed
(Sutherland et al., 1976). In a more recent review
Winsor et al. (1978) concluded that the risk of an
abnormal child resulting from recombination within
a pericentric inversion was greater for « large » in¬
versions than for « small » ones. In the present kin¬
dred it is not possible to determine such a risk
because of uncertainty about the number of recom¬
binants in the family. On the basis of medical re¬
cords III.27 was almost certainly a recombinant, and
VI. 1 was documented as such by Mulcahy et al.
(1979). Since the family was investigated one preg¬
nancy has been monitored by amniocentesis (V.12)
and shown to have a 46,XY karyotype and confir¬
med after birth as a normal male infant. This is in
addition to the pregnancy monitored antenatally by
Mulcahy et al. (1979) in Western Australia (VI.2).
Allderdice and Frecker (1979) found two recombi¬
nants among eight pregnancies monitored antenatal¬
ly, where one parent was a member of their inv (3)
kindred.
Large inversions are potentially valuable as mar¬
kers for gene mapping by exclusion when offspring
with duplication/deficiency chromosomes are avai¬
lable. Mulley et al. (1980) excluded the unassigned
loci JK, GPT and PI from (3) (p25->pter) by dele¬
tion mapping of the propositus. Furthermore, the lod
scores between PI and the inversion indicate that
close linkage of this locus to 3p25 or 3q23 is unli¬
kely. Similarly, lod scores between GM and the in¬
version suggest that all but loose linkage with 3p25
or 3q23 is unlikely. In view of the loose linkage
between PI and GM (Noades and Cook. 1976) this
linkage groupe is excluded from most of chromosome
3 on the basis of deletion mapping and linkage
analysis within this family. The only other significant
lod score was that for GALT and the inversion if
11.10 was assumed to have the phenotype GALT N,
a fair assumption given the absence of other GALT
alleles in 16 of her nieces and nephews tested. This
is, however, of minimal significance now that GALT
has been assigned to chromosome 9 (Sparkes et al.,
1980).
In natural populations where pericentric inver¬
sions are present as adaptive polymorphisms there
is no recombination within the inverted segments in
structural heterozygotes (White and Morley, 1955).
However, newly arisen inversions in insects (White
and Morley, 1955 ; White, 1961) and in man do not
behave in this fashion. Renwick (1971) has consi¬
dered the theoretical use of inversions for gene map¬
ping. Recombination within the inversion is reduced,
especially between inversion breakpoints and markers
within small inversions. For large inversions in man
recombination can occur within the inverted seg¬
ment as a result of two-strand double crossovers at
meiosis. Van der Linden et al. (1975) observed three
out of 40 inversion loops resulting from an inv (4)
which they interpreted at diakinesis as having two
crossovers within the inverted sequence. However,
according to Haldane (1931). « ...if crossing over
occurs in any section, the probability of crossing over
in adjacent sections is reduced... », hence any inver¬
sion would need to be of a minimum size before
more than one chiasma would occur within it. If it
were possible to determine the minimum size of an
inversion necessary for two-strand double crosso¬
vers then inversions below this size would be very
useful for gene mapping since the observation of a
single event of recombination between such an in¬
version and a gene locus would exclude that locus
from within the inversion.
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Summary
The incidence of SCE in the lymphocytes of mothers and their newborn infants
was determined. A detailed antenatal history of parental habits such as smoking,
alcohol consumption and possible exposure to DNA-damaging agents was docu¬
mented. The results showed that the SCE rate in the newborn is significantly less
than that of their mothers. Mothers who consumed alcohol, but not cigarette
smokers, had a significantly increased SCE rate compared to control mothers.
However, these maternal habits did not affect the SCE rate of their infants.
Neonates with neural tube defects showed a significantly increased SCE rate
compared to normal babies.
Sister-chromatid exchange (SCE) represents the reciprocal interchange of DNA
between chromatids at apparently homologous loci. Although the precise nature and
mechanism involved in the formation of SCE are unknown, SCE analysis has come
into use as a sensitive means of detecting DNA damage. SCE analysis has been
shown to be useful for assessing the affect upon DNA of cytotoxic drugs (Perry and
Evans, 1975; Nakanishi and Schneider, 1979), viruses (Kurvink et al., 1978) and
environmental pollutants in man (Crossen et al., 1978).
The exposure of the fetus to agents which damage DNA might result in birth
defects or cancer. Kram et al. (1979) showed SCE analysis to be a sensitive method
for the detection of the mutagenic affects of cyclophosphamide, mitomycin C and
adriamycin in female mice and their fetuses. Funes-Cravioto et al. (1977) observed
* Reprint requests.
0165-1161 /82/0000-0000/S02.75 © Elsevier Biomedical Press
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that children of mothers occupationally exposed to organic solvents had an increased
SCE rate implying thay they had been exposed in utero to DNA-damaging agents.
The present study was undertaken to determine whether SCE analysis of mothers
and their neonates would detect in utero exposure of the fetus to DNA-damaging
agents and to determine whether neonates with birth defects of unknown aetiology
may have been exposed to DNA-damaging agents.
Materials and methods
Study subjects
Mothers for this study were chosen from the antenatal clinics of a large maternity
hospital and a detailed interview was conducted prior to delivery. The following
parental data were recorded: smoking habits, use of drugs, alcohol, coffee, hair dyes,
details of the environment in which the mother lived during the antenatal period and
details of acute or chronic illness. At the time of delivery details of the procedures
involved and neonatal observations such as the nature of anaesthetic agents used,
obstetric complications, Apgar scores, birth weight and presence of birth defects
were recorded. The data-collection interviews were conducted by a trained inter¬
viewer and the information was not available to the investigators until after SCE
scoring had been completed. Cord-blood samples were collected from neonates, and
venous samples from their mothers within a few hours of delivery.
Samples were also obtained from babies with multiple birth defects, neural tube
defects and Down syndrome; in some of these instances the maternal history and
blood samples were not available. A control group of 20 healthy adults (age range
21-40 years, mean 29.9 years) and a group of 19 healthy children aged 10 years or
less (age range 1-10 years, mean 7.7 years) were also studied. No members of these
groups were on drugs (except for oral contraceptives in some women) or smoked
cigarettes.
Cytogenetics
Preparations suitable for SCE determination were made as previously described
(Seshadri et al., 1981). All SCE counts were made by one observer from coded slides.
20 metaphases were scored from each subject; exchanges at the centromere were
included in the count (Tice et al., 1975).
Control mother and baby groups
The control population of 30 mothers (age range 17-38 years, mean 29.4 years)
were those who had a normal antenatal period, normal delivery and normal healthy
infants. None of these mothers were smokers or used hair dyes. 11 of the mothers
had a history of alcohol consumption during the antenatal period but the amount
consumed was small and the frequency less than once a week. 15 of the mothers had
general anaesthetics during delivery. Mothers included in this control group lived
within the Adelaide metropolitan area and to the best of their knowledge had no
other exposure to environmental pollutants. All babies included in this control group
had normal birth weights, gestations, physical findings and karyotypes.
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Definition of smokers
This group of 23 mothers (age range 17-43 years, mean 23.3 years) were similar
to the control group except that they smoked cigarettes during the antenatal period.
The degree of smoking ranged from 5 to more than 15 cigarettes per day. The
alcohol consumption of these mothers was similar to the control group. The babies
in this group were clinically normal.
The "alcoholic" mother group
This group consisted of 9 mothers (age range 17-35 years, mean 23.2 years) who
had alcohol consumption ranging from moderate amounts daily to abuse. All these
mothers smoked more than 15 cigarettes a day and many had used marijuana, LSD
and other illicit narcotics. Only 2 of these mothers were regarded clinically as
alcoholics. All infants born to this group of mothers were clinically normal.
Miscellaneous groups
13 mothers had various chronic problems such as mental retardation, diabetes,
malignancy and cardiac problems. 7 mothers were epileptics who had been on
anticonvulsants during pregnancy. All the infants born to the mothers in these
groups were clinically normal.
Results
Figs. 1 and 2, and Table 1, summarise the data on the number of sister-chromatid
exchanges observed per mitotic figure in the groups studied. The SCE rates in
smoker mothers and normal age matched controls were not different from each
other. The "alcoholic" mothers had an SCE rate which was significantly higher than
-h-
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Fig. 1. Mean SCE rate per mitosis in the following study groups. (1) Normal adults. (2) Normal mothers.
(3) Normal babies (cord blood). (4) Smoker mothers. (5) Babies born to smoker mothers. (6) "Alcoholic"
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Fig. 2. Mean SCE rate per mitosis in babies. (1) Normal babies. (2) Babies with Down syndrome.
(3) Babies with multiple congenital malformations. (4) Babies with neural tube defects.
the above groups (Wilcoxon rank sum test, p < 0.01). The SCE rates of babies born
to the control mothers, the smoking mothers and the "alcoholic" mothers were not
significantly different from one another.
Table 2 shows the SCE rates in mothers with chronic illnesses and their babies.
TABLE 1
DATA ON SCE IN THE GROUPS STUDIED
Group No. Mean SCE S.E.M.
per cell
A dults
Controls 20 10.95 0.32
Control mothers 30 11.35 0.40
Smoker mothers 23 11.88 0.41
Alcoholic mothers 9 13.5 0.23
Babies
Control mothers' babies 30 8.95 0.37
Smoker mothers' babies 25 9.01 0.28
"Alcoholic" mothers' babies 10 9.71 0.61
Multiple congenital malformations 26 9.50 0.39
Neural tube defects 24 10.34 0.46
Down syndrome 13 9.37 0.50
Children
1-20 years, normal 19 9.23 0.33
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TABLE 2
SCE DATA ON MOTHERS WITH CHRONIC ILLNESS AND THEIR INFANTS
Age Disorder Treatment a Number of Alcohol Mean SCE/mitosis
cigarettes intake
smoked in mother in baby
24 Epilepsy Dilantin and
Tegretol Nil Nil 9.45 15.05 b
19 Epilepsy Tegretol Nil Nil 11.50 9.05
23 Epilepsy Dilantin Nil Nil 11.20 10.00
23 Epilepsy Dilantin Nil Nil 11.35 8.80
19 Epilepsy Dilantin < 5/day Small 9.13 7.20
22 Epilepsy Dilantin <15/day Small 10.85 12.35
30 Epilepsy Mysolin Nil Moderate 9.05 6.65
17 Mental
retardation Nil Nil Nil - 10.45
23 Mental
retardation Nil Nil Nil 8.13 8.60
32 Psychiatric Phenothiazine Nil Small 7.53 7.35
21 Psychiatric Phenothiazine >15/day Small 10.65 7.40
40 Psychiatric Phenothiazine Nil Nil 14.15 8.50
26 Diabetes Insulin > 15/day Small 14.05 10.75
31 Diabetes Insulin Nil Nil 10.25 8.90
31 Pituitary Dilantin and
malignancy radiotherapy a Nil Nil 14.25 9.20
27 Hodgkin's Chemotherapy and
disease radiotherapy a Nil Nil 14.05 14.25 b
28 Malignant
melanoma Surgical excision a Nil Small 12.95 8.20
29 Cardiac Nil Nil Nil 10.55 8.20
30 Multiple
scletosis Nil > 15/day Nil 19.86 b -
34 Benign intra¬
cranial tension Lumbar puncture Nil Small 9.75 7.55
a All treatment occurred during pregnancy, except for treatment of neoplasms.
b SCE level >2 S.D. above the control mean for babies.
Only 1 mother had an SCE rate which was more than 2 S.D. above the mean of the
control group, this was a mother with multiple sclerosis, the SCE rate in her baby
was not determined. 2 babies had SCE rates that were significantly elevated, 1 born
to an epileptic and 1 born to a woman who had Hodgkin's disease.
The SCE rate of babies with neural tube defects (Table 1) was significantly
elevated compared to the control babies (/? < 0.01). The mean SCE rate of babies
with multiple congenital malformations and with Down syndrome were no different
from normal infants (Table 1). However, 1 baby with multiple congenital malforma¬
tions had an SCE rate of 16.6. In this baby and in those with neural tube defects the
maternal history did not point to any difference in the maternal environment during
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pregnancy compared to mothers in the normal group. The SCE rates of the parents
of some of the children with neural-tube defects were studied and found to be within
the normal range. The SCE rates in normal newborns and normal children under the
age of 10 were not significantly different from one another. However, the normal
adult controls over the age of 20 had SCE rates which were significantly higher than
those of the normal newborns (p < 0.01).
Discussion
Before attempting 10 examine the affects of environmental agents upon SCE rates
in mothers and infants it was important to establish control ranges for SCE in
mothers immediately post-partum and for cord bloods. A group of mothers and
their neonates were studied by Ardito et al. (1980) but they did not establish that
there was no difference in SCE between mothers and controls who had not recently
been pregnant. Our data shows that there is no difference in SCE rate between our
control mother, smoker mother and healthy adult control groups.
The SCE rate measured from cord blood, capillary or venous blood in infants was
found to be highly significantly less than that of adults. Whilst we did not
specifically examine the affect of age on SCE we are unable to support the
contention of Morgan and Crossen (1977) that SCE is not affected by age. Our data
is in agreement with that of Ardito et al. (1980) who found a considerably lower SCE
rate in cord blood than in mothers blood, with Husgafvel-Pursiainen et al. (1980)
who found that children with a mean age of 1.5 years had significantly lower SCE
than adults and is supported by the animal studies of Kram et al. (1980) who found
female mice to have higher SCE than their fetuses.
There is controversy concerning the affect of cigarette smoking on SCE. Cigarette
smoke condensate has been shown to be a potent inducer of SCE in vitro (Hopkin
and Evans, 1979) but studies of SCE on smokers themselves have yielded incon¬
sistent findings. Higher SCE levels in smokers than non-smokers have been found in
some studies (Husgafvel-Pursiainen et al., 1980; Lambert et al., 1978; Murthy, 1979),
but not in others (Ardito et al., 1980; Hollander et al., 1978). Our data, like that of
Ardito et al. (1980) was not able to establish any difference between smokers and
non-smokers (Sutherland et al., 1980). Ethanol, via its first metabolite acetaldehyde,
has been shown to increase SCE in vitro (Ristow and Obe, 1978; Obe and Ristow,
1979; Obe et al., 1979) and in vivo in alcohol fed mice (Obe et al., 1979; Alvarez et
al., 1980). Obe et al. (1980) have shown that clinically diagnosed alcoholics have an
increase in chromosome aberrations in lymphocytes. The finding in the present
study of an increase in SCE in the alcoholic mother group is complicated because all
this group smoked cigarettes and others used a variety of illicit drugs. Interaction
between cigarette smoke and alcohol in the aetiology of malignancy has been
described (Tuyns, 1979).
Of the mothers suffering from chronic illness, one with multiple sclerosis had an
elevated SCE rate; it appears that patients with MS have increased SCE rates
(Sutherland et al., 1980). Only one group of abnormal infants had elevated SCE
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rates and this was those with neural tube defects. It should be noted that most of
these infants with neural-tube defects were studied in the first few days or weeks of
life and many had either been recently operated upon or were taking medications
such as panadol or chloral hydrate which could have influenced the results. When
studied the parents of this group had normal SCE and this elevation of SCE in
neural-tube defects is worthy of further investigation.
All the infants born to the epileptic and "alcoholic" mothers in this study were
normal and had normal SCE rates. Explanations for this could include a diminished
ability of fetal cells to form SCE, although this is unlikely in view of the animal
studies of Kram et al. (1979, 1980); the inability of relevant metabolic products to
cross the placenta; or possible metabolic differences in mothers which may influence
the conversion of putative mutagens to active components which could cross the
placenta. It would be of interest to study SCE in the abnormal offspring of epileptics
and alcoholics to determine whether there was any evidence of DNA damage.
The finding that the SCE rate of infants was not influenced by the exposure of
their mothers to a variety of environmental pollutants and drugs indicates that
neonatal SCE rate is probably not a useful indicator of intrauterine exposure of
normal infants to DNA-damaging agents. Kram et al. (1980) found in their mouse
study that fetal SCE response to DNA-damaging agents decreased with gestation,
but also concluded that the mutagen concentrations required to produce a marked
increase in SCE were well below those required for teratogenesis. In our study only
one infant with non-specific multiple malformations had an elevated SCE level.
Although there was no specific maternal history of exposure to potential DNA-
damaging agents in this instance the possibility that some infants with multiple
malformations result from intrauterine exposure to DNA-damaging agents, which is
reflected in an elevated SCE at birth, requires further study.
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SUMMARY : Exclusions for unassigned markers were
determined by deletion mapping at the following seg¬
ments : (4)(p15.1 ->16.1) - F13A„ F13B. TF ; (4)(q27-»31) -
TF ; (9)(p22^pter) - F13B ; (12)(p12) - TF ; (12)(pter) ■
TF ; (18)fq22) - F13A. K and LU ; (19)(p or qter) - TF ;
(22)(pter->q11) - F13B. GC was excluded from (4)(p15.1^
16.1) and (4)(q27-s>31). GALT was excluded from (9)(p22^>
pter).
KEY-WORDS : Deletion mapping. — Exclusion mapping. — Chro¬
mosomal deletions.
Further exclusions arising from deletion mapping
are presented. These were derived from patients
with monosomic segments defined by trypsin-
Leishman G-banding or BrdU replication banding.
The detection of two alleles implies heterozygosity
and clearly excludes that locus from the defined
monosomic segment in the corresponding indivi¬
dual.
MATERIALS AND METHODS
A large range of genetic markers were examined from
individuals with the deleted autosomal segments listed in
table I. All deletions examined were spontaneous in origin
except the deletion in patient 1 resulting from a familial
pericentric inversion inv(3)(p25q23) (Sutherland, Mulley and
Goldblatt, 1981) and the deletions in patients 7 and 8 resul¬
ting from familial translocations t(9;22)(p22;qll) and
t(10;18)(q26;q21) respectively. Partial karyotypes for
patients 1. 3, 4, 6, 9, 10 and 12 in table I were given
previously (Mulley et al., 1980) and for patients 2, 5, 7,
8, 11 and 13 are shown in figure 1. Isoelectric focusing was
used to subtype GC 1 into IS and IF, PI M into Ml, M2
and M3 and TF C into CI, C2 and C3. No GM results
were presented for infants younger than six months of age.
RESUME : Les exclusions suivantes pour les localisations
des marqueurs genetiques non encore localises ont ete
determinees par la methode des deletions : (4)(p15.1^>
16.1) - F13A, F13B, TF ; (4)(q27e>31) - TF ; (9)(p22e>pter) -
F13B ; (12)(p12) - TF ; (12)(pter) - TF ; (18)(q22) - F13A.
K et LU ; (19)(p ou qter) - TF ; (22)(pter^q11) - F13B,
GC a ete exclu de (4)(p. 15.1 -s>16.1) ei de (4)(q27e>31).
GALT a ete exclu de (9)(p22e>pter).
MOTS-CLES : Methode des deletions. — Methode d'exclusion. —
Deletions chromosomiques.
RESULTS AND DISCUSSION
The results of genetic marker studies are given
in table I. F13A, F13B, TF, K and LU are unassi¬
gned, although TF may be located on chromosome
3 (Oslo Conference, 1981). The exclusions shown
for these unassigned markers, and markers known
to be syntenic with monosomic segments, are poten¬
tially valuable for regional localisation. New exclu¬
sions are : F13A from (4)(p 15.1->16.1), (18)(q22) ;
F13B from (4)(pl5.l»-16.1), (9)(p22->pter), (22)
(pteOql 1) ; TF from (4)(pl5.1->16.1), (4)(q27
■>31), (12)(p 12), (12)(pter), (19)(p or qter) ; K and
LU from (18)(q22) (table 1). Recent gene assign¬
ments have been JK to chromosome 2, MNS to chro¬
mosome 4, GM and PI to chromosome 14, GPT to
chromosome 16 and C3 to chromosome 19 (Oslo
Conference, 1981). The numerous exclusions given
for these loci (table I) are trivial if assignments for
these loci are correct.
Cytogenetics Unit. Department of Histopathology, Adelaide
Children's Hospital, 72, King William road, NORTH ADE¬
LAIDE, S.A. 5006 (Australia).
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TABLE I. — Exclusions determined by deletion mapping.
Patient No. Segment deleted Locus excluded
1 (3)(p25>pter) GC
2 (4)(p15.1>16.1) F13A, F13B, GC, PI, IF,
GALT,
PGM1, PGP
3 (4)(q27>31) GC, GPT
4 (4)(q27>31) TF
5 (5)(p13) PI, ADA, ESD, PGM1
6 (7)(q22) GC
7 (9)(p22> pter) and
(22)(pter->-q11)
C3, F13B, GC, PI, ACPI,
ADA, GALT, GLO, PGM1,
PGP
8 (10)(q26) HPA", PI, AK1, ESD,
GL01, PGP




11 (18) (p11) C3, GC", AK1, GL01,
PGM1"
12 (18)(q21 >23) GM
13 (18)(q22) F13A, FY", JK", K, LU,
MNS", RH, GC", ACP1",
GALT, PGM1"





Fig. 1. — Partial karyotypes from patients 2, 5, 7, 8, 11 and 13.
BrdU banded karyotypes : (a) patient 2, del(4)(p15.1 -^-p16.1) ; (b)
balanced form of t(9;22)(p22;q11), patient 7 had karyotype 45,XY,
—9,-22, + der(9)t(9;22)(p22;q11) ; (c) balanced form of t(10;18)(q26;q21),
patient 8 had karyotype 46,XY,der(10)t(10;18)(q26;q21) ; and G-banded
karyotypes ; (d) patient 5, del(5)(p13) ; (e) patient 11, del(18)(p11)
and (f) patient 13, del(18)(q22).
GC and GALT are each excluded from portions
of the chromosome to which they are assigned. GC
is excluded from (4)(pl5.1 16.1) and (4)(q27
■>31) (table I) which is compatible with the regional
assignment of GC to (4)(ql 1^13). GALT is exclu¬
ded from (9)(p22->-pter) (table I) which is compati¬
ble with the regional localisation of GALT to (9)
(pi3) and tight linkage between GALT and 9qh
variants with a lod score of 3.67 at 0 = 0 (Sparkes
et al., 1980). Close linkage of GALT to the centro¬
mere is further supported in « family 2 » of Suther¬
land and Eyre (1981) which is segregating for an
unusual G-band variant near be centromere of the
short arm of chromosome 9. Portion of this pedigree
is informative giving a positive lod score of 0.90 at
0 - 0, (z, 4:0), resulting in a total positive lod
score of 4.57 at 0 =0.
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In order to detect any underlying DNA abnormality that may
be present in multiple sclerosis (MS), the incidence of SCE, X-radiation
sensitivity, and the frequency of 6-thioguanine resistant cells were
determined in the lymphocytes of 34 MS patients. As a group, MS patients
showed an increase in the SCE rate compared to control. However, there
was no increase in X-radiation sensitivity. The frequency of 6-thioguanine
, ■*
resistant mutant cells was also normal.
In recent years several methods have been described to detect
DNA damage and repair processes. Of these, biological methods such as
the analysis of rates of sister chromatid exchange (SCE)(Nakarishi and
Schneider, 1970), and assessment of cell survival following X-irradiation
(Agarwal et_ al_., 1977; Taylor et al_., 1975; Weichselbaum et al. , 1980)
are being used because of their simplicity. A new method for measuring
DNA damage in man may be the enumeration of 6-thioguanine-resistant
presumptively mutant lymphocytes; this approach seems capable of detecting
an increased number of mutants although there is uncertainty as to its
specificity when the number of mutants is low (Strauss and Albertini,
1979; Morley et al_., 1982). The evidence that 6TG resistant cells are
mutants is indirect, and is based on the observation that increased
frequency of resistant cells occur after cancer therapy with mutagens
(Strauss and Albertini, 1979) and that X-irradiation of lymphocytes in vitro
increases the frequency of 6TG resistant cells (Evans and Vijayalaxmi, 1981;
Dempsey and Morley, 1982).
Although each of these tests appears to be a sensitive method
of detecting DNA damage, a detailed analysis of the correlation between
these tests has not been performed. SCE rate is increased after exposure
to many mutagens and carcinogens (Perry and Evans, 1975), and there
appears to be a correlation between SCE and mutation (Carrano et a]_., 1978).
The assessment of cell survival following X-irradiation has been valuable
in detecting inherited disorders with DNA repair abnormalities (Taylor
et al., 1975; Weichselbaum et al., 1980). However, the relationship
between SCE rate, X- radiation sensitivity and somatic mutation as
measured by the frequency of 6TG resistant cells is unclear.
- 2 -
In an earlier communication, we reported that multiple sclerosis
(MS) patients have an increased rate of SCE (Sutherland et al., 1980).
Since Gipps and Kidson (1981) observed that lymphoblastoid cells of MS
patients have a greater sensitivity to ionizing radiation than those of
normal individuals, we investigated the correlation between SCE rate,
X- radiation sensitivity and spontaneous mutation rate as measured by
the 6TG resistant cells in MS patients and appropriate controls.
Materials and Methods
Volunteers were obtained from the South Australian MS
Rehabilitation Unit, and blood samples were collected from inpatients
with MS; data on current and long-term drug usage, alcohol consumption
and smoking habits were collected. The control group consisted of healthy
persons between the ages of eight and 80 years. None were taking drugs
except for oral contraceptives in some women, and only six smoked cigarettes.
SCE determination
Lymphocyte cultures were established from venous blood samples
in Ham's F10 culture medium; harvesting and differential staining were
performed as previously described (Seshadri et al ., 1981). SCE rates
were determined by examination of 20 metaphases; SCE's at the centromere
were included in the count. All SCE rates were determined from coded
slides by one observer (E.B.). Where possible those patients with
elevated SCE rates were re-studied at a later date.
- 3 -
T-lymphocyte colony survival following X-irradiation
/
Hypaque-Ficol1 separated peripheral blood lymphocytes were cloned
in soft agar in the presence of phytohaemagglutinin and irradiated feeder
cells, and colony survival following X-irradiation was determined as
described (Kutlaca et al., 1982) for each patient and an age-matched
control. All MS patients and controls were aged less than 60 years.
Mutation assay
The assay is based on the principle that lymphocytes with a
mutation at the HGPRT locus are resistant to 6-thioguanine (6TG) and,
when grown in the presence of 6TG, are able to enter DNA synthesis,
incorporate 3H-thymidine and become identifiable using autoradiography.




Thirty-four patients with MS of varying severity were studied.
The SCE rate in MS patients was higher than that of the control group
(p<0.01 by Wilcoxon rank sum test) (Figure 1). Half of the patients
with MS smoked cigarettes but none had excessive consumption of alcohol.
All but 10 of the MS patients were taking one or more of the following
drugs: methenamine mandelate, diazepam, laxatives, steroids, cimetidine
and imipramine.
- 4 -
Repeat studies were done in three patients showing initial
SCE rates (Table) above the normal adult range of 11.2 ± 3.3 exchanges/cell
determined in this laboratory. Although in one case the number of cells
suitable for SCE analysis was small it is apparent that even after a
considerable time the SCE rates were still at the top of or above the
control range.
Radiation sensitivity
The results of lymphocyte colony survival following X-irradiation
are shown in Figure 2 and it can be seen that there is no evidence of
increased radiation sensitivity of lymphocyte colonies of MS patients.
Mutation assay
Figure 3 shows the frequency of 6TG resistant cells in MS
patients and control. There was no evidence of increased frequency of
6TG resistant cells in MS patients compared with controls. Radiation
sensitivity and 6TG-resistant cell frequency in four patients who had
a high SCE rate showed no abnormalities (data not shown).
Discussion
The present study confirms the previous preliminary observation
(Sutherland et al_., 1980) that the SCE rate in MS patients is higher than
that of normal individuals. Although half the patients with MS smoked
cigarettes there was no difference in SCE rates between the smokers and
non-smokers in this group (data not shown). In a previous study there was
also no difference in the SCE rate of smokers and non-smokers
- 5 -
(Seshadri et al., 1982) and it is therefore unlikely that the increase
in the SCE rate of the MS patient group is due to the inclusion of smokers.
Since many of the MS patients were taking various drugs, the possibility
that the drugs could be responsible for the increased SCE rate should
be considered, but there is no evidence that the drugs used by the MS
patients caused any increase in SCE. The possibility that MS may be
caused by a slow virus has been suggested (Fraser, 1977), and viral
infections have been shown to cause an increase in SCE (Kurvink et al. ,
1978).
The observation that SCE rate is elevated in MS patients in
conjunction with the observation of Gipps and Kidson (1981) that some
patients with MS have an increased sensitivity to ionizing radiation
may indicate a basic DNA abnormality in MS that could be responsible
for the clinical manifestations of the disorder. However, the present
study does not confirm that patients with MS are sensitive to X-rays.
Furthermore, there was no increase in the somatic mutation frequency.
Thus, it appears that MS patients do have a higher SCE
frequency than appropriate controls but that a search for other
abnormalities of DNA has been unrewarding. The reasons for and the
significance of the increased SCE rate in MS remain unknown.
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Table: Results of repeat SCE studies on MS patients with
initial high SCE levels
Patient Date of Study Mean SCE/Cel1 + SD No. of Cells
W August 1981 16.4 ± 7.4 20
February 1982 15.3 ± 6.0 20
E June 1979 15.1 ± 3.4 20
February 1982 14.2 ± 4.6 18
0 September 1979 15.5 ± 6.2 20
February 1982 13.3 ± 2.3 6
References
Agarwal, S.S., D.Q. Brown, E.J. Katz and L.A. Loeb (1977) Screening
for deficits in DNA repair by the response of irradiated human
lymphocytes to phytohaemagglutinin, Cancer Res., 37, 3594-3598.
Carrano, A.M., L.H. Thompson, P.A. Lindl and J.L. Minkler (1978)
Sister-chromatid exchange as an indicator of mutagenesis,
Nature, 271, 551-553.
Dempsey, J.L. and A. A. Morley (1982) Evidence that thioguanine-
resistant lymphocytes detected by autoradiography are mutant cells,
accepted for publication (Mutation Res.).
Evans, H.J. and Vijayalaxmi (1981) Induction of 8-azaguanine
resistance and sister-chromatid exchange in human lymphocytes
exposed to mitomycin C and X-rays in vitro, Nature, 292, 601-505.
Fraser, K.B. (1977) Multiple sclerosis: a virus disease,
Brit. Med. Bull., 33, 28-32.
Gipps, E. and C. Kidson (1981) Ionizing radiation sensitivity in
multiple sclerosis, Lancet, 1, 8226; 947.
Kurvink, K., C.D. Bloomfield and J. Cervenka (1978) Sister-chromatid
exchange in patients with viral disease, Exp. Cell Res., 113,
450-454.
Kutlaca, R., S.J. Alder, R.S. Seshadri and A.A. Morley (1982) Radiation
sensitivity of human lymphocytes, Mutation Res., 94, 125-131.
Morley, A.A., S. Cox, D. Wigmore, R. Seshadri and J.L. Dempsey (1982)
Enumeration of thioguanine resistant lymphocytes using autoradiography,
Mutation Res., 95, 353-375.
Nakariski, Y. and E.L. Schneider (1970) In vivo sister-chromatid
exchange. A sensitive measure of DNA damage, Mutation Res., 60,
329-337.
Perry, P. and H.J. Evans (1975) Cytological detection of mutagen-
carcinogen exposure by sister-chromatid exchange, Nature, 259,
121-125.
Seshadri, R., E. Baker, P. Leonard, G. Sutherland and A. A. Morley
(1981) Sister-chromatid exchange in aplastic anaemia, Cancer
Genetics and Cytogenetics, 3, 81-84.
Seshadri, R., E. Baker and G. Sutherland (1982) Sister-chromatid
analysis in mothers exposed to DNA-damaging agents and their
newborn infants, Mutation Res., 97, 139-145.
Strauss, G.H. and R.J. Albertini (1979) Enumeration of 6-thioguanine
resistant peripheral blood lymphocytes in man as a potential test
for somatic cell mutations arising in vivo, Mutation Res., 61,
353-379.
Sutherland, G.R., E. Baker, R. S. Seshadri and A. Black (1980)
Increased sister-chromatid exchange in, multiple sclerosis,
N. Engl. J. Med., 303, 1126.
Taylor, A.M.R., D.G. Harnden, C.F. Arlett, S.A. Harcourt, R.R. Lehmann,
S. Stevens and B.A. Bridges (1975) Ataxia telangiectasia: a human
mutation with abnormal radiation sensitivity, Nature, 258, 427-429.
, *
Weichselbaum, R.R., J. Nove and J.B. Little (1980) X-ray sensitivity
of fifty-three human diploid fibroblast cell strains from patients
































SCE rates in controls and MS patients (p<0.01 by
Wilcoxon rank sum test)
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Figure 2: Lymphocyte colony survival following X-irradiation
normal controls, MS patients (mean ± standard
error).
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Mutation frequency: the thick and interrupted line shows
the mean and the 95% confidence limits, respectively,
of the frequency of 6TG-resistant cells in normal controls.
Dots represent the values in MS patients (see text for
details).




A New Allele of a 1 -Antitrypsin: PI*NADELAIDE
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Summary. The allele PI*NADELAIDE (PI*NADE) was named in
accord with nomenclature guidelines and specifies a new co-
dominant variant of aiAT. Discovery was achieved by IEF and
the isoelectric point of NADE is between N and NHAM.
Familial inheritance of PI*NADE was demonstrated and both PI
M2NADE and PI M3NADE phenotypes were observed. The
mobility of PI*NADE is identical to PI M by both starch and
agarose electrophoresis. PI*NADE apparently confers normal
on AT serum concentrations and is probably unrelated to disease.
Results and Discussion
The isoelectric point of the unknown variant was shown to lie
cathodal to that of PI N and anodal to PI NHAMPTON (NFIAM)
(Fig. 1). The allele responsible for this new variant was named PI*-
Introduction
ai-Antitrypsin (aiAT) is the major regulator of protease activity
in serum. Phenotypes are determined by multiple alleles at a
locus designated PI, for protease inhibitor system. The frequency
of the PI*S and PI*Z variants exceed 0.01 in most populations;
and PI is highly polymorphic when the common phenotype (PI
M) is subtyped. The remainder of the 32 alleles recognised at the
nomenclature meeting in 1978 (Cox et al. 1980) occur with
frequencies of less than 0.01, and many are extremely rare. All
alleles recognised to date have recently been summarised (Cox
1981). Another allele is described in this report.
Fig. 1. Variants as seen by IEF. Anode at top. 1 — M1M2, 2 — M2M3,
3 — M2NADE, 4 — M1N, 5 — M3NADE, 6 — MIN, 7— M3NADE,
8 — NHAMS
Materials and Methods
The family studied was of Anglo-Saxon origin in which there was
a fragile site at 10q23 segregating (Family Ay of Sutherland
1979). The propositus and his brother were mentally retarded,
but otherwise healthy. Sera and plasma were collected and stored
at -20°C until studied.
Separator isoelectric focusing (IEF) as described by Frants
and Eriksson (1978) detected an unknown PI variant. Details of
IEF differed from Mulley (1980) only by the use of LKB
ampholine in the pH 3.5-5 range rather than the mixture of pH
3.5-5 and pH 4-6 ranges. Subsequently, acid starch gel
electrophoresis and agarose electrophoresis were carried out as
previously described (Cox 1981). aiAT wa3 quantitatcd by radial
immunodiffusion (Mancini et al. 1965). Allelic and phcnotypic
designations follow standard recommendations (Shows et al.
1979). Procedures for naming alleles and the confirmation of
new variants follow recommendations of the International PI
Committee (Cox et al. 1980).
Offprint requests to: J. C. Mulley
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Fig. 2. Variants as seen by starch gel electrophoresis. Anode at top.
1 — NHAMZ, 2 — M2NADE, 3 — Ml, 4 — M3NADE, 5 — M3,




Fig. 3. Pedigree showing inheritance of PI*NADE. aiAT concentrations
(g/1) are shown in parentheses
NADELAIDE (PI*NADE). Bands were confirmed as aiAT by
immunofixation after IEF. By acid starch gel electrophoresis and
agarose electrophoresis, M1=M3 = NADE. However, on the
runs with especially good resolution. Ml >M3 = NADE>M2,
with both M3 and NADE only slightly cathodal to Ml (Fig. 2).
The pedigree is presented together with observed phenotypes
and aiAT concentrations (Fig. 3). There is no evidence that the
PI*NADE allele reduces ai AT concentration as all carriers were
within the normal range (2-4 g/1). The mean aiAT concentration
for the four carriers was 2.7 g/1 which is similar to the normal
mean value of 3.1 g/1.
The family study described has confirmed the inheritance of
PI*NADE and demonstrated expression consistent with co-
dominance. The same PI pattern was obtained at repeat
collection from the propositus. Three generations were investi¬
gated and the variant was present in four family members from
two generations. The deceased father of the propositus must
also have carried PI*NADE.
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The development of methods of diagnosing genetic disorders in the early fetus via
amniocentesis are discussed. The role that this technique can play in genetic counselling
is emphasised and it is stressed that this service should be offered to all couples who have
a high risk of producing children with a disease that can be diagnosed in utero. It is also
suggested that the screening of fetuses at moderate to low risk would be an economically
viable public health measure which could significantly reduce the incidence of mongolism
in the community.
One of the difficulties facing the genetic
counsellor is that he can usually only give
prospective parents an indication of the risk
involved in having an affected child. If this
risk is high then the parents may choose to
have no children and request termination of
any pregnancies which may arise. This can
create ethical problems which were summarised
by Pitt (1969) when he said "that to perform
an abortion for a one in four risk of abnor¬
mality is to run a three in four chance of losing
a normal infant". In cases where the risk is as
high as one in four, many parents would not be
prepared to take the chance of having, what
would be to the majority in this situation,
another affected child. When the risks are lower,
say of the order of 5%, then decisions regarding
further children and those of terminating
pregnancy become more difficult. Such pro¬
blems could be largely overcome if any fetal
abnormality could be accurately determined
early enough for therapeutic abortion of
affected fetuses. This would allow parents
with a high risk of having an affected child
to have a normal family and should go much
of the way to solving the problem outlined
by Pitt.
The problem of attempting to find out
whether a pregnancy will result in an affected
child has received increasing attention in the
last few years. The main method of this
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fetal diagnosis is by a study of the amniotic
fluid. In a procedure known as amniocentesis
a sample of about 10 ml. of this fluid can be
fairly readily obtained by puncture of the
uterus from early in the second trimester on¬
wards. The fluid so obtained is a clear amber
colour and it contains a number of cells which
are almost certainly of fetal origin (Votta et al.,
1968) although their exact source is uncertain.
A full discussion of the techniques used to
obtain amniotic fluid is beyond the scope of
this paper. Early workers tried the trans¬
vaginal approach and had a high incidence of
fetal complications. Riis and Fuchs (1966)
had three spontaneous abortions and one still¬
birth out of eleven cases using this method.
The transabdominal approach (see Thiede,
1968 for details of this technique) seems to
carry little risk. Gerbie et al. (1971) reported
no complications, either fetal or maternal, after
256 such procedures and knew of 170 others
which had been performed without complica¬
tion. Ferguson-Smith et al. (1971) have had
no complications in 30 cases and now use
ultrasonography to locate the placental site
and to exclude multiple pregnancy which is a
contra-indication to amniocentesis.
A sample of amniotic fluid provides three
avenues for study, the composition of the fluid
itself, the cells present in the fluid and the
culture of these cells.
Amniotic Fluid
There is controversy regarding the origin of
amniotic fluid in early pregnancy (Emery,
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1970). However, there is little doubt that
fetal urine contributes to the fluid and that
this contribution becomes more significant as
gestation proceeds. The total volume of
amniotic fluid increases throughout pregnancy
from 50 ml. at 12 weeks to 150 ml. at 15
weeks and 450 ml. at 20 weeks (Emery, 1970).
As amniotic fluid is composed partly of fetal
urine it would be reasonable to assume that
it could be put through the series of tests
which are normally applied to urine when
screening for metabolic disorders. However,
it will not be until normal values for all
relevant components (as a function of gesta¬
tional age) have been determined that the
validity of this approach will be known. At
present it is not known how the ability of the
fetal kidney to secrete various metabolites
varies with gestation and, possibly, with the
diet of the mother. Nadler et al. (1970) re¬
ported a case of Pompe's disease in which the
enzyme normally absent, a-l,4-glucosidase,
was present in the amniotic fluid but not in
the cells cultured from it; some enzymes in
amniotic fluid may be maternal in origin.
Matalon et al. (1970) reported that Hurler's
syndrome could be diagnosed by the presence
of excessive amounts of heparatin sulphate in
the amniotic fluid at 14 weeks, Brock et al.
(1971) failed to confirm this and missed
diagnosing a case using similar criteria; genetic
heterogeneity of this disease may explain this
apparent contradiction. Jeffcoate et al. (1965)
have diagnosed the adrenogenital syndrome by
demonstrating grossly elevated levels of 17-
ketosteroids and pregnanetriol in the amniotic
fluid shortly before birth. As the source of
these steroids is presumably the fetal urine and
as the fetal adrenal cortex functions by the
fourteenth week, the possibility of diagnosing
this syndrome early enough for termination
of the pregnancy arises. However, Merkatz
et al. (1969) were unable to diagnose this
syndrome in early pregnancy using these
criteria, in fact, the steroid levels were only
suggestive of the diagnosis at term.
To date, amniotic fluid studies have been
generally equivocal and much more data on
the composition of this fluid in normal and
diseased states will be necessary before con¬
fident diagnosis of genetic disorders can be
made early in pregnancy. When the production
of an abnormal metabolite is not present at
birth but depends on diet (e.g. phenylketonuria)
it is difficult to see how the condition could be
diagnosed from the amniotic fluid.
Amniotic Fluid Cell Studies
At present the information which can be
obtained from the cells without tissue culture
is limited to sex chromatin determination, the
ABO blood groups and, recently, electron
microscopy studies.
Sex Chromatin
In 1956, several workers independently
found that fetal sex could accurately be deter¬
mined by X-chromatin studies on the cells
present in amniotic fluid. This technique has
been extended, and probably increased in
reliability, since the discovery of the quinacrine
fluorescence pattern of the Y chromosome in
interphase nuclei (Pearson et al., 1970) was
extended to amniotic fluid cells (Rook et al.,
1971). By combining these methods it should
be possible to accurately determine the sex
chromosome complement in all cases.
The determination cf X-chromatin on
amniotic fluid cells was first used by Riis and
Fuchs (1960) in the management of the preg¬
nancies of two women who were carriers of
the gene for haemophilia. The technique is,
however, applicable to all cases where an X-
linked gene is responsible for a disease which
cannot be specifically diagnosed. When a
woman carries such a gene, half her sons
would be affected but all her daughters would
be normal. By terminating the pregnancies
where the fetus is a male the parents concerned
can have a family of normal girls. This does
not completely solve the problem of Pitt
(1969) although it reduces the chance of
losing a normal infant from three in four to
one in two and has been used by numerous
genetic counsellors to manage pregnancies
involving X-linked conditions (e.g., Gerbie et
al. 1971) where male fetuses have been abort¬
ed. Edwards (1970) has suggested that fetal
sex determination could be used as the basis for
aborting the female fetuses fathered by men
who carry X-linked diseases (e.g. Haemophilia)
as this "... could allow the reduction of such
diseases to the level maintained by mutation,
the virtual elimination of familial cases, and
progress in therapy without the prospect of in¬
creasing the incidence of disease."
Blood Groups
The determination of the fetal ABO blood
groups is possible using cells from the amniotic
fluid as early as 1 1 weeks gestation (Sachs et
al., 1956). However, attempts to demonstrate
the Rh groups have been unsuccessful (Scott
et al., 1969). Such information is of little use
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in genetic counselling at present but may be¬
come useful when genetic maps of the auto¬
somes have been constructed, especially if it
becomes possible to determine other blood
groups from these cells. In cases of close
linkage where the probability of recombination
is small, it may be easier to determine the
bleed group than to assay for its closely
linked disease-producing gene. So far, the only
such close linkage known is that of the ABO
locus to the gene for nail-patella syndrome, and
possibly the MNS blocd group locus to that for
sclerotylosis (Renwick, 1969).
Electron Microscopy Studies
The ultrastructure of normal amniotic fluid
cells has been studied by Hoyes (1968) who
found two recognisable cell types. Bartman
(1971) studied cultured amniotic fluid cells
and found only one cell type similar to fibro¬
blasts cultured from other sources. Hug et al.
(1970) found that amniotic fluid cells obtained
during the 36th week of gestation from a
woman carrying a child subsequently shown to
have Pompe's disease, had abnormal lysosomes
and suggested that it may be possible to diag¬
nose this disease early in pregnancy by electron
microscopy of uncultured amniotic fluid cells.
Amniotic Fluid Cell Culture Studies
This aspect of fetal diagnosis will probably
prove to be by far the most important. Two
broad fields of study are opened up by culturing
the cells present in the amniotic fluid, viz.,
cytogenetics and biochemistry. Although much
work has been done on the methodology of
culturing these ceils, the optimum conditions
have probably not yet been found. Hence,
the time required to produce results is longer
than ideal especially when a result may indicate
termination of a pregnancy; to produce a
karyotype requires two to three weeks and a
biochemical result may take significantly longer.
Biochemical Studies
Davidson (1970) lists about 30 different cell
phenotypes which can be distinguished in
cultures of fibroblasts grown from skin biopsy.
Harris (1970) estimates that these represent
about one-third of the metabolic disorders in
which the biochemical defect is known. This
knowledge cannot be directly applied to fetal
diagnosis until it has been established that the
cells cultured from amniotic fluid cells similarly
and consistently express the same biochemical
phenotypes as those grown from skin. It would
be necessary to establish this for each enzyme
or other property separately and any variations
during gestation would need to be known. For
these reasons work on fetal diagnosis of bio¬
chemical disorders is proceeding slowly; each
disorder requires a separate technique for diag¬
nosis and each technique will require highly
skilled staff, separate reagents and often
expensive laboratory equipment. At present,
biochemical techniques can only be applied to
individual families who have already produced
an affected child, the detection of heterozygotes
in the population is not feasible unless the
detection is reasonably simple and the gene
frequency in the population is high, e.g.,
screening for carriers of Tay-Sachs disease in
some Jewish populations where their frequency
is as high as 1 in 30.
Biochemical studies on cultured cells involve
three main types of approach, autoradiography,
histochemistry and the assaying of enzyme
levels on cell homogenates. These are all
sophisticated methods which are prone to
technical difficulties. The procedures are also
lengthy, autoradiography usually requiring at
least a week to prepare after sufficient cells
have been grown. However Fujimoto et al.
(1968) reported the autoradiographic diagnosis
of a female fetus heterozygous for the Lesch-
Nyhan syndrome 22 days after amniocentesis.
The main histochemical technique is the stain¬
ing for metachromatic granules in the cyto¬
plasm using toluidine blue. These granules
have been demonstrated in a number of condit¬
ions including the polysaccharidoses and cystic
fibrosis of the pancreas. It is, however, difficult
to distinguish homozygotes from heterozygotes
and the metachromasia may not develop until
after two to three months in cell culture
(Fratantoni et al., 1969), in fact this technique
should not be used for diagnostic purposes
at its present stage of development. The assay¬
ing of enzyme levels in cultured cell homo¬
genates generally requires a large number of
cells which may take several weeks to produce.
However, specific enzyme deficiencies in
cultured cells have been demonstrated for
galactosemia, metachromatic leukodystrophy,
lysosomal acid phosphatase deficiency and
Pompe's disease (Nadler and Gerbie, 1971),
in each case making intrauterine diagnosis
possible. Regan et al., (1971) have diagnosed
xeroderma pigmentosum, an autosomal reces¬
sive disease in which there is a lack of
functional ultraviolet endonuclease, from
cultured amniotic fluid cells. Their technique
which was able to clearly distinguish normals
from homozygotes and from heterozygotes was
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based on shifts in the DNA sedimentation
constants after the cells had repaired ultra¬
violet induced lesions in the presence of 5-
bromodeoxyuridine and then been subjected to
further irradiation.
Cytogenetic Studies
Shortly after Klinger first grew amniotic
fluid cells in tissue culture, two small series of
cultures reported by Steele and Breg (1966)
and by Thiede et al. (1966) confirmed that
the cells would grow in culture and that they
could be used for chromosome analysis, thus
making available a technique for the antenatal
diagnosis of chromosome abnormalities. The
bringing of this technique to perfection and its
widespread application has been slow and is
far from complete at present. It is, however,
better developed than the majority of bio¬
chemical techniques, largely because the
methods used are few, well established and
largely within the competence of established
cytogenetic units. Nevertheless, only one large
series of cases of chromosome analysis as a
result of amniocentesis has been reported, that
of Gerbie et al. (1971) who successfully karyo¬
typed 238 out of 250 samples of amniotic
fluid. Such remarkable success has not been
widespread, Nelson and Emerv (1970) were
successful in culturing only 49 out of 90
samples; although Ferguson-Smith et al. (1971)
were successful in 29 out of 30 cases referred
for genetic counselling (repeat amniocentesis
was, however, required in five cases) they
managed to obtain karyotypes in only 17 of
24 samples obtained at hysterotomy.
The results of successful amniocentesis per¬
formed for genetic counselling purposes which
required chromosome analysis are summarised
in Table 1. The results reveal some surprises.
The finding of three pregnancies with Down's
syndrome amongst 85 where the mother had
had a previous regular mongol is, as Ferguson-
Smith et al. (1971) point out, much higher
than the generally accepted recurrence risk for
this syndrome. Also the 5 abnormal fetuses
(three cases of Down's syndrome, one of
Klinefelter's syndrome and one XYY male)
found in 130 women with advanced age at the
time of pregnancy (older than 40 years in
most caces) is more than expected. Advanced
maternal age is a factor in the production of
both Down's and Klinefelter's svndromes but
the rick figures are generally believed to be
less than found here.
Whilst the theoretical expected risk of pro¬
ducing unbalanced offspring from Robertsonian
translocations involving non-homologous
chromosomes is 33%, it has been found in
practice to be in the region of 4-9% depending
TABLE 1


























Previous child with regular
mongolism 5(1) 67(2) 13 85(3)
Previous child with other
chromosome abnormality 1 1
Parent with balanced
translocation KD 2(1) 41(10) 1(1) 4 49(13)
Maternal mosaic for mongolism 1 1
Increased maternal age 1 6(1) 119(4) 4 130(5) +
Family history of mongolism 1 3 4
Exposure to mutagens 2 6 1 9
Total 4(1) 2(1) 18(2) 227(16) 1(1) 27 279(21)
+ Three mongols, one XXY and one XYY male
Figures in parentheses indicate number of abnormal fetuses diagnosed and, except for two cases of Nadler
and Gerbie, also indicate that these fetuses were therapeutically aborted.
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on the sex of the carrier parent and the exact
chromosomes involved (Hamerton, 1970). The
reasons for the finding of 13 out of 49 affected
fetuses from balanced translocation carriers,
apparently in aggreement with the theoretical
figure, is not known. Apart from the small
number of cases, a possible reason for the
finding of an apparent excess of abnormal
fetuses in all the groups studied could be
that these findings in mid-pregnancy should
not be directly compared with expected fre¬
quencies of chromosome abnormalities in
liveborn neonates. With two exceptions, all
the chromosomally abnormal fetuses were
therapeutically aborted. It is possible that
some of these would have spontaneously
aborted had they continued, this could have
reduced the incidence of neonates with
chromosome abnormalities amongst these
groups closer to the expected levels. This is,
however, unlikely because most chromosomally
abnormal abortuses are lost during the
first trimester, and amongst mid-trimester
spontaneous abortuses there are only about
3% with chromosome abnormalities (Carr,
1970).
Hence it can be seen that antenatal chromo¬
some analysis is an effective means of pre¬
dicting the chromosomal status of the fetus and,
if followed by abortion of affected fetuses, can
reduce the incidence of chromosomal disorders
at birth. Unfortunately, misdiagnosis has
occurred and a normal fetus has been aborted
on at least one occasion iKohn and Robinson,
1970), however, no chi'd with an unknown
chromosome abnormality has been born after
amniocentesis although in the series of Gerbie
et al. (1971) two fetuses diagnosed as female
by amniocentesis were in fact males with
normal karyotypes. The reason for this error
was probably an overgrowth of contaminant
maternal cells.
Future Prospects
When any relatively safe technique which
can prevent or improve the prognosis of a
disease is discovered the question of screening
populations at risk arises. Amniocentesis is
such a technique, and it is worth considering
whether it could be usefully employed as a
screening test for disorders which can be diag¬
nosed in utero, either with a view to terminat¬
ing the affected pregnancies or initiating
treatment of the fetus or the subsequent neo¬
nate. The decision regarding termination or
treatment or neither will depend on the particu¬
lar disease, the attitudes of parents, doctors and
the law. In a liberal atmosphere fetuses with
treatable disorders te.g. phenylketonuria if it
becomes detectable at this stage) would prob¬
ably be terminated as would those with any
sex chromosome abnormality and perhaps even
those with balanced autosomal rearrangements,
the termination of this last group is however
difficult to justify on genetic grounds (Hamer¬
ton, 1970). In a more restrictive climate,
probably only those with severely debilitating
and unbeatable disorders would be terminated.
Littlefield (1970) suggested that amniocente¬
sis was appropriate for four distinct groups of
women ranging from those with high risks of
producing abnormal fetuses to those with a low
to moderate risk. 1 would suggest that in the
high risk cases amniocentesis is not only
appropriate but its offer should be an essential
part of genetic advice (where facilities are
available) in the following instances:
1. Either parent carries a chromosomal re¬
arrangement or has a chromosome abnor¬
mality, e.g. where the mother is XXX or the
father XYY.
2. The parents are known to be carriers of
autosomal recessive genes for any disease diag-
nosable in utero These would normally have
been ascertained via a previously affected child.
3. When one parent carries an autosomal
dominant condition which can be diagnosed
in utero.
4. When the mother is known to be the carrier
of an X-linked condition, even when the
specific condition cannot be diagnosed.
Where facilities are available amniocentesis
is being offered in most of these cases at
present and it can be expected that in the
near future most major centres will have at
least one unit capable of providing antenatal
diagnostic services for such cases.
Apart from cytogenetic abnormalities,
screening for other disorders is not feasible at
present. This is because each requires a
separate technique and even with considerable
selection the incidence of fetuses with any
single disorder is very low. The most common
would probablv be Tay Sachs disease with an
incidence of about one per thousand in some
Jewish populations but even here it is pre¬
ferable to screen prospective parents for
heterozygosity.
Apart from the high risk groups outlined
above, there are two other groups which are
probablv worth screening for chromosome
abnormalities. These are:
(a) Women who have produced a child with
a chromosome abnormality.
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(b) Women who become pregnant towards the
end of their reproductive iife when the chances
of producing children with chromosome abnor¬
malities is increased.
In general women in these categories are not
being offered amniocentesis for several reasons.
These include the inability of present cyto¬
genetic units to handle the numbers which
would be involved and reluctance on the part
of obstetricians to perform a new procedure
when its risks and benefits may not be fully
understood and who are worried about the
problem of technical failure to produce a
result, necessitating repeat amniocentesis. The
first problem can be overcome fairly easily
because when the costs involved are compared
to the resulting benefits, the saving to the com¬
munity is great, hence government support for
the establishment of adequate cytogenetic
facilities should be forthcoming. The compli¬
cations of amniocentesis, both fetal and mater¬
nal have been discussed and although present
data suggests that this is a procedure which
involves very low risks, more information is
required from large series before this can be
fullv confirmed. The problem of failure will
probably diminish as more experience is gained
by laboratories in amniotic fluid cell culture.
If such a screening programme were applied
to Australia, what could we expect? The
mothers who had produced a previous child
with a known chromosome abnormality would
constitute only a small group and could prob-
ablv be handled without expansion of existing
facilities: this group will not be considered
further. If 40 years was taken as an age above
(and including) which women would be
screened then in Australia in 1967 there would
have been about 5.400 out of 230,000 mothers
included ^Sutherland, 1970). The chromosome
abnormalities which this group would have
been responsible for are estimated in table 2.
TABLE 2
Chromosome Abnormalities which would have been
produced by 5,400 women 40 years or older in
Australia in 1967
Abnormality No. of Cases
Down's syndrome (47.G + ) 65
Edward's syndrome (47.E+) 3
Patau's syndrome (47,D+) 3
Klinefelter's syndrome (47.XXY) 15
Trinle-X female (47.XXX) 5
"YY-males" (47,XYY) 5
Other abnormalities 10
The cost to the community of these abnor¬
malities in human terms cannot be calculated;
it is sufficient to say that they will result in
considerable anguish to the families concerned.
It is, however, easier to calculate the cost in
financial terms, especially for the cases of
Down's syndrome which constitute the most
significant group. If each case required 20
years institutionalisation at a cost of $2000 per
year, this amounts to $2,600,000. It is more
difficult to estimate the costs to the community
of the other abnormalities which would be
found. The Edward's and Patau's syndrome
ca~es could not be expected to live for more
than six months but would require hospital
care for most of the time till death. It is
difficult to estimate the costs to the community
of the cases with sex chromosome abnormali¬
ties. The XXY and XXX individuals do have
a tendency towards mental deficiency, be¬
havioural disturbance and subsequent institu¬
tionalisation (Bartholomew and Sutherland,
1971). They can develop normally except for
sterility in the case of XXY, however the
proportion of each which develops normally is
not accurately known. The XYY males present
even more of a problem, Australian experience
(Sutherland et al., 1972) suggests that they
have a tendency towards institutionalisation
but this is denied in Britain (Jacobs et ah,
1971). This is a problem which still requires
much more study.
I would estimate that to screen these women
over 40 years would cost about $500,000 per
annum (this allows for a centre in each state).
Hence the spending of about half a million
dollars would save about three million.
Although these cost estimates are extremely
approximate they are of the correct order of
magnitude, hence there would be about a
tenfold/fivefold return on money spent on this
type of preventative medicine. The problem of
"discounting" is beyond the scope of this review
but it will tend to reduce the magnitude of the
return on money spent on such population
screening. However if the age above which
pregnant women were screened was lowered to
35 years then it has been estimated (W.H.O.,
1972) that "the cost of such a programme
would be substantially less than half that of
institutional care for the trisomic population."
If further experience with the technique of
amniocentesis confirms that the risks involved
are almost negligible, or at least significantly
less than the chance of having a child with a
chromosome abnormality, then screening could
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be extended to younger women, e.g. those in
the 35-39 age group. Carter (1970) stated
that in Britain, women of 35 and over produce
about half the mongols, yet comprise only
about 10% of the pregnant populuation.
I can only conclude by wholeheartedly
agreeing with Ferguson-Smith et al. (1971)
when they say "... it is important that
amniocentesis should not be undertaken . . .
for trivial purposes such as choosing the sex
of offspring".
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Culture of Cells from the Urine
of Newborn Children
The increasing importance of amniocentesis for the diagnosis
of disease in utero has focused attention on the cells obtained
by this procedure. Culture of amniotic fluid cells is becoming
an established procedure for the identification of foetuses with
chromosomal and metabolic abnormalities. Cytogenetic and
biochemical studies of these cells in culture and morphological
studies of the uncultured cells have shown that they are of
foetal origin1-3. However, the exact origin of the cells which
grow remains speculative and several possibilities have been
suggested including exfoliated cells from the amnion or from
foetal skin2'3 and also from the foetal respiratory4 and uro¬
genital3,4 tracts. Since foetal urine undoubtedly contributes to
the amniotic fluid as gestation progresses5 it seemed reasonable
to assume that some of the cells cultured from amniotic fluid
could be derived from the foeta! urinary tract.
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Fig. 1 Cells cultured from (a) urine and (b) amniotic fluid as
seen 24 h after the third subculture (stain toluidine blue, x 100).
Samples of urine were collected in sterile bags from four
infants less than two days old. For tissue culture, the urine
samples were then treated as amniotic fluids; they were centri-
fuged at 1,000 r.p.m. for 10 min, the supernatant decanted, the
cells resuspended in tissue culture medium and then transferred
to Petri dishes containing cover slips. Ham's F10 TCM
containing streptomycin and penicillin with the addition of
30% foetal calf serum was used. Cultures were incubated at
37° C in an atmosphere of 5% C02 in air. Although one
culture showed contamination within 24 h, the remaining three
were successfully maintained and proliferating cells were first
observed at 6, 9 and 10 days respectively. Sufficient cells were
present to allow harvesting for chromosome studies at 12 days
in the first case and at 17 days for the other two. These culture
times are similar to those being obtained at the present time in
this laboratory for amniotic fluid cell cultures.
Using light microscopy the cultured urine cells appear mor¬
phologically similar to those cultured from amniotic fluid
(Fig. 1); but further characterization of these two types of cell
strain is required. Cell cultures have now been set up using
urines from a total of eight infants aged less than 2 days and of
gestational ages ranging from 31 to 40 weeks. Seven of these
cultures have produced primary cell strains, one of which has
now reached the seventh pass. A small number of cultures
from older children have failed to grow. The only previous
attempt to culture cells from urine is that of Jacobson and
Barter4 who set up cultures from sheep urines and bladder
aspirates from four human foetuses; however, only one of the
former was successful.
The culture of cells from neonatal urine, embodying sim¬
plicity in collection and in culture technique, could provide a
non-traumatizing procedure for cytogenetic investigations
when studies on tissue other than blood are required. More¬
over, the most potentially useful application of this technique
may be the production of primary cell strains for use in the
investigation of inborn errors of metabolism at a biochemical
and molecular level.
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Lysosomal enzymes in amniotic fluid
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Edinburgh (U.K.)
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The possible use of amniotic fluid for the prenatal detection of inborn errors of
metabolism due to lysosomal enzyme defects is of increasing interest. However, Emery1
and Nadler and Gerbie2 have stated that the lack of data on the normal levels of enzymes
in amniotic fluid is a limiting factor. We have measured the levels of certain lysosomal
enzymes in amniotic fluid in an attempt to provide some of this information.
Amniotic fluid was obtained from hysterotomy specimens and from amniocentesis
on rhesus isoimmunized women. The cells were removed by centrifugation. Lysosomal
enzymes were assayed after van Hoof and Hers3 using 4-methylumbelliferone phosphate
or glycoside conjugates as substrates. For a-fucosidase, however, the nitrophenol glycoside
was used. Protein was determined by the method of Miller4. The results obtained to date
are given in Table I.
Although at the moment this is only a small series, the results seem to indicate,
particularly when displayed graphically, that the enzyme levels vary with gestational age.
Apparently /3-glucuronidase, a-mannosidase and protein show peak levels at around
25 weeks' gestation. Acid phosphatase and (V-acetyl-0-D-gIucosaminidase appear to increase
and (3-glucosidase and a-arabinosidase to decrease as gestation proceeds. Another feature of the
results is that at any particular gestation age each enzyme showed considerable variation in
activity.
The use of amniotic fluid for the detection of lysosomal enzyme defects may be of
limited value in view of the variation in enzyme level at any gestational age. Owing to this
variation, enzyme values on amniotic fluid alone are unlikely to be reliable and assays will
generally be required on cultured cells. It is hoped that further work in progress along these
lines may clarify the position.
We thank Drs. F. Cockburn, J.G. Robertson and J. Scrimgeour for the amniotic
fluids.
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TABLE I
LYSOSOMAL ENZYMES IN AMNIOTIC FLUID
Enzyme * Gestation (weeks)
12-17 18-24 25- 30 31+
//•Glucuronidase 0.06-0.25 a 0.30-1.55 0.64-1.97 0.26-0.52
0.2 b 0..7 1.1 0.4
O-Manno sidase 0.02-0.32 0.23-0.60 0.37-1.10 0.17-0.32
1.8 3.8 6.9 2.6
Acid phosphatase 0.47-2.00 4^ 1 -J 4*. O 2.53-9.93 1.93-3.87
1.4 3.4 5.3 2.7
7V-acetyl-//-D-gluco saminidase 1.82-13.44 7.25-21.30 10.45-23.73 6.80—22.6C
6.5 12.0 16.0 12.2
//Gluco sidase 0.97-7.25 0.67-9.59 0.26-5.50 0.03-0.26
3.0 4.5 2.0 0.2
Ct-Arabinosidase 0.51-2.83 0.10-3.33 0.67-1.13 0.0-1.26
1.4 1.6 0.9 0.4
Of-Fucosidase 0.10-1.36 0.63-2.43 1.47-3.31 0.44-1.56
0.7 1.4 2.1 1.1
Protein 0.55-4.80 3.25-9.02 3.62-6.83 2.52-5.87
2.5 5.1 5.2 4.0
Number of samples 9 4 3 9
* nmoles 4-methylumbelliferone/min/ml of amniotic fluid
a Range; " Mean
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Metaphase Chromosomes from Neonatal Urine
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Summary. Tissue culture of the cells present in the urine of neonates has been demonstrated
to be a suitable means of obtaining metaphase chromosomes whenever cytogenetic studies
are required on cells other than blood lymphocytes. The advantages of this type of cell culture
compared with the use of fibroblast culture from skin biopsy are discussed.
Zusammenfassung. Es konnte gezeigt werden, daB Gewebekulturen von Zellen aus dem
Urin Neugeborener sich zur Gewinnung von Metaphasenchromosomen eignen, wenn cyto-
genetische Untersuchungen nicht allein an Blutlymphocyten durchgefiihrt werden sollen.
Es werden die Vorteile diskutiert, die diese Art der Zellkultur gegeniiber der Fibroblasten-
kultur aus Hautbiopsien bietet.
Mitotic metaphase preparations for chromosome analyses in the neonate are
usually obtained from blood lymphocyte cultures but if further studies are indi¬
cated then fibroblasts cultured from a skin biopsy arc most commonly used. Skin
fibroblast culture has the disadvantage that results are not obtained for many
weeks, skin biopsy is a traumatising procedure and is consequently not readily
repeatable. It is now possible to culture cells from the urine of the neonate (Suther¬
land and Bain, 1972) and these can be used for cytogenetic studies.
Materials and Methods
Urine is collected into standard sterile urine collecting bags and transported to the labo¬
ratory. The urine is centrifuged at 1000 r.p.m. for 10 min and the supernatant removed.
The pellet of cells is resuspended in tissue culture medium and pipetted into a 50 mm plastic
(Nunclon) petri dish containing 4 or 5 glass coverslips (6x22 mm). Duplicate cultures are set
up, the cells from approximately 5 ml of urine being used for each. The tissue culture medium
is Ham's F10 with 30% fetal calf serum added. Antibiotics incorporated in the medium are
kanamycin, or penicillin and streptomycin in combination. The cultures are incubated at 37°C
in an atmosphere of 5% C02 in air and left relatively undisturbed for 1 week after which time
half the medium is replaced thrice weekly. The cultures are examined regularly for signs of
cell proliferation (almost always first seen on one of the coverslips) which are usually observed
after a period of 7 to 14 days.
When an area of proliferating cells appear large enough for harvesting, the medium is fully
changed and incubation continued for a further 16 hrs. The coverslip, on which the cells to
be harvested are attached, is then removed to a separate petri dish or suitable tube and
covered in fresh medium to which Colcemid at a final concentration of 1 pg/ml has been added.
Incubation is continued for a further 5—6 hrs after which time the medium is aspirated from
the tube and replaced by warm (37°C) 0.075 M KC1. Hypotonic treatment is terminated after
5 min by the addition of an equal volume of fixative (1 part acetic acid to 3 parts methanol)
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Fig. 2. Banded karyotype prepared using the method of Grace and Bain (1972) from a primary
urine cell strain in the 13th passage
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to the KC1. Half the KCl/fixative mixture is removed after 1 min and replaced by fixative.
This step is repeated twice following which the coverslip is put through two changes of
fixative, each of about 5 min. The coverslip is allowed to dry in air at room temperature,
stained with Giemsa and mounted on a slide.
By allowing the cells remaining in the original petri dish to proliferate they can be sub-
cultured to produce a primary cell strain suitable for further cytogenetic studies.
Results
A number of neonates have now been karyotyped successfully by tissue culture
of urine. High mitotic activity is present in primary cultures harvested by this
method (Fig. 1) and preparations suitable for fluorescent and banding studies have
been obtained (Fig. 2).
Discussion
The technique of culturing urine cells for the purpose of cytogenetic study
should prove a valuable addition to the techniques already in widespread use. It
has several advantages over skin biopsy in that no trauma is involved in collect¬
ing the urine and repeat specimens can be readily obtained if contamination or
other problems arise. The method is simple and should be within the capability of
any laboratory involved in tissue culture. Results are obtained in 2—3 weeks,
sooner than is usually possible in the case of skin biopsy and much less technical
work is involved.
The main difficulty encountered is in the collection of the urine samples. Care
should be taken as the urine may be contaminated by organisms which will
multiply in the culture medium in spite of the antibiotics used. This problem could
be overcome by collecting the urine via suprapubic bladder aspiration, a procedure
certainly less traumatic than skin biopsy.
In the absence of microbial contamination the proportion of successful cultures
has been high and would appear to be independent of the gestational age of the
baby but the success rate almost certainly decreases as post-natal age increases.
Possible factors which may influence the ability of the cells present in urine to
proliferate in tissue culture are being investigated.
We are grateful to the staff of the Paediatric Special Care Unit of the Simpson Memorial
Maternity Pavilion, especially Dr. F. Cockburn and Sisters B. Elliott and J. Shaw for collecting
the urine specimens.
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LYSOSOMAL ENZYMES OF CULTURED AMNIOTIC FLUID CELLS
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SUMMARY
1. The levels of some lysosomal enzymes in a minimum of 38 amniotic fluid
cell strains cultured to the third passage were as follows (mean i standard deviation):
AUacetyl-/9-D-glucosaminidase 52.1 i 16.70, acid phosphatase 7.73 i 2.82, /?-
galactosidase 4.59 i 1.97, /S-glucuronidase 1.30 ± 0.52, /S-glucosidase 0.072 ± 0.030,
a-galactosidase 0.42 ± 0.15, a-arabinosidase 0.53 ± 0.25, a-glucosidase 0.38 + 0.18
and a-mannosidase 0.65 T: 0.30 nmole 4-methylumbelliferone/min/mg protein.
2. No correlation was observed between the levels of these enzymes and gesta¬
tional age.
3. The levels of these enzymes in uncultured cells tended to be lower than in
the corresponding cultured cells. Occasionally, very low levels of certain of the en¬
zymes were found in uncultured cells, although normal levels were found in the
corresponding cultured cells.
INTRODUCTION
Amniocentesis combined with biochemical analysis of the amniotic fluid or cells
is increasingly being utilized for the antenatal diagnosis of genetic disease. The uses
and possibilities of this procedure have been reviewed1-3. Great caution must be exer¬
cised if amniotic fluid or amniotic fluid cells are used directly for enzyme analysis2. A
more reliable indication of the presence of enzyme activity in the foetus is obtained
from cultured amniotic fluid cells4. However, the variation in the activity of lysosomal
enzymes of cultured amniotic fluid cells has not previously been investigated in detail
and is presented here.
MATERIALS AND METHODS
Amniotic fluid samples were obtained from hysterotomy specimens and by
amniocentesis on rhesus isoimmunised women with no history of inborn errors of
metabolism involving lysosomal enzymes. Primary cultures of cells from these fluids
were established5 and subsequently subcultured, using 0.25% trypsin in phosphate-
buffered saline to remove the cells from the Petri dish, into a glass culture bottle with
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a growth surface area of approximately 20 cm2. The cells were then similarly subcul-
tured into and maintained in bottles twice this size. Ham's Fro tissue culture medium
(Flow Lab. Ltd.) supplemented with 30% foetal calf serum (Bio-Cult Lab. Ltd.) was
used; antibiotics incorporated were kanamycin (xoopig!ml) or penicillin (60pigjml) and
streptomycin (100 pig/ml) in combination. Culture bottles were flushed with 5% CO,
in air prior to stoppering.
The cells were harvested on reaching confluency after the third subculture.
Trypsin (0.25%) in phosphate-buffered saline was used to remove the cells from the
glass. After washing in phosphate-buffered saline and centrifuging at 600 xg for 5 min
at 50 the cells were taken up in 4 ml of ice-cold 100 mM sodium chloride and sonicated
for 15 sec at maximum power using a "Soniprobe" (Dawes Instruments). The homo-
genates were centrifuged at 25000xg for 10 min at 5° and stored at —65°.
The methods of enzyme estimation were those of Butterworth et al.6 with two
modifications:
/^-glucuronidase—1 mM conjugate, 0.1 M acetate buffer pH 4.0, 30 min
a-glucosidase—2 mM conjugate, 0.2 M phosphate/citrate buffer pH 4.5, 60 min.
RESULTS
The results obtained for the enzymes assayed in a series of cultured amniotic
fluid cells are presented in Figs. 1 and 2. Table I gives the mean, standard deviation
and range for each enzyme. The levels of the enzymes differed greatly, varying from
52.1 d; 16.7 nmole/min/mg protein for Ar-acetyi-/5-u-glucosaminidase to 0.072 +
0.030 nmole/min/mg protein for /Lglucosidase. Each of the enzymes showed a
fairly narrow range of values except for a few cell strains showing unusually high
150—
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Fig. 1. Specific activities (nmole 4-methylumbelliferone/min/mg protein) of N-acetyl-/?-D-gluco-
sarainidase, acid phosphatase, /t-galactosidase, ^-glucuronidase in amniotic fluid cells after the
third passage of culture.
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Fig. 2. Specific activities (nmole 4-methylumbelliferone/min/mg protein) of /S-glucosidase, a-
galactosidase, a-arabinosidase, a-glucosidase and a-mannosidase in amniotic fluid cells after the
third passage of culture.
levels of enzyme activity. Consequently 95% confidence limits based on a normal
distribution produce lower limits for the enzyme specific activities which are well
below those actually measured. Hence Table I gives the upper and lower values
(range) actually measured. The correlation coefficients (r) for the enzyme specific
activities with gestational age are given in Table I from which it can be seen that none
of the enzymes exhibits any relationship with this factor.
In Table II a comparison is made between the levels of the enzymes assayed
for uncultured and cultured amniotic fluid cells derived from three amniotic fluid
samples. One feature, with five exceptions, is the lower level of these enzymes in the
TABLE I
LYSOSOMAL ENZYMES OF CULTURED AMNIOTIC FLUID CELLS
Enzyme Number Enzyme specific activitya Correlation coefficient
of cell Mean Standard Range (r) °f enzyme activity
strains Deviation with gestational ageb
JV-Acetyl-/f-D- 39 52.10 16.70 28.70-91.85 — 0.196
glucosaminidase
Acid phosphatase 38 7-73 2.82 4.34-12.69 0.198
/3-Galactosidase 41 4-59 1.97 2.37-10.69 -0135
/5-Glucuronidase 38 130 0.52 0.62-2.02 0.284
/3-Glucosidase 39 0.072 0.030 0.03-0.17 — 0.083
a-Galactosidase 38 0.42 0.15 0.22-0.78 -0.158
a-Arabinosidase 40 053 0.25 0.22—1.30 — 0.081
a-Glucosidase 40 0.38 0.18 0.17-0.97 0.218
a-Mannosidase 39 0.65 0.30 0.28-1.27 -0.093
a nmole 4-Methylumbelliferone/min/mg protein.
b (r) > 0.325 P{r = o) < 0.05 df 35.
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TABLE II
SPECIFIC ACTIVITY"1 OF LYSOSOMAL ENZYMES OF UNCULTURED AND CULTURED AMNIOTIC FLUID CELLS
Enzyme Sampleb
Uncul¬ Cultured Uncul¬ Cultured Uncul¬ Cultured
tured1 tured1 tured3
N-Acetyl-/?-D- 8.28 52 37 23-18 47.26 4.46 3'-4°
glucosaminidase
Acid phosphatase 7.20 7-55 17-59 7-63 3.26 4.84
/J-Galactosidase O.IO 436 0.30 3-91 0.25 4-J9
^-Glucuronidase 2.20 0.94 2.94 1-34 °-73 I.02
^-Glucosidase 0.012 0.089 0.028 0.122 0.012 °-°35
a-Galactosidase 0.023 °-37 0.075 °-35 0.018 0.32
a-Arabinosidase 0.008 o-43 0.040 °-43 0.040 0.60
a-Glucosidase 0.05 0.42 0-57 0.30 0-45 0.25
a-Mannosidase 0.25 055 0.28 0.62 0.20 0.50
a nmole 4-MethyIumbelliferone/min/mg protein.
b Gestational age: Sample 1: 23 weeks; 2: 21 weeks; 3: 16 weeks.
uncultured compared with the cultured cells. The low level in uncultured cells of some
of these enzymes, such as /S-galactosidase, a-galactosidase and a-arabinosidase, would
make it very difficult to assert that an absence of enzyme in this material was due
to a possible inborn error of metabolism. The need for great caution in the use of
uncultured amniotic fluid cells for antenatal diagnosis is clearly demonstrated by
sample 1. In this sample, the levels of a-glucosidase and a-arabinosidase were very
low in the uncultured cells, but were normal in the corresponding cultured cells.
DISCUSSION
Nadler7 suggested that the activity of glucose-6-phosphate dehydrogenase in
cultured amniotic fluid cells may show a correlation with gestational age and remarked
that there was no such correlation for acid phosphatase, /^-glucuronidase and a-gluco¬
sidase. Indeed, in the present study, this latter group of enzymes, together with the
other lysosomal enzymes assayed, did not show a correlation with gestational age.
A similar lack of correlation for some lysosomal enzymes has been reported in uncul¬
tured amniotic fluid cells8.
The results presented here form part of an investigation of factors affecting
the levels of lysosomal enzyme activity in cultured amniotic fluid cells. The third
passage was the earliest at which it was possible to obtain sufficient cells for the
enzyme assays and still maintain all of the cell strains. The enzyme levels in the third
passage can, however, be taken as representative of at least the first five passages9.
The use of cells from the third passage results in some delay after amniocentesis before
the enzymes can be estimated. This delay varied from 4-10 weeks, although 75%
of the cell strains could be assayed before 6 weeks. This time-lapse could be a problem
in relation to antenatal diagnosis. However, even by using the first passage a maxi¬
mum of only 2 weeks could be saved.
The relative merits of uncultured and cultured amniotic fluid cells for the bio¬
chemical studies involved in antenatal diagnosis of inborn errors of metabolism are
not yet resolved. The assay of uncultured cells, if feasible, would avoid the uncer¬
tainty of culture and permit early diagnosis10. Indeed Tay-Sachs' disease11 and
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Pompe's disease12 have been diagnosed in utero. However, the reliability of using un¬
cultured cells for diagnosing these diseases has been seriously questioned13-15. Nadler
and Gerbie2 have emphasised the need for great caution in the direct assay of uncul¬
tured amniotic fluid cells due to the possibility of maternal blood cell contamination,
enzyme instability and inadequate numbers of viable cells. They suggested that the
enzyme of interest should be related to another control enzyme in order to minimise
any such problems. However, our results indicate that this could be hazardous as it is
possible for uncultured cells to have some enzymes virtually absent and others nor¬
mal, whilst the corresponding cultured cells have all their enzyme activities in the
control range. In contrast, no enzyme level in cultured cells from the whole series of
normal amniotic fluid samples was low enough to suggest that a particular enzyme
was absent. However, the suggestion of Nadler and Gerbie2 should be applied when
using cultured amniotic fluid cells for antenatal diagnosis of inborn errors of metabolism
involving lysosomal enzymes in order to check that the culture and assay conditions
have not produced uniformly low enzyme levels.
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SUMMARY
A number of factors which may correlate with the
levels of a-glucosidase and S-glucosidase in cultured
amniotic fluid cells have been investigated. Fluct¬
uations in enzyme activity occurred as passage numbers
increased. Whereas a-glucosidase showed a consistent¬
ly lower activity in the earlier passages compared to
the later ones, the results for G-glucosidase were
equivocal. Both enzymes showed an increase in activity
correlated with the time taken by the cells to reach
confluency in the third passage. When replicate
cultures were assayed daily after subculture, neither
enzyme showed any change correlated with time. When
cultures were grown in parallel in Ham's F10 and
Eagle's M.E.M. tissue culture media, the activity of
both enzymes was unaffected. Cell strains cultured
from serial samples of amniotic fluid from the same
woman had differing enzyme levels unrelated to gestat¬
ional age.
A number of diseases have been shown to be due to a defic¬
iency in the activity of a lysosomal enzyme (1,2,3,4). These
enzymes are normally present in cultured amniotic fluid cells
(5,6,7) and it has been found that an enzyme deficiency in the
foetus is reflected in these cells (8,9,10). Although studies
have been undertaken on the fluctuations in the activity of
lysosomal enzymes in cultured fibroblasts (11-18), very little
attention (11,19) has been paid to the variations in lysosomal
enzymes in cultured amniotic fluid cells. With the rapidly
expanding demand for antenatal diagnosis of inborn errors of
lysosomal enzyme metabolism, a greater knowledge of the variations
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in the levels of these enzymes in cultured amniotic fluid cells
is necessary. Hence an investigation of some of the conditions
of cell culture that may affect the levels of a-glucosidase and
13-glucosidase was undertaken.
METHODS
Amniotic fluid samples were obtained from hysterotomy
specimens and by amniocentesis on Rhesus iso-immunised women
who had no history of inborn errors of metabolism involving lyso¬
somal enzymes. Primary cell cultures were set up (20) then
subcultured, harvested, homogenized (7), and the lysosomal enzymes
assayed using 4-methylumbelliferone conjugates (7,21).
The reproducibility of the combined culture and enzyme assay
techniques was tested by establishing twelve replicate cultures
of one cell strain at two different passages. The twelve repli¬
cates were harvested when they had simultaneously reached con-
fluency and then assayed for enzyme activity. To study enzyme
activity with respect to passage, six cell strains were subcultur¬
ed for up to fifteen passages and the enzyme levels assayed at
intervals. All the cell strains were assayed at the third
passage and the time interval between subculture and harvest
(confluency) noted. The variation in enzyme level within a
passage was followed by establishing a series of replicate cul¬
tures which were harvested for enzyme assay at daily intervals
for up to seven days. The effect of culture medium on enzyme
activity was followed by performing enzyme assays on six cell
strains cultured in parallel for three passages in Ham's F10
and Eagle's M.E.M. tissue culture media (supplemented with 30%
foetal calf serum).
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RESULTS
The reproducibility of the combined culture and assay system
for each enzyme is presented in Table I. The variation of the
total experimental procedure (coefficient of variance) was less
than 10% for both enzymes. The variation in the levels of the
enzymes with passage is given for six cell strains in Figs. 1
and 2. The coefficient of variance of the mean enzyme levels
TABLE I
Reproducibility of Culture and Assay System
Enzyme Mean* Standard Coefficient
Deviation of Variance (%)
a-GLUCOSIDASE 0.41a 0.035 8.5
0.81b 0.027 3.3
8-GLUCOSIDASE 0.154a 0.012 7.8
0.053b 0.005 9.3
* Enzyme activity in nmoles 4-methylumbelliferone/
min./mg. protein for twelve replicates,
a - Assay tenth passage; b - Assay twentieth
passage.
for the different cell strains was 8.9 - 42.6% for a-glucosidase
and 32.9 - 65.0% for 8-glucosidase. These values are much
greater than for the experimental procedure and indicate that
there are changes occurring in the enzyme levels in any one cell
strain as culture progresses.
Marked variations in the levels of both enzymes occurred
with passage. In the case of a-glucosidase there was a rise in
activity as culture progressed. This was shown by the lower
activity (P < 0.005) of this enzyme in the first five passages










The activity of a-glucosidase in serial passages
of six strains of cultured amniotic fluid cells.
compared with the next ten. In addition the mean activity in the
third passage was lower (P < 0.01) than that in the tenth passage
of ten strains studied. For 6-glucosidase cell strains 1 and 6
showed a positive correlation (P < 0.05) and strains 3,4 and 5 a
similar negative one with passage number. Although the levels of
this enzyme were also lower in the first five passages (P < 0.05)
than in the next ten, the comparison of activities at the third
and tenth passages showed no difference.
The relationship of the enzyme activity in cell strains
at the third passage to the time at which confluency (harvest) was
reached is given in Fig. 3. Both a-glucosidase (r = 0.48) and
B-glucosidase (r = 0.63) showed a significant positive correlation
with this factor. The correlation was still significant even if
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FIG. 2
The activity of G-glucosidase in serial passages











TIME TO HARVEST (0AVSI
B-GLUCOSIDASE
2 A 6 8
TIME TO HARVESTI0AVSI
FIG. 3
Relationship of the activity of a-glucosidase
and B-glucosidase in cultured amniotic fluid
cells with time to reach confluency (harvest).
All days Without 9-12 days.
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the few cell strains requiring 10-12 days to reach confluency were
not considered.
The fluctuations in the levels of the two enzymes were not
related to the time after subculture and no consistent change was
associated with the point at which confluency was reached (Fig. 4).
TIME AFTER SUBCULTURE TIME AFTER SUBCULTURE
IDAVSI |DiYS|
FIG. 4
The activity of a-glucosidase and (3-glucosidase
in six strains of amniotic fluid cells in
relation to time since subculture.
t Confluency; Strain 1 not confluent by 7 days.
Analysis of variance of the mean enzyme levels over three
passages for each cell strain in the two culture media was perform¬
ed. No significant difference was found for either cc-glucosidase
(F = 2.1, FQ Q5 (1,5) = 6.61) or 13-glucosidase (F = 1.0).
Cell strains were grown from serial samples of amniotic fluid
obtained from several Rhesus iso-immunised women and the levels of
the enzymes, at the third passage, are given in Table II. The
activity of the two enzymes showed considerable variability within
each series, but this did not seem to be related to the gestation¬
al age.
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TABLE II
Enzyme Levels* in Cell Strains at the Third Passage
Cultured from Serial Samples of Amniotic Fluid




18 0. 30 0.059
22 0. 47 0.057
1 24 o CO CO 0.048
33 0. 58 0.081
35 0. 24 0.025
23 o CO 00 0.064
2 26 0. 44 0. 072
28 0.20 0. 069
3
22 0. 57 0. 167
26 0. 67 0. 117
4
27 COCDO 0.050
34 0. 31 0.049
* Enzyme activity - nmoles 4-Methylumbelliferone/
min./mg. protein.
DISCUSSION
Several studies have been undertaken of the influence of
culture conditions on the levels of lysosomal enzymes in fibro-
blast-like cells (11-18). However, very little work of this
nature has been reported using cultured amniotic fluid cells (11).
This may well be due to the supposed difficulty in obtaining cell
strains from amniotic fluid (22,23). However, in our laboratory
it has been possible to culture the majority of the amniotic fluid
cell strains to the tenth passage with some still growing well at
the twentieth (24).
The fluctuations observed in the levels of the two enzymes
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studied with passage has not been previously reported for
amniotic fluid cells, although it has been noted for fibroblasts
(25). The increase in the level of a-glucosidase with passage
observed in this study probably reflects the decrease in the
ratio of the epithelioid to fibroblast-like cells which occurs
with time in culture (22). The situation with regard to
B-glucosidase is equivocal. Since the activity of B-glucosidase,
unlike a-glucosidase, can show opposite trends in different cell
strains, it seems very unlikely that these trends can be related
to changes in cell type. This interpretation is supported by
the data of Gerbie et ad.. (19) on the activity of these two
enzymes in epithelioid and fibroblast-like cultured amniotic
fluid cells.
The positive correlation between the levels of both enzymes
and time to harvest (confluency) is an unexpected result and may
reflect the proportion of dividing to resting cells in cultures
growing at different rates. The lack of any relationship between
the enzyme activities and time after subculture is perhaps not
surprising as such a relationship has only been demonstrated using
homogeneous cell populations (13,16,17,18).
A significantly lower level of 13-glucosidase has been found
in fibroblasts grown in Ham's F10 compared with Eagle's M.E.M.
(11,17). Beutler et ad.. (11) claimed that this enzyme was also
lower in activity in amniotic fluid cells grown in an enriched
medium. In the present study, however, the high concentration
of serum supplement used may have tended to obscure any real
difference in enzyme activity attributable to the chemically
defined components of the medium.
There has been no previous report on the levels of lysosomal
enzymes in cells cultured from amniotic fluid obtained from the
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same women at different stages of pregnancy. The apparent lack
of a correlation of enzyme activity with the gestational age of
the amniotic fluid agrees with results obtained using samples from
different women (7).
The marked variations due to conditions of culture which
occur in the levels of a-glucosidase and 8-glucosidase do not pre¬
clude the antenatal diagnosis of Pompe's or Gaucher's disease, but
they would render the detection of heterozygotes very difficult.
A complete understanding of the causes of these variations will
require further investigation.
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Antenatal Diagnosis of Inborn Errors of Metabolism:
Tissue Culture Aspects
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Summary. The cells from 62 amniotic fluids have been cultured to the stage at which
biochemical studies could have been undertaken. Although all cultures showed initial signs
of cellular proliferation in only 90% of these were sufficient cells obtained for biochemical
assay. If a time limit of 6 weeks was to be imposed, only 58% of the cultures could have been
regarded as successful. The problems involved in culturing amniotic fluid cells for the antenatal
diagnosis of inborn errors of metabolism are discussed.
Zusammenfassung. Yon 62 Amnionfliissigkeits-Proben wurden die Zellen bis zu einem
Stadium kultiviert, in dem biochemische Untersuchungen moglich wurden. Obwohl alle Kul-
turen anfiinglich Zeichen einer Zellproliferation zeigten, wurden nur in 90% geniigend Zellen
fur biochemische Untersuchungen gewonnen. Unter Annahme einer Zeitbegrenzung von
6 Wochen konnten sogar nur 58% aller Kulturen als erfolgreich betrachtet werden. Die Pro-
bleme bei der Kultivierung von Amnionzellen fiir die pranatale Diagnose angeborener Stoff-
wechselstdrungen werden diskutiert.
Cultured amniotic fluid cells are almost always required when the antenatal
diagnosis of an inborn error of metabolism is to be made. Except where histo-
chemical techniques are available, this usually means many more cells are required
than for cytogenetic studies. Gerbie et al. (1971) successfully karyotyped 95% of
250 amniotic fluids and other groups have reported similar high success rates.
Little comparable data exists for success in culturing amniotic fluid cells to the
stage where biochemical assays are possible. The time is usually limited to between
6 and 8 weeks for the culture of sufficient cells if a pregnancy may be terminated
on the result. Hence it is valuable to report the experience in culturing cells from
all the amniotic fluids received in this laboratory over a 1-year period.
31aterials and Methods
Amniotic fluids were obtained from hysterotomy specimens and by amniocentesis of
Rhesus iso-immunised women. The 62 amniotic fluids were taken from 47 women. When more
than one sample was collected from any woman it was always from the same pregnancy.
Thi3 study includes all such amniotic fluids received in this laboratory over the year ending
November 1972.
The methods used for primary culture have been previously described (Sutherland et al.,
1973). The primary culture vessel was a 50 mm Nunclon plastic petri dish which'contained
four or five 6 X 22 mm glass coverslips. In the majority of cases one or two of these coverslips
were removed from the culture for cytogenetic studies (Sutherland et al., 1973). The primary
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cultures were subcultured according to Butterworth et al. (1973) into a glass culture bottle
with a growth surface area of 20 cm2. On reaching confluency the cell strains were further
subcultured into a glass culture bottle with a growth surface area of 40 cm2. When the cell
strains reached confluency after this second subculture the time since the amniotic fluid had
been collected was noted and this was regarded as the time required to produce enough
cells for a biochemical assay. Cell homogenates prepared from this quantity of cells contain
%—1 mg of protein and are adequate for a number of biochemical assays (Butterworth et al.,
1973).
Results
The results are summarized in Table 1 and Fig. 1. There were 62 amniotic
fluids, 21 from hysterotomy specimens and 41 from Rhesus iso-immunised women.
All cultures showed cell proliferation as observed under the inverted microscope.
Table 1. Data on the origin and cultural behaviour of the amniotic fluids in this series
Origin No. Gestational ages No. of Time to biochemical




Rhesus 41 28.0 18—36 3 42.4 25—74
Hysterotomy 21 16.8 12—23 3 39.5 29—63 '




0 0 O [o]
• - Hysterotomy specimen





1 I I I I I I I I I I I I I I I I I I I I I I I I
11 12 14 16 18 20 22 24 26 28 30 32 34 36
GESTATION {WEEKS)
Fig. 1. Distribution of times taken to achieve sufficient cells for biochemical study
Antenatal Diagnosis of Inborn Errors of Metabolism 253
Table 2. Times required for biochemical and cytogenetic results from serial samples of amniotic
fluid collected from three pregnancies
Preg¬ Gesta¬ Time to bio¬ Time to cyto¬
nancy tion chemical result genetic result
(days) (days)
1 23 42 N
26 36 N
28 25 12
2 24 44 N
30 43 18
32 64 14





a This cell strain degenerated after the third subculture.
N = Cytogenetic preparations not made in the minimum time.
There were two cytogenetic failures due to degeneration of the primary culture
before a chromosome result could be obtained. Four other cultures were successful
cytogenetically but failed from the biochemical point of view, one degenerated
in primary culture after a chromosome result had been obtained, two were lost
to microbial contamination after the first subculture and one degenerated after
the first subculture. Hence, if there was no limit on the time taken to produce
enough cells for biochemical assay, the success rate was 56 out of 62. If a time
limit of 8 weeks was to be imposed then the success rate would fall to 49 out of
62 and if the time limit was to be reduced to 6 weeks then the success rate would
fall to 36 out of 62 or 58%.
There is no correlation between gestational age and time to a biochemical
result, either for the whole series or within the Rhesus or hysterotomy groups.
Similarly, the mean time to such a result for specimens of less than 20 weeks
gestation is not different from the time required by those of 20 weeks or more.
All except 11 primary cultures had at least one coverslip harvested for cyto¬
genetic studies. It might be expected that removal of some of the earliest pro¬
liferating cells would increase the time required for biochemical success. This was
not so as the time to result was not significantly different for the two groups.
The collection of serial samples of fluid from women with Rhesus iso-immuni-
sation problems affords the opportunity of studying the behaviour of these serial
samples in tissue culture. Three women contributed three or more samples and
data on these are shown in Table 2. The times taken to reach a biochemical result
within each series are no more related to each other than to the series as a whole.
Although there appears to be some relationship between the times taken to achieve
cytogenetic and biochemical results, a quick cytogenetic result does not neces¬
sarily mean that a quick biochemical result will follow.
251 G. R. Sutherland and A. D. Bain
Discussion
Commenting on tissue culture aspects of antenatal diagnosis, Brock (1973) has
said "... that success to the biochemist is more elusive than success to the cyto-
geneticist". The main problem is one of time. Only 4 out of 62 amniotic fluids
failed to reach a biochemical result because of their inability to proliferate suf¬
ficiently. Two were lost to microbial contamination; this should not happen
and highlights the need for meticulous technique. In practice, if more than
6 to 8 weeks were required to produce enough cells any antenatal diagnosis for
the purpose of terminating affected pregnancies would have to be regarded as a
failure.
There is little data in the literature on this problem. Most authors discussing
amniotic fluid cell culture have claimed the successful repeated subculture of
primary cultures but the proportion in which this is achieved is usually not stated.
The ability of these cells to proliferate sufficiently has been questioned by Little-
field (1971). Nadler and Gerbie (1970) were only able to subculture 75% of 155
successfully cultivated amniotic fluid cell strains more than three times. The most
useful study in this regard is that reported by Uhlendorf (1970) who managed
to achieve "massive cultures" from 77% of 114 amniotic fluid samples. 4—11
weeks were required to produce two 32 oz. prescription bottle monolayers, several
subcultures being necessary. The time range was very similar to that in the present
study although a higher number of cells were taken as the end point. In many
cases "fairly large amounts" of amniotic fluid were used to initiate cultures
whereas in the present series the volumes of fluid used were always less than
20 ml and often less than 10 ml.
The results from the serial samples taken during individual pregnancies indicate
that each sample of fluid can behave differently. If as Uhlendorf (1970) has stated,
there are less than 10 colony forming cells per millilitre of amniotic fluid, fluc¬
tuations in the number in any given sample of, say, 5 ml could be considerable. It
is perhaps significant that although the cellular content of amniotic fluid increases
throughout pregnancy (Nelson and Emery, 1970) the time required for a bio¬
chemical result is not related to gestation.
One problem not apparent in antenatal cytogenetic diagnosis is the degener¬
ation of primary cultures. If an amniotic fluid culture for cytogenetic purposes
is not proliferating after 7 to 10 days, amniocentesis can usually be repeated and
another sample of fluid cultured. Most reported series of cytogenetic antenatal
assessments contain a proportion of such instances. If, however, the primary
culture grows well initially and then degenerates, it is usually too late to repeat
amniocentesis and start again. A similar situation arises if degeneration takes
place after the first or second subculture. A means of overcoming this problem,
and of producing a quicker result in all cases, may be in the application of histo-
chemical techniques. Uhlendorf (1970) described the use of histochemistry for
the antenatal diagnosis of GM1 -gangliosidosis by staining cells for /3-galactosidase
activity. Hill and Puck (1973) have devised an autoradiographic method for the
detection of galactosaemia which utilizes less than 1000 cultured cells. Such
techniques could be carried out on primary cultures and perhaps produce a bio¬
chemical result in the same time as required for a cytogenetic result.
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Xacller and Gerbie (1970) have stated . . the major limiting factor appears
to be the difficulty in obtaining an adequate number of cells for biochemical
analysis". Unless this problem can be overcome the chances of success in this type
of antenatal diagnosis will remain low enough to give doubts as to its clinical
application. Unless the techniques for the culture of amniotic fluid cells can be
improved then efforts should be made towards developing histochemical tech¬
niques and micro assay methods for the enzymes involved in inborn errors of
metabolism.
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The antenatal diagnosis of trisomy 18
George Gordon, Grant R. Sutherland, Rhona Bauld, and A. Douglas Bain
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The antenatal diagnosis of a fetus with trisomy 18 in a 41-year-old woman is reported. The
pregnancy was terminated and the diagnosis confirmed cytogenetically and morphologically. The
pathological findings in the fetus arc discussed.
Received 23 July, accepted for publication 18 August 1973
The antenatal screening of mothers of ad¬
vanced age for fetal chromosome abnormal¬
ities has been advocated by a number of
authors. Although the main reason for this
screening is the prevention of Down's syn¬
drome (e.g., Stein et al. 1973), other chro¬
mosome abnormalities will inevitably be
detected. We wish to report the antenatal
diagnosis of a fetus with trisomy 18 in a
41-year-old mother and the subsequent
pathological findings in the abortus.
Case Report
Pregnancy History
The pregnancy was the fifth pregnancy of
a 41-year-old woman but the first with her
second husband. In her first marriage two
uncomplicated pregnancies were followed
by two spontaneous abortions at 9 and 13
weeks.
She was first seen at 12 weeks of preg¬
nancy when she expressed anxiety about the
possibility of having a mongol child be¬
cause of her age. In view of this anxiety
amniocentesis was performed at 16 weeks'
gestation when 8 ml of amniotic fluid was
withdrawn. This fluid was unsatisfactory in
culture (see below); consequently the amnio¬
centesis was repeated at 19 weeks' gestation
when 15 ml of fluid was withdrawn. At this
time the uterus was found to be smaller
than expected for the gestation. Negative
ICleihauer counts were obtained after each
amniocentesis and the fetal heart, monitored
by Sonicaid, was unaffected. From this
second sample of amniotic fluid the fetus
was shown to have trisomy 18. Lower seg¬
ment hysterotomy through a small Pfannen-
stiel incision was performed at 23 completed
weeks of gestation and the conceptus re¬
moved intact. At this time the uterus was
again noted to be small, as was the placenta.
Post-operative recovery was uneventful. The
moiher is contemplating another pregnancy
on the understanding that amniocentesis
will again be performed.
Cytogenetic Findings
The first amniotic fluid sample contained
very few cells and showed poor growth in
culture. After 2 weeks there were only a few
This work was supported in part by the Scottish Advisory Committee on Medical Research and
the Secretary of State for Scotland.
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scattered proliferating ceils, growing too
slowly for chromosome studies. The cells
obtained from the second sample did grow
and after 20 days in culture a fetal karyo¬
type of 47,XX, + 18 was established.
The pregnancy was terminated by hys¬
terotomy and cultures from fetal heart
blood, skin and fascia all confirmed the
antenatal diagnosis of trisomy 18 (see Table
1).
Pathological Findings
The fetus (Fig. 1) had a crown-rump length
of 18.5 cm and a crown-heel length of 27
cm. There were multiple external abnor¬
malities. The ears were low set with under¬
developed helices which were adherent to
the scalp. There was a small preauricular
skin tag on the right, and two subcutaneous
nodules in the left preauricular area. There
was micrognathia but no cleft lip and the
palate appeared normal. Both hands showed
flexion deformities of the fingers and the
palmar creases were atypical. Both feet had
a rocker-bottom appearance and the first
toes were shorter than the second. There
was only a single umbilical artery.
Internally there also were multiple mal¬
formations. There was complete esophageal
atresia with a tracheo-esophageal fistula.
The heart showed a high interventricular
septal defect. There was a complete horse¬
shoe kidney. A Meckel's diverticulum was




Fig. 1. The fetus at necropsy. Note low set ears,
micrognathia, flexion deformities of the fingers and
the horse-shoe kidney.
at its tip; histologically this proved to be
pancreatic tissue without islet cells. The only
abnormality of the brain was an anterior






Fetus amniotic fluid 9 47,XX,+18
heart blood 30 47,XX,+18
fibroblasts (a) skin 15 47,XX,+18
(b) fascia 15 47,XX,+ 18
Mother blood 30 46,XX
Father blood 30 46,XY
Discussion
The case illustrates two main points. The
first is the value of antenatal diagnosis of
fetal abnormality when this can be followed
by abortion. The second is that chromosome
abnormalities other than mongolism will be
encountered when fetal karyotyping is per¬
formed on women of advanced age (Suther¬
land 1972). The prevention of children with
these other chromosome abnormalities is an
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added benefit in any attempt to reduce the
incidence of Down's syndrome (Stein et al.
1973).
The amniocenteses were apparently with¬
out any ill effect. There were no maternal
complications, the sac was intact at hys¬
terotomy and the fetus showed no evidence
of injury.
There are only two previously reported
instances of the antenatal diagnosis of tri¬
somy 18. The first, diagnosed at 31 weeks'
gestation, proceeded to term and resulted in
a stillbirth with the features of Edwards'
syndrome (Milunsky et al. 1972). The sec¬
ond (Hsu et al. 1973) was a case similar to
the present one, diagnosed in a 40-year-old
woman and aborted at 20 weeks' gestation.
The pathological findings in the fetus are
typical of those seen in neonates and older
children with this syndrome (Taylor 1968).
It is of interest that this fetus and the one
described by Hsu et al. (1973) both had a
Meckel's diverticulum with a small nodule
at its tip. In the present case this proved to
be heterotopic pancreatic tissue. One of the
cases described by Taylor (1968) also had
heterotopic pancreatic tissue but apparently
not in association with a diverticulum.
The fetus had a crown-rump length which
corresponded to only 20 weeks' gestation
and the placenta was small. The finding of
a small placenta in this syndrome has been
recorded by Hecht (1963) and by Hsu et al.
(1973). The study of fetuses such as this
may help to determine the time of onset of
the retardation in growth and development
usually associated with chromosome abnor¬
mality.
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Summary
Fifteen primary amniotic fluid cultures were established from a single
sample of amniotic fluid. Three different methods were used to set up these
cultures which yielded 13 cell strains. Nine lysosomal enzymes (acid phospha¬
tase, ^-glucuronidase, (3-galactosidase, a-galactosidase, a-glucosidase, a-man-
nosidase, a-arabinosidase, V-acetyl-(3-D-glucosaminidase and arylsulphatase A)
were assayed in these 13 cell strains. The coefficients of variation of these
enzyme levels were less than the coefficients for enzyme levels in cell strains
grown from different samples of amniotic fluid but greater than those for the
combined culture and assay system used. No assay values were found which
could have suggested a possible enzyme deficiency disease.
Introduction
Lysosomal enzymes are involved in a number of inborn errors of metabo¬
lism, many of which can now be diagnosed antenatally [1]. The activities of
these enzymes fluctuate in amniotic fluid cell strains [2—4] and fibroblast-like
cell strains [5,6] assayed at different stages of culture. Multiple fibroblast-like
cell strains grown from a single skin biopsy have been shown to have consider¬
able variation in the activity of five lysosomal enzymes [7]. This variation was
so great as to suggest that a lysosomal enzyme deficiency disease might have
been wrongly diagnosed. The possibility that a similar situation may exist for
cell strains cultured from a single sample of amniotic fluid has been investi¬
gated.
Materials and Methods
Amniotic fluid was collected from a pregnancy of 18 weeks gestation,
terminated because of severe maternal pre-eclamptic toxaemia. The fluid was
divided into 15 aliquots of 5 ml and one primary culture was established from
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each aliquot. Three different methods were used to establish the primary cul¬
tures:
(I) Five cultures were set up using the method of Gray et al. [8], The
amniotic fluid was added to the culture vessel and left for one week. At this
time half the amniotic fluid was replaced by culture medium and thereafter
half the medium changed three times per week.
(II) Five cultures were set up [9] by centrifuging the amniotic fluid at
200 X g for 10 min, the cell pellet was resuspended in culture medium and
added to the culture vessel. After one week half the culture medium was
replaced three times per week.
(III) Five cultures were set up as in method II except that half the me¬
dium was changed after 24 h and thereafter three times per week.
In all cases the culture vessel was a 50 mm plastic Nunclon Petri dish and
the culture medium was Ham's F10 with 30% fetal calf serum supplement and
antibiotics [9]. The cultures were subcultured and maintained as previously
described [10]. After subculture of the primary culture the fetal calf serum
supplement in the culture medium was reduced to 15%. Enzyme assays were
carried out on each cell strain at the third and sixth passage. Cells were har¬
vested for enzyme assay on the day they reached confluency.
The cells were washed twice with phosphate-buffered saline, scraped off
the glass into 4 ml of water, sonicated for 30 s at maximum power using a
"Soniprobe" (Dawes Instruments), centrifuged at 800 X g for 10 min at 5° and
stored at —65°. Protein levels were estimated [11] using bovine serum albumin
as standard. Arylsulphatase A was assayed [12] using p-nitrocatechol sulphate
as the substrate. For all the other enzymes 4-methylumbelliferone conjugates
were utilized [10] under the following conditions:
Acid phosphatase — 1 mM conjugate, 0.1 M acetate buffer pH 5.0,
30 min incubation.
j3-Glucuronidase — 1 mM, 0.1 M acetate buffer pH 4.0, 60 min.
(i-Galactosidase — 1 mM, 0.2 M phospho-citrate buffer pH 4.0 +
100 mM NaCl, 60 min.
a-Galactosidase — 2 mM, 0.1 M acetate buffer pH 4.8, 60 min.
a-Glucosidase — 2 mM, 0.2 M phospho-citrate buffer pH 4.5, 60 min.
a-Mannosidase — 2 mM, 0.1 M acetate buffer pH 4.0, 60 min.
a-Arabinosidase — 1 mM, 0.2 M phospho-citrate buffer pH 4.5, 60 min.
A-Acetyl-j3-D —- 2 mM, 0.2 M phospho-citrate buffer pH 4.5, 30 min.
glucosaminidase
Results
Cultures established by Method I were very slow growing, one degenerated
in primary culture and could not be subcultured and another did not survive
after the first subculture. Hence there were 13 cell strains available for enzyme
assay. Details of times in culture for the three methods of establishing cultures
are given in Table I. Comparison of these times shows that Method I was
significantly worse than Methods II and III which did not differ. On the basis
of behaviour in culture the cell strains were divided into one group of 10 and
another group of 3 derived from the cultures setup using Method I.
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TABLE I
TIMES IN CULTURE FOR THE 3 METHODS OF ESTABLISHING CULTURES
Behaviour of the 15 amniotic fluid cultures (a—o) with time in primary culture and time from the first


















c 38 46 60
d 36 53 78
e 36 51 82
II f 25 37 51
g 28 39 58
h 25 39 58
i 22 37 53
j 22 37 51
III k 22 39 56
1 23 37 58
m 22 39 60
n 22 39 58
o 22 37 58
*
Cell strain died in the first passage.
**
Primary culture degenerated and could not be subcultured.
The assay values of the nine lysosomal enzymes measured at the third and
sixth passages are shown in Table II. To compare the variations in enzyme level
in the two passages and to establish their relationship with the variations found
in a series of amniotic fluid cell strains cultured from different samples of
amniotic fluid [10], the coefficients of variation were calculated and are shown
in Table III. For this calculation the values for the three cell strains derived
from primary cultures established using Method I were excluded because of
their different behaviour in tissue culture. The coefficients of variation of the
combined assay and culture system, determined by assays on replicate cultures
as previously described [2], are also included in Table III.
The coefficients of variation for each enzyme in the third and sixth pas¬
sages are similar in magnitude for all enzymes except a-mannosidase and a-
arabinosidase. The coefficients for all the enzyme levels in the third and sixth
passages are smaller than those found for the control series of cell strains
cultured from different samples of amniotic fluid and greater than those for the
combined culture and assay system.
Discussion
Cultured amniotic fluid cells are the most reliable material for enzyme
assay on which antenatal diagnoses of inborn errors of lysosomal enzyme me¬
tabolism are to be based [1,13,14]. It is thus essential that the two principle
techniques involved in such diagnoses, tissue culture and enzyme assay, must
combine to produce reliable and reproducible results. The establishment of a
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number of primary cultures from a single large sample of amniotic fluid and
enzyme assay on the cell strains subsequently produced allows both laboratory
procedures to be tested simultaneously.
Much of the delay in achieving sufficient cells for a biochemical assay is
taken up by the time in primary culture. Hence three methods of primary
culture were tested. The first method used has been claimed to produce such
rapid growth of primary cultures that sufficient cells for cytogenetic studies
could be obtained in an average of seven days [8]. No other published method
of primary culture has reported such rapid cell growth. The second method
used has been employed to study the delay due to tissue culture in the antena¬
tal diagnosis of inborn errors of metabolism [15]. The third method involved a
modification of the culture maintenance schedule of the second, similar to that
of other published methods [16,17]. The results show that the first method
was inferior to the other two for this sample of amniotic fluid. In addition, the
variation in the enzyme levels in the three cell strains eventually derived from
the primary cultures set up using the first method was greater than that seen in
the 10 strains derived from the other primary cultures.
There are two main features of this variation in enzyme levels in a series of
cell strains derived from one sample of amniotic fluid. The first is that this
variation is considerably less than that found in a series of cell strains derived
from different amniotic fluid samples. There are several reasons for this other
than the common origin of the cell strains; they were all in tissue culture at the
same time, receiving the same batch of culture medium and fetal calf serum and
all the enzymes were assayed at the same time. In spite of these constant
conditions of tissue culture and enzyme assay the highest value of some en¬
zymes was more than twice the lowest. Such variation would cast doubt upon
heterozygote identification based on enzyme assay of a single sample of cul¬
tured cells. Some cell strains even retained widely different enzyme levels in
both passages as, for example, the a-glucosidase level in strain n which was
approximately twice that in strain o in both passages assayed. If the cell strains
derived from cultures established by method I are considered then this varia¬
tion is even more marked. Strain d had /3-galactosidase and arylsulphatase A
levels which were much greater than in the other cell strains although the rest
of the enzymes in this culture were within the range for the other cell strains.
The second main feature of the results is their relationship to the only
comparable study [7], in which cultured fibroblast-like cells were used. Great
variations were found in the levels of several lysosomal enzymes in multiple
fibroblast-like cell strains grown from a single human foreskin. For /3-galac-
tosidase, there was more than a 3-fold difference between the highest and
lowest values whereas in the present study this difference was relatively small.
The two series agree on the finding for AI-acetyl-jS-D -glucosaminidase which
showed little variation and for /3-glucuronidase in which there was a 2.5-fold
difference between the highest and lowest assay values. The results of the
present study for arylsulphatase A are not comparable with those quoted by
Milunsky et al. [7] as their substrate and experimental conditions were not
specific for arylsulphatase A [18,19].
The results of this study on cell strains derived from one sample of am¬
niotic fluid are in agreement with previous findings [10] on cell strains derived
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from different amniotic fluids. Enzyme assay of normal amniotic fluid cell
strains should not produce values suggestive of an enzyme deficiency disease.
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Lysosomal enzymes of amniotic fluid in relation
to gestational age
J. BUTTERWORTH, M.Sc., Ph.D.
D. M. BROADHEAD, B.Sc..
G. R. SUTHERLAND, M.Sc.
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Edinburgh, Scotland
The activities of ten lysosomal enzymes were assayed in more than 100 amniotic
fluids. Wide variations in enzyme activity were found at any particular
gestational age. However, various patterns of enzyme activity were apparent in
relation to gestational age. Three enzymes, /3-glucosidase, a-glucosidase, and
a-arabinosidase, showed high initial values, falling rapidly to a very low level after
20 weeks' gestation. The enzymes f3-glucuronidase and a-mannosidase showed a peak
of activity at about 26 weeks, and N-acetyl-P-D-glucosaminidase and a-fucosidase had
higher values at midgestation, declining toward term. Acid phosphatase exhibited no
obvious pattern. Higher values of a-galactosidase and fi-galactosidase were noted
near term, but at all times the levels of these two enzymes were minimal. The findings
are discussed in relation to possible sources of the enzymes and antenatal
diagnosis of inborn errors of metabolism.
Increasing attention has been focused
on the analysis of the constituents of amni¬
otic fluid as an indicator of the health of the
fetus.1"7 In order that any particular param¬
eter of amniotic fluid may be utilized in
this connection it is necessary to obtain the
normal range of values throughout gesta¬
tion."' An earlier report8 indicated that lyso¬
somal enzymes may show changes related to
gestational age and the results on a larger
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series of amniotic fluids are presented con¬
firming these trends.
Materials and methods
Samples of amniotic fluid were obtained
at different stages of pregnancy. For the
gestational range of 11 to 23 weeks amniotic
fluid samples were obtained by aspiration of
the intact amniotic sac following hysterotomy
(n = 19) performed for social reasons and
by transabdominal amniocentesis (n = 10)
when performed for antenatal chromosome
analysis. Between 21 and 37 weeks the sam¬
ples (n = 76) were obtained by trans¬
abdominal amniocentesis of rhesus isoim-
munized women. For 38 to 41 weeks, samples
were obtained at the induction of labor by
Drew-Smythe catheter. Cells and debris were
removed by centrifugation at 1,500 g for
five minutes at 5° C. and the fluids stored at
-70° C. The enzymes were assayed" with 4-
methylumbelliferone conjugates except for
a-fucosidase, where the p-nitrophenol glyco-
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Fig. 1. Activities of /3-galactosidase, /3-glucosidase, /3-glucuronidase, acid phosphatase, and
N-acetyl-/3-D-glucosaminidase in aminotic fluid.-*; Hysterotomy/antenatal diagnostic samples;
•
, rhesus up to 27 weeks; 38+ weeks term samples.
side was utilized. Protein was determined10
with bovine serum albumin as the standard.
Results
Although all 10 enzymes assayed could be
detected, the activities of /3-galactosidase, a-
galactosidase, and a-arabinosidase were very
low. The variations in the activity of the
lysosomal enzymes in amniotic fluid with
gestational age are presented in Figs. 1 and
2. The enzyme activities were expressed on a
volume basis as the protein concentration
Volume 119
Number 6
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Fig. 2. Activities of a-glucosidase, n>mannosidase, a-galactosidase, a-arabinosidase, and a-
fucosidase in amniotic fluid. Hysterotomy/antenatal diagnostic samples; •, rhesus up to
27 weeks; 38+ weeks term samples.
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Table I. Lysosomal enzyme activity* in serial samples of amniotic fluid from six rhesus isoimmunize
Gestational










18 0.16 5.39 18.2 7.6 0.020 0.33
22 0.20 7.48 23.5 3.7 0.013 0.29
24 0.18 6.13 26.0 2.0 0.003 0.36
33 0.08 3.05 21.8 3.6 0.011 0.34
35 0.08 2.71 21.1 4.1 0.011 0.33
20 0.14 4.09 15.5 3.9 0.027 0.44
23 0.14 4.56 13.1 2.0 0.003 0.46
26 0.08 5.49 21.4 2.5 0.005 0.73
29 0.06 4.31 14.5 2.1 0.010 0.39
18 0.08 4.00 10.3 3.5 0.023 0.45
25 0.17 7.53 14.9 3.5 0.003 0.77
31 0.08 7.67 22.2 5.4 0.027 0.97
19 0.12 4.67 8.00 4.4 0.013 0.47
30 0.07 4.31 12.3 3.2 0.023 0.78
33 0.05 3.83 9.7 2.5 0.012 0.77
23 0.16 5.18 15.6 4.9 0.009 0.47
26 0.28 7.81 20.7 2.8 0.009 0.46
28 0.50 8.51 24.7 3.7 0.009 0.50
24 0.20 6.29 12.5 4.2 0.023 0.42
30 0.11 2.99 6.9 3.4 0 0.44
32 0.11 3.18 7.7 3.2 0 0.43
*Nmole 4-methylumbelliferone/min./ml.; a-fucosidase. nmole p-nitrophenol/min./ml.
fOptical density difference at 450 nm,11
(Fig. 3) of amniotic fluid varied with gesta¬
tional age, showing a peak at about 26
weeks' gestation. The results obtained for the
enzymes in the serial samples of amniotic
fluid from a number of women are given in
Table I and show the same trends observed
in the large series from different women. A
comparison of the optical density differences
at 450 nm. for the rhesus isoimmunized am¬
niotic fluids and enzyme activity indicated
that they were apparently unrelated.
Although a wide variation in enzyme
activity was found at any particular gesta¬
tional age, various patterns of enzyme activ¬
ity were apparent (Table II). Three en¬
zymes, /3-glucosidase, a-glucosidase, and <*-
arabinosidase, showed a declining pattern of
activity, reaching a very low level by 20
weeks. When enzyme activity was expressed
on a protein basis, this pattern was still
clearly apparent (Fig. 3). Two enzymes, /?-
glucuronidase and a-mannosidase, showed a
peak of activity at about 26 weeks' gestation.
Acid phosphatase showed no pattern, al¬
though occasional high values were found
throughout gestation. N-acetyl-/3-D-gluco-
saminidase and a-fucosidase had higher
values at midterm and declined toward term,
although neither of these patterns was clear-
cut. For (8-galactosidase and a-galactosidase
higher values were found near term, but at
no time was the activity of these two enzymes
more than minimal.
Comment
Amniotic fluid provides a potential means
of investigating fetal development and pre¬
dicting fetal disease. It is clearly necessary
to obtain accurate information on the nor¬
mal level of any constituent in relation to
gestational age prior to its use in assessing
fetal health.12 A knowledge of variations in
lysosomal enzyme levels in amniotic fluid
could be of use for following both fetal de¬
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>men
3-Glucosidase a-Galactosidase a-Glucosidase a-Arabinosidase ce-Mannosidase a-Fucosidase
0.058 0.010 1.41 0.013 0.37 1.56
0.015 0.008 0.45 0 0.40 1.81
0.004 0.007 0.13 0 0.38 1.75
0.003 0 0.20 0 0.39 1.22
0.004 0 0.26 0 0.35 1.11
0.049 0.003 0.83 0.018 0.51 1.97
0.019 0 0.25 0.011 0.28 1.35
0.009 0 0.21 0.011 0.46 1.39
0.003 0 0.12 0.010 0.25 0.81
0.059 0.003 1.81 0.025 0.57 0.90
0.012 0 0.35 0.010 0.54 1.77
0.003 0 0.26 0.010 0.42 1.28
0.046 0.017 1.16 0.017 0.35 1.74
0.029 0.017 0.12 0.009 0.37 1.84
0.020 0.003 0.14 0.007 0.20 1.45
0.035 0.008 0.41 0.006 0.52 0.90
0.011 0.006 0.19 0 0.47 1.64
0.007 0.006 0.14 0 0.47 1.77
0.020 0.013 0.38 0.010 0.41 0.99
0.013 0 0.07 0.006 0.28 0.46
0.010 0 0.10 0.006 0.18 0.68
Table II. Enzyme-specific activity* in relation to gestational age
Gestational age (wk.)
Enzyme 11-15 16-20 21-25 26-30 31-35 36-41
/3-Glucosidase 0.066f 0.043 0.020 0.004 0.003 0.002
0.033J 0.024 0.015 0.003 0.002 0.001
a-Glucosidase 1.53 1.40 0.51 0.18 0.16 0.21
0.80 0.68 0.42 0.07 0.07 0.12
ff-Arabinosidase 0.024 0.018 0.008 0.008 0.006 0.005
0.012 0.011 0.003 0.003 0.004 0.004
a-Mannosidase 0.31 0.34 0.44 0.39 0.28 0.26
0.10 0.11 0.12 0.11 0.09 0.06
/3-Glueuronidase 0.25 0.38 0.57 0.63 0.44 0.35
0.15 0.23 0.27 0.24 0.21 0.13
N-acetyl-jS-D-glucosaminidase 9.94 11.85 16.54 16.01 13.70 12.25
5.17 4.43 5.66 6.16 6.42 3.69
a-Fucosidase 0.87 1.05 1.59 1.45 1.04 1.06
0.48 0.50 0.60 0.54 0.33 0.35
&'-Galactosidase 0.005 0.006 0.009 0.008 0.011 0.016
0.004 0.004 0.004 0.006 0.006 0.011
jd-Galactosidase 0.020 0.022 0.018 0.016 0.020 0.029
0.017 0.013 0.018 0.014 0.016 0.018
Acid phosphatase 2.84 3.94 4.62 3.75 4.63 4.84
1.92 2.61 2.97 2.29 2.75 2.38
Protein (mg./ml.) 2.85 3.99 6.75 5.38 3.53 2.81
1.26 1.42 1.96 2:07 1.31 0.82
*Nmole 4-methylumbelliferone/min./ml-; a-fucosidase, nmole p-nitrophenol/min./ml.
fMean.
JStandard deviation.
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Fig. 3. Protein levels and activities of /?-glucosidase and a-glucosidase on a protein basis in
amniotic fluid. Hysterotomy/antenatal diagnostic samples; •, rhesus up to 27 weeks:
38+ weeks term samples.
The present results together with previous
work8- 14 demonstrate that lysosomal en¬
zymes show patterns of activity related to
gestational age. The fall in activity of a-
glucosidase to a very low level by 20 weeks'
gestation has previously been reported.8' 13' 14
No clear pattern was found14 for N-acetyl-/?-
D-glucosaminidase. A similar lack of a rela¬
tionship was noted for acid phosphatase,15
although a rise near term has been demon¬
strated.14 Jonasson13 demonstrated that the
acid phosphatase level was similar in sam¬
ples of amniotic fluid from normal and
rhesus isoimmunized pregnancies, indicating
that the latter source of amniotic fluid could
be included in obtaining normal patterns of
activity. This would also seem to be the case
for the enzymes in the present study.
The average levels of /Tgalactosidase and
N-acetyl-/3-D-glucosaminidase found in the
present studies differ from those of Lowden
and associates.2 The average level of N-
acetyl-/?-D-glucosaminidase was about twice
as high as that found by Lowden and associ¬
ates.2 The average level of /J-galactosidase
was about ten times lower in the present
study and was effectively absent, a finding in
agreement with other reports.16' 17 It is also
Volume 119
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noticeable that the values for these enzymes
in cultured amniotic fluid cells given by
Lowden and associates2 are far in excess of
those found by other workers.3' 18' 19> 20
The dynamic state of amniotic fluid is
clearly shown by the differing patterns ob¬
tained for many constituents.1, 5' G> 21' 22' 23 It
is of interest that the total amniotic fluid
volume follows a pattern,24 reaching a peak
at about 34 weeks' gestation, to which
changes in constituents do not relate. The
causes, of the observed fluctuations in the
levels of the lysosomal enzymes in amniotic
fluid are unknown. It is noteworthy, how¬
ever, that many enzymes show a change in
their level of activity at about 20 weeks' ges¬
tation, a time when the fetal skin becomes
impermeable to water25 and fetal urine be¬
comes an important source of amniotic
fluid.20 The finding of a decrease in the
activity of the lysosomal enzymes of the
placenta10 at about 20 weeks may also be
relevant. The disappearance of a-glucosidase
at midpregnancy has been suggested13 to re¬
flect the complete assumption of glucose
homeostasis by the fetal liver. However, this
would not explain the changes observed for
the other enzymes and their relationship to
fetal development must await further investi¬
gation.
The levels of certain lysosomal enzymes
have been utilized in the detection of inborn
errors of metabolism.2' 27' 28 However, prior
to using amniotic fluid for antenatal diag¬
nosis it is necessary to demonstrate that the
enzyme being measured is the one involved
in the disease. In the case of a-glucosidase,
its use was seriously questioned29 and it was
later shown30 that the enzyme present in am¬
niotic fluid is not the one missing in Pompe's
disease. The N-acetyl-/?-D-glucosaminidase
present in amniotic fluid has been shown31 to
be similar to that involved in the Tay-Sachs
complex. However, while an absence of this
enzyme could be used for an unequivocal
diagnosis of Sandhoff's disease,19 the much
lower percentage of N-acetyl-/3-D-gluco-
saminidase A present as compared to that
in cultured amniotic fluid cells3 leaves much
less room for error in the diagnosis of Tay-
Sachs disease.27 The low level of certain en¬
zymes, the wide range in enzyme levels at a
particular gestational age, and the variations
with gestational age make difficult the use of
amniotic fluid lysosomal enzyme levels for
antenatal diagnosis. Any such diagnosis made
on the basis of amniotic fluid should be con¬
firmed by enzyme assay of cultured amniotic
fluid cells.18
We thank Drs. J. G. Robertson and J. B.
Scrimgeour for the amniotic fluids and the
former for the optical density difference values
of the rhesus isoimmunized amniotic fluid sam¬
ples.
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Lysosomal enzyme levels in human
amniotic fluid cells in tissue culture
II. a-galactosidase, p-galactosidase and a-arabinosidase
G. R. Sutherland, J. Butterworth, D. M. Broadhead, and A. D. Bain
Department of Pathology, Royal Hospital for Sick Children and
University of Edinburgh, Scotland
Changes in the activities of a-galactosidase, /l-galactosidase and a-arabinosidase in amni¬
otic fluid cells with time in culture were studied. Marked fluctuations in all three en¬
zymes occurred with passage. In certain cell strains, /?-galactosidase showed a marked
rise in activity correlated with passage. The activity of all three enzymes, in amniotic
fluid cells at the third passage, was correlated with the total time taken to reach con-
fluency. There was no consistent pattern of enzyme activity associated with the time
after subculture. Enzyme levels in cell strains derived from serial samples of amniotic
fluid from several women showed large differences in activity unrelated to gestational
age.
Received 12 December 1973, accepted for publication 7 January 1974
The number of diseases resulting from a
known deficiency of a lysosomal enzyme
has increased rapidly in recent years. With
the demonstration that these deficiencies
can be detected in cultured amniotic fluid
cells, antenatal diagnosis for inborn errors
of lysosomal metabolism has become prac¬
ticable (Brady 1973, Nadler 1970, 1972,
Prescott et al. 1972). However, little atten¬
tion has been paid to possible fluctuations
in the levels of lysosomal enzymes in cultu¬
red normal amniotic fluid cells (Beutler et
al. 1971, Butterworth et al. 1973a, b, Ger-
bie et al. 1972). The effect of culture time
on the activity of lysosomal enzymes in
normal amniotic fluid cell strains has, there¬
fore, been investigated. The results for a-ga¬
lactosidase, p-galactosidase and a-arabino¬
sidase are presented as part of this study.
Methods
Amniotic fluid samples were obtained from
hysterotomy specimens and by amniocen¬
tesis of Rhesus iso-immunised women who
had no history of inborn errors of lysoso¬
mal metabolism. Primary cell cultures were
set up (Sutherland et al. 1973), then subcul-
tured, harvested and homogenized (Butter¬
worth et al. 1973a), and the lysosomal en¬
zymes a-galactosidase, p-galactosidase and
a-arabinosidase assayed using 4-methylum-
belliferone glycosides (Butterworth et al.
1972). Protein concentration was assayed
(Miller 1959) using bovine serum albumin
as standard.
The reproducibility of the combined cul¬
ture and enzyme assay methods was tested
by establishing 12 replicate cultures of one
This work was supported by the Advisory Committee on Medical Research for Scotland.
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cell strain at two different passages. The
12 replicates were harvested when they had
simultaneously reached confluency, and
then assayed for enzyme activity. To study
enzyme activity with respect to passage,
six cell strains were subcultured for up to
15 passages and the enzyme levels assayed
at intervals. All the cell strains were as¬
sayed at the third passage, and the time
interval between subculture and harvest
(confluency) noted. The variation in enzyme
level within a single passage was followed
by establishing a series of replicate cultures,
which were harvested for enzyme assay at
daily intervals for up to 7 days.
Results
The reproducibility of the combined culture
and assay system for each enzyme is pre¬
sented in Table 1. The variation of the to¬
tal experimental procedure (coefficient of
variation) was below 6.0% for all the en¬
zymes. The variation in the levels of the
three enzymes with passage is given for
six cell strains in Figs. 1-3. The coefficient
of variation of the mean enzyme levels for
the different cell strains was 20-33% for
a-galactosidase, 27-68% for p-galactosidase
Table 1
Reproducibility of culture and assay system
Coefficient























* Enzyme activity in nmol 4-methylumbelliferone min"1
mg-1 protein for 12 replicates
a - Assay tenth passage; b- Assay twentieth passage
PASSAGE NUMBER
Fig. 1. The activity of a-galactosidase in serial passa¬
ges of six strains of cultured amniotic fluid cells.
and 18-39% for a-arabinosidase. Thus, all
three enzymes showed much greater fluctu¬
ations with passage than could be attributed
to experimental error alone.
A comparison of the enzyme levels in the
first five passages with those in the next
10 for these six cell strains showed that
/J-galactosidase activity was lower (P <C
0.005) in the earlier passages. However,
the mean activity of /Tgalactosidase in the
third and tenth passages of these six strains,
plus an additional six strains, was not sig-
B-GALACTOSIDASE
PASSAGE NUMBER
Fig. 2. The activity of /?-galactosidase in serial pas¬
sages of six strains of cultured amniotic fluid cells.
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Fig. 4. Relationship of the activity of «-galactosidase
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PASSAGE NUMBER
Fig. 3. The activity of «-arabinosidase in serial pas¬
sages of six strains of cultured amniotic fluid cells.
nificantly different. In these 12 strains the
activities of a-galactosidase and a-arabino-
sidase at the third and tenth passages did
not differ significantly. The contradictory
results for /3-galactosidase could be accoun¬
ted for by three of the six strains examined
in detail (strains 4-6, Fig. 2), which showed
2-
2 A 6 8 10
TIME TO HARVEST (Days)
12
Fig. 5. Relationship of the activity of ^-galactosidase
in cultured amniotic fluid cells with time to reach
confluency (harvest).
a marked rise in activity with passage not
apparent in the other strains.
The relationship of the enzyme activity
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TIME TO HARVEST (Days)
12
Fig. 6. Relationship of the activity of a-arabinosidase
in cultured amniotic fluid cells with time to reach
confluency (harvest).
All days Without days 10-12
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1 2 3 A 5 6 7
TIME AFTER SUBCULTURE (Days)
Fig. 8. The activity of /?-galactosidase in six strains
of amniotic fluid cells in relation to time since sub¬
culture.
f Confluency; Strain 1 not confluent by 7 days
(H
2 12 3^567
TIME AFTER SUBCULTURE (Days)
Fig. 7. The activity of a-galactosidase in six strains
of amniotic fluid cells in relation to time since sub¬
culture.
t Confluency; Strain 1 not confluent by 7 days
time at which confluency (harvest) was
reached is given in Figs. 4-6. A significant
correlation between these two parameters
was found for a-galactosidase (r = 0.42),
(3-galactosidase (r = 0.64) and a-arabino-
sidase (r = 0.61). However, if the few cell
strains requiring 10-12 days to reach con-
-ARABINOSlDASE
1 2 3 A 5 6 7
TIME AFTER SUBCULTURE [ Days)
Fig. 9. The activity of «-arabinosidase in six strains
of amniotic fluid cells in relation to time since sub¬
culture.
f Confluency; Strain 1 not confluent by 7 days
fluency were not considered, only the cor¬
relation for a-arabinosidase (r = 0.37) was
still significant.
Table 2
Enzyme levels* in cell strains at the third
passage cultured from serial samples of










18 0.30 2.87 0.47
22 0.59 4.51 0.74
1 24 0.78 5.01 0.88
33 0.30 9.55 0.66
35 0.44 5.48 0.38
23 0.35 2.87 0.48
2 26 0.33 4.63 0.38
28 0.29 4.96 0.22
22 0.65 10.76 1.11
26 0.37 7.85 0.74
27 0.32 3,17 0.53
34 0.35 2.67 0.31
* Enzyme activity - nmol 4-methylumbelliferone min-1
mg-1 protein
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The fluctuations in the levels of the
three enzymes in relation to time after
subculture are given in Figs. 7-9. No con¬
sistent change was associated with the time
after subculture. There was also no consis¬
tent change in enzyme activity after the
time at which the cells became confluent.
Cell strains were grown from serial sam¬
ples of amniotic fluid obtained from several
Rhesus iso-immunised women and the lev¬
els of the enzymes, at the third passage,
are given in Table 2. The activity of all
three enzymes showed considerable varia¬
tion within each series, that did not relate
to gestational age.
Discussion
The activities of a-galactosidase, |3-galacto-
sidase and a-arabinosidase in normal amni¬
otic fluid cells have been shown to vary
with the time in tissue culture. The signi¬
ficance of the results will be considered
in relation to similar studies on other lyso¬
somal enzymes in the following paper (But-
terworth et al. 1974).
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Lysosomal enzyme levels in human
amniotic fluid cells in tissue culture
III, p-glucuronidase, N-acetyl-P-D-glucosaminidase,
a-mannosidase and acid phosphatase
J. Butterworth, G. R. Sutherland, D. M. Broadhead,
and A. D. Bain
Department of Pathology, Royal Hospital for Sick Children and
University of Edinburgh, Scotland
Fluctuations in the levels of /(-glucuronidase, N-acetyl-/?-D-g!ucosaminidase, a-mannosi¬
dase and acid phosphatase in amniotic fluid cells with time in culture were studied. The
four enzymes fluctuated markedly with passage; no consistent trends were apparent. The
activity of a-mannosidase in amniotic fluid cell strains at the third passage was corre¬
lated with the time taken to reach confluency. There was no consistent pattern of
enzyme activity associated with the time after subculture. Enzyme levels in cell strains
derived from serial samples of amniotic fluid from several women showed large diffe¬
rences in activity unrelated to gestational age. The significance of the findings are
discussed in relation to antenatal diagnosis of inborn errors of lysosomal metabolism.
Received 12 December 1973, accepted for publication 7 January 1974
Previous reports (Butterworth et al. 1973a,
Sutherland et al. 1974) have shown that the
levels of five lysosomal enzymes (a-gluco-
sidase, [3-glucosidase, a-galactosidase, /f-ga-
lactosidase, a-arabinosidase) in amniotic
fluid cells fluctuate with time in tissue cul¬
ture. Similar studies have been carried out
on four oiher lysosomal enzymes (/(-glucu¬
ronidase, N-acetyl-/?-D-glucosaminidase,
a-mannosidase, acid phosphatase), all of
which are involved in inborn errors of
metabolism.
Methods
The amniotic fluid cell strains were cul¬
tured under the experimental conditions
described in previous papers (Butterworth
et al. 1973a, Sutherland et al. 1974). The
cells were harvested and the enzymes /(-glu¬
curonidase, N-acetyl-/3-D-glucosaminidase,
a-mannosidase and acid phosphatase as¬
sayed using 4-methylumbeIliferone conju¬
gates as substrates (Butterworth et al. 1972,
1973b).
Results
The reproducibility of the combined cul¬
ture and assay system for each enzyme is
presented in Table 1. The variation of the
total experimental procedure (coefficient of
variation) was below 7.5% for all four
enzymes. The variations in the levels of
This work was supported by the Advisory Committee on Medical Research for Scotland.
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Table 1
Reproducibility of culture and assay system
Coefficient
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. 7.11" 0.37 5.2Ac.d Phosphatase ^ 0-55 7.4
N -ACETYL-13 - D -GLUCOSAMINIDASE
PASSAGE NUMBER
Fig. 2. The activity of N-acetyl-/?-D-glucosaminidase
in serial passages of six strains of cultured amniotic
fluid cells.
*
Enzyme activity in nmol 4-methylumbelliferone min-1
mg-1 protein for 12 replicates
a - assay tenth passage; b - assay twentieth passage
the four enzymes with passage is given for
six cell strains in Figs. 1-4. The coefficient
of variation of the mean enzyme levels for
the different cell strains was 27-38% for
/f-glucuronidase, 16-38% for N-acetyl-/J-.D-
glucosaminidase, 23-52% for a-mannosi-
dase and 18-45% for acid phosphatase. All
four enzymes, therefore, showed fluctua¬
tions with passage greater than could be
expected from experimental error. None
B-GLUCURONIDASE
S ' 1 1 1 1 ' 1—
0 2 A 6 6 10 12 It
PASSAGE NUMBER
Fig. 4. The activity of acid phosphatase in serial
passages of six strains of cultured amniotic fluid
cells.
Fig. 1. The activity of /^-glucuronidase in serial pas¬
sages of six strains of cultured amniotic fluid cells.
o< - MANNOSIDASE
0 2 A 6 6 10 12 14
PASSAGE NUMBER
Fig. 3. The activity of a-mannosidase in serial passa¬
ges of six strains of cultured amniotic fluid cells.
1 1 1 1 1 1 r~
2 A 6 8 10 12 K
PASSAGE NUMBER
ACID PHOSPHATASE
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of these fluctuations in enzyme levels sho¬
wed a consistent pattern of activity related
to passage, as judged by previously descri¬
bed criteria (Butterworth et al. 1973a,
Sutherland et al. 1974).
The results were examined to determine
whether the enzyme levels of the cell strains
at the third passage were related to the time
at which confluency (harvest) was reached.
The only significant correlation (r = 0.58)
was for a-mannosidase (Fig. 5). This was
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Fig. 6. The activity of ^-glucuronidase in
strains of amniotic fluid cells in relation to
since subculture.






Fig. 5. Relationship of the activity of a-mannosidase
in cultured amniotic fluid cells with time to reach
confluency (harvest).
All days Without days 10-12
cell strains requiring 10-12 days to reach
confluency were not included.
Figs. 6-9 show the fluctuations in the
levels of the four enzymes related to the
time after subculture for six amniotic fluid
cell strains. No consistent pattern of en¬
zyme activity related to this parameter was
noted. Moreover, no consistent increase in
enzyme activity was noted after the cell
strains had become confluent.











1 2 3 A 5 6 7
TIME AFTER SUBCULTURE ( Days)
Fig. 7. The activity of N-acetyl-/?-D-glucosaminidase
in serial strains of amniotic fluid cells in relation
to time since subculture,
f Confluency; Strain 1 not confluent by 7 days








E 12 3 15 6 7
TIME AFTER SUBCOLTURE (Days)
Fig. 8. The activity of a-mannosidase in serial strains
of amniotic fluid cells in relation to time since sub¬
culture.
t Confluency; Strain 1 not confluent by 7 days
ACID PHOSPHATASE
1 2 3 A 5 6
TIME AFTER SUBCULTURE
(DAYS)
Fig. 9. The activity of acid phosphatase in serial
strains of amniotic fluid cells in relation to time
since subculture.
f Confluency; Strain t not confluent by 7 days
serial samples of amniotic fluid obtained
from four Rhesus iso-immunised women.
The levels of the four enzymes in the third
passage of these cell strains are given in
Table 2. Within each series the activity of
the four enzymes showed considerable vari¬
ability, unrelated to gestational age.
Discussion
The known number of inborn errors of
metabolism due to a lysosomal enzyme
deficiency has increased rapidly in the last
few years (Brady 1973, Milunsky 1973,
Nadler 1972). Post-natal diagnosis of these
diseases is made by enzyme assay using
leukocytes and cultured fibroblasts. The
properties and variations in activity of lyso¬
somal enzymes in these cell types have been
reported (Hultberg et al. 1973, Milunsky et
al. 1972, Ryan et al. 1972).
With the demonstration that lysosomal
enzymes are present in cultured amniotic
fluid cells (Kaback & Cooke 1970), and
that an enzyme deficiency in the fetus is
reflected in these cells (Padeh & Navon
1971, Salafsky & Nadler 1971), antenatal
diagnosis of inborn errors of lysosomal
metabolism became possible. Indeed, there
are now several reports (Brady et al. 1971,
Dssnick et al. 1973, Kaback et al 1973,
O'Brien et al. 1971, van der Hagen et al.
1973) of the successful antenatal diagnosis
of such enzyme deficiency diseases. This
very success has had the result of increas¬
ing the demand for antenatal diagnosis.
However, whilst there are many reports
concerning lysosomal enzyme deficiencies
in cultured amniotic fluid cells (Milunsky
1973), much less attention has been paid
to fluctuations of these enzymes in cells
cultured from normal amniotic fluids
(Beutler et al. 1971, Butterworth et al.
1973a, 1973b, Gerbie et al. 1972). A study
of the activities of nine lysosomal enzymes
in cultured amniotic fluid cells has been
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Table 2
Enzyme levels* in cell strains at the third passage cultured from serial







18 0.60 44.4 0.28 6.35
22 0.83 64.0 0.87 12.69
1 24 0.76 57.3 0.95 11.69
33 0.63 61.3 0.81 10.05
35 0.75 32.2 0.42 4.41
23 0.43 68.5 0.52 7.15
2 26 1.09 76.3 0.37 5.90
28 0.42 34.4 0.41 11.52
22 0.98 91.9 0.88 9.15
26 0.90 62.1 0.96 10.52
27 0.66 66.3 1.08 6.85
34 0.64 39.4 0.59 9.67
* Enzyme activity - nmol 4-methylumbelliferone min-1 mg ' protein
undertaken. The findings for five lysosomal
enzymes have been reported (Butterworth
et al. 1973a, Sutherland et al. 1974) and
these will be considered together with the
present results.
The levels of all the lysosomal enzymes
investigated showed marked fluctuations
with passage in amniotic fluid cell strains,
a finding in agreement with the results of
Milunsky et al. (1972) for cultured skin
fibroblasts. Some amniotic fluid cell strains
showed a significant pattern of increase in
specific activity with passage for certain
enzymes such as /?-glucosidase and /f-galac-
tosidase, but only for a-glucosidase was
this increase consistent. This contrasts with
the general rise in lysosomal enzyme acti¬
vity with passage noted in cultured fibro¬
blasts by Hultberg et al. (1973). The ratio
of epithelioid to fibroblast-like cells in
amniotic fluid cell culture has been repor¬
ted (Melancon et al. 1971) to change with
passage. As the lysosomal enzyme levels
differ between these cell types (Gerbie et
al. 1972), it is possible that the patterns
of change observed in the present studies
reflect this change in cell type.
In cultured fibroblasts, acid phosphatase
(Christofalo & Kritchevsky 1969), N-acetyl-
/3-D-glucosaminidase (Okada et al. 1971)
and /^-glucuronidase (DeMars 1964, Leroy
& DeMars 1967, Russell et al. 1971) levels
have been shown to be related to the time
after subculture. No such relationship was
consistently found for the lysosomal enzy¬
mes in cultured amniotic fluid cells. Simi¬
larly, the rise in the level of N-acetyl-/?-D-
glucosaminidase (Okada et al. 1971) and
/5-glucosidase (Ryan et al. 1972) activity in
cultured fibroblasts after confluency was
not apparent in cultured amniotic fluid
cells. However, a positive correlation was
noted between the activities of some of the
enzymes in amniotic fluid cells and the
time taken to reach confluency. This ap¬
parent relationship may reflect a difference
between the cell types found in slowly and
rapidly growing cell strains. The lack of a
correlation between gestational age and the
level of the lysosomal enzymes in cells
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cultured from serial samples of amniotic
fluid is consistent with previous findings
using only one sample from any pregnancy
(Butterworth et al. 1973b).
Hence, cells cultured from amniotic fluid
of any gestational age will provide suitable
control material for antenatal diagnosis of
a disease involving any of these lysosomal
enzymes. Similarly, cells at any stage of
culture up to at least the fifteenth passage
can be used as control material. One pos¬
sible exception is a-glucosidase, where cells
in later passages may have higher enzyme
levels. The possibility still remains, how¬
ever, that an error in diagnosis could arise
due to a change in the isoenzyme pattern
with gestational age or time in culture.
These possibilities clearly need to be taken
into consideration when making an ante¬
natal diagnosis of a disease where only one
isoenzyme is deficient.
The marked variations in the activity of
the nine lysosomal enzymes described in
this series of studies clearly have implica¬
tions with regard to antenatal diagnosis of
inborn errors of lysosomal metabolism. The
fluctuations of enzyme activity in amniotic
fluid cell strains with culture time, and even
in cells cultured from serial samples of
amniotic fluid from the same woman, re¬
sult in a wide range of normal values which
would make identification of heterozygotes
extremely difficult. When undertaking an¬
tenatal diagnosis of recessively inherited
diseases, half the fetuses encountered will
be heterozygotes. If the variation in enzyme
activity is as large for these heterozygotes
as for the normals, then in those diseases
in which the enzyme deficiency is only
partial, the heterozygote could well be mis¬
taken for an affected homozygote.
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Summary
1. Possible changes in lysosomal enzyme activity of cultured amniotic
fluid cells with serum concentration, type of medium and the pH of the me¬
dium were studied.
2. Apart from a small, but significant, decrease in the activity of j3-galac-
tosidase, none of the enzymes changed with increasing serum concentration.
3. No significant changes in enzyme activity were found between cells
cultured in Ham's F10 and Eagle's MEM medium.
4. Lysosomal enzyme levels were unaffected by culturing cells for up to 9
days at pH 7.0, 7.4 and 7.9.
Introduction
As cultured amniotic fluid cells are now being used in the antenatal diag¬
nosis of inborn errors of lysosomal enzyme metabolism, a better understanding
of the reasons for the fluctuations observed in the levels of lysosomal enzymes
in normal cultured amniotic fluid cells [1-4] is clearly required. It is also
important to determine whether the different normal levels of enzyme activity
obtained by different laboratories [5] could be attributed to variations in cell
culture. Hence the effects of serum concentrations, type of tissue culture me¬
dium (Ham's F10, Eagles's MEM) and the pH of the medium on the levels of
some lysosomal enzymes in cultured normal amniotic fluid cells were investi¬
gated.
* To whom correspondence should be addressed.
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Methods
Cell strains were initiated [6], subcultured and maintained [1] as previ¬
ously described.
To study the effects of fetal calf serum concentration in the culture
medium on lysosomal enzyme activity, 3 lots of culture medium (Ham's F10)-
were prepared with fetal calf serum concentrations of 15, 20 and 30%. The
Ham's F10 (Flow Lab. Ltd) and fetal calf serum (Biocult Labs. Ltd) came from
single batches: this condition was adhered to for all the culture experiments. A
cell strain which had been maintained in medium with a 30% fetal calf serum
concentration was used to seed 12 replicate culture bottles. 4 cultures were
maintained at each serum concentration until harvested at confluency for en¬
zyme assay. This procedure was carried out for 3 cell strains.
The effect of using two commercially available culture media, Ham's F10
(Flow Lab. Ltd) and Eagle's MEM (Wellcome Ltd) on the enzyme levels was
compared. Both media were supplemented with 15% fetal calf serum. 6 cell
strains which had been maintained in Ham's F10, were used for this experiment.
Duplicate cultures which had been maintained in these two media for two
passages were harvested at confluency for enzyme assay.
The effect of the pH of the medium on the enzyme levels was studied
using Ham's F10 culture medium supplemented with 15% fetal calf serum and
buffered with tricine [7]. Solutions of M tricine were prepared and the pH
adjusted with 6 N NaOH so that when added to medium to give a final concen¬
tration of 50 mM, pH values of 7.0, 7.4 and 7.9 were obtained. In an initial
experiment 12 replicate cultures were grown to confluency in Ham's F10 with
15% fetal calf serum and a bicarbonate buffer system. At this point 4 bottles
were maintained in medium buffered at each of the three pH values and the
cells harvested for enzyme assay 24 h later. Since this initial experiment indi¬
cated that pH did not affect the enzyme levels, another experiment was de¬
signed to determine whether growing the cells in media at different pH values
from the time of seeding would affect the enzyme levels. 15 replicate cultures
were prepared and medium at each pH was added to 5 bottles. To minimize pH
changes the culture medium was changed every day. One culture at each pH
was harvested for enzyme assay on days 1, 3, 5, 7 and 9 after the cultures had
been set up. The experiment was carried out on two cell strains simultaneously,
one an amniotic fluid derived fibroblast-like cell strain and the other, a similar¬
ly derived cell strain of mixed epithelioid type II and III cells [8].
The preparation of cell homogenates, protein estimation and the assay of
the lysosomal enzymes were carried out as previously described [9].
Results
The levels of the lysosomal enzymes in three strains of amniotic fluid cells
cultured with 15, 20 and 30% fetal calf serum supplement in the medium are
given in Table I. Analysis of variance of the results indicated that there was a
small, but significant, decrease in the activity of |3-galactosidase (P < 0.05) from
15 to 30% serum levels. None of the other comparisons of enzyme activity
were significantly different. There was a significantly higher level of protein
(P < 0.05) for cell strains cultured in 30% compared to 15% serum.
TABLEI LYSOSOMALENZY EACTIVITI SFTHR EAMN OTICFLUIDC LLS RAINSCUL UREDGDIFFERENTCON ENTRATIONSFF TALALFSERUM Figuresrep esentthm a sof4exp riments;sta dardd via ioi parentheses. Enzymeactivity( moles/min/mgprotein);fetalc lfs ruconce tration(%) Acidphosphatase -Y-Acetvl-.j-D- glucosaminidase ii-Galactosidasc fi-Glucuronidase a-Galactosidase a-Arabinosidase a-Mannosidase a-Glucosidase (3-Glucosidase Arylsulphatase Protein(mg/ml)1520 8.06 (0.43) 36.2 (1.9) 6.42 (0.84) 0.52 (0.01) 0.27 (0.01) 0.24 (0.01) 0.64 (0.03) 0.44 (0.03) 0.07 (0.02) 0.98 (0.07) 0.30 (0.02)7.37 (0.42) 36.6 (1.5) 6.27 (0.74) 0.50 (0.04) 0.27 (0.02) 0.23 (0.01) 0.64 (0.03) 0.40 (0.04) 0.08 (0.02) 1.11 (0.11) 0.33 (0.02)30152030
15
8.90 (0.92) 33.4 (4.3) 5.94 (0.86) 0.55 (0.05) 0.28 (0.04) 0.20 (0.02) 0.60 (0.06) 0.35 (0.04) 0.06 (0.01) 1.09 (0.16) 0.38 (0.05)
5.45 (0.35) 36.5 (0.7) 4.51 (0.16) 0.76 (0.06) 0.28 (0.02) 0.18 (0.01) 0.78 (0.03) 0.70 (0.04) 0.06 (0.01) 1.07 (0.17) 0.24 (0.02)
5.94 (0.29) 33.2 (2.6) 4.19 (0.32) 0.68 (0.04) 0.28 (0.01) 0.16 (0.01) 0.74 (0.06) 0.63 (0.06) 0.07 (0.02) 0.98 (0.05) 0.24 (0.02)
5.18 (0.66) 31.7 (2.6) 3.70 (0.34) 0.62 (0.05) 0.27 (0.03) 0.14 (0.01) 0.68 (0.04) 0.56 (0.06) 0.06 (0.02) 0.84 (0.11) 0.28 (0.03)
9.62 (1.40) 88.9 (8.4) 10.96 (1.26) 0.75 (0.17) 0.55 (0.06) 0.34 (0.04) 1.41 (0.22) 1.71 (0.11) 0.27 (0.06) 0.07 (0.01)
20
9.71 (1.23) 91.0 (11.0) 10.38 (0.88) 1.00 (0.22) 0.55 (0.02) 0.34 (0.04) 1.15 (0.10) 1.49 (0.15) 0.27 (0.07) Notdone 0.09 (0.02)
30





LYSOSOMAL ENZYME ACTIVITIES OF AMNIOTIC FLUID CELLS CULTURED USING HAM'S F10
AND EAGLE'S MEM MEDIUM
Figures represent the means of 12 experiments; standard deviations in parentheses.
Enzyme Enzyme activity (nmol es/min/mg protein)
Ham's F10 Eagle's MEM
















Arylsulphatase A 2.38 2.70
(0.73) (1.08)
Protein (rag/ml) 0.083 0.059
(0.009) (0.013)
The levels of the lysosomal enzymes in amniotic fluid cells cultured in
Ham's F10 and Eagle's MEM medium are given in Table II. Whilst some of the
enzymes in certain of the cell strains showed differences between the two
media, a comparison of the results (f-test) indicated that there were no signifi¬
cant differences for any of the enzymes. However, the level of protein in cell
strains cultured in Ham's F10 was significantly higher (P < 0.05) than when
using Eagle's MEM.
The initial experiment on the effects of pH showed that there were no
significant differences between the lysosomal enzyme activities of amniotic
fluid cells when monolayer cultures were maintained at three different pH
values (7.0; 7.4; 7.9) for 24 h. The results of the second experiment in which
cell strains were cultured for up to 9 days at these three pH values are given in
Figs 1—3. The pattern of activity with time in culture of some of the enzymes,
such as a-mannosidase (Fig. 2) and arylsulphatase A (Fig. 3), was different for
the two cell strains. Inspection of Figs 1—3 indicated that for only j3-glucuroni-
dase was there an apparent effect of pH, in that the enzyme activity at pH 7.9
was lower than that at 7.4 and 7.0 after 5 days of culture. However, a compari¬
son (analysis of variance) of the mean enzyme activities throughout the period
of culture indicated that there was no significant difference between the en¬
zyme levels at the three pH values.
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Fig. 1. The levels of acid phosphatase, A/-acetyl-/3-D-glucosaminidase, /3-galactosidase and ^-glucuronidase
in amniotic fluid cells cultured for 9 days in medium at three pH values.
Discussion
Apart from the effects of culture time [2—4], the study of variations in
lysosomal enzyme activity of amniotic fluid cells with culture variables has
been neglected. The effect of serum concentration on cell growth and enzyme
activity has been largely confined to cell lines requiring very low levels of serum
and few studies have been undertaken using high concentrations [10,11].
Growth of rat fibroblasts was shown [10] to increase as the serum was in¬
creased from 5 to 30% with a concomitant increase in mucopolysaccharide
production. A change in serum from 10 to 20% had no effect on the growth
rate of human fibroblasts, but an increase to 30% led to a reduction in cell
growth [11]. In the present study cell growth, as judged by protein levels,
















Fig. 2. The levels of o-galactosidase, a-arabinosidase, o-mannosidase and a-glucosidase in amniotic fluid
cells cultured for 9 days in medium at three pH values.
activity remained constant. A possible explanation for this is that the cell
strains used were adapted to growing in 30% serum. Attempts to increase the
serum concentration to 30% once amniotic fluid cells were adapted to growing
in 15% were unsuccessful, due to marked reduction in cell growth. In view of
these effects of serum concentration on cell growth and metabolism, it is
perhaps surprising that the lysosomal enzymes of amniotic fluid cells are unaf¬
fected; the statistically significant finding for j3-galactosidase is probably fortui¬
tous and of little biological significance. The finding [12] that the level of acid
phosphatase in mouse fibroblasts remained unaltered when the serum concen¬
tration was changed from 0 to 10% is in accord with the present study.











Fig. 3. The levels of j3-glucosidase and arylsulphatase A in amniotic fluid cells cultured for 9 days in
medium at three pH values.
ceived little attention [5,13,14]. The specific activity of lactate dehydrogenase
and glucose-6-phosphate dehydrogenase has been shown [13] to be affected by
the type of medium in which Earle's L cells were cultured. In cultured human
fibroblasts the level of j3-glucosidase was lower in cells grown in Ham's F10 than
Eagle's MEM [5,14]. In the present study on amniotic fluid cells the level of
acid phosphatase was found to be unaffected by these two media, in agreement
with a finding for cultured human fibroblasts [14]. Although the level of
arylsulphatase A has been found to be lower in fibroblasts [14] cultured in
Ham's F10, no such affect was observed in amniotic fluid cells. The higher
protein levels for amniotic fluid cells grown in Ham's F10 may reflect a genuine
difference in the ability of these two media to support amniotic fluid cell
culture, but it is more likely to be a consequence of having used cell strains
adapted to growing in Ham's F10.
Although the effect of the pH of the medium on lysosomal enzyme activi¬
ty has been little investigated, its affects on other aspects of metabolism have
been studied. Collagen synthesis by human fibroblasts was found [15] to be
greater at pH 7.4 and 8.0 than at 7.0. The effect of pH on mucopolysaccharide
metabolism is perhaps of more relevance to studies involving lysosomal en¬
zymes. The production of mucopolysaccharides by rat fibroblasts was found
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[16] to be greater at pH 6.6 than pH 7.4. It was also shown [16,17] that
[35S]sulphate was incorporated differently into the various mucupolysaccha-
rides at these pH values. In contrast, human fibroblast mucopolysaccharide
content was found to increase with a change in the pH of the medium from
6.65 to 7.9 and this appeared to be due to a difference in degradation rather
than synthesis [18]. This resulted in a great increase in intracellular mem¬
brane-bound bodies producing an abnormal ultrastructure in cells growing at
their optimal pH. As acid phosphatase, a lysosomal marker, was shown [19]
histochemically to be increased in activity at the higher pH there seems to be a
paradox of increased lysosomal enzyme activity and at the same time decreased
mucopolysaccharide degradation. In the present study biochemical assay of
lysosomal enzyme levels did not reveal any difference between the activity in
amniotic fluid cells cultured at about pH 7.8 as compared to lower pH values.
However, the demonstration of enzyme activity in a cell homogenate or by
histochemical techniques does not necessarily prove that the enzyme is func¬
tional in the living cell. It should be borne in mind that the changes in growth
and metabolism of cells in a normal culture system which occur as the pH of
the medium falls, may be the result of the accumulation of a metabolite, such
as lactate [20], rather than to a pH change as such.
The lack of any changes in lysosomal enzyme activity of amniotic fluid
cells due to the serum concentration, type of medium (Ham's F10, Eagle's
MEM) and the pH of the medium indicates that these factors are unrelated to
previously observed [2-4] fluctuations in these enzymes during amniotic fluid
cell culture.
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Summary. Observations made on 31 amniotic fluid cell strains serially cul¬
tured until senescent are recorded. The cell strains had an average life in culture of
13-9 passages (range 3-29). The source of the amniotic fluid from which the cul¬
tures were initiated did not influence the behaviour of the cell strains. The be¬
haviour of the cell strains was unrelated to the growth characteristics of the primary
cultures from which they were derived. Cell strains derived from serial samples of
amniotic fluid from three women were compared and their characteristics were no
more related to each other than to the group as a whole. The cell types found in
amniotic fluid cultures are described. The karyology of 12 of the cell strains was
monitored and no significant changes from normal diploidy were seen. Possible
reasons for the highly variable and unpredictable behaviour of amniotic fluid cell
strains are discussed.
Cultured amniotic fluid cells are now in wide¬
spread use for the antenatal diagnosis of chromo¬
some disorders and inborn errors of metabolism
(Emery, 1970; Sutherland, 1972; Emery, 1973;
Milunsky, 1973). An accurate knowledge of the
behaviour of normal cultured amniotic fluid cell
strains is therefore essential for their use in genetic
studies. However, little appears to be known
about the characteristics of these cells in tissue cul¬
ture. It has been stated (Melancon, Lee, and
Nadler, 1971) that there are at least two morpho¬
logically distinguishable cell types in amniotic fluid
cell cultures—an epithelial type which cannot be
subcultured more than two to five times and a
fibroblast-like cell which can be cultured for more
than 30 passages. On the other hand, Littlefield
(1971) has said that '. . . 6 to 8 weeks of rapid cul¬
ture can approach the limit of the growth potential
of amniotic fluid cells . . .'. This report records
observations made during the long-term culture of
31 amniotic fluid cell strains.
Materials and Methods
Amniotic fluids were obtained from hysterotomy
specimens (HS), by amniocentesis on Rhesus iso-
immunized women (RhS) and by artificial rupture of
Received 5 November 1973.
membranes (ARM) for the induction of labour. The
primary cultures were set up as previously described
(Sutherland and Bain, 1972) and subcultured according
to the method of Butterworth et al (1973). The cell
strains were maintained in 250-ml glass vessels with a
growth surface area of 40 cm2 and regularly subcul¬
tured on reaching confluency, using a 1:2 subculture
ratio. Throughout this study, all cell strains were cul¬
tured in Ham's F10 tissue culture medium supple¬
mented with 30% fetal calf serum and with the anti¬
biotics kanamycin, or penicillin and streptomycin in
combination. The methods used for cytogenetic studies
on primary cultures have been described (Sutherland,
Grace, and Bain, 1973b). Once cell strains became
established, chromosome preparations were made using
standard methods. Cell strains were stored in 10%
dimethyl sulphoxide in culture medium in the vapour
phase of a liquid nitrogen unit.
Results
The 31 cell strains were derived from amniotic
fluid samples taken from 25 women, ie, one woman
contributed four samples, another three, and another
two at different stages of pregnancy. The gesta¬
tional ages, means of collection, and chromosomal
sexes of the amniotic fluids are shown in Table I.
All had normal karyotypes with the exception of two
samples from one pregnancy which had a karyotype
46,XY,t(l;12)(p21;q21).
190
Observations on human amniotic fluid cell strains in serial culture 191
TABLE I
GESTATIONAL AGES, ORIGINS AND CHROMOSOMAL
SEX OF THE 31 AMNIOTIC FLUIDS WHICH
YIELDED CELL STRAINS











ARM (n = 1) 39 1
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THE DISTRIBUTION OF THE NUMBER OF PASSAGES
FOR WHICH THE 31 AMNIOTIC FLUID CELL
STRAINS COULD BE CULTURED UNTIL DEATH
No. of passages 0-4 5-8 9-12 13-16 17-20 21-24 >25
No. of cell strains 3 3 8 7 5 3 2
to which a cell strain could be cultured or the mean
interval between subcultures. Similarly, the num¬
ber of passages was not correlated with the time in
primary culture. There was, however, a signifi¬
cant (pcO-Ol) correlation (r= — 0-550) between
mean subculture interval and the number of pas¬
sages (Fig. 1).
All cell strains which survived more than five or
six passages were stored in the liquid nitrogen unit.
Thirteen strains have been retrieved and then cul¬
tured to senescence. The mean number of passages
before death of the 13 strains was 14-5 (range 5-25)
and after storage the mean was 13-4 (range 5-24).
Most of the retrieved cell strains died within ±3
passages of the corresponding strain which had not
been stored. The greatest difference was one strain
which survived for 17 passages before storage and
for only 12 passages after being stored at the fourth
passage.
When more than one amniotic fluid sample was
collected at different stages from a single pregnancy
it was possible to compare the cell strains derived
from these samples. Some data relating to three
such groups of cell strains are shown in Table IV.
Some data on the cell strains are shown in Table
II. The differences between the HS and RhS are
not significant for any of these parameters. The
number of passages is the number of times a cell
strain could be subcultured, using a 1:2 subcultiva-
tion ratio, before the cell strain died. Death of a
cell strain was defined as the point at which it would
no longer grow to confluency after subculture. The
time as a cell strain was the interval between sub-
culturing the primary culture and the death of the
cell strain. The mean interval between subcul¬
tures was the time as a cell strain divided by the
number of passages till death, and was a crude esti¬
mator of the overall rate of growth of a cell strain.
The distribution of the number of passages is shown
in Table III.
The data were examined to see if any of the para¬
meters of the amniotic fluid were related to the be¬
haviour of the cell strain in culture. There was no
correlation between gestational age and the follow¬
ing : time in primary culture, the number of passages
1 1 1
o 5 lO 15
Mean interval between subcultures ( Days )
Fig. 1. Relationship between the number of passages for which cell
strains could be cultured before death and mean interval between
passages. (r= —0-550.)
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TABLE IV



























































* This group has a constitutional chromosome abnormality (see text).
The cell strains in each group do not show uniform
behaviour, they vary as greatly as cell strains derived
from different pregnancies. This may indicate that
the genetic make-up of the cells is not responsible
for the variable behaviour of the cell strains.
The cell morphology was monitored throughout
the period of culture by direct observation under the
inverted microscope and by the examination of
Giemsa-stained monolayers grown on flying cover-
slips. There were five readily recognizable cell
types.
1. Macrophages (Fig. 2). These were visible
the day after primary cultures had been set up.
They appear to divide in culture but cannot be sub-
cultured. They degenerate and are overgrown by
other cell types. Very few macrophages are seen
in amniotic fluid cell cultures except when the
amniotic fluid comes from an anencephalic preg¬
nancy, when they are present in considerable num¬
bers (Sutherland, Brock, and Scrimgeour, 1973a).
2. Epithelioid Type I Cells (Fig. 3) which
grow in 'islands' in primary culture. These cells
can apparently be subcultured but lose their ten¬
dency to grow in 'islands' after subculture.
Fig. 3. Epithelioid type I cells after 18 days in primary culture.
(Phase contrast, x 200.)
I W
Fig. 2. Macrophages from anencephalic amniotic fluid after 20
hours in culture. (Giemsa stain, x 200.)
Fig. 4. Epithelioid type II cells after 23 days in primary culture.
There are fibroblast-like cells growing between the epithelioid cells.
Note one binucleate epithelioid cell and the fibrillar nature of the
cytoplasm. (Phase contrast, x 200.)
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3. Epithelioid Type II Cells (Fig. 4). These
are very large cells with much cytoplasm and some¬
times with more than one nucleus. Under phase
contrast the cytoplasm of these cells has a fibrillar
appearance. These cells can be subcultured at
least 20 times. Almost all primary cultures of
amniotic fluid contain these cells.
4. Epithelioid Type III Cells (Fig. 5) which
morphologically resemble type I except that they do
not grow in islands in primary cultures. In their
growth patterns these cells show some of the features
of the next cell type. These cells can be readily
subcultured.
Fig. 5. Epithelioid type III cells in the twenty-second passage of
culture. (Giemsa stain, x 200.)
5. Fibroblast-iike Cells (Fig. 6) which can be
readily subcultured. These are morphologically
indistinguishable from fibroblast-]ike cells cultured
from human embryonic lung or skin biopsy.
Most cell strains were a mixture of cell types
throughout their life in culture. However, in some
cases one type or the other predominated. In this
Fig. 6. Fibroblast-)ike cells in the fourth passage of culture.
(Giemsa stain, x 200.)
series there was a tendency for the more fibroblastic
cultures to live longer; however, some died after less
than 10 passages whereas strains in which epi¬
thelioid cells predominated lived for more than 20
passages.
The karyology of 12 of the cell strains was moni¬
tored to within at least three passages before cell
death. At least 10 metaphases per cell strain were
examined at this stage and no departure from nor¬
mal diploid complements was seen," except for that
present in two of the cell strains as a constitutional
abnormality.
All except five cell strains were tested for myco¬
plasma contamination on at least one occasion near
the end of their life in culture. All cell strains
tested were reported free of mycoplasmas.
Discussion
It is apparent that amniotic fluid cell strains have
a highly variable yet finite life-span in culture. In
the series reported here senescent strains and ac¬
tively proliferating strains were in culture at the
same time, receiving the same culture medium and
being kept under apparently identical conditions.
This would suggest that culture factors were not re¬
sponsible for the variation. The longest surviving
cell strain in this series survived 29 subcultures.
This, however, is not the upper limit of life of an
amniotic fluid cell strain; Melancon et al (1971)
have reported that some can be cultured for more
than 30 passages, and other cell strains since this
series was completed have survived more than 50
passages.
The reasons for the variability in the life of the cell
strains remain unclear. In all cases they are de¬
rived from fetal tissue and as the survival in culture
was not correlated with gestational age, it is unlikely
that the variable age of the cells which initiate the
primary culture is the reason. Martin, Sprague,
and Epstein (1970) have shown that the life span of
fibroblast-like cells in tissue culture depends on the
tissue used to establish the culture. Skin-derived
fibroblasts survived longer than those derived from
muscle, testis, or bone marrow spicules. Although
the tissue of origin of the cells in amniotic fluid is
uncertain they probably come from more than one
source (Sutherland and Bain, 1972). Some of the
variability seen could possibly be due to different
samples of amniotic fluid having different propor¬
tions of cells from each possible source, each with a
different survival potential in tissue culture.
As there are only a relatively small number of
points of outgrowth in the primary culture the num¬
ber of cell doublings would be much higher than the
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number of passages would imply. This may well
be the reason why amniotic fluid cell strains appear
to have a shorter life in culture than cell strains
grown from other fetal tissues. However, if this
was the reason for the variation in the length of life
in culture, a correlation between number of passages
till death and time in primary culture would be ex¬
pected : this was not found. The fact that the life in
culture is finite is not surprising as Hayflick (1965)
has shown that human diploid cells have a limited
life span of 50 ± 10 passages when grown from fetal
tissue.
The finding that the faster growing cell strains
live longer is unexpected. This has not been pre¬
viously reported for human diploid cell strains and
the reasons for it remain unknown. Hay (1970) has
in fact reported the exact opposite effect for chick
embryo fibroblasts.
The variability in life-span of the amniotic fluid
cell strains is very like that described by Swim and
Parker (1957) for fibroblast-like cell strains. These
workers found that the number of times they could
subculture cell strains grown from neonatal fore¬
skins ranged from 10 to 34 with a mean of 24. Cell
strains grown from other tissues, including human
embryonic lung, survived from two to 32 subcul¬
tures. They attributed this variability to inade¬
quate tissue culture medium. Perhaps the same
explanation may apply to the amniotic fluid cell
strains. Using medium similar to that used in the
present series but with only 15% fetal calf serum
supplement, Nadler and Gerbie (1970) were able
to subculture only 75% of 155 successful primary
amniotic fluid cell cultures more than three times.
Sutherland and Bain (1973) found that 90% of 62
primary cultures could be subcultured to yield cell
strains which could be maintained for at least two
subcultures.
The findings in the groups of cell strains grown
from serial samples of amniotic fluid are not sur¬
prising. As none of the properties studied are re¬
lated to gestation there is no reason why these cell
strains should show either constant features or any
trends within the groups. It would be of interest
to culture a number of cell strains from a single
amniotic fluid sample and to see if they showed the
same degree of variation as seen in these groups.
Melancon et al (1971) suggested that cell type
may influence length of life in culture. If cell type
did affect life in culture then the number of pas¬
sages till death would be expected to show a multi¬
modal distribution. In this series the distribution
of the number of passages is fairly evenly around the
mean.
The variety of cell types present in amniotic fluid
has received little attention. Gerbie et al (1972)
have said that amniotic fluid cell strains are com¬
posed of two major cell types, epithelial-like cells
and fibroblast-like cells. Melancon et al (1971)
have commented that the epithelial-like cells are
difficult to subculture and can be maintained for
only two to five passages. It is recognized that
medium composition can alter cell morphology (eg,
Griffiths, 1973). In this regard it should be noted
that for this series the medium was prepared in
large batches and that the various cell types not only
co-existed in the same culture vessel but cell strains
of predominantly different morphologies were being
cultured concurrently. The only comprehensive
report of the various cell types is that of Uhlendorf
(1970). He has described fibroblast-like cells and
epithelial-like cells corresponding to types II and
III of this report. The 'small fusiform cells' which
he describes probably correspond to the type I epi¬
thelioid cells of this report. When the islands in
which these cells grow become large, the cells in the
centre of the island become crowded and take on an
appearance very similar to that shown in Uhlen-
dorf's Fig. 2. In addition, Uhlendorf described a
cell type not recognized in the present series (Fig.
5 in Uhlendorf, 1970).
It is clear that amniotic fluid cell strains are com¬
posed of a number of different cell types and that
some, if not all, of these can persist as long as the cell
strain survives. If the various tissue culture media
in general use and the variety of conditions under
which these cells can be cultured had the effect of
selecting against any particular cell type then this
could explain the apparent differences reported in
the behaviour of amniotic fluid cell strains. The
very act of subculturing may in fact be such a selec¬
tive mechanism as the fibroblast-like cells are more
readily removed from the growth surface than epi¬
thelial-like ones. Melancon et al (1971) have indeed
used this feature to select cell strains of different
morphology.
The findings of normal karyology in the cell
strains monitored until senescence is not surprising.
The types of chromosome changes which have been
described in senescent human diploid fibroblast-like
cells (Saksela and Moorhead, 1963) would not have
been demonstrated due to the small number of cells
examined but any major departure from euploidy
would have been detected. No cell lines or cell
strains other than those derived from amniotic
fluid or urine (Sutherland and Bain, 1972) were
handled in the laboratory during the time this work
was in progress.
The main question posed by this work is, why
cannot all amniotic fluid cell strains be maintained
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for the same length of time as cell strains derived
from other fetal tissues? One reason is probably the
low cell number used to initiate cultures but this is
only part of the answer. The reasons for the vari¬
ability in life expectancy of these cell strains remain
speculative. The factors which prevent these cul¬
tures from having a prolonged existence should be
identified. The loss of valuable amniotic fluid cell
strains at an early passage is a hindrance to building
up adequate controls for the antenatal diagnosis of
genetic disease using cultured amniotic fluid cells.
We are grateful to Professor A. E. H. Emery for help¬
ful criticisms during the preparation of this report3 and
to Dr S. Stewart for the Mycoplasma testing. This
work was supported in part by the Scottish Advisory
Committee on Medical Research and the Secretary of
State for Scotland.
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Amniotic fluid macrophages and the antenatal
diagnosis of anencephaly and spina bifida
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Summary. The macrophage content of amniotic fluid has been measured and
the upper limit of normal on an arbitrary scale is 41. Amongst 65 amniotic fluids
collected for antenatal diagnostic studies before 22 weeks' gestation there were eight
which had macrophage counts ranging from 82 to 6226, three of these were shown
to have anencephaly and two spina bifida. The reasons for three apparently false
positives are as yet undetermined. Rhesus iso-immunized amniotic fluids were
found to have macrophage counts of up to 276 and a possible explanation for this is
considered. It is argued that an elevated amniotic fluid macrophage count may
indicate a CNS defect or possibly other fetal abnormality.
The finding by Sutherland, Brock, and Scrim-
geour (1973) of large numbers of macrophages in
the amniotic fluid from two cases of anencephaly has
been used by Nelson, Ruttiman, and Brock (1974)
to make the antenatal diagnosis of a further case.
The macrophage content of spina bifida and anen-
cephalic amniotic fluids has been quantitated and
compared with that from normal pregnancies.
counted and this number was adjusted to relate to 10 ml
of amniotic fluid, ie, if the cells from 5 ml of amniotic
fluid had been inoculated into the Petri dish then the
number was multiplied by two. The resultant macro¬
phage count (glass adherent cells/10 low power fields/
10 ml of amniotic fluid) has been used to compare dif¬
ferent samples of amniotic fluid. Amniotic fluid a-
fetoprotein was measured according to Brock and Sut-
cliffe (1972).
Materials and methods
Amniotic fluids were obtained by amniocentesis for
antenatal chromosome studies, a-fetoprotein estimation,
during the management of Rhesus iso-immunized preg¬
nancies and at induction of labour in cases where the
fetus was known to have anencephaly.
Amniotic fluid cultures were established as previously
described (Sutherland, Grace, and Bain, 1973). The
culture vessel was a 50 mm Petri dish which contained
five or six 6 x 22 mm glass coverslips. The culture
medium was Ham's F10 supplemented with 30% fetal
calf serum. The day after cultures had been set up
(usually about 20 hours later) one of the coverslips was
aseptically removed from the Petri dish, washed well in
phosphate buffered saline, fixed with methanol, stained
with Giemsa, and mounted on a slide. The number of
glass adherent cells in 10 low power fields ( x 100) were
Received 21 June 1974.
* Present address and reprint requests to: Cytogenetics Unit,
Department of Pathology, The Adelaide Children's Hospital, North
Adelaide 5006, Australia.
Results
The macrophage counts for the 94 fluids studied
are shown in Fig. 1. All the fluids classed as 'nor¬
mal' had low macrophage counts (range 0-41), and
there was no reason to suspect fetal CNS abnor¬
mality either because the infant had been delivered
or because the amniotic fluid a-fetoprotein levels
were not elevated. Four amniotic fluids from cases
of hydramnios of unknown aetiology had macro¬
phage counts within the normal range. A number
of samples of amniotic fluid showing different de¬
grees of blood staining had normal macrophage
counts. Rhesus iso-immunized amniotic fluids had
highly variable macrophage counts ranging up to
276. Where serial samples were obtained from
these pregnancies the macrophage counts tended to
decrease as gestation progressed.
Details of the cases with anencephaly or spina
bifida are shown in Table I. In all except one of
these fluids the macrophage count was elevated,









DATA ON AMNIOTIC FLUIDS FROM THE TWIN










1 21 6226 238 ASB
2 17 1540 254 ASB
18 1640 250
3 36 660 6.4 ASB
4 33 590 26 ASB
35 10 21
5 29 630 44 ASB
6 15 576 680 ASB
7 14 168 181 SB
16 189 173
8 13 82 143 SB
15 84 118
* ASB = anencephaly and spina bifida; SB = spina bifida.
ranging from 82 to 189 for the spina bifida fluids and
from 576 to 6226 for the anencephalics. The fluid
in which the macrophage count was not elevated was
the second sample received from a twin pregnancy
in which one of the twins was normal and the other
anencephalic. Details of this case are shown in
Table II.
There are three cases, listed as 'false positive' in
Fig. 1 which are a problem in that they had ele¬
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Fig. 1. Macrophage counts of amniotic fluids in this study in rela¬
tion to gestation. Cases 1 and 2 have been previously reported
(Sutherland et al, 1973a).
TABLE I
DATA PERTAINING TO EIGHT CASES WITH
CNS ABNORMALITIES IN THIS STUDY
levels. These pregnancies were allowed to continue
and the one which had the highest macrophage
count went into premature labour at 33 weeks'
gestation and resulted in a normal male infant.
The placenta showed multiple recurrent infarctions,
there was a small succenturiate lobe and the cord
had many false knots. The two other similar
pregnancies are continuing.*
The possibility that interfering with the amniotic
fluid cultures on the day after they have been set up
may affect their success was tested by comparing the
times required to achieve cytogenetic results from
the first 25 normal cultures on which macrophage
counts were performed (mean 13.0 days) with the
20 similar cultures studied before macrophage
counts were being done routinely (14.5 days). In
all cases where a cytogenetic result was required
after macrophage counts had been performed this
was achieved. It was not possible to differentiate
between amniotic fluids with normal and raised
macrophage counts (except in those cases where the
macrophage count was grossly elevated) by direct
inspection of the cultures with the inverted micro¬
scope. Quantitation of stained material was neces¬
sary for this purpose and its preparation did not
prejudice the success of the cultures in any way.
Discussion
The antenatal diagnosis of anencephaly and spina
bifida can be achieved with a high degree of success
using amniotic fluid a-fetoprotein measurements
(Lancet, 1974). Ideally all samples of amniotic
fluid, collected for any reason before mid-pregnancy,
should have a-fetoprotein estimations carried out.
The two cases of spina bifida in this report were
diagnosed from amniotic fluids collected primarily
for antenatal chromosome studies.
The nature and origin of the glass-adherent cells
in the amniotic fluid must be considered before
their clinical relevance is discussed. All the glass-
adherent cells in amniotic fluid are probably not
macrophages but erythrophagocytic properties
* These subsequently led to the birth of full-term normal infants.
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(Sutherland et al, 1973a) and ultrastructural
studies (G. R. Sutherland, unpublished observa¬
tions) have shown that at least a proportion of them
are. In the cases where there is an open CNS
lesion there are two likely sources of the macro¬
phages. The CSF is in free communication with
the amniotic fluid and the CSF is known to contain
macrophages (Greenfield and Carmichael, 1925;
Chester, Penny, and Emery, 1971). In these cases
with open lesions there is considerable exposure of
highly vascularized tissue, with only a membrane
between the fetal circulation and the amniotic
fluid; this should present little hindrance to the pas¬
sage of circulating macrophages into the amniotic
fluid. In the absence of a fetal lesion the origin of
the macrophages is unclear, however cytological
(Casadei et al, 1973) and ultrastructural (Hoyes,
1968) studies of normal amniotic fluid have revealed
the presence of macrophages. The finding of in¬
creased macrophage counts in Rhesus iso-immu-
nized amniotic fluids is of interest since an increase
in placental macrophages (Hofbauer cells) has been
described in this condition (Fox, 1967). In the
Rhesus iso-immunized fetus there is an increase in
extramedullary haemopoiesis (Morison, 1961),
hence it is possible that an increase in circulating
macrophages could be responsible for the increase in
both the Hofbauer cells and the amniotic fluid
macrophages. The mechanism of escape of the
macrophages into the amniotic fluid is unknown but
migration via the lungs and kidney tubules are possi¬
bilities.
There are a number of conditions which might
lead to elevated amniotic fluid macrophage counts.
Such conditions could include any fetal lesion which
is not covered with skin, apart from the CNS defects
exomphalos is one possibility. Conditions other
than Rhesus iso-immunization in which there is in¬
creased extramedullary haemopoiesis such as the
chondrodystrophies (Potter, 1961) and intra-uterine
infection (Bain et al, 1956) might be expected to
show an increase in amniotic fluid macrophages.
Macrophage counts would appear to be of value
in two circumstances. Firstly, as an independent
confirmation of an antenatal diagnosis based on a-
fetoprotein levels; this may be particularly helpful if
a-fetoprotein levels are equivocal. Second, where
a-fetoprotein is not being routinely measured on
amniotic fluids which are collected for other pur¬
poses a raised macrophage count would be a strong
indication that a-fetoprotein levels should be esti¬
mated. There have been no false negative results
in this series except for the unaccountable finding
from the second sample from the twin pregnancy.
Hence it appears unlikely that the macrophage
count would be normal in cases of open fetal CNS
defects. The main problem appears to be false
positive results, the proportion of which will depend
on the local incidence of CNS lesions. In the pre¬
sent series there were eight out of 65 amniotic
fluids of less than 22 weeks' gestation examined
blindly which had elevated macrophage counts and
five of these proved to have open CNS lesions.
Perhaps macrophage counts greater than 500 will
prove to be diagnostic of anencephaly but at present
it would be unwise to diagnose fetal abnormality on
the basis of a raised macrophage count alone.
Further studies of the macrophages in amniotic
fluid are required to assess fully the usefulness of this
parameter in antenatal diagnosis. The false posi¬
tives require special attention to try and determine
whether they are of any significance. It may well be
that a raised amniotic fluid macrophage count is a
non-specific indication that all is not well with the
fetus.
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Chromosomal mosaicism
in amniotic fluid cell cultures
Grant R. Sutherland*, Susan M. Bowser-Riley and A. Douglas Bain
Department of Pathology, Royal Hospital for Sick Children, and
University of Edinburgh, Edinburgh, Scotland
Six cases of chromosomal mosaicism detected in amniotic fluid cultures are described.
In five of these there was no evidence of fetal mosaicism. In one case fetal mosaicism
was demonstrated but only by the study of fibroblasts since blood cultures showed only
normal cells. The implications of amniotic fluid mosaicism are discussed and it is con¬
cluded that this usually does not indicate fetal mosaicism. The value of repeated amnio¬
centesis in the diagnosis of fetal mosaicism was demonstrated by findings in three of the
cases. It is recommended that amniotic fluid cultures be harvested in situ for chromosome
studies and that cytogenetic results be expressed as number of colonies karyotyped rather
than as number of cells analyzed.
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The occurrence of chromosomal mosaicism
in amniotic fluid cell cultures has been re¬
ported by several authors (Kajii 1971, Lee
et al. 1972, Hsu et al. 1973, Cox et al. 1974)
but only once has this been shown to reflect
the fetal chromosome constitution (Bloom
et al. 1974). Six further cases of mosaicism
in amniotic fluid cell culture are described;
however, in only one of these was fetal mo¬
saicism demonstrated.
Materials and Methods
Amniotic fluids collected by transabdomi¬
nal amniocentesis, for a variety of reasons,
are studied in this laboratory. The culture
methods and chromosome harvesting tech¬
niques have been previously described (Su¬
therland et al. 1973). The culture vessel was
a 50 mm plastic Petri dish containing a
number of 6 X 22 mm glass coverslips.
When coverslips were ready for harvesting
they were removed aseptically from the
Petri dish, exposed to colchicine in another
vessel and processed with the cells in situ.
Hence a harvested coverslip contained the
cells from one or more colonies fixed in situ.
When the cells remaining in the Petri dish
became confluent they were subcultured and
chromosome preparations made using
standard trypsin suspension methods. Chro¬
mosome studies on fetuses and neonates
were carried out using standard methods.
Fetal C.S.F. was treated similarly to am¬
niotic fluid.
* Present address: Department of Histopathology, The Adelaide Children's Hospital,
Adelaide, Australia.
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Results
Six amniotic fluid cultures have been exam¬
ined which showed chromosomal mosaic¬
ism. Since each case was different they will
be presented individually.
Case 1. Amniocentesis was carried out at
14 weeks' gestation on a 26-year-old woman
who had had a child with Down's syn¬
drome. Routine amniotic fluid a-fetoprotein
estimation indicated the presence of a fetal
CNS abnormality and the pregnancy was
terminated (Case 7, Sutherland et al. 1975)
at which time a further sample of amniotic
fluid was obtained and fetal tissues were
collected for fibroblast culture. The cyto¬
genetic findings are summarized in Table
1. The fetus was found to have an open
myelomeningocele but no malformations
indicative of autosomal trisomy. The colo¬
nies on the first coverslip harvested were
very diffuse so that it was not possible to
define where one ended and the next began.
The best quality metaphases had karyotype
47,XX, + D, but a few of the poorer quality
cells appeared to be normal. Subsequent
coverslips contained only normal cells but
subculture of the remaining cells in the Petri
Table 1
Cytogenetic data pertaining to Case 1
Table 2
Cytogenetic data pertaining to Case 2
Culture
Karyotype






first coverslip 1* 3 2* 17
subsequent coverslips 9 0
after subculture 19 9
Second amniotic fluid:












after subculture 73 7
Second amniotic fluid:
after subculture 65 1
Fetal skin 30 0
see text.
dish produced a cell strain which was about
30 % trisomic. The pregnancies relating to
all the amniotic fluid cultures in the labora¬
tory at that time have now concluded and
there has been no unexpected D-trisomic
infant.
Case 2. Amniocentesis at 13 weeks' gesta¬
tion was carried out on a 39-year-old wo¬
man because of the risk of Down's syn¬
drome. Amniotic fluid a-fetoprotein estima¬
tion indicated the presence of a fetal CNS
defect and the pregnancy was terminated
(Case 8, Sutherland et al. 1975) at which
time a further sample of amniotic fluid and
fetal tissues were obtained for culture. One
cell colony from the first sample of am¬
niotic fluid showed karyotype 45,XX, — G.
The cytogenetic findings are summarized in
Table 2. The finding of one cell with a G-
group chromosome missing in 66 from the
second sample of amniotic fluid was not
regarded as significant.
Case 3. Amniocentesis was carried out at 21
weeks' gestation on a 31-year-old woman
who had had a child with Down's syn¬
drome. The amniotic fluid culture showed
sex chromosome mosaicism; the cytogenetic
findings are summarized in Table 3. A nor¬
mal male infant was born at term but it has
not been possible to carry out cytogenetic
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studies. The mosaicism was presumably due
to maternal cellular contamination of the
amniotic fluid.
Case 4. Amniocentesis at 16 weeks' was car¬
ried out on a 35-year-old woman because of
the risk of Down's syndrome. Two colonies
of cells were found with a karyotype inter¬
preted as 45,X, the remaining colonies being
of normal male karyotype. The cytogenetic
data are summarized in Table 3. Cultures
were tested for mycoplasma and reported
not to contain these organisms. The preg¬
nancy was allowed to continue even though
the possibility that the fetus was a mosaic
could not be ruled out. A phenotypically
Table 4
Cytogenetic data pertaining to Case 6
Culture
Karyotype














Cytogenetic data pertaining to Cases
3, 4 and 5
Karyotype






















after subculture 0 50
Cord blood 0 100
46,XX
46,XX,










after subculture 40 0
Cord blood 100
normal male infant was delivered but suf¬
ficient studies could not be carried out to
exclude the possibility of mosaicism as only
cord blood cultures were examined.
Case 5. Amniocentesis at 13 weeks' was car¬
ried out on a 29-year-old woman who had
a previous child with spina bifida. One
colony of cells was found with an appar¬
ently balanced translocation t(2p— ;F? + ).
The cytogenetic findings are summarized in
Table 3. The cultures were tested for myco¬
plasma and reported not to contain these
organisms.
Case 6. Amniotic fluid was collected at 27
weeks' from a 41-year-old woman due to
Rhesus isoimmunization to be used for other
studies in the laboratory; the chromosomes,
however, were routinely checked. Since an
extra small metacentric chromosome was
found in the cells of one colony, further
samples of amniotic fluid, collected during
the management of the Rhesus isoimmun¬
ization, were studied and the mosaicism
confirmed. Because of the severe Rhesus
isoimmunization the pregnancy was inter¬
rupted by Caesarean section at 34 weeks'
and a male infant delivered. Skin, cord,
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amnion and cord blood were cultured for
chromosome study. The cytogenetic findings
are summarized in Tabic 4. The infant sur¬
vives as a small boy and at 6 months of age
has no detectable phenotypic abnormality
which could be attributed to his karyotype.
Discussion
The finding of mosaicism in amniotic fluid
cultures causes difficulties in interpretation
of the results and raises a difficult clinical
problem. When there are two (or more) cell
populations present in an amniotic fluid cul¬
ture there are a number of possibilities: 1)
twin pregnancy; 2) if one of the cell popu¬
lations is female there might be mixture of
fetal and maternal cells; 3) the fetus is not a
mosaic but for some reason the culture
shows mosaicism; or 4) the fetus is a mosaic.
The possibility of twins leading to culture
mosaicism does not seem to have been re¬
alized, as there are reports of twins follow¬
ing amniocentesis where culture mosaicism
was not evident.
When one cell population is female the
question of maternal cellular contamination
of the amniotic fluid sample arises. This is
presumably the explanation in the case of
the XX/XY mosaic in this series and in
other similar cases (e.g. Macintyre 1971).
True fetal mosaicism will remain difficult
to detect antenatally for two reasons. The
first is the difficulty in the interpretation of
chromosome mosaicism detected in amniotic
fluid cultures. Repeated amniocentesis
should be most helpful in this regard. In
the present series, mosaicism was not ap¬
parent in the second sample of the two cases
(1 and 2) in which repeat samples were
examined. In the case where fetal mosaicism
was present the mosaicism was seen in cul¬
tures from three samples of amniotic fluid
collected at different times during preg¬
nancy.
The second reason for the difficulty is
that even if large numbers of metaphases
are available for analysis these may come
from a small number of colonies. The
monokaryology of colonies in mosaic cul¬
tures suggests that these are clones. This
suggestion is supported by the work of
Uhlendorf (1970) on amniotic fluid cul¬
tures heterozygous for the Lesch-Nyhan
syndrome. Cox et al. (1974) found that on
average three colonies per Petri dish were
analyzable cytogenetically, hence an anal¬
ysis performed on two Petri dishes would
yield a result based on only about six fetal
cells. In this laboratory there are usually
one to three colonies per coverslip available
for analysis, but up to six coverslips can
be harvested from a single Petri dish.
Another problem arises in either confirm¬
ing or excluding fetal mosaicism by extra¬
uterine studies once it has been diagnosed
in utero. The only case of fetal mosaicism
detected in the present series would have
gone unconfirmed if only blood cultures had
been examined. Some of the other fetuses
in this and other series where blood was
the only tissue studied may have been
mosaics.
The reasons for mosaicism in amniotic
fluid cultures, apart from cellular conta¬
mination, remain obscure. The possibility of
a colony arising from a single aberrant cell
seems most likely but in at least two of the
cases in the present series more than one
aberrant colony appeared to be present. It is
of some interest that the six Cases presented
in this report occurred within a 2-month
period at the beginning of 1974; over this
time about 20 % of the amniotic fluid cul¬
tures studied were mosaics. During the 3
years in which this laboratory has been
karyotyping amniotic fluid cultures, no
other mosaics have been detected and no
cytogenetic errors, including sex determina¬
tion, have been made from the study of
over 200 fluids. This clustering in a short
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time may be due to chance, or perhaps
during this period there was some agent in
the culture medium causing aneuploidy, al¬
though the fetal mosaic and the XX/XY
mosaic were probably not due to influ¬
ences of the culture conditions. Schnei¬
der et al. (1974) have shown that Myco¬
plasma contamination of cultures could
cause structural rearrangements likely to
lead to diagnostic errors. In the present
cases no cultures were found to contain
mycoplasmas when tested.
The cytogenetic analysis of amniotic fluid
cultures must be approached with greater
caution than that of other tissues. As Cox et
al. (1974) have pointed out, the harvesting
of cultures in situ has advantages over other
methods, especially in interpreting results, if
more than one cell population is detected.
The expression of results as number of colo¬
nies karyotyped is more meaningful than if
expressed as number of cells analyzed. In
the majority of cases when more than one
cell population is detected in an amniotic
fluid culture the fetus will not be a mosaic.
Repeat amniocentesis would be, however,
essential in order to confirm this.
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Lysosomal enzyme levels in human
amniotic fluid cells in tissue culture
IV. %A N-acetyl-ft-D-glucosaminidase
J. Butterworth, G. R. Sutherland, G. J. Guy, S. Bowser-Riley, and A. D. Bain
Department of Pathology, Royal Hospital for Sick Children, and
University of Edinburgh, Edinburgh, Scotland
Total and % A hexosaminidase were similar for primary cultures and later passages of
amniotic fluid cells. The culture variables - through serial passage, within a passage and
replicate primary cultures - resulted in some variation in total hexosaminidase, but an
insignificant change in % A hexosaminidase. They are unlikely to give rise to any problems
in the antenatal diagnosis of Sandhoff's and Tay-Sachs diseases.
Received 7 October, accepted for publication 22 December 1975
Although the activity of lysosomal enzymes,
including hexosaminidase (Butterworth et al.
1974), is known to fluctuate in amniotic
fluid cells during culture, the extent to
which % A hexosaminidase varies during
culture has not previously been reported.
Methods
To investigate the effect of passage on hexo¬
saminidase, primary amniotic fluid (second
trimester) cell strains were divided between
plastic T-flasks and petri-dishes containing
three 5 X 22 mm glass coverslips. At con-
fluency the T-flasks were similarly subdivided
until the tenth passage, and two of the cover-
slips were removed for biochemical studies
and the other for morphological study at each
passage. To find the effect of subculture, am¬
niotic fluid cells were added to r. petri-dish
containing eleven 6 X 22 mm glass cover-
slips; and one was removed for assay on
each successive day. To study variation in
enzyme activity between primary cultures
derived from the same amniotic fluid, five
6 X 22 mm glass coverslips were removed
from six separate primary cultures for assay.
For cell extraction, the coverslips were
washed twice with phosphate-buffered saline
and placed in 0.5 ml distilled water. The cells
were scraped off, the extract spun at
800 X g for 10 min at 5°C and stored at
— 65°C until assay.
The activity of hexosaminidase was esti¬
mated using 2mM 4-methylumbelliferyl-2-
acetamido-2-deoxy-(3-D-glucopyranoside
(Koch-Light Lab. Ltd.) in 0.2M phosphate /
0.1M citrate buffer pH 4.5 and related to
protein (Lowry et al. 1951). The % A hexo¬
saminidase was estimated using a DEAE-
cellulose batch technique (Butterworth 1975).
Results
At least for the four strains used, total hexo¬
saminidase activity and % A did not show
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Table 1
Total activity* and % A of hexosaminidase in five replicates of six primary amniotic
fluid cell cultures
Strain 1 2 3
Replicato 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5
Total activity 62 62 44 61 72 57 38 59 51 42 51 55 58 68 62











Fig. 1. The activity of total and % A hexosaminidase
in serial passages of four strains of cultured amniotic
fluid cells.
TIME AFTER SUBCULTURE (DAYS)
Fig. 2. The activity of total and % A hexosaminidase
in two strains of amniotic fluid cells in relation to
time since subculture.
marked variations or a consistent trend
with passage (Fig. 1) and differences in
morphological cell type - strains 1 and 2
were epithelioid and strains 3 and 4 fibro¬
blastic - had little effect. The primary cul¬
ture levels did not show any consistent
difference from the later passages.
Although cell strain 1 (epithelioid) exhi¬
bited more fluctuations during a subculture
than strain 2 (fibroblastic), the variations in
total enzyme activity and % A were not
marked (Fig. 2). Total hexosaminidase ac¬
tivity fluctuated more markedly in primary
replicates than the % A which fell within
a narrow range for each cell strain (Table 1).
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Table 1
(cont.)
Strain 4 5 6
Replicate 12345 12345 12345
Total activity 40 45 46 51 52 53 64 49 52 43 57 53 53 55 40
°/o A 75 77 73 79 78 73 71 75 72 71 69 75 68 71 73
In general, whilst fluctuations in the % A
occurred in amniotic fluid cells through
serial passage, within a single passage and
in primary replicates, they were less than
for total hexosaminidase activity.
Discussion
The present study indicates that amniotic
fluid cells cultured on glass coverslips can
be used for the investigation of enzyme
activity in relation to culture variables, and
that replicate enzyme results can be obtain¬
ed at the primary culture stage without the
possibility of losing the culture at subcul¬
ture. Hence an antenatal diagnosis can be
undertaken in a shorter time than by con¬
ventional techniques, and the method has
already been utilized to screen for Sand-
hoff's disease (Butterworth & Broadhead
1975).
Unlike results obtained with cultured skin
fibroblasts (Okada et al. 1971, Milunsky et
al. 1972, Hultberg et al. 1973), cultured
amniotic fluid cells showed no consistent
trend in % A within a subculture, less re¬
plicate variation and no increasing hexo¬
saminidase activity with passage. The con¬
stancy of % A found in amniotic fluid cells
with passage, within a passage and replicate
culture, indicates that it is unlikely that an
error due to these culture variables would
occur in the antenatal diagnosis of Tay-
Sachs disease.
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AMNIOTIC-FLUID ALPHA-FETOPROTEIN IN
TURNER SYNDROME
Sir,— There have been conflicting reports about the level of
amniotic-fluid j-fetoprotein (a.f.p.) when a fetus has Turner
syndrome.' 1 We have studied a pregnancy in which Turner
syndrome was diagnosed antenatally. The pregnancy was ter¬
minated by hysterotomy at 20 weeks' gestation, and the intact
gestation sac was removed (Dr R. Wurm) and transported to
the laboratory withm an hour. Cord-blood lymphocyte culture
confirmed the fetal karyotype to be 45,X.
Fetus with Turner syndrome after 30 ml of fluid had been aspir¬
ated from left cervical pouch.
During collection of amniotic fluid from the sac one of the
large fetal cervical pouches was inadvertently punctured, and
30 ml of clear amber liquid which looked like amniotic fluid
was obtained without difficulty. Subsequent inspection of the
cervical pouches showed a needle mark in the left pouch but
little apparent decrease in size (see figure). Amniotic fluid was
obtained from the sac.
Analyses of the amniotic and pouch fluids are shown in the
table. The cord-blood a.f.p. was 1045 mg/1. Cells from both
fluids grew in culture to show 45,X karyotypes, although only
the pouch fluid had a raised macrophage-count.3 Neither fluid
was macroscopically bloodstained. The a.f.p. level in the fluid
obtained at the diagnostic amniocentesis at 15 weeks' gestation
was 16 mg/1 (normal range 5-32 mg/1).
We suggest that the high levels of amniotic-fluid a.f.p.
reported in some instances of Turner syndrome' may result
2
COMPOSITION OF AMNIOTIC AND CKRVTCAI.-POICH FT I'll) A I 20
weeks' gestation






from aspiration of the fetal cervical pouches at amniocentesis.
The Huid obtained would macroscopically and chemically
resemble amniotic Huid. Fluid from a cervical pouch may have
an increased macrophage-count and a.f.p. level as in this case.
There is no reason to suggest that the pouches leak4 a.f.p. into




North Adelaide, South Australia 5006 GRANT R. SUTHERLAND
Department of Chemical Pathology,
Adelaide Children's Hospital DEN1SE HOLT
Genetics Research Unit,
Royal Children's Hospital Research Foundation,






1 Hunter. A.. Hammerton, J. L., Basket!, 1 ., Lyons, L. Lancet, 1976, 1, 596.
2. Seller, m. j. ibid p. 807.
3. Sutherland, g. R., Brock, d. J. H., Scnmgeour, J. B. J. mcd. Genet. 1975,
12,135.
4. Seller, M. J., Creasy, M. R., Alberman, E. D. Br. med.J 19"4, u, 524.
Printed in
Great Britain
©1 977 The Lancet,
7, Adam Street, Adelphi, London, W.G.2.
C 58
Prenatal Diagnosis of Chromosome Abnormalities
by Grant R. Sutherland, Cytogenetics Unit, Department of Histopathology,
The Adelaide Children's Hospital
It is now 13 years since Fuchs and Philip
(1963) claimed, in an abstract published in
Norwegian, that they had successfully cultured
the cells from two out of three samples of
amniotic fluid but that they had not managed
to complete chromosome studies. Three years
later Steele and Breg (1966) were the first to
fully document the culture of, and chromosome
studies from, amniotic fluid cells. This ability to
karyotype amniotic fluid was rapidly con¬
firmed by several other groups (e.g. Thiede
et at., 1966; Jacobson and Barter, 1967).
Prenatal diagnosis of chromosome abnormal¬
ities as a practical procedure was demonstrated
when Gerbie et at. (1971) reported success¬
fully karyotyping 238 out of 250 successive
samples of amniotic fluid. Not all subsequent
published series have recorded such high
success rates; however most laboratories now
have a success rate of 90-95 per cent for
karyotyping samples of amniotic fluid and
better than 95 per cent success in prenatal
diagnosis.
PREREQUISITES FOR SUCCESSFUL
AMNIOTIC FLUID CELL CULTURE
1. The laboratory facilities must be adequate
and the staff experienced in all aspects of
tissue culture. Constant attention to the many
details of this technique is essential as success
or failure in tissue culture is not usually the
result of any single factor. A reliable source of
high quality tissue culture medium is also
essential. The serum component of the medium
can present considerable problems and each
new batch of serum to be used requires
extensive testing to ensure that its growth
promoting properties are adequate. Different
batches of serum can result in different average
times required to produce results and poor
serum can result in culture failure (Laxova et
a I., 1975).
2. The sample of amniotic fluid should be of
adequate volume, not contaminated with blood
and must not be maternal urine. Whilst most
laboratories can produce results from small
volumes of grossly blood-stained fluid such
material is obviously undesirable. The dif¬
ferentiation of maternal urine from amniotic
fluid is relatively simple and should be
routinely performed (Pirani et a!., 1976;
Guibaud et at., 1976) by quantitation of such
components as urea, creatinine or potassium.
SOURCES OF CULTURE FAILURE
Even the most successful laboratories are
unable to obtain satisfactory growth in tissue
culture from 1-2 per cent of amniotic fluids.
It would appear that this small proportion of
fluids contains inadequate numbers of colony-
forming cells for culture to be successful. Other
failures are due to inadequate laboratory
technique; although some workers claim that
heavy blood-staining of the fluid can be a
source of culture failure and delayed results
(Laurence and Gregory, 1976; Milunsky and
Atkins, 1975), others find that this does not
lead to problems (Robinson et at., 1973).
Sources of failure due to inadequate laboratory
technique include microbial infection of cul¬
tures, laboratory accidents, use of inadequately
tested culture medium and failure of cyto¬
genetic processing techniques (Milunsky and
Atkins, 1975; Laurence and Gregory, 1976).
SOURCES OF ERROR
All laboratory techniques are prone to a number
of errors, such as confusion, loss and mis¬
labelling of samples, accidents, etc., but these
will not be discussed further.
Maternal cell growth
It has been estimated that in about 1 per cent
of cases of amniotic fluid cell culture, maternal
cells and notfetal cells are cultivated (Milunsky,
1973). Whilst this cannot be readily overcome
there are a number of steps which may be
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TABLE I Chromosome analysis of colonies in amniotic fluid cell cultures in which mosaicism has
been detected
Colony Counts Amniotic Fluid Infant
Authors NormaI Abnormal Karyotype Karyotype
Cox etal. (1974)
Case 1 32 1
Case 2 33 2
Case 3 42 1
Case 4 79 1
Sutherland et al (1975b)
Case 1 10 2
Case 2 8 1
Case 3 3 2
Case 4 13 2
Case 5 4 1
Case 6 1111
Nuzzo et al. (1 975)
Case 1 11
Case 2 9 1
46, XX/46, XX, t (2 ; E) 46, XX
46, XY/46, XY, t (B ; C)/47, XY, + C 46, XY
46,XY/47,XY, +2 46, XY
46, XX/47, XX, — C 46, XX
46.XX/47, XX, + D 46, XX
45, XX, — G/46.XX 46, XX
46, XX/46, XY 46, XY
45, X/46.XY 46,XY
46, XX/46, XX, t (2 ;F) 46, XX
46, XY/47, XY, + mar 46, XY/47, XY, + mar *
46, XX/46, XX, t (3 ; 12) 46, XX
46, XY/46,XY, del (5q) 46,XY
* Not seen in 100 cells from blood but present in cultures of skin, cord and amnion.
taken to recognize the problem. Sex determina¬
tion of the amniotic fluid, by X and Y chromatin
study, can usually identify those cases in
which the fetus is male but the chromosome
results predict a female. Furthermore, harvest¬
ing of chromosomes from more than one
culture vessel and the harvest of primary
cultures in situ can also help overcome this
problem (Macintyre, 1971 ; Sutherland et a/.,
1975b). Apparent XX/XY mosaicism will almost
always be due to maternal cellular contamina¬
tion and the fetus will have a normal male
karyotype; XX/XY mosaicism in the fetus will
be extremely rare. A greater difficulty is
presented when the fetus is female and
maternal cells are cultured. The only practical
means of overcoming this problem is a study
of chromosomal variants using C- and Q-
banding techniques which should differentiate
fetal from maternal karyotypes (Hauge et al.,
1975; Muller et al., 1975; Alfi et al., 1975).
This, of course, requires that paternal chromo¬
somes be studied, hence collection of blood
from both parents at or near the time of
amniocentesis for such studies has much to
recommend it (Mulcahy and Jenkyn, 1973;
Alfi et a/., 1975). This should not be left until a
fetal karyotype presenting difficulties of
interpretation is encountered as requesting
parental blood samples two to three weeks
after an amniocentesis (Macintyre et al., 1974)
which has not yet produced a result can only
cause parental anxiety. It is, however, doubtful
whether the routine study of chromosomal
variants in both parents and all female
amniotic fluid cultures is worthwhile. If one in
100 female amniotic fluids is in fact a culture
of maternal cells, and if one amniotic fluid in
30 is abnormal, then this will lead to an
erroneous diagnosis in about one case in
3,000. If this is the only error inherent in this
procedure it must be one of the most precise
laboratory examinations known.
It has been recently suggested (Hsu et at.,
1976b) that the presence of increased numbers
of macrophages in amniotic fluid cell cultures
is evidence of maternal cellular contamination.
This is not so (Sutherland, 1976). Increased
numbers of macrophages are more likely to be
an indication of a fetal CNS lesion than of
maternal cellular contamination (Sutherland
et al., 1975a). The report attributing this
relationship to maternal cellular contamination
(Hsu et a!., 1976b) suggested that these
maternal macrophages divided in culture and
were capable of being subcultured. It is highly
improbable that mature maternal macrophages
will divide in tissue culture and almost certain
that they are not capable of being sub-
cultured.
Mosaicism
Mosaics have been diagnosed in amniotic
fluid cultures on numerous occasions (Suther¬
land et at., 1975b; Nuzzo et a!., 1975;
Neirmeijer et al., 1976; Laurence and Gregory,
1976) but confirmation of mosaicism in the
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fetus or subsequently born infant has only
rarely occurred (Sutherland et al., 1975b).
Hence it is apparent that mosaicism in
amniotic fluid cultures is in most cases an
artefact. A possible explanation for this lies in
terms of the growth patterns of amniotic fluid
cells in tissue culture. Each colony in an
amniotic fluid cell culture appears to be a
clone. The relative size of the numerous clones
within any one culture varies considerably to
the extent that one clone may tend to pre¬
dominate within a culture vessel. If such a
clone had arisen from a single cell carrying a
chromosome aberration, and the culture was
harvested for chromosome studies, most of the
cells would have the particular chromosome
abnormality concerned. Most workers now
advocate the harvesting of amniotic fluid
cultures in situ rather than subculturing them
prior to harvest (Ferguson-Smith et al., 1971 ;
Cox et al., 1974; Sutherland et al., 1975b;
Nuzzo et al., 1975). Cultures harvested for
chromosome studies in situ can be analysed in
such a way that the chromosomal constitution
of each colony is determined. The finding of
one colony with a chromosome aberration can
generally be regarded as of little significance
(Table I). Antenatal diagnosis of true mosaics
is obviously fraught with difficulty. However,
the finding of more than one aberrant clone
would strongly suggest this diagnosis, especi¬
ally if it was found in more than one culture
vessel. The confirmation of such a diagnosis
should really rest on a repeat amniocentesis
yielding the same findings (Sutherland et al.,
1975b). The possibility that twin pregnancy
could give rise to apparent mosaicism has not
been recorded as only one sac is usually
entered at amniocentesis unless a deliberate
attempt is made to sample each sac (Bang et
al., 1975).
Two prenatal diagnostic errors have been
recorded in which some form of hidden
mosaicism was advanced (Kardon et a!., 1972)
as a plausible reason for the error. Kardon et al
(1972) found a karyotype 45,X in an amniotic
fluid culture but on termination the fetus was
found to have a normal male karyotype.
Katayama etal. (1974) reported a normal male
karyotype in an amniotic fluid culture and a
female Down syndrome infant with regular
karyotype was born.
The contamination of amniotic fluid cell
cultures with organisms such as mycoplasmas
can cause chromosomal damage which may
suggest mosaicism (Schneider et al., 1974).
Whilst in practice this should present little
problem, amniotic fluid cultures should be
regularly monitored for the presence of myco¬
plasma contamination.
Misinterpretation
The analysis of chromosomes from amniotic
fluid cell cultures is a situation in which a
cytogenetic diagnosis is required with virtually
no clinical information. Hence it becomes of
use to know the sex of the fetus (as mentioned
earlier) and to have access to chromosome
preparations from the parents. In the absence
of parental chromosome studies the interpreta¬
tion of chromosomal variants can present
problems (Wahlstrom, 1975). Stengel-
Rutkowski et al. (1976) have recommended
the routine use of G-banding when analysing
amniotic fluid cell cultures. These authors
present a number of cases of misinterpretation
of karyotypes without G-banding, for example
the confusion of a female Down syndrome
with a Klinefelter karyotype and the confusion
of a male Down syndrome with an XYY
karyotype. However, the routine use of such
techniques on karyotypes which are apparently
normal by unbanded criteria is probably un¬
necessary as the number of errors which will
result in the birth of a defective fetus as a result
of not using banding techniques will be
virtually nil. All necessary techniques should,
however, be used to confirm the precise
nature of any abnormal karyotype detected in
amniotic fluid cell culture.
The finding of apparently balanced de novo
translocations causes difficulties (Epstein et al.,
1972; Niermeijer et al., 1976) as it is usually
impossible to be certain that the translocation
is balanced. There is some suggestion (Jacobs,
1976) that such de novo translocations may
be associated with mental retardation.
The early errors of interpretation encountered
with tetraploid cells (Kohn and Robinson,
1970) should no longer cause problems as it
is well known that a high proportion of cells
from amniotic fluid cultures can be tetraploid
even though the fetus will virtually always be
normal in these circumstances (Walker et al.,
1970; Tegenkamp and Hux, 1974). The ante¬
natal diagnosis of fetal tetraploidy or tetraploid/
diploid mosaicism would be virtually impos¬
sible, however such conditions are extremely




The technique of prenatal chromosome study
is thus established as a reliable, accurate and
safe (Hsu et a/., 1976a) procedure. The next
question which arises is to which pregnancies
should it be directed.
The obvious answer is any pregnancy in
which there is a significant risk of aneuploidy
in the fetus. The decision as to what risk is
significant must vary according to the facilities
available, the frequency of morbidity associated
with amniocentesis and the attitudes of the
patients. Niermeijer et at. (1976) regarded a
risk of greater than 1 per cent as adequate
indication for prenatal diagnostic studies. The
most obvious high risk group is that in which
one of the parents has a chromosome
abnormality. Here the risk of aneuploidy can
be as high as 50 per cent but is usually lower
than this, ranging from 2-20 per cent.
Another high risk group to which prenatal
chromosome study is applicable is that in
which the mother carries an X-linked disorder
which cannot be specifically diagnosed ante-
natally. Half the male fetuses in this group will
be affected, hence fetal sexing with termina¬
tion of male fetuses is often the procedure of
choice in such cases. Fetal sexing should be
done on chromosome preparations and should
not rely solely on X and Y chromatin study of
uncultured amniotic fluid cells (Laurence and
Gregory, 1976).
All other groups to which prenatal chromo¬
some study may be applied are at a lower risk
of producing aneuploid offspring. These
include women of advanced age and couples
who have had a previous child with Down
syndrome. It can be shown, however, that
there is considerable financial benefit to the
community in screening these groups, particu¬
larly the older mothers (Stein et a/., 1973;
Hagard and Carter, 1976).
A previous child with regular Down syn¬
drome is often regarded as an indication for
prenatal chromosome study. Epidemiological
studies have suggested that the risk of having
a child with Down syndrome is not influenced
by having had such a child previously (Kirman,
1972). However, maternal anxiety about such
recurrence is often adequate justification for
amniocentesis. A family history of Down
syndrome always requires careful investigation
before amniocentesis is offered as this is not in
itself an indication for amniocentesis (Laxova
et a!., 1975). Such families deserve a thorough
genetic workup, indeed a geneticist should be
part of the team evaluating any request for
amniocentesis before it is performed. Most
laboratories handling amniotic fluid receive
samples which were collected for inappropriate
reasons.
PROGRESS
The results of a number of series of diagnostic
prenatal chromosome studies are shown in
Table II. This table incorporates the North
American data assembled by Milunsky and
Atkins (1975) and series published from else¬
where which contained more than 50 cases.
Examination of the data in Table II shows
that the frequency of chromosome abnormal¬
ities detected is much higher than epidemio¬
logical data would suggest for all groups, with
the possible exception of parental translocation
carriers. A review of 6,000 prenatal diagnoses
by Galjaard (1976), (cited by Niermeijer et a/.,
1976) indicated that in mothers older than
38-40 years the risk of chromosome abnormal¬
ity was 4.6 per cent. Using epidemiological







Maternal age > 40 years
Maternal age 2= 35 < 40 years
Previous Down syndrome
























* From Milunsky and Atkins (1975) and other major (>50 cases) series published outside North America (Philip
et al., 1974; Wahlstrom et af, 1974; Karjalainen and Aula, 1975; Laxova et at, 1975; Laurence and Gregory, 1976 ;
Niermeijer et at., 1 976).
263
data and correcting for incomplete ascertain¬
ment Hood (1976) estimated the risk of Down
syndrome in mothers aged 35-39 to be 0.4 per
cent and in mothers 40-44 to be 1.3 per cent.
Analysis of prenatal diagnostic findings in such
women by Ferguson-Smith (1976) gave risks
of gross chromosome abnormality to mothers
aged 35-39 to be 1.5 per cent and those aged
40 or more to be 5.2 per cent. There are a
number of possible reasons for the apparent
excess of chromosome abnormalities found by
prenatal diagnosis. Most epidemiological data
are probably based on fairly incomplete
ascertainment of chromosome abnormalities.
It has been shown that about 5-6 per cent of
infants dying in the perinatal period have
chromosome abnormalities (Machin, 1975;
Bauld et at., 1974). In addition, a number of
chromosomally abnormal fetuses would prob¬
ably be spontaneously aborted even if not pre-
natally diagnosed. It has been estimated that
65 per cent of trisomy 21 conceptuses are lost
spontaneously between 10 and 26 weeks'
gestation (Creasy and Crolla, 1974). Such
chromosome abnormalities are most unlikely
to be included in epidemiological data.
Two groups from Table II require close
scrutiny. Firstly, those studied because of a
family history of Down syndrome. Only one
chromosome abnormality was detected in this
group of 88 pregnancies; this was a trans¬
location form of Down syndrome (Milunsky
and Atkins, 1975). Presumably this was a
familial translocation as the Down syndrome
was familial although no information about this
was provided. Genetic investigation of familial
Down syndrome would ensure that trans¬
location carriers at risk were offered amnio¬
centesis and that in other instances where the
risk of recurrence is small the procedure would
not be unnecessarily carried out.
The group where the indications for chromo¬
some analysis were miscellaneous is shown in
more detail in Table III for those series which
provided adequate information. Most of the
miscellaneous indications were amongst the
following: previous child with chromosome
abnormality other than Down syndrome,
parental anxiety, previous malformed child
and exposure to radiation/viral hazards.
Niermeijer et at. (1976) also included some
showing intrauterine growth retardation in the
second trimester. There were six alleged
abnormalities detected in this group. However,
four of them should not perhaps be included.
The findings in the case of chromosome
fragmentation from radiation/viral damage are
of unknown significance, as acknowledged by
the authors (Atkins et at., 1974). The case of
Down syndrome found by Laxova et at. (1975)
in their miscellaneous group was in a 35-year-
old woman; age alone would have been
adequate justification for the amniocentesis
and this case should not be regarded as
miscellaneous. Niermeijer et at. (1976) found
two abnormalities in their group. The first was
detected at 35 weeks' gestation and cannot be
strictly considered as part of a prenatal
diagnostic series as it was too late for termina¬
tion of the pregnancy. Their second case, an
XYY male, was detected as the result of a
miscellaneous indication, the mother having
had two spontaneous abortions and retarded
relatives. Laurence and Gregory (1976)
detected two abnormalities in their mis¬
cellaneous group. The first, with karyotype
TABLE III Details of prenatal diagnoses carried out for miscellaneous reasons
Authors No. Abnormals Comment
Milunsky and Atkins (1975) 116 'fragmentat
Hsu and Hirschhorn (1974) 58 •—
Laurence and Gregory (1976) 25 + 21
Gp +
Niermeijer et at. (1 976) 19 + 18
XYY
Allen era/. (1974) 16 —
Laxova et at. (1975) 16 + 21
Wahlstrom et at. (1974) 14 —
Rary et at. (1974) 10 —
Philip etat. (1974) 7 —
Doran et at. (1974) 6 —
Robinson et at. (1973) 6 —
Total 293 6
? radiation/viral damage, normal child born
maternal anxiety, age not given
pregnancy terminated, no other details
diagnosed at 3b weeks
2 previous abortions and retarded relatives
maternal age 35 years, previous "abnormal" child
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46, XY,Gp+, was found in a woman who had
a previous abnormal child of unspecified type,
no further information was provided about this
except that the pregnancy was terminated. If
this was a genuinely abnormal karyotype then
it is probable that it was familial and again
should not be included in the miscellaneous
group. Their second abnormality was a case of
Down syndrome in a woman of unspecified
age manifesting anxiety as to the outcome of
her pregnancy, again this case would seem
to be one of few detected as a result of a
miscellaneous indication.
Hence there are only two cases of chromo¬
some abnormality detected where the indica¬
tions for the test can be genuinely considered
to be miscellaneous. This is no more than
would be expected from unselected preg¬
nancies as it is not different from the incidence
of chromosome abnormality expected in un¬
selected liveborn neonates (Nielsen and
Sillesen, 1975). Whilst it can be seen that
where the indications for prenatal chromosome
study are miscellaneous there is apparently no
increased risk that the fetus will be aneuploid,
this does not necessarily mean such studies
are contraindicated as marked parental anxiety
can be a very good reason for this procedure.
Some of the other miscellaneous indications
should not indicate prenatal diagnostic studies.
This is especially the case where the parents
have had a previous malformed child which
has not been specifically diagnosed. A previous
child with a structural chromosome abnormal¬
ity, when parental chromosomes are normal,
should not indicate prenatal chromosome
studies as the recurrence risk here is very small.
Trisomy of other than chromosome 21 may
well be a reasonable indication as a few cases
have been reported of recurrent numerical
chromosome abnormalities, for example Atkins
et at. (1974) recorded a recurrence of trisomy
18. Boue and Boue (1973) have presented
data which suggest that trisomy in one
pregnancy may lead to an increased risk of
trisomy in subsequent pregnancies.
In conclusion it should be stressed that pre¬
natal chromosome analysis is a reliable and
safe procedure which, if correctly applied, can
be of immense benefit to individual couples
and the community. If incorrectly applied or
inadequately performed it can, like any other
procedure, bring disrepute to itself and those
involved with it. The procedure should be
offered to all those who can benefit from it but
they must be adequately investigated and




I have two questions. Firstly, you mentioned to
us that there was a 1 per cent risk of culturing
maternal cells rather than fetal cells. You said
that the risk in making a misclassification is 1 in
3,000. It was not obvious to me that the risk
was not higher than this. Perhaps you could
elaborate. Secondly, would it be possible to
make use of genetic markers to identify
maternal cells? I am thinking specially of the
HL-A locus which is highly polymorphic. In a
number of situations it would be possible,
using say a fluorescently labelled antiserum, to
distinguish fetal cells from maternal cells quite
rapidly.
G. Ft. Sutherland:
Firstly, you're right in saying that if we're
growing maternal cells 1 per cent of the time,
we will be making an error in 1 percent of cases.
However, as I think I showed, most of the
group that we looked at had a frequency of
chromosome abnormality that would indicate
termination of pregnancy of about 1 in 30. I
think we can multiply these figures together so
that it will only be in about 1 in 3,000 cases
that this error will be serious and I regard a
serious error as the birth of a child with a
chromosome abnormality, which, had it been
detected, would have been aborted. The second
question is something that, perhaps, you may
know more about than I do. The problem is, I
think, getting adequate numbers of cultured
cells in time.
R. F. Carter, Adelaide:
You've mentioned the probability of finding a
chromosomal abnormality in random samples
of amniotic fluid as being around 1 per cent.
You know that we and many other people
karyotype fluids sent up for alphafetoprotein
estimation or for the detection of inborn
metabolic errors. In view of your attitude,
which seems to me to be a little bit against
looking at these random fluids, do you think
we ought to go on karyotyping these as they
are really in your miscellaneous group?
G. R. Sutherland:
Yes, I think we should. I think once an
amniocentesis has been performed it's up to
us to do as much as is reasonably practical. I
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think every amniotic fluid collected for any
reason should have chromosome studies and
alphafetoprotein done on it as a bare minimum.
M. A. Ferguson-Smith, Glasgow:
Grant, you mentioned whether or not you
should do banding of amniotic cell cultures. I
think really one ought to but perhaps the
solution to getting the diagnosis rapidly to the
parents would be to give a preliminary report
on the basis of conventional techniques. We
do this. It takes longer to get banding results.
We use the banding results for confirmation.
We still have plenty of time to do something if
a result has to be retracted.
In our case with the 9p+ syndrome, we
would not have been able to diagnose this
antenatally without using banding.
The second point is, have you any adequate
explanation for the reason why the abnormality
rate in mothers over the age of 40 is greater
than 5 per cent rather than 1J per cent as
predicted by epidemiological studies and
similarly that the rate in women 35-39 is about
1J per cent, rather than 0.3 per cent? Thirdly,
the techniques of prenatal diagnosis have been
available to us for a number of years now.
We're concerned that the numbers of cases
being studied are really very small indeed. I
think the opportunity of prenatal diagnosis has
been offered to very few people at risk, because
in the West of Scotland in the last seven years,
we've only done 1,000 amniocenteses; we
reckon that only one-tenth of the women who
really need it are having it made available to
them. And I wonder if you have any thoughts
about how we can put this right ?
G. R. Sutherland:
I will answer the questions in the order that
they were presented. I wonder how often
you've had to retract a preliminary report after




In cases of unbalanced translocations or
potential unbalanced translocations, you may
require banding. With regard to the dis¬
crepancy between the frequency of chromo¬
some abnormalities at prenatal diagnosis and
what epidemiology predicts: I'm not sure of
the reasons but I think that a number of
chromosome abnormalities would be lost
spontaneously if those pregnancies weren't
terminated immediately after the prenatal
diagnosis. Creasy and Crolla recently suggested
that 65 per cent of conceptions with trisomy 21
were lost between 10 and 26 weeks. We also
know from work that Geoffrey Machin did in
London, that I did in Edinburgh, and Kuleshov
and colleagues in Russia have done, that about
5 per cent of all infants dying in the perinatal
period have a chromosome abnormality. I think
a lot of these haven't been included in the past
in the epidemiological information on which
the recurrence figures that we use in counselling
are based. The problem of the small number of
cases that come to prenatal diagnosis has been
perplexing me for a long time too. I think it's
unfortunate that we have such a reliable, safe
procedure which isn't being taken advantage
of and which has been shown to be of benefit
to the individuals involved and to the com¬
munity as a whole. The community can make
money by promoting prenatal diagnosis and I
am at a loss, like Professor Ferguson-Smith, to
know exactly why this is so slow in getting off
the ground.
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Fragile Sites on Human Chromosomes: Demonstration
of Their Dependence on the Type of Tissue Culture Medium
Abstract. The observation of heritable fragile sites on human chromosomes pre¬
pared from lymphocyte cultures has been shown to depend on the type of tissue
culture medium in which the lymphocytes are grown. The sites are observed at a
much greater frequency when medium 199 is used than when RPMI 1640, Ham's
FIO, Eagle's (basal), and CMRL 1969 are used. One site on the X chromosome is of
clinical significance in that it is a markerfor X-linked mental retardation.
Heritable fragile sites have been de¬
scribed on a number of human chromo¬
somes, including numbers 2, 12, 16, 17,
X, and unidentified C-group chromo¬
somes (1, 2). When the autosomes are in¬
volved these sites are apparently of no
clinical significance, but the site on the X
is associated with some forms of X-
linked mental retardation (3).
1 recently attempted to reexamine a
fragile site on chromosome 2 which had
been identified and shown to be familial
some years before. Initial studies were
puzzling because the fragile site ap¬
peared to have vanished. Investigation
of this led to the finding that the fre¬
quency of lesions at the fragile site de¬
pended on the type of tissue culture me¬
dium in which the lymphocytes used
to produce the chromosomes were cul¬
tured. This observation was extended to
and confirmed for fragile sites on the X,
10, and 20 (Fig. 1).
Chromosome preparations from lym¬
phocyte cultures grown in parallel in sev¬
eral different commercially available tis¬
sue culture media were scored for the
presence or absence of a lesion at the
fragile site on a number of occasions.
The results are shown in Table 1. The
frequency of lesions at the fragile site
was always much greater when medium
199 was used than with any of the other
media. This difference was not so pro¬
nounced when the frequency of the le¬
sions was low. When a medium other
than 199 was used the frequency of these
sites was so low that they would have es¬
caped detection by routine clinical
chromosome analysis.
The reasons for these differences in
frequency of breakage at the fragile sites
according to the type of culture medium
are unknown. They may represent either
a nonspecific phenomenon related to fac¬
tors such aspH or osmolarity, or be due
to a specific chromosome breaking agent
present at higher concentrations in medi¬
um 199 than the other media used or only
present in 199. Delineation of the mecha¬
nisms responsible for this effect would
be of considerable use.
The findings reported here are of im¬
portance in the study of X-linked mental
Table 1. Frequency of observation of fragile sites according to the type of tissue culture medium
used. Tissue culture media used were purchased at single strength (except for Eagle's basal
medium which was purchased as a x 10 concentrate) from Commonwealth Serum Laborato¬
ries, Melbourne. Australia. Lymphocyte cultures consisting of 4 ml of medium, 1 ml of fetal
bovine serum. 0.1 ml of phytohemagglutinin. and 0.2 ml of venous blood were harvested ac¬
cording to standard methods after 72 hours of incubation; colchicine was applied for 2 hours and
the hypotonic solution used was 0.075A4 KC1. A cell was considered to display evidence of a
fragile site if one or both chromatids were broken at the site, if there was chromosome material
either in addition or missing which corresponded to the parts of the chromosome on either side
of the fragile site, or if a triradial figure was present. Results are expressed as number of cells


















1 2q 1 September 1972 23/50
May 1976 34/55 3/55
June 1976 25/50 0/50 3/50 3/50 2/50
September 1976 34/50 0/50
2 10q23 October 1973 36/50
May 1976 22/55 1/55
June 1976 7/50 0/50 1/50 1/50 0/50
September 1976 23/50 0/50
3 20pl 1 November 1973 33/50
May 1976 13/50 5/50 3/50 2/50
September 1976 24/50 1/50 0/50 2/50
4* 20pl 1 September 1976 22/50 0/50 2/50
5t Xq27 or 8 May 1976 8/50 5/50 0/50
64 Xq27 or 8 May 1976 4/50 0/50 0/50 0/50
June 1976 5/50 0/50 0/50 0/50
'Sibling of subject No. 3. tMale. iMother of subject No. 5.
^ . « «9 m V
f•„ •- '/ S; «*} \
a. b. c. d.
Fig. 1. Different appearances of lesions (arrowed) at fragile sites, (a) Breakage of a single
chromatid at 2ql. (b) Triradial figure caused by duplication of chromatids distal to lesion at
10q23. (c) Unstained region ofboth chromatids at 20pll. (d) Unstained region of both chroma¬
tids at Xq27 or 8.
retardation, which has been estimated to
account for one-fifth of males with an
IQ in the 30 to 55 range (4). Most de¬
scriptions of X-linked mental retarda¬
tion have included chromosome studies,
but with few exceptions (d) these have
shown nothing unusual. The fragile site
on Xq, which is directly associated with
at least one form of X-linked mental re¬
tardation, would probably have been
missed if such studies were not carried
out using medium 199; consequently,
they should be repeated.
This association of the fragile site on
Xq with one form of mental retardation
could provide a means of prenatal diag¬
nosis if the fragile site can be demon¬
strated in fibroblast cultures. Most re¬
ports of fragile sites do not include stud¬
ies on fibroblast cultures, although Fer¬
guson-Smith (/) found the frequency
of lesions at a site at 2q to be much lower
in these cultures than in lymphocyte cul¬
tures. 1 have been unable to demonstrate
the fragile sites in fibroblast cultures
from any of the cases in Table 1 regard¬
less of the type of culture medium used.
Further studies of fragile sites are re¬
quired to determine whether they all be¬
have similarly, what exactly their pheno-
typic effects are, their frequency in the
population, and their relationship to
chromosome structure. Identification of
the factors in medium 199 responsible for
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tant portion of the administered L-tryptophan (via L-5-HTP) to se¬
rotonin. From this hypothesis, it may be inferred that the raphe nu¬
clei that contain most of the brain serotonin cell bodies — the latter
being the site of synthesis of L-tryptophan hydroxylase — were ei¬
ther intact or only partially degenerated. Furthermore, an exten¬
sive post-mortem study of the brain of our Case 2 has revealed no
detectable lesion in the midline structures of the brainstem.' If it is
accepted that neuronal loss exceeding 50 per cent can be detected
when cell counts are impracticable, our negative neuroanatomic
findings suggest that at least 50 per cent of the neurons in the raphe
nuclei had survived to anoxic damage.
In the light of these data, our findings suggest that this apparent
reduction of serotoninergic mechanisms reflect not only moderate, if
any, postanoxic neuronal degeneration in raphe nuclei but also
functional alteration in serotoninergic activity of intact neurons in
raphe nuclei.
Jacques De L£an, M.D.
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CREl"I ZFELDT-JAKOB DISEASE AND SHEEP BRAIN
(CONT.)
To the Editor: The postulated relation of Creutzfeldt-Jakob dis¬
ease to the consumption of animal brain by Alter et al. (Alter M,
Hoenig E, Pratzon G: Creutzfeldt-Jakob disease: possible associa¬
tion with eating brains. N Engl J Med 296:820-821, 1977) contin¬
ues to be based on circumstantial evidence. A focus of relatively
high incidence among Libyan Jews in Israel implies, according to
that hypothesis, that the etiologic agent is prevalent in domestic
animals, especially in sheep, in the Middle East. If ingestion of
sheep brain can be responsible for transmission of the virus from
animal to man parenteral inoculation of the brain tissue should al¬
so be likely to do so. That "experiment" is conducted daily on large
numbers of persons who are exposed to rabies in Cairo, Egypt. The
rabies vaccine in current (1975) use in Egypt is a suspension of
rabies-virus-infected sheep brain treated with formalin. The dose is
5 ml, taken from a pool of refrigerated suspension in a beaker.
There is no record of Creutzfeldt-Jakob disease as a result of the in¬
oculations although the slow "viruses" are notoriously resistant to
formalin inactivation (nor are there records of transmission of viral
hepatitis by the common needle, nor of postvaccinal encephalitis,
which might be expected from the injection of so much brain tis¬
sue).
Follow-up studies of vaccinated persons in Cairo might yield
abundant data on the relation of sheep brain to Creutzfeidt-Jakob
disease, or lack of it. If affirmative, the data could point to enzooti-
cally infected flocks.
J. Frederick Bell, M.D.
Hamilton, MT 59840 USPHS Rocky Mountain Laboratory
MARKER X CHROMOSOMES AND MENTAL
RETARDATION
To the Editor: It has recently been shown1-2 that one form of X-
linked mental retardation is associated with a fragile site on the long
arm of the X chromosome in band Xq27 or 8. I have studied two
families in which X chromosomes with such a fragile site are segre¬
gating and producing mental retardation in males who received the
marker chromosome from their carrier mothers. I have found3 that
it is necessary to culture lymphocytes for chromosome prepara¬
tions in culture medium 199 if the fragile sites are to be seen. In oth¬
er commonly used culture mediums (Ham's F10, Eagle's BEM,
CMRL 1969 and RPMI 1640 have been tried) the fragile sites are
seen either not at all or at such a low frequency that they would not
be ascertained by routine clinical cytogenetic analysis. The finding
also applies to autosomal fragile sites at 2ql, 10q23, 11 q 13 and
20pll. As a result of these observations, my laboratory has revert¬
ed to using medium 199 for lymphocyte cultures for chromosome
analysis.
Detection of the marker chromosome in carrier females is more
difficult. Harvey ef al 2 could not find the marker X chromosome in
two women who were obligate carriers. In both families that I have
studied I have not been able to demonstrate the marker chromo¬
some in some of the females who are obligate carriers. I have an im¬
pression from the small numbers involved that the older the female,
the less likely the demonstration of the marker chromosome.
Prenatal diagnosis of an affected fetus is also likely to be difficult.
I have examined fibroblast cultures grown in medium 199 and in
Ham's F10 from four retarded boys in two families and have not
been able to detect any evidence of the fragile site at Xq27 or 8 al¬
though this evidence is present in lymphocyte cultures. Similarly, I
have not been able to detect autosomal fragile sites, known to be
present in lymphocyte chromosomes, in skin fibroblast chromo¬
somes regardless of the type of culture medium in which they have
been grown. Consequently, the suggestion2 that mental retardation
is amenable to prenatal diagnosis should be treated with caution at
present, and the offer of anything more than fetal sexing would be
unwise until the factors responsible for the induction of fragile sites
present in medium 199 can be isolated and perhaps used to induce
the sites in fibroblast chromosomes.
North Adelaide, S.A. 5006, Grant R. Sutherland, Ph.D.
Australia Adelaide Children's Hospital, Inc.
1. Giraud F, Ayme S, Mattei JF, et al: Constitutional chromosomal break¬
age. Hum Genet 34:125-136, 1976
2. Harvey J, Judge C, Wiener S: Familial X-linked mental retardation with
an X chromosome abnormality. J Med Genet 14:46-50, 1977
3. Sutherland GR: Fragile sites on human chromosomes: demonstration of
their dependence on the type of tissue culture medium. Science (in press)
EVALUATION OF BURN CARE
To the Editor: The recent paper by Linn, Stephenson and Smith1
provides some useful insights, particularly into the importance and
difficulty of measurements of severity in burn injury, and the quan¬
tification of the economic penalties accruing to hospitals providing
specialized burn care.
Given the exceptional costs of specialized burn facilities, the
questions raised in the article concerning the benefits of these facil¬
ities are highly important. The authors note that "Patients in hos¬
pitals with special facilities for burn care never did significantly bet¬
ter statistically in mortality or morbidity than patients in hospitals
without such special facilities." Two important additional bits of in¬
formation are essential before any conclusions can be drawn from
this finding. In the first place, there is great variability among facil¬
ities for treatment of burns. From the article it is not possible to de¬
termine what capabilities the three specialized facilities in Florida
have. Secondly, whenever a negative conclusion is drawn in a sta¬
tistical test it is important to know what size difference the test is
likely to be able to find. This is a question concerning the statistical
power of the test, which can be calculated for matched-pair designs
by the method of Miettinin.2 If the power at important levels of dif¬
ference is low, these levels of difference are quite likely not to be dis¬
covered by the study. The data necessary to calculate this power are
not in the article. Thus, we encourage the authors to provide this
power calculation. Without such power estimates, negative find¬
ings may be misleading.
D 61
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Adolescent Health, which took place at a recent
meeting in Sydney on the subject of the health
and medical care of young people. The Associa¬
tion aims to promote the health of young people
in Australia, and to encourage the development
of appropriate education, research and services
in this field. Membership is open to medical
practitioners and members of other professional
disciplines; inquiries should be directed to me,
as interim convener of the Association, at this
address.
Murray Williams.




Sir; The publicity in your press and elsewhere
of the current measles epidemic and vaccination
seems unfortunate. Surely many children in the
late incubation phase or in the early prodroma
of measles will now be vaccinated with live
attenuated virus. Surely there must be a risk of
the vaccination aggravating an existing attack
before antibodies become effective. Such an
hypothesis could explain the reported high
incidence of serious complications, for example,
encephalitis (Daily Telegraph, October 17). If
so, caution should be exercised in vaccination
during measles epidemics.
37 Earlsfield Road, Terence Lee.
London, SW18 3DB, England.
Sir: Terence Lee raises several interesting
points regarding the current measles epidemic.
Immunization tends to be neglected until an
epidemic brings home forcefully to parents the
need for protecting their children against certain
infectious diseases. Of the viral exanthemata
endemic in our community, measles is the most
serious. While it occurs every year, the incidence
is usually higher in alternate years. As the attenu ¬
ated measles virus vaccine is both safe and
effective it is recommended for all children
between the ages of 1 2 months and 1 5 months.
The use of the vaccine markedly reduces the
risks of measles complications, especially pneu
monia, encephalitis and subacute sclerosing
panencephalitis (SSPE). The attack rate of
encephalitis after immunization by live attenuated
measles vaccine is about one per million vac¬
cinated persons, compared with one per thousand
cases of natural measles.1 The incidence of
SSPE after natural measles was recently
estimated to be five to 20 times greater than that
after measles vaccination.2
If immunization is carried out at the time of an
epidemic there is, as Lee points out, the pos¬
sibility that the vaccine may be given to a
susceptible child who has already been exposed
to natural measles. No untoward effects have
been observed.1 During the long incubation
period of viral exanthemata the numbers of viral
particles in the host increase in logarithmic
fashion in many tissues, reaching levels in the
order of 108 particles per gram of tissue by the
late incubation or early prodromal stages of the
disease.3 4 5 The injection of vaccine virus at
this time represents an infinitesimal amount of
added virus compared with that already present
in the host. Should vaccination be carried out
shortly after the child has been infected with
measles virus it is possible that active immunity
may result from the milder vaccine induced
attack (which may have a slightly shorter
incubation period than wild measles), and so
attenuate the attack of natural measles.1 The
best way of protecting a susceptible child
contact in whom, because of current ill-health,
unmodified measles is inadvisable, is by the
administration of pooled human immune
globulin.
The article in the Daily Telegraph to which
Terence Lee refers (Tuesday, October 17, 1978)
THE MEDICAL JOURNAL OF AUSTRALIA
did not actually state that the incidence of
serious complications in the present measles
epidemic is any higher than expected. It stated
that the epidemic was extensive and that
Fairfield Hospital, Sydney, had received 26
serious cases including six patients in a critical
condition because of complications, four with
encephalitis and two with pneumonia; similarly,
23 patients had been admitted to Liverpool
District Hospital with severe measles in the past
two months. Patients referred to hospital usually
represent the tip of the iceberg, that is, those
patients with severe attacks or complications.
These figures confirm what has already been
said that measles is a severe disease, it always
has been, and all children should now be
protected against it by means of active
immunization.
C. R. Boughton.
The Prince Henry Hospital,
Anzac Parade,
Little Bay, N.S.W. 2036.
1 Krugman. S., and Ward, R., Infectious Diseases of
Children and Adults, 5th ed., C. V. Mosby. St Louis, 1973:
439.
2 Morbidity and Mortality Weekly Report, Subacute
sclerosing panencephalitis and measles, United States
Department of Health, Education and Welfare. 1977,
September 23, No. 26: 309.
3 Fenner, F., Lancet, 1948, 2: 915.
4 Fenner, F., J. Path. Bad., 1948, 65: 29.
5 Mims, C. A., The Pathogenesis of Infectious Diseases.
Academic Press, London, 1976.
CARRIER DETECTION IN X-LINKED
MENTAL RETARDATION
Sir: Dr Mulcahy (Journal, November 4) has
suggested that the report by Harvey et alii1 of an
association between "terminal appendages" on
the distal end of the long arm of the X
chromosome and one form of X linked mental
retardation is unproven.
Data from this laboratory 2"6 have shown that
the "terminal appendages" are due to the
presence of a fragile site in bands Xq27 or 28.
For this fragile site to be expressed in lymphocyte
cultures it is necessary that the concentration of
folic acid and thymidine in the culture medium
be close to zero. The fragile site on the X
chromosome has not been seen in bone marrow
or skin fibroblast derived chromosomes. The
fragile site at Xq27 or 28 behaves similarly with
regard to folic acid and thymidine sensitivity as
other heritable fragile sites at 2q1, 10q23,
11 q 1 3, 16p12 and 20p11, but differently from
the one at 1 6q22.
The association of the fragile site with mental
retardation1 has been confirmed in four extended
families and a number of other retarded males.
The form of X linked retardation is almost
certainly the same6 as that which has been
described in association with macro-
orchidism,7"9 this clinical finding being present
well before puberty (the youngest such child
examined was 3^ years old).6 There has never
been any suggestion that all X-linked mental
retardation is associated with the fragile site on
Xq: two further families suspected of having
X linked mental retardation in them do not have
the fragile site.
There are considerable difficulties in carrier
detection. The proportion of metaphases from
any individual showing the fragile site can be
increased by manipulation of the culture medium.
The "best recipe" which can be readily prepared
is culture medium 199 buffered with 20mM
hepes to pH 7.6 to pH 7.8. There is a strong
correlation between pH and the proportion of
metaphases showing the fragile site. However,
even using this medium, carrier detection is
difficult. I have not been able to demonstrate
the fragile site in obligate carrier females over
the age of 35 years, although at least six such
females have been extensively studied. In
females up to the age of about 20 years the
fragile site can be readily demonstrated although
December 30, 1 978
the reliability with which this can be done is
uncertain.
I would disagree with Dr Mulcahy that carrier
detection is unwarranted and unwise. In some
families with X-linked mental retardation the
demonstration of the fragile site and macro
orchidism can establish the diagnosis unequi¬
vocally. In families without the fragile site the
diagnosis of X linked retardation can only be
suggested from the pedigree: there is no definitive
diagnosis in these families. Because of the
difficulty of carrier detection in older females it
can be extremely difficult to determine whether a
single case in a family is the result of mutation,
but if the mother is young and there are related
young females in the family available for
examination the quality of genetic counselling
can be greatly enhanced by carrier detection
studies.
I would agree with Dr Mulcahy that prenatal
diagnosis presents considerable problems. Since
the fragile site is not seen in skin fibroblast
derived chromosomes it is unlikely that it would
be present in amniotic fluid derived chromosomes.
One can speculate that, if chromosome study
can be successfully carried out on fetal blood
samples obtained at fetoscopy, the fragile site
would be expressed and definitive prenatal
diagnosis would be possible.
Since this form of mental retardation is not
rare (there are 18 males in South Australia
known to suffer from it) any diagnostic clinical
cytogenetic study of a retarded male in which
the possibility of a fragile site at Xq27 or 28 is
not excluded must be regarded as incomplete.
Grant R. Sutherland.
Cytogenetics Unit,
Adelaide Children's Hospital Inc.,
North Adelaide, S A. 5006.
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1977, 14: 46.
2 Sutherland, G. R., Science, 1977, 197: 265.
3 Sutherland, G. R., New Engl. J Med., 1977, 296:
1415.
4 Sutherland, G. R., Amer. J. hum. Genet.. 1979 (a).
in the press.
6 Sutherland, G. R., Amer. J. hum. Genet. 1979 (b).
in the press.
6 Sutherland, G. R , and Ashforth, P L. C., 1978
submitted for publication
7 Turner, G., Eastman, C , Casey. J., et alii. J med
Genet. 1975, 12: 367.
8 Cantu, J. M., Scaglia, H. E , Medina. M . et alii.
Hum. Genet.. 1976. 33: 23.
9 Cantu, J.-M., Scaglia, H. E . Gonzalez Diddi, M .
et alii. Hum. Genet., 1978, 41 : 331.
Sir: We would like to support Grant
Sutherland's letter advocating screening for
Xq27h in families with X-linked mental retarda
tion. Our findings are almost identical to those,
which he reports. We have found that, in one
third of families with histories consistent with
X-linked mental retardation, all of the affected
males have had the Xq27h abnormality. All of
these affected males have also had macro
orchidism.
In complete contrast to the uniform presence
of Xq27h in the affected males, not all of the
carriers demonstrate this abnormality. Eight such
families have been studied. Four of the 11
obligatory carriers and five of the 16 possible
carriers have had the X chromosome marker.
Our evidence supports Dr Sutherland's conten
tion that any study of X-linked mental retardation
should include Xq27h studies. This research
was supported by a grant from the Apex





Department of Preventive Paediatrics
and Cytogenetics Unit,
Prince of Wales Children's Hospital,
Randwick, N.S.W. 2031.
Am J Hum Genet 31:125-135, 1979
D 62
Heritable Fragile Sites on Human Chromosomes I. Factors
Affecting Expression in Lymphocyte Culture
Grant R. Sutherland1
summary
The expression of heritable fragile sites on human chromosomes has been
shown to be dependent upon composition of the tissue medium for sites at
2qll, 10q23, 11 q 13, 16p 124, 20plland Xq27 or 28 but not for the site at
16q22. Expression of the fragile sites is inhibited by folic acid, thymidine,
folinic acid, and probably bromodeoxyuridine, and induced by methotrexate.
In addition, there is a correlation between frequency of expression of the sites
and pH of the culture medium for the sites on 2q, lOq and Xq. Possible
reasons for these findings are discussed, and a definition and classification of
fragile sites is proposed.
Heritable fragile sites on human chromosomes have been the subject of numerous
reports since that of Dekaban [1], There are now eight well documented heritable
fragile sites and others awaiting confirmation [2]. Expression of fragile sites in
metaphase chromosomes obtained from lymphocyte cultures only occurs when culture
medium 199 is used compared to several other media tested [3], Medium 199 is
relatively deficient in folic acid. Preliminary studies showed folic acid to be important
in that it inhibited expression of some of the sites which could also be induced by the
folic acid antagonist methotrexate. Some mutant cell lines grow in the presence of folic
acid inhibitors if thymidine, glycine, and hypoxanthine are present [4], These
compounds were tested, but only thymidine was found to affect expression of fragile
sites. It was found, incidentally, that the pH of the culture medium had an effect on
some fragile sites. A systematic examination of these factors was carried out, and a
definition and classification of fragile sites is proposed.
Received August 29, 1978; revised November 1, 1978.
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S.A., 5006 Australia.




Fragile sites studied were from individuals and families documented in the following paper
[2], Lymphocyte cultures were established and harvested after 72 hr as previously described [3]
with the exception that the fetal bovine serum supplement to the culture medium was reduced to
5%. Various culture media (as indicated in the results section) were used. These were purchased
from Commonwealth Serum Laboratories, Melbourne, Australia, either as single strength media
or as concentrates. All media were standard commercial products except for a special batch of
Eagle's minimal essential medium (MEM-FA) for suspension cultures from which folic acid had
been omitted (table 1). Some medium was buffered with bicarbonate, whereas for other
experiments 20 mM HEPES was used.
MEM-FA with various concentrations of thymidine (Sigma, St Louis, Mo.) and folic acid
(Abbotts Laboratories, Chicago, 111.) were used for studying the effects of these components.
The effect of the time of addition of folic acid and thymidine was studied by adding these at con¬
centrations of 1.0 and 5.0 mg/1 respectively at varying times during culture. Cultures set up in
Ham's F10 (bicarbonate buffered) had 10 mg/1 of methotrexate (Lederle, Pearl River, N.Y.)
added at varying times during culture. HEPES buffered MEM-FA was set up over a pH range
from approximately 6.8-8.0. The pH of each culture was measured at the time of addition of
colchicine using a Corning 175 automatic blood pH and gas analysis meter. Fifty cells per culture
were scored to determine the frequency of expression of the fragile sites.
RESULTS
Effect ofFolic Acid
The effect of addition of folic acid on the frequency of lesions at the fragile sites is
shown in figure 1 a and b. Some sites require higher concentrations of folic acid to
inhibit their expression than others. The majority are almost completely inhibited by
0.2 mg/1, although the sites on 2q and lOq usually required 0.5-1.0 mg/1 for
inhibition. The site on 16q appears to be independent of folic acid concentration over
the range shown and showed no sensitivity up to 80 mg/1. The frequency of the
TABLE 1
Composition of MEM-FA Medium Used
Component Amount/liter Component Amount/liter
NaCl 6.8 g
KC1 0.4 g








Pyridoxal. HC1 1.0 mg
Riboflavin 0.1 mg
Thiamine.HC1 1.0 mg
1-Arginine. HC1 105 mg
1-Histidine.HCl.HoO 31 mg
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satellited appearance of chromosome 17 in one sample of blood was independent of
folic acid concentration over the range from 0-80 mg/1.
The time of addition of the folic acid is important (fig. lc and d). For those sites
which are folic acid sensitive, expression of the fragile sites is almost totally inhibited
if the folic acid is added 24 hr prior to harvest. (The site on 16p has not been studied
this way.) The expression is progressively inhibited if the folic acid is added during the
last 24 hr of culture. Even when added with the colchicine (2 hr prior to harvest) the
frequency of expression is usually reduced compared to cultures which remain folic
acid free (shown as time = 0 in fig. lc and d).
Folinic acid has a similar affect to folic acid. At a concentration of 5 mg/1 it almost
totally inhibited expression of sites on 2q, lOq, 1 lq, 16p, and Xq. (The other folic acid
sensitive sites were not studied.) The constriction on 17p was not effected by 40 mg/1
of folinic acid. (The site on 16q was not studied.)
Effect of Thymidine
The effect of the addition of thymidine on the frequency of expression of the fragile
sites is shown in figure 2a and b. The inhibitory effect on the expression of the fragile
sites is less rapid and less complete with increasing concentration than for folic acid.
The frequency of lesions at the sites is reduced to less than 10% by 3 mg/1 of thymidine
for all sites studied except 16q, which is independent of thymidine concentrations up to
20 mg/1. This site (subject B, [2]) was in the same cell as one on Xq; while the site on
Xq was inhibited by folic acid and thymidine, the one on 16q was not. The satellited
chromosome 17 showed no inhibition by concentrations of thymidine up to 40 mg/1.
The time of addition of thymidine is also important (fig. 1c and d). For thymidine
sensitive sites, (the site on 16p was not studied in this way) maximum inhibition is 24
hours prior to harvest. As with folic acid, addition of thymidine continues to be
inhibitory up to the time of colchicine addition. Preliminary experiments have shown
that bromodeoxyuridine (BrdU) at 10 mg/1 inhibits expression of the sites almost
completely for the sites on 2q and Xq, but not the one on 16q. Cytidine and uridine at
10 mg/1 did not inhibit sites on 2q, 16q, or Xq.
The effects of thymidine and folic acid are somewhat additive. Figure 3 shows the
effect of varying both folic acid and thymidine concentrations simultaneously on
expression of the fragile site at 2ql. This was done in MEM-FA buffered with
bicarbonate. This is the reason for the apparent increase in frequency of lesions when
the folic acid concentration is 0.01 mg/1 compared with zero. The folic acid was in an
alkaline solution which raised the pH of the culture and hence the frequency of
expression of the sites, especially at the lowest folic acid concentrations (see later).
Similar curves have been obtained for the other folic acid and thymidine sensitive
fragile sites. The site on 16q did not show inhibition by folic acid (10 mg/1) and
thymidine (10 mg/1) in combination.
Effect of Methotrexate
In view of the sensitivity of fragile sites to folic acid, the effect of methotrexate was
studied on lymphocytes cultured in Ham's F10. This medium contains 1.32 mg/1 of
folk acid and 0.73 mg/1 of thymidine and almost totally inhibits expression of fragile
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Fig. 3. —Effect of simultaneous variation of folic acid {FA) and thymidine concentrations on frequency of
lesions at 2ql. FA concentration is in mg/l; in MEM-FA with bicarbonate buffer.
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sites. Methotrexate caused poor growth of the cultures which led to some problems. At
a concentration of 10 mg/l, sufficient growth could usually be obtained to allow 50
metaphases to be scored. Figure 4a and b show the effect of addition of methotrexate
(10 mg/l) throughout the period of culture. Note that methotrexate induces lesions at
the fragile site if added 24 hr or more before harvest, but that its effect diminishes
during the last 24 hr of culture. Methotrexate is not as effective or consistent at
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TIME PRIOR TO HARVEST OF ADDITION OF METHOTREXATE (10mg/l)
Fig. 4.—Effect of addition of methotrexate (10 mg/l) in inducing lesions at fragile sites in lymphocytes
cultured in Ham's F10. Sites as in figure la and b respectively. Time in hours.
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TABLE 2
Effect of Addition of 10 mg/1 of MT on Expression of Fragile Sites Compared with Growth
in FA Deficient Culture Medium
Culture Medium
Site Ham's F10 Ham's F10 and Mt MEM-FA (pH 7.35)
2q 11 3/100 27/100 47/100
10q23 1/100 19/100 60/100
11 q 13 1/100 5/100 22/100
16p 124 0/ 50 6/ 50 20/ 40
16q22* 8/100 15/ 89 8/ 50
20p 11 0/100 14/100 36/100
Xq27 or 8* 0/100 2/ 89 12/ 50
X27 or 8 0/100 8/100 40/100
* Both fragile sites in the same patient, subject B [2],
shows the frequency of expression of the fragile sites in MEM-FA and in Ham's F10
with and without methotrexate. Allowing for this difference in frequency of lesions at
the sites, it can be seen that the shape of the curve in figure 4a and b is approximately
the inverse of that in figure lc and d. Methotrexate did not effect the expression of the
site on 16q, and the satellited 17 was not studied in this manner.
Effect ofpH
The experiments with folic acid showed that its addition to the medium caused a pH
rise, hence a control experiment was conducted to ensure that the inhibition of fragile
sites was not due to pH. Increasing the pH caused the frequency of lesions at the fragile
sites to increase rather than decrease. This pH effect was studied, and the results are
shown in figure 5a and b. The effect was highly significant for the sites on 2q, 20p, and
Xq, but not for those on lOq, 1 lq, or 16q. Preliminary data suggests that the pH effect
may not be significant for the satellited 17, but for the site on 16p the results were
equivocal.
discussion
Based on data in this paper and in [2], the following definition of a fragile site is
proposed: A fragile site is a specific point on a chromosome which is liable to show the
following features: (1) a non-staining gap of variable width which usually involves
both chromatids, (2) the site is always at exactly the same point on the chromosome in
cells examined from any individual patient or kindred, (3) the site is inherited in a
Mendelian dominant fashion, and (4) fragility must be evident by the production (under
appropriate in vitro conditions) of acentric fragments, deleted chromosomes, triradial
figures, and the like. In accord with the Paris Conference [5], fragile sites will be
described by the tripletfra such that the correct designation of the site on 2q would be
fra(2)(ql 1). The practice of recording them as/;+ should be discontinued as there is no
evidence that heterochromatin is involved.
The fragile sites which suit the proposed definition are those indicated in figure 9 of
the following paper [2], by the solid arrows. The satellited chromosome 17 does not fit
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Fig. 5.—Effect of pH on frequency of lesions at fragile sites (identified as in fig. la and b respectively).
Linear regression lines are shown. The correlation coefficients in a (2q, r=.%, p<.001; 20pll, r=.87,
pC.Ol; Xq27 or 8 from subject B [2], r=.82, pC.OOl) are all statistically significant. In b the correlation
coefficients (10q24, r=.250, N.S.; llql3, r=.37, N.S.; 16q22, r=.50, N.S.) are not significant except for
the site at Xq27 or 28 from a retarded male with no other fragile site (r= .77; p<.01).
this definition, since the constriction which gives rise to this has not been shown to be
fragile. A classification of fragile sites can be made on the basis of their in vitro
behavior. A proposed classification is shown in table 3. This must be regarded as
tentative, as some fragile sites have been studied only in a single individual and in most
cases, in a single kindred. The only established fragile site which has not been
available for study is that at 12q 13. This must await classification, but there is no doubt
that it fits the proposed definition of a fragile site (H. R. McCreanor, personal
communication, 1977). The site at 11 q 13 is certainly a fragile site, but it has yet to be
shown to be heritable.
Fragile sites had been regarded as rare variants, and their dependence on conditions
of culture was not known prior to an earlier report from this laboratory [3], Biihler et al.
[6] had investigated the effect of different techniques of harvesting cultures on
expression of a fragile site at 2ql but reached no conclusions. The reduction of
expression of the fragile site in their autoradiography preparations was not commented
upon. It was presumably due to the use of thymidine as a radioactive label. However,
the addition of tritiated thymidine has been reported to have reduced the frequency of
lesions at a site at 2ql [7], Noel et al. [8] reported a much lower frequency of triradial
TABLE 3
Classification of Heritable Fragile Sites According to their Expression under Different
Tissue Culture Conditions. Response to Folic Acid and Thymidine
Sensitive
Resistant pH correlated pH independent
16q22, (??17p) 2ql 1, 20pl1, Xq27 or 28 10q23, llql3*, 16pl24
* Not yet shown to be heritable.
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figures in blood cultures from a patient with a fragile site at 2ql when BrdU had been
added compared with BrdU free cultures. These studies are the only corroboration
available in the literature for the findings in the present report.
In most cells in which fragile sites are expressed, the appearance is that of an
isochromatid gap. In only a small proportion of cells has there been a break at the gap
giving rise to an acentric fragment, triradial, or other manifestation of fragility.
Chaudhuri [9] examined the nature of chromatid gaps (although not those associated
with fragile sites) and concluded that gaps result from extreme despiralization of the
DNA due to failure of compact folding in the metaphase chromosome. He considered
four factors to be involved in spiralization of chromosomes: the DNA itself, histones,
non-histone proteins, and divalent cations. Increasing the calcium ion concentration in
culture medium does not effect the expression of fragile sites (Sutherland, unpublished
results). Since fragile sites could be heritable isochromatid gaps, they are probably
manifestations of DNA coded information.
Sporadic chromatid gaps are thought to be due to some process occurring in G,, but
occurring in G, for isochromatid gaps. The frequency of expression of fragile sites can
be altered by changes to the composition of the culture medium at the time of addition of
colchicine (2 hr prior to harvest). Therefore, expression of the sites must be influenced
directly at the time of spiralization of the chromatids in late G2 or early prophase. This
process would have to be a reversible one. The nature of this process, the disruption of
which could be involved in the expression of the fragile sites, remains unclear.
An alternative explanation is suggested by the nature of the inhibitors and inducer of
fragile sites indicating that the process of expression is more likely to be operating
during DNA synthesis. The area of metabolism involved could be the following
reaction catalyzed by thymidylate synthetase [10, 11]: Uridine monophosphate
(dUMP) + 5,10-methylene tetrahydrofolate (5,10-meTHFA) —» thymidine mono¬
phosphate (dTMP) + dihydrofolate (DHFA). If this reaction were slower than normal,
or if more than a normal amount of dTMP were required, there could be a relative
deficiency of dTMP available for DNA synthesis. That this might be the area of
metabolism involved is evidenced by the inhibition of fragile sites directly by thymi¬
dine and probably by its analogue, BrdU. Furthermore, an increase in folic acid
concentration could result in an increase in THFA and 5,10-MeTHFA, leading to
increased production of dTMP. Induction of the fragile sites by methotrexate can be
explained in terms of the above reaction, since this blocks the conversion of DHFA
back to THFA by inhibition of dihydrofolate reductase. This would inhibit production
of dTMP.
This alternative explanation implies that the fragile site is due to a section of
thymidine rich DNA (or DNA which cannot complete synthesis when the thymidine
supply is restricted) and consequently does not compact normally for mitosis. If the
chromosomes come through metaphase intact, this could be repaired during G, or early
in the next S period. DNA synthesis studies with tritiated thymidine are being done to
see if expression of fragile sites is determined during S or G2.
Fragile sites could also be sites of viral DNA modification. If so, the virus may only
be able to modify specific DNA sequences. Adenovirus 12 causes specific lesions on
chromosomes 1 and 17 [12, 13, 14] which superficially resemble the lesions seen at
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fragile sites. Study of individuals with fragile sites for abnormal DNA may be
rewarding.
The effect of the culture medium's pH on the expression of some fragile sites could
result from almost any area of metabolism affected by this factor [15]. For example,
folic acid has different ionic forms at different pHs [16]; these may have different rates
of transport into the cells. Furthermore, Ceccarini [17] has shown that the cellular
uptake of thymidine is affected by the pH of the culture medium. This pH effect is of
practical value in that the culture medium can be modified to maximize expression of
fragile sites. Apparently the best formula for this purpose is MEM-FA buffered to
about pH 7.6 with HEPES. Detection of fragile sites is important in the case of the
clinically relevant site on Xq; no clinical cytogenetic report on a retarded male can be
regarded as complete without positive exclusion of this fragile site.
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Heritable Fragile Sites on Human Chromosomes II.
Distribution, Phenotypic Effects, and Cytogenetics
Grant R. Sutherland1
summary
Individuals and families have been documented in which there are a number
of fragile sites on chromosomes. These include sites at 2qll, 10q23, 11 q 13,
16pl24, 16q22, 20p 11, and Xq27 or 28. Fragile sites reported in the
literature are compiled. The cytogenetics of the sites is discussed. The
phenotypic effects of the sites are considered, and it is speculated that
homozygosity of the autosomal sites might be deleterious as is hemizygosity
of the site on Xq. These sites are used in the previous report which
documents the effect of tissue medium components on their expression.
Since Dekaban [1] reported the first fragile site on the long arm of a C-group
chromosome in 1965, there have been numerous reports of fragile sites on a variety of
chromosomes. Lejeune [2] was the first to show that such sites were heritable when he
described a site at 2ql in a woman and her daughter. Most fragile sites have been
regarded as normal variants. One, however, on the end of the long arm of the X
chromosome has been shown to be a marker for one form of X-linked mental
retardation [3, 4, 5].
Sutherland [6, 7] showed that the expression of fragile sites in lymphocyte culture
was dependent upon the composition of the tissue culture medium used. The main
factor necessary for expression of these sites is that the culture medium be deficient in
folic acid and thymidine. This report documents families and individuals with fragile
sites located at 2qll, 10q23, 1 lq 13, 16p 124, 16q22, 20pll, and Xq27 or 28.
Lymphocytes from individuals in these families were used for the studies reported in
the preceeding paper [7].
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MATERIALS AND METHODS
All lymphocyte cultures were set up and harvested as previously described [6]. In some cases
Eagle's minimal essential medium (MEM) was used rather than medium 199, and the fetal
bovine serum concentration was reduced to 5% in most cultures in the latter part of this study.
Some cultures were grown in a special folic acid free MEM (MEM-FA), [7], Bone marrow was
collected directly in either MEM or medium 199 containing 1 Mg/ml colchicine and harvested 2
hr later using the same method as for blood lymphocyte cultures (except that the exposure time to
.075M KC1 was 20 min). Lymphoblastoid cultures were established by the method of Pope et al.
[8] except that they were cultured in medium 199 supplemented with 10% fetal bovine serum.
Skin fibroblast cultures were grown in medium 199 and harvested for chromosome studies
using a standard trypsin method.
Until 1973 this Cytogenetics Unit used medium 199 for routine diagnostic work, and some
families in this report had been detected prior to that time. Since late 1976, all diagnostic
lymphocyte cultures have been grown in medium 199 and Ham's F10, and additional families
ascertained. Institutionalized retarded males were screened by lymphocyte culture to detect
individuals with a fragile site at Xq27 or 28. In routine diagnostic cultures 30 metaphases have
been examined. At least 50 metaphases have been examined looking for fragile sites on the X.
All data presented on the frequency of fragile sites are based on examination of at least 50 cells.
FAMILY STUDIES
Family F
This family (fig. 1 a) has a fragile site at 2ql. The propositus was a severely retarded
boy referred for chromosome study at 12 years as part of investigation of his
retardation. He has no major physical malformations and no satisfactory explanation
for his retardation has been found. Cytogenetic results have been described [6]. The
chromosomal expressions of the fragile site are shown in figure 2.
Family Ay
This family (fig. 1 b) has a fragile site on 10q23. The propositus was a 31-year-old
retarded schizophrenic male referred for chromosome study as part of an investigation
of his severe mental retardation of unknown origin. Cytogenetic results have been
previously summarized for the propositus [6]. Different forms resulting from this
fragile site are shown in figure 3.
Subject At
This girl has a fragile site at 11 q 13. At 11 years she was retarded, had epilepsy, and
spastic quadriplegia. Her retardation was thought to be due to a combination of
prematurity, maternal pre-eclamptic toxemia, and a neonatal convulsion. Initial
cytogenetic studies in 1973 showed a fragile site to be present in 20% of cells
examined. In 1977 the site was seen in 44% of cells cultured in medium 199. Extensive
studies of her parents revealed no evidence of the fragile site. The appearances of this
site are shown in figure 4.
Family D
This family (fig. Id) has a fragile site at 16p 124. The proposita was a 7-year-old
girl with Laurence-Moon-Biedl syndrome and an ill-defined lymphoreticular malig¬
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Fig. 1.—Family pedigrees: a, Family F; b, Family Ay; c, Family Mi; d, Family D, e, Family E;/,
Family Ma. Note—symbols for e and/ are the same.
from what appeared to be the same condition. The proposita is of normal intelligence
and has responded well to standard leukemia remission induction therapy. The ap¬
pearances of the fragile site are shown in figure 5.
Subject B
This 29-year-old mildly retarded male was detected in an institutional survey. He has
fragile sites at 16q22 and Xq27 or 28. The cause of his retardation was unknown; he
has no physical abnormalities. Family studies have not yet been carried out. The
appearances of his fragile sites are shown in figure 6.
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Fig. 2.—Appearances of the fragile site on 2q; a, single chromatid break; b, chromosome break; c,
triradial configuration; d, single chromatid break (small arrow) and acentric fragment (large arrow) of
2q,—>2qter; e, quadriradial configuration;/, lesion at the fragile site from a skin fibroblast metaphase; g-j,
G-banded chromosomes showing the break point for the site at 2q at the distal end of 2ql 1; g, no lesion at
fragile site; h-j, chromosome gaps at the fragile site.
Fig 3.—Appearances of the fragile site on lOq; a, single chromatid break; b, chromosome break; c,
triradial configuration; d, pentaradial configuration; e and/, G-banded chromosomes showing break point at
the distal end of band 10q23; g, G-banded chromosome showing deletion of the chromosome distal to the
fragile site; h, G-banded triradial configuration.
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Fig 4.—Appearances of the fragile site at 11 q 13; a-c, G-banded chromosomes 11 and 12 showing the
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Fig. 5.—E-group chromosomes from cells with a lesion on 16p; a, chromosome gap; b, triradial
configuration; c, G-banded chromosomes showing fragile site at band 16p 124; d, G-banded chromosomes
showing deletion of material distal to the fragile site.
This family (fig. lc) has a fragile site on 20pl 1. The propositus was a profoundly
retarded 6-year-old boy who was referred for chromosome studies. His retardation is
presently regarded as being due to CNS degeneration of unknown cause despite
intensive investigation. Results of cytogenetic studies on the propositus and his normal
brother have been recorded [6]. The appearances of the fragile site are shown in figure 7.
Fig. 6.—E-group chromosomes from cells with a lesion at the proximal end of band 16q22;u, G-banded
triradial configuration; b, G-banded chromosome showing lesion (arrow) at 16q22; c, C-banded chromo¬
somes from a metaphase not showing a lesion; d, unhanded chromosomes showing chromosome break at the
fragile site; e, metaphase showing lesions at fragile sites at 16q22 and Xq27 or 28.
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Fig. 7.—Appearance of the fragile site on 20p; a-c, G-banded chromosomes showing the site at band
20pl 1; d, unhanded F-group chromosomes showing triradial configuration resulting from the fragile site.
Family Ma
This family (fig. If) has a fragile site at Xq27 or 28. The propositi were three mildly
retarded boys who are their parents only children. They were ascertained as part of a
search for families with possible X-linked mental retardation. Cytogenetic data on this
family have been given in [6] and are shown in more detail in table 1. Appearances of
the fragile site are shown in figure 8.
This family (fig. le) also has a fragile site at Xq27 or 28. The propositi were mildly
retarded twin boys. They were referred for chromosome study because the family was
thought to be one in which there was X-linked mental retardation. The appearance of
the fragile site is identical to that in family Ma. Cytogenetic data are shown in table 1.
The fragile site at 2ql was the first to be shown to be heritable [2]. Since then there
have been numerous reports of individuals and families with this site which have
recently been reviewed [9], Conen and Erkman [10] recorded a child with Down
syndrome and leukemia who showed breakage in the short arm of chromosome 2 near
the centromere in a number of cells. Parental chromosomes were not studied; a fragile
site at this location must therefore await confirmation. Similarly, Tartaglia et al. [11]
reported a patient with congenital erythroid hypoplasia who had an achromatic lesion in
the middle of one arm of chromosome 1. The lesion appeared to affect only one
chromatid, and the published karyotypes show its position to vary. Parental chromo¬
somes were not studied. It is unlikely that they had a patient with a heritable fragile site
as previously defined [7]; Biihler et al. 112] were also of this opinion.
Brpgger [13] reported a mentally retarded boy with a gap in the middle of one arm of
chromosome 3 which appeared to be fragile. This appeared to affect one chromatid
Family E
DISTRIBUTION OF FRAGILE SITES
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TABLE 1
Frequency of Fragile Site at Xq27 or 28 in Lymphocyte Metaphases
Subject Culture medium Proportion of cells with fragile sites
Family Ma:
II 2 199 0/30
II 3 199 0/100
MEM-FA 0/100
III 9 199 7/50
MEM-FA 30/200
III 10 199 5/50
IV 4 199 18/50
MEM-FA 51/100
IV 5 199 7/50
IV 6 199 1/50
IV 7 199 (1st culture) 8/50
199 (2nd culture) 5/50
MEM-FA 15/50
Family E:
II 4 199 0/50
III 4 199 1/40
III 7 199 5/50
ill 8 199 0/50
IV 1 199 4/50
IV 2 199 8/100
IV 3 199 9/50
IV 5 199 (1st culture) 10/50
199 (2nd culture) 16/50
IV 6 199 (1st culture) 0/50
199 (2nd culture) 10/50
more often than both and in some cells was present on both number 3 chromosomes.
Parental chromosomes were normal. It is unlikely that this report concerned a heritable
fragile site.
A number of C-group chromosomes with fragile sites reported prior to chromosome
banding have been reviewed by Giraud et al. [4], They were the first to specifically
identify such C-group chromosomes and reported fragile sites at 10q242 and 12q 13.
The present report of a site at 10q23 probably involves the site Giraud et al. [4]
reported to be at 10q242. They used R-banding, whereas G-banding has been used in
this report suggesting that the site is near the distal end of band 10q23. Savage [14] has
drawn attention to discrepancies in breakpoint localization when different banding
methods are employed.
There have been reports of abnormal fragility in the C-band heterochromatin of
chromosome 9 [15. 16, 17], The karyotypes published by Fraccaro et al. [16] suggest
that chromosome 11 or 12 is more likely to be involved. Two other reports are more
convincing about identification of chromosome 9. although in the absence of banding,
this remains uncertain. Neither case showed multiradial chromosomes resulting from
the fragility in chromosome 9. Further study is necessary before the possibility of a
fragile site in or adjacent to the C-band on chromosome 9 can be confirmed. The fragile
site at 11 q 13 is the first recorded at this location. There are few positively identified
paracentric fragile sites on C-group chromosomes. Giraud et al. [4] recorded two cases
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Fig. 8.—Appearances of the fragile site on Xq; a-c, usual "satellited" appearance in metaphase
chromosomes; d, appearance in prophase; e and/, "double satellited" appearance equivalent to triradial
configuration; g-i, G-banded chromosomes show the fragile site on the very distal end of Xq.
involving chromosome 12, and McCreanor (personal communication, 1977) has
studied a family in which such a fragile site is segregating. This site at 12q 13 is the
only well established fragile site which has not been available for study in this
laboratory. There is only one previous report [18] concerning a site on 16p in a man
who also appeared to have a translocation involving chromosome 18; his parents were
not studied. The present report shows that a fragile site on 16p is certainly heritable. A
large kindred in which a chromosome with a fragile site at 16q22 was segregating
without apparent phenotypic effect has been documented [19]. A further six individu¬
als, of whom two were father and son, with this fragile site have been recorded [4],
Drets et al. [20] recorded a family in which several members had one chromosome 16
replaced in a proportion of their cells by what appeared to be a chromosome 16 with a
greatly lengthened long arm, and a fragile site near its mid-point. This fragile site is
certainly heritable, but without chromosome banding its origin and location remain
unknown.
The site on 20pl 1 has not been previously described. Apart from the family in this
report, another unrelated and less well-documented family is known with the same site.
The site on the distal end of Xq was first described by Lubs [3], shown to be
heritable, and its association with mental retardation recorded. Harvey et al. [5]
confirmed this site as a marker for one form of X-linked mental retardation. The two
families recorded here further document this association. Other retarded males with
this site, such as subject B, have been detected, and other families not included in this
report are known.
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The well-documented and potential fragile sites are summarized in figure 9.
Chromosome 17 is not included in this summary and requires further discussion. This
chromosome undoubtedly contains a heritable constriction on the short arm which
gives rise to its so-called satellited appearance in some families [21, 22]. It has also
been reported in homozygous form in a normal woman [23]. This chromosome
behaves differently in several ways from all the fragile sites which have been
examined. It appears not to be fragile in that the satellites do not appear to separate
from the chromosome as a minute fragment, nor are double satellited chromosomes
(equivalent to the triradials of the fragile site chromosomes) produced. This satellited
appearance is not dependent upon conditions of culture as are all the other fragile sites
studied (except for that at 16q22 [7]). These satellited chromosomes are undoubtedly
heritable variants, but they do not have a fragile site as this term applies to the other
chromosomes discussed [7].
There is virtually nothing known about the frequency of fragile sites in the
population. Most neonatal surveys aimed at establishing frequencies of chromosome
abnormalities and variants have not used culture medium suitable for the demonstration
of fragile sites. Furthermore, such surveys have been based on the examination of a very
small number of cells, usually two, per individual. Consequently, even if fragile sites
were expressed, they would not always be detected. The only fragile site detected in
a neonatal survey [24] was one in a C-group chromosome (probably an 11 or 12) in one
infant out of 3,543 studied. None of the infants in this survey had any phenotypic
abnormality.
Fragile sites have not been reported in other species, possibly due to the relatively
few individuals usually studied. White [25] reported a type of fragile site in a meiotic
study of an undescribed species of morabine grasshopper. Breakage occurred at a
specific locus during first premetaphase in all cells examined from a single individual
but not in the remaining members of the species studied. Fragile sites in man have not
been studied in meiosis.
CYTOGENETICS
The cytogenetics of fragile sites has been discussed in some detail [26, 27, 28], The
most striking appearance of the sites is the multiradial configurations. These were
12 16 20 x
Fig. 9.—Known fragile sites. Solid arrows indicate well established fragile sites, and broken arrows
indicate sites for which definitive evidence is lacking.
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originally claimed by Lejeune [2] to be the result of selective endoreduplication. Others
[26, 27] have suggested that they could be due to nondisjunction of an acentric
chromatid following breakage at the site. This suggestion has been confirmed [28, 29]
using BrdU incorporation and differential sister chromatid staining. The term
"branched chromosomes" has been used to refer to such multiradials [27].
Lubs [3] studied DNA replication by autoradiography in a female with a site at Xq27
or 28 and found that the X with the fragile site did not appear to be selectively
inactivated. Fraccaro et al. [30] similarly studied a site at 2ql and noted that in most
cells there was no detectable asynchrony in DNA synthesis between homologs. In one
cell they found a triradial with the whole section distal to the fragile site late labeling
and despiralized. Noel et al. [28] recorded a number of such chromosomes with
despiralization distal to the fragile site. Such chromosomes have been seen occasion¬
ally in the present study but not at the frequency recorded by Noel et al. [28],
TISSUE OF ORIGIN OF CHROMOSOMES
Fragile sites in the present study were found almost exclusively in blood lymphocyte
cultures. There was limited opportunity to examine bone marrow chromosomes. Bone
marrow from a male with a site at Xq27 or 28 did not show a single fragile site in 200
metaphases. Blood lymphocytes cultured at the same time expressed the site in 10% of
cells in medium 199, and 30% in MEM-FA. Similarly, bone marrow from a carrier of a
site at 16pl2 showed no evidence of the site in 60 metaphases, but it was present in
46% of metaphases from blood lymphocytes collected at the same time and cultured in
medium 199. Magenis et al. [19] found the site on 16q in two of 41 metaphases from
bone marrow. Dr. H. R. McCreanor (personal communication, 1977) found the site on
2q in 36 out of 168 bone marrow metaphases. Other reports do not mention the study of
bone marrow chromosomes.
Skin fibroblast cultures were established from individuals with the following fragile
sites: 2ql, 10q23, llql3, 16q22, 20p 11 and Xq27 or 28. Fragile sites were rarely
identified in these fibroblast cultures even when grown in medium 199, as shown in
table 2. Fraccaro et al. [16] could not detect a fragile site at 2ql in fibroblast cultures,
and Magenis et al. [19] could not detect the site on 16q in 165 metaphases from
fibroblast culture. Ferguson-Smith [26] found the site at 2ql in fibroblast culture but at
TABLE 2
Frequency of Fragile Sites in Skin Fibroblast Cultures, Medium 199
Site Proportion of cells with fragile sites
2ql 2/50
10q23 0/50
11 q 13 2/50
16q22 (Subject B) 0/100
20pl 1 1/50
Xq27 or 28 (Family Ma) 0/50
Xq27 or 28 (Family E) 0/50
Xq27 or 28 (Subject B) 0/100
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a lower frequency than in lymphocyte cultures. Dekaban [1] presented data on skin
fibroblast culture which suggested that the site was not present in this material. The
reasons why some authors can detect fragile sites in fibroblast cultures and others
cannot remain unknown. However, in view of the strong dependence of their
expression in lymphocyte cultures on the culture conditions, this is not surprising.
Transformed lymphocyte cultures were established from individuals with fragile
sites at 2q, and Xq27 or 28. No expression of the fragile site was seen in either case in
50 cells examined. No other authors have examined such cultures from individuals
with fragile sites.
PHENOTYPIC EFFECTS OF FRAGILE SITES
No abnormal phenotype is associated with the autosomal fragile sites. Many of these
sites were detected in abnormal individuals, but probably this only reflects the type of
person undergoing chromosome analysis. Williams and Howell [9] suggested that
breakage at the fragile site in vivo could give rise to a variety of aneuploid cell lines
leading to abnormal development. While this appears possible, there is little evidence
that fragile sites are expressed in vivo; indeed, they may be artefacts of tissue culture.
The variety of phenotypic abnormalities associatied with the sites suggests that they are
without phenotypic effect in the heterozygote. By analogy with mutant reciprocal
translocations which can be associated with phenotypic abnormality [31 j, when a
fragile site newly arises it might produce an abnormal phenotype. There is no reliable
evidence in the literature regarding fragile sites which are new mutants. Several authors
found no fragile sites in the parents of their index cases, but because of the previously
unknown dependence of these sites on culture conditions, such findings cannot be
regarded as definite evidence of mutation. The retarded girl described in this report
with a fragile site at 11 q 13 appears to be a mutant, although paternity has not been
checked, and the cause of her mental retardation is largely conjectural.
The fragile site on Xq is undoubtedly a marker for one form of X-linked mental
retardation. This was first shown by Lubs [3] for one family and subsequently by
Harvey et al. [5] in four more families; this group has since detected several additional
such families (Weiner, personal communication, 1977). Giraud et al. [4] described a
number of retarded males with this fragile site. Two families are documented in the
present report, and several others are currently being studied as a result of screening
203 institutionalized retarded males for fragile sites. Among these, five (two are
brothers) with fragile sites at Xq27 or 28 were identified. This condition is apparantly
not rare, but because the appearance of the fragile site is not spectacular, and in some
instances is expressed in only a small proportion of metaphases, and because
lymphocytes must be cultured in specific types of culture medium, it has gone largely
unrecognized. The nature of the association between the fragile site and the mental
retardation remains obscure. Not all families with X-linked mental retardation show the
fragile site. It may be that demonstration of the site in some families is more difficult
than in others. Even in those retarded males studied, the proportion of metaphases in
which the site is expressed ranged from less than 5% up to more than 30%. There is,
however, no reason why X-linked mental retardation could not be a group of different
conditions, only one of which is associated with the fragile site.
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The fragile site on Xq is associated with mental retardation in the hemizygote but not
the heterozygote. This would allow the speculation that homozygosity for the
autosomal folic acid sensitive fragile sites would lead to an abnormal phenotype. Such
homozygosity has not been reported, although a normal female homozygous for a
"satellited" chromosome 17 has been recorded. Rare autosomal recessive disorders
should be reexamined chromosomally as some may be due to homozygosity for fragile
sites.
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X-Linked Mental Retardation With Macro-Orchidism
and the Fragile Site at Xq27 or 28
G. R. Sutherland* and P. L. C. Ashforth
Cytogenetics Unit, Department of Histopathology, Adelaide Children's Hospital,
North Adelaide, S.A. 5006, Australia
Summary. Data are presented suggesting that the form of X-linked mental
retardation with macro-orchidism and the form associated with a fragile site
at Xq27 or 28 are the same entity.
Introduction
Mental retardation with macro-orchidism in males, with probably X-linked
inheritance, has been described by Turner et al. (1975) and Cantu et al. (1976,
1978). It has now been established that one form of X-linked mental retardation
is associated with the fragile site on the distal end of the X chromosome (Harvey
et al., 1977; Sutherland, 1977, 1979b). Data are presented suggesting that these
two forms of mental retardation are the same entity.
Materials and Methods
Thirteen males with mental retardation and the fragile site at Xq27 or 28, identified from family
histories and chromosomal surveys of retarded males (Sutherland, 1979b), were available for
study. Measurements of testicular length (/) and width (w) were carried out with a ruler. The
volume was calculated from the formula n/6.l.w.2 (Cantu et al., 1976). Control values were
obtained from the literature and by measurement of ten retarded males with normal karyotypes.
Penile length (stretched) was measured with a ruler, and midshaft circumference with a
measuring tape. Control values were obtained as for testicular volume.
The ages and genital measurements of the males with the fragile site at Xq27 or 28
are shown in Table 1. All measurements are in centimetres, and the estimated
accuracy of each measurement is ±0.2 cm. The control group of retarded males
* To whom offprint requests should be sent
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Table 1. Genital measurements (cm) of males with fra(X)(q27 or 28)
Subject Age Penis Testes
(years) Length Circum- Right Left
terence
Length Width Volume Length Width Volume
(ml) (ml)
Family Ea
III, 26 13.0 9.0 6.5 4.5 69 6.0 4.0 50
IV5 37,2 5.0 4.5 2.5 1.7 3.8 2.5 1.5 2.9
IV6 37,2 6.0 5.0 2.5 1.5 2.9 2.5 1.5 2.9
Family Ma"
IV5 107,2 6.0 5.0 2.5 2.0 5.2 2.7 2.0 5.6
IV6 67,2 6.5 4.5 2.5 1.0 1.3 2.5 1.2 1.8
IV, 56/,2 5.0 4.0 2.5 1.5 2.9 3.0 1.5 3.5
P 137,2 12.0 7.5 5.5 3.5 35 5.0 3.0 24
Fe 18 9.0 10.0 5.5 3.5 35 5.5 3.0 31
Fi 23 9.0 9.0 5.0 3.5 32 5.0 3.5 32
Family B
N 27 12.5 9.5 5.5 3.5 35 5.0 3.5 32
A 28 10.0 11.0 6.0 3.5 39 5.0 3.0 24
Mi 65 13.0 11.0 3.0 2.5 10 4.5 2.5 15
E 16 14.0 8.0 7.0 3.5 45 7.0 4.0 59
Ba 30 10 7.0 6.5 4.0 54 7.0 4.0 59
a From Sutherland (1979b); other subjects have not been published. Individuals from family B are
brothers
ranged in age from 23 to 35 years (mean 29.0); penile length was 8—15 cm (mean
12.5 cm), penile circumference 8—12 cm (mean 9.2 cm), right testicular volume
9—24 ml (mean 17.8 ml), and left testicular volume 9—24 ml (mean 16.2 ml).
Figure 1 compares the mean of the right and left testicular volumes of all those
measured with normal values taken from the literature.
Discussion
The data in the literature regarding genital size are conflicting, due to various
methods of measurement and possible population differences (Farkas, 1972).
Prader (1974) gives 10—17 cm as the normal length of the stretched penis after
puberty; the penile length of both groups of postpubertal males described in the
present report approximates to this range, but this measurement is significantly
affected by the degree of stretching during measurement. Prader (1974) gives the
length of the stretched penis as 4—8 cm and the circumference as 3—6 cm before
puberty. The prepubertal males in this report appear to have penises of normal
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Fig. 1. Average (left and right) testicular volume of males with the fragile site (X) and control
group (•). The 90% line is the percentile given by Prader (1974) from ages 10—20 and his upper
limit of normal up to the age of 10 years. All males aged 25 years or more are shown as >25
size. Farkas (1972) gives the mean penile circumference, measured similarly to in
the present study, as 9.6 cm, with a standard deviation of 0.83 cm and a range of
7.7—12.0 cm. The penile circumference of the present groups of postpubertal
males is within this range.
Testicular volume can only be estimated, either by measurement of length and
width or by the use of an orchidometer and comparative palpation. Using the
orchidometer, Prader (1974) gives a prepubertal testicular volume range of
0.75 ml to a maximum of 2 ml. Zachmann et al. (1974) give a mean volume of
about 19 ml in postpubertal males, with a volume of about 23 ml as the 90th
percentile. Rundle and Sylvester (1962) reported larger volumes calculated from
length and width measurements, but used a formula that would have given
volumes about 35% greater than those calculated from the formula of Cantu et al.
(1976).
The control group of retarded males in the present study had testicular
volumes well within the range of Zachmann et al. (1974). The testicular volume of
the postpubertal males with the fragile site ranged from 32 to 69 ml for the right,
and from 24 to 59 ml for the left, if subject Mi is excluded. Subject Mi is 65 years
old and may have undergone some testicular atrophy. These volumes are not as
great as those recorded by Cantu et al. (1976, 1978), which ranged from 68 to
128 ml in adults, but are all above the 90th percentile. In three subjects in
particular (Family E, IIU; D; and B) the testicular volume is far greater than that
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of normal males. The volumes in the present study are more in accord with those
found by Turner et al. (1975), which ranged from 25 ml in a 13-year-old up to
approximately 45 ml in adults.
All the prepubertal males, except for one, have testicular volumes above the
upper limit of normal (Prader, 1964). Cantu et al. (1976) indicated that testicular
size was probably increased trom birth, and the mother of one of the present
subjects said that his genitals had always been larger than those of other males in
the family. It would appear that increased testicular size is present in this form of
retardation from birth and not only after puberty.
The results presented suggest that the X-linked mental retardation with
macro-orchidism described by Turner et al. (1975) and by Cantu et al. (1976,
1978) is the same entity as X-linked mental retardation associated with the fragile
site at Xq27 or 28. Reports of normal chromosomes in males with macro-
orchidism by Turner et al. (1975) and by Cantu et al. (1976, 1978) cannot be
regarded as definitive, since the need to use culture medium deficient in folic acid
and thymidine for the demonstration of fragile sites (Sutherland, 1979a) was then
unknown. Chromosome studies on the patients described by these authors should
be repeated if possible, to determine whether they have the fragile site on Xq.
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Heritable Fragile Sites on Human Chromosomes
III. Detection of fra(X)(q27) in Males with X-Linked Mental Retardation and in Their Female Relatives
G. R. Sutherland
Cytogenetics Unit, Department of Histopathology, Adelaide Children's Hospital, North Adelaide S. A., 5006 Australia
Summary. The fragile site at Xq27 which is associated
with X-linked mental retardation with macro-
orchidism has been studied in 21 retarded males. These
males were from 12 families, and studies of nine of the
families were possible. Detection of carrier females is
difficult, especially with increasing age. The fragile site
was demonstrated in only five of 13 obligate carrier
females. It is concluded that using present methods,
cytogenetic detection of carriers is fairly reliable in
females aged less than 20—25 years but unreliable in
older females.
Introduction
It is now established that the fragile site at Xq27 is
associated with, and may even be the cause of, the form
of X-linked mental retardation with macro-orchidism
(Harvey et al., 1977; Turner et al., 1978 a, b; Sutherland
and Ashforth, 1979; Sutherland et al., 1979). Never¬
theless, demonstration of the fragile site is not easy and
has been the subject of controversy (Mulcahy, 1978;
Sutherland, 1978; Turner et al., 1978a; Wiener and
Judge, 1979); in particular, the determination of carrier
status in females remains difficult and unreliable. This
paper records studies of the fragile site in 21 mentally
retarded males, 13 obligate carrier females and 26
potential carrier females.
Materials and Methods
Peripheral blood cultures were established and harvested as
previously described (Sutherland, 1977a). The culture media
used were TC 199 and Eagles Minimal Essential Medium special¬
ly formulated (Sutherland, 1979a) without folic acid (MEM-FA).
Fetal bovine serum supplement concentration was 5%. First
studies were usually carried out using TC199 with bicarbonate
buffer. When the first study yielded a low frequency of fragile
sites the study was repeated using TC199 or MEM-FA with
20 mM Hepes buffer and a pH greater than 7.5.
Males with fra(X)(q27) were detected by studying families
with suspected X-linked mental retardation, retarded males
referred for clinical cytogenetic analysis and screening institu¬
tionalised retarded males.
Results
The Patients. Fig. 1 shows the family trees of the index
cases where relatives have been studied. Families Ma
and E are shown in Fig. 1 of Sutherland (1979 b); family
Ma is represented here, since results of additional
studies have been added.
Cytogenetics. The individuals studied fall into three
groups—retarded males, obligate carriers and potential
carriers. The frequency of observation of the fragile
sites when first studied in the retarded males (Table 1)
ranged from zero in two cases up to 44%. Repeat
studies usually yielded a higher frequency of fragile
sites, ranging from 4 to 56%. One male (T.K.) who had
a retarded brother with the fragile site had been studied
in another laboratory and had not been found to have
fra(Xq) was re-studied in this laboratory after both
brothers had been found to have macro-orchidism
(Sutherland et al., 1979). He was found to have the
fragile site in 4% of his lymphocytes.
Results of studies on obligate carriers have been dis¬
appointing. Table 2 shows that of 13 obligate carriers
studied only five showed any evidence of the fragile site
0340-6717/79/0053/0023/$ 01.00






Fig. 1. Family trees of index cases where relatives have been studied
G. R. Sutherland: X-Linked Mental Retardation and fra(Xq)









Family Ea III.7 24 5/50
IV.1 9 4/50 —
IV.5 1 >2 10/50 16/50
IV.6 1'/: 0/50 10/50
Family Ma 111.10 4 18/50 28/50
III.11 7 7/50 26/100
III.12 5 1/50 30/100
III.13 3 8/50 17/50
Family Pb II.7 12 6/50 10/50
Family Feb IV.6 18 7/50 22/50
Family Fib II.1 22 13/50 21/50
Family Bb II.4 27 6/50 —
II.5 28 3/50 6/50
Family Elb III.3 16 9/50 23/50
Family Eve II. 1 20 2/50 —
II.3 17 12/50 16/50
II.5 13 8/50 —
Family Se III. 1 4!4 22/50 —
Subject Bb 30 1/50 12/50
Subject Mib 65 1/50 5/50
Subject T.K.C 15 0/50d 6/150
a
From Sutherland (1979b)
b Same identification as in Sutherland and Ashforth (1979),
except E is now El
c From Sutherland et al. (1979)
d Studied in another laboratory
No data on these previously published
and in one of these only one cell in 140 examined had
the site.
Of the potential carriers, there were 17 (including
one set of identical twins) who were daughters of ob¬
ligate carriers (Table 3). Nine of these, including the
twins, were shown to carry the fragile site; another (Ma
1.2) is a probable carrier, since she has a retarded son
who has not been studied and was about 60 years old
when her chromosomes were examined. Of the other
potential carriers, there were two mothers of retarded
males who had the fragile site but there was no other
known retarded male in the family. It should be noted
that some of the obligate carriers were originally in this
group until results from other female members of their
families showed that they must have been carriers. A
daughter of one of the mothers of a sporadic case, two
nieces of an obligate carrier and one sister and one half-
sister of an obligate carrier and a mother and a grand¬
daughter of an obligate carrier completed the group of
25








Family E II.4 56 199 0/50
III.4 31 199 1/40
33 199 0/50
MEM-FA 0/50
III.8 26 199 0/50
28 199 0/50
MEM-FA 0/50
Family Ma 1.1 - 65 199 0/30
1.3 58 199 0/100
MEM-FA 0/150
II.1 35 199 12/150
MEM-FA 16/82
II.9 34 199 7/50
MEM-FA 45/300
11.11 30 199 9/100
32 199 0/50
MEM-FA 0/100
Family Fe III.2 44 199 0/50
MEM-FA 0/50
Family B 1.1 60 + MEM-FA 0/50
Family El II.2 43 199 0/60
Family Ev 1.1 40 199 0/50
MEM-FA 0/50
Family S II.2 23 199 0/150
MEM-FA 3/50
possible carriers. None of these were shown to carry the
fragile site.
Age at the time of study appears to be a relevant
factor in the demonstration of carrier status in females
but not in the frequency of observation in males. Of the
obligate carrier females, the fragile site was demon¬
strated in five of the six aged less than 35 years, but in
none of the seven older than 35. In subject Ma II. 11 the
site was demonstrated readily at age 30 but could not be
shown 2 years later.
Discussion
Other authors who have been able to demonstrate the
fragile site in retarded males have had trouble doing so
in carrier females. Lubs (1969) studied two obligate
carrier females: the older one aged 59 years did not
express the fragile site, but in her niece aged 24 years it
was present in 28% of cells. In the younger sister of the
niece, aged 22 years, it was present in only 2% of cells.
Giraud et al. (1976) studied five retarded males who
had the fragile site in 20—50% of their cells. In only one
26 G. R. Sutherland: X-Linked Mental Retardation and fra(Xq)
Table 3. Frequency of observation of fra(X)(q27) in potential carrier females
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Niece of obligate carrier
Niece of obligate carrier




























Daughter of obligate carrier, has retarded son
Daughter of obligate carrier
Daughter of obligate carrier
Daughter of obligate carrier
Daughter of obligate carrier
Daughter of obligate carrier, mentally retarded
Grand-daughter of obligate carrier
Daughter of obligate carrier
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Mother of obligate carrier
Half-sister of obligate carrier
Daughter of obligate carrier







Daughter of obligate carrier
Daughter of obligate carrier







Mother of ? sporadic retarded male
Sister of'? sporadic retarded male
Family P 1.8 44 0/350 Mother of ? sporadic retarded male
of these was the mother studied (age not given), and was
found to have the fragile site in 2% of the cells
examined. Similarly, a non-retarded 3-month-old girl
had the site in 20% of her cells but her mother had it in
only 2%. Turner et al. (1978 a) demonstrated the fragile
site in four of 11 obligate carriers and five of 16 pos¬
sible carriers. Howard-Peebles et al. (1979) did not
detect the fragile site in an obligate carrier, however
they stated that the technical quality of their cultures
was poor.
Harvey et al. (1977) have been the most successful in
demonstrating the fragile site in carriers. They studied
six obligate carrier females, and only in two aged 59 and
35 years were they unable to demonstrate the site. The
ages (Judge, personal communication, 1978) and the
frequencies of detection of the fragile sites were
(pedigree reference-numbers are for Harvey etal., 1977)
for AI.6, greater than 70 years. 2%; for All.9, 44
years, 8%; for BI.4, 82 years, 6%; and for BII.l, ap¬
proximately 50 years, 24%. Harvey et al. also detected
one other carrier aged about 50 years (AII.3) with the
site in 7% of cells examined and a younger carrier
female (AIII. 10) with the site in 17% of cells examined.
In the present study the oldest female who has been
shown to be a carrier is 35 years old. Amongst younger
daughters of obligate carriers, about half have also
been shown to be carriers. This suggests that carrier
detection may be fairly reliable below the age of about
20—25 years. However, for obligate carriers above this
age cytogenetic carrier detection is highly unreliable.
Sutherland (1979b) has reported that the fragile site
on Xq is not detectable in skin fibroblast or lympho-
blastoid cell cultures from males with this fragile site.
At present, this probably precludes the specific prenatal
diagnosis of the associated form of mental retardation
by amniotic fluid cell culture (Sutherland, 1977b). If
fetal blood samples were available, such diagnosis
might be possible.
The diagnosis of X-linked mental retardation with
macro-orchidism remains difficult. Not all the retarded
males with the fragile site have macro-orchidism
(Sutherland et al., 1979). Furthermore, the fragile site
can often be demonstrated in only a small proportion of
metaphases from some retarded males even when the
diagnosis is virtually certain on clinical grounds, and
from a study of the family history and other affected
relatives. Despite the methods developed for manip¬
ulation of the composition of the culture medium to
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increase the frequency of fragile site expression in males
(Sutherland, 1979a) this remains totally inadequate for
females and less than satisfactory for males.
Further experiments are required to induce expres¬
sion of the fragile site in a higher proportion of lympho¬
cytes, particularly from females, and in other cell types.
Acknowledgments. I thank the physicians who referred some of
the index cases for chromosome study and who helped with
family studies, and Helen Eyre, Lynene Hinton, Trudy Hocking,
Peter Leonard and Erica Woollatt for technical assistance.
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Heritable Fragile Sites on Human Chromosomes
IV. Silver Staining
G. R. Sutherland* and P. Leonard
Cytogenetics Unit, Department of Histopathology, Adelaide Children's Hospital, North Adelaide, S.A., 5006 Australia
Summary. The chromosomal gaps associated with frag¬
ile sites at 2ql 1, 10q23, 1 lq 13, 16q22, 20pl 1 and Xq27
do not stain with silver nitrate as do NOR regions of the
acrocentric chromosomes.
medium 199 or MEM-FA (Sutherland, 1979a), which allow ex¬
pression of fragile sites, were used for chromosome preparations.
Silver staining was carried out using the Ag-I method of
Bloom and Goodpasture (1976) modified to the extent that slides
covered with 50% AgNOj were incubated for 5 h at 75°C.
Introduction
The nucleolus organizer regions (NOR) of human
chromosomes are the satellite stalks of the acrocentrics,
as has been shown using N-banding (Hayata et al.,
1977) and silver staining (Goodpasture et al., 1976).
Fragile sites on human chromosomes have a region
similar in appearance to satellite stalks (indeed the site
near the distal end of Xq gives rise to a satellited ap¬
pearance of this chromosome) but these do not take
part in satellite associations with the acrocentric chro¬
mosomes (Harvey et al., 1977; Sutherland, 1979b).
Oliver et al. (1978) have shown that the variant of
chromosome 17p, often referred to as a satellited
marker, does not exhibit silver staining. Sutherland
(1979a) has demonstrated that this variant 17 is not due
to the presence of a fragile site of the type seen on other
autosomes and the X chromosome. Silver staining for
NOR has been carried out on the folic acid- and
thymidine-sensitive fragile sites at 2qll, 10q23, 11 q 13,
12p 11 and Xq27 and the resistant site at 16q22.
Materials and Methods
Individuals with the fragile sites studied have been previously
documented (Sutherland, 1979b). Lymphocytes cultured in
* To whom offprint requests should be sent
Results
None of the fragile sites exhibited any silver staining
over the non-staining gap which characterises such sites
(Fig. 1). There was silver staining of the NOR of the
acrocentrics indicating that the technique was working
well and suggesting that if the fragile sites contained
material capable of causing silver deposition, staining
would have occurred.
Discussion
Oliver et al. (1978) concluded from their finding of the
absence of silver staining of the satellited 17p that its
appearance was not due to translocation of satellites
from one of the acrocentrics. A similar conclusion can
be drawn regarding the fragile sites, that is, that they are
not due to insertion of a satellite stalk from an acro¬
centric chromosome. It has been shown that a satellite
stalk involved in a translocation can retain its silver
staining property (Neu et al., 1976).
The specificity of Ag staining of NOR's remains
unclear. Miller et al. (1977) concluded that Ag probably
stained a protein rather than DNA or RNA. The
regions of silver deposition correspond to the loci
0340-6717/79/0053/00297$ 01.00
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Fig. 1. NOR-stained partial metaphases showing the following
fragile sites: (a) 2qll; (b) 10q23; (c) 1 lq 13; (d) 16q22; (e) 20pll;
(f) Xq27
which contain rDNA, but probably indicate activity of
the rRNA genes rather than just their location (Miller et
al., 1976). Whether other gene products, either RNA or
protein, could be stained with silver in metaphase prep¬
arations is not known. The nature of the non-staining
gaps pioduccd al ftagilt sites iciuains speculative.
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Heritable Fragile Sites on Human Chromosomes.
V. A New Class of Fragile Site
Requiring BrdU for Expression
Grant R, Sutherland,1 Elizabeth Baker,1 andR. S. Seshadri2
summary
A new fragile site at 10q25 is described, representing a new class of fragile
site that requires bromodeoxyuridine (BrdU) in the culture medium for
expression. This new fragile site is present in approximately one in 30 of the
Australian population; it has only been observed in heterozygotes.
introduction
Heritable fragile sites on human chromosomes have been defined and provisionally
classified according to their expression under different conditions of tissue culture [1,
2], A new fragile site at 10q25 is described which requires BrdU in the culture medium
for expression and which is present as a polymorphism in the population studied.
materials and methods
Sister chromatid exchange (SCE) studies were carried out on several groups of individuals as
part of another project. These individuals were selected for a variety of reasons, such as the
presence of neoplastic disease; exposure to possible environmental mutagens or teratogens
during pregnancy, in which cases maternal blood and cord blood pairs were studied; and controls
for these groups. Whole blood lymphocyte cultures were established in Ham's F10 (Common¬
wealth Serum Laboratories, Melbourne, Australia), supplemented with 20% fetal bovine serum
to which 10 mg/liter of BrdU (Sigma, St. Louis, Mo.) had been added. The folic acid and
thymidine-free culture medium used was that described by Sutherland [1], Cultures were set up
and harvested as described [3] after 2 hrs exposure to colchicine. Differential chromatid staining
was by a modification of the method of Korenberg and Freedlender [4], Unbanded chromosomes
Received October 25, 1980.
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were stained with Leishman stain and G-banded chromosomes by a trypsin-Leishman method.
Silver staining was carried out as described [5]. All estimates of the proportion of metaphases
within a culture showing lesions at the fragile site are based on the examination of 50 metaphases
unless otherwise stated.
RESULTS
There have been 12 independent ascertainments of the fragile site at 10q25. The
fragile site appears to be in the middle of band q25 (fig. 1). Five families have been
studied (fig. 2) and have shown that the fragile site is inherited as a Mendelian
codominant. Titration of BrdU shows that 5-10 mg/liter of it is essential for
maximum expression of the fragile site (fig. 3). The effect of the time prior to harvest
of the addition of BrdU is shown in figure 4. From this, it can be seen that if BrdU is
present from late S or earlier, the maximum fragile-site expression is achieved. Fragile
sites could not be suppressed by addition of up to 20 mg/liter of folic acid nor induced
in the absence of BrdU by methotrexate (10 mg/liter). Culture in folic acid and
thymidine-free medium did not induce fragile-site expression in the absence of BrdU.
The frequency of fragile-site expression was not related to culture medium pH over the
range 7.2-7.7. Addition of high concentrations of thymidine (greater than 20
mg/liter) did inhibit the fragile site, although this effect was minimal.
Fig. 1. — Appearances of the fragile site: a and b, G-banded chromosome pair 10 showing a chromatid
gap in middle of band 10q25; c, chromosome break; d, gap in light-staining chromatid; e, chromatid gap
with SCE at fragile site; /and g, isolated fragment 10q25-10qter; h and i, triradial configuration at fragile
site; and j and k, third-division metaphases confirming SCE at fragile site in previous divisions; and /,
silver-NOR-stained metaphase showing fragile site to be negative for this stain.
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Fig. 2. —Pedigrees of families studied
CYTOGENETICS
Lesions at the fragile site have a variety of appearances in a variable proportion of
cells. Table 1 shows the frequency of the different fragile-site appearances in randomly
selected metaphases from II.2 in family Le. Table 2 lists the more common
appearances and their frequencies in the propositi; these data relate to metaphases
showing differential chromatid staining; hence, they apply to cells which have
undergone two rounds of replication in BrdU.
Metaphases showing two rounds of replication in BrdU and only a single chromatid
break have only been seen in the bifilarly (light-staining) substituted chromatid. If the
break is in both chromatids, then an SCE has often occurred at or very close to the
fragile site. Some metaphases show only a single chromatid break, but SCE has
occurred at the fragile site. In metaphases in the third division after exposure to BrdU,
it can be confirmed that SCE has occurred at the fragile site (four out of 41 in table 1).
There is an impression that SCE is more common at the fragile site than would be
expected if SCE points were distributed at random. Figure 1 shows a variety of
different appearances of the fragile site, which is Ag-NOR stain negative.
INCIDENCE
The presence of this fragile site was unrelated to the reasons for the original study.
Out of 276 individuals and 60 mother-child pairs studied, the fragile site was
ascertained 12 times. Detection of the site in a mother-child pair was counted as only a
single ascertainment. This gives a carrier frequency of approximately 1/30 and a
"gene" frequency of approximately 1/60. No other BrdU-requiring fragile sites have
been detected.
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Fig. 3. —Effect of concentration of BrdU on frequency of expression of fragile site. Three curves
represent studies on three unrelated individuals.
DISCUSSION
The behavior of this fragile site at 10q25 fulfills the definition of a heritable fragile
site previously put forward [1]. The major difference between this fragile site and those
previously documented lies in the tissue culture conditions required for expression. The
main requirement is that BrdU be present with a concentration of 5- 10 mg/liter for the
maximum expression frequency. The site is not inhibited by folic acid concentrations
up to 20 mg/liter. High concentrations of thymidine tend to inhibit the site, but the
most probable explanation for this is that excess amounts of thymidine swamp the
BrdU and compete with it for a fixed number of incorporation sites which can utilize
either thymidine or BrdU [6]. The pH of the medium had no effect on the frequency of
lesions at the fragile site, although this factor is important in the expression of other
fragile sites which have been described [1].
Many workers (e.g., [7, 8]) have shown BrdU to affect chromosome morphology,
such as in the enhancement of secondary constrictions and the elongation of the
centromere regions. Hsu and Somers [9] studied the effect of BrdU on Chinese hamster
ovary cells and reached two conclusions: "(1) with BrdU concentration at 25 /ug/ml,
breakages occurred as early as 12 hours after treatment, and (2) the great majority
(86%) of the breakages was found at the secondary constriction" (of the number one
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Fig. 4. —Effect of time prior to harvest of addition of BrdU on frequency of expression of fragile site in
three unrelated individuals.
chromosomes). This report [9] is the only reference to breakage induced by BrdU at a
specific locus. We found that there was no more nonspecific breakage than is seen in
cultures without BrdU.
The action mechanism of BrdU in inducing the fragile site is unclear. Mazrimas and
Stetka [6] have shown that unincorporated BrdU can cause SCE when present at
concentrations of about 10~4 M. The fact that BrdU can cause expression of this fragile
site when present during late S, but not after this stage, suggests that incorporation of
BrdU into the DNA is a requirement for expression. Band 10q25 is fairly early
replicating as shown by BrdU incorporation studies [10, 11]; however, since only a
specific locus in the middle of this band is involved in the fragility, this could possibly
be incorporating BrdU in late S without making the whole band appear late replicating.
It would seem that for expression, the chromatid must have at least unifilarly
substituted DNA. However, the cytological appearance of chromatid breaks indicates
TABLE 1
Different Forms of Fragile-Site Expression in Unselected Metaphases from One Individual
Form of expression
no. rounds replication in BrdU
1 2 3
Not expressed 7 43 16
Chromosome gap or break 5 7 10
Chromatid gap or break (in light chromatid if differentially stained) 4 20 8
Chromatid gap or break with SCE ••• 3
Chromosome break or gap with SCE ••• 1 4
Triradial configuration ••• •*• 2
Additional fragment 10q25—»10qter ••• 3 1
Total cells examined 16 77 41
TABLE2
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that bifilarly substituted chromatids are more fragile. Another possible mechanism may
lie in the suggestions that BrdU can alter protein binding or protein synthesis [11], The
knowledge that fragile sites on chromosomes require specific tissue-culture conditions
for expression [3] has led to the confirmation of one of the fragile sites as a marker for
one form of X-linked mental retardation, and the speculation that homozygosity for the
folic-acid-sensitive autosomal fragile sites may be deleterious [2], There is no base
from which to extrapolate when considering any potential phenotypic effects of the
BrdU-requiring fragile site. There is no consistent phenotypic abnormality in individu¬
als who are heterozygous for the site at 10q25, suggesting that this fragile site is
without phenotypic effect in heterozygotes, as are the other autosomal fragile sites [2],
The frequency of this fragile site, being present on approximately 1/60 number 10
chromosomes, is much higher than that of other fragile sites [12], and can be regarded
as a polymorphism. Approximately one in 4,000 conceptions would be expected to be
homozygous for the fragile site at 10q25. Provided such homozygosity is not lethal or
semilethal in the fetus, then roughly the same frequency of neonates should also be
homozygous for this site. If this homozygous state is associated with any disease, then
that disease would mimic an autosomal recessive disorder which would be common in
the population. Efforts should be made to detect homozygotes for this fragile site.
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Familial X-Linked mental retardation with an X
chromosome abnormality and macro-orehidism
Sir,
Two forms of X-linked mental retardation have
been described, one associated with an X chromo¬
some which has a fragile site at Xq27 or 28,1 2 and
the other associated with macro-orchidism. 3 4 5 As a
result of measuring the external genitals and calcu¬
lating testicular volumes of retarded males with the
fragile site at Xq27 or 28, Sutherland and Ashforth6
have suggested that these two forms of mental re¬
tardation are the same entity.
We have recently measured the genitals and
calculated testicular volumes of some of the retarded
males with fragile sites at Xq27 or 28 who were
originally described by Harvey et al.1 Of the seven
males examined (figure, table), six had testicular
volumes greater than the 90th centile of Prader.7
Turner et als have independently re-examined the
chromosomes, under conditions appropriate for
demonstration of fragile sites,9 of the males originally
described with mental retardation and macro-
orchidism. They found that these males do have the
fragile site at Xq27 or 28. That finding, in conjunction
with the report of Sutherland and Ashforth6 and the
data presented here, confirm that the two forms of
X-linked mental retardation recorded in published
reports are the same. Hence, it is now possible to
add large testes, as well as small ones, to the list of
indications for chromosome studies.
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Age (y)
figure Average (left and right) testicular volume of
retarded males examined. The 90°/o line is the centile
given by Trader1 for ages 10 to 20 years. All males
aged 25 years or more are shown as >25.
table Genital measurements of males with mental
retardation and fra (X) (q27 or 28).
Subject Age Penis Testicular volume (ml)
Length Circum- Right Left
ference
Family A
II.4 54 110 8 0 42 24
11.10 46 90 80 24 32
11.11 44 13 0 7-5 18 21
III.9 17 10 0 8-5 38 38
Family B
III. 1 23 100 90 39 58
Subject TK 15 no 8-5 37 29
Subject NK 18 120 100 30 29
Family identification as in Harvey et at.1 Subjects TIC and NK are
brothers from another family mentioned in their addendum.
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Heritable Fragile Sites on Human Chromosomes
VI. Characterization of the Fragile Site at 12q 13
Grant R.Sutherland and Lynene Hinton
Cytogenetics Unit. Department of Histopathology, Adelaide Children's Hospital, North Adelaide. S.A. 5006, Australia
Summary. A kindred is described in which six members have a
fragile site at 12q 13. This fragile site was found to be sup¬
pressed by folic acid and thymidine in lymphocyte culture. An
updated classification of known fragile sites is presented.
Introduction
In a report of the factors affecting expression of fragile sites in
lymphocyte culture Sutherland (1979) was able to study all the
existing documented fragile sites except the one at 12q 13. This
fragile site has been recorded by Giraud et al. (1976), Donti et
al. (1979), and McCreanor (personal communication 1977). but
its response in lymphocyte culture to folic acid, thymidine, and
other culture medium variables has not been previously docu¬
mented.
Materials and Methods
Methods of chromosome study and tissue culture medium composition
have been previously described (Sutherland 1979). Silver staining was
performed according to the method described by Sutherland and
Leonard (1979) and BrdU replication banding as described in Suther¬
land and Eyre (to be published). All frequencies of expression of the
fragile site are based upon the study of 50 metaphases from lympho¬
cyte cultures.
The fragile site was found in a family (Fig. 1) studied because
several members had autosomal dominant Kobner-type epidermolysis
bullosa.
Results
The appearance of fra(12)(ql3) was similar to that of other
fragile sites (Fig.2a-c). There was a lesion at 12q 13 in about
30% of metaphases in cultures grown in MEM-FA for three
days. The lesion was mainly a chromosome or chromatid gap,
but deletions, triradials etc., were seen in 2—5% of metaphases.
G-banding (Fig. 2e and f) and bromodeoxyuridine (BrdU)
replication banding (Fig. 2g and h) showed the fragile site to be
in the middle of band 12ql3. The fragile site was NOR-silver
stain negative (Fig. 2d).
The effect of the addition of folic acid and thymidine to
medium MEM-FA is shown in Fig. 3. The fragile site is highly
sensitive to folic acid being completely suppressed by 0.1 mg/1.
Sensitivity to thymidine is present but not so marked; 5 mg/1
was required for complete suppression. The fragile site was not
affected by the pFl of the culture medium over the range 7.09 to
7.90. The fragile site was affected by BrdU added at the time
cultures were initiated, 5 mg/1 suppressed fragile site expression
from 30% of metaphases to 4% and 10 mg/1 to 2%. The time in
culture prior to harvest (Fig. 4) was important in that the
maximum frequency of expression was not reached until day 4.
Discussion
The response of the fragile site at 12q 13 to variations in culture
medium composition is very similar to that of the fragile sites at
10q23, 11 q 13, and 16p 12 and differs from the other folic acid
sensitive sites only by its expression being unrelated to the pFl
of the culture medium (Sutherland 1979).
Jacobs et al. (1979) have indicated that the frequency of
expression of the fragile site at Xq27 is influenced by the time in
culture. Similar behaviour by other fragile sites has been
observed (Sutherland, unpublished observations) and is docu¬
mented here for fra(12)(ql3). In particular, the difference in
frequency of expression from day 2 to day 3 is considerable;
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Fig. 2. Appearances of the fragile site, a chromosome gap. b chromatid gap, c additional fragment 12q 13-*12qter. d NOR-silver stained preparation.
e,f G-banded number 12 chromosomes from two metaphases, the chromosome expressing the fragile site is on the right, g,h BrdU replication
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Fig. 3. Effect of the addition of folic acid and thymidine on frequency
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Fig. 4. Effect of duration of lymphocyte culture prior to harvest on
frequency of expression of fra(12)(ql3)
unrewarding. Furthermore, the maximum frequency of ex¬
pression is usually reached after four days when it may remain
stable but usually declines (along with the quality of the
chromosome preparation).
Cytologically, fra( 12)(q 13) behaves in a similar way to the
other fragile sites, being expressed mainly as a chromosome or
chromatid gap with a small proportion of cells having deletions
or duplications of chromosome material distal to the fragile
site. The associations between the fragile site and satellites of
the acrocentric chromosomes described by Donti et al. (1979) in
their case of fra(12)(ql3) were not seen in any members of the
present family with this fragile site. As with other fragile sites,
fra( 12)(q 13) is NOR-silver stain negative (Sutherland and
Leonard 1979).
Table 1. Classification of heritable fragile sites according to expression
under different tissue culture conditions
BrdU requiring
Yes No




10q25 2qll.20pll.Xq27 10q23. 1 Iql3\12ql3.16pl2 16q22
Not yet shown to be heritable
219
The documentation of fra(12)(ql3) as being sensitive to folic
acid and thymidine, and independent of pH completes classifi¬
cation of the well established fragile sites (Sutherland 1979),
There are now at least three types of fragile site known
(Table 1), the majority being sensitive to folic acid and
thymidine but the one at 16q22 being resistant and the common
one at 10q25 requiring BrdU for expression (Sutherland et al.
1980; Scheres and Hustinx 1980). Fragile sites other than those
shown in Table 1 have not been documented although a prob¬
able folic acid sensitive fragile site at 9p21 has been partly
characterised (Manuel, personal communication 1980).
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A brother and sister have been detected who are homozygous for the
bromodeoxyuridine (BrdU)-requiring fragile site at 10q25. The children
are phenotypically normal, indicating that homozygosity for this fragile
site is harmless, at least during childhood.
INTRODUCTION
A fragile site at 10q25 requiring BrdU for expression was reported independently
by Sutherland et al. [ 1] and by Scheres and Hustinx [2] and shown to be polymor¬
phic in an Australian Caucasian population [1]. Since the fragile site at Xq27
produces mental retardation in hemizygous males, the possibility that fra( 10)(q25)
would be deleterious in homozygotes was investigated. Two homozygous siblings
have been detected and are phenotypically normal children.
MATERIALS AND METHODS
All clinical case referrals to the Cytogenetics Unit and a series of unselected neonates
studied by cord blood lymphocyte culture were examined for the presence of fra( 10)(q25) as
described [ 1]. When an individual with the fragile site was ascertained, family studies were
undertaken when possible, including chromosome studies of the spouses of individuals with
fra(10)(q25).
RESULTS
Fra(10)(q25) has been ascertained 49 times, and family studies have produced
35 couples of which only one spouse had this fragile site. Both of the 36th couple.
Received February 17. 1981: revised April 7, 1981.
This work was supported by a grant from the Adelaide Children's Research Trust.
1 Cytogenetics Unit. Department of Histopathology. Adelaide Children's Hospital, North Adelaide.
S.A. 5006, Australia.
© 1981 by the American Society of Human Genetics. 0002-9297/81/3306-0011 $02.00
946
FRAGILE SITES ON HUMAN CHROMOSOMES VII 947
studied as the result of finding the fragile site in a male neonate, were found to be
carriers of this fragile site. The couple, neither of whom are related to each other,
has four children (fig. 1), two homozygous and two heterozygous for the fragile
site. One of the homozygotes is a 12-year-old girl who is phenotypically normal
and doing well at school. The other is the neonatal male who, at six weeks, is
developmentally normal.
Cytogenetics
The cord blood study on the propositus did not work well, and only 35 cells
were available for examination (table 1). Two of these apparently showed the
fragile site on both no. 10 chromosomes. On repeat culture by heel prick, 19% of
cells showed the fragile site on both chromosomes (fig. 2). The homozygous sister
of the propositus expressed the fragile site on both no. 10 chromosomes in 25% of
her metaphases.
DISCUSSION
In heterozygotes, the fragile site at 10q25 is usually seen in 15%—80% of meta¬
phases, although it is occasionally seen at frequencies outside this range [1], The
forms of expression are variable, and in one heterozygote a single metaphase
showed the site apparently expressed on both chromosomes. A similar observa¬
tion in a heterozygote was recorded by Scheres and Hustinx [2]. In the family
studies, there was no difficulty in differentiating the homozygotes from the hetero¬
zygotes.
The only fragile site for which homozygosity has probably been demonstrated is
the one at 16q22 [3]. This fragile site is not sensitive to folic acid, thymidine, or
#■ fra(10)q25 homozygote
OD not tested
® fra(10)(q25) not seen
Fig. 1.—The family pedigree
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TABLE 1
Expression of fra(10)(q25) in Family Members
homoi.ogues
PEDIGREE NO. 0 12 TOTAL CELLS
II. 38 12 0 50
II, 36 9 0 45
III," 18 27 15 60
III 31 19 0 50
III", 25 25 0 50
III,: Cord blood 24 9 2 35
Capillary blood 50 69 26 145
BrdU, but can be induced by distamycin A [3]. The homozygote described was a
normal male. Whether he is truly homozygous is uncertain since Schmid et al. [3]
divided the fra(16)(q22) into two types: one a true fragile site, and the second,
more like a secondary constriction or nonstaining gap that did not show fragility.
The homozygote had one of each of these types of fragile site. Similarly, homo¬
zygosity for the "satellited" 17p, which is somewhat similar in appearance to a
fragile site but is not regarded as one [4], has been described in a normal woman
[5],
Since the folic acid-sensitive fragile site at Xq27 produces mental retardation in
hemizygous males, and mild mental deficiency in some heterozygous females [6], it
Fig. 2.—Two metaphases showing homozygous expression of the fragile site, (a) Unhanded cell in
which one chromosome 10 has a chromatid gap and the other a chromosome gap: (b) G-banded
chromosomes showing the fragile site at 10q25.
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has been speculated that homozygosity for the other folic acid-sensitive fragile
sites could be deleterious [4]. Since the fragile site at 10q25 appears to be unique in
that it is the only one known to require BrdU for expression in humans and is
present in polymorphic frequencies [I], there is no basis for speculation about its
effects on homozygotes.
The family reported here demonstrates that if homozygosity has any effect, it is
not apparent in children. Homozygosity for this fragile site could result in some
problem, however, in older individuals.
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VIII. Preliminary Population Cytogenetic Data
on the Folic-Acid-Sensitive Fragile Sites
Grant R. Sutherland1
summary
The incidence of the autosomal folic-acid-sensitive fragile sites in 524
institutionalized retardates (.0095) was found to be significantly higher
than in 1,019 unselected neonates (.00098), suggesting that heterozygosi¬
ty for these fragile sites may not be as harmless as previously thought.
When one of the parents of an index case was found to carry the fragile
site, that parent was always the mother. The fragile site at Xq27 was not
found among the neonates studied, but was present in 1.6% of the insti¬
tutionalized retarded males examined; if this fragile site occurs in normal
males, then it does so rarely. Further cytogenetic studies of fragile sites
are required on both normal and abnormal populations.
INTRODUCTION
There are now nine known folic-acid-sensitive fragile sites on the human karyo¬
type [1, 2]. The frequencies of these in normal and abnormal populations are
unknown. Chromosomal surveys of randomly selected neonates that have estab¬
lished the frequencies of other constitutional chromosomal anomalies have not
provided data on fragile sites because they were mostly carried out using unsuit¬
able culture medium and were based upon the examination of small numbers
(usually two) of cells. The only such survey to record a fragile site [3] was a
two-cell study that found one child with a fragile site on C group chromosome
among 3,543 phenotypically normal infants studied. This was almost certainly an
incomplete detection of the fragile sites in that population.
Received July 28. 1981; revised August 25, 1981.
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1 Cytogenetics Unit. Department of Histopathology, Adelaide Children's Hospital. North Adelaide,
S.A. 5006, Australia.
© 1982 by the American Society of Human Genetics. All rights reserved. 0002-9297/82/3403-0010$02.00
452
HERITABLE FRAGILE SITES 453
Three groups within the South Australian population have been examined for
folic-acid-sensitive fragile sites. These were unselected neonates, patients referred
for diagnostic chromosome study, and institutionalized retardates.
MATERIALS AND METHODS
Neonates
Cord blood was collected by the nursing staff from the first 20 infants born after 8 p.m.
Sunday each week in an obstetric hospital in which there were approximately 3.000 deliv¬
eries per year. As these criteria were not rigorously adhered to. some minor selection may
have been exercised. Cultures were established in MEM-FA supplemented with 5% fetal
bovine serum as described [4. 5], and harvested after 72 hrs using standard methods. Two
unbanded cells were fully analyzed microscopically, and a further 48 examined for fragile
sites.
Patients
Since late 1976, most patients referred for diagnostic chromosome study have had their
lymphocytes cultured in medium suitable for the expression of fragile sites. Initially, this
was medium 199, but more recently MEM-FA has been used. Venous blood was studied in
the majority of cases, but in neonates and small children, capillary blood collected by heel
or finger prick was used. Thirty unbanded metaphases per person were examined micro¬
scopically, a further two or three G-banded metaphases were also examined, and a banded
karyotype prepared. In retarded males suspected clinically of having the fra(X)(q27), a
further 20 metaphases were examined for fragile sites. The patients were not all retarded,
but covered the spectrum seen in a general cytogenetics unit (e.g.. retardates, couples with
reproductive problems, and dysmorphic children). When families were studied, only the
index case of any family is shown in table 1.
TABLE 1
Folic-Acid-Sensitive Fragile Sites in the Groups Studied
Fragile sites
Group no. studied Xq27 Autosomal
Neonates:
Males 522 0 0
Females 497 0 1
Patients 2,237 7 10
Minda Home:
Males 298 5 1
Strathmont:
Males IQ > 36 98 2 2
Other males 6 0 0
Females 35 0 0
Ru Rua:
Males 42 0 2
Females 45 0 0
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Retardates
AI! the male residents with otherwise normal chromosomes from Minda Home, a resi¬
dential institution for the retarded, were studied by capillary blood culture in the first
instance. If a fragile site was detected or suspected, then a repeat culture from venous blood
was performed. All residents of Ru Rua. an institution for the totally dependent mentally
retarded, with otherwise normal karyotypes, were studied from venous blood. Strathmont.
a residential institution for the retarded that has been previously studied for major chromo¬
some anomalies [6] was restudied in part. Initially, all males with an otherwise normal
karyotype and I.Q.s greater than 36 were studied from venous blood: thereafter, both males
and females with otherwise normal karyotypes who were venipunctured for other reasons
were studied. Institutional residents' lymphocytes were cultured in MEM-FA. and at least
50 unbanded metaphases per person were examined for fragile sites.
RESULTS
The number of individuals in each of the populations studied and the fragile
sites found are shown in table 1. The numbers in the patient and neonate groups
are those in which the requisite number of metaphases could be scored and not the
total number studied. The incidence of the autosomal fragile sites in the retardates
is significantly greater than that in the neonates (xq = 3.87, P < .05) but not
different from that in the patient group (x:i = 1-6, not significant). Similarly, the
difference between the retardate and patient groups is not significant (x2i = 1.19.
not significant).
Details of the 16 propositi with the autosomal folic-acid-sensitive fragile sites
are shown in table 2. The most common fragile site seen in this group was that at
10q23, which accounted for seven ascertainments. All the other fragile sites detect¬
ed have been documented previously except for the one at 9q31. This showed the
typical behavior of a folic-acid-sensitive fragile site with regard to response to
culture medium composition, although medium pH was not studied. Cytogenet-
ically, the appearance was typical, showing chromosome and chromatid breaks at
9q31 and, more importantly for confirmation as a fragile site, triradial figures and
deletions [2],
Family studies showed the mothers of the index cases to have the fragile site in
all but two instances when it could not be detected in either parent. In these two
instances, genetic marker studies showed a high probability of correct paternity.
In a further two cases, family studies could not be carried out.
All the index cases with fra(X)(q27) were retarded males, with one exception in
the patient group being a borderline retarded female. Family studies of a number
of these have been reported [7]; in most cases, the fra(X)(q27) was found in other
family members, although in three instances, extensive studies suggested that the
index case may have been the result of a new mutation. One of the males with
fra(X)(q27) also had fra(16)(q22), but family studies in this instance were not
achieved (subject B [5]).
DISCUSSION
The detection of fragile sites is still not without difficulties; hence the data
presented is for a minimum incidence of fragile sites. Even using the best-known
TABLE2







































































































































































conditions for lymphocyte culture, the site at Xq27 is not detectable in some
females who are obligate carriers of it and is seen in a very low percentage of
metaphases in some males [7]. The section of this work carried out using capillary
blood is probably less reliable than that carried out using venous blood. One of the
males in Minda Home had the fra(X)(q27) in only 2% of cells from capillary blood
but in 10% from venous blood. A possible reason for this difference is the observa¬
tion that microbial contamination of lymphocyte cultures renders them useless for
fragile-site detection, even if adequate metaphases are present to permit karyotyp¬
ing; such low-grade contamination is more common in capillary blood than in
venous blood cultures.
Demonstration of the autosomal fragile sites can also be a problem in some
families, and presumably in some individuals. Table 2 shows that the fragile site
was detected in less than 5% of metaphases in some family members. Two of the
autosomal fragile sites detected seemed to be new mutants in that they were not
detected in either of the parents of the index cases. However, a better explanation
may be that these apparent new mutants were familial cases but that the fragile
sites were not detected in the carrier parents; it is not possible to be certain about
this. If a new mutant fragile site is harmless, then it is most unlikely that two such
rare events would be detected in this small series. There is often morbidity asso¬
ciated with new mutant translocations [8]; perhaps the same could hold for new
mutant fragile sites, in which case their detection in abnormal individuals would
not be unexpected. Three of the retarded males with fra(X)(q27) appear to be new
mutants; indeed, if the reproductive fitness of these males is zero (and the muta¬
tion rates in the two sexes are equal), then one-third of new cases would be
expected to be mutants [9].
The finding of a higher incidence of autosomal fragile sites in retardates than in
neonates was unexpected since it had been thought that heterozygosity for the
autosomal fragile sites was without phenotypic effect [10]. The findings from the
present study require close examination. The significance may be due to chance or
possibly to bias. Only one fragile site was found in the neonates; if one more had
been found in this group, then the significance would disappear. Since there may
have been some minor selection in the neonates studied, it could be argued that if
heterozygosity for the fragile sites was deleterious then such infants may not have
been studied. This is possible but unlikely as all infants born in the hospital during
the period of the survey who had clinical indications for chromosome studies were
scored for fragile sites and none were found. Further bias comes from the fact that
some of the retardates were known to have fragile sites prior to the survey; indeed,
it was the availability of such individuals that first stimulated the author's interest
in fragile sites some years ago. The possibility that expression of fragile sites in
cord blood lymphocytes is different from that in lymphocytes of older individuals
could also account for these results. There is no evidence available on this point;
however, there is usually no special difficulty in demonstrating fragile sites in
young children; indeed, the fragile site at Xq27 becomes increasingly difficult to
detect with advancing age in females [7]. This work needs to be repeated on other
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retarded populations, a more rigorously selected group of neonates, and a group
of age-matched controls for the retardates.
If the difference in incidence of fragile sites in retardates and normal individuals
is confirmed, the mechanism of the effect is worth considering. Williams and
Howell [11] suggested that breakage of the fragile sites at critical stages of devel¬
opment could lead to monosomic cell lines that might persist and have a delete¬
rious effect either genetically or through poor viability. In individuals with fragile
sites, 5%-10% of metaphases expressing the fragile site are aneuploid as a result of
breakage at this site. If this breakage occurs in vivo, even to a lesser extent, it could
explain why some but not all carriers of fragile sites are phenotypically abnormal
and why there is no consistent pattern to the abnormalities.
In all instances in which family studies yielded a parent of an index case with the
autosomal fragile site, this parent was the mother. While the probability of this
occurring by chance is small, it is difficult to attribute any biological significance
to it since males readily transmit fragile sites. Could it be that if heterozygosity for
the autosomal recessive fragile sites can be deleterious then this deleterious effect is
more likely to occur if the fragile site is inherited from the mother?
In the retarded populations in Minda and Strathmont, 1.7% of males had the
fra(X)(q27). In these institutions, about 12%-15% of the males had Down syn¬
drome [6, 12], Most of the males with fra(X)(q27) function at about the same
intellectual level as Down syndrome patients. Hence, if the calculation of Herbst
and Miller [13] of an incidence of fra(X)(q27) in males of .92 per 1,000 is correct,
then almost the same number of fra(X)(q27) males as Down syndrome males
would have been expected, especially since there is no evidence of the increased
infant mortality in fra(X)(q27) males that is seen in Down syndrome. Even with
the limitations of technique in detecting fra(X)(q27), there is no doubt that in the
institutions studied there are many more Down syndrome individuals than indi¬
viduals with fra(X)(q27). It would appear that the estimate of Herbst and Miller
[13] may be a very considerable overestimate. Not enough retarded females have
been studied to allow comment upon the finding [14] that 7% of mildly retarded
females without physical stigmata have the fra(X)(q27).
This preliminary study of the population cytogenetics of fragile sites has asked
more questions than it has answered. The incidence of the folic-acid-sensitive
fragile sites in the general population remains unknown. The possibility that these
fragile sites might be deleterious in some heterozygotes, particularly if inherited
maternally, has been raised. The fragile site at Xq27 was not detected among the
neonates studied; however, all that can be concluded from this is that it is much
less common in such a population than it is in retarded populations and that if it
does occur in normal males [15], then it does so rarely. The fra(X)(q27) was
recognized in about 2% of institutionalized retarded males with otherwise normal
karyotypes. It would seem that its incidence is considerably less than that estimat¬
ed by Herbst and Miller of .92/1,000 males [13], Further population cytogenetic
studies of normal and retarded populations are required to help elucidate the
biological significance of fragile sites.
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ADDENDUM
Further studies on the family of 587/73 (table 2) have indicated that the subject's fragile site
is familial since it was found in his siblings; hence, it was undetected in an obligate carrier
parent. Another male with fra(X)(q27) was identified in Minda Home (total now six) after
his mildly retarded sister was independently ascertained to have the fragile X. This male
had been studied by capillary blood culture when the institution was surveyed but was not
identified at that time.
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Heritable Fragile Sites on Human Chromosomes.
IX. Population Cytogenetics and Segregation Analysis of the
BrdU-Requiring Fragile Site at 10q25
Grant R. Sutherland1
summary
The frequencies of the bromodeoxyuridine (BrdU)-requiring fragile site at
10q25 in 1,026 unselected neonates, 901 patients referred for chromo¬
some studies, and 87 institutionalized retardates were not significantly
different from each other. The gene frequency was .013, and the popula¬
tion was in Hardy-Weinberg equilibrium. Segregation analysis confirmed
that the fragile site followed codominant inheritance. This fragile site
and its nonfragile allelomorph can be considered to constitute the first
true chromosomal polymorphism to be described in man.
introduction
A BrdU-requiring fragile site at 10q25 was independently reported by Scheres and
Hustinx [1] and Sutherland et al. [2]. This fragile site was subsequently shown to
be common in the Australian population and to be without recognizable pheno-
typic effect in homozygous children [3]. Several groups within the population have
now been studied for the presence of this fragile site that can be regarded as the
first true chromosomal polymorphism to be described in man.
materials and methods
Three groups have been studied: unselected newborn infants; patients referred for diag¬
nostic chromosome studies since late 1979; and the residents of Ru Rua, an institution for
the totally dependent mentally retarded. Details of these three groups have been published
[4], The neonates were studied from cord blood lymphocyte culture, the Ru Rua residents
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from venous blood samples, and most of the patients irom venous blood samples, although
some of the youngest patients were studied from capillary blood collected by heel or
finger-prick. All lymphocyte cultures were established in Ham's F10 culture medium sup¬
plemented with 20% (more recently 5%) fetal bovine serum and 10 mg/1 of BrdU. Cultures
were harvested after 72 hrs using standard methods. Twenty unhanded metaphases per
individual were examined for fragile sites, and the location of the fragile site was confirmed
in each individual using trypsin-Leishmann G-banding.
When any individual was found to have the fragile site, family studies were carried out
when possible. To avoid ascertainment bias in the calculation of segregation ratios, the
index cases and their direct ancestors in each generation were eliminated from considera¬
tion, as were unkaryotyped individuals. Not all parents of individuals used in the calcula¬
tions had been karyotyped: when only one parent had been karyotyped and was found to
have the fragile site, the other parent was assumed not to have it; similarly, when the one
karyotyped parent was found not to have the fragile site, the other was presumed to have it.
In some sibships, neither parent had been studied, and it was assumed that only one had the
fragile site.
The numbers of individuals studied in each group and the numbers with
fra(10)(q25) are shown in table 1. The differences in the frequency of the fragile
site between the three groups studied are not significant. The gene frequency is
.013, and the heterozygote incidence is 1 in 40 persons. The population is in Hardy-
Weinberg equilibrium (table 2). No other BrdU-requiring fragile sites have been
detected. All the individuals found to carry the fragile site were of British or other
northern European origin. The numbers in other racial groups studied were too
small to attach significance to this finding.
Both parents of the index cases were studied on 27 occasions. In 18 instances,
the mother was found to carry the fragile site; in seven, the father; in one, neither;
and in the case of the homozygous neonate, both parents [3], Paternity testing in
the family in which neither parent was found to have the fragile site after repeated
chromosome studies in which a total of 85 metaphases were examined from the
father and 75 from the mother showed that there was a 96.6% probability of
correct paternity.
The segregation ratios derived from 21 families in which known or presumed



















Total 2.014 1 49
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TABLE 2
Genotypes Observed and Expected on the Basis
of Hardy-Weinberg Equilibrium
Genotype Observed Expected
Homozygous N ... 1.964 1,963.3
Heterozygotes 49 50.4
Homozygous Ira 1 0.3
Total 2.014 2.014.0
ratio of carriers to noncarriers is not significantly different from 1:1 (54:49). In the
only known mating of two fragile-site carriers, there were two homozygotes and
two heterozygotes for the fragile site, one of the homozygotes being the index
case [3].
DISCUSSION
Detection of the fragile site at 10q25 has usually presented no difficulties with
the frequencies of expression ranging from 8% to 91% of cells examined among
individuals who carry it. However, the finding that neither parent of one individ¬
ual with the fragile site appeared to carry it suggests that the technique may not
always detect the fragile site when it is present. Since this fragile site is common
and apparently innocuous, the alternative explanation that this case represents a
new mutation is unlikely.
The segregation analysis, which showed a nonsignificant excess of carriers over
noncarriers, indicates that if the fragile site follows Mendelian codominant inher¬
itance there has not been any significant problem in the detection of carriers. Con¬
versely, if it is accepted that the detection of individuals with the fragile site is
virtually complete, then the segregation ratios obtained are compatible with co-
dominance. Although the population is apparently in Hardy-Weinberg equilibri¬
um, little significance may be attached to this because the frequency of the fragile
site was estimated primarily from the number of heterozygotes. For example, the
TABLE 3
Sex and Karyotype of Offspring of Carriers of fra(I0)(q25)
Married to Noncarriers
Offspring
fra CARRIER fra NOT PRESENT
Mating type Males Females Males Females
Mother carrier 11 12 14 7
Father carrier ... 15 8 9 10
Carrier parent unknown 4 4 5 4
Total 30 24 28 21
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population would still appear to be in equilibrium even if only half the fragile site
heterozygotes had been detected.
Polymorphism is defined as the occurrence of two or more distinct forms in
such proportions that the rarest cannot be maintained by mutation alone [5], It is
generally accepted that the rare form must be more common than 1%~2% to
qualify as a polymorphism [6, 7]. Most chromosomal variation in man does not fit
the definition of a polymorphism since those variants that are distinct are too rare,
and those that are common are the result of continuous variation such as that seen
in the C-band regions of some autosomes. Consequently, the fragile site at 10q25
and its nonfragile allelomorph can be considered to constitute the first true
chromosomal polymorphism to be described in man. The biological significance
of this polymorphism is unknown; homozygotes for the fragile site are apparently
phenotypically normal [3]. It will be of interest to see whether or not the frequency
of the fragile site at 10q25 differs between various ethnic groups.
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The Autosomal Fragile Sites
Grant R. Sutherland
Fragile sites on chromosomes have
attracted much attention recently,
mainly because the one on the X chro¬
mosome is now known to be associated
with a common mental retardation syn¬
drome. However, there are at least 14
other fragile sites in addition to the one
on the X. All these fragile sites, with the
exception of the one at 10q25, are rare
and their significance remains to be de¬
termined.
Fragile sites have been known since
the mid-60s and have been the subject
of many case reports but it was not
until the 1970s that Giraud et al. (1976)
and Harvey et al. (1977) showed that
the fragile site on the X chromosome
was associated with one form of X-
linked mental retardation and was not
an isolated rare finding as it had been
considered since it was first described
by Lubs in 1969. The two papers from
the mid-70s kindled interest in fragile
sites and this combined with the find¬
ing of the essential method for detect¬
ing fragile sites in lymphocyte cultures
by Sutherland (1977) opened up a new
area of cytogenetics.
Definition
A fragile site (Sutherland, 1979) is
a specific point on a chromosome which
is liable to show the following features:
1) a non-staining gap of variable width
which usually involves both chromatids;
2) is always at exactly the same point
on the chromosome in cells examined
from any individual patient or kindred;
3) fragility must be evident by the
production of acentric fragments, de¬
leted chromosomes, triradial figures,
etc. The hallmark of a fragile site is the
triradial (or multiradial) figure since this
is evidence that breakage at the fragile
site has occurred in the mitosis prior to
the metaphase in which it is seen
(Ferguson-Smith, 1973) and is not an
artefact of chromosome preparation.
Fragile sites are almost never seen in all
metaphases, the proportion expressing
them ranging from only a few percent
up to greater than 80% depending upon
the individual and the conditions of
lymphocyte culture.
The heritable fragile sites must be
differentiated from several other phe¬
nomena which can be confused with
fragile sites. There is a heteromorphic
form of chromosome 17 which can have
a satellited appearance and cytologically
can resemble a fragile site. This is not re¬
garded as a fragile site at present since it
has not been shown to be fragile; its
expression is unrelated to culture me¬
dium composition. The multibranched
chromosomes seen in some immuno¬
deficiency states (Tiepolo et al., 1979)
are not currently considered to be herit¬
able fragile sites as these appear to be
products of the diseases in which they
occur.
All chromosomes can occasionally
show isochromatid gaps which are not
fragile sites and should not be called fra¬
gile sites. In particular, there are loci at
6q26 and 3pl4 at which these gaps
occur more frequently than would be
expected by chance, indeed the one at
6q26 can be confused with the fragile
site at Xq27 (Leversha et al., 1980).
These gaps at 6q26 and 3pl4 have not
been shown to be heritable, are present
in only a small portion of metaphases
(usually < 5%) and do not show the
multiradial configurations characteristic
of fragile sites.
What is a Fragile Site?
The nature of fragile sites remains
speculative. It would appear that the
fragile site represents a region of chro¬
mosome which fails to compact normal¬
ly as the chromosome goes through
mitosis. All that is known about fragile
sites suggests that this is due to a prob¬
lem with the DNA in this region rather
than with histone or protein. However,
further research is needed to help de¬
fine the exact nature of the lesion.
Classification of Fragile Sites
The known fragile sites are shown in
Figure 1. These can be classified into
three groups.
Group 1. This group contains the fra¬
gile sites which are folate sensitive
and includes the one on the long
arm of the X which is of great clini¬
cal importance. This group can be
subdivided according to the relation¬
ship between expression of the fra¬
gile sites and pH of the medium,
however, not all fragile sites have
been studied for this effect; this sub¬
division probably has little practical
value. For these fragile sites to be ex¬
pressed the apparently essential con¬
dition of tissue culture is that a state
of thymidine starvation exists. This
can be achieved by depleting endo¬
genous thymidine synthesis by hav¬
ing low or absent folic acid and thy¬
midine present in the medium, by
blocking folate metabolism with
methotrexate, or by inhibiting the
formation of thymidine monophos¬
phate by blocking the enzyme thy-
midylate synthetase with fluorode-
oxyuridine (FUdR).
Group 2. This group contains only the
fragile site at 16q22 which is appar¬
ently independent of the conditions
of lymphocyte culture for expression
although this is reportedly enhanced
by distamycin A. A probable homo-
zygote for this fragile site has been
reported to be phenotypically nor¬
mal.
Group 3. This group also contains only
one fragile site, that at 10q25 which
is the only common fragile site, being
present in one in 40 members of the
Australian population. This fragile
site is the only true chromosomal
polymorphism in man and is only
seen when bromodeoxyuridine
(BrdU) has been present in the cul¬
ture medium for the last 8-12 hours
before harvest. Bromodeoxycytidine
is as effective as BrdU in inducing
this fragile site. Children homozy¬
gous for this fragile site are pheno¬
typically normal.
Cytogenetics
The appearance of some of the fra¬
gile sites are shown in Figure 2. There
is usually a non-staining gap, which
mostly affects both chromatids but
may only affect one. In 2%-5% of meta¬
phases there is usually evidence of fra¬
gility such as separation within the
metaphase of the parts of the chromo¬
some distal and proximal to the fragile
site following breakage, or deletion or
duplication of the chromosome distal
to the fragile site.
The proportion of metaphases in
which the fragile site is expressed can be
highly variable. Since their expression is
so dependent upon conditions of cul¬
ture and possibly other unknown fac¬
tors, comparison of frequencies of ex¬
pression between laboratories, and even
within one laboratory over time, is un¬
reliable. Fragile sites have been reported
in 100% of metaphases examined (An-
neren, 1981) but in the author's labora¬
tory are usually found in 20%-50% of
metaphases, although they have been
seen in more than 80% of metaphases.
However, in some individuals who are
obligate carriers they can be found in a
very small proportion of cells and even
not detected on occasions. Detection of
the autosomal fragile sites is not as dif¬
ficult as detection of the fragile X in
females.
Since any diagnostic cytogenetics
laboratory should be looking for the fra¬
gile site on the X chromosome if re¬
tarded individuals are karyotyped, why
not look for the autosomal sites as well?
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If any laboratory is not currently cap¬
able of detecting the folate sensitive
fragile sites then a change in methodo¬
logy is overdue and simple to imple¬
ment.
The current best method to detect
fragile sites is as follows:
1. Use a folate deficient culture medi¬
um. Standard TCI99 is adequate if
one of the new folate-free media is
not available.
2. Buffer strongly (e.g. 20mM Hepes)
to a pH of 7.5 - 7.6. The pH of the
medium should be greater than 7.3
at the time of harvest.
3. Use only 5% serum supplement.
4. Harvest after 96 hours if possible,
72 hours suffices but 48 hours is in¬
adequate.
5. Use venous rather than capillary
blood since any microbial contami¬
nation of the culture will render it
useless for fragile site detection.
6. Examine unbanded chromosomes.
Fragile sites are easier to see on these
than banded chromosomes, particu¬
larly if a trypsin banding technique
is used.
This methodology is easy to incor¬
porate into any diagnostic laboratory.
There is also no need to run parallel
cultures in other media since this meth¬
od consistently results in good chromo¬
some preparations suitable for other
cytogenetic techniques. In any individ¬
ual in whom a fragile site is suspected
an additional culture in a folate rich
medium which is deficient in thymi¬
dine (e.g. RPMI 1640) to which 0.01
mg/1 of FUdR is added 24 hours before
harvest might help if the fragile site is
not being adequately detected by the
above technique.
Clinical Significance
The fragile sites at 16q22 and 10q25
are probably of no clinical significance;
homozygotes for both of them have
been found and were normal.
The full significance of the folate
sensitive fragile sites remains to be de¬
termined. Since hemizygosity for the
fragile site on the X chromosome pro¬
duces a mental retardation syndrome it
is reasonable to speculate that homozy¬
gosity for the autosomal folate sensitive
fragile sites would be deleterious. No
such homozygote has been described. If
such homozygosity were compatible
with survival to birth and was deleter¬
ious then the resultant problem would
follow apparent autosomal recessive in¬
heritance. Rare recessive disorders
should be looked at for the presence of
fragile sites. On the other hand, if
homozygosity were lethal it might re¬
sult in sub-fertility or recurrent abor¬
tion. Couples being karyotyped for
these problems should be looked at for
fragile sites.
The only population cytogenetic
data on autosomal folic acid sensitive
fragile sites (Sutherland, 1982) showed
a tenfold increase in these amongst the
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Figure 1. The known fragile sites. Group 1, small arrows, at
2ql3, 6p23, 7pl1, 8q22, 9q21, 9q32, 10q23, llql3, llq23,
12q 13, 16pl2, 20pl 1 and Xq27; Group 2, open arrow, 16q22;
Group 3, broad arrow, 10q25.
Figure 2. Appearance of some of the fragile sites: a, despirali-
sation of chromosome material distal to 2ql3; b, duplication
of chromosome distal to 6p23; c, chromosome gap at 9p21;d,
chromosome gap at 10q23; e, chromosome gap at 10q25; f,
duplication of chromosome distal to 11 q 13.
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mentally retarded compared with unse-
lected newborn infants. However, these
population cytogenetic data are very
limited and much more information is
required before any claim is made that
heterozygosity can result in mental re¬
tardation. If heterozygosity does indeed
result in mental retardation then the
mechanism suggested by Williams and
Howell (1976) may be responsible.
Their suggested mechanism was based
upon the observation that a small per¬
centage of metaphases in lymphocyte
cultures from fragile site heterozygotes
are monosomic or trisomic for the seg¬
ment of chromosome distal to the fra¬
gile site. If such aneuploid cells arose
early in development they could gener¬
ate clones of aneuploid cells which
either because of their aneuploidy or
poor viability would result in abnormal
development. This rather non-specific
mechanism could account for the rea¬
son why phenotypically abnormal
heterozygotes are not clinically similar
to each other.
Incidence
The only fragile site for which there
is reliable incidence data is the one at
10q25. This is present in one in 40
members of the Australian population.
All the other autosomal fragile sites are
rare, some being the subject of only sin¬
gle case reports. An examination of re¬
ported cases suggests that the two com¬
monest fragile sites are those at 2ql3
and 10q23, possibly the one at 16q22
being the next commonest and the rela¬
tive frequencies of the others not able
to be assessed at present. The relative
frequencies of the fragile sites may vary
from population to population making
the above assessment unreliable. In the
author's laboratory the site at 10q23
accounts for approximately half all
autosomal Group 1 fragile site ascer¬
tainments.
The absolute incidence of fragile
sites in unknown. Most of the cytoge¬
netic surveys of randomly selected new¬
born infants have been performed using
media unsuitable for fragile site detec¬
tion and have been based on the exami¬
nation of a small number of cells, usu¬
ally two, which would be unlikely to
detect fragile sites expressed in small
proportions in metaphases.
The only neonatal survey to specifi¬
cally look for fragile sites (Sutherland,
1982) found only one amongst 1,019
neonates but found five amongst 524
institutionalized retardates. This differ¬
ence is statistically significant but this
work needs to be repeated before this
difference can be regarded as estab¬
lished. Much more population cytoge¬
netic data on fragile sites are needed.
Other Cell Types
All the above discussion of fragile
sites pertains to their behaviour in short
term PHA stimulated lymphocyte cul¬
tures. Apart from the fragile X, very
little work has been done on attempting
to demonstrate these in other cell types.
The folate sensitive fragile sites are dif¬
ficult to demonstrate in fibroblast and
lymphoblastoid cell cultures but, by
analogy with the fragile X, can probably
be induced in these cell types with
FUdR or methotrexate (Brookwell et
al., 1982; Jacobs et al., 1982). The fra¬
gile site at 10q25 can be induced in
fibroblasts by the addition of BrdU
prior to harvest but has not been
studied in lymphoblastoid cells. The
16q22 fragile site has not been seen in
cells other than lymphocytes; attempts
to demonstrate it in fibroblasts have
been unsuccessful but it may be worth
trying to induce it with distamycin A.
Conclusions
Unfortunately none of the methods
of detection of fragile sites are com¬
pletely satisfactory. The propensity for
a fragile site to be expressed must be
present in every cell otherwise Mende-
lian inheritance would not occur. The
reasons why fragile site expression can¬
not be induced in all metaphases re¬
mains unclear. Why is it that in some
metaphases the fragile site is expressed
on one chromatid and not the other?
Until some of these problems have been
solved and it becomes possible to induce
fragile site expression in the majority of
metaphases the current methods need to
be persevered with. The fact that the
methods for fragile site detection are
not perfect should not inhibit their
widespread use for they will detect the
majority of individuals with fragile sites
and contribute to a better understand¬
ing of the significance of these chromo¬
somal aberrations.
Summary
There is still much to be learned
about the exact nature of fragile sites
and their expression in metaphase chro¬
mosomes. There are no meaningful data
on the incidence of folate sensitive fra¬
gile sites. The clinical significance of the
folate sensitive fragile sites remains to
be determined in both heterozygates
and homozygotes. The detection of the-
fragile site on the X chromosome should
be part of any diagnostic cytogenetic
assessment and since the same method¬
ology will also detect the autosomal fra¬
gile sites this presents & great opportu¬
nity to collect further data on this fasci¬
nating phenomenon.
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The fragile X chromosome has recently been recognized to be associated with,
if not the cause of, a common form of X-linked mental retardation in males and
possibly females. While the exact contribution of this chromosome aberration to
mental retardation remains to be determined, it is at least of the same magnitude
as Down syndrome and possibly more important genetically as it is usually
familial (Gerald, 1980).
This chromosomal fragile site at Xq27, which has now become known as the
fragile X chromosome, was first described by Lubs in 1969 in association with
mental retardation. His discovery had become no more than another rare chro¬
mosomal curiosity confined to a single family until the independent reports of
Giraud et al. (1976) and Harvey et al. (1977) demonstrated the probable associa¬
tion of this fragile site with one common form of X-linked mental retardation.
The key to the widespread confirmation of these reports was the discovery that
the fragile site was expressed only under highly specific conditions of lympho¬
cyte culture which were not those employed by most cytogenetics laboratories in
the late 1970s.
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The fragile X and its associated syndrome of mental retardation in males have
now been found in most countries where this has been sought and in many racial
groups. However, there are still problems with the demonstration of the fragile X
in some males and many females, and controversy about the clinical syndrome
which the fragile X produces in males and the extent of mental handicap it is
responsible for in females. Very little is known about the population cytogenetics
of the'fragile X and the nature of its association with mental retardation remains
obscure, especially since some allegedly normal males have been reported to
have the fragile X.
II. What Is the Fragile X?
The fragile X is so called because it has a fragile site at the distal end of the
long arm. Fragile sites are morphological features of chromosomes which were
defined by Sutherland (1979a) as specific points which are liable to show the
following features:
1. A nonstaining gap of variable width which usually involves both
chromatids.
2. Is always at exactly the same point on the chromosome in an individual or
kindred.
3. Is inherited in a Mendelian codominant fashion.
4. Exhibits fragility by the production of acentric fragments, deleted chromo¬
somes, triradial figures, etc.
The triradial (or multiradial) figure is the most spectacular cytogenetic man¬
ifestation of the fragile site (Fig. 1) and also an essential manifestation for
confirmation as a fragile site rather than some other phenomenon causing chro¬
mosomal damage. While the triradial was originally considered to be due to
selective endoreduplication (Lejeune et al., 1968), it was proposed by Ferguson-
Smith (1973) and subsequently confirmed by Ferguson-Smith (1977) and Noel et
al. (1977) that the mechanism for production of triradials was breakage at the
fragile site followed by nondisjunction (Fig. 2).
While the nature of a fragile site, in terms of chromosome structure, is un¬
known it presumably represents a segment of chromosome which does not under¬
go normal compaction for mitosis. Rarely, cells are seen in which all the chro¬
mosome material distal to the fragile site is not normally compacted at mitosis
(Fraccaro et al., 1972). Fragile sites have not been studied in meiotic cells hence
it is unknown whether they are expressed in them.
To date 15 fragile sites have been detected and these are shown in the partial
ideogram (Fig. 3) and partial karyotype (Fig. 4). These fragile sites fall into three
Fig. 1. Multiradial figures produced by fragile sites, (a) Triradial at 2q 13; (b) triradial at 6p23;
(c) triradial at 9p21; (d) triradial at 9q23; (e) pentaradial at 10q23; (f) triradial at IOq25; (g) triradial at
llql3; (h) triradial at 16p 12; (i) triradial at 20pll.
Fig. 2. Mechanism of production of triradial figures and deleted chromosomes by breakage at
the fragile site followed by nondisjunction. (After Ferguson-Smith, 1973.).
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Fig. 3. The known fragile sites. Group 1, small arrows, at 2ql3, 6p23, 7pl 1, 8q22. 9p21, 9q32,
10q23, 11 q 13, llq23, 12q 13, 16pl2, 20pl 1, and Xq27; Group 2, open arrow, 16q22: Group 3, broad
arrow, 10q25. Reprinted front Sutherland el a!., American Journal of Human Genetics, May 1983.
by permission of the University of Chicago Press.
groups. The first group, the folate-sensitive fragile sites, contains all except two
of the known sites which each conies into separate categories. The multibranched
chromosomes formed by various combinations of the arms of chromosomes 1, 9,
and 16 seen in some immunodeficiency states (Tiepolo et al., 1979; Hulten,
1978) are not currently considered to be heritable fragile sites since they appear
to be products of the diseases involved.
Group I. The folate-sensitive fragile sites are those at 2ql3. 6p23, 7pll,
8q22, 9p21. 9q32. 10q23, llql3. 1lq23, 12q13, 16pl2. 20pll, and Xq27.
They are termed folate sensitive because removal of folic acid (and thymidine)
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from culture medium was the first factor found to be essential for their demon¬
stration in lymphocyte culture.
Group 2. This group contains only the fragile site at 16q22. This fragile site is
not dependent upon conditions of tissue culture (Sutherland, 1979a) but its
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Fig. 4. Partial karyotype showing the known fragile sites. The left chromosome of each pair is
unhanded and the right G-banded. (Pair number 8 courtesy Dr. N. B. Kardon. pair number 7 courtesy
Dr. G. C. Webb.)
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cultures (Schmid et al., 1980). If the variant chromosome 17, sometimes re¬
ferred to as a satellited 17, is shown to be fragile and is accepted as a fragile site
then it might be classified within this group.
Group 3. This group contains only the fragile site at 10q25. This fragile site
was independently discovered by Scheres and Hustinx (1980) and Sutherland et
al. (1980a) and shown to be a polymorphism present in 1 in 40 members of the
Australian population sample studied (Sutherland, 1982b). This fragile site is
unique in that its expression is dependent upon the presence of BUdR or BCdR in
lymphocyte cultures some hours prior to harvest. This is the only common fragile
site (Sutherland, 1982b).
Hence, while the fragile site on the X chromosome may have a number of
features which distinguish it from the other fragile sites, any attempts to elucidate
the nature of this fragile site should not ignore the fact that it is one of only a
number of folate-sensitive fragile sites.
The correct nomenclature for the fragile X remains to be finalized. Lubs
(1969) called it a marker X chromosome so this form certainly has priority and is
preferred by some (Jacobs et al., 1980; Turner and Opitz, 1980). However, in
1969 it was not known that the marker X was due to a fragile site, now a well-
documented phenomenon, on the distal end of the long arm and the more specific
term fragile X is preferable to the nonspecific term, marker X. Every structurally
changed X chromosome is a marker X until the structural change is specified.
The triplet fra was suggested by Sutherland (1979a) and has gained fairly wide
acceptance. The exact location of the fragile site is yet to be finalized. The rather
cumbersome Xq27 or 28 was originally used to indicate this uncertainty, but
evidence from Turner et al. (1978) suggested that Xq27 was correct.
Others have opted for Xq28, and it will not be until good prophase banding of
this area of chromosome is produced that the matter will be finalized. Most of the
prophase banding methods are incompatible with a high level of fragile site
expression and Jennings et al. (1980) found that the position of the fragile site
was unresolved using this technology. Until the matter is resolved, fra(X)(q27)
will be used to specify the fragile X.
III. Tissue Culture Conditions
Fragile sites have mainly been demonstrated in PHA-stimulated lymphocyte
cultures and their expression in other cell types is discussed below. To elicit
expression of fragile sites, including the fragile X, Sutherland (1977b) showed
that it was necessary to culture lymphocytes in medium 199 rather than a range of
other culture media examined. The essential feature of medium 199 was subse¬
quently found to be its deficiency in folic acid and thymidine (Sutherland,
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1979a). Addition of folic acid or thymidine to medium 199 inhibited expression
of the fragile sites, as did the biologically related compounds folinic acid and
BUdR. Dose-response curves were produced for the effect of folic acid and
thymidine on expression of the fragile X (Sutherland, 1979a). These effects of
folic acid, thymidine, and BUdR on inhibition of fragile site expression have
been fully confirmed by Glover (1981).
When folic acid deprivation was found to be important for fragile site ex¬
pression. methotrexate, an inhibitor of folate metabolism, was found to induce
expression of fragile sites in medium which contained folate (Ham's F10). al¬
though not to the extent that absence of folic acid did (Sutherland, 1979a).
Unfortunately this work was carried out in Ham's F10 which also contains
thymidine. Fonatsch (1981b) using skin fibroblasts, has induced the fragile X in
a high proportion of cells using methotrexate in Dulbecco's medium which does
not contain thymidine.
The time of deprivation of folic acid and thymidine is critical for expression of
fragile sites. Deprivation during the last few hours of culture time is necessary
for expression (Sutherland, 1979a) indicating that expression of fragile sites is
determined either late in S or early in G2-
Another factor involved in expression of some fragile sites, including the
fragile X, is the pH of the culture medium. A significant positive correlation was
found between the pH of medium 199 or MEM-FA at the time of harvest and
fragile X expression (Sutherland, 1979a). Others (e.g., Gustavson et al., 1981;
Howard-Peebles and Pryor, 1981) have confirmed this pH effect, although using
"M" medium, essentially Ham's F10 without folic acid, thymidine, or hypox-
anthine. Jacobs et al. (1980) considered pH to be unimportant.
In lymphocyte cultures the duration of the culture before harvesting might be
important in maximizing the frequency of expression of the fragile X. Jennings et
al. (1980) considered that 96- and 120-hour cultures were better than 72-hour
cultures, whereas Gustavson et al. (1981) observed no difference between 72-
and 94-hour cultures. Howard-Peebles and Pryor (1981) found that increasing
the length of culture time enhanced fragile X expression. Jacobs et al. (1980)
preferred 96-hour cultures for their studies of the fragile X. Harvey et al. (1977)
found only half the frequency of expression in 2-day cultures compared with 3-
day cultures. In the author's laboratory 2-day cultures have been found to be
unsatisfactory for studying fragile sites because of very low frequencies of ex¬
pression. 1'he frequency of expression at 4 days is usually greater than at 3 days,
but the difference is small, whereas in 5-day or longer cultures the frequency of
expression declines along with the quality of the preparation. The reasons for the
apparent increase in frequency of expression with time in culture are not clear but
depletion of media components which inhibit expression may account for it.
Howard-Peebles and Pryor (1979, 1981) have claimed that serum concentra¬
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higher levels of expression at lower serum concentrations. This effect has not
been documented by detailed study. The widespread use of only 5% fetal bovine
serum in fragile site work is probably more determined by cost than any proven
need for low serum concentrations. Indeed. Webb et al. (1982) found that
increasing the fetal calf serum concentration from 5 to 14% gave an improved
yield of nietaphases without affecting fragile X expression.
The next factor in culture medium composition to be regarded as important
was the need for methionine. Howard-Peebles et al. (1980) and Howard-Peebles
and Pryor (1981) demonstrated that even under conditions of folic acid and
thymidine deprivation methionine was essential for fragile X expression, al¬
though their results were not clear-cut. One black male expressed the fragile X in
the absence of methionine. Attempts to confirm this role of methionine have
been inconclusive because lymphocytes grow poorly in the absence of meth¬
ionine. The limited data produced (Table I) have tended to support the observa¬
tions of Howard-Peebles and Pryor (1981) although again these results are not
unequivocal. Gardner et al. (1982) claimed that high levels of methionine (115
mg/iiter) added to medium 199 produced a 2- to 4-fold increase in expression of
the fragile X in skin fibroblast cultures. Glover and Howard-Peebles (1981) have
shown that the need for methionine can be overcome when FUdR is used to
induce fragile X expression.
Glover (1981) and Tommerup et al. (1981b) showed that FUdR would induce
the expression of the fragile X even in the presence of normally inhibiting
concentrations of folic acid. FUdR is a powerful inhibitor of thymidvlate syn¬
thetase and this finding supported and added to the original suggestion of Suther¬
land (1979a) that the area of metabolism involved is that shown in Fig. 5, and
that fragile site expression is dependent upon a deficiency of thymidine mono¬
phosphate which leads to impaired DNA synthesis (Tommerup et al., 1981b).
Brookwell et al. (1982). in a major study of FUdR on fragile X expression in
lymphocytes and fibroblasts, found that the level of fragile X expression induced
in lymphocytes by FUdR was not dependent upon the medium used. This agrees
with Glover (1981) who recommended raising folic acid levels when FUdR is
used to help combat its toxicity. Brookwell et al. (1982) also claimed that FUdR
induction of the fragile X resulted in an enhancement of expression by about
30%, however, they did not separate their freshly cultured bloods from those in
which delays in culture occurred where they claimed enhancement of up to
500%. There is a need to determine whether FUdR will induce a higher level of
fragile site expression in freshly cultured lymphocytes than occurs in folic acid
and thymidine-free medium and to confirm that any drop in expression with
delay in culturing can be overcome by FUdR induction.
A variety of other studies on the conditions of lymphocyte culture have been
reported. Fonatsch (1981a) reported a marked decrease in the frequency of
expression of the fragile X in blood which had been stored for 5 days prior to







Fig. 5. The area of folate metabolism involved in fragile site expression (after Erbe, 1975; Scott
and Weir, 1981). The enzymes controlling the various reactions are (1) methionine synthetase, (2)
glutamate formiminotransferase, (3) serine hydroxymethyltransferase, (4) methylene-THF reductase,
(5) formimino-THF cyclodeaminase. (6) dihydrofolatc reductase. (7) thymidine kinase, (8) thymidyl-
ate synthetase. THF. Tetrahydrofolate; DHF. dihydrofolate; dUMP, uridine monophosphate, dTMP.
thymidine monophosphate.
culture compared with freshly cultured blood. Jacobs et al. (1980) generally
found lower levels of fragile X expression in Hawaii from blood which was in
transit for up to 5 days than in Saskatoon where it was studied while fresh,
however, to draw any conclusions from a comparison between laboratories is
hazardous. Brookwell et al. (1982) found that delay in culturing lymphocytes
decreased fragile X expression but that the addition of FUdR to the cultures
enhanced expression to the level which might have been expected had the delay
not occurred. Gustavson et al. (1981) regarded time between sampling and
culture to be unimportant in fragile X expression. Eberle et al. (1981) claimed
that cocultivation of male fragile X lymphocytes with female fragile X or normal
lymphocytes resulted in a decrease in fragile X expression in the male but did not
enhance expression in the female lymphocytes.
All available evidence suggests that the folate-sensitive fragile sites will be
expressed if there is a relative deficiency of thymidine monophosphate available
for DNA synthesis during late S. (The possibility that the fragile site could be
repaired during G2 cannot be discounted and requires investigation.) The action
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of methotrexate can be explained by its inhibition of the dihydrofoiate reductase -
controlled conversion of DHF to THF, an essential cofactor for thymidylate
synthetase to produce thymidine monophosphate. This also accounts for the
action of FUdR which specifically inhibits thymidylate synthetase in the pres¬
ence of folate. It is more difficult to see how the need for methionine and some of
the other amino acids (claimed to effect fragile X expression, Lejeune, 1980)
involved in one carbon transfers fit into this scheme. It.is difficult to see why
methionine is apparently essential for fragile site expression. According to Scott
and Weir (1981) methionine deficiency will depress DNA synthesis and cell
division and this is seen in lymphocyte cultures which grow very poorly under
such conditions. Since methionine deficiency also leads to intracellular folate
deficiency it would be expected that methionine deficiency would enhance frag¬
ile site expression rather than depress it.
Even though it now seems clear that the area of metabolism shown in Fig. 5 is
involved it is not clear how it is involved. Why is it that in some cells the fragile
site is expressed only on one chromatid? Analogously, in two homozygotes for
the fragile site at 10q25 the fragile site was more often expressed on one chromo¬
some than on both (Sutherland, 1981) even though environmental conditions
which surrounded the homologous chromosomes during DNA synthesis must be
more similar to each other than that in different cells. Two possible explanations
for these phenomena can be suggested. First, that in conditions appropriate for
expression of fragile sites they are expressed in close to 100% of chromosomes at
the completion of S but are gradually repaired during G2. This could account for
expression in a single chromatid since presumably the repair events would be
independent for each chromatid but expression, if it does occur during S, would
not be. Second, fragile sites may be expressed, under appropriate conditions, in
virtually 100% of metaphases but that some physical stretching of the chromo¬
some during the process of harvesting may be required to separate the two
segments of chromosome across the fragile site (P. B. Jacky, personal commu¬
nication), thus making it visible.
Effects of harvesting techniques on fragile site expression have been found and
give some support to the concept that physical forces on the chromosome might
be important. Jacky (1980) found that Na citrate used as a hypotonic agent
resulted in a higher frequency of expression of the fragile X in fibroblast cultures
than if KC1 was used; Gardner et al. (1982) supported the use of Na citrate as the
preferred hypotonic agent for fibroblast cultures. Btihler et al. (1970) investigat¬
ed the effects of harvesting on the expression of the fragile site at 2q 13 and found
a higher level of expression when Na citrate was the hypotonic solution used in
harvesting than when KC1 or a combination of the two was used. Howard-
Peebles and Prvor (1981) reported a higher frequency of fragile X expression if
slides were air dried rather than flame dried.
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IV. Cytogenetics
A. Lymphocytes
Some of the morphological appearances of the fragile X are shown in Fig. 6. It
will be noted that the appearance is more distinctive in the unhanded preparations
than in the G-banded ones. When G-banding methods which employ trypsin are
used the segment of chromosome distal to the fragile site becomes merely a
fuzziness which is not as readily detected as the striking appearance of the fragile
X on unhanded chromosomes. Buckton (1981) (in Hecht et al., 1982) reports
that if the ASG banding technique of Sumner et al. (1971) is used then the fragile
X is easier to score microscopically than from unhanded preparations.
Cytogenetic investigations of the nature of fragile sites have not been very
fruitful. In good quality preparations a fine strand of chromosome material can






Fig. 6. The fragile X. (a-c) Expression on chromosomes at different stages of compaction; (d)
despiralization of the chromosome material distal to the fragile site; (e.f) double satellited appearance
equivalent to triradial; (g) expression in skin fibroblast metaphase (courtesy Dr. P. B. Jacky); (h-j)
G-banded appearance; (k) BUdR labeling showing early replicating fragile X (broad arrow) and late
replicating normal X (small arrow); (1) similar to k but with fragile X late replicating.
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chromosome gap. None of the fragile sites stains with Ag-NOR stain (Sutherland
and Leonard, 1979; Howard-Peebles and Howell, 1979). Fragile sites have not
been examined by electron microscopy due to the technical problem of examin¬
ing a specific area of a specific chromosome. The nature of the material across
the gap in fragile sites remains to be determined. Howard-Peebles and Howell
(1981) studied the chromosome core with silver stain and showed that the core
ends were fused in the centric portion of the chromosome in a proportion of
metaphases from individuals with the fragile X and fra( 16)(q22). These fusions
were not visible when the chromosomes were stained with Giemsa. This interest¬
ing observation has not been repeated by others and its significance remains
unclear.
Lubs (1969) reported that X-inactivation was random with respect to the
fragile X in females. Similar studies using BUdR labeling rather than tritiated
thymidine and autoradiography by Jacobs et al. (1980) and Martin et al. (1980)
support Lubs (1969) but there is still a paucity of data in this area. Technical
difficulties arise in that both BUdR and thymidine inhibit expression of the
fragile X and, when BUdR labeling is used, the fragile site may be more difficult
to see on the late labeling X because it is pale staining (Fig. 6). More data in this
area are needed in view of its relevance to explaining the clinical findings in
females with the fragile X.
One problem which arises when examining chromosomes for fragile sites is
the occurrence of chromatid gaps and breaks which occur at a higher frequency
in all cultures grown under the conditions required for expression of fragile sites
than when cells are grown in complete medium. The occurrence of these gaps
and breaks appears to be nonrandom and there are a number of "hot spots"
where they are seen more frequently than would be expected by chance. These
hot spots include bands 3pl4, 6q26. and 16q23.1 and gaps or breaks in these
regions will be referred to as autosomal lesions. These are differentiated from
fragile sites because they rarely occur in more than 3-4% of metaphases from
any individual, inheritance has not been demonstrated, and the classical triradial
configuration produced by fragile sites has not been reported. The factors in¬
volved in expression of autosomal lesions appear to be similar to those involved
in fragile site expression (Glover, 1981).
The autosomal lesions can cause problems when they mimic the known fragile
sites (Leversha et al., 1981). The 6q26 lesion can resemble the fragile X on
unhanded preparations; Leversha et al. (1981) have observed this lesion in up to
3.5% of metaphases and Soudek and McGregor (1981) recorded it in 1.2% of
metaphases from 31 individuals. In this group they also recorded 0.9% of cells
with other C-group chromosomes mimicking the fragile X. If doubt exists as to
whether unhanded preparations have a low frequency of the fragile X or the 6q26
lesion then G- or Q-banding of scored slides will allow resolution of this uncer¬
tainty. There appears to be a fragile site and an autosomal lesion (Sutherland,
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1979b: Jennings et al., 1980) at 16q22 and the resolution of confusion between
the two could be difficult (Cote and Katsantoni, 1980) but might be resolved by-
culture of cells in a range of medium types, the use of distamycin A (Schmid et
al., 1980), and family studies.
In view of the many factors which influence the expression of fragile sites it is
perhaps pointless to compare frequencies at which they are detected in different
laboratories. In general, fragile sites are seen in less than 100% of metaphases,
indeed there is only one report of a fragile site (at 2q 13) being seen in all cells
(Anneren and Gustavson, 1981). The fragile X has been reported in up to 56% of
lymphocyte metaphases (Jacobs et al., 1980; Brookwell et al., 1982; Webb et
al., 1982) and 71% of fibroblast metaphases (Fonatsch. 1981b) but is more
usually seen in less than 50% of metaphases. In a 3-year-old girl 82% of lympho¬
cyte metaphases were found to express the fragile X (A. Daniel and R. Brook-
well, personal communication). Jacobs et al. (1982) have suggested that the
maximum frequency of expression possible might be 50%.
There is sometimes difficulty in inducing expression of fragile sites. In obli¬
gate carriers of the autosomal fragile sites they are occasionally not detected or
found at such low frequencies that it is difficult to be certain that they are actually
present. This problem appears to be greater for the fragile X and the situation in
males and females differs.
In males the problems associated with expression of the fragile X are only
beginning to be appreciated. There is usually no difficulty in detecting the fragile
X which is usually present in 10-30% of metaphases if lymphocytes are grown
under the currently known optimal conditions. There are. however, reports of
individuals who on clinical or family history grounds would appear to be certain
to have this chromosome in which it cannot be detected at all or barely detected.
For example, only one of a pair of brothers originally-studied by Harvey et al.
(1977) showed the fragile X. After repeated study the second brother was found
to have this in only 3% of cells (Sutherland, 1979c). Jacobs et al. (1980) have
suggested that the fragile X should be detected in 4% or more of metaphases
before an individual is considered to have it, although Rhoads et al. (1982)
reported a probable obligate carrier female with 3% of her cells expressing a
fragile X on one occasion and only 1 in 125 cells on another. This 4% rule would
appear to be conservative since an apparent fragile X (as distinct from the 6q26
autosomal lesion) has not been seen in normal individuals in spite of extensive
study in the author's laboratory. Herbst et al. (1981) suggested 1% might be a
better cut off point to use than 4%. Proops and Webb (1981) reported the fragile
X in up to 3% of lymphocytes of individuals who probably did not have this
chromosome but it is not clear whether they excluded the 6q26 lesion from their
data. No fragile X was seen in seven normal males studied in detail by Jennings
et al. (1980). Jacobs ct al. (1980) recorded a control female with fragile X in
5/389 cells. In the author's experience any individual in whom even one fragile
THE FRAGILE X CHROMOSOME 121
X chromosome is seen should be regarded as probably having the chromosome
until this can be disproved by extensive and repeated chromosome studies or an
improvement in technology in this area. This holds particularly when there is
good family or clinical suspicion. Soudek et al. (1981) have claimed that the
proportion of cells showing the fragile X is a familial character and that most
members of any one family will have similar frequencies of expression. Howev¬
er, Proops and Webb (1981) remarked upon the inconsistency within the same
family. Rhoads et al. (1982) noted individuals to have similar frequencies of
expression when sampled over a period of several months.
In females, expression of the fragile X appears to be a different problem from
that in males. In many females who are obligate carriers of the fragile X it has not
been demonstrated. This problem has been encountered and verified by almost
all those who have studied females who are obligate or potential carriers of this
chromosome. It appears that the proportion of metaphases showing the fragile X
decreases with advancing age. Many obligate carriers aged 30 years and above
either do not express the fragile X or do so in a very low proportion of meta¬
phases. On the other hand, in females who are potential carriers and aged 20
years or less (these are usually the sisters of young retarded males with the fragile
site) the proportion found to have the fragile site is close to 50% (Sutherland.
1979c). Howard-Peebles (1980) has suggested that there may be two types of
families with the fragile X, those in which the females are dull and readily
express it regardless of age, and those in which they are of normal intelligence
and in which expression decreases with age.
Jacobs et al. (1980) have claimed that there is a correlation between the
frequency of expression of the fragile X in females and their IQ, as well as their
age, with the duller females having a higher frequency of expression. They
suggest that it is the brighter females (and consequently those with absent or very
low frequencies of expression) who are most likely to reproduce and be encoun¬
tered in family studies as obligate carriers possibly making the apparent age
affect either an illusion resulting from ascertainment bias or possibly the result of
two different factors affecting expression. Rhoads et al. (1982) found the cor¬
relation between IQ and frequency of expression in several carrier females in
their Japanese family contrary to the suggestion of Howard-Peebles (1980) that
there are two types of family in this regard. Herbst et al. (1981) were also unable
to support this suggestion of Howard-Peebles (1980). In those young carrier
females reported by Sutherland (1979c) there was only one who was regarded as
dull so this does not support the IQ as opposed to age association with expression
at least in younger females.
Jacobs et al. (1980) put forward two hypotheses to account for problems of
expression of the fragile X in females. The first is that there is selection against
cells in which the active X is fragile and that if the fragile site is more easily
demonstrated when it is on an active X chromosome there will be a decrease in
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the proportion of X chromosomes expressing the fragile X as age increases. This
hypothesis depends upon the easier demonstration of the fragile X on active X
chromosomes and there is no evidence to suggest that this is so and some to
suggest otherwise.
The second hypothesis of Jacobs et al. (1980) is that the chromosome material
distal to the fragile site may be lost from some cells and that if it is lost from the
active X. the cell dies but if from the inactive X (he cell survives. This would
lead to selection of cells in which the active X did not have the fragile site, the
deleted inactive X not being able to be detected cytologically would appear
normal and there would be an apparent decrease in fragile sites with increasing
age. Since carriers with lower intelligence are presumably the result of differen¬
tial X inactivation they would start out with a higher proportion of active X
fragile chromosomes than carriers of normal intelligence.
Both the above hypotheses are speculative but are the only ones put forward to
date to help explain the puzzling and frustrating behavior of the fragile X chro¬
mosome in females. Unfortunately FUdR induction of the fragile X does not
enhance expression in female carriers where this is low or absent (Rhoads et al.,
1982; Brookwell et al., 1982). Much more data on females who are carriers or
potential carriers are required.
B. Other Cell Types
Almost all the above discussion of fragile X chromosomes has pertained to
their expression in PHA-stimulated lymphocyte cultures. Most studies on fragile
sites have used these cells and only limited studies have been performed on other
cell types.
1. Bone Marrow
Only two studies of bone marrow chromosomes on individuals with folate
sensitive fragile sites have been reported. The late Dr. H. R. McCreanor (person¬
al communication) found the site at 2q 13 in 36 out of 168 bone marrow nreta-
phases but the technique used was not recorded. Sutherland (1979b) examined
200 metaphases from a boy with the fragile X but did not detect it in the bone
marrow. This study employed an in vitro time of only 2 hours. It would have
been of interest to culture the bone marrow for longer in folate-free medium or in
the presence of FUdR and so determine whether the fragile X could be induced.
These very limited data do not indicate whether fragile sites are expressed as
fragile sites in vivo, a question of critical importance to the above hypotheses
relating to expression of the fragile X in females and possible deleterious effects
of other fragile sites (Sutherland. 1982b) in heterozygotes.
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2. Lymphoblastoid Cell Lines (LCL)
LCL from individuals with fra(2)(ql3) and the fragile X were examined by
Sutherland (1979b) and under conditions of folic acid and thymidine deprivation
were not found to express the fragile sites. Subsequently it has been confirmed
that the fragile X is not seen in these cells under such conditions but its ex¬
pression can be induced by FUdR (Jacobs el a!., 1982). The use of LCL, with
induction of fragile sites by FUdR, may provide a useful system for studying
fragile sites, the study of which until now has been hampered by the need to
collect fresh blood samples from patients whenever experimental work was
done. Furthermore, the expression of the fragile X in these lines derived from
female carriers may provide insight into this difficult area and possibly provide a
reliable means of carrier detection.
3. Fibroblasts
Fibroblasts have been used to prepare chromosomes to be examined for fragile
sites without success by Fraccaro et al. (1971) and Magenis et al. (1970).
Ferguson-Smith (1973) found the fragile site at 2q 13 in fibroblasts. Sutherland
(1979b) examined fibroblasts cultured under conditions suitable for the demon¬
stration of fragile sites in lymphocytes from carriers of the fragile sites at 2q 13,
10q23, 11 q 13, 16p22, 20p 11, and Xq27. Some of the autosomal fragile sites
were seen in up to 4% of metaphases but the fragile X was not seen in fibroblasts
from three individuals.
It was not until Jacky and Dill (1980) demonstrated the fragile X in fibroblasts
by severe restriction of folic acid and thymidine that the possibility of using these
cells for studies of fragile sites became feasible. Unfortunately the method of
Jacky and Dill (1980) has proved difficult to reproduce consistently (Jacobs et
al., 1980; Turner et al., 1980a; Mattei et al., 1981).
The development of reliable methods for the demonstration of fragile sites in
fibroblasts has proceeded slowly. Glover (1981) reported inducing the fragile X
in 20 and 25% of fibroblasts using FUdR at concentrations of 0.05 or 0.1 \xM, 24
or 48 hours prior to harvest. Tommerup et al. (1981a) reported generally lower
frequencies of expression in two males and one female studied using a range of
FUdR concentrations added 24 hours prior to harvest. Fonatsch (1981b), al¬
though only having studied one male, reported having induced the fragile X in up
to 71% of metaphases in fibroblasts cultured in Dulbecco's medium with the
folate antagonists methotrexate and aminopterine. Mattei et al. (1981) reported
inducing the fragile X reliably in fibroblasts using medium 199 and methotrex¬
ate. Several groups (Tommerup et al., 1981a; A. Daniel, R. Brookwell, G.
Turner, and J. Fishburn, 1981, in Hecht et al., 1982; Jenkins et a!., 1981) have
reported demonstration of the fragile X in the fibroblasts of female carriers who
did not express it in their lymphocytes. If this finding can be confirmed and
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extended then a reliable method of carrier detection may become possible.
Jenkins et al. (1981) have used FUdR to induce expression of the fragile X in
cultured amniotic fluid cells thus making prenatal diagnosis of the fragile X
possible. However, in view of the difficulties involved in this area Sutherland
and Jacky (1982) have suggested that this be approached with great caution.
4. Somatic Cell Hybrids
The only report of the fragile X in somatic cell hybrids is that of Bryant et al.
(1981) who attempted to determine whether the normal genome could suppress
fragile site expression by complementation. Expression of the fragile X was not
suppressed by the normal genome.
V. Genetics
All the known fragile sites appear to behave in a Mendelian codominant
fashion. Only one has been subjected to segregation analysis and no distortion of
expected segregation ratios was observed (Sutherland, 1982b). There has been
the suggestion that the fragile X may not follow expected ratios and be preferen¬
tially transmitted (Harvey et al., 1977). The same possibility has been raised for
X-linked mental retardation without the fragile X (Renpenning et al., 1962).
There is great difficulty in trying to establish preferential transmission of either
form of retardation because of problems of ascertainment. Families in which
there are multiple affected individuals are much more likely to be ascertained
than those with small numbers of or single affected individuals. Indeed, many of
the families which have been studied to date were ascertained because of mental
retardation which followed an X-linked pattern of inheritance. Such families are
likely to include more affected males and more carrier females than families
identified via a single individual. Howard-Peebles et al. (1979) found 51% of the
males in their families to have the fragile X but this was without any correction
for ascertainment bias. If preferential transmission of the fragile X does occur
this needs to be confirmed because it has major implications for genetic counsell¬
ing. Perhaps the best way of studying this problem would be prospectively.
There should be no bias in a recording of all the offspring born (or prenatally
diagnosed when this becomes routine) to known carrier females. Such data
should finally determine the segregation pattern shown by the fragile X.
The racial origin of most fragile X males has been European (Herbst, 1980)
but they have been identified in American blacks (Howard-Peebles and Stod¬
dard, 1980a), Japanese and Filipino (Rhoads et al., 1982), several of the racial
groups in South Africa (Venter et al., 1981), and Australian aboriginals (Turner,
1981). Hence it would appear that the fragile X will be found to be present in
most racial groups where it is sought.
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There have been anecdotal reports of a possible association between fragile sites
and two separate phenomena, the first being an increased incidence of the fragile X
in individuals with other major chromosome abnormalities such as XXY (Wilmot
et al., 1980). XYY (McCarthy, 1981). Down syndrome (Jacobs et a!., 1980; J.
Lafourcade, personal communication to H. Rivcira et al., 1981), and Trisomy 8
(de Grouchy. 1981; Turleau et al., 1979). In the Dunn et al. (1963) family a Down
syndrome child was produced by a carrier female. Kaiser-McCaw and Hecht
(1980) reported a female with a deleted fragile X, del(X)(q22q26), the presence of
the fragile site proving that the deletion was interstitial. Shabtai et al. (1980)
recorded an XXY male and his mother with the fragile site at 16q22. Second, there
might be an increased incidence of other chromosome abnormalities in families in
which chromosomes with fragile sites are segregating (Cote et al., 1978; Sprensen
etal.. 1979). This latter phenomenon is most likely the result of ascertainment bias
but the former one is difficult to assess since it is also undoubtedly influenced by
selective case reporting. Only further data will determine whether female carriers
of the fragile X are more liable to produce aneuploid gametes, with or without the
fragile X, than are noncarriers.
In an X-linked disease where the reproductive fitness of affected males is zero
and the mutation rates in the two sexes equal, one-third of affected males should
be new mutants. The reproductive fitness of males with the fragile X is certainly
not zero (G. C. Webb et al., 1981; Nielsen et al.. 1981b) but probably closely
approaches it. Because of the difficulty in excluding the fragile X from mothers
of sporadic fragile X males it is difficult to be certain that any sporadic males are
new mutants. Several have been found where this is the most probable explana¬
tion of their origin. On the other hand, there is no convincing example of a new
mutant for other fragile sites and such claims are most probably due to failure to
detect the fragile site in one parent (Sutherland, 1982a).
There has been only one reported demonstration of linkage between a fragile
site and another genetic marker; this was the fragile site at 16q22 and HPA
(Magenis et al., 1970). The fragile site at 6p23 has been formally shown to be
linked to HLA (Mulley and Sutherland, unpublished). Fried and Sanger (1973)
found possible linkage between a form of X-Iinked mental regardation and XG
but with the localization of XG to the opposite end of the X chromosome from the
fragile site there can be no linkage between these markers. The fragile X status of
Fried's (1972) family is unknown. Linkage has been formally demonstrated
between the two fragile sites on lOq and a map distance of 11 female cM between
them calculated (Sutherland et al., 1982). Since fragile sites are manifested as
defects in chromosome compaction for mitosis it is possible that if such defects
were present during meiosis they could affect crossing-over and distort the genet¬
ic length of the chromosome near them. Only accurate gene localization near
fragile sites, by means other than segregation with fragile sites, together with
information from segregation analysis will determine this.
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The genes HPRT and G6PD have been mapped closely to the fragile site at
Xq27 although no linkage studies with the G6PD locus have been reported.
Carroll and Howard-Peebles (1981) found normal levels and electrophoretic
mobilities of G6PD in erythrocytes and fibroblasts of fragile X males. Similar
findings for G6PD were made by Mareni and Migeon (1981) who also measured
mutation rate at the HPRT locus and found no difference between fragile X males
and controls. This work of Mareni and Migeon (1981) suggests that the difficulty
in obtaining expression of the fragile X in some cells is not because the chro¬
mosomal material distal to the fragile site has been lost.
There is very little information on the population cytogenetics of any of the
fragile sites except for the one at 10q25 which is polymorphic in the Australian
population (Sutherland, 1982b). There is a suggestion, based on inadequate
numbers, that the autosomal folic acid-sensitive fragile sites may be more com¬
mon among the mentally retarded than unselected neonates (Sutherland, 1982a),
but this work needs to be extended before this suggestion can be confirmed or
refuted. The available data on the population cytogenetics of the fragile X are
shown in Table II. This shows that the fragile X is not common, is not usually
found in other than retarded males and their female relatives, and that apparently
normal males with the fragile X must be rare.
TABLE II
Population Cytogenetic Data on the Fragile X
Number Number
Series Group studied fra(X)
Sutherland (1982b) Male neonates 522 0
Female neonates 497 0
Patients referred for diagnostic 2237 7
chromosome studies




Males with 36 < 1Q < 70 98 ->
Other males 6 0
Females 35 0
Totally dependent profoundly




Turner el at. (1980b) Girls with 55 < IQ < 75
Normal phenotype 72 5
Abnormal phenotype 56 0
Soudek and Gorzny (1980) Norma] adult males 57 0
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The incidence of the fragile X and its contribution to mental handicap in males
and females are not known. Turner and Turner (1974) estimated that the preva¬
lence of all forms of X-linked mental retardation resulting in an 1Q in the range
30-55 (moderate mental retardation) was 0.53/1000 males (Turner and Opitz,
1980). In a more recent examination of the same population Fishburn et al.
(1982) estimated this prevalence as 0.55/1000 males. If approximately one-half
of X-linked mental retardation is due to the fragile X (Herbst, 1980; Brookwell et
al., 1982) and if two-thirds of affected males come into the 1Q range 35-55, then
the incidence of the fragile X would be approximately 0.40/1000 males. Fish-
burn et al. (1982) estimated the prevalence of fragile X males with moderate
mental retardation to be 0.19/1000 males. Herbst and Miller (1980) have esti¬
mated that 0.92/1000 live born males in British Columbia would have the fragile
X. This latter estimate is probably an overestimate since, after the increased
infant mortality in Down syndrome this would make the fragile X a more com¬
mon cause of mental retardation than Down syndrome in males. Enough work
has been done to know that this is not so. Sutherland (1982a) has shown that in
an institution in which 10-15% of the inmates have Down syndrome only 1.6%
had the fragile X. This would indicate that mental retardation due to the fragile X
is less common than Down syndrome but since Turner (1981) and Fishburn et al.
(1982) claim that fragile X males are less liable to institutionalization because of
their relatively normal appearance and amicable nature than other males with the
same degree of retardation the fragile X males may be underrepresented in the
institutional sample. All estimates of the incidence of the fragile X are unreliable
to a greater or lesser extent because the standard assumptions used when making
estimates involving X-linked conditions, that the condition is lethal (reproduc-
tively) in the male and fully recessive in the female, just do not apply to the
fragile X.
The contribution of the fragile X to mental handicap in females remains
uncertain. Turner et al. (1980b) and Fishburn et al. (1982) have suggested that as
many as 30% of carriers are borderline or mildly retarded and their studies
remain the only ones which have examined a population of retarded girls. Again
this aspect of fragile X work is bedevilled by the problem of ascertainment and
this question is in urgent need of an answer for genetic counselling.
VI. Clinical Aspects
The autosomal fragile sites have usually been considered to be without phe-
notypic effect (Sutherland, 1979b). Homozygotes for the folate-sensitive autoso¬
mal fragile sites have not been identified but Sutherland (1979b) has speculated
that such homozygosity could be deleterious. Homozygotes for the BUdR requir¬
ing fragile site at 10q25 are phenotypically normal (Sutherland, 1981) as are
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probable homozygotes for fra(16)(q22) (Schmid et al., 1980). Sutherland
(1982a) found the autosomal fragile sites to be 10 times more common among
institutionalized retardates than unselected newborns; this difference was statis¬
tically significant although the groups studied were small and this work needs
repeating on other groups. If this finding is confirmed then heterozygotes for the
autosomal fragile sites may be at some increased risk of being mentally retarded
although the majority will not be. The only fragile site which is unequivocally
associated with a mental retardation syndrome is the one on the X chromosome.
X-linked mental retardation has been recognized for many years and achieved
respectability as a result of the publications of Lerke (1972, 1974). The main
publications prior to this were those of Martin and Bell (1943), Dunn ct al.,
(1963), and Renpenning et al. (1962). The name of the senior author of this last
paper had come into eponymous use to describe "nonspecific" X-linked mental
retardation. However, since the family described by Renpenning et al. (1962)
does not have the fragile X chromosome (Fox ct al., 1980) the term Renpenning
syndrome should be restricted to one of those forms of X-linked mental retarda¬
tion which does not have the fragile X chromosome. Indeed there would appear
to be at least four categories of X-linked mental retardation which have now been
recognized clinically (Turner and Opitz, 1980; Fishburn et al.. 1982) and Herbst
and Miller (1980) have estimated that there could be between 7 and 19 X-linked
genes responsible for X-linked mental retardation. Good reviews of the develop¬
ment of X-linked mental retardation as a clinical concept have been published
(Turner and Opitz, 1980; Herbst, 1980) and only the form associated with the
fragile X will be considered further.
The form of X-linked mental retardation associated with the fragile site has no
generally accepted succinct name. Turner and Opitz (1980) suggested MOMX
syndrome for wacroorchidism-warker X but this is inappropriate since rnac-
roorchidism is not a constant or the only clinical feature of the condition and is
certainly inappropriate to apply to those females who are retarded as a conse¬
quence of carrying the fragile X. Fragile X-linked mental retardation was sug¬
gested by Kaiser-McCaw et al. (1980) and modified to fragile (X)-linked mental
retardation by Brookwell et al. (1982) and this is preferred since it can be applied
to either sex.
A. The Phenotype in Males
Before the fragile X had been recognized as a common entity there were a
number of reports of a syndrome of mental retardation associated with mac-
roorchidism (Cantu et al., 1976, 1978; Turner et al., 1975; Ruvalcaba et al.,
1977) which was thought to be X-linked. After the discovery of the conditions
necessary to demonstrate the fragile X it was shown by Sutherland and Ashforth
(1979) Turner et al. (1978), and Rivera et al. (1981) that the form of X-linked
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mental retardation with macroorchidism and that with the fragile X were the
same entity. It now appears that X-linked mental retardation with macroorchid¬
ism and other features of fragile (X)-linked mental retardation can exist without
the fragile X (Herbst ct al., 1981; Fishburn ct al., 1982).
Apart from widespread interest in the association of macroorchidism with the
fragile X there have been few detailed clinical studies of a series of males with
this chromosome. The first such study was that of Turner et al. (1980a) who
examined 25 males from 7 families. They proposed a clinical syndrome in males
with the fragile X composed of the following features:
1. Mental retardation which was usually moderate but varied from severe to
mild.
2. Speech delay greater than motor development delay. The speech tended to
be narrative and compulsive and was referred to as litany speech.
3. Behavior problems in some cases which had been labeled as autistic and
hyperactive.
4. Macroorchidism, generally present in adults and possibly in prepubertal
males.
5. Birth weight greater than that of siblings, the mean of 22 males was on the
seventieth percentile.
6. Increased head circumference before puberty returning to normal in
adulthood.
7. Normal but characteristic facial appearance due to (a) large forehead with
supraorbital fullness, (b) prominent chin, (c) large ears, and (d) pale irides (in 22
of 25 males examined).
This concept of a syndrome comprising any more than mental retardation and
possibly macroorchidism associated with the fragile X has been challenged (Kai-
ser-McCaw and Hecht, 1980; Kaiser-McCaw et al., 1980). Each of the compo¬
nents of this syndrome will be examined.
Mental retardation is almost always present. Proops and Webb (1981) re¬
corded IQs ranging from 20 to 65 in 1 1 males who unequivocally had the fragile
X. In the original family of Lubs (1969) one male had a measured IQ of 70 but
others in the family were more severely retarded. The males described by Jen¬
nings et al. (1980) were all severely retarded. Martin et al. (1980) reported
brothers with IQs of 57 and 67. Gustavson et al. (1981) reported males with IQs
from severely retarded to 70. There are numerous other reports which taken
together indicate that most of the males are moderately retarded, however, it
would appear that there is a broad range of IQs shown by fragile X males with a
small proportion coming into the normal range. Some of the mildly retarded
males have reproduced (Jacobs et al., 1980), as have some of the normally
intelligent ones (G. C. Webb et al., 1981; Nielsen et al., 1981b).
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The spectrum of intellectual development in fragile X males raises the pos¬
sibility of this chromosome being present in normal males. Daker et al. (1981)
reported brothers of normal intelligence who appear to have the fragile X but full
family studies were not carried out and folic acid sensitivity of the fragile X was
not demonstrated. Rhoads et al. (1982) recorded a probable hemizygote of
normal intelligence who on pedigree data has transmitted the fragile X to a
retarded grandson; strangely, the fragile X could not be demonstrated in this
normal man. Nielsen et al. (1981b) described a family in which three non-
retarded males apparently transmitted the fragile X to retarded grandchildren. G.
C. Webb et al. (1981) were the first to document the fragile X in a normal male,
his daughter and retarded grandson. At present it is reasonable to conclude that
the great majority of fragile X males will be retarded although in some instances
only mildly, with a small number having normal intellectual function. A practi¬
cal consequence of this is that the fragile X can be transmitted from normal males
to their retarded grandsons (G. C. Webb etal.. 1981) and this pattern of segrega¬
tion should always be considered when carrying out family studies. Furthermore,
nonretarded male siblings of fragile X males should have their chromosomes
studied.
The question of a specific developmental problem in regard to speech has been
considered by Herbst (1980) and Herbst et al. (1981) who concluded that there
was no association between language abilities and the fragile X. This conclusion
is in the face of many reports summarized by Flerbst (1980) in which a verbal
problem has been either noted clinically or documented by a difference between
verbal and performance 1Q scores. Unfortunately most of this work was done
before the fragile X was recognized to be present in a proportion of cases of X-
linked mental retardation and is based on a heterogeneous group with this diag¬
nosis. Jacobs et al. (1980) reported speech patterns similar to the litany speech of
Turner ct al. (1980a) and suggested it was characteristic enough to suspect the
fragile X on this basis alone. Rhoads et al. (1982) found a relative verbal
disability among the affected males in their Japanese family and the only one
fully assessable had litany speech. Howard-Peebles et al. (1979) and Howard-
Peebles and Stoddard (1979) examined the verbal abilities of individuals with X-
linked mental retardation with and without the fragile X and found no distinctive
pattern. The verbal disabilities of the two groups were not different from each
other or from other retarded groups studied, however, the numbers studied were
small and the authors indicated that further studies of males with X-linked mental
retardation were required. Further documentation of the verbal abilities of males
with the fragile X is required before a deficit in this area can be regarded as
proven.
Turner et al. (1980a) reported behavior problems in only three of the males
they studied. Rhoads et al. (1982) recorded a Japanese male with autistic behav¬
ior and hyperactivity. Herbst (1980) considered behavior problems in her series.
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and although they had been recorded in more than half the males concluded that
they may be no more a feature of X-linked mental retardation (the heterogeneous
group) than of other forms of mental retardation. Brown et al. (1982) recorded
four fragile X males with autism. Most authors have studied adults with the
fragile X and there is little doubt that these rarely have behavior problems and are
not difficult to manage either in institutions or in the community (Turner et al.,
1980a). Giraud et al. (1976) noted behavior problems in two of five fragile X
boys. Lejeune (1982) noted severe behavior problems, including psychotic com¬
plication of mental retardation and autism, in 8 out of 16 fragile X males. The
author's impression from dealing with a number of children with the fragile X is
that apart from mental retardation, behavior problems are the main feature of the
condition which causes parental complaint. The problems have mostly been
related to hyperactivity but some of the children had been labeled as autistic prior
to diagnosis and others have psychotic features to their behavior. In general,
these problems appear to have improved with age. Again, more data are required
to document a possible association between the fragile X and childhood behavior
problems.
There still appears to be confusion about the relationship between mac-
roorchidism and the fragile X. Turner et al. (1978), Sutherland and Ashforth
(1979), Sutherland et al. (1980a), and Rivera et al. (1981) concluded that the
form of X-linked mental retardation associated with macroorchidism and that
associated with the fragile X were the same entity. Jacobs et al. (1979) claimed
that there was no correspondence between the two forms of mental retardation
and that either could exist separately but later (Jacobs et al.. 1980) withdrew this
claim emphasizing the point made by Howard-Peebles and Stoddard (1980b) that
clinical impressions of macroorchidism were useless and that actual measure¬
ment of testicular volume was required. It would now seem that X-linked mental
retardation with macroorchidism [and the other features of fragile (X)-linked
mental retardation] can exist without the fragile X being present (Herbst et al.,
1981; Fishburn et al.. 1982). Such a family was described by Ruvalcaba et al.
(1977) where Jennings et al. (1980) were unable to demonstrate the fragile X.
This condition will be considered later in Section VII.
Testicular volume is a difficult parameter to measure in the living male and
can be approached using the Prader orchidometer which has limitations in that
the largest bead on the standard model is 25 ml. For testes larger than this (and
for smaller ones) length and width can be measured and the volume calculated
from the formula n/6/iv2 where / is the length and vv the width of the testis (Cantu
ct al.. 1976). Normal data have been provided for Caucasian males by Prader
(1974), Farkas (1972), and Zachmann et al. (1974) and it has been suggested
(Rhoads et a!.. 1982) that different criteria of normality may be required for
other racial groups. Benign macroorchidism has been described by Padron et al.
(1979) who found 15 out of 202 normal Cuban males to have testes greater than
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25 ml in volume. Of these, six had volumes calculated from measurement to be
greater than 2 SD above the mean and ranged from 58 to 74 ml. Semen analysis
was normal but the volume of ejaculate and sperm counts were much greater than
in males with normal testicular volumes.
An analysis of the published and unpublished testicular volumes of retarded
adult males of Caucasian origin with the fragile X, ascertained via mental retar¬
dation rather than macroorchidism, shows that the mean testicular volumes of 83
such males is 48 ml. The range is from 15 to 127 ml (Jacobs et al.. 1980). The
distribution (Fig. 7) is skewed such that the modal volume is in the range 35-40
ml. Hence it would appear that the fragile X chromosome has the effect of
increasing the mean testicular volume in males from about 19 ml (Zachmann et
al.. 1974) in normal males to 48 ml and about 80% of fragile X males will have a
mean testicular volume of greater than 30 ml. There can be little doubt that
macroorchidism is a feature of most males with the fragile X, and in all families
with the fragile X at least some of the males with this chromosome have
macroorchidism.
Histological studies of enlarged testes from fragile X males have been carried
out by Cantu et al. (1976, 1978), Ruvalcaba et al. (1977). Bowen et al. (1978),
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Fig. 7. Distribution of mean testicular volume of 83 adult Caucasian fragile X males in whom
macroorchidism was not a factor in ascertainment. Mean volume is the average of the right and left
testicular volume.
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and Turner et al. (1975) and the only consistent finding seems to be a relatively
normal testis with interstitial edema. Ruvalcaba et al. (1977) concluded that
macroorchidism was due to an increase of water content in the testis. Normal
semen analysis was reported by Cantu et al. (1976).
The use of macroorchidism as a means of screening males to identify those
with the fragile X has produced conflicting results. Brown et al. (1981) screened
15 males with nonspecific mental retardation and found five with one or both
testicles having a volume of greater than 25 ml; four were shown to have the
fragile X. Nielsen etal. (1981a) screened 178 retarded males and, using the same
criteria as Brown et al. (1981), identified 10 with macroorchidism of whom only
one had the fragile X. On the other hand, Pozsonyi et al. (1981) screened 818
retarded males, again using the same criteria as Brown et al. (1981), and found
190 with macroorchidism of whom only nine had the fragile X. This latter
finding would suggest that macroorchidism is either very common among the
retarded group studied or that the criteria for determining it were wrong. Some of
the males identified in this way presumably had X-linked mental retardation with
macroorchidism but without the fragile X. In the survey of Fishburn et al.
(1982), of 18 families with X-linked mental retardation and macroorchidism, 12
had the fragile X and 6 did not.
There are only limited data available on birth weight of fragile X males. Those
studied by Turner et al. (1980a) had an average birth weight on the seventieth
percentile and in 12 of 16 their birth weight was on average greater than that of
their unaffected siblings. In the two families of Ruvalcaba et al. (1977) birth
weights were noted to be above the nintieth percentile for gestational age. Herbst
et al. (1981) recorded birth weights of nine fragile X males and only one had a
birth weight greater than all his siblings. Hence the information on birth weights
is equivocal and more data are needed on this aspect of development.
There is not much data on head circumference in children with the fragile X
other than that presented by Turner et al. (1980a). Jennings etal. (1980) reported
the head circumference on a 5-year-old boy to be greater than the nintieth
percentile. Jacobs et al. (1980) recorded head circumferences on three children
and two of these are at the nintieth percentile. Herbst et al. (1981) recorded head
circumferences of two boys and seven adult fragile X males and all were normal.
The limited data available indicate probable increased head circumference in
children but not adults (Turner et al.. 1980a), although Rhoads et al. (1982)
recorded an increased head circumference in adult Japanese males with the
fragile X.
The characteristic facial appearance described by Turner et al. (1980a) has
been confirmed by others but challenged by some. Jacobs et al. (1980) referring
to this remarked they appear "to be cast in the same mould." Jennings et al.
(1980) state that facial appearance is unique and describe it as mid-facial hypo¬
plasia with large prominent ears and prognathism. Fox et al. (1980) found the
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characteristic fragile X syndrome in members of the original Dunn et al. (1962)
family which has the fragile X but not in that described by Renpenning et al.
(1962) which does not have the fragile X. Herbst et al. (1981) noted normal faces
in many of their fragile X males but suggested a tendency toward long narrow
faces, prominent jaws, and large or lop ears. Kaiser-McCaw and Hecht (1980)
have challenged the existence or at least the constancy of the phenotype after
study of a number of retarded males in a large Spanish kindred.
One feature of the fragile X syndrome not mentioned by Turner et al. (1980a)
is the hypogonadal appearance of some of the adult fragile X males. This can
include sparse body hair with a female pubic hair distribution and gynecomastia.
In their original description of the syndrome Turner et al. (1975) reported one
male to have minimal beard growth, female pubic hair distribution, gyne¬
comastia, and striae on the buttocks, abdomen, and axillae; this man's brother
was similarly affected in this way. Ruvalcaba et al. 1977) commented upon a
male having lack of secondary sexual development at the age of 16.7 years.
Bowen et al. (1978) recorded gynecomastia in one male, as did Webb et al.
(1982). Although the endocrinological investigations of fragile X males have
been normal (Cantu et al., 1976; Bowen et al., 1978; Ruvalcaba et al., 1977)
this is an area which may reward further study. Numerous other clinical findings
have occasionally been mentioned by various authors but the only others to occur
frequently are clumsiness with poor fine motor control, large hands and feet, and
an increased incidence of seizures. Fishburn et al. (1982) report exaggerated
reflexes without clinical spasticity to be common in fragile X males.
It would seem that from the literature and the author's experience that there is
indeed a syndrome associated with the fragile X in males (Fig. 8) but that it is
variable although the variation is probably no greater than that seen in other
dysmorphic syndromes, especially those associated with chromosome abnor¬
malities. Not every fragile X male will be diagnosed clinically but as a retarded
male will be worthy of chromosome study.
B. The Phenotype in Females
No female homozygous for the fragile X has been described so that all clinical
data on the fragile X in females are derived from heterozygotes. The main study
of heterozygotes is that of Turner et al. (1980b) who karyotyped 128 mentally
retarded girls of whom 72 were regarded as being physically phenotypically
normal; among the 72 there were five who had the fragile X chromosome. This
study suggested that 1% of girls with an IQ in the range 55 to 75 and who have no
physical abnormality may be retarded because they carry the fragile X. In the
families of these girls 18 heterozygotes were identified (excluding the index
cases) of whom six were at least educationally retarded. This would suggest that
one-third of fragile X carriers may be mildly retarded or worse. Fishburn et al.
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Fig. 8. Facial appearances of five retarded fragile X males (a) aged 3 years, (b) aged 5 years, (c)
aged 11 years, (d) aged 16 years, (e) aged 62 years. Macroorchidism shown by a fragile X male, note
size of testes in relation to 25 ml orchidometer bead (f).
(1982), from a more extensive study of 40 families, confirm that one-third of
female heterozygotes are borderline or mildly mentally retarded but have no
physical abnormality.
Physical examination of the index cases identified by Turner et al. (1980b)
showed no abnormality other than obesity in four of the five, and pale irides in
two. Webb et al. (1982) reported a severely retarded heterozygote (IQ less than
30) with a moderately retarded niece; neither had dysmorphic features although
both were mildly obese, one had bright blue irides and the other hazel irides.
Many authors have recorded retarded heterozygotes but have not commented
upon their physical phenotype and there is a need for further study in this area.
C. Treatment
Lejeune (1982) has claimed that treatment of fragile X males with oral or
intramuscular folate derivatives has resulted in an improvement in the behavior
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of seven out of eight who had psychotic behavior. The basis of this treatment is
entirely empirical since no abnormality of folate metabolism has been demon¬
strated in fragile X males (Jennings et al., 1980; Popovich et al., 1980). No other
treatment trials have been reported and there is need for a blind trial of folate
treatment to determine whether the claim of Lejeune (1982) can be substantiated.
A vitamin treatment study of the mentally retarded was reported by Harrell et al.
(1981) in which small increases in 1Q were recorded for most of those studied
except for one boy whose 1Q at age 7 years was 25 to 30, but after treatment at
the age of 9 years was about 90. Did this child have the fragile X?
D. Genetic Counselling and Prenatal Diagnosis
Genetic counselling in fragile X families is very difficult for a number of
reasons. The inability to detect the fragile X in many obligate carriers makes
carrier detection uncertain, even when females are studied at an early age. It is
not possible to be absolutely certain that males with the fragile X will be retarded
although the degree of uncertainty here is so small that for practical purposes this
problem can be ignored. Another problem is the possibility that normal males in
these families could have the fragile X and not manifest it (Rhoads et al., 1982)
although again the probability of this is very low. The risks to a carrier female of
having a child who has the fragile X are still uncertain and could be greater than
50% (see Section V). If this is so then some carrier females may be reluctant to
embark upon prenatal diagnosis if their aim is to have a child (male or female)
who does not have the fragile X. If prenatal diagnosis is offered to carrier
females then there is a problem when a female fetus is found with the fragile X.
Her probabilities of being a bit dull, mildly or moderately retarded, or worse are
not known although Turner et al. (1980b) and Fishhurn et al. (1982) have
estimated that one-third of such females are retarded to some degree. Most
couples undertaking prenatal diagnosis would not wish to continue with a female
pregnancy if there was a one in three chance that the child was going to be
retarded and for this reason the usual practice of fetal sexing in X-linked condi¬
tions. with abortion of male fetuses, will be of limited use in fragile (X)-linked
mental retardation.
The concept of prenatal diagnosis has been mooted for a long time and was
suggested by Lubs (1969) in his original description of the fragile X. Harvey et
al. (1977) also proposed this as an option for carrier females. These suggestions
were made before the difficulties in obtaining fragile X expression in fibroblasts
were appreciated (Sutherland. 1977a). Jenkins et al. (1981) were the first to
demonstrate the fragile X in cultured amniotic fluid cells by induction with FUdR
and Shapiro et al. (1982) achieved a prospective prenatal diagnosis using the
same approach. T. Webb et al. (1981) used lymphocyte culture from fetal blood
sampling via fetoscopy to show that a male fetus had the fragile X. Either of
these approaches should be successful in prenatally diagnosing the fragile X if
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they are only utilized by those with considerable laboratory experience in demon¬
strating this chromosome in a variety of cell types (Sutherland and Jacky, 1982).
VII. Karyotype-Phenotype Relationship
There is little doubt that the fragile X chromosome is associated with a mental
retardation syndrome in most males who have it. It is also clear that a proportion
of females who carry the fragile X are mildly retarded or worse. Furthermore, the
mental retardation syndrome seen in males with the fragile X can exist in males
in whom the fragile X cannot be demonstrated (Fishburn et at., 1982).
The nature of the association between the fragile X and its associated syn¬
drome is unclear. The possibility of a locus for the mental retardation syndrome
being so closely linked to the fragile site that recombination will not usually be
seen within any family could explain some of the observed facts. It could cer¬
tainly account for the finding of the syndrome associated with the fragile site in
some families and not in others and with the finding of normal males with the
fragile X (Daker et at., 1981). It cannot however readily account for normal
males transmitting the fragile X and mental retardation to their grandsons
(Rhoads et at., 1982; G. C. Webb et at.. 1981; Nielsen et at.. 1981a). This
would, on a linkage hypothesis, require such males to have married females who
were carriers of the locus and for recombination to have occurred in their daugh¬
ters before the recombinant chromosome was transmitted—a series of events so
improbable that it can be discounted. The most likely explanation for apparently
normal fragile X males is that either the genetic effect of the fragile X is
nonpenetrant or only very mildly expressed. There is a suggestion in the family
described by Nielsen et at. (1981b) that the normal fragile X males were less
intelligent than their brothers without the fragile X who were of superior intel¬
ligence. Presumably the deleterious effect of the fragile X is imposed upon the
genetic component of intellectual endowment and where this is very high even
substantial impairment of it could result in normal intelligence. No fragile X
male of superior intelligence has been reported.
Until any further evidence to the contrary is presented it is probably safe to
conclude that the fragile site at Xq27 is a cytological manifestation of the gene
responsible for the mental retardation syndrome seen in association with it. The
gene may not be 100% penetrant and its expression can certainly, vary both
clinically and cytologically. Mental retardation seen in female carriers of the
fragile X is presumably the result of differential X-inactivation.
There is still the problem of those males without the fragile X but with the
clinically indistinguishable syndrome of X-linked mental retardation with its
associated physical findings including macroorchidism. There are several possi¬
ble explanations for this phenomenon and it is not possible to choose between
them at this time. There is still a paucity of clinical information about these males
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and it might be that they will be found eventually to be a separate clinical entity.
If this is not so then two main possibilities arise. First, all such males have the
fragile X but under conditions of culture it is not expressed. Soudek et al. (1981)
suggested that fragile X families had a characteristic frequency of expression of
the fragile site in lymphocyte culture and that on average males in some families
had a very low frequency of expression. If Soudek's suggestion is true, then in
some families expression may be so difficult to elicit using current technology
that males in these families may appear not to have the fragile X. Attempts to
demonstrate a fragile X in fibroblast or lymphoblastoid cultures in these males
may help resolve this matter, or further technical advances in the demonstration
of fragile sites may be needed before it can be finally resolved. Second, there
may be an allelic mutation which will not result in expression as a fragile site but
which results in an abnormal gene product with the same phenotypic conse¬
quences as the mutation which is expressed as a fragile site, such mutation could
be in the form of a small deletion. Genetic heterogeneity is commonly found in
well-studied genetic diseases and there is no reason to think fragile (X)-linked
mental retardation will be any different.
VIII. Conclusions
The fragile X chromosome is a common cause of mental retardation in males
and females. Much more information is required on the nature and effects of the
fragile X in virtually every area where it has been examined from chromosome
structure, the biochemistry involved in expression in different cell types, the
incidence in various populations and its contribution to mental retardation, the
nature of its association with abnormal phenotypes in most males and some
females, its possible role in chromosome segregation of both the X chromosome
carrying it and other chromosomes, and its linkage relationships with other genes
on the X chromosome to its relationship to the autosomal fragile sites. Perhaps
some of these questions will not be answered until recombinant DNA technology
has been applied to fragile sites (Gerald. 1980); nevertheless even at this present
state of rudimentary' knowledge study of the fragile X chromosome is an essential
part of clinical cytogenetics where its contribution to diagnosis, prevention, and
possibly treatment of mental handicap is just beginning.
IX. Apologia
Gerald (1981) has expressed the hope that the circumstances surrounding my
finding that fragile sites depend upon conditions of tissue culture for expression
(Sutherland, 1977b) would be documented. In 1975 shortly after 1 had taken up
my present appointment in Adelaide I attempted to restudy some of the autoso-
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mal fragile sites which had been found in the mid-1960s in patients studied in the
Unit. This was only intended to be a short project to occupy my time until I
settled into my new job and decided upon some more worthwhile activity.
Between the time these patients were ascertained and my arrival the laboratory
(along with many others around the world) had switched from using TCI99 for
lymphocyte culture and was using RPMI 1640 which I soon changed to Ham's
F10. which 1 had been using in Edinburgh, so that we could use a single medium
for culture of lymphocytes, fibroblasts, and amniotic fluid cells. My early at¬
tempts to study fragile sites used Ham's F10, and, needless to say, were quite
unsuccessful. In late 1975 1 visited my old laboratory in Melbourne and Jill
Harvey, who was my successor there, showed me her work on the fragile X
which was subsequently published (Harvey et al., 1977).
I guessed that this marker X chromosome (as it then was) probably had a
fragile site similar to the autosomal ones 1 was attempting to restudy (mainly
because of the double satellited appearance occasionally seen) and guessed that I
would not be able to demonstrate it. On returning to Adelaide 1 briefly tried a few
changes to my culturing technique attempting to induce the vanished autosomal
sites by reproducing the Melbourne conditions. Initially I tried steptomycin in
my Ham's F10 because this was in use in Melbourne, whereas I was using only
penicillin. Eventually I decided to try and duplicate the Melbourne conditions as
faithfully as 1 could and purchased some TC199. Under these conditions my
vanished autosomal fragile sites miraculously reappeared and study of a few
families suspected of having X-linked mental retardation soon allowed me to
confirm the common occurrence of the fragile X and provided material for
further studies. To my chagrin, one of the fragile X males had been studied and
pronounced to have a normal karyotype by me during rnv period in the
Melbourne laboratory. Jill Harvey assured me that checking of the preparation 1
had examined showed it to be of fairly poor quality but this was probably just Jill
being nice to me. Had I been observant enough at the time, Lubs' initial discov¬
ery would well have been confirmed shortly after it had been made.
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Genetic Length of a Human Chromosomal Segment
Measured by Recombination Between Two Fragile Sites
Abstract. Two families were studied in which the same homolog of chromosome
pair 10 expressed both the fragile sites on the long (q) arm at 10q23 and !0q25.
Recombination between the fragile sites was observed in 3 of the 27 offspring in
whom it could occur. The •genetic length of chromosome between the fragile sites
was 11 female centimorgans within a 95 percent probability interval of 4 to 28
centimorgans. This estimate of genetic length is comparable to those obtained with
other methods.
Fragile sites are morphological fea¬
tures of human chromosomes that can be
recognized cytologically when lympho¬
cytes are cultured under appropriate
conditions (/). Since any fragile site is
always expressed at the same locus in
individuals from the same kindred, kin¬
dreds in which fragile sites are segregat¬
ing can be used for gene mapping (2).
Two fragile sites have been described on
chromosome 10. One, in band I0q23, is
expressed only under conditions of folic
acid and thymidine deprivation (/), and
the other, in band 10q25. is expressed
only if bromodeoxyuridine or bromo-
deoxycytidine is present in the tissue
culture medium for some hours before
harvest (3). The discovery of two fam¬
ilies in which both of these fragile sites
were present on one chromosome (Fig.
1) provided an opportunity to measure
the genetic length of the segment be¬
tween the fragile sites by segregation
analysis.
The two families are not known to be
related to each other, although both are
of British origin. The families were as¬
certained through mildly retarded girls,
but other members of these families who
have the fragile sites on chromosome 10
were normal. Examples of number 10
chromosomes expressing both the fragile
sites are shown in Fig. 2. On G-banded
preparations, one fragile site is at the
distal end of 10q23 (/), probably at
10q23.32 or 10q23.33, and the other in
the middle of 10q25 (3). probably at
10q25.2 (4).
The frequency of expression of the
fragile sites is shown in Table 1. One
member of family Ho, 111-12, has been
omitted from consideration because in
the small number of cells available for
examination, it was not possible to be
sure that fra(10)(q25) was absent. Fragile
sites were present on the same homolog
of chromosome 10 in several individuals,
including 1-6 from family Ho and 1-1
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from family Ch. In those individuals in
whom the fragile sites were not found, at
least 50 metaphases were usually exam¬
ined for each fragile site.
Three recombinants were detected in
family Ho, but none were seen in family
Ch. Recombination occurred in 3 of the
27 offspring of females who expressed
the fragile sites on the same homolog
of chromosome 10. The recombination
fraction is 11 percent (3/27), and since
double crossovers are unlikely for such a
small segment, the estimate of the genet¬
ic length of chromosome between the
fragile sites in females is 11 centimorgans
(cM) with a 95 percent probability inter¬
val of 4 to 28 cM (5). In general, the
female map length is approximately
twice that of males (6). On this basis the
length of segment between the fragile
sites in males would be about 6 cM with
95 percent probability interval of 2 to 21
cM (5), provided the general relationship
between male and female recombination
rates is applicable to this chromosomal
segment.
An estimate of the genetic length of
the segment of chromosome between the
fragile sites from meiotic studies in males
is 3.8 cM, with a possible maximum
Table 1. Frequency of expression of the frag¬
ile sites in family members.




















length of 13.5 cM, according to Hulten's
model (7). Direct measurement of the
segment between the bands expressing
the fragile sites from prometaphase chro¬
mosomes (4) shows that the segment is
about 18 percent of mitotic length of the
long arms of chromosome 10 and that the
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Fig. I. Pedigrees of the two families.
Fig. 2. Chromosome 10 from four metaphases showing both fragile sites expressed. The fragile
site at I0q23 is indicated by the broad arrow and the one at I0q25 by the small arrow. To induce
simultaneous expression of both fragile sites, lymphocytes were cultured in MEM-FA (/), and
bromodeoxycytidine (75 mg/liter) was added 6 hours before harvest.
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the proximal half of the distal third of the
long arm of the mitotic chromosome.
The meiotic map of the human genome
put forward by Cook et al. (6) indicates
that the distal third (in mitotic length) of
the long arm of chromosome 10 is ap¬
proximately 36 cM for males. The seg¬
ment between the fragile sites corre¬
sponds to a male length of approximately
19 cM with Cook's map.
There is good agreement between the
estimates of the genetic length of the
chromosomal segment between the frag¬
ile sites from segregation analysis and
meiotic observation. Furthermore, the
95 percent probability interval of the
estimate from segregation analysis en¬
compasses the estimate from Cook's
meiotic map, but Hulten's maximum es¬
timate is shorter than that obtained from
Cook's map. Cook et al. (6) have indicat¬
ed they believe that Hulten's model un¬
derestimates genetic length.
The possibility that fragile sites could
affect crossing-over should be consid¬
ered. Crossing-over occurs in chromo¬
somes in which the DNA is compacted,
although not to the degree seen in C-
metaphases. Fragile sites are defects in
chromosome compaction for mitosis. If
this defect in compaction also holds for
meiosis, the fragile sites could in some
way inhibit or possibly even facilitate
recombination. This could lead to biased
estimates of genetic length when fragile
sites are used as genetic markers for
linkage studies. The level of recombina¬
tion observed between the fragile site at
16q22 and the haptoglobin locus Hp (2)
may help to clarify this issue when Hp is
precisely localized by methods other
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At the International Congress of Human Genetics (Jerusalem, September, 1981) a
Workshop was held on the fragile X chromosome; it was entitled "The Fragile X
Chromosome: Current Methods." It was to focus on laboratory methods required
to detect or to enhance the detection of the fragile X.
The fragile site on the X chromosome is one of 13 proven fragile sites known in
humans. (A diagram of these sites is provided.) The fragile site on the X is sensitive
to the concentration of folic acid in the medium in which cells are cultured. Cyto-
logically, gaps and breaks are increased at the X fragile site, which is located at
band Xq27-28. To enhance expression in lymphocytes, prolongation of culture
time to 96 hours, elevation of the pH, diminution of the colcemid effect, and ait-
drying of slides are helpful. The need for methionine in low-folate media can be
overridden by the addition of fluorodeoxyuridine (FUdR). Detection of the fragile
X in males requires meticulous attention to methods of lymphocyte culture and
metaphase preparation and then the examination of a sufficient number of mi¬
toses, eg, 50-100 metaphases per individual. Detection of the fragile X in female
carriers is often more difficult. Uniform detection of all obligate female carriers
has not been achieved. Difficulty may correlate with increasing age or intelligence
of females.
Key methodologic advances with the fragile X include the addition of metho¬
trexate, trifluorothymidine or, especially of FUdR to the culture medium. FUdR,
for example, is helpful in demonstrating the fragile X in lymphoblastoid cell lines
and fibroblasts. Both of these cell types now represent an opportunity to study the
biochemistry of the fragile X.
The success of the FUdR technique with skin fibroblasts heralds the feasibility
of demonstrating the fragile X chromosome in cultured amniocytes. Since the
Workshop, it has been reported that with FUdR the fragile X could in fact be de¬
tected in 46,XY amniotic fluid cells.
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PREAMBLE
The program for an International Congress on a subject such as Human Genetics
has, by necessity, to be developed long in advance of the meeting. This was the case
with the most recent International Congress of Human Genetics. Between the time the
Congress was conceived and the time it was held, certain topics emerged as of unusual
interest. Among these topics was the "fragile X chromosome." No session wholly de¬
voted to the fragile X had been contemplated at first, but due to a rising tide of interest,
Peter Jacky initiated a workshop on the fragile X with the cooperation of the orga¬
nizing committee and program commitrtee. The Workshop was chaired by Frederick
Hecht. This summary was prepared by the authors with the generous help of many of
the participants in the Workshop.
This synopsis is intended to be in the general style utilized by Nature, so formal
references to research in print or in press are not given.
INTRODUCTION
The "fragile X chromosome" is currently an active interest for many investigators
in human genetics.
Clinical interest stems from the intimate association between the fragile X and
X-linked mental retardation; hemizygous males are usually (perhaps always) mentally
retarded. Further clinical interest derives from the association between the fragile X
and the tendency to intellectual dullness in female carriers.
Laboratory interest in the fragile X jumped in 1977 when Sutherland discovered
that the fragile X phenomenon was "folic acid sensitive," ie, invisible in "complete"
media but can be seen in all affected males and a proportion of carrier females whose
lymphocytes have been cultured in "deprived" media (such as medium 199) deficient in
folic acid and thymidine.
Many other crucial investigations such as those by Tubs (1969) have contributed
to our current knowledge of the fragile X. The evolution of past work on X-linked
mental retardation and the fragile X is outlined in the December, 1980 issue of the
American Journal ofMedical Genetics, which contains a set of articles on it and allied
topics.
MAPOF FRAGILESITES
Sutherland has noted, and the Workshop agreed, that the fragile X is one of 13
proven "fragile" sites in the human genome. "Fragile" meaning thai chromosomes tend
to break preferable at these sites.
The X fragile site is now firmly established as being near the end of Xq. There is
still some uncertainty whether the site is at band Xq27 or band Xq28 or at the interface
of these 2 bands.
The known fragile sites now include locations on chromosomes 2, 6, 7, 9-12, 16,
20, and the X (Fig. I). There are two fragile sites on chromosomes 9, 10, and 16; and
one on the rest. In addition, there are "look-alike" sites on other chromosomes such as
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Fig. 1. Current map of heritable human fragile sites. The thin arrows point to folic acid sensitive sites in¬
cluding that on Xq. The thick arrow points to the BrdU inducible site on chromosome 10 and the dashed
arrow indicates the location of the constitutive fragile site on chromosome 16 linked by genetic family stud¬
ies to the a-haptoglobin locus.
on chromosome 6. There was agreement that the "look-alike" sites such as that on 6q
are not true fragile sites, since they do not appear to be heritable.
Only two of the fragile sites that have been fully studied are not sensitive to the
concentration of folic acid in the culture medium. Sutherland suggested that in the long
run virtually all fragile sites may prove to be folic acid sensitive. Alternatively Hecht
suggested that the current prevalence of folic acid sensitive sites may reflect the con¬
temporary utilization of folic acid deficient media in the search for fragile sites.
Clearly, time will tell.
CYTOLOGIC BEHAVIOR OF FRAGILE SITES
The cytologic behavior of fragile sites, including that on the X, is now establish¬
ed. The chromosome at these sites tends to elongate and display a negatively hetero-
chromatic gap. Sutherland has found that unbanded chromosome spreads are best for
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analysis of fragile sites; however, Karen Buckton (Edinburgh, United Kingdom) and
others employ banded preparations for reading fragile sites. Although gaps are most
common, single chromatid and chromosome breaks at fragile sites are clearly increased
in frequency. The portion of the chromosome distal to the fragile site can sometimes be
seen in multiple copies within the cell. Although it was originally proposed that this was
due to selective endoreduplication, Ferguson-Smith (Glasgow, United Kingdom) as¬
cribed it to nondisjunction and he and Noel subsequently proved this was so, using
BrdU labelling of chromatids.
GENETICS OF FRAGILE SITES
Fragile sites are heritable cytologic markers. Aside from the fragile X, all proven frag¬
ile sites are on autosomes and are inherited in a codominant pattern.
Fragile sites provide an exciting addition to the formidable armory of available
markers for linkage and mapping purposes. The demonstration by Magenis, Lovrien
and Hecht in 1970 that a fragile site on chromosome 16 was linked to the alpha-hapto-
globin gene locus helped chart the "geography" of this chromosome. Sutherland's
group is studying a family segregating for two fragile sites on chromosome 10; both
sites are on lOq (Fig. 1) and cytologically are not far from one another; a rough recom¬
bination frequency of 16 centimorgans has been found.
FRAGILE X IN LYMPHOCYTES
To optimize the expression of the fragile X in lymphocytes, Patricia Howard-
Peebles (Birmingham, Alabama and Dallas, Texas) stressed the need to prolong time in
culture to 4 days (96 hours), to raise the pH of the culture medium to pH 7.2 or above
(particularly toward the time of final harvest), to decrease colcemid concentration (or
time of exposure to colcemid) and to air-dry (not flame-dry) slides. Howard-Peebles
noted that numerous factors do not enhance fragile X frequency. For example, the ad¬
dition of 5-azacytidine, distamycin A, betaine, or ethionine does not facilitate fragile X
expression.
Methionine has been found by Howard-Peebles to be required for fragile X ex¬
pression. Thomas Glover (Tempe, Arizona) and Howard-Peebles have shown that this
effect of methionine is a secondary one that can be overridden by the addition of
FUdR, a potent inhibitor of thymidylate synthetase. With FUdR, it no longer matters
whether methionine is present or absent. The simplest explanation of these data is that
inhibition of DNA synthesis is involved in the expression of the fragile X. It would ap¬
pear from the literature that males with the fragile X are always easy to detect in the lab¬
oratory. This is incorrect. Their lymphocytes must be cultured with meticulous atten¬
tion to the fastidious requirements of the fragile X. Metaphases must be prepared
appropriately and, equally important, if the fragile X is not readily seen, the sample of
good metaphases must be sufficiently large (eg, 50-100) to ensure reliable results. For
example, Barbara Kaiser-McCaw and Glover (Tempe, Arizona) have on occasion
needed to examine 50-100 metaphases from a suspect male to score him as having the
fragile X.
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THE CASE OF THE "VANISHING" CARRIER
By pedigree analysis, it is clear that some females are obligate carriers of the frag¬
ile X. They may have an affected brother and an affected son, so they must carry the
fragile X. Yet it appears that every laboratory with experience has had the frustration
of utterly failing to detect the fragile X in one or more obligate carriers.
Why is fragile X expression in carriers so inconstant? The answer generally given
is that it is a matter of age; ie, in older carriers the fragile X vanishes. However, it
should be noted that no one has yet demonstrated this phenomenon by serial studies
over time in a carrier. Thus, at the moment this is a supposition.
Could it be that the fragile X does not vanish with age? Might another factor be
responsible for the situation? This question was raised and discussed by Patricia Jacobs
(Honolulu, Hawaii). Jacobs proposed that intelligence might be the key factor or, at
least, another factor.
The idea is that some females are more intelligent because they are favorable
Lyonization mosaics. The smaller the "mutanC'cell line; the smarter the woman is, and
the greater is the chance that she will be ascertained kite for reproductive genetic coun¬
seling. By contrast, other females with the fragile X may be dull because they are un¬
favorable Lyonization mosaics. The larger the "mutant" cell line, the less intelligent is
the female. And the duller she is, the greater is the chance that she will be ascertained
and studied early.
The problem — age per se or intelligence—is clearly amenable to study and should
soon, we hope, be solved.
OTHER MYSTERIES SURROUNDING THE FRAGILE X
Lest we convey the mistaken impression that the fragile X phenomenon is well
understood, questions about it abounded in the Workshop. For example, can the
fragile X be seen in at most 50% of cells from an individual, as Patricia Jacobs
(Honolulu, Hawaii) suggested? Or, is there a significant familial correlation in the pro¬
portions of cells showing the fragile X, as was suggested by D. Soudek (Ontario,
Canada)?
Does the fragile X occur in normal males? This is, of course, a critical question.
A brief letter reporting two "normal" males allegedly with the fragile X appeared in the
Lancet. The general reaction of the Workshop was one of considerable doubt. This
doubt was deepened by Sutherland's examination of a thousand normal neonates (both
sexes) for folic acid sensitive sites and his failure to find the fragile X in any normal
newborn. More work is needed on this point before we accept the idea that the fragile X
can be seen in normal males.
Docs the fragile X occur more commonly in association with other chromosome
abnormalities than would be expected? There were at the Workshop numerous anec¬
dotal reports of its association with XXY, XYY, trisomy 8, etc. Together with Barbara
Kaiser-McCaw (Tempe, Arizona), Hecht observed the fragile X in an intellectually nor¬
mal female with 46,X,del(Xq) Ullrich-Turner syndrome; the apparent fragile site was
at or near the end of the abbreviated Xq.
Conversely, does the fragile X predispose to other chromosome abnormalities?
For example, does it predispose to sporadic translocations, to trisomy, etc.?
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NEWER METHODS FOR ENHANCING EXPRESSION
J.-F. Mattei (Marseille, France) observed that the addition of methotrexate (10
mg/1) for the last 24 hours is useful with lymphocytes cultured for a total of 96 hours in
TC 199. The same two factors —prolongation of culture time in TC 199 and addition of
methotrexate—gave satisfactory results in fibroblasts.
The observation that folic acid and thymidine inhibit and methotrexate induces
the fragile site suggests that the biochemical reaction dUMP — dTMP catalyzed by
thymidylate synthetase might be involved in this process. Recently further evidence for
this was presented independently by Glover and by Niels Tommerup (Glostrup, Den¬
mark): FUdR, a specific inhibitor of thymidylate synthetase, was shown to be an effec¬
tive inducer of the X fragile site in both lymphocytes and fibroblasts. With K.
Brdndum-Niclsen and M. Mikkelsen, Tommerup also found FUdR able to induce the
folic acid dependent heritable fragile sites at 2q 13, 10q24, llql 1, and 12q 13. Prelimi¬
nary evidence suggests one possibility: that the induction of these fragile sites is due to
specific inhibition of dTMP formation, and not due to inhibition of DNA synthesis per
se. Trifluorothymidine, another agent inhibiting thymidylate synthetase, was found to
induce the X fragile site, but hydroxyurea and deoxyadenosine, which inhibit DNA
synthesis by other means, did not. By addition during the last 24 hours of the culturing
period of FUdR to the culture medium (TC 199 + 20% pooled human serum + 4%
bovine embryo utrafiltrate extract), the fragile X was induced in fibroblasts from seven
males and one female, all mentally retarded and showing the fragile X in their lympho¬
cytes. Likewise, the fragile X was induced in fibroblasts from two obligate carriers and
one female at risk (50%) in whose lymphocytes fra(X) was not expressed despite re¬
peated attempts. (The optimal concentration of FUdR is that which ensures both a rea¬
sonable number of mitoses and a high frequency of fragile sites.) Two control cultures
treated with FUdR did not express the X fragile site. These data suggest to Tommerup
and coworkers that fibroblasts might be a more reliable cell-system for carrier-detec¬
tion than lymphocytes.
Arthur Daniel (Randwick, Australia and Helena, Montana) reported work done
with R. Brook well, G. Turner, and J. Fish burn on the effect of FUdR on the expression
of fra(X) in lymphocytes and/or fibroblasts in 15 affected males and 3 females from 9
families. Six different culture media were used: Ham's F10/5% serum/pH 7.3 (37°C),
Medium 199/5% serum/pH 7.6 (37°C), Folate-free 199/5% serum pH 7.6 (37°C), and
these three media with FUdR (0.0125 /«M). In lymphocytes there was no-significant dif¬
ference in the percentage of expressing cells between any of the FUdR containing
media. The maximum percentage of expressing cells seen in lymphocyte cultures with
FUdR was 62%. The average enhancement with FUdR in the 199 and folate-free 199
media was 26%. This relative enhancement with FUdR was very much higher in a few
blood specimens delayed in transit. FUdR may prevent some of the false-negative re¬
sults obtained from mailed specimens. FUdR did not induce the marker in cultures
from three obligate carriers with previously negative results. In skin fibroblasts from
affected males, cells were grown in the six specific media for the final 48 hours. Two of
the six culture media yielded reproducibly positive results. These were 199-FUdR and
folate-free 199-FUdR with mean percentages of expressing cells of 12.4 ± 6.8% and
11.3 ± 6.1%, respectively. Ham's FUdR (which contains thymidine) did not permit ex¬
pression of the marker in fibroblasts but was as effective as the thyntidine-frce medium
for lymphocytes. Daniel and coworkers concluded that FUdR shows promise as an
agent to enhance the detection of the marker in cultured fibroblasts and lymphocytes.
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LYMPHOBLASTOID CELL LINES WITH THE FRAGILE X
Lymphocytes were the first type of cells shown to express the fragile X. Next
came skin fibroblasts. The newest cell system was announced by Richard Erbe (Boston,
Massachusetts). Erbe and Jacobs have transformed fragile X carrying lymphocytes
into permanent lymphoblastoid cell lines. Using FUdR, they were able to detect the
fragile X in lymphoblasts. Lymphoblasts now represent an enticing cell type for study
of the biochemistry of the fragile X.
PRENATAL DIAGNOSIS OF THE FRAGILE X
It was noted by Tommerup, Daniels, and other participants in the Workshop that
FUdR is so successful with fibroblast cultures that prenatal diagnosis of the fragile X
with the Glover-Tommerup method should soon be feasible. Since the Workshop
ended (and during the revision of this paper), it was announced in a press conference in
Albany by Governor Carey of New York that this had been accomplished. Subse¬
quently it was reported in the Lancet of December 6, 1981 by H. Wisniewski, W.T.
Brown, and A. Jenkins (Staten Island, New York) that, using FUdR, they had indeed
found the fragile X in amniocytes cultured from a male conceptus.
Clearly this feat will need to be repeated before there is full agreement that the
fragile X can be readily and definitely demonstrated in male amniocytes. (The test
metaphases should ideally be read blindly by two or three microscopists, looking also at
suitable nonfragile-X male control amniocytes.) Further, the consistent prenatal dem¬
onstration of the fragile X in carrier female amniocytes may be horrendously difficult,
even with FUdR. Time again will tell.
TREATMENT
This is an area of controversy. Jerome Lejeune (Paris, France) and coworkers
have administered folic acid to nine males with the fragile X. In six of nine patients
"mental improvement" was noted with "alleviation of the psychotic-like component of
behavior." However, this will need to be confirmed.
More to the point, can the mental retardation associated with the fragile X be pre¬
vented? If so, how? With folic acid? And when does the treatment need to be insti¬
tuted? Before birth? At birth? Before a month of age?
MECHANISMS AND THE FUTURE
The mechanisms of the fragile X and its associated mental retardation are still ob¬
scure. Much is now known about the fragile X. And much, it is clear, remains to be
learned in the years ahead.
ACKNOWLEDGMENTS
The Workshop could not have been held were it not for the assistance of our
colleagues in Israel who arranged the Congress. Contributors to the Workshop and to
key advances on the fragile X have been cited in some instances above by name; others
whom we have failed to name have unquestionably made crucial contributions. The
valuable parts of this synopsis were made possible by our colleagues. The errors are our
doing.
Am J Hum Genet 35:000-000, 1983
Heritable Fragile Sites on Human Chromosomes.
X. New Folate-Sensitive Fragile Sites:
6p23, 9p21, 9q32, and llq23
Grant R. Sutherland,' Peter B. Jacky,1 Elizabeth Baker,1
and Anne Manuel2
summary
Four new folate-sensitive fragile sites are documented at 6p23, 9p21,
9q32, and 11 q23. These have all been shown to be heritable except for
the one at 9p21, which has been seen only in a single individual. As
with the other autosomal fragile sites, these appear to be innocuous in
heterozygotes.
introduction
Known heritable fragile sites on human chromosomes have been summarized by
Sutherland and Hinton [ 1J. At that time, seven folate-sensitive fragile sites had
been documented, although the one at 1 lq 13 had not been shown to be heritable.
Pavey and Webb [2j have since documented a folate-sensitive fragile site at 7p 11
in several members of a family, and Kochen and Kardon 13] described an apparent
folate-sensitive fragile site at 8q22 in siblings, but not in their parents. Previously
undocumented fragile sites at 6p23, 9p21, 9q32, and 1 lq23 are described.
materials and methods
Lymphocyte cultures were established and harvested using MEM-FA and Ham's F10,
and folic acid and thymidine sensitivities of the fragile sites were tested as described [4],
Fluorodeoxyuridine (FudR)-induced expression of fragile sites was after Glover [5].
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RESULTS
The fragile site at 6p23 was found in a 2-year-old boy with developmental
delay and dysmorphic features. Family studies (fig.' 1) revealed the same fragile
site in others, none of whom were mentally or physically abnormal. The appearance
of the fragile site is shown in figure 2; on G-banding, it appears to be near the
distal end of p23. The frequency of expression of this fragile site under various
conditions of tissue culture is shown in table 1.
TABLE I
Frequency of Expression of the Fragile. Sites
under Different Conditions of Culture
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The fragile site at 9q32 has been ascertained twice. The first time was in an
11-year-old boy (S. B.) with gynecomastia. This fragile site was not detected in
either of his parents or in four of his siblings who were studied. The second
ascertainment was in an 8-year-old boy with mild mental retardation and minor
dysmorphic features. Studies on the rather small family (fig. Ifi) shoyved his
normal mother to also have the fragile site. The appearance of the fragile site is
shown in figure 2; on G-banding, it appears to be in the proximal part of q32.
The frequency of expression of this fragile site is shown in table 1.
The fragile site at 9p21 was found in the mother of a neonate with Down
syndrome. The infant had karyotype 46,XX —21, -Ft(21q21q). The mother's parents
were deceased, and studies on her only sibling, a paternal aunt, and a maternal
uncle have not shown the fragile site 16J. The appearance of the fragile site is
shown in figure 2 and its expression under various conditions of tissue culture
in table 1. On G-banding, the fragile site was shown to be in the proximal part
of p21.
The fragile site at 1 lq23 was found in the father of a neonate studied because
the child was homozygous for the bromodeoxyuridine (BrdU)-requiring fragile
site at 10q25 [7], The father thus has both fragile sites. Results of family studies
are shown in figure lc, and the appearance of the fragile site in figure 2. G-
banding studies showed the fragile site to be near the distal end of q23.3. The
frequency of expression of this fragile site is shown in table 1.
Complete dose-response curves for frequency of expression of the fragile sites
to concentrations of thymidine and folic acid were obtained for the fragile
sites at 6p23 and 9p21 (fig. 3), confirming their status as folate-sensitive fragile
sites. For 9q32, complete dose-response curves were not obtained, but in III. 1,
expression of the fragile site was fully suppressed by either 0.5 mg/i of folic acid
or 5 mg/1 of thymidine added to MEM-FA. Dose-response data were not obtained
for fra( 1 1 )(q23); however, although this fragile site was not expressed in Ham's
F10 or RPMI, it was expressed in TC199 and Mil' FA and elicited with FUdR
in Ham's F10 and RPMI. Hence, although fra(l)Mq23) has not been formally
proven to be folate sensitive, there is overwhelming evidence that it is.
DISCUSSION
Documentation of the four fragile sites in this report brings to 15 the number
of known fragile sites (fig. 4). All of these fragile sites have now been shown to
be heritable except for the one at 9p21, which, in view of its behavior as a typical
fragile site, will probably eventually be found to be heritable. Two families have
been studied in which the fragile site at 11 q 13, which had not previously been
shown to be heritable [8, 9], is segregating.
All the known fragile sites, with the exception of those at 7pll, 8q22, and
9p21, have been ascertained at least once in the Adelaide laboratory. Pavey and
Webb (2] ascertained the 7p 1 1 fragile site twice and showed it to be both heritable
and folate sensitive. Kochen and Kardon (3J demonstrated the 8q22 site in siblings
and in one in 50 of their father's cells examined and showed that fragility of 8q22
was enhanced in medium 199 (N. Kardon, personal communication, 1981). While
it is probable that this fragile site is folate sensitive, further characterization is
required.
The problem in failing to demonstrate fra(9)(q32) in either parent of subject
S B. is one that has been occasionally encountered with other autosomal folate-
sensitive fragile sites. Similarly, there remains some uncertainty as to which
member of generation 1 carries fra( 11 )(q23). Other kindreds have been studied
in which obligate carriers of autosomal folate-sensitive fragile sites have not
expressed the fragile site using either methods of folate deprivation or of FUdR
induction [5, 10). One possible explanation for this finding is that the propositus
represents a new mutation. However, it is much more likely that current methods
are inadequate for fragile site detection in some individuals. A similar situation
is the well-documented failure to detect fra(X)(q27) in some obligate carrier
females [11].
The fact that all the folate-sensitive fragile sites appear to behave similarly in
response to variations in culture medium composition suggests that they all share
a common underlying mechanism of expression. A relative deliciency of thy-
midylate late in the S period of the cell cycle appears to be the essential factor
imposed by all the methods used to elicit fragile site expression [II], although
it remains to be determined why this is important.
The increasing number of folate-sensitive fragile sites that have been reported
from very few sources suggests that as more laboratories begin to routinely employ
culture conditions suitable for fragile site detection many more will likely be
found. It is important that these he documented with full family studies and, in
particular, that the search for individuals homozygous for folate-sensitive fragile
sites continues so that more information may be gained about the clinical sig¬
nificance of the autosomal folate-sensitive fragile sites in both heterozygotes and
homozygotes. Because of the rarity of the individual fragile sites (and there are
no data on their incidence other than that even the most common one is probably
present in less than one in 1,000 individuals [ 11 J.), homozygotes will be exceedingly
rare, probably less than one in 10^live births if homozygosity is compatible with
live birth. If homozygosity is lethal, then study of couples with repeated abortion
may yield some cases in which both are heterozygous for the same fragile site.
If homozygosity is deleterious but not lethal, then the abnormal phenotype should
be recognized to follow apparent autosomal recessive inheritance. Individuals
with rare autosomal recessive disorders should be studied for fragile sites.
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FlO. 1.—The families. Half-shaded symbols indicate carriers of the fragile sites; N indicates that
the fragile site was not detected.
Fic. 2.—The new fragile sites: a, 6p23; b, 9p21; c, 9q32; d, llq23. Chromosome to the left of
each group is unhanded; the middle one, G banded; and the right one shows duplication of chromosome
material distal to the fragile site.




Flo. 3.—F.ffecl of various concentrations of folic acid (open symbols) and thymidine (solid symbols)
added to MEM-FA on frequency of expression of the fragile sites at 9p2I (circles) and 6p23 (squares).
Fig. 4.—-The known fragile sites. Small arrows indicate the folate-sensitive fragile sites at 2ql3,
6p23, 7 p 1 1, 8q22, 9p21, 9q32, IOq23, llql3, I lq23, 12ql3, 16pl2, 20pl 1, and Xq27; open arrow
shows the fragile site at 16q22; broad arrow shows the BrdU-requiring fragile site at 10q25.
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INTRODUCTION
Chromosome abnormalities are seen in most malignant cells, indeed
chromosomal damage or breakage and subsequent rearrangement is
probably one of the primary events in the induction of some
malignancies (Radman et al., 1982). An understanding of the
mechanisms involved in chromosome breakage could provide insights
into cellular processes of malignant transformation. Chromosomal
fragility occurs, apparently non-specifically and sporadically at
a very low level, in all individuals. It is seen at higher
levels and with some specificity in the chromosome instability
syndromes and at much higher levels at a specific locus in
carriers of heritable fragile sites. The chromosomal fragility
which occurs at fragile sites is the only type for which a
biochemical basis is at least partly known.
THE HERITABLE FRAGILE SITES
Fragile sites are morphological features of chromosomes which
were defined by Sutherland (1979a) as specific points which are
liable to show the following features :
(1) A non-staining gap of variable width which usually involves
both chromatids.
(2) Is always at exactly the same point on the chromosome in an
individual or kindred.
(3) Is inherited in a Mendelian co-dominant fashion.
(4) Exhibits fragility by the production of acentric fragments,
deleted chromosomes, triradial figures, etc.
The triradial (or multiradial) figure is the most spectacular
cytogenetic manifestation of the fragile site (Fig.l) and also
an essential manifestation for confirmation of a lesion as a
2.
fragile site rather than some other phenomenon causing chromosome
damage. Whilst the nature of a fragile site, in terms of
chromosome structure, is unknown it presumably represents a
segment of chromosome which does not undergo normal compaction
for mitosis.
To date 15 fragile sites have been detected and these are shown
in the partial ideogram (Fig.2) and partial karyotype (Fig.3).
These fragile sites can be classified into three groups.
The first group, the folate sensitive fragile sites, contains
all except two of the known sites which each come into separate
categories.
Group 1
The folate sensitive fragile sites are those at 2ql3, 6p23, 7pll,
8q22, 9p21, 9q32, 10q23, llql3, llq23, 12ql3, 16pl2, 20pll and
Xq27, They are termed folate sensitive because removal of
folic acid (and thymidine) from culture medium was the first
factor found to be essential for their demonstration in
lymphocyte culture. '
Group 2
This group contains only the fragile site at 16q22. This fragile
site is not dependent upon conditions of tissue culture
(Sutherland, 1979a) but its expression is reportedly enhanced by
the addition of distamycin A to lymphocyte cultures (Schmid et al.,
1980). If the findings of Croci (1982) are confirmed then this
fragile site may be regarded as a BrdU requiring fragile site
similar to the one in Group 3.
3.
Group 3
Contains only the fragile site at 10q25. This common fragile site
was independently discovered by Scheres and Hustinx (1980) and
Sutherland et al. (1980) and shown to be a polymorphism present
in one in 40 members of the Australian population sample studied
(Sutherland, 1982a). This fragile site is unique in that its
expression is dependent upon the presence of BrdU or BrdC in
lymphocyte cultures some hours prior to harvest.
Of all the fragile sites only the one at Xq27 (the fragile X)
has been proven to be of clinical significance in that it is
associated with, if not the cause of, one form of X-linked
mental retardation (Sutherland, 1982b). However, none of the
folate sensitive fragile sites have been seen in homozygotes
and it has been suggested that they could be deleterious in
this situation (Sutherland, 1979b). On the other hand,
heterozygotes for the autosomal folate sensitive fragile sites
have been found to be 10 times more common amongst the mentally
retarded than amongst neonates but this data is very limited
r
and more information is required before it can be asserted that
such heterozygotes (most of whom are intellectually normal) are
at increased risk of mental retardation (Sutherland, 1982b).
4.
III. THE BIOCHEMISTRY OF FRAGILE SITE EXPRESSION
A number of factors have been shown to be important in fragile
site expression since Sutherland (1977) showed that they were
expressed in lymphocyte cultures only if the cells were grown
in medium 199 and not in a range of other commercially available
culture media. Sutherland (1979a) subsequently demonstrated
that fragile site expression will only occur if the culture
medium is free of folic acid and thymidine, that it is enhanced
by a culture medium pH of greater than 7.3, that in the presence
of folic acid it can be induced by the folate antagonist
methotrexate, and that the folic acid precursor folinic acid
or the thymidine analogue BrdU will suppress it in folate free
medium (Sutherland, 1979a). Addition of fluorodeoxyuridine (FudR),
an inhibitor of the enzyme thymidylate synthetase will induce
expression in the presence of folic acid but not thymidine
(Glover, 1981). Methionine has been shown to be essential for
fragile site expression even in folic acid free medium
(Howard-Peebles and Pryor, 1981; Sutherland, 1982bX but the
reasons for this may be indirect in that cell cycle times are
r
greatly increased in the absence of methionine and the effect
of methionine deprivation can be overcome by FudR induction
(Glover and Howard-Peebles, 1982).
All available data suggest the areas of metabolism involved is
that shown in Fig.4 and that any pertubation of conditions of
tissue culture which lead to a relative deficiency of thymidine
monophosphate towards the end of S will result in fragile site
expression. Even though it now seems clear that this is the
5.
area of metabolism involved it is not clear how it is involved.
Why is it that in some cells the fragile site is only expressed
on one chromatid? Analogously, in two homozygotes for the
fragile site at 10q25 the fragile site was more often expressed
on one chromosome than on both (Sutherland, 1981) even though
environmental conditions which surrounded the homologous
chromosomes during DNA synthesis must be more similar to each
other than in different cells. One possibility is that in
conditions appropriate for expression of fragile sites they are
expressed in close to 100% of cells at the completion of S but
are gradually repaired during G2. This could account for
expression in a single chromatid since presumably the repair
events would be independent for each chromatid, but expression,
if it does occur during S, would not be.
IV. 'SPONTANEOUS' CHROMOSOMAL FRAGILITY
Chromosome breakage in lymphocyte cultures has been a recognised
phenomenon for many years and some genetic toxicology testing is
t
based upon increases of particular types of chromosome damage
after exposure to potentially toxic agents. Chromosome breakage
is difficult to quantitate cytogenetically, partly because of
difficulties in distinguishing between chromosomal gaps and breaks.
Chromosomal breakage in proliferating cell systems, which include
PHA-stimulated lymphocyte cultures, is followed by the formation
of micronuclei which can be easily scored in interphase cells and
provide a reliable approach to quantitation of chromosome breakage
(Heddle et al., 1978; Beek et al., 1980; Obe and Beek, 1982).
6.
In proliferating lymphocyte cultures micronucleus frequency has
been found to reach a peak after five days (Fig.5) and fragile site
carriers have been found to have higher frequencies of micronucleus
formation (Table I) than do appropriate controls without fragile
sites (Beek et al., 1982) when the cultures are grown under
conditions of folic acid and thymidine deprivation suitable for
fragile site expression. When these components are present in
the culture medium only low micronucleus frequencies are seen in
cultures from fragile site carriers and controls (Table I).
This difference in micronucleus frequency seen for all individuals
studied, whether fragile site carriers or controls, between cells
cultured in the absence or presence of folic acid or thymidine
suggests that the same mechanisms which control fragile site
expression might also be involved in the manifestation of
'spontaneous' chromosomal breakage. This means that the study
of fragile sites may be able to be used as a model for the study
of spontaneous chromosome breakage which is the primary event in
at least some forms of carcinogenesis.
V. THE CHROMOSOME INSTABILITY SYNDROMES
There are a number of rare genetic diseases, mostly inherited in
an autosomal recessive manner, in which there is an increase in
various types of chromosomal breakage (Hecht and McCaw, 1977).
In all these disorders there is a marked predisposition to develop
different types of cancers.
7.
In Bloom syndrome, which predisposes mainly to non-lymphocytic
leukaemias, the chromosome breakage is non-random and is usually
shown by the presence of quadriradials involving homologous
chromosomes. The rate of spontaneous sister chromatid exchange
is also markedly increased. Patients with Fanconi anaemia
have an increased risk of developing leukaemia, squamous cell
carcinomas and hepatic adenomas and have an increase in
apparently random chromatid breakage (Fig.6) : sister chromatid
exchange is normal. In ataxia telangiectasia there is a marked
increase in malignancies of the lymphoreticular system and
increased breakage of the chromosome, rather than chromatid,
type which is apparently at random although clones of cells
with a translocation involving a break at 14qll-12 are frequently
seen in such patients. There are also a number of other
chromosome instability syndromes which predispose to cancer but
which are not as well documented as the ones mentioned here.
None of the chromosome instability syndromes, or other syndromes
involving defects of DNA repair which have been reported not to
show chromosomal instability, have been studied to determine
whether the type of chromosome breakage which they manifest can
be affected by varying the concentrations of folic acid and
thymidine in the medium in which the cells are cultured for
chromosome studies. This should be done and could be approached




Various types of chromosome fragility have been reviewed and two
of them, the one associated with heritable fragile sites and
at least one form of 'spontaneous' chromosome breakage, have
been shown to be greatly influenced by concentrations of folic
acid and thymidine in tissue culture medium. Since chromosome
breakage is probably the primary event in the genesis of some
forms of cancer it is not improbable that these compounds may be
found to be important in protecting against malignant
transformation at the cellular level.
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TABLE I
Frequency of micronuclei in 5-day lymphocyte cultures in medium
deficient in and supplemented with folic acid and thymidine or
in Ham's F10 from fragile site carriers and controls.
(Data from Beek et al., 1982 and Jacky et al., 1982.)
Medium Supplement








fra(X)(q27) 9.2 1.8 1.2
Control 1 6.6 1.7 0.9
2 6.5 0.2 0.6
3 4.4 0.4 0
4 1.0 0 0




Fig.1 Multiradial figures produced by fragile sites.
a, triradial at 2ql3; b, triradial at 6p23;
c, triradial at 9p21; d, triradial at 9q23;
e, pentaradial at 10q23; f, triradial at 10q25;
g, triradial at llql3; h, triradial at 16pl2;
i, triradial at 20pll.
Fig. 2
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Fig.3 Partial karyotype showing the fragile sites.
The left chromosome of each pair is unhanded and the
right G-banded. (Pair number 8 courtesy Dr. N.B. Kardon,
pair number 7 courtesy Dr. G.C. Webb.)
homocysteine methionine





Fig.4 The area of folate metabolism involved in fragile site
t
expression (after Erbe, 1975; and Scott and Weir, 1981).
t
The enzymes controlling the various reactions are
1. methionine synthetase, 2. glutamate formiminotransferase,
3. serine hydroxymethyltransferase, 4. methylene-THF reductase,
5. formimino-THF cyclodeaminase, 6. dihydrofolate reductase,
7. thymidine kinase, 8. thymidylate synthetase.
Abbreviations used : THF - tetrahydrofolate, DHF - dihydrofolate,
dUMP - uridine monophosphate, dTMP - thymidine monophosphate.
Fig.5 Micronucleus frequencies in lymphocytes from carriers of
fragile sites (fra) and controls (N) cultured in folic acid
and thymidine deficient medium and harvested at different
times (data from Beek et al., 1982).
Fig.6 Partial metaphases from a patient with Fanconi anaemia and
coincidently, a fragile site at 10q25 (large arrow).
Note assymetric chromatid exchange figures (small arrows)
which are typical of the chromosome damage seen in this
disorder.
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HERITABLE FRAGILE SITES AND MICRONUCLEUS FORMATION
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Human leukocytes from individuals carrying different fragile sites,
including the fragile X, show elevated frequencies of micronucleus
formation in interphase cells after cultivation in media deficient
in folic acid and thymidine. Less elevated frequencies of
micronucleus formation were also observed in two control subjects
studied using comparable culture conditions, indicating the
occurrence of a high frequency of "spontaneous" chromosomal breakage
under culture conditions suitable for the expression of fragile sites.
This effect may be suppressed by the addition of the thymidine
analogue bromodeoxyuridine (BUdR) or by cultivation in Ham's F10,
a medium containing folic acid and thymidine. These results point
to a possible common link between a particular type of "spontaneous"
chromosomal breakage and the expression of folate sensitive fragile
sites.
INTRODUCTION
Heritable fragile sites on human chromosomes have attracted much
attention recently, especially because of the association of the
fragile X chromosome with a common form of mental retardation.
Fragile sites are generally characterised by an achromatic gap
at exactly the same location on a particular chromosome in an
individual, by their inheritance in a Mendelian co-dominant
manner, and by an actual fragility as indicated by the formation
of acentric fragments, deleted chromosomes and triradials
(Sutherland, 1982). Whilst chromosomal breakage can occur at
fragile sites its exact quantification in metaphase preparations
is very difficult, especially because of the known problems in
discriminating between achromatic chromosome lesions and true
chromosome breaks.
The occurrence of chromosomal breakage in proliferating cell
systems, such as phytohaemagglutinin (PHA)-stimulated human
leukocyte cultures, is followed by the formation of micronuclei
which can be easily scored in interphase cells and provide a
t
reliable approach to the quantification of chromosomal
breakage (Heddle et al., 1978; Beek et al., 1980; Obe and Beek,
1982a). In this communication we report on micronucleus
formation in individuals with different heritable fragile sites
and control subjects whose leukocytes were grown under different




Human leukocyte cultures (5 ml) were set up with heparinised
blood (0.2 ml per culture) from two laboratory staff members
as controls, and from five individuals carrying six different
fragile sites (Fig.l). The carrier of fra(16)+fra(X) is
subject B of Sutherland (1979b), the one with fra(12) is IV^
of Sutherland and Hinton (1981), the one with fra(9) is
documented by Sutherland et al. (1982) and the one with
fra(6) is Hjo Sutherland et al. (1982). Culture medium
was Ham's F10 or TC199 (pH 7.6, 20 mM HEPES) with or without
the addition of bromodeoxyuridine (BUdR, 10 pg/ml) added at
culture initiation, or Eagle's MEM-FA (Sutherland, 1979a).
All cultures contained 5% fetal calf serum, 0.1 ml PI1A, and
100 U/ml penicillin. BUdR-containing cultures were incubated
in the dark, and colchicine was added to all cultures one hour
prior to chromosome harvest carried out using standard
techniques which included hypotonic treatment with 0.075 M KCl
for five minutes and fixation in methanolracetic acid (3:1).
The slides were stained with Leishman stain. Fifty metaphases
were scored in determining the frequency of expression of a
fragile site and at least 1,000 interphases were scored from
coded and randomised slides in determining the frequency of
micronucleus formation.
RESULTS
Fig.2 shows a comparison of the frequency of expression of
fragile sites at metaphase with the frequencies of interphase
micronuclei at different culture times (1-6 days), scored
from the same slide. Maximum frequencies of fragile site
expression were reached either on day 3 or day 4 of culture,
and declined at later culture times. An increase in the
micronucleus frequency is seen from day 4 of culture onwards,
reaching a maximum of about 12-14% either on day 5 or day 6 of
culture. It appears that maximum frequencies of expression
of fragile sites are followed by increases in micronucleus
frequency with a delay of one or two days.
Figs.3 and 4 show results from two independent but similar
experiments. Leukocytes from either a fra(6) carrier and a
control (Fig.3) or a fra(2) carrier and a different control
(Fig.4) were grown in TC199 with and without BUdR.
Additionally, in each of the experiments leukocytes from the
respective fragile site carriers were grown in Ham's F10.
The micronucleus frequency was determined over the period of
culture up to six days. While in both experiments low
micronucleus frequencies predominate up to culture times of
three days, increases in the micronucleus frequencies are seen
with increasing culture time, followed in most cases by a
slight decrease by day 6. The most pronounced increases in
micronucleus frequencies in both experiments were found in
cultures set up with blood from the fragile site carriers using
TC199 without BUdR, but increases were also observed with control
leukocytes under the same culture conditions (Fig.4).
The addition of BUdR to leukocyte cultures grown in TC199
5.
clearly suppressed micronucleus formation in cultures from the two
fragile site carriers, and from one of the control subjects (Fig.4).
A more marked suppression of micronucleus formation however was
found after cultivation of the fragile site leukocytes in Ham's F10
medium in comparison with cultivation in TC199.
During the scoring of metaphases for fragile sites micronucleus derived
premature chromosome condensation (MN-PCC) was seen (Obe and Beek, 1982b).
In the 4 day culture from the fra(2) carrier MN-PCC were observed in
12 of 359 metaphases scored. Both G„- and S-type PCC were seen (Fig.6).
DISCUSSION
The expression of most heritable fragile sites on human chromosomes
is dependent on culture conditions, namely a deficiency in folic
acid and thymidine (Sutherland, 1979a). Consequently, the folate
sensitive fragile sites can be demonstrated only by the use of
culture media deficient in these compounds, such as TC199 or MEM-FA,
and not with culture media containing normal levels of folic acid
and thymidine, such as Ham's F10. Addition of folic acid, folinic
acid, thymidine or its analogue BUdR to deficient media inhibits
the expression of the folate sensitive fragile sites. Similarly,
the addition of inhibitors of folate and thymidine metabolism to medium
containing normal concentrations of these substances will elicit
the expression of the folate sensitive fragile sites (Hecht et al.,
1982). Culture time also seems to play an important role in that
maximum expression is usually found at day 3 or 4 of culture,
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being lower at earlier or later culture times (Sutherland, 1982).
Micronuclei in interphase cells are the consequence of induced
or "spontaneous" chromosomal damage in a proliferating cell system
(Obe and Beek, 1982b). As shown in Figs.2-4, high micronucleus
frequencies were found in human leukocytes cultivated under
conditions necessary for the expression of fragile sites from
about day 3 of culture onwards, indicating a high frequency of
chromosomal aberrations in these cells. From the results presented
in Fig.2 it seems likely that the expression of fragile sites can be
followed by chromosomal breakage. Although the maximum frequencies
of micronuclei reached during leukocyte cultivation of the various
fragile sites are higher than those found with control leukocytes,
the control material is inadequate to decide whether fragile site
leukocytes exhibit a higher frequency of chromosomal damage than
controls under the conditions of culture studied. Further
investigations are necessary to determine this. A higher sensitivity
of fragile site cells to an increase in "spontaneous" chromosomal
breakage under conditions of folate and thymidine deprivation
offers a possible explanation for the known or suspected
*
deleterious effects of fragile sites. No homozygote for a folate
sensitive fragile site has yet been recorded (Sutherland, 1982).
■Medium composition in human leukocyte culture is known to have an
influence on chromosomal breakage, both "spontaneous" (Obe et al.,
1976) and induced (Beek and Obe, 1974). However, the effect of
folate and thymidine deprivation seems to be surprisingly large
in fragile site leukocytes, and also in controls (Fig. 4).
Moreover, the results shown in Figs.3 and 4 indicate that this
effect may be compensated for by the addition of the thymidine
7.
analogue BUdR, at a concentration that has been reported to be
without any influence on cell cycle progression (Tice et al., 1976),
or by cultivation in folic acid and thymidine rich Ham's F10.
Hence, the area of DNA precursor metabolism which appears to be
related to the expression of fragile sites could also be involved
in formation of "spontaneous" chromosomal damage, possibly pointing
to a common underlying mechanism.
In fragile site leukocytes the part of the chromosome distal to the
fragile site (the presumptive fragment) could be expected to
contribute to the pool of lagging chromatin leading to the
formation of micronuclei. However, it seems clear that an
unknown but probably high proportion of micronuclei may be
derived from chromosomal damage that has occurred at other sites
in the genome. This would appear to be so from the findings in
the control cultures and also by the observation during micronucleus
scoring that there was considerable size variation of micronuclei
irrespective of the fragment size attributable to the particular
fragile site under investigation (Fig.5). Investigations of the
distribution of micronuclei sizes CYamamoto and Kikuchi, 1980) in
t
leukocytes with different fragile sites may lead to an elucidation
of the contribution of breakage at the fragile site to the pool of
lagging chromatin. Breakage at the fragile site could be at least
partly responsible for the reduced frequencies of fragile site
expression seen when culture time is extended beyond four days (Fig.2).
The formation of micronuclei probably represents part of a selection
mechanism against cells with unstable chromosomal damage in
proliferating cell systems, both in vivo and jin vitro.
Micronucleus formation is followed by the occurrence of MN-PCC
8.
irrespective of the origin of chromosomal damage (Obe and Beek,
1982b). This type of PCC was observed in the course of the
present study (Fig.6).
More questions have been raised than answered by the results of
this study but the micronucleus technique may provide a useful
approach to the study of heritable fragile sites, and their
relation to a particular type of spontaneous or perhaps DNA
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Fig.l The fragile sites in this study (arrows) :
2q13, 6p23, 9p21, 12ql3, 16q22, Xq27. These fragile
sites are all folate sensitive except for 16q22.
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Frequencies (%) of expression of fragile sites in
metaphases (fra; right ordinate, A ) and of interphases
with nricronuclei (MN; left ordinate, • ) in human
leukocyte cultures harvested at different culture times.
Cultures were set up in MEM-FA.
• fra(6),199
. N,199





Micronucleus (MN) frequencies (%) in hunian leukocytes
cultured in TC199 or Ham's F10 from a fra(6) carrier
and a control (N) harvested at different culture times.
BUdR : Addition of BUdR, 10 pg/ml at culture initiation.
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Fig.4 Micronucleus (MN) frequencies (%) in human leukocytes
cultured in TC199 or Ham's F10 from a fra(2) carrier
and a control (N) harvested at different culture times.
BUdR : Addition of BUdR, 10 pg/ml at culture initiation.
Fig.5 Examples of main nuclei with micronuclei in interphase from
human leukocytes set up with blood from a fra(2) carrier.
a, Id, d. ; interphases with one micronucleus; c_ : interphase
with two micronuclei. Note the variable size of the micronuclei.
Fig.6 Examples of MN-PCC in human leukocyte metaphases from the
fra(2) carrier. a-d : pulverised S-type PCC; e-g : broken
ladder-like double-stranded G2~type PCC.
tracks (Fig. 1) show that the character of
the magnetic anomalies is generally
smoother and of longer wavelength for
the approximately east-west trending
tracks than for the north-south trending
tracks.
The Mesozoic sequence of magnetic
anomalies from M9 (— 121 million years
old) through M25 (— 153 million years
old) are symmetric about a ridge formed
at the time of anomaly M9. These seg¬
ments appear to be offset left-lateraily
from east to west and to be normal to the
Davie fracture zone, but more magnetic
data is required to confirm this and to
determine if oblique sea-floor spreading
occurred. The Jurassic magnetic quiet
zone is observed on both sides of the
ridge axes landward of magnetic anoma¬
ly M25. We identified a large amplitude
magnetic anomaly on both landward
sides of the Jurassic quiet zone. This
anomaly may represent the ocean-conti¬
nent boundary, as has been proposed for
similar magnetic anomalies bordering
other passive continental margins (for
example, the magnetic anomaly off east¬
ern North America (18) or anomaly G
bordering the South Atlantic margin
(19)]. The magnetic anomalies are dis¬
turbed in places by seamounts and is¬
lands in the southern part of the basin.
Some of the islands have experienced
volcanism since the Miocene (20).
The magnetic data point to the motion
of Madagascar relative to Africa being
from the north, with the Africa-Mada¬
gascar separation beginning during the
time of the Jurassic quiet zone (— 165
million years ago) and ending at a time of
formation of anomaly M9 (—121 million
years ago). The Africa-Madagascar sepa¬
ration thus began at about the same time
as the breakup of Gondwanaland and the
separation of North America from Afri¬
ca. We used the Mesozoic time scales
(21) for dating these anomalies, and de¬
rived half-spreading rates of 1.7 to 1.8
cm year"'. We note that the results of
recent deep sea drilling in the North
Atlantic on the older parts of the Meso¬
zoic sequence may reduce the age as¬
signed to magnetic anomaly M25 and the
Jurassic quiet zone (22) and hence in¬
crease the spreading rates.
Deep Sea Drilling Project (DSDP) site
241 (23) is located on the lower continen¬
tal rise off northeastern Kenya and
southeastern Somalia in the Jurassic qui¬
et zone and just landward of magnetic
anomaly M25. A multichannel seismic
section from our recent Vema cruise
across this site (24) is shown in Fig. 3.
Relative motion between Madagascar
and Africa ceased — 121 million years
ago, about 25 million years before cre¬
ation of the purple reflector [Early Sen-
onian (Fig. 3), corresponding to the age
of the oldest sediment recovered during
drilling]. Schlich et al. (25) and Simpson
et al. (23) conclude, primarily from the
drilling results, that the continental mar¬
gin off northeastern Kenya and south¬
eastern Somalia has been evolving pas¬
sively for at least the last 90 million years
and argue that it is unlikely that Mada¬
gascar occupied a position adjacent to
that part of Africa during those 90 million
years. Our marine magnetics data and
seismic analysis are in good agreement
with these drilling results (23, 25).
Philip D. Rabinowitz
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Station 77843, and Lamont-Doherty
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evidence for this phenomenon is the for¬
mation of multiradial figures at meta¬
phase, which arise from breakage and
malsegregation of the chromosome frag¬
ment distal to the fragile site (2). Fragile
Fragile Sites in Chromosomes: Possible
Model for the Study of Spontaneous Chromosome Breakage
Abstract. The tissue culture condition that is requiredfor the type of chromosome
breakage seen at most fragile sites, namely, the absence offolic acid and thymidine
in the medium, greatly enhanced micronucleus formation in proliferating lymphocyte
cultures from normal individuals. This suggests that chromosome breakage at fragile
sites and the apparently spontaneous damage that gives rise to micronuclei are
controlled by the same mechanism.
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sites can be detected in preparations of
lymphocyte chromosomes if the lympho¬
cytes are grown in a tissue culture medi¬
um that is deficient in folic acid and
thymidine (/).
Chromosome breakage in proliferating
cells gives rise to micronuclei (3). The
finding that micronuclei may appear
more often in individuals with fragile
sites than in individuals without them
suggests that chromosome fragments re¬
sulting from breakage at such sites are
eliminated by micronucleus formation
(4). We report that, in lymphocytes from
normal individuals, more micronuclei
are formed when the cells are grown in
medium lacking folic acid and thymidine
than when they are grown in medium
containing either of these compounds.
Blood from healthy volunteers was
used to establish lymphocyte cultures.
Each culture contained blood (0.2 ml),
phytohernagglutinin (0.1 ml), penicillin
(100 U/ml), and 5 ml of minimum essen¬
tial medium free of folic acid and thymi¬
dine and supplemented with 5 percent
fetal bovine serum (/). Replicate cultures
were grown in this medium or in the
same medium containing folic acid (5
mg/liter) or thymidine (10 mg/liter). After
5 days micronucleus frequency reached
a maximum (4) and the cells were har¬
vested by standard techniques. Slides
were randomized and coded and micro-
nucleus frequency was determined by
examining 500 interphase nuclei per cul¬
ture. Only nuclei that showed evidence
of blastic transformation were counted.
The average frequency of micronuclei
in lymphocytes grown in medium with¬
out folic acid and thymidine was 4.4
percent, compared to 0.4 percent in me¬
dium with folic acid or thymidine (Table
1). Micronucleus frequency varied in ac¬
cordance with the concentration of folic
acid and thymidine in the culture medi¬
um (Fig. 1). The dose-response relation
is very similar to that seen for the
Table 1. Frequency of occurrence of micronu¬
clei in cultured lymphocytes from normal
volunteers. The lymphocytes were cultured
for 5 days in minimum essential medium con¬
taining folic acid (FA; 5 mg/liter) or thymidine




Age Sex FA T
Nei¬
ther
l 12 F 1.7 0.9 6.6
2 23 M 0.2 0.6 6.5
3 32 F 0.4 0.0 4.4
4 40 F 0.0 0.0 1.0
5 18 F 0.2 0.6 3.6
6 22 F 0.0 0.4 3.4
7 55 F 0.4 0.2 2.9
8 37 F 0.6 0.4 5.8
9 35 M 0.2 0.6 5.0
Mean 0.4 0.4 4.4
expression of fragile sites under identical
culture conditions (/).
The influence of culture medium com¬
position on spontaneous (5) and induced
(6) chromosome breakage has been doc¬
umented but has not generally been rec¬
ognized to be of the magnitude reported
here. An increase in the frequency of
random and nonrandom gaps and breaks
has been reported in chromosomes of
lymphocytes cultured under conditions
suitable for fragile site expression (7-9).
Some of the more common nonrandom
damage includes gaps and breaks at
Iqter, 2q23, 3 p 14, 6q26. 9ql3, and
13qter. These regions can mimic true
fragile sites but have not been shown to
be heritable or to give rise to the triradial
figures that characterize fragile sites, and
they are usually seen in only a small
portion of chromosomes in metaphase
(9). Investigators of chromosomal aber¬
rations or micronucleus formation will
need to take the concentration of folic
acid and thymidine in the culture medi¬
um into account.
The suppression of chromosome dam¬
age in lymphocytes cultured under the
same conditions that suppress the
Fig. 1. Relation between mi¬
cronucleus frequency in 5-
day-old lymphocyte cultures
and concentration of folic acid
and thymidine in the medium
for volunteers 8 and 9.
expression of fragile sites suggests that a
similar mechanism underlies both the
chromosome damage resulting from frag¬
ile sites and the apparently spontaneous
damage exhibited by normal individuals.
Expression of fragile sites probably de¬
pends on a reduced amount of thymidine
monophosphate during the late stages of
DNA synthesis. This can be achieved by
reducing the concentration of folic acid
and thymidine in the culture medium to
virtually zero (/); by adding methotrex¬
ate, an inhibitor of folate metabolism, to
folic acid-containing medium (10)\ or by
adding fluorodeoxyuridine, an inhibitor
of thymidylate synthetase, which con¬
verts uridine monophosphate to thymi¬
dine monophosphate (//, 12). This inhi¬
bition can be overcome by adding excess
thymidine but not excess folic acid (II).
Perhaps there is a general class of chro¬
mosome breakage, of which the heritable
fragile sites are special cases, that results
from a deficiency of DNA precursor
substances. Further studies of the mech¬
anism by which heritable fragile sites are
expressed may lead to a wider under¬
standing of the mechanisms of spontane¬
ous chromosome damage.
Peter B. Jacky
Cytogenetics Unit, Department of
Histopathology, Adelaide Children's
Hospital, North Adelaide, South
Australia 5006, Australia
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REGIONAL LOCALISATION FOR HLA BY RECOMBINATION
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A family with a fragile site on chromosome 6 at band p23 was
examined for recombination between the fragile site and HLA.
Recombination was observed in four of the 20 offspring in whom
it could occur. The estimate of the genetic length of
chromosome between the fragile site and HLA is 20 centimorgans
with a.lower 95 percent probability limit of 8.5 centimorgans.
The likely1 regional localisation for HLA is proximal to about the
midpoint of 6p22. The basis for exclusion of 6p23 and the distal
half of 6p22 is that fragile sites do not measurably disrupt
recombination frequency and that the "allele" predisposing to the
expression of a fragile site is situated at the fragile site.
Conversely, the validity of these assumptions is reinforced given
the general agreement of this HLA localisation with methods that
do not involve recombination with the fragile site.
2.
INTRODUCTION
The regional localisation for HLA on chromosome 6 between p21.2
and p23 is well established (1).. There is evidence from
exclusion mapping for its elimination from the distal portion of
this interval (2,3,4). A family segregating for a fragile site
in the distal region of band p23 on chromosome 6 provided an
opportunity to localise HLA by measuring the genetic distance
x i
between these markers. Given a proximal limit for HLA at 6p21.2,
the distance between HLA and the fragile site must be less than 25
map units according to the male meiotic map presented by Cook et
al (5). Hence, HLA and this fragile site can be assumed to be linked.
MATERIALS AND METHODS
The family was examined for folate sensitive fragile sites by
standard procedures. Part of this family and the fragile site
have been previously described (6).. At least 50 metaphases were
routinely scored for the presence of fragile sites. HLA haplotypes
at the A, B and C loci were determined by the microcytotoxicity test.
3.
RESULTS
Four generations were available for study (Fig.l). The fragile
site at 6p23 was detected without difficulty in every generation.
Eight carriers were detected and one untested individual (11.11)
was an obligate carrier. It is highly improbable that the other
untested, unrelated individuals (1.3, II.4, 11.12) would carry the
fragile site since this is the only family in which this fragile
site has been recorded. The frequency of expression was 44% from
the propositus (11.13), and ranged from seven to 30 percent of
cells for the other carriers. For the purpose of linkage analysis
the fragile site in this family may be regarded as a heritable
condominant variant.
The inheritance of the fragile site and HLA haplotypes are shown
in Fig.l. HLA haplotypes have been coded as indicated in Table 1.
The IILA phenotypes could be inferred in the untested individuals
as 7/8 in 1.3, 6/? in II.4, 2/8 in 11.11 and 11/12 in 11.12.
There were three definite non-crossovers (NCO) in generation IV.
There were seven definite NCO and two definite crossovers (CO) in
generation III. Given prior knowledge of linkage, it is highly
probable that there are five NCO and two CO in generation II
rather than five CO and two NCO.
The combined male and female recombination frequency (0) is 20% (4/20),
well within the maximum expected male recombination frequency of less
than 25%. The recombination frequency is equivalent to map distance
expressed as centimorgans (cM) because the relationship between map
distance and 0 is approximately linear up to 0 = 0.25. The lower 95%
probability limit for this interval is 8.5 cM and was determined by
subtracting 5% of the area under the truncated relative probability
curve from one end of the curve. The curve was truncated at 6p21.2.
4.
Given that the female meiotic map is about twice the length of the
male meiotic map, the estimate of 20 cM for the interval between
HLA and the fragile site at 6p23 is probably an over estimate for
comparison with a map expressed in male cM. The maximum lod score
was 1.7 at 0 = 0.2. These results suggest a probable regional
localisation for HLA between about the mid-point of 6p22 (near to
6p22.2) and the previously known proximal limit for HLA at 6p21.2.
HLA is not tightly linked to the fragile site and is unlikely to lie
within 6p23 or the distal half of 6p22 (Fig.2).
DISCUSSION
Considerable information already exists for the regional localisation
of HLA. Family study with a translocation t(6;21) (p22;qll)
suggested the probable localisation of HLA proximal to 6p22 (2).
A translocation family with t(6;20) (p21;pl3) demonstrated close
linkage (0 = 0.05) between the breakpoint (in 6p21 near 6p22) and
HLA (3). While the effect of reciprocal translocations on
recombination is not definitely known there is unlikely to be any
major disruption (7). Ferrando et al. (4) reported the absence of
a duplicated set of parental HLA antigens in a child partially trisomic
for 6p22.2-»pter derived from a balanced translocation t(6;10)
(p22.2;pter). This excluded HLA from 6p22.2->pter. These results
suggest a regional localisation for HLA proximal to 6p22.2 which agrees
very closely with the distal 95% probability limit derived from
recombination with the fragile site at 6p23. Berger et al. (8) (and
personal communication) proposed a more precise localisation for HLA:
5.
suggesting that a chromosomal break at 6p21.2 or at the interface
of 6p21.2 and 6p21.3 was within the HLA cluster.
There is no evidence for any major disruption to recombination in
the chromosomal segments near the loci of expression of fragile sites.
The intervals between the fragile sites at 10q23 and 10q25 in families
with both fragile sites (9) and now between HLA and the fragile site
at 6p23, have been estimated by recombination and fall within limits
established by other procedures. HP and the fragile site at 16q22
are probably as close to each other as is indicated by the low
frequency of recombination between them (10).
The alleles responsible for the expression of fragile sites are
probably situated on the chromosomes at or verynear to the fragile
site. This has been verified for the fragile sites at 10q23, 10q25 (9)
and now 6p23. The interval between genes responsible for the
expression of fragile sites at 10q23 and 10q25 was estimated by
recombination and is consistent with that expected from their locations
on mitotic chromosomes. A positive lod score between HLA and the
fragile site at 6p23 is consistent with existing knowledge of the
location of HLA and the position of the fragile site at 6p23.
Control of fragile site expression must be within the homologue
expressing the fragile site since confirmed heterozygous carriers
do not express fragile sites in both homologues.
The rapid rate of discovery of fragile sites (6) indicates that
many more of these are likely to exist and be used for linkage
studies. Fragile sites have advantages over other chromosomal
variants because they are not restricted to paracentromeric regions.
6.
Because they are precisely mapped by banding, fragile sites are ideal
both for use in searching for linkages with unassigned markers in
chromosome regions devoid of polymorphic genetic markers, and for
the regional localisation of markers shown to be -near regions of
fragile site expression. The fragile site at 6p23 confirms a more
exact regional localisation for HLA and consequently the cluster
of genes that are known to be linked to HLA. Confirmation that
the location of DNA responsible for a fragile site is at the locus
of expression may now permit the characterisation of this DNA by
study of the relevant chromosomal segments.
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A SEARCH FOR LINKAGE IN FAMILIES WITH FRAGILE SITES









Linkage relationships to unassigned and provisionally assigned genetic
markers were examined from 53 families segregating for various fragile
sites. Fragile sites were at Xq27, 2q13, 6p23, 9p21, 9q32, 10q23,
10q25, 11q13, 11q23, 12q13 and 16p12. No new assignments were made
but extensive exclusion data is presented for the markers F13A, F13B,
CHE2, _K, TF, GPT, C3 and Lu arising from linkage comparisons with
fragile sites and other genetic markers. Exclusions of at least
10cM involving fragile site markers were made for F13A (6p23, 9q32,
10q25 ), F13B (10q23, 10q25, 16p12), CHE2 (16p12), K (10q23),
TF (10q23, 10q25, 11q13 ), GPT (10q23, 10q25, 11ql3 ), C3 (10q23,
10q25 ) and Lu (10q25, 11ql3).
2.
INTRODUCTION
Linkage analysis using a heritable chromosomal marker was responsible
for the first autosomal gene assignment in man (Donahue et al., 1968)
The common heteromorphisms of C-band chromatin and fluorescence
intensity have since been used extensively for linkage analysis,
but have not provided any new assignments (Ferguson-Smith and Aitken,
1982). Linkage data are now presented for families in which fragile
sites are segregating.
MATERIALS AND METHODS
Fifty-three families with fragile sites were analysed for linkage by
the computer program LIPED (Ott, 1976). The fragile sites (number
of families in parentheses) were at Xq27 (12), 2q13 (1), 6p23 (1),
9p21 (1), 9q32 (2), 10q23 (7), 10q25 (26), 11q13 (2), 11q23 (1),
12q13 (1) and 16p12 (2). Three families were segregating for more
than one fragile site. The conditions necessary for expression of
fragile sites have been described previously (Sutherland, 1979;
Sutherland et al., 1980) and their G-band positions demonstrated
(Sutherland, 1983). In those individuals in whom the fragile sites
were not detected at least 50 metaphases were usually examined for fragile
sites. Genetic marker nomenclature is in accord with Shows and
McAlpine (1982).
Penetrance of the autosomal fragile sites is apparently complete in
most instances, however minor anomalies were observed in five families.
The 9q32 site was present in a single individual and could not be
detected in either of his parents. The two 11q13 families did not
3.
show the fragile site in an obligate carrier parent at three and four
generations back, respectively. Among offspring of these non-
expressing parents were four carriers from eight, and six carriers
from 12, suggesting that non-expression is not a major problem.
The 10q25 fragile site could not be demonstrated in parents of a
child who carried the fragile site in one instance among 26 pedigrees
with this fragile site. The site at 16p12 was not detected in
parents of a child who carried the fragile site in one two-generation
family but there was no difficulty in detecting this fragile site
from another large kindred of three generations. '
RESULTS
Results of linkage tests with fragile sites are given in Table 1.
Lod scores are presented for the comparisons between fragile sites
and unassigned or provisionally assigned test loci. Lod scores
for comparison between the test loci of Table 1 and all other
informative markers are given in Table 2. This data was derived
from families in which fragile sites were detected irrespective
of whether the family was informative for linkage with the fragile site.
DISCUSSION
No measurable disruption occurs to recombination in chromosomal segments
adjacent to the fragile sites at 10q23, 10q25 and 6p23 (Sutherland et al.,
1982; Mulley et al., 1983). There is unlikely to be any disruption to
recombination anywhere else in the genome of individuals in whom these
fragile sites have been demonstrated because the genetic material
4.
responsible for fragile site expression is at the fragile site locus
(Mulley et al., 1983). It is reasonable to assume that fragile sites
do not affect recombination and that lod scores are unbiased from all
families in which fragile sites are segregating.
The loci F13A, F13B, CHE2, K_ and TF are unassigned (Human Gene Mapping
6, 1982). C3 and Lu are provisionally placed on chromosome 19 and
GPT is inconsistently assigned to chromosomes 8 and 16 (Shows and
McAlpine, 1982). There is no evidence of an assignment for any of
these loci (Tables 1 and 2), but the information presented represents
a considerable addition to the exclusion map. Exclusion data was
only presented where lod scores were less than -2 at 0 = 0.05,
representing an exclusion from at least 1OcM of chromosome.
Such data were not presented where previous exclusion data
(Keats, 1981; Keat et al., 1979) had already provided an exclusion
to at least 0 = 0.2. The value of exclusion data to gene mapping
has been clearly demonstrated by Cook et al. (1980) and by many
instances of regional localisation following gene asssignment.
Few lod scores were positive and these were only presented if they
reached +1. The F13A:C3 comparison almost reached +1 at 0 = 0.1.
The CHE2:HP comparison reached +1 at 0 = 0.05, however the
provisional status given to the CHE2.-HP linkage (Shows and McAlpine,
1979) is no longer recognised (Shows and McAlpine, 1982).
The GPT:PGP comparison reached +1.7 at 9 = 0.2. These
observations are not sufficient evidence to suggest linkage.
5.
In contrast to many polymorphic markers, the locations of fragile
sites on banded chromosomes are precisely defined. Herein lies
their value as markers for use in linkage tests. Fragile sites
are not commonly used in linkage analysis because of their rarity.
Their potential for gene assignment is largely restricted to the
mapping of loci not expressed in somatic cells.
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TABLE 1
LOD SCORES BETWEEN SELECTED MARKERS AND FRAGILE SITES
TEST LOCUS MARKER LOCUS
Q
.05 .1 .2
F13A 6p23 -3.8 -2.2 -0.9
9q32 -2.0 -1 .A -0.8
1 0q25 -6. A -3.5 -0.9
F13B 10q23 -2.0 -1 .2 -0.5
10q25 -A. A -2.A -0.7
16p12 -2.5 -1 .A -0.6
CHE2 16p12 -1 .9 -1 .1 -0.5
K 1 0q23 -2.8 -2.0 -1.2
TF 1 0q23 -2.6 -1 .A -0. A
1 Oq25 -3.6 -1 .8 -0. A
11 q 13 -5.1 -2.9 -1.0
GPT 10q23 -7.1 -A.7 -2.2
10q25 -11 .2 -6.5 -2.3
11 q 13 -A. 2 -2.A -0.9
03 10q23 -A.8 -2.6 -0.8
10q25 -7.2 -3.7 -0.9
Lu 10q25 -1 .9 -1 .2 -0.6
11 q 13 -2.6 -1 .6 -0.7
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THYMIDYLATE SYNTHETASE INHIBITORS
AND FRAGILE SITE EXPRESSION IN LYMPHOCYTES








The ability of three thymidylate synthetase inhibitors,
fluorodeoxyuridine, fluorodeoxycytidine and trifluorothymidine,
to induce the expression of eight different folate sensitive fragile
sites has been investigated in 22 patients and compared with the
efficacy qf simple folate deprivation for inducing fragile site
expression. Fluorodeoxyuridine and fluorodeoxycytidine were
equal in their ability to elicit fragile site expression but
fluorodeoxycytidine proved less cytotoxic under comparable culture
conditions. Both fluorodeoxyuridine and fluorodeoxycytidine were
found to be more efficient than trifluorothymidine at comparable
concentrations but less efficient than simple folate deprivation
in eliciting fragile site expression in lymphocytes. Since the
three inhibitors induced expression of eight different folate
sensitive fragile sites it is likely that all folate sensitive
fragile sites have a common underlying mechanism of expression.
The practical application of thymidylate synthetase inhibitors in
the routine detection of heritable fragile sites is discussed.
2.
INTRODUCTION
The fragile X chromosome and other heritable folate sensitive fragile
sites are expressed in lymphocytes cultured under conditions which
lead to a relative deficiency of thymidine monophosphate for DNA
synthesis. This can be achieved by culture in the absence of folic
acid and thymidine or by the presence of inhibitors of folate
metabolis'm such as methotrexate [ 1 ]. More recently it has been
shown [2,3] that the thymidylate synthetase (TS) inhibitor
5-fluorodeoxyuridine (FUdR) can induce fragile sites in the presence
of folic acid but not in the presence of thymidine. The ability of
other TS inhibitors, 5-fluorodeoxycytidine (FCdR) and trifluorothymidine
(F3TdR), to induce fragile sites has been investigated and compared with
the efficacy of simple folate deprivation for the induction of fragile
sites.
MATERIALS AND METHODS
Patients and Lymphocyte Culture. Lymphocyte cultures were
established from 22 individuals each carrying a folate sensitive
fragile site (Table 1). For each individual whole blood cultures
were established in Eagle's Minimal Essential Medium without folic
acid (FA) and thymidine (MEM-FA) [1] and RPMI 1640 medium (GIBCO)
containing 1.0 mg/1 FA but lacking thymidine, and Ham's F10 medium (CSL)
containing 1.32 mg/1 FA and 0.73 mg/1 thymidine. Culture media were
routinely supplemented with 5% fetal bovine serum, 100 U/ml penicillin
and 2% M-PHA (GIBCO) at culture initiation. Cultures were harvested
after 72 or 96 hours using standard methods following exposure to
1 mg/1 colchicine for one hour. Where possible 50 unbanded metaphases
per culture were scored for fragile sites.
TS Inhibitors. Three specific TS inhibitors were studied,
FUdR (Sigma) and FCdR (Calbiochem-Behring) were tested at
concentrations from 0.001 to 1.0 mg/1, and F3TdR (Sigma) was tested
from 0.005 to 1.0 mg/1. All substances were dissolved in distilled
water and added to the cultures 24 hours prior to chromosome harvest
in keeping with the earlier recommendations of Glover [2] and
Tommerup et al. [3,4] for FUdR. Initial studies indicated that
x *
there was no difference in frequency of expression between cultures
harvested 72 or 96 hours after initiation. Thus most of this work
was on 72 hour cultures.
RESULTS
In order to determine an optimal concentration and culture medium
each TS inhibitor was first tested for six patients over a range of
concentrations in different culture media. For three patients
(Patients B, G and M) any of the TS inhibitors, even at relatively
low concentrations, studied in MEM-FA were found to be too cytotoxic
for chromosome analysis. Results for each of the substances at
varying concentrations in RPMI 1640 were presented in Table 2.
When less than 50 metaphases were available for scoring this was
an indicator of the toxicity of the inhibitor. While FUdR and FCdR
proved equally effective in their ability to elicit fragile site
expression, FCdR was generally found to be more useful because of
its lower toxicity (Table 2). F3TdR was found to be less
cytotoxic than either FUdR or FCdR at similar concentrations but
also less effective in eliciting fragile site expression.
There was no difference in the ability of the inhibitors to
induce fragile sites in either RPMI 1640 or Harn's F10 in five
patients tested with both media.
4.
Results comparing maximum frequencies of fragile site expression
obtained for each patient in MEM-FA and RPMI 1640 plus FUdR or FCdR
are presented in Table 1. Maximum frequencies of expression were
generally obtained at inhibitor concentrations of 0.01 to 0.05 mg/1
(Table 2). Eight of the 22 patients studied showed differences in
frequencies of expression when comparing MEM-FA with RPMI 1640 + FUdR
(Patients^C, D, E, F, K, 0, R, S). With the exception of Patient K,
these frequencies were all higher in MEM-FA. In comparisons between
FUdR and FCdR frequencies of expression were considered to be
different in four of the eight patients studied. Patients K and L
showed higher frequencies with FUdR while Patients B and E showed
higher frequencies with FCdR. In five patients with the fra(X) and
one with the fra(11)(q13) studied with F3TdR, frequencies of
expression were consistently lower (maximum frequency of expression
seen was 10%) using this TS inhibitor than those obtained either
with FUdR or FCdR.
Lymphocytes from three fra(X) patients (N, P, T) were also tested
using RPMI 1640 plus 10 mg/1 methotrexate (Lederle) according to the
recommended protocols of Sutherland [1] and Fonatsch [5] for
eliciting fragile site expression. Frequences of expression for
all three patients (N, 29%; P, 13%; T, 16%) using this culture
condition were comparable to those obtained with MEM-FA.
In an attempt to confirm the report of Brookwell et al. [6] of enhanced
frequencies of fragile site expression using FUdR for blood samples
delayed in transit, samples from five fragile site patients were stored
at 4°C for up to nine days after venepuncture and periodic cultures
were initiated in MEM-FA and RPMI 1640 plus 0.01 mg/1 FUdR (Table 3).
For two of these five patients (A, T) the frequencies of expression
5.
under either culture condition were not different for cultures initiated
as much as five days after venepuncture. Patient P showed a decrease
in frequencies of expression for both culture conditions with increasing
storage time, and Patient Q showed little change in the frequency of
expression in MEM-FA and a decrease in the frequency of expression in
RPMI 1640 + FUdR over seven days in storage. For a similar period of
storage Patient M showed a decrease in frequency of expression in MEM-FA
v \
and an increase in frequency of expression using FUdR (Table 3).
Study of this problem is complicated by a deterioration in the
proliferative potential of lymphocytes with extended periods in storage.
DISCUSSION
The use of a TS inhibitor to induce fragile sites on chromosomes was
proposed and demonstrated independently by Glover [2] and Tommerup et al.
[3]. The basis of this was that the conditions found by Sutherland [1]
to be essential for fragile site expression led to thymidylate depletion
in tissue culture. The first TS inhibitor used was FUdR [2-4] and
Tommerup also reported using F3TdR [7]. FCdR was studied after the
suggestion of Kalman (personal communication and [8]) that it was an
effective TS inhibitor which was less cytotoxic than FUdR. The
cytotoxicity of FUdR is probably due to its partial degradation to
5-fluorouracil which directly interferes with cellular RNA metabolism
[8,9]. Finding no difference in the ability of TS inhibitors to
induce fragile sites in either RPMI 1640 or Hams' F10 is not consistent
with earlier reported methods stressing the use of thymidine free
medium (i.e. RPMI 1640) with TS inhibitors for eliciting folate
sensitive fragile sites [2]. However, varying amounts of folic acid and
thymidine in culture media probably result in different concentrations
of inhibitors required to induce fragile sites and result in differences
in inhibitor cytotoxicity in different tissue culture media.
6.
The TS inhibitor FUdR has proved essential for the demonstration of
the fragile X in lymphoblastoid cell lines [ 10]. It may be more
reliable than earlier reported methods [l] for demonstration of
the fragile X in fibroblasts [2,4] and it has proved useful for
demonstration of the fragile X in cultured amniotic fluid cells
[12,13]. FCdR has not previously been shown to induce folate
sensitive fragile sites and in view of its lower toxicity may be
more useful than FUdR for fragile site induction in lymphoblastoid
and fibroblast cell lines. This is the first demonstration that
TS inhibitors will induce folate sensitive fragile sites other
than the fragile X, fra(11)(q13) and fra(12)(q13) [7] and is further
evidence that all the folate sensitive fragile sites likely share a
common underlying mechanism of expression.
We were unable to support the findings of Brookwell et al. [6] that
FUdR when added to TC199, folate free TC199 or Ham's F10 enhanced
fragile site expression by about 30% compared to simply culturing
cells in TC199 or in folate free TC199. A possible explanation for
this could be that in the present study RPMI 1640 medium was the
culture medium in which TS inhibitors were used from fragile site
induction whilst folate free conditions were provided by MEM-FA, MEM-FA
in combination with TS inhibitors was found unsatisfactory for adequate
culture growth and chromosome analysis. However, MEM-FA and TC199
have been found to work equally well for fragile site induction [14]
and others have used various folate free media with equal
satisfaction (e.g. "M" medium, [15]). Similarly, we were unable
to substantiate the claim of Brookwell et al. [6] that TS
inhibitors produce a fragile X frequency of expression five times
greater than folate free medium for blood samples delayed in transit.
The present study did not involve bloods delayed in transit and
7.
storage at 4°C may not adequately simulate an in transit delay.
However, the data of Brookwell et al. [6] pertained only to four
samples of blood. This potentially useful application of TS
inhibitors requires further examination.
Little' has been reported in the way of direct comparisons between
v i
frequencies of fragile site expression induced by TS inhibitors
and frequencies possible with other folate antagonists such as
methotrexate or aminopterin. These latter substances actively
'inhibit conversion of dihydrofolate to tetrahydrofolate by
competitively inhibiting dihydrofolate reductase (DHFR) and
metabolically affect a folate deficiency [1,14,15]. For the
limited number of patients tested with methotrexate in this
study, frequencies of fragile site expression were all comparable
to those obtained using either MEM-FA or TS inhibitor culture
conditions. Sutherland [1] found frequencies of expression of
seven different fragile sites to be lower when induced with
methotrexate than by folate deprivation with MEM-FA.
Unfortunately he cultured cells in Ham's F10 for induction with
methotrexate and since this medium contains thymidine it would
be expected to result in lower frequencies of fragile site
expression than whan a thymidine free medium such as RPMI 1640 or
Dulbecco's Modified Eagle medium [5] is used. Cytotoxicity
problems similar to those associated with TS inhibitors have
also been described using DHFR inhibitors [16,17] and further
comparison between such substances and TS inhibitors or
simple folate deprivation are required.
There is no doubt that TS inhibitors will induce expression of the
folate sensitive fragile sites and that it would appear that FCdR
is the inhibitor of choice, at least in lymphocyte cultures, bccau
of its lower toxicity. Nevertheless the use of simple folate
deficient culture medium is equally, if not more, effective in
demonstrating folate sensitive fragile sites, both in terms of
maximising frequencies of expression and for yielding sufficient
metaphases for chromosome analysis, and from a practical point of
view this provides for an easier laboratory routine. These new
findings with FCdR are consistent with earlier reported findings
concerning the metabolic requirements for fragile site expression,
namely in creating a relative deficiency in thymidylate.
The mechanism operating between meeting such a tissue culture
requirement and the actual expression of the lesion on the
chromosome remains to be elucidated.
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a=Frequencyoff gilesitexpr ssioninMEM-FAfromTabl1. n.g.=Scoredasogrowth.
TABLE 3
FREQUENCIES OF FRAGILE SITE EXPRESSION FOR CULTURES INITIATED FROM BLOOD
SAMPLES STORED FOR VARIOUS PERIODS FOR FIVE PATIENTS.










































































a = Frequency of fragile site expression at storage day zero from Table 1.
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PROTEASE INHIBITOR (PI) PHENOTYPE OF INDIVIDUALS
WITH CHROMOSOMAL FRAGILE SITES





North Adelaide, S.A. 5006
Australia.
SUMMARY
One hundred and four fragile sites were ascertained from 95
unrelated families. In each family the ancestry of the fragile
site was traced as far as possible and the PI phenotype of the
carrier in the earliest generation determined. Mildly
deficient PI phenotypes were more prevalent than expected among
earliest carriers of folate sensitive fragile sites, but not
for BrdU dependent fragile sites. The significance of this
finding is unclear and is based upon relatively small numbers.
Another series of fragile site carriers would need to be studied
and similar results found before the question of any relationship




Fragile sites are non-staining gaps in chromosomes inherited as
codominant markers. The folate sensitive fragile site at Xq27
is associated with mild to severe mental retardation in males,
and mild mental retardation in some females (Sutherland, 1983 [9]).
The significance of the autosomal folate sensitive fragile sites
is unclear at present, but in some carriers could possibly be
associated with mental retardation (Sutherland, 1982 [8]). The
common BrdU dependent site at 10q25 is phenotypically harmless
even when homozygous (Sutherland, 1983 [9]). Similarly, the
fragile site at 16q22, which in some individuals has no special
tissue culture requirements for expression, appears to be
phenotypically harmless in both heterozygous and homozygous
carriers (Schmid et al. 1980 [6]).
The PI locus (protease inhibitor system) has a major influence upon
levels of alpha-l-antitrypsin (aiAT), the predominant regulator of
proteolytic activity in body fluids. The common alleles PI"Ml,
PI*M2 and PI*M3 are associated with normal levels of aiAT, while some
of the less frequent alleles, PI*S, PI*Z, PI*I, PI*F and others,
are associated with reduced levels of aiAT. Mildly deficient PI
phenotypes have been associated with some chromosomal aberrations:
but the evidence is unconvincing (Fagerhol and Cox, 1981 [2]) .
The nature of the mutations which give rise to fragile sites are unknown and
this investigation examines the possibility of an association between
mildly deficient PI phenotypes and mutations to fragile sites.
3.
MATERIALS AND METHODS
This investigation is unusual in that the chromosomal lesion is
a heritable characteristic and any association between mutation to
the fragile site and PI phenotype is directly testable in families
only at the generation in which the mutation arose. Evidence for
such association would be eroded in successive generations by
Fig.l independent assortment (Fig. la) and non PI*M alleles could easily
associate with fragile sites by chance (Fig.lb). For this reason
only the carrier in the earliest available generation of each family
was examined for statistical association to eliminate as far as
possible effects of independent assortment and association by chance.
This provided a sample of carriers as close as possible to the
mutational event required for the expression of fragile sites.
Table 1 The earliest carrier, whether propositus or otherwise (Table 1), was
determined prior to PI typing. The number of generations available
for study depended on the availability and co-operation of family
members.
All the fragile sites ascertained fit the criteria for classification
as true fragile sites (Sutherland, 1979 [7]). PI typing was
carried out as previously described for the determination of allele
frequencies in the normal population (Mulley, 1980; 1982 [3,4]).
Fragile site acertainments were grouped for statistical analysis
into three classes : folate sensitive at Xq27, folate sensitive at
autosomal loci and BrdU dependent at 10q25. There were insufficient
fragile sites at 16q22 for meaningful statistical analysis.
4.
Of the families with folate sensitive fragile sites, 18 of the 40
ascertained had been examined for the presence of the BrdU
dependent fragile site. All BrdU dependent fragile site
ascertainments had been examined for folate sensitive fragile
sites.
RESULTS
A total of 104 fragile sites were ascertained from 95 unrelated
families. There were 17 ascertainments for the fragile site at
Xq27, 23 for various folate sensitive autosomal sites, 59 for the
BrdU dependent site and 5 for the site at 16q22. More than one
fragile site was found in 8 families. One family had three fragile
sites, two at 10q25 (homozygous in two individuals) and one at llq23.
The remaining seven families were all double ascertainments : an
Xq27 with 16q22, two cases of 10q23 with 10q25, three cases of 10q25
with 16q22 and a 20pll with 16q22. In all 8 families the earliest
carrier for one fragile site was also the earliest carrier for
another fragile site. The earliest carrier was the propositus for
three families, the parent of the propositus in two families and the
grandparent of the propositus in three families.
The distribution of PI phenotypes determined from the earliest
Table 2 carrier of all fragile site ascertainments is shownin Table 2.
For example, the phenotypes given for the pedigrees in Fig.l are
presented in Table 2 as M1Z (Fig.la) and Ml (Fig.lb). Comparisons
of the fragile site groups with those in a random sample from the
population (phenotypes classified as either PI M or noil PI M) are
Table 3 given in Table 3. Non PI M phenotypes have at least one allele
other than PI*M1, PI*M2 or PI*M3. The distribution of PI phenotypes
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was similar to that of the general population for the BrdU
2
dependent fragile site sample (xi = 0.36, 0.50 < P < 0.75).
The corresponding comparison for the autosomal folate sensitive
2
fragile sites is significant (xi = 4.34, P < .05). The data
derived from the limited sample of 17 ascertainments with the
2
fragile site at Xq27 also detected an association (xl = 8.41, P < .01).
DISCUSSION
There is strong selection against the folate sensitive fragile site
at Xq27, which in terms of reproductive fitness, is virtually
lethal in affected males and in some females. A significant
proportion of independent Xq27 fragile site ascertainments are
expected to result from new mutations and many of the remaining
ascertainments are likely to be of relatively recent mutational
origin. This group of fragile site families is therefore likely
to provide the most sensitive test of any hypothetical relationship
between PI phenotype and mutagenesis to fragile sites. An association
was indeed found in this study. Unfortunately, the identification
of new mutants is uncertain given the difficulty in detecting this
fragile site in some female carriers (Sutherland, 1983 [9]).
If a relation between PI phenotype and mutation to the fragile site
at Xq27 does exist, then a similar relationship may also exist for the
other fragile sites. While it is not inconceivable that recent
mutations are represented amongst the autosomal folate sensitive
fragile site sample, the mutational origin would be expected to be
more remote than for the fragile site at Xq27. Most heterozygotes
for the autosomal folate sensitive fragile sites are normal
individuals and any selection pressure against them is small.
6,
Whilst these sites might prove harmful in homozygotes, by analogy
with known clinical effects of hemizygosity for the fragile site
at Xq27, no such homozygote has been recorded. In view of the
probable long period of elapsed time in generations between mutation
and ascertainment, any relationship that might exist between PI
phenotype and mutation to the autosomal folate sensitive fragile
sites would be unlikely to be detected. Surprisingly, an association
was found in the present study.
A third class of fragile site at 10q25 is a harmless polymorphism.
Lack of selection against this fragile site implies that virtually
all ascertainments are far removed in generations from the actual
mutational events, and genetic drift might be responsible for
its common occurrence. No association was found between PI phenotype
and this fragile site as expected.
The molecular mechanism underlying fragile site expression is unclear.
The chromosomal phenotype is probably associated with a mutant gene
given the heritable nature of fragile sites. Linkage between the
fragile sites at 10q23 and 10q25 (Sutherland, et al. 1982 [lO]) and
between the fragile site at 6p23 and HLA (Mulley, et al. 1983 [5]) confirms
that the genes responsible are at the position of fragile site
expression. They may affect either condensation of DNA, DNA repair or
DNA synthesis. Penetrance and expressivity at the cellular level is
largely dependent upon the culture environment.
The statistical association between mildly deficient PI phenotypes
and carriers of the folate sensitive fragile sites may be only
coincidental because the numbers analysed were low. This could be
7.
confirmed by an independent investigation of a separate series,
but folate sensitive fragile sites are extremely rare and a
separate series will not be available to the present investigators
in the immediate future.
Another matter for speculation arising from the series
studied concerns the apparent high rate of double ascertainment.
The observed rate is a lower limit because 22 families known to
have folate sensitive fragile sites were not examined with BrdU
for the presence of the fragile site at 10cj25. The detection
of the fragile site at 16q22 can be difficult and in some patients
requires the addition of distamycin A to lymphocyte cultures 24 hours
prior to harvest (Schmid, et al. 1980 [6]) or high (30mg/l) levels
of BrdU 6-8 hours prior to harvest (Croci, 1983 [lj). Consequently
the significance of double ascertainment involving the site at
16q22 is unknown as culture conditions for expression of this fragile
site were suboptimal in the great majority of individuals examined.
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Fig.l Pedigrees showing segregation of fragile sites and PI
alleles to demonstrate the need to consider only the
earliest carrier.
a) The true relationship is eroded in generations II and III
by independent assortment,



































10 9 3 1 23
10q25 25 20 13 1 59
16q22 3 1 1 0 5
41 41 20 2 104
TABLE 2
PI PHENOTYPE IN THE EARLIEST CARRIER
OF EACH FRAGILE SITE ASCERTAINMENT
Fragile Site No. PI M Non PI M
Ml M1M2 M1M3 M2M3 MIS M2S M3S M1Z M1F M2F Mil




2ql3 2 - 1 - - 1 - - - - -
6p23 1 - - - - - - - - - 1
9p21 1 - - - - - - - - 1 -
9q32 2 2 - - - - - - - - -
10q23 9 5 2 1 1 - - - - - -
llql3 2 - - 1 1 - - - - - -
11 q 2 3 1 - - 1 - - - - - - -
12ql 3 1 1 - - - - - - - - -
16pl2 2 - 1 - - - - - 1 - -
20pll 2 - - - - 1 - - 1 - -
Total 23 8 A 3 2 2 0 0 2 1 0 1
10q25 59 31 12 6 2 5 1 0 0 1 1
16q22 5 3 0 0 0 2 0 0 0 0 0
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HERITABLE FRAGILE SITES ON HUMAN CHROMOSOMES.
XI. FACTORS AFFECTING EXPRESSION OF FRAGILE SITES












The fragile sites at 10q25, 16q22 and 17p12 can all be induced
in lymphocyte culture by BrdU or BrdC added 6-12 hours prior
to harvest. Without induction fra(10)(q25) is rarely
expressed spontaneously whereas fra(16)(q22) is frequently
expressed spontaneously. Fra(17)(p12) is frequently expressed
spontaneously but it is unknown whether it will only be expressed
after induction in some individuals. Distamycin A, Netropsin
and Hoechst 33258 induced high levels of expression of
fra(16)(q22) and fra(17)(p12) but did not enhance expression of
fra(10)(q25). The mechansims of induction of fra(l6)(q22) by
BrdU and Distamycin A appear to be different since the time of
action of BrdU reaches a maximum about 12 hours prior to harvest
whereas induction by Distamycin A requires much longer exposure.
The fragile sites at 10q25 and 16q22 were both induced in
fibroblast culture by BrdU. Fra(17)(p12) is accepted as a
fragile site because preliminary studies show that it behaves
similarly in lymphocyte culture to frat 16)(q22), however there
is only limited evidence for fragility at 17p12.
2.
INTRODUCTION
Of the known heritable fragile sites on human chromosomes only
two are not suppressed by the addition of folic acid to
lymphocyte culture [1] . The first of these, at 16q22, was
originally considered to be insensitive to conditions of tissue
culture [2] but it has been shown that its expression can be
greatly enhanced by the addition of either Distamycin A [3] or
BrdU [A] to lymphocyte culture. Expression of the fragile site
at 10q25 has been shown to require BrdU to be present in
lymphocyte cultures for some hours prior to harvest [5] .
Since both these fragile sites can be induced with BrdU a
detailed study was undertaken to determine whether they behave
in similar ways under a variety of conditions of tissue culture
in lymphocytes and fibroblasts. The variant chromosome 17,
the so-called satellited 17, was not accepted by Sutherland [1]
as a fragile site although Shabtai et al. [6] have proposed that
it is one. Preliminary studies have suggested that it is a




The fragile site at 16q22 has been studied in seven individuals,
one of whom also has the fragile X (Subject B [7]), two are
brothers JE and TE, two are mother and daughter, Mrs. L. and PL,
land there were two unrelated women (CI and Co) who also have the
BrdU requiring fragile site at 10q25 (Fig.1). The fragile site
at 10q25 has been ascertained more than 75 times and more than
200 individuals with it have been studied [8]. Data relating
to eight individuals (numbered 1-8) are presented in the results.
One individual with fra(17)(p12) has been available for study.
Lymphocytes have been cultured in a variety of media including
TC199, RPMI 1640, Ham's F10 and Eagle's MEM without folic acid
(MEM-FA [2]). The media were supplemented with 5% fetal bovine
serum and methods of culture and harvesting for chromosome studies
have been previously described [2]. Expression of the fragile
sites was studied in media used without additives and with
Distamycin A, Netropsin, Bromodeoxyuridine (BrdU),
Bromodeoxycytidine (BrdC), Hoechst 33258 and thymidine added at
different concentrations and at different times prior to harvest
as shown in the results.
Fibroblast cultures obtained from Subject B and several individuals
with fra(10)(q25) were grown in Ham's F10 with 10% fetal bovine
serum. The chromosome preparations from fibroblasts were obtained
using an in situ method [11] except that 0.075 M KC1 was used as
the hypotonic solution. The effects of BrdU, BrdC and Distamycin A
at various concentrations and for various times, as shown in the
results, on the expression of the fragile sites was studied.
4.
Once the location of the fragile site in any individual had been
confirmed by chromosome banding all other studies were carried
out on unbanded material and frequencies of expression were
determined from the examination of at least 50 metaphases.
RESULTS
Spontaneous expression in lymphocytes
Frequencies of expression of the fragile site at 16q22 in various
media without any additives are shown in Table I. There were no
consistent differences in the frequency of expression according
to the type of media used, but there were considerable
fluctuations for any individual studied. The fragile site at
10q25 has not been detected under these conditions of culture in
more than 200 individuals studied who had been shown to carry it
following BrdU induction. Rarely, in fra(10)(q25) carriers, one
or two metaphases out of 50 examined from cultures to which BrdU
or another inducing agent had not been added did appear to be
expressing the fragile site. It is difficult to be sure from
unbanded chromosomes that this finding of a very low frequency of
expression is any more than would be seen in individuals who do
not carry this fragile site. Fra(17)(p12) has been ascertained
nine times and seen in parent-child pairs twice. All these
ascertainments resulted from spontaneous expression of the
fragile site.
5.
Induction in lymphocytes by BrdU and BrdC
The effects of BrdU and BrdC on expression of 16q22 are shown in
Table II for several individuals and from this it can be seen that
addition of either of these substances at the time of culture
initiation had little effect on the frequency of expression of
the fragile site. Either substance, when added closer to the
time of harvest usually caused a large increase in the frequency
at which this fragile site was expressed. A more detailed study
of the action of these compounds for Subject B is shown in
Table III. The frequency of expression is maximised by
addition of the compounds 6-12 hours prior to harvest.
Dose response curves for BrdU and BrdC added eight hours prior
to harvest to cultures from Subject TE are shown in Fig.2 and
it can be seen that maximum induction of the fragile site had
not been reached even when 200 mg/1 of the inducer was used.
Table IV shows the effect of BrdU and BrdC upon expression of
fra(10)(q25) in five individuals. Both compounds are effective
in inducing this fragile site although slightly higher
frequencies of expression were usually seen when the less toxic
BrdC was used. BrdC was present at a higher molar concentration
and this may explain the difference. Further data on the
response of fra(10)(q25) to BrdU has been published [5] and the
dose response and time course for the induction of this fragile
site by BrdC are shown in Figs. 3 and 4. The maximum induction
of this fragile site had not apparently been reached even by the
use of 200 mg/1 of BrdC. At higher concentrations toxicity
became a problem and resulted in low numbers of metaphases
suitable for examination. The time course data show that with
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50 mg/1 BrdU maximal induction occurred about 12 hours prior to
harvest but with the lower concentration (15 mg/1) a longer
exposure was required for this.
Induction in lymphocytes by DNA binding substances
Data obtained with Distamycin A is somewhat limited due to the
current unavailability of this compound. Table V shows the
response of six individuals with fra(16)(q22) to 100 mg/1
Distamycin A added 21 or 24 hours prior to harvest, two of these
individuals also have fra(10)(q25) and one also has fra(X)(q27).
One individual with fra(10)(q25) alone is also included in
Table V. From this table it can be seen that Distamycin A
greatly increased the frequency of expression of fra(16)(q22)
but had no effect upon fra(10)(q25) or fra(X)(q27). The time
of addition of Distamycin A is shown for Subject Co in Table III,
in two other individuals addition of Distamycin A at culture
initiation or 21 hours prior to harvest greatly increased the
frequency of expression (from 5% to 54% and 58% respectively in
Subject PL and from 25% to 85% and 80% respectively in her mother)
but had no effect when added at eight hours prior to harvest
(5% to 4% and 25% to 24%). A dose response curve for
expression of fra(16)(q22) to Distamycin A is shown in Fig.5.
A dose of 75 mg/1 appeared to result in maximal induction and
the decreased induction at 100 mg/1 in Subject B may reflect
toxicity of this compound. Netropsin greatly enhanced expression
of fra(16)(q22) in Subject B. The frequency of expression of this
fragile site was 40% in RPMI but addition of 100 mg/1 or 200 mg/1
of Netropsin gave frequencies of 66% and 60% respectively.
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Hoechst 33258 was found to induce fra(l6)(q22) and a dose response
curve for this induction is shown in Fig.6. Maximum induction
was achieved by the addition of 50-150 mg/1 of this compound
24 hours prior to harvest. The time prior to harvest of
maximum induction is not certain, but in Subject CI where
spontaneous expression of frad6)(q22) was seen in 4% of
metaphases in RPMI 1640, addition of 50 mg/1 of Hoechst 33259
ten hours prior to harvest increased expression to 40% of
metaphases and at 36 and 48 hours prior to harvest to 50% of
metaphases. Hoechst 33258 did not induce fra(10)(q25) in
Subject CI when added 24 hours prior to harvest at concentrations
up to 150 mg/1.
The results of preliminary studies on fra(17)(p12) are given in
Table VI. These show a low but consistent spontaneous
expression of the fragile site (6% to 14%) in the various
culture media used without addition of an inducing substance.
Addition of BrdU or BrdC greatly enhanced expression (24% to 74%)
and even further enhancement was seen in the presence of
Distamycin A and Netropsin (up to 100% of metaphases examined).
Hoechst 33258 induced the lesion in 68% of metaphases but the
concentration was low (10 mg/1) and further induction may have
occurred if higher concentrations had been used.
Fragile site induction in fibroblasts
Fragile sites at 10q25 and 16q22 were induced in fibroblasts.
There were no fibroblasts from any individual with fra(17)(p12)
available for study. Table VII shows a comparison of the
maximum frequency of expression of the fragile sites induced
with BrdU in fibroblasts and lymphocytes from the same individual.
Generally the frequency of expression was found to be higher in
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lymphocytes than fibroblasts. Fig.7 shows the dose response curve for the
induction of fra(10)(q25) with BrdU added 48 hours prior to harvest.
It can be seen from this figure that maximum induction of the
fragile site was not achieved since increasing the concentration
of BrdU was too toxic. Furthermore, it was generally seen that
addition of BrdU to cultures 48 hours prior to harvest resulted in
higher frequencies of expression than at 24 hours prior to harvest.
Preliminary experiments suggested that Distamycin A would not
induce frat 10)(q25) in fibroblasts but this study could not be
pursued due to the unavailability of Distamycin A. Similarly,
induction of fra(l6)(q22) in fibroblasts with this substance
could not be tested.
DISCUSSION
The tissue culture conditions for expression of the folate
sensitive fragile sites and the area of metabolism involved
in this are known, if not completely understood [1]. There are
only three fragile sites which are not folate sensitive and this
study has attempted a detailed examination of the tissue culture
requirements for the expression of these in the hope of defining
the area of metabolism involved or the chromosomal mechanism
underlying fragile site expression. The results indicate that
although these fragile sites have several features in common,
there are differences between fra (10){q25) which is only induced
by BrdU or BrdC, and fra(16)(q22) and fra(17)(p12) which are very
similar and are also induced by the DNA binding compounds studied.
Table VIII briefly summarises the properties of each of these
fragile sites.
9.
The fragile sites at 16q22 and 17P12 are spontaneously expressed
in a variable proportion of metaphases from lymphocyte culture.
The fragile site at 10q25 is rarely expressed spontaneously and
is usually only seen after induction by BrdU. There are two
reports [12,13] of spontaneous expression of this fragile site
in families in which expression was greatly enhanced by BrdU,
and there is one report [14] of familial spontaneous expression
which was not enhanced by BrdU. It is possible that there is no
real difference in the ability of these three fragile sites to
spontaneously express themselves. All the fra(10)(q25) individuals
in Adelaide were found as a result of specific induction of this
fragile site with BrdU and none were seen to spontaneously
express it whereas the fra(16)(q22) and fra(17)(p12) individuals
were selected on the basis that they spontaneously expressed these
fragile sites. Schmid et al. [3] recorded several members of
two families in which fra(16)(q22) was not expressed spontaneously.
There is no information available on the induced versus spontaneous
expression of fra(17)(p12) since this is the first report
indicating that it can be induced and presumably all previous
reports related to its spontaneous expression.
Croci [A] was the first to show that fra(16)(q22) could be induced
with BrdU and he increased the frequency of expression from less
than 5% of metaphases up to 50% of metaphases by the addition
of 30 mg/1 of BrdU to lymphocyte cultures 6 to 65 hours prior
to harvest and suggested that the reason Sutherland [2] had not
found such an effect was that he added 10 mg/1 of BrdU at
initiation of culture. This suggestion appears to be correct
in part since the results of the present study show that the
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induction of the fragile site is maximised by addition of BrdU
6 to 8 hours prior to harvest and confirms that the addition of
10 mg/1 at culture initiation has little effect on the expression
of this fragile site. The three fragile sites in this study were
all induced by BrdU and BrdC.
BrdC has been found to be a very useful alternative to BrdU.
Unpublished data shows that it is less toxic, and particularly at
high concentrations or after longer exposure times, the quality
of chromosomes is much better and the number of usable metaphases
per slide (either for SCE determiantion of fragile site scoring)
is higher than when equimolar concentrations of BrdU have been used.
BrdC has been used as an alternative to BrdU for SCE determiantion
[15,16] and in reporting in vivo studies with this compound in
grasshoppers Pijnacker and Ferwerda [17] noted that it appeared
to be less toxic than BrdU. BrdC has been found to be as
effective as BrdU in induction of fragile sites. In this
discussion wherever BrdU is reported to have had an effect it can
be assumed that a similar effect was obtained with BrdC unless
otherwise stated.
Since BrdU is an analog of thymidine, exposure of lymphocyte cultures
to excess thymidine was performed but this did not induce the
fragile sites (data not shown). Sutherland et al. [5] showed
that addition of increasing amounts of thymidine in the presence
of BrdU gradually inhibited expression of fra(10)(q25). Similar
data (not shown) were obtained for fra(16)(q22). Such findings
are in line with the suggestion [18] that BrdU and thymidine
compete for available incorporation sites and that the effect of
BrdU can be swamped by excess thymidine. This is in contrast to
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the mechanism of BrdU induced mutagenesis in mammalian cells [19]
where the effect of BrdU is enhanced by thymidine. Presumably
the mechanism of BrdU induction of fragile sites is not the
same as that of BrdU mutagenesis. The chromosomal mechanism
responsible for expression of both the BrdU inducible and folate
sensitive fragile sites remains poorly understood.
There exists some doubt and controversy as to whether the
undoubted morphological variant of the short arm of chromosome 17
is really a fragile site. There have been numerous reports
(see [20] for collation) of this chromosome variant, which shows
many features of a fragile site. It is usually seen in only a
proportion of metaphases, although it has been reported to be in
all of them in some cases (e.g. [21]). It is undoubtedly
heritable and constant in position, however it has only been
rarely reported to be fragile. Cytogenetically this fragile site
is different from all the others. The appearance is usually that
of an incomplete gap, not unlike that described by Schmid et al. [3]
for their type 2 Distamycin A inducible lesion at 16q22.
Complete gaps are uncommon and breaks even more uncommon.
Shabtai et al. [6] published "triradial-like figures" thought to
result from this fragile site, but a convincing triradial of the
type described for all the other fragile sites has not been
documented. Since the behaviour of this chromosomal variant
in response to manipultion of conditions of tissue culture is
apparently identical to that shown by the fragile site at 16q22
it is tentatively accorded the status of a fragile site, although
the evidence for fragility at 17P12 is minimal.
12.
The specific induction of the fragile site at 16q22 by Distamycin A
was first reported by Schmid et al. [3]. They found that this
fragile site was not expressed spontaneously in members of two
families studied but was seen if 100 mg/1 of Distamycin A was
added to the culture medium 24 hours prior to harvest. Indeed
this fragile site was undoubtedly missed on some occasions in
the Adelaide laboratory. The finding of 2% to 4% of metaphases
with this fragile site was not rare and erroneously lead
Sutherland [1] to conclude that there was an autosomal lesion as
well as a fragile site at this locus. Subsequent re-study of
some of these individuals using either BrdU or Distamycin A
induction has confirmed that they have the fragile site.
Since the oligopeptide antibiotic Distamycin A was found to induce
the fragile sites at 16q22 and 17p12, the effects of a similar
antibiotic, Netropsin, which also binds to A-T rich regions of
DNA [10], and Hoechst 33258 which also binds to such regions [22]
were studied. These three compounds all strongly induced both
fragile sites. Repeated attempts to induce the fragile site
at 10q25 with Distamycin A and one attempt to induce it with
Netropsin and Hoechst 33258 at different concentrations have been
unsuccessful. It is reasonable to conclude that none of these
compounds will induce fra(10)(q25).
Both Distamycin A and Netropsin are oligopeptide antibotics which
bind in the minor groove of DNA at A-T rich regions [10] and
Hoechst 33258 probably binds to the major groove in such regions
[22,23]. The ability of these compounds to induce the fragile sites
at 16q22 and 17p12 might suggest that these fragile sites are A-T
rich regions of DNA and with the compound bound to the DNA,
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chromosomal compaction for mitosis is inhibited and results in
expression of a fragile site.
It is of interest to note that the times of action of Distamycin A
and BrdU in inducing fra(16)(q22) are different. At 12 hours
prior to harvest Distamycin A has no effect as a fragile site
inducer yet the maximal effect of BrdU on induction occurs about
this time. This would suggest that the two types of inducer
operate via different mechanisms. Jacky and Dill [24] found
that Ethidium bromide, Hoechst 33258, Olivomycin, Netropsin and
Actinomycin D had no effect on expression of the fragile X in
lymphocyte cultures and this presumably holds for the other
folate sensitive fragile sites. These substances and others
which bind to DNA should be tested for their ability to induce
expression of the folate insensitive fragile sites.
Whilst this study has not shed much light on the mechanism of
expression of fragile sites or revealed the area of metabolism
involved in their expression it is perhaps reasonable to conclude
that since BrdU induction can be achieved so close to harvest
that the fragile sites are late replicating regions of DNA,
and since frad6)(q22) and fra(17 ) (p12 ) can be induced with DNA
ligands that these are regions of A-T rich DNA.
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TABLE I
Proportion of metaphases showing expression of fra(16)(q22)






199 MEM-FA F10 RPMI
B. 4/4/78 21/100 8/50 8/100
12/6/78 10/50 6/41 19/50
21/2/83 20/50 19/50 10/50 20/50
P.L. 5/100
Mrs. L. 17/100 25/100
T.E. 2/8/82 12/50 21/100




Percentage of metaphases expressing fra(16)(q22) when 10 rag/1
of BrdU (or 15 mg/1 of BrdC) was added at culture initiation
(h-72) or 50 mg/1 when either was added 21 {h—21) or 8 (h-8)








































Expression of fra(16)(q22) induced by BrdU and BrdC in
Subject B and by Distamycin A in Subject Co. Effect of

















24 19/50 21/50 36/50 35/50 22/50
16 19/50 30/50 30/50 30/50 16/50
12 24/50 39/50 5/50
8 31/50 36/50 29/50 40/50 0/50
6 37/50 39/50
4 27/50 17/50 22/50 24/50 2/50
Control 40/100 40/100 40/100 40/100 10/100
TABLE IV
Comparison of BrdU (10 mg/1) and BrdC (15 mg/1) in
induction of fra(10)(q25) in Ham's F10 (Subjects 1-A
or RPMI 16A0 (Subject Co).
SUBJECT CONTROL BrdU BrdC
1 0/50 6/25 13/25
2 0/50 3/50 10/50
3 0/50 8/21 A/30
A 0/50 2A/50 35/50
Co 0/50 9/50 1 A/50
TABLE V
The effect of addition of 100 mg/1 of Distamycin A to
RPMI 16A0 on expression of the fragile site.
SUBJECT
CULTURE MEDIUM
RPMI 1640 RPMI 16A0 + DA
B. fra(16) 20/50 36/50
fra(X) 0/50 0/50
P.L. fra(16) 5/100 27/50
Mrs. L. fra(l6) 25/100 A3/50
T.E. fra(16) 21 /100 30/50
Co fra(10) 0/50 0/50*
f ra(16) 10/100 33/50
CI fra(10) 0/50 0/50*
fra(16) 2/50 32/50
2 fra(10) 0/50 0/50*
* The fragile site at 10q25 was induced in 9/50 metaphases
in Subject Co and 11/50 metaphases in Subject CI by
10 mg/1 BrdU added at culture initiation and in 20/50
metaphases in Subject 2 by 100 mg/1 BrdC added at culture
initiation. The fragile X in Subject B was seen in
17/50 metaphases in MEM-FA.
TABLE VI
Effect of various additives on expression of fra(17)(p12).









RPMI 1640 Nil 7/50
ii BrdU 10 20/50
ii BrdU 50 12/50
ii BrdC 15 19/50
ii BrdC 50 37/50
ii Distamycin A 50 43/50
n Distamycin A 100 50/50
it Netropsin 200 47/50
ii Netropsin 300 46/50
ii Hoechst 33258 5 31 /50
it Hoechst 33258 10 34/50
TABLE VII
Comparison of expression of fragile sites induced with BrdU
in lymphocytes and fibroblasts from the same subject.
SUBJECT FRA LYMPHOCYTES FIBROBLASTS
5 1 0q25 30/50 22/50
6 10q25 35/50 1 A/50
7 1 0q25 16/50 2/50
8 10q25 . 32/50 12/50
B 1 6q22 31/50 3/100
TABLE VIII
Summary of properties of the fragile sites at 10q25, 16q22
and 17p12 -
PROPERTY 1 0q25 1 6q22 17p12
Spontaneously expressed Very rarely Yes Yes
Induced by 10 mg/1 BrdU
at culture initiation Yes Minor effect Not known
Induced by 50 mg/1 BrdU
8 hours prior to harvest Yes Yes Yes
Time of maximum induction
by BrdU 6-12 hours 6-12 hours 6-12 hours
Induced by Distamycin A No Yes Yes
Induced by Netropsin No Yes Yes
Induced by Hoechst 33258 No Yes Yes
Time of maximum induction
by Distamycin A Not relevant 24+ hours ? 24+ hours
Fig.1 Partial rnetaphase showing simultaneous expression of
fra(10)(q25) (large arrow) and fra(l6)(q22) (small arrow).
Concentration (mg/l)
Fig.2 Dose response curves for BrdU (0) and BrdC (A) added
eight hours prior to harvest on expression of
fra(16)(q22) in lymphocyte cultures.
Fig.3 Dose response curves for expression of fra(10)(q25) in
lymphocyte culture with concentration of BrdC, in two
individuals (0, A). The BrdC was added 2A hours prior
to harvest.
Time Prior to Harvest (hours)
Fig. A
/
Effect of time prior to harvest of addition of BrdC at
concentrations of 50 mg/1 (A) and 10 mg/1 (0) upon
expression of fra(10)(q25).
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Fig.5 Dose response curves for expression of fra(16)(q22) in
lymphocyte cultures from two individuals (0, A) with
concentration of Distamycin A.
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Fig.6 Dose response curves for expression of fra(l6)(q22) in
lymphocyte cultures from two individuals (0, A) with
concentration of Hoechst 33258.
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Dose response curves for expression of fra(10)(q25)
in fibroblast cultures with concentration of BrdU from
two individuals.
